{
    "5e6157cb1af46fc13000000e_1": [
        {
            "start_logit": 9.859375,
            "end_logit": 9.3359375,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -2.1953125,
            "text": "Ret",
            "probability": 9.894371032714844e-06
        },
        {
            "start_logit": -2.720703125,
            "end_logit": 9.3359375,
            "text": "syndrome",
            "probability": 3.4570693969726562e-06
        },
        {
            "start_logit": -6.07421875,
            "end_logit": 9.3359375,
            "text": "t syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.2421875,
            "end_logit": 9.3359375,
            "text": "with Rett syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.3359375,
            "text": "methyl-CpG-binding protein-2 gene (MECP2) are commonly associated with Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": 9.3359375,
            "text": "associated with Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.3359375,
            "text": "commonly associated with Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.3359375,
            "text": "Mutations in the methyl-CpG-binding protein-2 gene (MECP2) are commonly associated with Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.3359375,
            "text": "are commonly associated with Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.3359375,
            "text": "the methyl-CpG-binding protein-2 gene (MECP2) are commonly associated with Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.3359375,
            "text": "-CpG-binding protein-2 gene (MECP2) are commonly associated with Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.3359375,
            "text": "in the methyl-CpG-binding protein-2 gene (MECP2) are commonly associated with Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 9.3359375,
            "text": "CpG-binding protein-2 gene (MECP2) are commonly associated with Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.2421875,
            "end_logit": -2.1953125,
            "text": "with Ret",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": -2.1953125,
            "text": "methyl-CpG-binding protein-2 gene (MECP2) are commonly associated with Ret",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": -2.1953125,
            "text": "associated with Ret",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -2.1953125,
            "text": "commonly associated with Ret",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -2.1953125,
            "text": "Mutations in the methyl-CpG-binding protein-2 gene (MECP2) are commonly associated with Ret",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -2.1953125,
            "text": "are commonly associated with Ret",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_2": [
        {
            "start_logit": 9.8046875,
            "end_logit": 9.375,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -2.314453125,
            "text": "Ret",
            "probability": 8.344650268554688e-06
        },
        {
            "start_logit": -2.642578125,
            "end_logit": 9.375,
            "text": "syndrome",
            "probability": 3.933906555175781e-06
        },
        {
            "start_logit": -6.15234375,
            "end_logit": 9.375,
            "text": "t syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.2265625,
            "text": "Rett syndrome (",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.265625,
            "text": "Rett syndrome (RS",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.328125,
            "text": "Rett syndrome (RS)",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.328125,
            "text": "Rett syndrome (RS) is a debilitating neurological disorder affecting mostly girls with heterozygous mutations in the gene encoding the methyl-CpG",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.3515625,
            "text": "Rett syndrome (RS) is a debilitating neurological disorder affecting mostly girls with heterozygous mutations in the gene encoding the methyl-CpG-binding",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.3671875,
            "text": "Rett syndrome (RS) is a debilitating neurological disorder affecting mostly girls with heterozygous mutations in the gene encoding the methyl-CpG-",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.3828125,
            "text": "Rett syndrome (RS) is a debilitating neurological disorder affecting mostly girls with heterozygous mutations in the gene encoding the methyl-CpG-binding protein MeCP2 on the X",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.390625,
            "text": "Rett syndrome (RS) is a debilitating neurological disorder affecting mostly girls with heterozygous mutations in the gene encoding the methyl-CpG-binding protein MeCP2",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.3984375,
            "text": "Rett syndrome (RS) is a debilitating neurological disorder affecting mostly girls with heterozygous mutations in the gene encoding the methyl-CpG-binding protein MeC",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.421875,
            "text": "Rett syndrome (RS) is a debilitating neurological disorder affecting mostly girls with heterozygous mutations in the gene encoding the methyl-CpG-binding protein MeCP2 on the",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.421875,
            "text": "Rett syndrome (RS) is a debilitating neurological disorder affecting mostly girls with heterozygous mutations in the gene encoding the methyl-CpG-binding protein",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.4296875,
            "text": "Rett syndrome (RS) is a debilitating neurological disorder affecting mostly girls with heterozygous mutations in the gene encoding the methyl-CpG-binding protein MeCP2 on",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.4375,
            "text": "Rett syndrome (RS) is",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.4375,
            "text": "Rett syndrome (RS) is a debilitating neurological disorder affecting mostly girls with heterozygous mutations in the gene encoding the methyl-CpG-binding protein MeCP2 on the X chromosome",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.4453125,
            "text": "Rett syndrome (RS) is a debilitating neurological disorder affecting mostly girls with heterozygous mutations in the",
            "probability": 0.0
        },
        {
            "start_logit": -2.642578125,
            "end_logit": -8.2265625,
            "text": "syndrome (",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_3": [
        {
            "start_logit": 9.9140625,
            "end_logit": 9.5,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -2.048828125,
            "text": "Ret",
            "probability": 9.715557098388672e-06
        },
        {
            "start_logit": -2.38671875,
            "end_logit": 9.5,
            "text": "syndrome",
            "probability": 4.589557647705078e-06
        },
        {
            "start_logit": -6.13671875,
            "end_logit": 9.5,
            "text": "t syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 9.5,
            "text": "disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.1171875,
            "text": "Rett syndrome (",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.1953125,
            "text": "Rett syndrome (RTT)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.234375,
            "text": "Rett syndrome (RT",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.328125,
            "text": "Rett syndrome (RTT",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.5,
            "text": "neurodevelopmental disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.5,
            "text": "Mutations in the MECP2 gene cause the neurodevelopmental disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.5,
            "text": "the neurodevelopmental disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.5,
            "text": "in the MECP2 gene cause the neurodevelopmental disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.5,
            "text": "cause the neurodevelopmental disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.5,
            "text": "the MECP2 gene cause the neurodevelopmental disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": 9.5,
            "text": "gene cause the neurodevelopmental disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.5,
            "text": "MECP2 gene cause the neurodevelopmental disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.64453125,
            "end_logit": -2.048828125,
            "text": "disorder Ret",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": -2.048828125,
            "text": "neurodevelopmental disorder Ret",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -2.048828125,
            "text": "Mutations in the MECP2 gene cause the neurodevelopmental disorder Ret",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_4": [
        {
            "start_logit": 9.8828125,
            "end_logit": 9.4609375,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -2.158203125,
            "text": "Ret",
            "probability": 9.000301361083984e-06
        },
        {
            "start_logit": -2.47265625,
            "end_logit": 9.4609375,
            "text": "syndrome",
            "probability": 4.291534423828125e-06
        },
        {
            "start_logit": -6.02734375,
            "end_logit": 9.4609375,
            "text": "t syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.1640625,
            "text": "Rett syndrome is",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.234375,
            "text": "Rett syndrome is a",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.2734375,
            "text": "Rett syndrome is a severe neurodevelopmental disorder mainly",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.2890625,
            "text": "Rett syndrome is a severe neurodevelopmental disorder mainly caused by mutations in the transcriptional regulator MeCP2",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.3125,
            "text": "Rett syndrome is a severe neurodevelopmental disorder mainly caused by mutations in the transcriptional",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.328125,
            "text": "Rett syndrome is a severe neurodevelopmental disorder mainly caused by mutations in the transcriptional regulator MeC",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.3359375,
            "text": "Rett syndrome is a severe neurodevelopmental disorder mainly caused by mutations",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.3359375,
            "text": "Rett syndrome is a severe neurodevelopmental disorder mainly caused",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.34375,
            "text": "Rett syndrome is a severe neurodevelopmental disorder mainly caused by mutations in",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.359375,
            "text": "Rett syndrome is a severe neurodevelopmental disorder mainly caused by mutations in the",
            "probability": 0.0
        },
        {
            "start_logit": -2.47265625,
            "end_logit": -8.1640625,
            "text": "syndrome is",
            "probability": 0.0
        },
        {
            "start_logit": -2.47265625,
            "end_logit": -8.234375,
            "text": "syndrome is a",
            "probability": 0.0
        },
        {
            "start_logit": -2.47265625,
            "end_logit": -8.2734375,
            "text": "syndrome is a severe neurodevelopmental disorder mainly",
            "probability": 0.0
        },
        {
            "start_logit": -2.47265625,
            "end_logit": -8.2890625,
            "text": "syndrome is a severe neurodevelopmental disorder mainly caused by mutations in the transcriptional regulator MeCP2",
            "probability": 0.0
        },
        {
            "start_logit": -2.47265625,
            "end_logit": -8.3125,
            "text": "syndrome is a severe neurodevelopmental disorder mainly caused by mutations in the transcriptional",
            "probability": 0.0
        },
        {
            "start_logit": -2.47265625,
            "end_logit": -8.328125,
            "text": "syndrome is a severe neurodevelopmental disorder mainly caused by mutations in the transcriptional regulator MeC",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_5": [
        {
            "start_logit": 9.890625,
            "end_logit": 9.4609375,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -2.126953125,
            "text": "Ret",
            "probability": 9.357929229736328e-06
        },
        {
            "start_logit": -2.4609375,
            "end_logit": 9.4609375,
            "text": "syndrome",
            "probability": 4.351139068603516e-06
        },
        {
            "start_logit": -6.0859375,
            "end_logit": 9.4609375,
            "text": "t syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.2578125,
            "text": "Rett syndrome, a",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 9.4609375,
            "text": "Mutations in the MeCP2 gene cause Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 9.4609375,
            "text": "cause Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.4609375,
            "text": "in the MeCP2 gene cause Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.4609375,
            "text": "MeCP2 gene cause Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.4609375,
            "text": "gene cause Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.4609375,
            "text": "the MeCP2 gene cause Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -2.126953125,
            "text": "Mutations in the MeCP2 gene cause Ret",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": -2.126953125,
            "text": "cause Ret",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": -2.126953125,
            "text": "in the MeCP2 gene cause Ret",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": -2.126953125,
            "text": "MeCP2 gene cause Ret",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": -2.126953125,
            "text": "gene cause Ret",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": -2.126953125,
            "text": "the MeCP2 gene cause Ret",
            "probability": 0.0
        },
        {
            "start_logit": -2.4609375,
            "end_logit": -8.2578125,
            "text": "syndrome, a",
            "probability": 0.0
        },
        {
            "start_logit": -6.0859375,
            "end_logit": -8.2578125,
            "text": "t syndrome, a",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": -8.2578125,
            "text": ", a",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_6": [
        {
            "start_logit": 9.8671875,
            "end_logit": 9.46875,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -2.1796875,
            "text": "Ret",
            "probability": 8.64267349243164e-06
        },
        {
            "start_logit": -2.451171875,
            "end_logit": 9.46875,
            "text": "syndrome",
            "probability": 4.410743713378906e-06
        },
        {
            "start_logit": -5.88671875,
            "end_logit": 9.46875,
            "text": "t syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.97265625,
            "text": "Rett syndrome (RT",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.0625,
            "text": "Rett syndrome (RTT)",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.1171875,
            "text": "Rett syndrome (",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.15625,
            "text": "Rett syndrome (RTT",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.2265625,
            "text": "Rett syndrome (RTT) is a debilitating neurological disorder caused by mutations in the gene encoding the transcription factor Methyl CpG Binding Protein 2 (MECP2)",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.234375,
            "text": "Rett syndrome (RTT) is a debilitating neurological disorder caused by mutations in the gene encoding the transcription factor Methyl CpG Binding Protein 2 (MECP2",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.2421875,
            "text": "Rett syndrome (RTT) is a debilitating neurological disorder caused by mutations in the gene encoding the transcription factor Methyl CpG Binding Protein 2",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.25,
            "text": "Rett syndrome (RTT) is a debilitating neurological disorder caused by mutations in the gene encoding the transcription factor Methyl CpG Binding Protein 2 (MEC",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.2578125,
            "text": "Rett syndrome (RTT) is a debilitating neurological disorder caused by mutations in the gene encoding the transcription factor Methyl CpG Binding Protein 2 (",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.28125,
            "text": "Rett syndrome (RTT) is",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.2890625,
            "text": "Rett syndrome (RTT) is a debilitating neurological disorder caused by mutations in the gene encoding the transcription factor Methyl CpG Binding Protein",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.3203125,
            "text": "Rett syndrome (RTT) is a",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.328125,
            "text": "Rett syndrome (RTT) is a debilitating neurological disorder caused by mutations in the gene encoding the transcription factor Methyl CpG",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.3359375,
            "text": "Rett syndrome (RTT) is a debilitating neurological disorder caused by mutations in the gene encoding the transcription factor Methyl CpG Binding",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.3515625,
            "text": "Rett syndrome (RTT) is a debilitating neurological disorder caused by mutations in the",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.3515625,
            "text": "Rett syndrome (RTT) is a debilitating neurological disorder caused by mutations in the gene encoding the transcription",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_7": [
        {
            "start_logit": 9.8984375,
            "end_logit": 9.484375,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -2.107421875,
            "text": "Ret",
            "probability": 9.298324584960938e-06
        },
        {
            "start_logit": -2.412109375,
            "end_logit": 9.484375,
            "text": "syndrome",
            "probability": 4.5299530029296875e-06
        },
        {
            "start_logit": -5.8359375,
            "end_logit": 9.484375,
            "text": "t syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -7.7890625,
            "text": "Rett syndrome (RT",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -7.84765625,
            "text": "Rett syndrome (RTT)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -7.9921875,
            "text": "Rett syndrome (RTT",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.03125,
            "text": "Rett syndrome (",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.21875,
            "text": "Rett syndrome (RTT) is associated with mutations in the transcriptional repressor gene MeCP2",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.234375,
            "text": "Rett syndrome (RTT) is associated with mutations in the transcriptional repressor",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.2421875,
            "text": "Rett syndrome (RTT) is",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.25,
            "text": "Rett syndrome (RTT) is associated with mutations in the transcriptional",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.25,
            "text": "Rett syndrome (RTT) is associated with mutations",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.25,
            "text": "Rett syndrome (RTT) is associated with mutations in the transcriptional repressor gene MeC",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.265625,
            "text": "Rett syndrome (RTT) is associated with mutations in the",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.28125,
            "text": "Rett syndrome (RTT) is associated with mutations in",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.296875,
            "text": "Rett syndrome (RTT) is associated with mutations in the transcriptional repressor gene",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.3359375,
            "text": "Rett syndrome (RTT) is associated with",
            "probability": 0.0
        },
        {
            "start_logit": -2.412109375,
            "end_logit": -7.7890625,
            "text": "syndrome (RT",
            "probability": 0.0
        },
        {
            "start_logit": -2.412109375,
            "end_logit": -7.84765625,
            "text": "syndrome (RTT)",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_8": [
        {
            "start_logit": 9.890625,
            "end_logit": 9.4609375,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -2.126953125,
            "text": "Ret",
            "probability": 9.357929229736328e-06
        },
        {
            "start_logit": -2.4609375,
            "end_logit": 9.4609375,
            "text": "syndrome",
            "probability": 4.351139068603516e-06
        },
        {
            "start_logit": -6.0859375,
            "end_logit": 9.4609375,
            "text": "t syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.2578125,
            "text": "Rett syndrome, a",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 9.4609375,
            "text": "Mutations in the MeCP2 gene cause Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 9.4609375,
            "text": "cause Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.4609375,
            "text": "in the MeCP2 gene cause Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.4609375,
            "text": "MeCP2 gene cause Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.4609375,
            "text": "gene cause Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.4609375,
            "text": "the MeCP2 gene cause Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -2.126953125,
            "text": "Mutations in the MeCP2 gene cause Ret",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": -2.126953125,
            "text": "cause Ret",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": -2.126953125,
            "text": "in the MeCP2 gene cause Ret",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": -2.126953125,
            "text": "MeCP2 gene cause Ret",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": -2.126953125,
            "text": "gene cause Ret",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": -2.126953125,
            "text": "the MeCP2 gene cause Ret",
            "probability": 0.0
        },
        {
            "start_logit": -2.4609375,
            "end_logit": -8.2578125,
            "text": "syndrome, a",
            "probability": 0.0
        },
        {
            "start_logit": -6.0859375,
            "end_logit": -8.2578125,
            "text": "t syndrome, a",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": -8.2578125,
            "text": ", a",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_9": [
        {
            "start_logit": 9.8203125,
            "end_logit": 9.328125,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -2.29296875,
            "text": "Ret",
            "probability": 8.940696716308594e-06
        },
        {
            "start_logit": -2.736328125,
            "end_logit": 9.328125,
            "text": "syndrome",
            "probability": 3.516674041748047e-06
        },
        {
            "start_logit": -6.2578125,
            "end_logit": 9.328125,
            "text": "t syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.90625,
            "end_logit": 9.328125,
            "text": "in Rett syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.09375,
            "end_logit": 9.328125,
            "text": "with disease severity in Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 9.328125,
            "text": "Methyl-CpG-binding protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.328125,
            "text": "associated with disease severity in Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.328125,
            "text": "disease severity in Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.328125,
            "text": "-CpG-binding protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.328125,
            "text": "is associated with disease severity in Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -6.90625,
            "end_logit": -2.29296875,
            "text": "in Ret",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": -2.29296875,
            "text": "with disease severity in Ret",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": -2.29296875,
            "text": "Methyl-CpG-binding protein 2 (MECP2) mutation type is associated with disease severity in Ret",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -2.29296875,
            "text": "associated with disease severity in Ret",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -2.29296875,
            "text": "disease severity in Ret",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -2.29296875,
            "text": "-CpG-binding protein 2 (MECP2) mutation type is associated with disease severity in Ret",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": -2.29296875,
            "text": "is associated with disease severity in Ret",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": -8.2421875,
            "text": "with disease severity",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": -8.234375,
            "text": "Methyl-CpG-binding protein 2 (MECP2",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_10": [
        {
            "start_logit": 9.84375,
            "end_logit": 9.4375,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -2.22265625,
            "text": "Ret",
            "probability": 8.64267349243164e-06
        },
        {
            "start_logit": -2.501953125,
            "end_logit": 9.4375,
            "text": "syndrome",
            "probability": 4.351139068603516e-06
        },
        {
            "start_logit": -5.859375,
            "end_logit": 9.4375,
            "text": "t syndrome",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.015625,
            "text": "Rett syndrome (RTT), the second most common cause of mental retardation in females, has been associated with mutations in MeCP2, the archetypical member of the methyl-CpG binding domain",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.0859375,
            "text": "Rett syndrome (RT",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.140625,
            "text": "Rett syndrome (RTT), the second most common cause of mental retardation in females, has been associated with mutations in MeCP2, the archetypical member of the methyl-CpG binding domain (MBD)",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.1640625,
            "text": "Rett syndrome (RTT), the second most common cause of mental retardation in females, has been associated with mutations in MeCP2, the archetypical member of the methyl-CpG binding domain (MB",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.1953125,
            "text": "Rett syndrome (RTT), the second most common cause of mental retardation in females, has been associated with mutations in MeCP2, the archetypical member of the methyl-CpG binding domain (MBD",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.2109375,
            "text": "Rett syndrome (RTT",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.21875,
            "text": "Rett syndrome (RTT)",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.21875,
            "text": "Rett syndrome (RTT), the second most common cause of mental retardation in females, has been associated with mutations in MeCP2, the archetypical member of the methyl-CpG binding domain (",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.2265625,
            "text": "Rett syndrome (",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.234375,
            "text": "Rett syndrome (RTT), the second most common cause of mental retardation in females, has been associated with mutations in MeCP2, the archetypical member of the methyl-CpG binding",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.265625,
            "text": "Rett syndrome (RTT), the second most common cause of mental retardation in females, has been associated with mutations in MeCP2, the archetypical member of the methyl-CpG",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.28125,
            "text": "Rett syndrome (RTT), the second",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.296875,
            "text": "Rett syndrome (RTT), the second most common cause of mental retardation in females, has been associated with mutations in MeCP2, the archetypical member of the methyl-CpG binding domain (MBD) family",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.3046875,
            "text": "Rett syndrome (RTT), the second most common cause of mental retardation in females, has been associated with mutations in MeCP2, the archetypic",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.3203125,
            "text": "Rett syndrome (RTT), the second most common cause of mental retardation in females, has been associated with mutations in MeCP2",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.328125,
            "text": "Rett syndrome (RTT), the",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_11": [
        {
            "start_logit": 9.84375,
            "end_logit": 9.3984375,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -2.23828125,
            "text": "Ret",
            "probability": 8.821487426757812e-06
        },
        {
            "start_logit": -2.587890625,
            "end_logit": 9.3984375,
            "text": "syndrome",
            "probability": 3.993511199951172e-06
        },
        {
            "start_logit": -5.94140625,
            "end_logit": 9.3984375,
            "text": "t syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.84375,
            "end_logit": -7.96875,
            "text": "Rett syndrome (RT",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.0078125,
            "text": "Rett syndrome (RTT)",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.109375,
            "text": "Rett syndrome (",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.1171875,
            "text": "Rett syndrome (RTT",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.15625,
            "text": "Rett syndrome (RTT) is a severe neurodevelopmental disease caused by mutations in methyl-CpG",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.21875,
            "text": "Rett syndrome (RTT) is a severe neurodevelopmental disease caused by mutations in methyl-CpG-binding protein 2 (MECP2",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.2265625,
            "text": "Rett syndrome (RTT) is a severe neurodevelopmental disease caused by mutations in methyl-CpG-binding",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.2265625,
            "text": "Rett syndrome (RTT) is a severe neurodevelopmental disease caused by mutations in methyl-CpG-binding protein 2 (MECP2)",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.2421875,
            "text": "Rett syndrome (RTT) is a severe neurodevelopmental disease caused by mutations in methyl-CpG-binding protein 2 (MEC",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.2421875,
            "text": "Rett syndrome (RTT) is a severe neurodevelopmental disease caused by mutations in methyl-CpG-binding protein 2",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.25,
            "text": "Rett syndrome (RTT) is",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.2578125,
            "text": "Rett syndrome (RTT) is a severe neurodevelopmental disease caused by mutations in methyl-CpG-",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.2734375,
            "text": "Rett syndrome (RTT) is a",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.28125,
            "text": "Rett syndrome (RTT) is a severe neurodevelopmental disease caused by mutations in methyl-CpG-binding protein 2 (",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.28125,
            "text": "Rett syndrome (RTT) is a severe neurodevelopmental disease caused by mutations in methyl-CpG-binding protein",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.296875,
            "text": "Rett syndrome (RTT) is a severe neurodevelopmental disease caused by mutations in methyl-CpG-binding protein 2 (MECP2), which encodes a transcriptional",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_12": [
        {
            "start_logit": 9.8984375,
            "end_logit": 9.53125,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -2.095703125,
            "text": "Ret",
            "probability": 8.881092071533203e-06
        },
        {
            "start_logit": -2.333984375,
            "end_logit": 9.53125,
            "text": "syndrome",
            "probability": 4.827976226806641e-06
        },
        {
            "start_logit": -5.71875,
            "end_logit": 9.53125,
            "text": "t syndrome",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.015625,
            "text": "Rett syndrome (RT",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.1484375,
            "text": "Rett syndrome (",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.2109375,
            "text": "Rett syndrome (RTT",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.25,
            "text": "Rett syndrome (RTT)",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.2734375,
            "text": "Rett syndrome (RTT) is caused by mutations in the transcriptional repressor methyl CpG-binding protein 2",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.2734375,
            "text": "Rett syndrome (RTT) is caused by mutations in the transcriptional repressor methyl CpG-binding protein 2 (MEC",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.28125,
            "text": "Rett syndrome (RTT) is caused by mutations in the transcriptional repressor methyl CpG-binding protein 2 (MECP2",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.2890625,
            "text": "Rett syndrome (RTT) is caused by mutations in the transcriptional repressor methyl CpG-binding",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.2890625,
            "text": "Rett syndrome (RTT) is caused by mutations in the transcriptional repressor methyl CpG-binding protein 2 (MECP2)",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.2890625,
            "text": "Rett syndrome (RTT) is caused by mutations in the transcriptional repressor methyl CpG-binding protein 2 (",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.3125,
            "text": "Rett syndrome (RTT) is caused by mutations in the transcriptional repressor methyl CpG-",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.3203125,
            "text": "Rett syndrome (RTT) is caused by mutations in the transcriptional repressor methyl CpG",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.3359375,
            "text": "Rett syndrome (RTT) is caused by mutations in the transcriptional repressor methyl CpG-binding protein",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.359375,
            "text": "Rett syndrome (RTT) is caused by mutations in the transcriptional",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.3671875,
            "text": "Rett syndrome (RTT) is",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.375,
            "text": "Rett syndrome (RTT) is caused by mutations",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_13": [
        {
            "start_logit": 9.921875,
            "end_logit": 9.484375,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -2.03515625,
            "text": "Ret",
            "probability": 9.953975677490234e-06
        },
        {
            "start_logit": -2.421875,
            "end_logit": 9.484375,
            "text": "syndrome",
            "probability": 4.351139068603516e-06
        },
        {
            "start_logit": -6.078125,
            "end_logit": 9.484375,
            "text": "t syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.48828125,
            "end_logit": 9.484375,
            "text": "disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.015625,
            "text": "Rett syndrome (",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.234375,
            "text": "Rett syndrome (RTT)",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.25,
            "text": "Rett syndrome (RT",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.3359375,
            "text": "Rett syndrome (RTT",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.484375,
            "text": "neurodevelopmental disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.484375,
            "text": "Mutations in MECP2 cause the neurodevelopmental disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.484375,
            "text": "the neurodevelopmental disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.484375,
            "text": "in MECP2 cause the neurodevelopmental disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": 9.484375,
            "text": "cause the neurodevelopmental disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.48828125,
            "end_logit": -2.03515625,
            "text": "disorder Ret",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": -2.03515625,
            "text": "neurodevelopmental disorder Ret",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -2.03515625,
            "text": "Mutations in MECP2 cause the neurodevelopmental disorder Ret",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": -2.03515625,
            "text": "the neurodevelopmental disorder Ret",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": -2.03515625,
            "text": "in MECP2 cause the neurodevelopmental disorder Ret",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": -2.03515625,
            "text": "cause the neurodevelopmental disorder Ret",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_14": [
        {
            "start_logit": 9.8828125,
            "end_logit": 9.453125,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -2.1328125,
            "text": "Ret",
            "probability": 9.238719940185547e-06
        },
        {
            "start_logit": -2.501953125,
            "end_logit": 9.453125,
            "text": "syndrome",
            "probability": 4.172325134277344e-06
        },
        {
            "start_logit": -6.078125,
            "end_logit": 9.453125,
            "text": "t syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.328125,
            "text": "Rett syndrome , an autism spectrum disorder mainly",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.40625,
            "text": "Rett syndrome ,",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": 9.453125,
            "text": "of Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.453125,
            "text": "methyl-CpG-binding protein MECP2 are the major cause of Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.453125,
            "text": "-CpG-binding protein MECP2 are the major cause of Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.453125,
            "text": "cause of Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.453125,
            "text": "encoding the methyl-CpG-binding protein MECP2 are the major cause of Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.453125,
            "text": "Mutations in the gene encoding the methyl-CpG-binding protein MECP2 are the major cause of Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.453125,
            "text": "are the major cause of Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.453125,
            "text": "gene encoding the methyl-CpG-binding protein MECP2 are the major cause of Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": -2.1328125,
            "text": "of Ret",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -2.1328125,
            "text": "methyl-CpG-binding protein MECP2 are the major cause of Ret",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -2.1328125,
            "text": "-CpG-binding protein MECP2 are the major cause of Ret",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -2.1328125,
            "text": "cause of Ret",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": -2.1328125,
            "text": "encoding the methyl-CpG-binding protein MECP2 are the major cause of Ret",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": -2.1328125,
            "text": "Mutations in the gene encoding the methyl-CpG-binding protein MECP2 are the major cause of Ret",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_15": [
        {
            "start_logit": 9.8671875,
            "end_logit": 9.46875,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -2.1875,
            "text": "Ret",
            "probability": 8.58306884765625e-06
        },
        {
            "start_logit": -2.447265625,
            "end_logit": 9.46875,
            "text": "syndrome",
            "probability": 4.470348358154297e-06
        },
        {
            "start_logit": -5.9453125,
            "end_logit": 9.46875,
            "text": "t syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.0390625,
            "text": "Rett syndrome ( RT",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.1171875,
            "text": "Rett syndrome ( RTT )",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.1640625,
            "text": "Rett syndrome ( RTT ) is a severe neurodevelopmental disorder with features of autism that results from mutation of the gene encoding the transcriptional repressor methyl-CpG",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.1640625,
            "text": "Rett syndrome ( RTT",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.1953125,
            "text": "Rett syndrome (",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.21875,
            "text": "Rett syndrome ( RTT ) is a severe neurodevelopmental disorder with features of autism that results from mutation of the gene encoding the transcriptional repressor methyl-CpG binding protein ( MECP2)",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.25,
            "text": "Rett syndrome ( RTT ) is a severe neurodevelopmental disorder with features of autism that results from mutation of the gene encoding the transcriptional repressor methyl-CpG binding protein ( MECP2",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.2578125,
            "text": "Rett syndrome ( RTT ) is a severe neurodevelopmental disorder with features of autism that results from mutation of the gene encoding the transcriptional repressor methyl-CpG binding protein ( MEC",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.265625,
            "text": "Rett syndrome ( RTT ) is a severe neurodevelopmental disorder with features of autism that results from mutation of the gene encoding the transcriptional repressor methyl-CpG binding protein",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.28125,
            "text": "Rett syndrome ( RTT ) is a severe neurodevelopmental disorder with features of autism that results from mutation of the gene encoding the transcriptional repressor methyl-CpG binding protein (",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.28125,
            "text": "Rett syndrome ( RTT ) is a severe neurodevelopmental disorder with features of autism that results from mutation of the gene encoding the transcriptional repressor methyl-CpG binding",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.3359375,
            "text": "Rett syndrome ( RTT ) is a severe neurodevelopmental disorder with features of autism that results from mutation of the",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.3515625,
            "text": "Rett syndrome ( RTT ) is",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.359375,
            "text": "Rett syndrome ( RTT ) is a severe neurodevelopmental disorder with features of autism that results from mutation of the gene encoding the transcriptional",
            "probability": 0.0
        },
        {
            "start_logit": -2.447265625,
            "end_logit": -8.0390625,
            "text": "syndrome ( RT",
            "probability": 0.0
        },
        {
            "start_logit": -2.447265625,
            "end_logit": -8.1171875,
            "text": "syndrome ( RTT )",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_16": [
        {
            "start_logit": 9.875,
            "end_logit": 9.484375,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -2.154296875,
            "text": "Ret",
            "probability": 8.821487426757812e-06
        },
        {
            "start_logit": -2.41015625,
            "end_logit": 9.484375,
            "text": "syndrome",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": -5.953125,
            "end_logit": 9.484375,
            "text": "t syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.0078125,
            "text": "Rett syndrome (",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.0703125,
            "text": "Rett syndrome (RT",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.1328125,
            "text": "Rett syndrome (RTT) is an X",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.140625,
            "text": "Rett syndrome (RTT",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.1484375,
            "text": "Rett syndrome (RTT)",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.203125,
            "text": "Rett syndrome (RTT) is an X-linked",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.234375,
            "text": "Rett syndrome (RTT) is an X-linked neurodevelopmental disorder due to mutations affecting the neural transcription factor MeCP2",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.2421875,
            "text": "Rett syndrome (RTT) is an X-linked neurodevelopmental disorder due to mutations affecting the neural transcription factor MeC",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.265625,
            "text": "Rett syndrome (RTT) is",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.2734375,
            "text": "Rett syndrome (RTT) is an X-linked neurodevelopmental disorder due to mutations affecting the neural transcription factor",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.2890625,
            "text": "Rett syndrome (RTT) is an X-linked neurodevelopmental disorder due to mutations affecting the neural transcription",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.3125,
            "text": "Rett syndrome (RTT) is an X-linked neurodevelopmental disorder due to mutations affecting the neural",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.3125,
            "text": "Rett syndrome (RTT) is an X-linked neurodevelopmental disorder due to mutations",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.3203125,
            "text": "Rett syndrome (RTT) is an X-",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.328125,
            "text": "Rett syndrome (RTT) is an X-linked neurodevelopmental disorder due to mutations affecting the",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.3359375,
            "text": "Rett syndrome (RTT) is an",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_17": [
        {
            "start_logit": 9.890625,
            "end_logit": 9.453125,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -2.103515625,
            "text": "Ret",
            "probability": 9.59634780883789e-06
        },
        {
            "start_logit": -2.474609375,
            "end_logit": 9.453125,
            "text": "syndrome",
            "probability": 4.231929779052734e-06
        },
        {
            "start_logit": -5.97265625,
            "end_logit": 9.453125,
            "text": "t syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.08203125,
            "end_logit": 9.453125,
            "text": "as Rett syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.890625,
            "end_logit": -7.91015625,
            "text": "Rett syndrome (",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -7.9296875,
            "text": "Rett syndrome (RT",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.1171875,
            "text": "Rett syndrome (RTT)",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.1875,
            "text": "Rett syndrome (RTT",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.453125,
            "text": "known as Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.453125,
            "text": "disorder known as Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.453125,
            "text": "a delayed-onset neurodevelopmental disorder known as Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.453125,
            "text": "methyl-CpG-binding-protein 2 (MeCP2) cause a delayed-onset neurodevelopmental disorder known as Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.453125,
            "text": "factor methyl-CpG-binding-protein 2 (MeCP2) cause a delayed-onset neurodevelopmental disorder known as Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 9.453125,
            "text": "neurodevelopmental disorder known as Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.453125,
            "text": "cause a delayed-onset neurodevelopmental disorder known as Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.453125,
            "text": "onset neurodevelopmental disorder known as Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.453125,
            "text": "delayed-onset neurodevelopmental disorder known as Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.453125,
            "text": "-onset neurodevelopmental disorder known as Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.453125,
            "text": "Mutations in the transcription factor methyl-CpG-binding-protein 2 (MeCP2) cause a delayed-onset neurodevelopmental disorder known as Rett syndrome",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_18": [
        {
            "start_logit": 9.8515625,
            "end_logit": 9.4375,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -2.216796875,
            "text": "Ret",
            "probability": 8.761882781982422e-06
        },
        {
            "start_logit": -2.51171875,
            "end_logit": 9.4375,
            "text": "syndrome",
            "probability": 4.291534423828125e-06
        },
        {
            "start_logit": -6.03515625,
            "end_logit": 9.4375,
            "text": "t syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -8.1875,
            "text": "Rett syndrome is",
            "probability": 0.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -8.21875,
            "text": "Rett syndrome is a neurodevelopmental disorder caused by loss-of-function mutations in the gene encoding the transcription factor methyl-CpG-binding protein 2 (",
            "probability": 0.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -8.234375,
            "text": "Rett syndrome is a neurodevelopmental disorder caused by loss-of-function mutations in the gene encoding the transcription factor methyl-CpG-binding protein 2 (MeCP2)",
            "probability": 0.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -8.234375,
            "text": "Rett syndrome is a neurodevelopmental disorder caused by loss-of-function mutations in the gene encoding the transcription factor methyl-CpG",
            "probability": 0.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -8.25,
            "text": "Rett syndrome is a neurodevelopmental disorder caused by loss-of-function mutations in the gene encoding the transcription factor methyl-CpG-binding protein 2 (MeCP2",
            "probability": 0.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -8.265625,
            "text": "Rett syndrome is a neurodevelopmental disorder caused by loss-of-function mutations in the gene encoding the transcription factor methyl-CpG-",
            "probability": 0.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -8.265625,
            "text": "Rett syndrome is a neurodevelopmental disorder caused by loss-of-function mutations in the gene encoding the transcription factor methyl-CpG-binding",
            "probability": 0.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -8.265625,
            "text": "Rett syndrome is a neurodevelopmental disorder caused by loss-of-function mutations in the gene encoding the transcription factor methyl-CpG-binding protein 2",
            "probability": 0.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -8.2734375,
            "text": "Rett syndrome is a neurodevelopmental disorder caused by loss-of-function mutations in the gene encoding the transcription factor methyl-CpG-binding protein 2 (MeC",
            "probability": 0.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -8.2734375,
            "text": "Rett syndrome is a neurodevelopmental disorder caused by loss-of-function mutations in the gene encoding the transcription factor methyl-CpG-binding protein",
            "probability": 0.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -8.28125,
            "text": "Rett syndrome is a",
            "probability": 0.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -8.2890625,
            "text": "Rett syndrome is a neurodevelopmental disorder caused by loss-of",
            "probability": 0.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -8.2890625,
            "text": "Rett syndrome is a neurodevelopmental disorder caused by loss",
            "probability": 0.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -8.3515625,
            "text": "Rett syndrome is a neurodevelopmental disorder caused by loss-of-",
            "probability": 0.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -8.3515625,
            "text": "Rett syndrome is a neurodevelopmental disorder caused by loss-of-function mutations in the gene encoding the transcription",
            "probability": 0.0
        },
        {
            "start_logit": -2.51171875,
            "end_logit": -8.1875,
            "text": "syndrome is",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_19": [
        {
            "start_logit": 9.8671875,
            "end_logit": 9.4375,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -2.19140625,
            "text": "Ret",
            "probability": 8.821487426757812e-06
        },
        {
            "start_logit": -2.51953125,
            "end_logit": 9.4375,
            "text": "syndrome",
            "probability": 4.172325134277344e-06
        },
        {
            "start_logit": -6.08984375,
            "end_logit": 9.4375,
            "text": "t syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.25,
            "text": "Rett syndrome is",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.265625,
            "text": "Rett syndrome is a mono",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.296875,
            "text": "Rett syndrome is a",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.3046875,
            "text": "Rett syndrome is a monogenic disease due to de novo mutations in either MECP2",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.3203125,
            "text": "Rett syndrome is a monogenic disease due to de",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.328125,
            "text": "Rett syndrome is a monogenic disease",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.3359375,
            "text": "Rett syndrome is a monogenic disease due to de novo mutations in either MECP2 or CDKL",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.34375,
            "text": "Rett syndrome is a monogenic disease due to de novo mutations",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.34375,
            "text": "Rett syndrome is a monogenic disease due to de novo mutations in either MECP2 or CDK",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.3515625,
            "text": "Rett syndrome is a monogenic disease due to de novo mutations in either MECP2 or CDKL5 genes",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.3515625,
            "text": "Rett syndrome is a monogenic disease due to de novo mutations in either MECP2 or CDKL5",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.3515625,
            "text": "Rett syndrome is a monogenic disease due to de novo mutations in either MEC",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.359375,
            "text": "Rett syndrome is a monogenic disease due to de novo mutations in",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.359375,
            "text": "Rett syndrome is a monogenic disease due to de novo",
            "probability": 0.0
        },
        {
            "start_logit": -2.51953125,
            "end_logit": -8.25,
            "text": "syndrome is",
            "probability": 0.0
        },
        {
            "start_logit": -2.51953125,
            "end_logit": -8.265625,
            "text": "syndrome is a mono",
            "probability": 0.0
        }
    ],
    "58b6bd2622d300530900000c_1": [
        {
            "start_logit": 10.2109375,
            "end_logit": 9.453125,
            "text": "apoE2 isoform",
            "probability": 1.0
        },
        {
            "start_logit": 10.2109375,
            "end_logit": -1.2705078125,
            "text": "apoE",
            "probability": 2.2113323211669922e-05
        },
        {
            "start_logit": -2.427734375,
            "end_logit": 9.453125,
            "text": "isoform",
            "probability": 3.2782554626464844e-06
        },
        {
            "start_logit": -6.44921875,
            "end_logit": 9.453125,
            "text": "2 isoform",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.2109375,
            "end_logit": -7.57421875,
            "text": "apoE2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1875,
            "end_logit": 9.453125,
            "text": "common apoE2 isoform",
            "probability": 0.0
        },
        {
            "start_logit": 10.2109375,
            "end_logit": -8.21875,
            "text": "apoE2 isoform is encoded by the R158",
            "probability": 0.0
        },
        {
            "start_logit": 10.2109375,
            "end_logit": -8.3125,
            "text": "apoE2 isoform is encoded by the R1",
            "probability": 0.0
        },
        {
            "start_logit": 10.2109375,
            "end_logit": -8.375,
            "text": "apoE2 isoform is",
            "probability": 0.0
        },
        {
            "start_logit": -7.9375,
            "end_logit": 9.453125,
            "text": "the common apoE2 isoform",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 9.453125,
            "text": "and the common apoE2 isoform",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.453125,
            "text": ", and the common apoE2 isoform",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.453125,
            "text": "to type III hyperlipoproteinemia, and the common apoE2 isoform",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.453125,
            "text": "relationship to type III hyperlipoproteinemia, and the common apoE2 isoform",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.453125,
            "text": "ApoE2 polymorphism is well known for its relationship to type III hyperlipoproteinemia, and the common apoE2 isoform",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.453125,
            "text": "its relationship to type III hyperlipoproteinemia, and the common apoE2 isoform",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.453125,
            "text": "type III hyperlipoproteinemia, and the common apoE2 isoform",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.453125,
            "text": "well known for its relationship to type III hyperlipoproteinemia, and the common apoE2 isoform",
            "probability": 0.0
        },
        {
            "start_logit": -7.1875,
            "end_logit": -1.2705078125,
            "text": "common apoE",
            "probability": 0.0
        },
        {
            "start_logit": -7.9375,
            "end_logit": -1.2705078125,
            "text": "the common apoE",
            "probability": 0.0
        }
    ],
    "58b6bd2622d300530900000c_2": [
        {
            "start_logit": 10.2109375,
            "end_logit": 9.453125,
            "text": "apoE2 isoform",
            "probability": 1.0
        },
        {
            "start_logit": 10.2109375,
            "end_logit": -1.2705078125,
            "text": "apoE",
            "probability": 2.2113323211669922e-05
        },
        {
            "start_logit": -2.427734375,
            "end_logit": 9.453125,
            "text": "isoform",
            "probability": 3.2782554626464844e-06
        },
        {
            "start_logit": -6.44921875,
            "end_logit": 9.453125,
            "text": "2 isoform",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.2109375,
            "end_logit": -7.57421875,
            "text": "apoE2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1875,
            "end_logit": 9.453125,
            "text": "common apoE2 isoform",
            "probability": 0.0
        },
        {
            "start_logit": 10.2109375,
            "end_logit": -8.21875,
            "text": "apoE2 isoform is encoded by the R158",
            "probability": 0.0
        },
        {
            "start_logit": 10.2109375,
            "end_logit": -8.3125,
            "text": "apoE2 isoform is encoded by the R1",
            "probability": 0.0
        },
        {
            "start_logit": 10.2109375,
            "end_logit": -8.375,
            "text": "apoE2 isoform is",
            "probability": 0.0
        },
        {
            "start_logit": -7.9375,
            "end_logit": 9.453125,
            "text": "the common apoE2 isoform",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 9.453125,
            "text": "and the common apoE2 isoform",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.453125,
            "text": ", and the common apoE2 isoform",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.453125,
            "text": "to type III hyperlipoproteinemia, and the common apoE2 isoform",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.453125,
            "text": "relationship to type III hyperlipoproteinemia, and the common apoE2 isoform",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.453125,
            "text": "ApoE2 polymorphism is well known for its relationship to type III hyperlipoproteinemia, and the common apoE2 isoform",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.453125,
            "text": "its relationship to type III hyperlipoproteinemia, and the common apoE2 isoform",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.453125,
            "text": "type III hyperlipoproteinemia, and the common apoE2 isoform",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.453125,
            "text": "well known for its relationship to type III hyperlipoproteinemia, and the common apoE2 isoform",
            "probability": 0.0
        },
        {
            "start_logit": -7.1875,
            "end_logit": -1.2705078125,
            "text": "common apoE",
            "probability": 0.0
        },
        {
            "start_logit": -7.9375,
            "end_logit": -1.2705078125,
            "text": "the common apoE",
            "probability": 0.0
        }
    ],
    "54db62a3034aea571d000001_1": [
        {
            "start_logit": 8.0390625,
            "end_logit": 8.5546875,
            "text": "SERCA",
            "probability": 1.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 8.5546875,
            "text": "sarcoplasmic reticulum (SR) calcium pump (SERCA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.09375,
            "end_logit": 8.5546875,
            "text": "(SERCA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 8.5546875,
            "text": "SR) calcium pump (SERCA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.25,
            "end_logit": 8.5546875,
            "text": ") calcium pump (SERCA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0390625,
            "end_logit": -8.21875,
            "text": "SERCA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0859375,
            "end_logit": -8.21875,
            "text": "sarcoplasmic reticulum (SR) calcium pump (SERCA)",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": -8.21875,
            "text": "(SERCA)",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": -8.2734375,
            "text": "sarcoplasmic reticulum (SR) calcium pump",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": -8.296875,
            "text": "sarcoplasmic reticulum (SR) calcium",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": -8.328125,
            "text": "sarcoplasmic reticulum",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -8.21875,
            "text": "SR) calcium pump (SERCA)",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -8.2734375,
            "text": "SR) calcium pump",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": -8.3828125,
            "text": "sarcoplasmic reticulum (SR",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -8.296875,
            "text": "SR) calcium",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -8.21875,
            "text": ") calcium pump (SERCA)",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": -8.3984375,
            "text": "sarcoplasmic reticulum (",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -8.2734375,
            "text": ") calcium pump",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -8.296875,
            "text": ") calcium",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -8.3828125,
            "text": "SR",
            "probability": 0.0
        }
    ],
    "54db62a3034aea571d000001_2": [
        {
            "start_logit": 7.7890625,
            "end_logit": 8.8203125,
            "text": "SERCA",
            "probability": 1.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 8.8203125,
            "text": "Ca(2+)-ATPase (SERCA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.234375,
            "end_logit": 8.8203125,
            "text": "2+)-ATPase (SERCA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.25,
            "end_logit": 8.8203125,
            "text": "reticulum Ca(2+)-ATPase (SERCA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.265625,
            "end_logit": 8.8203125,
            "text": "the sarco/endoplasmic reticulum Ca(2+)-ATPase (SERCA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 8.8203125,
            "text": "(2+)-ATPase (SERCA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.3125,
            "end_logit": 8.8203125,
            "text": "(SERCA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.7890625,
            "end_logit": -8.3046875,
            "text": "SERCA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": -7.640625,
            "text": "Ca(2+)-ATPase",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -7.640625,
            "text": "2+)-ATPase",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -7.640625,
            "text": "reticulum Ca(2+)-ATPase",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": -7.640625,
            "text": "the sarco/endoplasmic reticulum Ca(2+)-ATPase",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": -7.640625,
            "text": "(2+)-ATPase",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -8.1484375,
            "text": "Ca(2+)",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -8.1484375,
            "text": "2+)",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -8.1484375,
            "text": "reticulum Ca(2+)",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": -8.1484375,
            "text": "the sarco/endoplasmic reticulum Ca(2+)",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": -8.1484375,
            "text": "(2+)",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -8.3046875,
            "text": "Ca(2+)-ATPase (SERCA)",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -8.3125,
            "text": "Ca",
            "probability": 0.0
        }
    ],
    "54db62a3034aea571d000001_3": [
        {
            "start_logit": 8.21875,
            "end_logit": 8.453125,
            "text": "SERCA",
            "probability": 1.0
        },
        {
            "start_logit": 8.21875,
            "end_logit": -7.8828125,
            "text": "SERCA, an endoplasmic reticulum (ER",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.21875,
            "end_logit": -8.0703125,
            "text": "SERCA, an endoplasmic reticulum (ER) calcium pump",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.21875,
            "end_logit": -8.078125,
            "text": "SERCA, an endoplasmic reticulum (ER) calcium pump, is solely responsible for transporting cytosolic calcium into the ER",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.21875,
            "end_logit": -8.109375,
            "text": "SERCA, an endoplasmic reticulum",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.21875,
            "end_logit": -8.1171875,
            "text": "SERCA, an endoplasmic reticulum (ER) calcium pump, is solely responsible for transporting cytosolic calcium into the ER lumen",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.21875,
            "end_logit": -8.15625,
            "text": "SERCA, an endoplasmic reticulum (ER) calcium",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.21875,
            "end_logit": -8.1875,
            "text": "SERCA, an endoplasmic reticulum (ER) calcium pump, is solely responsible for transporting cytosolic calcium into",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.21875,
            "end_logit": -8.203125,
            "text": "SERCA, an endoplasmic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.21875,
            "end_logit": -8.2578125,
            "text": "SERCA, an endoplasmic reticulum (ER) calcium pump,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.21875,
            "end_logit": -8.265625,
            "text": "SERCA, an endoplasmic reticulum (ER) calcium pump, is solely",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.21875,
            "end_logit": -8.2734375,
            "text": "SERCA, an",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.21875,
            "end_logit": -8.2734375,
            "text": "SERCA, an endoplasmic reticulum (ER) calcium pump, is solely responsible",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.21875,
            "end_logit": -8.28125,
            "text": "SERCA, an endoplasmic reticulum (ER) calcium pump, is solely responsible for transporting cytosolic calcium into the ER lumen.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.21875,
            "end_logit": -8.28125,
            "text": "SERCA, an endoplasmic reticulum (ER) calcium pump, is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.21875,
            "end_logit": -8.296875,
            "text": "SERCA, an endoplasmic reticulum (ER) calcium pump, is solely responsible for transporting cytosolic calcium into the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.21875,
            "end_logit": -8.3046875,
            "text": "SERCA, an endoplasmic reticulum (ER) calcium pump, is solely responsible for transporting cytosolic calcium",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.07421875,
            "end_logit": -8.28125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -7.8828125,
            "text": ", an endoplasmic reticulum (ER",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": -7.8828125,
            "text": "endoplasmic reticulum (ER",
            "probability": 0.0
        }
    ],
    "54db62a3034aea571d000001_4": [
        {
            "start_logit": 10.1640625,
            "end_logit": 9.7734375,
            "text": "Sarcoplasmic reticulum Ca(2+)-ATPase",
            "probability": 1.0
        },
        {
            "start_logit": 10.1640625,
            "end_logit": -1.4541015625,
            "text": "Sarcoplasmic",
            "probability": 1.329183578491211e-05
        },
        {
            "start_logit": -1.6279296875,
            "end_logit": 9.7734375,
            "text": "ATPase",
            "probability": 7.569789886474609e-06
        },
        {
            "start_logit": 10.1640625,
            "end_logit": -6.171875,
            "text": "Sarcoplasmic reticulum Ca(2+)-ATPase (SERCA)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.1640625,
            "end_logit": -6.4453125,
            "text": "Sarcoplasmic reticulum Ca(2+)-ATPase (SERCA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.09375,
            "end_logit": 9.7734375,
            "text": "reticulum Ca(2+)-ATPase",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.54296875,
            "end_logit": 9.7734375,
            "text": "-ATPase",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1640625,
            "end_logit": -7.31640625,
            "text": "Sarcoplasmic reticulum Ca",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.03125,
            "end_logit": 9.7734375,
            "text": ")-ATPase",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1640625,
            "end_logit": -7.8671875,
            "text": "Sarcoplasmic reticulum Ca(2",
            "probability": 0.0
        },
        {
            "start_logit": -7.5078125,
            "end_logit": 9.7734375,
            "text": "Ca(2+)-ATPase",
            "probability": 0.0
        },
        {
            "start_logit": 10.1640625,
            "end_logit": -8.0234375,
            "text": "Sarcoplasmic reticulum Ca(2+",
            "probability": 0.0
        },
        {
            "start_logit": 10.1640625,
            "end_logit": -8.0390625,
            "text": "Sarcoplasmic reticulum Ca(2+)-ATPase (",
            "probability": 0.0
        },
        {
            "start_logit": 10.1640625,
            "end_logit": -8.0390625,
            "text": "Sarcoplasmic reticulum Ca(2+)-ATPase (SERCA) is the pump crucial for calcium homeostasis",
            "probability": 0.0
        },
        {
            "start_logit": 10.1640625,
            "end_logit": -8.0546875,
            "text": "Sarcoplasmic reticulum Ca(2+)-ATPase (SERCA) is the pump",
            "probability": 0.0
        },
        {
            "start_logit": 10.1640625,
            "end_logit": -8.0703125,
            "text": "Sarcoplasmic reticulum Ca(",
            "probability": 0.0
        },
        {
            "start_logit": 10.1640625,
            "end_logit": -8.09375,
            "text": "Sarcoplasmic reticulum",
            "probability": 0.0
        },
        {
            "start_logit": 10.1640625,
            "end_logit": -8.1796875,
            "text": "Sarcoplasmic reticulum Ca(2+)-ATPase (SERCA) is",
            "probability": 0.0
        },
        {
            "start_logit": 10.1640625,
            "end_logit": -8.1796875,
            "text": "Sarcoplasmic reticulum Ca(2+)-ATPase (SERCA) is the pump crucial",
            "probability": 0.0
        },
        {
            "start_logit": 10.1640625,
            "end_logit": -8.1953125,
            "text": "Sarcoplasmic reticulum Ca(2+)-ATPase (SERCA) is the pump crucial for calcium homeostasis and",
            "probability": 0.0
        }
    ],
    "54db62a3034aea571d000001_5": [
        {
            "start_logit": 7.9921875,
            "end_logit": 8.6796875,
            "text": "SERCA",
            "probability": 1.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 8.6796875,
            "text": "(SERCA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 8.6796875,
            "text": "in the endoplasmic reticulum by Sarco/Endoplasmic Reticulum Calcium transport ATPases (SERCA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.265625,
            "end_logit": 8.6796875,
            "text": "the endoplasmic reticulum by Sarco/Endoplasmic Reticulum Calcium transport ATPases (SERCA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.6796875,
            "text": "endoplasmic reticulum by Sarco/Endoplasmic Reticulum Calcium transport ATPases (SERCA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.328125,
            "end_logit": 8.6796875,
            "text": "accumulated in the endoplasmic reticulum by Sarco/Endoplasmic Reticulum Calcium transport ATPases (SERCA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.34375,
            "end_logit": 8.6796875,
            "text": "actively accumulated in the endoplasmic reticulum by Sarco/Endoplasmic Reticulum Calcium transport ATPases (SERCA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.34375,
            "end_logit": 8.6796875,
            "text": "ATPases (SERCA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.9921875,
            "end_logit": -8.4140625,
            "text": "SERCA enzymes",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0390625,
            "end_logit": -8.4140625,
            "text": "(SERCA enzymes",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -8.265625,
            "text": "in the endoplasmic reticulum",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": -8.265625,
            "text": "the endoplasmic reticulum",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": -8.265625,
            "text": "endoplasmic reticulum",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -8.3515625,
            "text": "in the endoplasmic reticulum by Sarco",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": -8.265625,
            "text": "accumulated in the endoplasmic reticulum",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": -8.265625,
            "text": "actively accumulated in the endoplasmic reticulum",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -8.375,
            "text": "in the endoplasmic reticulum by Sarco/Endoplasmic Reticulum Calcium",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -8.390625,
            "text": "in the endoplasmic reticulum by Sarco/Endoplasmic Reticulum",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": -8.3515625,
            "text": "the endoplasmic reticulum by Sarco",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -8.3984375,
            "text": "in the endoplasmic reticulum by Sarco/Endoplasmic Reticulum Calcium transport",
            "probability": 0.0
        }
    ],
    "54db62a3034aea571d000001_6": [
        {
            "start_logit": 7.95703125,
            "end_logit": 8.640625,
            "text": "SERCA",
            "probability": 1.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 8.640625,
            "text": "(SERCA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.171875,
            "end_logit": 8.640625,
            "text": "sarco(endo)plasmic reticulum calcium pump (SERCA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.640625,
            "text": "(endo)plasmic reticulum calcium pump (SERCA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 8.640625,
            "text": "o(endo)plasmic reticulum calcium pump (SERCA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.95703125,
            "end_logit": -8.2734375,
            "text": "SERCA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.125,
            "end_logit": -8.2734375,
            "text": "(SERCA)",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -8.2734375,
            "text": "sarco(endo)plasmic reticulum calcium pump (SERCA)",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -8.3359375,
            "text": "sarco(endo)plasmic reticulum calcium",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -8.3359375,
            "text": "sarco(endo)plasmic reticulum",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -8.3515625,
            "text": "sarco(endo)plasm",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -8.359375,
            "text": "sarco(endo)plasmic",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -8.3671875,
            "text": "sarco(endo)plasmic reticulum calcium pump",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -8.3984375,
            "text": "sarco(endo",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": -8.2734375,
            "text": "(endo)plasmic reticulum calcium pump (SERCA)",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -8.4140625,
            "text": "sarco(endo)",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": -8.2734375,
            "text": "o(endo)plasmic reticulum calcium pump (SERCA)",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": -8.3359375,
            "text": "(endo)plasmic reticulum calcium",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": -8.3359375,
            "text": "(endo)plasmic reticulum",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": -8.3515625,
            "text": "(endo)plasm",
            "probability": 0.0
        }
    ],
    "54db62a3034aea571d000001_7": [
        {
            "start_logit": 8.0234375,
            "end_logit": 8.625,
            "text": "SERCA",
            "probability": 1.0
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -8.0625,
            "text": "SERCA is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -8.171875,
            "text": "SERCA is a membrane protein that belongs to the family of P-type ion translocating ATPases and pumps free cytosolic calcium into",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -8.171875,
            "text": "SERCA is a membrane protein that belongs to the family of P",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -8.171875,
            "text": "SERCA is a membrane protein that belongs to the family of P-type ion translocating ATPases and pumps free cytosolic calcium",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -8.1796875,
            "text": "SERCA is a membrane protein that belongs to the family of P-type ion translocating ATPases and pumps free cytosolic calcium into intracellular stores",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -8.1875,
            "text": "SERCA is a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -8.1875,
            "text": "SERCA is a membrane",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -8.1953125,
            "text": "SERCA is a membrane protein that belongs to the family of P-type ion transloc",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -8.1953125,
            "text": "SERCA is a membrane protein that belongs to the family of P-type ion translocating ATPases",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -8.2265625,
            "text": "SERCA is a membrane protein that belongs to the family of P-type ion translocating",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -8.2265625,
            "text": "SERCA is a membrane protein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -8.2265625,
            "text": "SERCA is a membrane protein that belongs to the family of P-type ion translocating ATPases and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -8.2421875,
            "text": "SERCA is a membrane protein that belongs to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -8.2578125,
            "text": "SERCA is a membrane protein that belongs to the family of P-type ion translocating ATPases and pumps free cytosolic calcium into intracellular",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -8.2578125,
            "text": "SERCA is a membrane protein that belongs to the family of P-type ion",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -8.265625,
            "text": "SERCA is a membrane protein that belongs to the family",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -8.265625,
            "text": "SERCA is a membrane protein that belongs to the family of P-type",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -8.28125,
            "text": "SERCA is a membrane protein that belongs to the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.34375,
            "end_logit": -8.171875,
            "text": "free cytosolic calcium into",
            "probability": 0.0
        }
    ],
    "54db62a3034aea571d000001_8": [
        {
            "start_logit": 8.34375,
            "end_logit": 8.4375,
            "text": "SERCA",
            "probability": 1.0
        },
        {
            "start_logit": 8.34375,
            "end_logit": -8.0859375,
            "text": "SERCA genes were identified-SERCA1, SERCA2, and SERCA3. SERCA is mainly represented by the SERCA2a isoform in the heart",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.34375,
            "end_logit": -8.09375,
            "text": "SERCA genes were identified-SERCA1, SERCA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.34375,
            "end_logit": -8.1015625,
            "text": "SERCA genes were identified-SERCA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.34375,
            "end_logit": -8.109375,
            "text": "SERCA genes were identified-SERCA1, SERCA2, and SERCA3. SERCA is mainly represented by the SERCA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.34375,
            "end_logit": -8.125,
            "text": "SERCA genes were identified-SERCA1, SERCA2, and SERCA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.34375,
            "end_logit": -8.15625,
            "text": "SERCA genes were identified-SERCA1, SERCA2, and SERCA3. SERCA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.4375,
            "text": "different SERCA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.34375,
            "end_logit": -8.2109375,
            "text": "SERCA genes were identified-SERCA1, SERCA2, and SERCA3. SERCA is mainly represented by the SERCA2a isoform in the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.34375,
            "end_logit": -8.21875,
            "text": "SERCA genes were identified-SERCA1, SERCA2, and SERCA3. SERCA is mainly represented by the SERCA2a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.34375,
            "end_logit": -8.2265625,
            "text": "SERCA genes",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.34375,
            "end_logit": -8.25,
            "text": "SERCA genes were identified-SERCA1, SERCA2, and SERCA3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.34375,
            "end_logit": -8.2578125,
            "text": "SERCA genes were identified-SERCA1, SERCA2, and SERCA3. SERCA is mainly represented by the SERCA2a isoform in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.34375,
            "end_logit": -8.2578125,
            "text": "SERCA genes were identified-SERCA1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.34375,
            "end_logit": -8.2578125,
            "text": "SERCA genes were identified-SERCA1, SERCA2, and SERCA3. SERCA is mainly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.34375,
            "end_logit": -8.265625,
            "text": "SERCA genes were identified-SERCA1, SERCA2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.34375,
            "end_logit": -8.2734375,
            "text": "SERCA genes were",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.34375,
            "end_logit": -8.2734375,
            "text": "SERCA genes were identified-SERCA1, SERCA2, and SERCA3. SERCA is mainly represented by the SERCA2a isoform",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.34375,
            "end_logit": -8.2734375,
            "text": "SERCA genes were identified-SERCA1, SERCA2, and SERCA3. SERCA is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.0,
            "end_logit": -8.0859375,
            "text": ". SERCA is mainly represented by the SERCA2a isoform in the heart",
            "probability": 0.0
        }
    ],
    "54db62a3034aea571d000001_9": [
        {
            "start_logit": 8.21875,
            "end_logit": 8.5,
            "text": "SERCA",
            "probability": 1.0
        },
        {
            "start_logit": -7.71484375,
            "end_logit": 8.5,
            "text": "sarcoplasmic reticulum Ca\ufffdz ATPase (SERCA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 8.5,
            "text": "The sarcoplasmic reticulum Ca\ufffdz ATPase (SERCA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 8.5,
            "text": "(SERCA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.34375,
            "end_logit": 8.5,
            "text": "reticulum Ca\ufffdz ATPase (SERCA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.21875,
            "end_logit": -8.203125,
            "text": "SERCA) is a membrane-bound pump that utilizes ATP to drive calcium ions from the myocyte cytosol against the higher calcium concentration in the sarcoplasmic reticulum",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.21875,
            "end_logit": -8.28125,
            "text": "SERCA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.21875,
            "end_logit": -8.2890625,
            "text": "SERCA) is a membrane-bound pump that utilizes ATP to drive calcium ions",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.21875,
            "end_logit": -8.2890625,
            "text": "SERCA) is a membrane-bound pump",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.21875,
            "end_logit": -8.296875,
            "text": "SERCA) is a membrane-bound pump that utilizes ATP to drive calcium ions from the myocyte cytosol against the higher calcium",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.21875,
            "end_logit": -8.3203125,
            "text": "SERCA) is a membrane-bound pump that utilizes ATP to drive calcium ions from the myocyte cytosol against the higher calcium concentration in the sarcoplasmic reticulum.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.21875,
            "end_logit": -8.3203125,
            "text": "SERCA) is a membrane-bound pump that utilizes ATP to drive calcium ions from the myocyte cytosol against the higher calcium concentration",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.21875,
            "end_logit": -8.3359375,
            "text": "SERCA) is a membrane-bound pump that utilizes ATP to drive calcium ions from",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.21875,
            "end_logit": -8.3515625,
            "text": "SERCA) is a membrane-bound pump that utilizes ATP to drive calcium",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.21875,
            "end_logit": -8.359375,
            "text": "SERCA) is a membrane-bound pump that utilizes ATP to drive calcium ions from the myocyte cytosol against the higher",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.21875,
            "end_logit": -8.359375,
            "text": "SERCA) is a membrane-bound pump that utilizes ATP to drive calcium ions from the myocyte cytosol against the higher calcium concentration in the sarcoplasmic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.21875,
            "end_logit": -8.3671875,
            "text": "SERCA) is a membrane-bound pump that utilizes ATP to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.0703125,
            "end_logit": -8.3203125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.71484375,
            "end_logit": -8.1875,
            "text": "sarcoplasmic reticulum Ca",
            "probability": 0.0
        },
        {
            "start_logit": -7.71484375,
            "end_logit": -8.203125,
            "text": "sarcoplasmic reticulum Ca\ufffdz ATPase (SERCA) is a membrane-bound pump that utilizes ATP to drive calcium ions from the myocyte cytosol against the higher calcium concentration in the sarcoplasmic reticulum",
            "probability": 0.0
        }
    ],
    "550739cf3b8a5dc045000002_1": [
        {
            "start_logit": 10.046875,
            "end_logit": 9.65625,
            "text": "AAUAAA",
            "probability": 1.0
        },
        {
            "start_logit": 10.046875,
            "end_logit": -1.7158203125,
            "text": "AA",
            "probability": 1.150369644165039e-05
        },
        {
            "start_logit": -1.904296875,
            "end_logit": 9.65625,
            "text": "AA",
            "probability": 6.4373016357421875e-06
        },
        {
            "start_logit": -5.296875,
            "end_logit": 9.65625,
            "text": "UAAA",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 10.046875,
            "end_logit": -7.76171875,
            "text": "AAUAAA hexamer",
            "probability": 0.0
        },
        {
            "start_logit": 10.046875,
            "end_logit": -7.85546875,
            "text": "AAUAAA hexa",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 9.65625,
            "text": "canonical AAUAAA",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.65625,
            "text": "most canonical AAUAAA",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.65625,
            "text": "The most canonical AAUAAA",
            "probability": 0.0
        },
        {
            "start_logit": -1.904296875,
            "end_logit": -7.76171875,
            "text": "AA hexamer",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -1.7158203125,
            "text": "canonical AA",
            "probability": 0.0
        },
        {
            "start_logit": -1.904296875,
            "end_logit": -7.85546875,
            "text": "AA hexa",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -1.7158203125,
            "text": "most canonical AA",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -1.7158203125,
            "text": "The most canonical AA",
            "probability": 0.0
        },
        {
            "start_logit": -5.296875,
            "end_logit": -7.76171875,
            "text": "UAAA hexamer",
            "probability": 0.0
        },
        {
            "start_logit": -5.296875,
            "end_logit": -7.85546875,
            "text": "UAAA hexa",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -7.76171875,
            "text": "canonical AAUAAA hexamer",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -7.85546875,
            "text": "canonical AAUAAA hexa",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -7.76171875,
            "text": "hexamer",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -7.76171875,
            "text": "most canonical AAUAAA hexamer",
            "probability": 0.0
        }
    ],
    "550739cf3b8a5dc045000002_2": [
        {
            "start_logit": 9.9140625,
            "end_logit": 9.5234375,
            "text": "AAUAAA",
            "probability": 1.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -2.0390625,
            "text": "AA",
            "probability": 9.5367431640625e-06
        },
        {
            "start_logit": -2.248046875,
            "end_logit": 9.5234375,
            "text": "AA",
            "probability": 5.185604095458984e-06
        },
        {
            "start_logit": -5.6796875,
            "end_logit": 9.5234375,
            "text": "UAAA",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.65234375,
            "end_logit": 9.5234375,
            "text": "polyadenylation signal AAUAAA",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.5234375,
            "text": "signal AAUAAA",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.5234375,
            "text": "ylation signal AAUAAA",
            "probability": 0.0
        },
        {
            "start_logit": -7.65234375,
            "end_logit": -2.0390625,
            "text": "polyadenylation signal AA",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -2.0390625,
            "text": "signal AA",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -2.0390625,
            "text": "ylation signal AA",
            "probability": 0.0
        },
        {
            "start_logit": -7.65234375,
            "end_logit": -8.3125,
            "text": "polyadenylation signal",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -8.3125,
            "text": "signal",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -8.3125,
            "text": "ylation signal",
            "probability": 0.0
        }
    ],
    "550739cf3b8a5dc045000002_3": [
        {
            "start_logit": 9.9140625,
            "end_logit": 9.5234375,
            "text": "AAUAAA",
            "probability": 1.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -2.0390625,
            "text": "AA",
            "probability": 9.5367431640625e-06
        },
        {
            "start_logit": -2.248046875,
            "end_logit": 9.5234375,
            "text": "AA",
            "probability": 5.185604095458984e-06
        },
        {
            "start_logit": -5.6796875,
            "end_logit": 9.5234375,
            "text": "UAAA",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.65234375,
            "end_logit": 9.5234375,
            "text": "polyadenylation signal AAUAAA",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.5234375,
            "text": "signal AAUAAA",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.5234375,
            "text": "ylation signal AAUAAA",
            "probability": 0.0
        },
        {
            "start_logit": -7.65234375,
            "end_logit": -2.0390625,
            "text": "polyadenylation signal AA",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -2.0390625,
            "text": "signal AA",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -2.0390625,
            "text": "ylation signal AA",
            "probability": 0.0
        },
        {
            "start_logit": -7.65234375,
            "end_logit": -8.3125,
            "text": "polyadenylation signal",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -8.3125,
            "text": "signal",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -8.3125,
            "text": "ylation signal",
            "probability": 0.0
        }
    ],
    "550739cf3b8a5dc045000002_4": [
        {
            "start_logit": 9.9453125,
            "end_logit": 9.671875,
            "text": "AAUAAA",
            "probability": 1.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -1.9345703125,
            "text": "AA",
            "probability": 9.000301361083984e-06
        },
        {
            "start_logit": -1.9130859375,
            "end_logit": 9.671875,
            "text": "AA",
            "probability": 7.033348083496094e-06
        },
        {
            "start_logit": -5.60546875,
            "end_logit": 9.671875,
            "text": "UAAA",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 9.671875,
            "text": "A polyadenylation signal (AAUAAA",
            "probability": 0.0
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 9.671875,
            "text": "polyadenylation signal (AAUAAA",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.0390625,
            "text": "AAUAAA) nearby the 3' end of pre",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.1015625,
            "text": "AAUAAA) nearby the 3' end of pre-mRNA",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.109375,
            "text": "AAUA",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.109375,
            "text": "AAUAAA) nearby the 3",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.1171875,
            "text": "AAUAAA)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.1328125,
            "text": "AAUAAA) nearby the 3' end",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.1875,
            "text": "AAUAAA) nearby the 3'",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.1953125,
            "text": "AAUAAA) nearby the 3' end of pre-mRNA is",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.203125,
            "text": "AAUAAA) nearby the 3' end of pre-mRNA is required for poly(A) synthesis",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.203125,
            "text": "AAUAAA) nearby the 3' end of pre-mRNA is required for poly(A)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.21875,
            "text": "AAUAAA) nearby the 3' end of pre-mRNA is required for poly(A",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.2265625,
            "text": "AAUAAA) nearby the 3' end of pre-mRNA is required for poly(A) synthesis.",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.2890625,
            "text": "AAUAAA) nearby the 3' end of pre-mRNA is required",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.2890625,
            "text": "AAUAAA) nearby the 3' end of pre-",
            "probability": 0.0
        }
    ],
    "5e764647c6a8763d23000016_1": [
        {
            "start_logit": 10.0234375,
            "end_logit": 9.6328125,
            "text": "CVD 103-HgR",
            "probability": 1.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -1.7958984375,
            "text": "CVD",
            "probability": 1.0848045349121094e-05
        },
        {
            "start_logit": -2.109375,
            "end_logit": 9.6328125,
            "text": "R",
            "probability": 5.364418029785156e-06
        },
        {
            "start_logit": -6.22265625,
            "end_logit": 9.6328125,
            "text": "103-HgR",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.52734375,
            "end_logit": 9.6328125,
            "text": "-HgR",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -7.11328125,
            "text": "CVD 103-Hg",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.9609375,
            "end_logit": 9.6328125,
            "text": "HgR",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -7.9140625,
            "text": "CVD 103-HgR (Orochol, Mutachol",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.0703125,
            "text": "CVD 103-",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.1171875,
            "text": "CVD 103-HgR (Orochol, Mutachol)",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.1328125,
            "text": "CVD 103-HgR (Orochol, Mutachol), the first genetically modified organism",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.140625,
            "text": "CVD 103-HgR (Orochol",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.171875,
            "text": "CVD 103-HgR (Orochol, Mutachol), the first genetically modified organism (GM",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.203125,
            "text": "CVD 103-HgR (Orochol, Mut",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.21875,
            "text": "CVD 103-HgR (Orochol, Mutachol), the first genetically modified organism (GMO",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.2421875,
            "text": "CVD 103",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.2578125,
            "text": "CVD 103-HgR (Orochol, Mutachol), the first genetically modified organism (GMO)",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.28125,
            "text": "CVD 103-HgR (Orochol, Mutachol), the first genetically modified organism (GMO) used as vaccine, was in its time (launched 1993",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.2890625,
            "text": "CVD 103-HgR (Orochol, Mutachol), the first genetically modified organism (GMO) used as vaccine, was in its time (launched 1993, Switzerland) the ideal cholera vaccine: single-dose, protective efficacy of 80",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.2890625,
            "text": "CVD 103-HgR (Orochol, Mutachol), the first genetically modified organism (",
            "probability": 0.0
        }
    ],
    "5319a7d2b166e2b806000029_1": [
        {
            "start_logit": 10.203125,
            "end_logit": 9.578125,
            "text": "Carboxyl terminus of hsc70-interacting protein (CHIP)",
            "probability": 1.0
        },
        {
            "start_logit": 10.203125,
            "end_logit": -1.357421875,
            "text": "Carboxyl",
            "probability": 1.7762184143066406e-05
        },
        {
            "start_logit": -2.087890625,
            "end_logit": 9.578125,
            "text": ")",
            "probability": 4.589557647705078e-06
        },
        {
            "start_logit": -3.7734375,
            "end_logit": 9.578125,
            "text": "(CHIP)",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -6.36328125,
            "end_logit": 9.578125,
            "text": "terminus of hsc70-interacting protein (CHIP)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.5078125,
            "end_logit": 9.578125,
            "text": "protein (CHIP)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.55078125,
            "end_logit": 9.578125,
            "text": "interacting protein (CHIP)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.203125,
            "end_logit": -7.21875,
            "text": "Carboxyl terminus of hsc70-interacting protein (CHIP) can",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.71484375,
            "end_logit": 9.578125,
            "text": "hsc70-interacting protein (CHIP)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.73828125,
            "end_logit": 9.578125,
            "text": "of hsc70-interacting protein (CHIP)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.203125,
            "end_logit": -7.53515625,
            "text": "Carboxyl terminus of hsc70-interacting protein (CHIP) can remodel mature aryl hydrocarbon receptor (AhR) complexes and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.0,
            "end_logit": 9.578125,
            "text": "CHIP)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.203125,
            "end_logit": -7.83984375,
            "text": "Carboxyl terminus of hsc70-interacting protein (CHIP) can remodel mature aryl hydrocarbon receptor (AhR)",
            "probability": 0.0
        },
        {
            "start_logit": -7.265625,
            "end_logit": 9.578125,
            "text": "-interacting protein (CHIP)",
            "probability": 0.0
        },
        {
            "start_logit": 10.203125,
            "end_logit": -7.96875,
            "text": "Carboxyl terminus of hsc70-interacting protein (CHIP) can remodel mature aryl hydrocarbon receptor (AhR) complexes and mediate ubiquitination of both the AhR and the 90 kDa heat-shock protein (hsp90)",
            "probability": 0.0
        },
        {
            "start_logit": 10.203125,
            "end_logit": -8.0390625,
            "text": "Carboxyl terminus of hsc70-interacting protein (CHIP) can remodel mature aryl hydrocarbon",
            "probability": 0.0
        },
        {
            "start_logit": 10.203125,
            "end_logit": -8.0390625,
            "text": "Carboxyl terminus of hsc70-interacting protein (CHIP) can remodel mature aryl hydrocarbon receptor (AhR) complexes and mediate ubiquitination of both the AhR and the 90 kDa heat-shock protein (hsp90",
            "probability": 0.0
        },
        {
            "start_logit": 10.203125,
            "end_logit": -8.0625,
            "text": "Carboxyl terminus of hsc70-interacting protein (CHIP) can remodel mature aryl hydrocarbon receptor (AhR",
            "probability": 0.0
        },
        {
            "start_logit": 10.203125,
            "end_logit": -8.0703125,
            "text": "Carboxyl terminus of hsc70",
            "probability": 0.0
        },
        {
            "start_logit": 10.203125,
            "end_logit": -8.0703125,
            "text": "Carboxyl terminus of hsc70-interacting protein (CHIP) can remodel mature aryl hydrocarbon receptor",
            "probability": 0.0
        }
    ],
    "5313058de3eabad02100000e_1": [
        {
            "start_logit": 8.0,
            "end_logit": 8.6171875,
            "text": "lumbosacral",
            "probability": 1.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 8.6171875,
            "text": "in lumbosacral",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.0,
            "end_logit": -7.55078125,
            "text": "lumbosacral transitional vertebrae",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 8.6171875,
            "text": ", a form of lumbago in lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.28125,
            "end_logit": 8.6171875,
            "text": "form of lumbago in lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.6171875,
            "text": "a form of lumbago in lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 8.6171875,
            "text": "of lumbago in lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 8.6171875,
            "text": "Bertolotti's syndrome (BS), a form of lumbago in lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 8.6171875,
            "text": "lumbago in lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0,
            "end_logit": -8.1328125,
            "text": "lumbosacral transitional",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0,
            "end_logit": -8.1953125,
            "text": "lumbosacral transitional vertebrae,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.15625,
            "end_logit": -7.55078125,
            "text": "in lumbosacral transitional vertebrae",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": -7.55078125,
            "text": ", a form of lumbago in lumbosacral transitional vertebrae",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": -7.55078125,
            "text": "form of lumbago in lumbosacral transitional vertebrae",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": -7.55078125,
            "text": "a form of lumbago in lumbosacral transitional vertebrae",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": -7.55078125,
            "text": "of lumbago in lumbosacral transitional vertebrae",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": -7.55078125,
            "text": "Bertolotti's syndrome (BS), a form of lumbago in lumbosacral transitional vertebrae",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": -7.55078125,
            "text": "lumbago in lumbosacral transitional vertebrae",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": -7.55078125,
            "text": "transitional vertebrae",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": -8.1328125,
            "text": "in lumbosacral transitional",
            "probability": 0.0
        }
    ],
    "5313058de3eabad02100000e_2": [
        {
            "start_logit": 8.34375,
            "end_logit": 8.3828125,
            "text": "lumbosacral",
            "probability": 1.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 8.3828125,
            "text": "with Bertolotti's syndrome have characteristic lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 8.3828125,
            "text": "Patients with Bertolotti's syndrome have characteristic lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 8.3828125,
            "text": "Bertolotti's syndrome have characteristic lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 8.3828125,
            "text": "characteristic lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 8.3828125,
            "text": "have characteristic lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.28125,
            "end_logit": 8.3828125,
            "text": "tolotti's syndrome have characteristic lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.328125,
            "end_logit": 8.3828125,
            "text": "lotti's syndrome have characteristic lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.34375,
            "end_logit": 8.3828125,
            "text": "s syndrome have characteristic lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.34375,
            "end_logit": 8.3828125,
            "text": "syndrome have characteristic lumbosacral",
            "probability": 5.960464477539063e-08
        }
    ],
    "5313058de3eabad02100000e_3": [
        {
            "start_logit": 8.203125,
            "end_logit": 8.5078125,
            "text": "lumbosacral",
            "probability": 1.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 8.5078125,
            "text": "symptomatic unilateral lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.5078125,
            "text": "unilateral lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 8.5078125,
            "text": "for symptomatic unilateral lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 8.5078125,
            "text": "treatment for symptomatic unilateral lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.359375,
            "end_logit": 8.5078125,
            "text": "Radiofrequency sensory ablation as a treatment for symptomatic unilateral lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3671875,
            "end_logit": 8.5078125,
            "text": "a treatment for symptomatic unilateral lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.203125,
            "end_logit": -8.15625,
            "text": "lumbosacral junction pseudarticulation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.203125,
            "end_logit": -8.1796875,
            "text": "lumbosacral junction pseudartic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.203125,
            "end_logit": -8.2890625,
            "text": "lumbosacral junction pseud",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2890625,
            "end_logit": -8.15625,
            "text": "symptomatic unilateral lumbosacral junction pseudarticulation",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": -8.15625,
            "text": "unilateral lumbosacral junction pseudarticulation",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": -8.1796875,
            "text": "symptomatic unilateral lumbosacral junction pseudartic",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": -8.1796875,
            "text": "unilateral lumbosacral junction pseudartic",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": -8.15625,
            "text": "for symptomatic unilateral lumbosacral junction pseudarticulation",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": -8.1796875,
            "text": "for symptomatic unilateral lumbosacral junction pseudartic",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": -8.15625,
            "text": "treatment for symptomatic unilateral lumbosacral junction pseudarticulation",
            "probability": 0.0
        },
        {
            "start_logit": -8.3515625,
            "end_logit": -8.15625,
            "text": "junction pseudarticulation",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": -8.1796875,
            "text": "treatment for symptomatic unilateral lumbosacral junction pseudartic",
            "probability": 0.0
        },
        {
            "start_logit": -8.359375,
            "end_logit": -8.15625,
            "text": "Radiofrequency sensory ablation as a treatment for symptomatic unilateral lumbosacral junction pseudarticulation",
            "probability": 0.0
        }
    ],
    "5313058de3eabad02100000e_4": [
        {
            "start_logit": 8.1640625,
            "end_logit": 8.5390625,
            "text": "Lumbosacral",
            "probability": 1.0
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -7.98046875,
            "text": "Lumbosacral transitional vertebra",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -8.1953125,
            "text": "Lumbosacral transitional",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -8.296875,
            "text": "Lumbosacral transitional vertebra is an anatomical variation of the fifth lumbar vertebra in which an enlarged transverse process",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -8.3125,
            "text": "Lumbosacral transitional vertebra is an anatomical variation of the fifth lumbar vertebra in which an enlarged transverse process can form a joint or fusion with the sacrum or ilium. The association of that variant with low back pain and the change in the biomechanical properties",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -8.328125,
            "text": "Lumbosacral transitional vertebra is an anatomical variation of the fifth lumbar vertebra",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -8.3359375,
            "text": "Lumbosacral transitional vertebra is an anatomical variation of the fifth lumbar vertebra in which an enlarged transverse process can form a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -8.3359375,
            "text": "Lumbosacral transitional vertebra is an anatomical variation of the fifth lumbar vertebra in which an enlarged transverse process can",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -8.34375,
            "text": "Lumbosacral transitional vertebra is an anatomical variation of the fifth lumbar vertebra in which an enlarged transverse process can form",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -8.3515625,
            "text": "Lumbosacral transitional vertebra is an anatomical variation of the fifth lumbar vertebra in which an enlarged transverse",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.2421875,
            "end_logit": -8.296875,
            "text": ". The association of that variant with low back pain and the change in the biomechanical properties of the lumbar spine",
            "probability": 0.0
        },
        {
            "start_logit": -7.2421875,
            "end_logit": -8.3125,
            "text": ". The association of that variant with low back pain and the change in the biomechanical properties",
            "probability": 0.0
        },
        {
            "start_logit": -7.2421875,
            "end_logit": -8.34375,
            "text": ". The association of that variant with low back pain and the change in the biomechanical properties of the lumbar spine is called Bertolotti",
            "probability": 0.0
        },
        {
            "start_logit": -7.2421875,
            "end_logit": -8.34375,
            "text": ". The association of that variant with low back pain and the change in the biomechanical properties of the lumbar spine is called Bertolotti'",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -8.296875,
            "text": "with low back pain and the change in the biomechanical properties of the lumbar spine",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -8.3125,
            "text": "with low back pain and the change in the biomechanical properties",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -8.296875,
            "text": "change in the biomechanical properties of the lumbar spine",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -8.3125,
            "text": "change in the biomechanical properties",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -8.34375,
            "text": "with low back pain and the change in the biomechanical properties of the lumbar spine is called Bertolotti",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -8.34375,
            "text": "with low back pain and the change in the biomechanical properties of the lumbar spine is called Bertolotti'",
            "probability": 0.0
        }
    ],
    "5313058de3eabad02100000e_5": [
        {
            "start_logit": 8.078125,
            "end_logit": 8.59375,
            "text": "lumbosacral",
            "probability": 1.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 8.59375,
            "text": "Transitional lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.078125,
            "end_logit": -8.2890625,
            "text": "lumbosacral vertebrae",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.28125,
            "end_logit": -8.2890625,
            "text": "Transitional lumbosacral vertebrae",
            "probability": 0.0
        }
    ],
    "5313058de3eabad02100000e_6": [
        {
            "start_logit": 8.2109375,
            "end_logit": 8.484375,
            "text": "lumbosacral",
            "probability": 1.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 8.484375,
            "text": "of surgically treated mechanical low back pain from the facet joint contralateral to a unilateral anomalous lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 8.484375,
            "text": "Case report of surgically treated mechanical low back pain from the facet joint contralateral to a unilateral anomalous lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.484375,
            "text": "to a unilateral anomalous lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.484375,
            "text": "low back pain from the facet joint contralateral to a unilateral anomalous lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.484375,
            "text": "a unilateral anomalous lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3125,
            "end_logit": 8.484375,
            "text": "the facet joint contralateral to a unilateral anomalous lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3125,
            "end_logit": 8.484375,
            "text": "back pain from the facet joint contralateral to a unilateral anomalous lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.328125,
            "end_logit": 8.484375,
            "text": "anomalous lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 8.484375,
            "text": "surgically treated mechanical low back pain from the facet joint contralateral to a unilateral anomalous lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 8.484375,
            "text": "facet joint contralateral to a unilateral anomalous lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 8.484375,
            "text": "unilateral anomalous lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.34375,
            "end_logit": 8.484375,
            "text": "from the facet joint contralateral to a unilateral anomalous lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 8.484375,
            "text": "mechanical low back pain from the facet joint contralateral to a unilateral anomalous lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 8.484375,
            "text": "report of surgically treated mechanical low back pain from the facet joint contralateral to a unilateral anomalous lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.2109375,
            "end_logit": -8.296875,
            "text": "lumbosacral articulation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": -8.296875,
            "text": "of surgically treated mechanical low back pain from the facet joint contralateral to a unilateral anomalous lumbosacral articulation",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": -8.296875,
            "text": "Case report of surgically treated mechanical low back pain from the facet joint contralateral to a unilateral anomalous lumbosacral articulation",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": -8.296875,
            "text": "to a unilateral anomalous lumbosacral articulation",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": -8.296875,
            "text": "low back pain from the facet joint contralateral to a unilateral anomalous lumbosacral articulation",
            "probability": 0.0
        }
    ],
    "5313058de3eabad02100000e_7": [
        {
            "start_logit": 8.0859375,
            "end_logit": 8.59375,
            "text": "lumbosacral",
            "probability": 1.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 8.59375,
            "text": "-S1 facet joint contralateral to an anomalous lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 8.59375,
            "text": "symptomatic L6-S1 facet joint contralateral to an anomalous lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 8.59375,
            "text": "to an anomalous lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 8.59375,
            "text": "Repeated fluoroscopically guided injections implicated a symptomatic L6-S1 facet joint contralateral to an anomalous lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.34375,
            "end_logit": 8.59375,
            "text": "an anomalous lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 8.59375,
            "text": "a symptomatic L6-S1 facet joint contralateral to an anomalous lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3671875,
            "end_logit": 8.59375,
            "text": "anomalous lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.375,
            "end_logit": 8.59375,
            "text": "S1 facet joint contralateral to an anomalous lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3828125,
            "end_logit": 8.59375,
            "text": "facet joint contralateral to an anomalous lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0859375,
            "end_logit": -8.171875,
            "text": "lumbosacral articulation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.234375,
            "end_logit": -8.171875,
            "text": "-S1 facet joint contralateral to an anomalous lumbosacral articulation",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": -8.171875,
            "text": "symptomatic L6-S1 facet joint contralateral to an anomalous lumbosacral articulation",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": -8.171875,
            "text": "to an anomalous lumbosacral articulation",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": -8.171875,
            "text": "Repeated fluoroscopically guided injections implicated a symptomatic L6-S1 facet joint contralateral to an anomalous lumbosacral articulation",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -8.25,
            "text": "-S1 facet joint",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": -8.25,
            "text": "symptomatic L6-S1 facet joint",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": -8.171875,
            "text": "an anomalous lumbosacral articulation",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": -8.25,
            "text": "Repeated fluoroscopically guided injections implicated a symptomatic L6-S1 facet joint",
            "probability": 0.0
        },
        {
            "start_logit": -8.3515625,
            "end_logit": -8.171875,
            "text": "a symptomatic L6-S1 facet joint contralateral to an anomalous lumbosacral articulation",
            "probability": 0.0
        }
    ],
    "5313058de3eabad02100000e_8": [
        {
            "start_logit": 8.234375,
            "end_logit": 8.453125,
            "text": "lumbosacral",
            "probability": 1.0
        },
        {
            "start_logit": -7.90625,
            "end_logit": 8.453125,
            "text": "with lumbosacral",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.1875,
            "end_logit": 8.453125,
            "text": "Bertolotti's syndrome refers to the association of back pain with lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 8.453125,
            "text": "back pain with lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.234375,
            "end_logit": -8.0234375,
            "text": "lumbosacral transitional vertebrae",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": 8.453125,
            "text": "association of back pain with lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": 8.453125,
            "text": "of back pain with lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.453125,
            "text": "tolotti's syndrome refers to the association of back pain with lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 8.453125,
            "text": "pain with lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 8.453125,
            "text": "the association of back pain with lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.328125,
            "end_logit": 8.453125,
            "text": "lotti's syndrome refers to the association of back pain with lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.328125,
            "end_logit": 8.453125,
            "text": "refers to the association of back pain with lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 8.453125,
            "text": "ti's syndrome refers to the association of back pain with lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.34375,
            "end_logit": 8.453125,
            "text": "to the association of back pain with lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 8.453125,
            "text": "syndrome refers to the association of back pain with lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3671875,
            "end_logit": 8.453125,
            "text": "'s syndrome refers to the association of back pain with lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.375,
            "end_logit": 8.453125,
            "text": "s syndrome refers to the association of back pain with lumbosacral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.234375,
            "end_logit": -8.2578125,
            "text": "lumbosacral transitional",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.90625,
            "end_logit": -8.0234375,
            "text": "with lumbosacral transitional vertebrae",
            "probability": 0.0
        },
        {
            "start_logit": -7.90625,
            "end_logit": -8.2578125,
            "text": "with lumbosacral transitional",
            "probability": 0.0
        }
    ],
    "554140ad182542114d000003_1": [
        {
            "start_logit": 10.03125,
            "end_logit": 9.6171875,
            "text": "mpMoRFsDB",
            "probability": 1.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -1.806640625,
            "text": "mpM",
            "probability": 1.0848045349121094e-05
        },
        {
            "start_logit": -2.146484375,
            "end_logit": 9.6171875,
            "text": "DB",
            "probability": 5.066394805908203e-06
        },
        {
            "start_logit": -5.4453125,
            "end_logit": 9.6171875,
            "text": "oRFsDB",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.19140625,
            "end_logit": 9.6171875,
            "text": "FsDB",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.03125,
            "end_logit": -7.73828125,
            "text": "mpMoRFs",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.3203125,
            "text": "mpMoRFsDB: a database of molecular recognition features in membrane proteins",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.34375,
            "text": "mpMoRFsDB: a database of molecular recognition features in membrane",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.359375,
            "text": "mpMoRFsDB: a database of molecular recognition features",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.3671875,
            "text": "mpMoRFsDB:",
            "probability": 0.0
        },
        {
            "start_logit": -2.146484375,
            "end_logit": -8.3203125,
            "text": "DB: a database of molecular recognition features in membrane proteins",
            "probability": 0.0
        },
        {
            "start_logit": -2.146484375,
            "end_logit": -8.34375,
            "text": "DB: a database of molecular recognition features in membrane",
            "probability": 0.0
        },
        {
            "start_logit": -2.146484375,
            "end_logit": -8.359375,
            "text": "DB: a database of molecular recognition features",
            "probability": 0.0
        },
        {
            "start_logit": -2.146484375,
            "end_logit": -8.3671875,
            "text": "DB:",
            "probability": 0.0
        },
        {
            "start_logit": -5.4453125,
            "end_logit": -7.73828125,
            "text": "oRFs",
            "probability": 0.0
        },
        {
            "start_logit": -5.4453125,
            "end_logit": -8.3203125,
            "text": "oRFsDB: a database of molecular recognition features in membrane proteins",
            "probability": 0.0
        },
        {
            "start_logit": -5.4453125,
            "end_logit": -8.34375,
            "text": "oRFsDB: a database of molecular recognition features in membrane",
            "probability": 0.0
        },
        {
            "start_logit": -5.4453125,
            "end_logit": -8.359375,
            "text": "oRFsDB: a database of molecular recognition features",
            "probability": 0.0
        },
        {
            "start_logit": -5.4453125,
            "end_logit": -8.3671875,
            "text": "oRFsDB:",
            "probability": 0.0
        },
        {
            "start_logit": -6.19140625,
            "end_logit": -7.73828125,
            "text": "Fs",
            "probability": 0.0
        }
    ],
    "554140ad182542114d000003_2": [
        {
            "start_logit": 10.0078125,
            "end_logit": 9.6484375,
            "text": "mpMoRFsDB",
            "probability": 1.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -1.865234375,
            "text": "mpM",
            "probability": 9.953975677490234e-06
        },
        {
            "start_logit": -2.087890625,
            "end_logit": 9.6484375,
            "text": "DB",
            "probability": 5.602836608886719e-06
        },
        {
            "start_logit": -5.59375,
            "end_logit": 9.6484375,
            "text": "oRFsDB",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.2578125,
            "end_logit": 9.6484375,
            "text": "FsDB",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -7.7578125,
            "text": "mpMoRFs",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -7.9140625,
            "text": "mpMoRFsDB provides valuable information related to disorder",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.140625,
            "text": "mpMoRFsDB provides valuable information related to disorder-based protein-protein interactions",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.1953125,
            "text": "mpMoRFsDB provides valuable information related to disorder-based protein-protein",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.2734375,
            "text": "mpMoRFsDB provides valuable information related to disorder-based protein-protein interactions in membrane",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.28125,
            "text": "mpMoRFsDB provides valuable information related to disorder-based protein-",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.3046875,
            "text": "mpMoRFsDB provides valuable",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.3125,
            "text": "mpMoRFsDB provides valuable information related to disorder-",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.359375,
            "text": "mpMoRFsDB provides valuable information related to disorder-based protein-protein interactions in",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.359375,
            "text": "mpMoRFsDB provides valuable information related to disorder-based protein",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.3671875,
            "text": "mpMoRFsDB provides",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.3671875,
            "text": "mpMoRFsDB provides valuable information related to disorder-based protein-protein interactions in membrane proteins",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.3828125,
            "text": "mpMoRFsDB provides valuable information related to disorder-based",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.3828125,
            "text": "mpMoRFsDB provides valuable information related",
            "probability": 0.0
        },
        {
            "start_logit": -2.087890625,
            "end_logit": -7.9140625,
            "text": "DB provides valuable information related to disorder",
            "probability": 0.0
        }
    ],
    "554140ad182542114d000003_3": [
        {
            "start_logit": 10.0859375,
            "end_logit": 9.6484375,
            "text": "mpMoRFsDB",
            "probability": 1.0
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -1.6591796875,
            "text": "mpM",
            "probability": 1.233816146850586e-05
        },
        {
            "start_logit": -2.068359375,
            "end_logit": 9.6484375,
            "text": "DB",
            "probability": 5.245208740234375e-06
        },
        {
            "start_logit": -5.328125,
            "end_logit": 9.6484375,
            "text": "oRFsDB",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.0859375,
            "end_logit": 9.6484375,
            "text": "FsDB",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -7.68359375,
            "text": "mpMoRFs",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -8.265625,
            "text": "mpMoRFsDB: a database of molecular recognition features in membrane proteins",
            "probability": 0.0
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -8.328125,
            "text": "mpMoRFsDB: a database of molecular recognition features",
            "probability": 0.0
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -8.3359375,
            "text": "mpMoRFsDB:",
            "probability": 0.0
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -8.34375,
            "text": "mpMoRFsDB: a database of molecular recognition features in membrane",
            "probability": 0.0
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -8.34375,
            "text": "mpMoRFsDB: a database",
            "probability": 0.0
        },
        {
            "start_logit": -2.068359375,
            "end_logit": -8.265625,
            "text": "DB: a database of molecular recognition features in membrane proteins",
            "probability": 0.0
        },
        {
            "start_logit": -2.068359375,
            "end_logit": -8.328125,
            "text": "DB: a database of molecular recognition features",
            "probability": 0.0
        },
        {
            "start_logit": -2.068359375,
            "end_logit": -8.3359375,
            "text": "DB:",
            "probability": 0.0
        },
        {
            "start_logit": -2.068359375,
            "end_logit": -8.34375,
            "text": "DB: a database of molecular recognition features in membrane",
            "probability": 0.0
        },
        {
            "start_logit": -2.068359375,
            "end_logit": -8.34375,
            "text": "DB: a database",
            "probability": 0.0
        },
        {
            "start_logit": -5.328125,
            "end_logit": -7.68359375,
            "text": "oRFs",
            "probability": 0.0
        },
        {
            "start_logit": -5.328125,
            "end_logit": -8.265625,
            "text": "oRFsDB: a database of molecular recognition features in membrane proteins",
            "probability": 0.0
        },
        {
            "start_logit": -5.328125,
            "end_logit": -8.328125,
            "text": "oRFsDB: a database of molecular recognition features",
            "probability": 0.0
        },
        {
            "start_logit": -5.328125,
            "end_logit": -8.3359375,
            "text": "oRFsDB:",
            "probability": 0.0
        }
    ],
    "5c632542e842deac6700000d_1": [
        {
            "start_logit": 9.671875,
            "end_logit": 9.6015625,
            "text": "magnetic resonance imaging",
            "probability": 1.0
        },
        {
            "start_logit": -2.05859375,
            "end_logit": 9.6015625,
            "text": "imaging",
            "probability": 7.987022399902344e-06
        },
        {
            "start_logit": 9.671875,
            "end_logit": -2.521484375,
            "text": "magnetic",
            "probability": 5.364418029785156e-06
        },
        {
            "start_logit": -3.865234375,
            "end_logit": 9.6015625,
            "text": "of magnetic resonance imaging",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": -6.3515625,
            "end_logit": 9.6015625,
            "text": "resonance imaging",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.7421875,
            "end_logit": 9.6015625,
            "text": "novel approach of magnetic resonance imaging",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.8046875,
            "end_logit": 9.6015625,
            "text": ". Here, we report a patient with CVG-ID that was diagnosed using the novel approach of magnetic resonance imaging",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.55859375,
            "end_logit": 9.6015625,
            "text": "approach of magnetic resonance imaging",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.65234375,
            "end_logit": 9.6015625,
            "text": "the novel approach of magnetic resonance imaging",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.671875,
            "end_logit": -7.90625,
            "text": "magnetic resonance",
            "probability": 0.0
        },
        {
            "start_logit": -7.8828125,
            "end_logit": 9.6015625,
            "text": "using the novel approach of magnetic resonance imaging",
            "probability": 0.0
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 9.6015625,
            "text": "a patient with CVG-ID that was diagnosed using the novel approach of magnetic resonance imaging",
            "probability": 0.0
        },
        {
            "start_logit": 9.671875,
            "end_logit": -7.98828125,
            "text": "magnetic resonance imaging and",
            "probability": 0.0
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 9.6015625,
            "text": "with CVG-ID that was diagnosed using the novel approach of magnetic resonance imaging",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 9.6015625,
            "text": "patient with CVG-ID that was diagnosed using the novel approach of magnetic resonance imaging",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 9.6015625,
            "text": "diagnosed using the novel approach of magnetic resonance imaging",
            "probability": 0.0
        },
        {
            "start_logit": 9.671875,
            "end_logit": -8.125,
            "text": "magnetic resonance imaging and we conduct a systematic review of all patients reported in the last 60 years, discussing the core clinical features of this syndrome.",
            "probability": 0.0
        },
        {
            "start_logit": 9.671875,
            "end_logit": -8.1953125,
            "text": "magnetic resonance imaging and we conduct a systematic review of all patients reported in the last 60",
            "probability": 0.0
        },
        {
            "start_logit": 9.671875,
            "end_logit": -8.2109375,
            "text": "magnetic resonance imaging and we conduct a systematic review of all patients reported in the last",
            "probability": 0.0
        },
        {
            "start_logit": -3.865234375,
            "end_logit": -2.521484375,
            "text": "of magnetic",
            "probability": 0.0
        }
    ],
    "5c632542e842deac6700000d_2": [
        {
            "start_logit": 9.6484375,
            "end_logit": 9.640625,
            "text": "magnetic resonance imaging",
            "probability": 1.0
        },
        {
            "start_logit": -2.01171875,
            "end_logit": 9.640625,
            "text": "imaging",
            "probability": 8.64267349243164e-06
        },
        {
            "start_logit": 9.6484375,
            "end_logit": -2.607421875,
            "text": "magnetic",
            "probability": 4.827976226806641e-06
        },
        {
            "start_logit": -4.53515625,
            "end_logit": 9.640625,
            "text": "of magnetic resonance imaging",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -6.6875,
            "end_logit": 9.640625,
            "text": "resonance imaging",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.78515625,
            "end_logit": 9.640625,
            "text": "novel approach of magnetic resonance imaging",
            "probability": 0.0
        },
        {
            "start_logit": 9.6484375,
            "end_logit": -7.8359375,
            "text": "magnetic resonance",
            "probability": 0.0
        },
        {
            "start_logit": -8.0,
            "end_logit": 9.640625,
            "text": "the novel approach of magnetic resonance imaging",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": 9.640625,
            "text": "a patient with CVG-ID that was diagnosed using the novel approach of magnetic resonance imaging",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.640625,
            "text": "using the novel approach of magnetic resonance imaging",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 9.640625,
            "text": "Here, we report a patient with CVG-ID that was diagnosed using the novel approach of magnetic resonance imaging",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.640625,
            "text": "approach of magnetic resonance imaging",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": 9.640625,
            "text": "we report a patient with CVG-ID that was diagnosed using the novel approach of magnetic resonance imaging",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 9.640625,
            "text": "patient with CVG-ID that was diagnosed using the novel approach of magnetic resonance imaging",
            "probability": 0.0
        },
        {
            "start_logit": 9.6484375,
            "end_logit": -8.1875,
            "text": "magnetic resonance imaging and",
            "probability": 0.0
        },
        {
            "start_logit": 9.6484375,
            "end_logit": -8.2734375,
            "text": "magnetic resonance imaging and we conduct a systematic review of all patients reported in the last 60",
            "probability": 0.0
        },
        {
            "start_logit": 9.6484375,
            "end_logit": -8.3359375,
            "text": "magnetic resonance imaging and we conduct a systematic review of all patients reported in the last",
            "probability": 0.0
        },
        {
            "start_logit": -4.53515625,
            "end_logit": -2.607421875,
            "text": "of magnetic",
            "probability": 0.0
        },
        {
            "start_logit": -2.01171875,
            "end_logit": -8.1875,
            "text": "imaging and",
            "probability": 0.0
        },
        {
            "start_logit": -2.01171875,
            "end_logit": -8.2734375,
            "text": "imaging and we conduct a systematic review of all patients reported in the last 60",
            "probability": 0.0
        }
    ],
    "587e3129c32c812009000002_1": [
        {
            "start_logit": 9.875,
            "end_logit": 9.390625,
            "text": "traseR",
            "probability": 1.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -2.185546875,
            "text": "tra",
            "probability": 9.357929229736328e-06
        },
        {
            "start_logit": -2.6171875,
            "end_logit": 9.390625,
            "text": "R",
            "probability": 3.7550926208496094e-06
        },
        {
            "start_logit": -6.12109375,
            "end_logit": 9.390625,
            "text": "seR",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.3046875,
            "text": "traseR: an R package",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.328125,
            "text": "traseR: an R package for performing trait-associated SNP enrichment analysis in genomic intervals",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.328125,
            "text": "trase",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.3828125,
            "text": "traseR: an R",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.4140625,
            "text": "traseR: an",
            "probability": 0.0
        },
        {
            "start_logit": -2.6171875,
            "end_logit": -8.3046875,
            "text": "R: an R package",
            "probability": 0.0
        },
        {
            "start_logit": -2.6171875,
            "end_logit": -8.328125,
            "text": "R: an R package for performing trait-associated SNP enrichment analysis in genomic intervals",
            "probability": 0.0
        },
        {
            "start_logit": -2.6171875,
            "end_logit": -8.3828125,
            "text": "R: an R",
            "probability": 0.0
        },
        {
            "start_logit": -2.6171875,
            "end_logit": -8.4140625,
            "text": "R: an",
            "probability": 0.0
        },
        {
            "start_logit": -6.12109375,
            "end_logit": -8.3046875,
            "text": "seR: an R package",
            "probability": 0.0
        },
        {
            "start_logit": -6.12109375,
            "end_logit": -8.328125,
            "text": "seR: an R package for performing trait-associated SNP enrichment analysis in genomic intervals",
            "probability": 0.0
        },
        {
            "start_logit": -6.12109375,
            "end_logit": -8.328125,
            "text": "se",
            "probability": 0.0
        },
        {
            "start_logit": -6.12109375,
            "end_logit": -8.3828125,
            "text": "seR: an R",
            "probability": 0.0
        },
        {
            "start_logit": -6.12109375,
            "end_logit": -8.4140625,
            "text": "seR: an",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": -8.328125,
            "text": "genomic intervals",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -8.328125,
            "text": "in genomic intervals",
            "probability": 0.0
        }
    ],
    "587e3129c32c812009000002_2": [
        {
            "start_logit": 9.796875,
            "end_logit": 9.2890625,
            "text": "traseR",
            "probability": 1.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -2.341796875,
            "text": "tra",
            "probability": 8.821487426757812e-06
        },
        {
            "start_logit": -2.8046875,
            "end_logit": 9.2890625,
            "text": "R",
            "probability": 3.337860107421875e-06
        },
        {
            "start_logit": -6.25,
            "end_logit": 9.2890625,
            "text": "seR",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.59765625,
            "end_logit": 9.2890625,
            "text": "present traseR",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.1171875,
            "text": "traseR, an easy-to-use R Bioconductor package",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.25,
            "text": "traseR, an easy-to-use R Bioconductor",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.2734375,
            "text": "trase",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.3359375,
            "text": "traseR, an easy-to-use R Bioc",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.3515625,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals with flexible options, including testing method, type of background and inclusion of SNPs in LD",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.3671875,
            "text": "traseR, an easy-to-use R Bioconduc",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.390625,
            "text": "traseR, an easy-to-use R",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.390625,
            "text": "traseR, an",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.40625,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.4375,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals with",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.4453125,
            "text": "traseR, an easy-to-use R Bioconductor package that",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.4453125,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals with flexible options, including testing method, type of background and inclusion of SNPs in",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.2890625,
            "text": "we present traseR",
            "probability": 0.0
        },
        {
            "start_logit": -7.59765625,
            "end_logit": -2.341796875,
            "text": "present tra",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": -2.341796875,
            "text": "we present tra",
            "probability": 0.0
        }
    ],
    "587e3129c32c812009000002_3": [
        {
            "start_logit": 9.828125,
            "end_logit": 9.375,
            "text": "traseR",
            "probability": 1.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -2.26953125,
            "text": "tra",
            "probability": 8.821487426757812e-06
        },
        {
            "start_logit": -2.6328125,
            "end_logit": 9.375,
            "text": "R",
            "probability": 3.874301910400391e-06
        },
        {
            "start_logit": -6.140625,
            "end_logit": 9.375,
            "text": "seR",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.5078125,
            "end_logit": 9.375,
            "text": "present traseR",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.203125,
            "text": "traseR, an easy-to-use R Bioconductor package",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.25,
            "text": "traseR, an easy-to-use R Bioconductor",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.25,
            "text": "trase",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.296875,
            "text": "traseR, an easy-to-use R Bioc",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.3359375,
            "text": "traseR, an easy-to-use R Bioconduc",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.34375,
            "text": "traseR, an easy-to-use R",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.3671875,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals with flexible options, including testing method, type of background and inclusion of SNPs in LD",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.3671875,
            "text": "traseR, an",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.390625,
            "text": "traseR, an easy-to",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.40625,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals with",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.4140625,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.4140625,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.421875,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals with flexible options, including testing method, type of background and inclusion of SNPs in",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 9.375,
            "text": "we present traseR",
            "probability": 0.0
        },
        {
            "start_logit": -7.5078125,
            "end_logit": -2.26953125,
            "text": "present tra",
            "probability": 0.0
        }
    ],
    "587e3129c32c812009000002_4": [
        {
            "start_logit": 9.8671875,
            "end_logit": 9.3828125,
            "text": "traseR",
            "probability": 1.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -2.181640625,
            "text": "tra",
            "probability": 9.5367431640625e-06
        },
        {
            "start_logit": -2.619140625,
            "end_logit": 9.3828125,
            "text": "R",
            "probability": 3.814697265625e-06
        },
        {
            "start_logit": -6.10546875,
            "end_logit": 9.3828125,
            "text": "seR",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.93359375,
            "text": "traseR, an easy-to-use R Bioconductor package",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.546875,
            "end_logit": 9.3828125,
            "text": "present traseR",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.1796875,
            "text": "traseR, an easy-to-use R Bioconductor",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.25,
            "text": "trase",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.25,
            "text": "traseR, an easy-to-use R Bioc",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.296875,
            "text": "traseR, an easy-to-use R Bioconduc",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.3125,
            "text": "traseR, an",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.3125,
            "text": "traseR, an easy-to-use R",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.359375,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.390625,
            "text": "traseR, an easy-to",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.390625,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals with",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.3984375,
            "text": "traseR, an easy-to-use R Bioconductor package that",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.3828125,
            "text": "we present traseR",
            "probability": 0.0
        },
        {
            "start_logit": -7.546875,
            "end_logit": -2.181640625,
            "text": "present tra",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": -2.181640625,
            "text": "we present tra",
            "probability": 0.0
        },
        {
            "start_logit": -2.619140625,
            "end_logit": -7.93359375,
            "text": "R, an easy-to-use R Bioconductor package",
            "probability": 0.0
        }
    ],
    "587e3129c32c812009000002_5": [
        {
            "start_logit": 9.9375,
            "end_logit": 9.4375,
            "text": "traseR",
            "probability": 1.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -2.033203125,
            "text": "tra",
            "probability": 1.043081283569336e-05
        },
        {
            "start_logit": -2.513671875,
            "end_logit": 9.4375,
            "text": "R",
            "probability": 3.933906555175781e-06
        },
        {
            "start_logit": -5.96484375,
            "end_logit": 9.4375,
            "text": "seR",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.21875,
            "text": "traseR: an R package",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.2734375,
            "text": "traseR: an R package for performing trait-associated SNP enrichment analysis in genomic intervals",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.296875,
            "text": "trase",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.3046875,
            "text": "traseR: an R",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.3515625,
            "text": "traseR: an",
            "probability": 0.0
        },
        {
            "start_logit": -2.513671875,
            "end_logit": -8.21875,
            "text": "R: an R package",
            "probability": 0.0
        },
        {
            "start_logit": -2.513671875,
            "end_logit": -8.2734375,
            "text": "R: an R package for performing trait-associated SNP enrichment analysis in genomic intervals",
            "probability": 0.0
        },
        {
            "start_logit": -2.513671875,
            "end_logit": -8.3046875,
            "text": "R: an R",
            "probability": 0.0
        },
        {
            "start_logit": -2.513671875,
            "end_logit": -8.3515625,
            "text": "R: an",
            "probability": 0.0
        },
        {
            "start_logit": -5.96484375,
            "end_logit": -8.21875,
            "text": "seR: an R package",
            "probability": 0.0
        },
        {
            "start_logit": -5.96484375,
            "end_logit": -8.2734375,
            "text": "seR: an R package for performing trait-associated SNP enrichment analysis in genomic intervals",
            "probability": 0.0
        },
        {
            "start_logit": -5.96484375,
            "end_logit": -8.296875,
            "text": "se",
            "probability": 0.0
        },
        {
            "start_logit": -5.96484375,
            "end_logit": -8.3046875,
            "text": "seR: an R",
            "probability": 0.0
        },
        {
            "start_logit": -5.96484375,
            "end_logit": -8.3515625,
            "text": "seR: an",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -8.2734375,
            "text": "performing trait-associated SNP enrichment analysis in genomic intervals",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.2734375,
            "text": "genomic intervals",
            "probability": 0.0
        }
    ],
    "587e3129c32c812009000002_6": [
        {
            "start_logit": 9.9375,
            "end_logit": 9.4375,
            "text": "traseR",
            "probability": 1.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -2.033203125,
            "text": "tra",
            "probability": 1.043081283569336e-05
        },
        {
            "start_logit": -2.513671875,
            "end_logit": 9.4375,
            "text": "R",
            "probability": 3.933906555175781e-06
        },
        {
            "start_logit": -5.96484375,
            "end_logit": 9.4375,
            "text": "seR",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.21875,
            "text": "traseR: an R package",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.2734375,
            "text": "traseR: an R package for performing trait-associated SNP enrichment analysis in genomic intervals",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.296875,
            "text": "trase",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.3046875,
            "text": "traseR: an R",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.3515625,
            "text": "traseR: an",
            "probability": 0.0
        },
        {
            "start_logit": -2.513671875,
            "end_logit": -8.21875,
            "text": "R: an R package",
            "probability": 0.0
        },
        {
            "start_logit": -2.513671875,
            "end_logit": -8.2734375,
            "text": "R: an R package for performing trait-associated SNP enrichment analysis in genomic intervals",
            "probability": 0.0
        },
        {
            "start_logit": -2.513671875,
            "end_logit": -8.3046875,
            "text": "R: an R",
            "probability": 0.0
        },
        {
            "start_logit": -2.513671875,
            "end_logit": -8.3515625,
            "text": "R: an",
            "probability": 0.0
        },
        {
            "start_logit": -5.96484375,
            "end_logit": -8.21875,
            "text": "seR: an R package",
            "probability": 0.0
        },
        {
            "start_logit": -5.96484375,
            "end_logit": -8.2734375,
            "text": "seR: an R package for performing trait-associated SNP enrichment analysis in genomic intervals",
            "probability": 0.0
        },
        {
            "start_logit": -5.96484375,
            "end_logit": -8.296875,
            "text": "se",
            "probability": 0.0
        },
        {
            "start_logit": -5.96484375,
            "end_logit": -8.3046875,
            "text": "seR: an R",
            "probability": 0.0
        },
        {
            "start_logit": -5.96484375,
            "end_logit": -8.3515625,
            "text": "seR: an",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -8.2734375,
            "text": "performing trait-associated SNP enrichment analysis in genomic intervals",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.2734375,
            "text": "genomic intervals",
            "probability": 0.0
        }
    ],
    "587e3129c32c812009000002_7": [
        {
            "start_logit": 9.8671875,
            "end_logit": 9.3828125,
            "text": "traseR",
            "probability": 1.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -2.181640625,
            "text": "tra",
            "probability": 9.5367431640625e-06
        },
        {
            "start_logit": -2.619140625,
            "end_logit": 9.3828125,
            "text": "R",
            "probability": 3.814697265625e-06
        },
        {
            "start_logit": -6.10546875,
            "end_logit": 9.3828125,
            "text": "seR",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.93359375,
            "text": "traseR, an easy-to-use R Bioconductor package",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.546875,
            "end_logit": 9.3828125,
            "text": "present traseR",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.1796875,
            "text": "traseR, an easy-to-use R Bioconductor",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.25,
            "text": "trase",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.25,
            "text": "traseR, an easy-to-use R Bioc",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.296875,
            "text": "traseR, an easy-to-use R Bioconduc",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.3125,
            "text": "traseR, an",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.3125,
            "text": "traseR, an easy-to-use R",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.359375,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.390625,
            "text": "traseR, an easy-to",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.390625,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals with",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.3984375,
            "text": "traseR, an easy-to-use R Bioconductor package that",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.3828125,
            "text": "we present traseR",
            "probability": 0.0
        },
        {
            "start_logit": -7.546875,
            "end_logit": -2.181640625,
            "text": "present tra",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": -2.181640625,
            "text": "we present tra",
            "probability": 0.0
        },
        {
            "start_logit": -2.619140625,
            "end_logit": -7.93359375,
            "text": "R, an easy-to-use R Bioconductor package",
            "probability": 0.0
        }
    ],
    "587e3129c32c812009000002_8": [
        {
            "start_logit": 9.875,
            "end_logit": 9.453125,
            "text": "traseR",
            "probability": 1.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -2.1640625,
            "text": "tra",
            "probability": 9.000301361083984e-06
        },
        {
            "start_logit": -2.51171875,
            "end_logit": 9.453125,
            "text": "R",
            "probability": 4.172325134277344e-06
        },
        {
            "start_logit": -6.09765625,
            "end_logit": 9.453125,
            "text": "seR",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.875,
            "end_logit": -7.85546875,
            "text": "traseR R package",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.875,
            "end_logit": -7.9140625,
            "text": "traseR R",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.21875,
            "text": "trase",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.3359375,
            "text": "traseR R package preloaded with up-to-date collection of trait-associated SNPs are freely available in Bioconductor zhaohui.qin@emory",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.3671875,
            "text": "traseR R package preloaded with up-to",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.375,
            "text": "traseR R package preload",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.3984375,
            "text": "traseR R package preloaded with up-to-date collection of trait-associated SNPs are freely available in Bioconductor zhaohui.qin@emory.",
            "probability": 0.0
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 9.453125,
            "text": "The traseR",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.421875,
            "text": "traseR R package preloaded with up-to-date collection of trait-associated SNPs are freely available in Bioconductor zhaohui.qin@emory.edu Supplementary data are available at Bioinformatics online",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.421875,
            "text": "traseR R package preloaded with up-to-date collection of trait-associated SNPs are",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.4453125,
            "text": "traseR R package preloaded with up-to-date collection of trait-associated SNPs are freely available in Bioconductor zhaohui.qin@emory.edu",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.4453125,
            "text": "traseR R package preloaded",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.4609375,
            "text": "traseR R package preloaded with up-to-date collection of trait-associated SNPs are freely available in Bioconductor zhaohui.qin",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.4609375,
            "text": "traseR R package preloaded with up-to-date collection of trait-associated SNPs are freely available in Bioconductor zhaohui.qin@emo",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.46875,
            "text": "traseR R package preloaded with up-to-date collection of trait",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.484375,
            "text": "traseR R package preloaded with up-to-date collection of trait-associated SNPs are freely available in Bioconductor zhaohui.qi",
            "probability": 0.0
        }
    ],
    "587e1bfdfc7e8dd84f000002_1": [
        {
            "start_logit": 9.9140625,
            "end_logit": 9.4921875,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -2.068359375,
            "text": "GBs",
            "probability": 9.5367431640625e-06
        },
        {
            "start_logit": -2.416015625,
            "end_logit": 9.4921875,
            "text": "e",
            "probability": 4.410743713378906e-06
        },
        {
            "start_logit": -6.0390625,
            "end_logit": 9.4921875,
            "text": "hape",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.125,
            "text": "GBshap",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.3828125,
            "text": "GBshape:",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.3828125,
            "text": "GBshape: a genome browser database for DNA shape",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.3984375,
            "text": "GBshape: a genome browser database",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.3984375,
            "text": "GBshape: a genome browser database for DNA shape annotations",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.4296875,
            "text": "GBshape: a",
            "probability": 0.0
        },
        {
            "start_logit": -2.416015625,
            "end_logit": -8.3828125,
            "text": "e:",
            "probability": 0.0
        },
        {
            "start_logit": -2.416015625,
            "end_logit": -8.3828125,
            "text": "e: a genome browser database for DNA shape",
            "probability": 0.0
        },
        {
            "start_logit": -2.416015625,
            "end_logit": -8.3984375,
            "text": "e: a genome browser database",
            "probability": 0.0
        },
        {
            "start_logit": -2.416015625,
            "end_logit": -8.3984375,
            "text": "e: a genome browser database for DNA shape annotations",
            "probability": 0.0
        },
        {
            "start_logit": -2.416015625,
            "end_logit": -8.4296875,
            "text": "e: a",
            "probability": 0.0
        },
        {
            "start_logit": -6.0390625,
            "end_logit": -8.125,
            "text": "hap",
            "probability": 0.0
        },
        {
            "start_logit": -6.0390625,
            "end_logit": -8.3828125,
            "text": "hape:",
            "probability": 0.0
        },
        {
            "start_logit": -6.0390625,
            "end_logit": -8.3828125,
            "text": "hape: a genome browser database for DNA shape",
            "probability": 0.0
        },
        {
            "start_logit": -6.0390625,
            "end_logit": -8.3984375,
            "text": "hape: a genome browser database",
            "probability": 0.0
        },
        {
            "start_logit": -6.0390625,
            "end_logit": -8.3984375,
            "text": "hape: a genome browser database for DNA shape annotations",
            "probability": 0.0
        }
    ],
    "587e1bfdfc7e8dd84f000002_2": [
        {
            "start_logit": 9.9921875,
            "end_logit": 9.5703125,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -1.892578125,
            "text": "GBs",
            "probability": 1.055002212524414e-05
        },
        {
            "start_logit": -2.216796875,
            "end_logit": 9.5703125,
            "text": "e",
            "probability": 4.947185516357422e-06
        },
        {
            "start_logit": -5.35546875,
            "end_logit": 9.5703125,
            "text": "hape",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.0703125,
            "text": "GBshape; freely available at http://rohslab.cmb.usc",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.0703125,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.125,
            "text": "GBshape; freely available at http://rohslab.cmb.us",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.15625,
            "text": "GBshape; freely available at http://rohslab",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.2109375,
            "text": "GBshape; freely available at http://rohslab.cm",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.21875,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.2265625,
            "text": "GBshape; freely available at http://rohslab.cmb",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.2578125,
            "text": "GBshape; freely available at http://rohslab.cmb.",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.2578125,
            "text": "GBshape; freely available at http://rohslab.",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.2578125,
            "text": "GBshap",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.265625,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape/",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.28125,
            "text": "GBshape; freely available at http:/",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.2890625,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBs",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.34375,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.375,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/",
            "probability": 0.0
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 9.5703125,
            "text": "Genome Browser for DNA shape annotations (GBshape",
            "probability": 0.0
        }
    ],
    "587e1bfdfc7e8dd84f000002_3": [
        {
            "start_logit": 9.96875,
            "end_logit": 9.5234375,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -1.935546875,
            "text": "GBs",
            "probability": 1.043081283569336e-05
        },
        {
            "start_logit": -2.330078125,
            "end_logit": 9.5234375,
            "text": "e",
            "probability": 4.5299530029296875e-06
        },
        {
            "start_logit": -5.8125,
            "end_logit": 9.5234375,
            "text": "hape",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.1484375,
            "text": "GBshap",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.359375,
            "text": "GBshape: a genome browser database for DNA shape",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.359375,
            "text": "GBshape:",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.375,
            "text": "GBshape: a genome browser database",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.3828125,
            "text": "GBshape: a genome browser database for DNA shape annotations",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.4140625,
            "text": "GBshape: a",
            "probability": 0.0
        },
        {
            "start_logit": -2.330078125,
            "end_logit": -8.359375,
            "text": "e: a genome browser database for DNA shape",
            "probability": 0.0
        },
        {
            "start_logit": -2.330078125,
            "end_logit": -8.359375,
            "text": "e:",
            "probability": 0.0
        },
        {
            "start_logit": -2.330078125,
            "end_logit": -8.375,
            "text": "e: a genome browser database",
            "probability": 0.0
        },
        {
            "start_logit": -2.330078125,
            "end_logit": -8.3828125,
            "text": "e: a genome browser database for DNA shape annotations",
            "probability": 0.0
        },
        {
            "start_logit": -2.330078125,
            "end_logit": -8.4140625,
            "text": "e: a",
            "probability": 0.0
        },
        {
            "start_logit": -5.8125,
            "end_logit": -8.1484375,
            "text": "hap",
            "probability": 0.0
        },
        {
            "start_logit": -5.8125,
            "end_logit": -8.359375,
            "text": "hape: a genome browser database for DNA shape",
            "probability": 0.0
        },
        {
            "start_logit": -5.8125,
            "end_logit": -8.359375,
            "text": "hape:",
            "probability": 0.0
        },
        {
            "start_logit": -5.8125,
            "end_logit": -8.375,
            "text": "hape: a genome browser database",
            "probability": 0.0
        },
        {
            "start_logit": -5.8125,
            "end_logit": -8.3828125,
            "text": "hape: a genome browser database for DNA shape annotations",
            "probability": 0.0
        }
    ],
    "587e1bfdfc7e8dd84f000002_4": [
        {
            "start_logit": 9.9765625,
            "end_logit": 9.578125,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -1.9072265625,
            "text": "GBs",
            "probability": 1.0192394256591797e-05
        },
        {
            "start_logit": -2.23828125,
            "end_logit": 9.578125,
            "text": "e",
            "probability": 4.947185516357422e-06
        },
        {
            "start_logit": -5.65234375,
            "end_logit": 9.578125,
            "text": "hape",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.2265625,
            "text": "GBshape can",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.25,
            "text": "GBshap",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.3515625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.375,
            "text": "GBshape can be",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.3984375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.3984375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.3984375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browse",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.40625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.421875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.4296875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.4296875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.4375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.4375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format,",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.4453125,
            "text": "GBshape can be used",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.4453125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.4453125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide",
            "probability": 0.0
        }
    ],
    "587e1bfdfc7e8dd84f000002_5": [
        {
            "start_logit": 9.96875,
            "end_logit": 9.5625,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -1.94140625,
            "text": "GBs",
            "probability": 1.0132789611816406e-05
        },
        {
            "start_logit": -2.248046875,
            "end_logit": 9.5625,
            "text": "e",
            "probability": 4.947185516357422e-06
        },
        {
            "start_logit": -5.62109375,
            "end_logit": 9.5625,
            "text": "hape",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.03125,
            "text": "GBshape; freely available at http://rohslab",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.0390625,
            "text": "GBshape; freely available at http://rohslab.cmb.usc",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.046875,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.0859375,
            "text": "GBshape; freely available at http://rohslab.cmb.us",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.1015625,
            "text": "GBshape; freely available at http://rohslab.cm",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.125,
            "text": "GBshape; freely available at http://rohslab.cmb",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.1640625,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBs",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.1953125,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape/",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.2109375,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.2109375,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.21875,
            "text": "GBshap",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.2265625,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape/) provides minor groove width",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.2265625,
            "text": "GBshape; freely available at http://rohslab.",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.234375,
            "text": "GBshape; freely available at http://rohslab.cmb.",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.2421875,
            "text": "GBshape; freely available at http:/",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.28125,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshap",
            "probability": 0.0
        }
    ],
    "587e1bfdfc7e8dd84f000002_6": [
        {
            "start_logit": 9.9765625,
            "end_logit": 9.578125,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -1.9072265625,
            "text": "GBs",
            "probability": 1.0192394256591797e-05
        },
        {
            "start_logit": -2.23828125,
            "end_logit": 9.578125,
            "text": "e",
            "probability": 4.947185516357422e-06
        },
        {
            "start_logit": -5.65234375,
            "end_logit": 9.578125,
            "text": "hape",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.2265625,
            "text": "GBshape can",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.25,
            "text": "GBshap",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.3515625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.375,
            "text": "GBshape can be",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.3984375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.3984375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.3984375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browse",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.40625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.421875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.4296875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.4296875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.4375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.4375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format,",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.4453125,
            "text": "GBshape can be used",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.4453125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.4453125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide",
            "probability": 0.0
        }
    ],
    "587e1bfdfc7e8dd84f000002_7": [
        {
            "start_logit": 9.9765625,
            "end_logit": 9.578125,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -1.9072265625,
            "text": "GBs",
            "probability": 1.0192394256591797e-05
        },
        {
            "start_logit": -2.23828125,
            "end_logit": 9.578125,
            "text": "e",
            "probability": 4.947185516357422e-06
        },
        {
            "start_logit": -5.65234375,
            "end_logit": 9.578125,
            "text": "hape",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.2265625,
            "text": "GBshape can",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.25,
            "text": "GBshap",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.3515625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.375,
            "text": "GBshape can be",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.3984375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.3984375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.3984375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browse",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.40625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.421875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.4296875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.4296875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.4375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.4375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format,",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.4453125,
            "text": "GBshape can be used",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.4453125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.4453125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide",
            "probability": 0.0
        }
    ],
    "587e1bfdfc7e8dd84f000002_8": [
        {
            "start_logit": 9.96875,
            "end_logit": 9.5234375,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -1.935546875,
            "text": "GBs",
            "probability": 1.043081283569336e-05
        },
        {
            "start_logit": -2.330078125,
            "end_logit": 9.5234375,
            "text": "e",
            "probability": 4.5299530029296875e-06
        },
        {
            "start_logit": -5.8125,
            "end_logit": 9.5234375,
            "text": "hape",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.1484375,
            "text": "GBshap",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.359375,
            "text": "GBshape: a genome browser database for DNA shape",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.359375,
            "text": "GBshape:",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.375,
            "text": "GBshape: a genome browser database",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.3828125,
            "text": "GBshape: a genome browser database for DNA shape annotations",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.4140625,
            "text": "GBshape: a",
            "probability": 0.0
        },
        {
            "start_logit": -2.330078125,
            "end_logit": -8.359375,
            "text": "e: a genome browser database for DNA shape",
            "probability": 0.0
        },
        {
            "start_logit": -2.330078125,
            "end_logit": -8.359375,
            "text": "e:",
            "probability": 0.0
        },
        {
            "start_logit": -2.330078125,
            "end_logit": -8.375,
            "text": "e: a genome browser database",
            "probability": 0.0
        },
        {
            "start_logit": -2.330078125,
            "end_logit": -8.3828125,
            "text": "e: a genome browser database for DNA shape annotations",
            "probability": 0.0
        },
        {
            "start_logit": -2.330078125,
            "end_logit": -8.4140625,
            "text": "e: a",
            "probability": 0.0
        },
        {
            "start_logit": -5.8125,
            "end_logit": -8.1484375,
            "text": "hap",
            "probability": 0.0
        },
        {
            "start_logit": -5.8125,
            "end_logit": -8.359375,
            "text": "hape: a genome browser database for DNA shape",
            "probability": 0.0
        },
        {
            "start_logit": -5.8125,
            "end_logit": -8.359375,
            "text": "hape:",
            "probability": 0.0
        },
        {
            "start_logit": -5.8125,
            "end_logit": -8.375,
            "text": "hape: a genome browser database",
            "probability": 0.0
        },
        {
            "start_logit": -5.8125,
            "end_logit": -8.3828125,
            "text": "hape: a genome browser database for DNA shape annotations",
            "probability": 0.0
        }
    ],
    "587e1bfdfc7e8dd84f000002_9": [
        {
            "start_logit": 9.96875,
            "end_logit": 9.5625,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -1.94140625,
            "text": "GBs",
            "probability": 1.0132789611816406e-05
        },
        {
            "start_logit": -2.248046875,
            "end_logit": 9.5625,
            "text": "e",
            "probability": 4.947185516357422e-06
        },
        {
            "start_logit": -5.62109375,
            "end_logit": 9.5625,
            "text": "hape",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.03125,
            "text": "GBshape; freely available at http://rohslab",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.0390625,
            "text": "GBshape; freely available at http://rohslab.cmb.usc",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.046875,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.0859375,
            "text": "GBshape; freely available at http://rohslab.cmb.us",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.1015625,
            "text": "GBshape; freely available at http://rohslab.cm",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.125,
            "text": "GBshape; freely available at http://rohslab.cmb",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.1640625,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBs",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.1953125,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape/",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.2109375,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.2109375,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.21875,
            "text": "GBshap",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.2265625,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape/) provides minor groove width",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.2265625,
            "text": "GBshape; freely available at http://rohslab.",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.234375,
            "text": "GBshape; freely available at http://rohslab.cmb.",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.2421875,
            "text": "GBshape; freely available at http:/",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.28125,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshap",
            "probability": 0.0
        }
    ],
    "53262cdcd6d3ac6a34000003_1": [
        {
            "start_logit": 9.796875,
            "end_logit": 9.609375,
            "text": "epidural blood patch",
            "probability": 1.0
        },
        {
            "start_logit": -2.08984375,
            "end_logit": 9.609375,
            "text": "patch",
            "probability": 6.854534149169922e-06
        },
        {
            "start_logit": 9.796875,
            "end_logit": -2.314453125,
            "text": "epidural",
            "probability": 6.616115570068359e-06
        },
        {
            "start_logit": -6.19921875,
            "end_logit": 9.609375,
            "text": "an epidural blood patch",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.33203125,
            "end_logit": 9.609375,
            "text": "blood patch",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.3984375,
            "end_logit": 9.609375,
            "text": "using an epidural blood patch",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.86328125,
            "end_logit": 9.609375,
            "text": "was treated for CSF leak using an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 9.609375,
            "text": "treated for CSF leak using an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -7.9296875,
            "end_logit": 9.609375,
            "text": "she was treated for CSF leak using an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.15625,
            "text": "epidural blood",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 9.609375,
            "text": "for CSF leak using an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": 9.609375,
            "text": "CSF leak using an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -6.19921875,
            "end_logit": -2.314453125,
            "text": "an epidural",
            "probability": 0.0
        },
        {
            "start_logit": -7.3984375,
            "end_logit": -2.314453125,
            "text": "using an epidural",
            "probability": 0.0
        },
        {
            "start_logit": -7.86328125,
            "end_logit": -2.314453125,
            "text": "was treated for CSF leak using an epidural",
            "probability": 0.0
        },
        {
            "start_logit": -7.8671875,
            "end_logit": -2.314453125,
            "text": "treated for CSF leak using an epidural",
            "probability": 0.0
        },
        {
            "start_logit": -7.9296875,
            "end_logit": -2.314453125,
            "text": "she was treated for CSF leak using an epidural",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": -2.314453125,
            "text": "for CSF leak using an epidural",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": -2.314453125,
            "text": "CSF leak using an epidural",
            "probability": 0.0
        },
        {
            "start_logit": -6.19921875,
            "end_logit": -8.15625,
            "text": "an epidural blood",
            "probability": 0.0
        }
    ],
    "53262cdcd6d3ac6a34000003_2": [
        {
            "start_logit": 9.7109375,
            "end_logit": 9.4140625,
            "text": "epidural blood patch",
            "probability": 1.0
        },
        {
            "start_logit": 9.7109375,
            "end_logit": -2.515625,
            "text": "epidural",
            "probability": 6.616115570068359e-06
        },
        {
            "start_logit": -2.529296875,
            "end_logit": 9.4140625,
            "text": "patch",
            "probability": 4.827976226806641e-06
        },
        {
            "start_logit": -6.3125,
            "end_logit": 9.4140625,
            "text": "blood patch",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.7109375,
            "end_logit": -8.2265625,
            "text": "epidural blood patch providing",
            "probability": 0.0
        },
        {
            "start_logit": 9.7109375,
            "end_logit": -8.234375,
            "text": "epidural blood patch providing the cornerstone",
            "probability": 0.0
        },
        {
            "start_logit": 9.7109375,
            "end_logit": -8.2890625,
            "text": "epidural blood patch providing the",
            "probability": 0.0
        },
        {
            "start_logit": 9.7109375,
            "end_logit": -8.296875,
            "text": "epidural blood patch providing the cornerstone of the invasive measures",
            "probability": 0.0
        },
        {
            "start_logit": 9.7109375,
            "end_logit": -8.3046875,
            "text": "epidural blood",
            "probability": 0.0
        },
        {
            "start_logit": 9.7109375,
            "end_logit": -8.34375,
            "text": "epidural blood patch providing the cornerstone of",
            "probability": 0.0
        },
        {
            "start_logit": 9.7109375,
            "end_logit": -8.3828125,
            "text": "epidural blood patch providing the cornerstone of the invasive",
            "probability": 0.0
        },
        {
            "start_logit": 9.7109375,
            "end_logit": -8.390625,
            "text": "epidural blood patch providing the cornerstone of the",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 9.4140625,
            "text": "with epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -2.515625,
            "text": "with epidural",
            "probability": 0.0
        },
        {
            "start_logit": -2.529296875,
            "end_logit": -8.2265625,
            "text": "patch providing",
            "probability": 0.0
        },
        {
            "start_logit": -2.529296875,
            "end_logit": -8.234375,
            "text": "patch providing the cornerstone",
            "probability": 0.0
        },
        {
            "start_logit": -2.529296875,
            "end_logit": -8.2890625,
            "text": "patch providing the",
            "probability": 0.0
        },
        {
            "start_logit": -2.529296875,
            "end_logit": -8.296875,
            "text": "patch providing the cornerstone of the invasive measures",
            "probability": 0.0
        },
        {
            "start_logit": -2.529296875,
            "end_logit": -8.34375,
            "text": "patch providing the cornerstone of",
            "probability": 0.0
        },
        {
            "start_logit": -2.529296875,
            "end_logit": -8.3828125,
            "text": "patch providing the cornerstone of the invasive",
            "probability": 0.0
        }
    ],
    "53262cdcd6d3ac6a34000003_3": [
        {
            "start_logit": 9.75,
            "end_logit": 9.4375,
            "text": "epidural blood patch",
            "probability": 1.0
        },
        {
            "start_logit": 9.75,
            "end_logit": -2.439453125,
            "text": "epidural",
            "probability": 6.973743438720703e-06
        },
        {
            "start_logit": -2.494140625,
            "end_logit": 9.4375,
            "text": "patch",
            "probability": 4.827976226806641e-06
        },
        {
            "start_logit": -6.46875,
            "end_logit": 9.4375,
            "text": "blood patch",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.74609375,
            "end_logit": 9.4375,
            "text": ", epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -7.921875,
            "end_logit": 9.4375,
            "text": "In high-risk patients , for example, age < 50 years, postpartum, large-gauge needle puncture, epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 9.4375,
            "text": ", age < 50 years, postpartum, large-gauge needle puncture, epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": 9.75,
            "end_logit": -8.3125,
            "text": "epidural blood",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 9.4375,
            "text": ", large-gauge needle puncture, epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": 9.75,
            "end_logit": -8.3671875,
            "text": "epidural blood patch should",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": 9.4375,
            "text": "< 50 years, postpartum, large-gauge needle puncture, epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": 9.4375,
            "text": ", postpartum, large-gauge needle puncture, epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": 9.75,
            "end_logit": -8.4296875,
            "text": "epidural blood patch should be",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.4375,
            "text": "age < 50 years, postpartum, large-gauge needle puncture, epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.4375,
            "text": "example, age < 50 years, postpartum, large-gauge needle puncture, epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 9.4375,
            "text": ", for example, age < 50 years, postpartum, large-gauge needle puncture, epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.4375,
            "text": "-gauge needle puncture, epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.4375,
            "text": "needle puncture, epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.4375,
            "text": "risk patients , for example, age < 50 years, postpartum, large-gauge needle puncture, epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.4375,
            "text": "patients , for example, age < 50 years, postpartum, large-gauge needle puncture, epidural blood patch",
            "probability": 0.0
        }
    ],
    "53262cdcd6d3ac6a34000003_4": [
        {
            "start_logit": 9.8359375,
            "end_logit": 9.609375,
            "text": "epidural blood patch",
            "probability": 1.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -2.228515625,
            "text": "epidural",
            "probability": 7.271766662597656e-06
        },
        {
            "start_logit": -2.103515625,
            "end_logit": 9.609375,
            "text": "patch",
            "probability": 6.616115570068359e-06
        },
        {
            "start_logit": -6.12890625,
            "end_logit": 9.609375,
            "text": "blood patch",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.828125,
            "end_logit": 9.609375,
            "text": "an epidural blood patch",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7890625,
            "end_logit": 9.609375,
            "text": "Both parturients were successfully managed using acupuncture rather than an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -8.09375,
            "text": "epidural blood",
            "probability": 0.0
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 9.609375,
            "text": "using acupuncture rather than an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.609375,
            "text": "than an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.609375,
            "text": "acupuncture rather than an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 9.609375,
            "text": "managed using acupuncture rather than an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.609375,
            "text": "parturients were successfully managed using acupuncture rather than an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.609375,
            "text": "successfully managed using acupuncture rather than an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.609375,
            "text": "were successfully managed using acupuncture rather than an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -6.828125,
            "end_logit": -2.228515625,
            "text": "an epidural",
            "probability": 0.0
        },
        {
            "start_logit": -7.7890625,
            "end_logit": -2.228515625,
            "text": "Both parturients were successfully managed using acupuncture rather than an epidural",
            "probability": 0.0
        },
        {
            "start_logit": -7.98046875,
            "end_logit": -2.228515625,
            "text": "using acupuncture rather than an epidural",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": -2.228515625,
            "text": "than an epidural",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": -2.228515625,
            "text": "acupuncture rather than an epidural",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -2.228515625,
            "text": "managed using acupuncture rather than an epidural",
            "probability": 0.0
        }
    ],
    "53262cdcd6d3ac6a34000003_5": [
        {
            "start_logit": 9.8046875,
            "end_logit": 9.59375,
            "text": "epidural blood patch",
            "probability": 1.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -2.28515625,
            "text": "epidural",
            "probability": 6.854534149169922e-06
        },
        {
            "start_logit": -2.09765625,
            "end_logit": 9.59375,
            "text": "patch",
            "probability": 6.735324859619141e-06
        },
        {
            "start_logit": -6.18359375,
            "end_logit": 9.59375,
            "text": "an epidural blood patch",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.1875,
            "end_logit": 9.59375,
            "text": "blood patch",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.6015625,
            "end_logit": 9.59375,
            "text": "by an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -7.75,
            "end_logit": 9.59375,
            "text": "a 17-yr-old girl had symptoms of a low-pressure headache after LP shunt placement alleviated by an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -7.83984375,
            "end_logit": 9.59375,
            "text": "case, a 17-yr-old girl had symptoms of a low-pressure headache after LP shunt placement alleviated by an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -7.890625,
            "end_logit": 9.59375,
            "text": "this case, a 17-yr-old girl had symptoms of a low-pressure headache after LP shunt placement alleviated by an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.59375,
            "text": "In this case, a 17-yr-old girl had symptoms of a low-pressure headache after LP shunt placement alleviated by an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.25,
            "text": "epidural blood",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.59375,
            "text": "old girl had symptoms of a low-pressure headache after LP shunt placement alleviated by an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": 9.59375,
            "text": "-yr-old girl had symptoms of a low-pressure headache after LP shunt placement alleviated by an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.59375,
            "text": "girl had symptoms of a low-pressure headache after LP shunt placement alleviated by an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 9.59375,
            "text": "-old girl had symptoms of a low-pressure headache after LP shunt placement alleviated by an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.59375,
            "text": "shunt placement alleviated by an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 9.59375,
            "text": ", a 17-yr-old girl had symptoms of a low-pressure headache after LP shunt placement alleviated by an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.375,
            "text": "epidural blood patch.",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.59375,
            "text": "17-yr-old girl had symptoms of a low-pressure headache after LP shunt placement alleviated by an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -6.18359375,
            "end_logit": -2.28515625,
            "text": "an epidural",
            "probability": 0.0
        }
    ],
    "53262cdcd6d3ac6a34000003_6": [
        {
            "start_logit": 9.5,
            "end_logit": 9.421875,
            "text": "epidural blood patch",
            "probability": 1.0
        },
        {
            "start_logit": -2.5234375,
            "end_logit": 9.421875,
            "text": "patch",
            "probability": 6.020069122314453e-06
        },
        {
            "start_logit": 9.5,
            "end_logit": -2.859375,
            "text": "epidural",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": -6.3984375,
            "end_logit": 9.421875,
            "text": "blood patch",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.5546875,
            "end_logit": 9.421875,
            "text": ") epidural blood patch",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.90234375,
            "end_logit": 9.421875,
            "text": "within 24-48 h of dural puncture) epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 9.421875,
            "text": "offered early (within 24-48 h of dural puncture) epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 9.421875,
            "text": "In high-risk patients (e.g. age < 50 years, post-partum, large-gauge-needle puncture), patients should be offered early (within 24-48 h of dural puncture) epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 9.421875,
            "text": "(within 24-48 h of dural puncture) epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.421875,
            "text": ", large-gauge-needle puncture), patients should be offered early (within 24-48 h of dural puncture) epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 9.421875,
            "text": ". age < 50 years, post-partum, large-gauge-needle puncture), patients should be offered early (within 24-48 h of dural puncture) epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.421875,
            "text": ", patients should be offered early (within 24-48 h of dural puncture) epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.421875,
            "text": "patients should be offered early (within 24-48 h of dural puncture) epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.421875,
            "text": "), patients should be offered early (within 24-48 h of dural puncture) epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.421875,
            "text": "be offered early (within 24-48 h of dural puncture) epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": 9.5,
            "end_logit": -8.2578125,
            "text": "epidural blood",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.421875,
            "text": "-needle puncture), patients should be offered early (within 24-48 h of dural puncture) epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.421875,
            "text": "< 50 years, post-partum, large-gauge-needle puncture), patients should be offered early (within 24-48 h of dural puncture) epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.421875,
            "text": "age < 50 years, post-partum, large-gauge-needle puncture), patients should be offered early (within 24-48 h of dural puncture) epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -7.5546875,
            "end_logit": -2.859375,
            "text": ") epidural",
            "probability": 0.0
        }
    ],
    "5c5b268986df2b9174000019_1": [
        {
            "start_logit": 10.015625,
            "end_logit": 9.3828125,
            "text": "DSMNC",
            "probability": 1.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -1.8330078125,
            "text": "DSM",
            "probability": 1.329183578491211e-05
        },
        {
            "start_logit": -2.48828125,
            "end_logit": 9.3828125,
            "text": "NC",
            "probability": 3.6954879760742188e-06
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.140625,
            "text": "DSMNC: a database",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.21875,
            "text": "DSMNC: a database of somatic mutations",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.234375,
            "text": "DSMNC: a database of somatic mutations in normal cells",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.3046875,
            "text": "DSMNC: a database of somatic mutations in normal",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.3359375,
            "text": "DSMNC:",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.359375,
            "text": "DSMNC: a database of somatic mutations in",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.359375,
            "text": "DSMNC: a",
            "probability": 0.0
        },
        {
            "start_logit": -2.48828125,
            "end_logit": -8.140625,
            "text": "NC: a database",
            "probability": 0.0
        },
        {
            "start_logit": -2.48828125,
            "end_logit": -8.21875,
            "text": "NC: a database of somatic mutations",
            "probability": 0.0
        },
        {
            "start_logit": -2.48828125,
            "end_logit": -8.234375,
            "text": "NC: a database of somatic mutations in normal cells",
            "probability": 0.0
        },
        {
            "start_logit": -2.48828125,
            "end_logit": -8.3046875,
            "text": "NC: a database of somatic mutations in normal",
            "probability": 0.0
        },
        {
            "start_logit": -2.48828125,
            "end_logit": -8.3359375,
            "text": "NC:",
            "probability": 0.0
        },
        {
            "start_logit": -2.48828125,
            "end_logit": -8.359375,
            "text": "NC: a database of somatic mutations in",
            "probability": 0.0
        },
        {
            "start_logit": -2.48828125,
            "end_logit": -8.359375,
            "text": "NC: a",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -8.140625,
            "text": "a database",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": -8.21875,
            "text": "of somatic mutations",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": -8.234375,
            "text": "of somatic mutations in normal cells",
            "probability": 0.0
        }
    ],
    "5c5b268986df2b9174000019_2": [
        {
            "start_logit": 9.9296875,
            "end_logit": 9.46875,
            "text": "DSMNC",
            "probability": 1.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -1.9736328125,
            "text": "DSM",
            "probability": 1.0609626770019531e-05
        },
        {
            "start_logit": -2.228515625,
            "end_logit": 9.46875,
            "text": "NC",
            "probability": 5.185604095458984e-06
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -4.92578125,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -4.96875,
            "end_logit": 9.46875,
            "text": "established DSMNC",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -5.95703125,
            "end_logit": 9.46875,
            "text": ". Here, we established DSMNC",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -6.8984375,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -7.515625,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -7.9296875,
            "text": "DSMNC: a database of somatic mutations in normal cells (http:/",
            "probability": 0.0
        },
        {
            "start_logit": -4.96875,
            "end_logit": -1.9736328125,
            "text": "established DSM",
            "probability": 0.0
        },
        {
            "start_logit": -2.228515625,
            "end_logit": -4.92578125,
            "text": "NC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn",
            "probability": 0.0
        },
        {
            "start_logit": -5.95703125,
            "end_logit": -1.9736328125,
            "text": ". Here, we established DSM",
            "probability": 0.0
        },
        {
            "start_logit": -2.228515625,
            "end_logit": -6.8984375,
            "text": "NC: a database of somatic mutations in normal cells (http://dsmnc.big.ac",
            "probability": 0.0
        },
        {
            "start_logit": -2.228515625,
            "end_logit": -7.515625,
            "text": "NC: a database of somatic mutations in normal cells (http://dsmnc.big",
            "probability": 0.0
        },
        {
            "start_logit": -4.96875,
            "end_logit": -4.92578125,
            "text": "established DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn",
            "probability": 0.0
        },
        {
            "start_logit": -2.228515625,
            "end_logit": -7.9296875,
            "text": "NC: a database of somatic mutations in normal cells (http:/",
            "probability": 0.0
        },
        {
            "start_logit": -5.95703125,
            "end_logit": -4.92578125,
            "text": ". Here, we established DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn",
            "probability": 0.0
        },
        {
            "start_logit": -4.96875,
            "end_logit": -6.8984375,
            "text": "established DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac",
            "probability": 0.0
        },
        {
            "start_logit": -4.96875,
            "end_logit": -7.515625,
            "text": "established DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big",
            "probability": 0.0
        },
        {
            "start_logit": -7.609375,
            "end_logit": -4.92578125,
            "text": "/dsmnc.big.ac.cn",
            "probability": 0.0
        }
    ],
    "5c5b268986df2b9174000019_3": [
        {
            "start_logit": 9.9765625,
            "end_logit": 9.4921875,
            "text": "DSMNC",
            "probability": 1.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -1.9189453125,
            "text": "DSM",
            "probability": 1.1026859283447266e-05
        },
        {
            "start_logit": -2.291015625,
            "end_logit": 9.4921875,
            "text": "NC",
            "probability": 4.708766937255859e-06
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -6.87890625,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1796875,
            "end_logit": 9.4921875,
            "text": "established DSMNC",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -7.78515625,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -7.9609375,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.0546875,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.109375,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsm",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.140625,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn/",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.140625,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn/), which provides most comprehensive catalogue of somatic SNVs in single cells from various normal tissues",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.1484375,
            "text": "DSMNC: a database of somatic mutations in normal cells (http:/",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.1484375,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.1640625,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn/)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.21875,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn/),",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.2734375,
            "text": "DSMNC: a database",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.296875,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn/), which provides most comprehensive catalogue of somatic SNVs",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.3203125,
            "text": "DSMNC: a database of somatic mutations in normal cells",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.3203125,
            "text": "DSMNC: a database of somatic mutations in normal",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.3203125,
            "text": "DSMNC: a",
            "probability": 0.0
        }
    ],
    "5c5b268986df2b9174000019_4": [
        {
            "start_logit": 10.0390625,
            "end_logit": 9.4765625,
            "text": "DSMNC",
            "probability": 1.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -1.7626953125,
            "text": "DSM",
            "probability": 1.3113021850585938e-05
        },
        {
            "start_logit": -2.28125,
            "end_logit": 9.4765625,
            "text": "NC",
            "probability": 4.470348358154297e-06
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.0546875,
            "text": "DSMNC: a database of somatic mutations in normal cells.Numerous non-inherited somatic mutations, distinct from those of germ-line",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.1015625,
            "text": "DSMNC: a database of somatic mutations in normal cells.Numerous non-inherited somatic mutations, distinct from those of germ-line origin, occur in somatic cells during DNA replication per cell-division",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.125,
            "text": "DSMNC: a database of somatic mutations in normal cells.Numerous non-inherited somatic mutations, distinct from those of germ-line origin, occur in somatic cells during DNA replication",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.1328125,
            "text": "DSMNC: a database of somatic mutations in normal cells.Numerous non-inherited somatic mutations, distinct from those of germ-line origin",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.1953125,
            "text": "DSMNC: a database of somatic mutations in normal cells.Numerous non-inherited somatic mutations, distinct from those of germ-line origin, occur in somatic cells during DNA",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.1953125,
            "text": "DSMNC: a database of somatic mutations in normal cells.Numerous non-inherited somatic mutations, distinct from those of germ-line origin, occur",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.1953125,
            "text": "DSMNC: a database of somatic mutations in normal cells.Numerous non-inherited somatic mutations",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.2109375,
            "text": "DSMNC: a database of somatic mutations in normal cells.Numerous non-inherited somatic mutations, distinct from those of germ",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.21875,
            "text": "DSMNC: a database of somatic mutations in normal cells.Numerous non-inherited somatic mutations, distinct from those of germ-line origin, occur in somatic cells during DNA replication per",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.21875,
            "text": "DSMNC: a database of somatic mutations in normal cells",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.21875,
            "text": "DSMNC: a database of somatic mutations in normal",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.2265625,
            "text": "DSMNC: a database",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.2265625,
            "text": "DSMNC: a database of somatic mutations",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.234375,
            "text": "DSMNC: a database of somatic mutations in",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.2421875,
            "text": "DSMNC: a database of somatic mutations in normal cells.Numerous non-inherited somatic mutations, distinct from those of germ-line origin, occur in somatic cells during DNA replication per cell",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.265625,
            "text": "DSMNC: a database of somatic mutations in normal cells.Numerous non-inherited somatic mutations, distinct from those of germ-line origin, occur in somatic cells during DNA replication per cell-",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.2734375,
            "text": "DSMNC: a database of somatic mutations in normal cells.Numerous non-inherited somatic mutations, distinct from those of germ-line origin, occur in somatic cells",
            "probability": 0.0
        }
    ],
    "5c5b268986df2b9174000019_5": [
        {
            "start_logit": 9.9765625,
            "end_logit": 9.4921875,
            "text": "DSMNC",
            "probability": 1.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -1.9189453125,
            "text": "DSM",
            "probability": 1.1026859283447266e-05
        },
        {
            "start_logit": -2.291015625,
            "end_logit": 9.4921875,
            "text": "NC",
            "probability": 4.708766937255859e-06
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -6.87890625,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1796875,
            "end_logit": 9.4921875,
            "text": "established DSMNC",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -7.78515625,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -7.9609375,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.0546875,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.109375,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsm",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.140625,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn/",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.140625,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn/), which provides most comprehensive catalogue of somatic SNVs in single cells from various normal tissues",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.1484375,
            "text": "DSMNC: a database of somatic mutations in normal cells (http:/",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.1484375,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.1640625,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn/)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.21875,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn/),",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.2734375,
            "text": "DSMNC: a database",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.296875,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn/), which provides most comprehensive catalogue of somatic SNVs",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.3203125,
            "text": "DSMNC: a database of somatic mutations in normal cells",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.3203125,
            "text": "DSMNC: a database of somatic mutations in normal",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.3203125,
            "text": "DSMNC: a",
            "probability": 0.0
        }
    ],
    "5a690487b750ff445500001f_1": [
        {
            "start_logit": 10.0546875,
            "end_logit": 9.6875,
            "text": "Epstein-Barr virus",
            "probability": 1.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -1.7197265625,
            "text": "Epstein",
            "probability": 1.1026859283447266e-05
        },
        {
            "start_logit": -1.880859375,
            "end_logit": 9.6875,
            "text": "virus",
            "probability": 6.496906280517578e-06
        },
        {
            "start_logit": -6.03515625,
            "end_logit": 9.6875,
            "text": "Barr virus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.296875,
            "end_logit": 9.6875,
            "text": "-Barr virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -7.85546875,
            "text": "Epstein-Barr virus (EBV)",
            "probability": 0.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -7.98046875,
            "text": "Epstein-Barr",
            "probability": 0.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -8.046875,
            "text": "Epstein-Barr virus (",
            "probability": 0.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -8.0546875,
            "text": "Epstein-Barr virus (EBV",
            "probability": 0.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -8.2734375,
            "text": "Epstein-Barr virus (EBV) is a highly prevalent virus, transmitted via saliva, which often causes asymptomatic infection in children but frequently results in infectious mononucleosis in adolescents. Heterophile antibody tests, including the Monospot test",
            "probability": 0.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -8.28125,
            "text": "Epstein-Barr virus (EBV) is a highly prevalent virus, transmitted via saliva, which often causes asymptomatic infection in children but frequently results in infectious mononucleosis in adolescents. Heterophile antibody tests, including the Monospot",
            "probability": 0.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -8.28125,
            "text": "Epstein-Barr virus (EBV) is a highly prevalent virus, transmitted via saliva, which often causes asymptomatic infection in children but frequently results in infectious mononucleosis in adolescents.",
            "probability": 0.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -8.2890625,
            "text": "Epstein-Barr virus (EBV) is",
            "probability": 0.0
        },
        {
            "start_logit": -1.880859375,
            "end_logit": -7.85546875,
            "text": "virus (EBV)",
            "probability": 0.0
        },
        {
            "start_logit": -1.880859375,
            "end_logit": -8.046875,
            "text": "virus (",
            "probability": 0.0
        },
        {
            "start_logit": -1.880859375,
            "end_logit": -8.0546875,
            "text": "virus (EBV",
            "probability": 0.0
        },
        {
            "start_logit": -1.880859375,
            "end_logit": -8.2734375,
            "text": "virus (EBV) is a highly prevalent virus, transmitted via saliva, which often causes asymptomatic infection in children but frequently results in infectious mononucleosis in adolescents. Heterophile antibody tests, including the Monospot test",
            "probability": 0.0
        },
        {
            "start_logit": -1.880859375,
            "end_logit": -8.28125,
            "text": "virus (EBV) is a highly prevalent virus, transmitted via saliva, which often causes asymptomatic infection in children but frequently results in infectious mononucleosis in adolescents. Heterophile antibody tests, including the Monospot",
            "probability": 0.0
        },
        {
            "start_logit": -1.880859375,
            "end_logit": -8.28125,
            "text": "virus (EBV) is a highly prevalent virus, transmitted via saliva, which often causes asymptomatic infection in children but frequently results in infectious mononucleosis in adolescents.",
            "probability": 0.0
        },
        {
            "start_logit": -1.880859375,
            "end_logit": -8.2890625,
            "text": "virus (EBV) is",
            "probability": 0.0
        }
    ],
    "5a690487b750ff445500001f_2": [
        {
            "start_logit": 9.9921875,
            "end_logit": 9.6171875,
            "text": "Epstein-Barr virus",
            "probability": 1.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -1.87890625,
            "text": "Epstein",
            "probability": 1.0132789611816406e-05
        },
        {
            "start_logit": -2.09375,
            "end_logit": 9.6171875,
            "text": "virus",
            "probability": 5.662441253662109e-06
        },
        {
            "start_logit": -6.35546875,
            "end_logit": 9.6171875,
            "text": "-Barr virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.5,
            "end_logit": 9.6171875,
            "text": ". Initial investigations revealed atypical lymphocytosis, thrombocytopenia, elevated liver enzymes, and a positive monospot test result. Further investigation showed the Epstein-Barr virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.5,
            "end_logit": 9.6171875,
            "text": ". Further investigation showed the Epstein-Barr virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.5078125,
            "end_logit": 9.6171875,
            "text": "Barr virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -7.5234375,
            "text": "Epstein-Barr",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.1484375,
            "text": "Epstein-Barr virus viral capsid antibody IgM/IgG and Epstein-Barr virus DNA by polymerase chain reaction to",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.15625,
            "text": "Epstein-Barr virus viral capsid antibody IgM/IgG and Epstein-Barr",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.171875,
            "text": "Epstein-Barr virus viral",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.1875,
            "text": "Epstein-Barr virus viral capsid antibody IgM/IgG and Epstein-Barr virus DNA by polymerase chain reaction to be negative; however, interestingly her cytomegalovirus (",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.1953125,
            "text": "Epstein-Barr virus viral capsid antibody IgM/IgG and Epstein-Barr virus DNA by polymerase chain reaction to be",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.1953125,
            "text": "Epstein-Barr virus viral capsid antibody IgM/IgG and Epstein-Barr virus DNA by polymerase chain reaction to be negative; however, interestingly her cytomegalovirus (CMV) IgM and IgG were",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.234375,
            "text": "Epstein-Barr virus viral capsid antibody IgM/IgG and Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.2421875,
            "text": "Epstein-Barr virus viral capsid",
            "probability": 0.0
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 9.6171875,
            "text": "woman presented with altered mental status, septic picture, and influenza-like symptoms. Initial investigations revealed atypical lymphocytosis, thrombocytopenia, elevated liver enzymes, and a positive monospot test result. Further investigation showed the Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 9.6171875,
            "text": "result. Further investigation showed the Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.265625,
            "text": "Epstein-Barr virus viral capsid antibody IgM/IgG and Epstein",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.2734375,
            "text": "Epstein-Barr virus viral capsid antibody IgM/IgG and Epstein-Barr virus DNA by polymerase chain reaction to be negative; however, interestingly her cytomegalovirus (CMV",
            "probability": 0.0
        }
    ],
    "5a690487b750ff445500001f_3": [
        {
            "start_logit": 10.0625,
            "end_logit": 9.59375,
            "text": "Epstein-Barr virus",
            "probability": 1.0
        },
        {
            "start_logit": 10.0625,
            "end_logit": -1.7138671875,
            "text": "Epstein",
            "probability": 1.233816146850586e-05
        },
        {
            "start_logit": -2.134765625,
            "end_logit": 9.59375,
            "text": "virus",
            "probability": 5.066394805908203e-06
        },
        {
            "start_logit": -6.140625,
            "end_logit": 9.59375,
            "text": ". He was taken to theatre for urgent splenectomy. The unifying diagnosis was infectious mononucleosis complicated by spontaneous splenic rupture secondary to Epstein-Barr virus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.140625,
            "end_logit": 9.59375,
            "text": ". The unifying diagnosis was infectious mononucleosis complicated by spontaneous splenic rupture secondary to Epstein-Barr virus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.140625,
            "end_logit": 9.59375,
            "text": ". This had likely caused referred pain through diaphragmatic irritation. He was taken to theatre for urgent splenectomy. The unifying diagnosis was infectious mononucleosis complicated by spontaneous splenic rupture secondary to Epstein-Barr virus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.37890625,
            "end_logit": 9.59375,
            "text": "Barr virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.3828125,
            "end_logit": 9.59375,
            "text": "-Barr virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.5078125,
            "end_logit": 9.59375,
            "text": "to Epstein-Barr virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0625,
            "end_logit": -7.51953125,
            "text": "Epstein-Barr",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0625,
            "end_logit": -7.875,
            "text": "Epstein-Barr virus infection",
            "probability": 0.0
        },
        {
            "start_logit": 10.0625,
            "end_logit": -8.109375,
            "text": "Epstein-Barr virus infection.",
            "probability": 0.0
        },
        {
            "start_logit": -7.890625,
            "end_logit": 9.59375,
            "text": "taken to theatre for urgent splenectomy. The unifying diagnosis was infectious mononucleosis complicated by spontaneous splenic rupture secondary to Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -7.984375,
            "end_logit": 9.59375,
            "text": "for urgent splenectomy. The unifying diagnosis was infectious mononucleosis complicated by spontaneous splenic rupture secondary to Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 9.59375,
            "text": "urgent splenectomy. The unifying diagnosis was infectious mononucleosis complicated by spontaneous splenic rupture secondary to Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -8.0,
            "end_logit": 9.59375,
            "text": "He was taken to theatre for urgent splenectomy. The unifying diagnosis was infectious mononucleosis complicated by spontaneous splenic rupture secondary to Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -6.140625,
            "end_logit": -1.7138671875,
            "text": ". He was taken to theatre for urgent splenectomy. The unifying diagnosis was infectious mononucleosis complicated by spontaneous splenic rupture secondary to Epstein",
            "probability": 0.0
        },
        {
            "start_logit": -6.140625,
            "end_logit": -1.7138671875,
            "text": ". The unifying diagnosis was infectious mononucleosis complicated by spontaneous splenic rupture secondary to Epstein",
            "probability": 0.0
        },
        {
            "start_logit": -6.140625,
            "end_logit": -1.7138671875,
            "text": ". This had likely caused referred pain through diaphragmatic irritation. He was taken to theatre for urgent splenectomy. The unifying diagnosis was infectious mononucleosis complicated by spontaneous splenic rupture secondary to Epstein",
            "probability": 0.0
        },
        {
            "start_logit": -6.5078125,
            "end_logit": -1.7138671875,
            "text": "to Epstein",
            "probability": 0.0
        }
    ],
    "5a690487b750ff445500001f_4": [
        {
            "start_logit": 9.9765625,
            "end_logit": 9.6953125,
            "text": "Epstein-Barr virus",
            "probability": 1.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -1.9169921875,
            "text": "Epstein",
            "probability": 9.059906005859375e-06
        },
        {
            "start_logit": -1.86328125,
            "end_logit": 9.6953125,
            "text": "virus",
            "probability": 7.212162017822266e-06
        },
        {
            "start_logit": -5.703125,
            "end_logit": 9.6953125,
            "text": "-Barr virus",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.00390625,
            "end_logit": 9.6953125,
            "text": "Barr virus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -7.87890625,
            "text": "Epstein-Barr virus (EBV)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -7.99609375,
            "text": "Epstein-Barr",
            "probability": 0.0
        },
        {
            "start_logit": -7.74609375,
            "end_logit": 9.6953125,
            "text": "with Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.046875,
            "text": "Epstein-Barr virus (EBV",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.2734375,
            "text": "Epstein-Barr virus (EBV) is almost ubiquitous in humans and generally occurs at two ages: infantile, which is usually asymptomatic and associated with poorer socioeconomic conditions, and adolescent, which causes infectious mononucleosis (IM) in ~25",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.296875,
            "text": "Epstein-Barr virus (EBV) is",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.296875,
            "text": "Epstein-Barr virus (EBV) is almost ubiquitous in humans and generally occurs at two ages: infantile, which is usually asymptomatic and associated with poorer socioeconomic conditions, and adolescent, which causes infectious mononucleosis (IM) in",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.3125,
            "text": "Epstein-Barr virus (EBV) is almost ubiquitous in humans and generally occurs at two",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": 9.6953125,
            "text": "Infection with Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -7.74609375,
            "end_logit": -1.9169921875,
            "text": "with Epstein",
            "probability": 0.0
        },
        {
            "start_logit": -1.86328125,
            "end_logit": -7.87890625,
            "text": "virus (EBV)",
            "probability": 0.0
        },
        {
            "start_logit": -1.86328125,
            "end_logit": -8.046875,
            "text": "virus (EBV",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": -1.9169921875,
            "text": "Infection with Epstein",
            "probability": 0.0
        },
        {
            "start_logit": -1.86328125,
            "end_logit": -8.2734375,
            "text": "virus (EBV) is almost ubiquitous in humans and generally occurs at two ages: infantile, which is usually asymptomatic and associated with poorer socioeconomic conditions, and adolescent, which causes infectious mononucleosis (IM) in ~25",
            "probability": 0.0
        },
        {
            "start_logit": -1.86328125,
            "end_logit": -8.296875,
            "text": "virus (EBV) is",
            "probability": 0.0
        }
    ],
    "5a690487b750ff445500001f_5": [
        {
            "start_logit": 9.9921875,
            "end_logit": 9.5703125,
            "text": "Epstein-Barr virus",
            "probability": 1.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -1.8759765625,
            "text": "Epstein",
            "probability": 1.0728836059570312e-05
        },
        {
            "start_logit": -2.205078125,
            "end_logit": 9.5703125,
            "text": "virus",
            "probability": 5.066394805908203e-06
        },
        {
            "start_logit": -6.25,
            "end_logit": 9.5703125,
            "text": "Barr virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.328125,
            "end_logit": 9.5703125,
            "text": "-Barr virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -7.84765625,
            "text": "Epstein-Barr",
            "probability": 0.0
        },
        {
            "start_logit": -7.75,
            "end_logit": 9.5703125,
            "text": "of Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.234375,
            "text": "Epstein-Barr virus viral",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.2734375,
            "text": "Epstein-Barr virus viral load (EBV",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.3046875,
            "text": "Epstein-Barr virus viral load (EBV-VL) in peripheral blood, neutrophil/lymphocyte/monocyte counts, C-reactive protein values, and monospot test]",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.3203125,
            "text": "Epstein-Barr virus viral load (EBV-VL",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.3359375,
            "text": "Epstein-Barr virus viral load",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.4140625,
            "text": "Epstein-Barr virus viral load (EBV-VL) in peripheral blood, neutrophil/lymphocyte/monocyte counts, C-reactive protein values, and monospot test",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.4375,
            "text": "Epstein-Barr virus viral load (EBV-",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.4375,
            "text": "Epstein-Barr virus viral load (EBV-VL) in peripheral blood, neutrophil/lymphocyte/monocyte counts, C-reactive protein values, and monos",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.4375,
            "text": "Epstein-Barr virus viral load (EBV-VL) in peripheral blood, neutrophil/lymphocyte/monocyte counts, C-reactive protein values, and monospot",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.5703125,
            "text": "measurement of Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.5703125,
            "text": "(RT-PCR), IgM/IgG antibodies measured with different assays [measurement of Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 9.5703125,
            "text": "with different assays [measurement of Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.5703125,
            "text": "), IgM/IgG antibodies measured with different assays [measurement of Epstein-Barr virus",
            "probability": 0.0
        }
    ],
    "5a690487b750ff445500001f_6": [
        {
            "start_logit": 9.9375,
            "end_logit": 9.5859375,
            "text": "Epstein-Barr virus",
            "probability": 1.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -2.029296875,
            "text": "Epstein",
            "probability": 8.940696716308594e-06
        },
        {
            "start_logit": -2.154296875,
            "end_logit": 9.5859375,
            "text": "virus",
            "probability": 5.543231964111328e-06
        },
        {
            "start_logit": -6.4453125,
            "end_logit": 9.5859375,
            "text": "Barr virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.46875,
            "end_logit": 9.5859375,
            "text": "-Barr virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.62890625,
            "end_logit": 9.5859375,
            "text": ". Epstein-Barr virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.6328125,
            "end_logit": 9.5859375,
            "text": ". The boy subsequently recovered in one week with total disappearance of his rash. Epstein-Barr virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9375,
            "end_logit": -7.55859375,
            "text": "Epstein-Barr",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.3359375,
            "text": "Epstein-Barr virus-related infectious mononucleosis was considered the",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.34375,
            "text": "Epstein-Barr virus-",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.34375,
            "text": "Epstein-Barr virus-related",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": 9.5859375,
            "text": ", and positive monospot test. The boy subsequently recovered in one week with total disappearance of his rash. Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": 9.5859375,
            "text": "his rash. Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.5859375,
            "text": "the peripheral smear, and positive monospot test. The boy subsequently recovered in one week with total disappearance of his rash. Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.5859375,
            "text": "recovered in one week with total disappearance of his rash. Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.5859375,
            "text": "and positive monospot test. The boy subsequently recovered in one week with total disappearance of his rash. Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -6.62890625,
            "end_logit": -2.029296875,
            "text": ". Epstein",
            "probability": 0.0
        },
        {
            "start_logit": -6.6328125,
            "end_logit": -2.029296875,
            "text": ". The boy subsequently recovered in one week with total disappearance of his rash. Epstein",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": -2.029296875,
            "text": ", and positive monospot test. The boy subsequently recovered in one week with total disappearance of his rash. Epstein",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": -2.029296875,
            "text": "his rash. Epstein",
            "probability": 0.0
        }
    ],
    "5a690487b750ff445500001f_7": [
        {
            "start_logit": 10.078125,
            "end_logit": 9.703125,
            "text": "Epstein-Barr virus",
            "probability": 1.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -1.6640625,
            "text": "Epstein",
            "probability": 1.1563301086425781e-05
        },
        {
            "start_logit": -1.86328125,
            "end_logit": 9.703125,
            "text": "virus",
            "probability": 6.556510925292969e-06
        },
        {
            "start_logit": -6.33984375,
            "end_logit": 9.703125,
            "text": "-Barr virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.41796875,
            "end_logit": 9.703125,
            "text": "Barr virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.078125,
            "end_logit": -7.1796875,
            "text": "Epstein-Barr virus (EBV)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.078125,
            "end_logit": -7.2734375,
            "text": "Epstein-Barr virus (EBV",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.078125,
            "end_logit": -7.38671875,
            "text": "Epstein-Barr",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.171875,
            "end_logit": 9.703125,
            "text": "against Epstein-Barr virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.078125,
            "end_logit": -7.86328125,
            "text": "Epstein-Barr virus (",
            "probability": 0.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -8.0859375,
            "text": "Epstein-Barr virus (EBV) by",
            "probability": 0.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -8.1640625,
            "text": "Epstein-Barr virus (EBV) by the Monospot slide test to diagnose acute infectious mononucleosis and tested for anti-CMV (",
            "probability": 0.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -8.171875,
            "text": "Epstein-Barr virus (EBV) by the Monospot slide test to diagnose acute infectious mononucleosis and tested for anti-CMV (IgM",
            "probability": 0.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -8.203125,
            "text": "Epstein-Barr virus (EBV) by the Monospot slide test",
            "probability": 0.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -8.203125,
            "text": "Epstein-Barr virus (EBV) by the Monospot slide test to diagnose acute infectious mononucleosis and tested for anti-CMV (IgM)",
            "probability": 0.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -8.21875,
            "text": "Epstein-Barr virus (EBV) by the Monospot slide test to diagnose acute infectious mononucleosis and tested for anti-CMV (IgM) by ELISA technique for the diagnosis of acute Cytomegalovirus (",
            "probability": 0.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -8.2578125,
            "text": "Epstein-Barr virus (EBV) by the Monospot slide test to diagnose acute infectious mononucleosis and tested for anti",
            "probability": 0.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -8.2734375,
            "text": "Epstein-Barr virus (EBV) by the Monospot slide test to diagnose acute infectious mononucleosis and tested for anti-CMV (IgM) by ELISA technique for the diagnosis of acute Cytomegalovirus (CMV)",
            "probability": 0.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -8.28125,
            "text": "Epstein-Barr virus (EBV) by the Monospot slide test to diagnose acute infectious mononucleosis and tested for anti-CMV (IgM) by ELISA technique for the diagnosis of acute Cytomegalovirus (CMV",
            "probability": 0.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -8.28125,
            "text": "Epstein-Barr virus (EBV) by the Monospot slide",
            "probability": 0.0
        }
    ],
    "5a690487b750ff445500001f_8": [
        {
            "start_logit": 10.078125,
            "end_logit": 9.6640625,
            "text": "Epstein-Barr virus",
            "probability": 1.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -1.666015625,
            "text": "Epstein",
            "probability": 1.1920928955078125e-05
        },
        {
            "start_logit": -2.009765625,
            "end_logit": 9.6640625,
            "text": "virus",
            "probability": 5.602836608886719e-06
        },
        {
            "start_logit": -6.37890625,
            "end_logit": 9.6640625,
            "text": "-Barr virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.49609375,
            "end_logit": 9.6640625,
            "text": "Barr virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.0625,
            "end_logit": 9.6640625,
            "text": "for Epstein-Barr virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.078125,
            "end_logit": -7.65625,
            "text": "Epstein-Barr",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 9.6640625,
            "text": "he had a positive Monospot test and immunoglobulin G for Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.6640625,
            "text": "positive Monospot test and immunoglobulin G for Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 9.6640625,
            "text": ", but he had a positive Monospot test and immunoglobulin G for Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.6640625,
            "text": "had a positive Monospot test and immunoglobulin G for Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.6640625,
            "text": "a positive Monospot test and immunoglobulin G for Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.6640625,
            "text": "Monospot test and immunoglobulin G for Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.6640625,
            "text": "but he had a positive Monospot test and immunoglobulin G for Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.6640625,
            "text": "and immunoglobulin G for Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.6640625,
            "text": "His septic screen was negative, but he had a positive Monospot test and immunoglobulin G for Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.6640625,
            "text": "pot test and immunoglobulin G for Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.6640625,
            "text": "test and immunoglobulin G for Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -7.0625,
            "end_logit": -1.666015625,
            "text": "for Epstein",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": -1.666015625,
            "text": "he had a positive Monospot test and immunoglobulin G for Epstein",
            "probability": 0.0
        }
    ],
    "5c89623bf9c2ba6b28000004_1": [
        {
            "start_logit": 10.1171875,
            "end_logit": 9.484375,
            "text": "c.19G>A",
            "probability": 1.0
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -1.390625,
            "text": "c",
            "probability": 1.9073486328125e-05
        },
        {
            "start_logit": -2.232421875,
            "end_logit": 9.484375,
            "text": "A",
            "probability": 4.351139068603516e-06
        },
        {
            "start_logit": -5.0234375,
            "end_logit": 9.484375,
            "text": "G>A",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -5.5390625,
            "end_logit": 9.484375,
            "text": "(c.19G>A",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.3671875,
            "end_logit": 9.484375,
            "text": ", we performed sequence analysis of the gene and a novel homozygous missense mutation in exon 2 (c.19G>A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.44921875,
            "end_logit": 9.484375,
            "text": ">A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -7.26171875,
            "text": "c.19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.80078125,
            "end_logit": 9.484375,
            "text": ".19G>A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.87109375,
            "end_logit": 9.484375,
            "text": "19G>A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -7.68359375,
            "text": "c.19G>A, p.Val7",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -7.80859375,
            "text": "c.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -7.91015625,
            "text": "c.19G>A, p.Val",
            "probability": 0.0
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -7.96484375,
            "text": "c.19G>A, p",
            "probability": 0.0
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -8.03125,
            "text": "c.19G",
            "probability": 0.0
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -8.0546875,
            "text": "c.19G>",
            "probability": 0.0
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -8.109375,
            "text": "c.19G>A, p.Val7Met",
            "probability": 0.0
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -8.1484375,
            "text": "c.19G>A, p.Val7Met)",
            "probability": 0.0
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -8.1875,
            "text": "c.19G>A, p.Val7Met) of CFL2 was identified in both siblings",
            "probability": 0.0
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -8.2578125,
            "text": "c.19G>A, p.Val7Met) of CFL2",
            "probability": 0.0
        }
    ],
    "56c85ed65795f9a73e000012_1": [
        {
            "start_logit": 8.4609375,
            "end_logit": 8.1875,
            "text": "inhibits",
            "probability": 1.0
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -8.234375,
            "text": "inhibits TCR-mediated signal transduction",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 8.1875,
            "text": "Herein, we show that dasatinib inhibits",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -8.2578125,
            "text": "inhibits TCR",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.015625,
            "end_logit": 8.1875,
            "text": "that dasatinib inhibits",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -8.296875,
            "text": "inhibits TCR-mediated signal",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.171875,
            "end_logit": 8.1875,
            "text": "we show that dasatinib inhibits",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 8.1875,
            "text": "dasatinib inhibits",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 8.1875,
            "text": "show that dasatinib inhibits",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 8.1875,
            "text": ", we show that dasatinib inhibits",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.98046875,
            "end_logit": -8.234375,
            "text": "Herein, we show that dasatinib inhibits TCR-mediated signal transduction",
            "probability": 0.0
        },
        {
            "start_logit": -7.98046875,
            "end_logit": -8.2578125,
            "text": "Herein, we show that dasatinib inhibits TCR",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": -8.234375,
            "text": "that dasatinib inhibits TCR-mediated signal transduction",
            "probability": 0.0
        },
        {
            "start_logit": -7.98046875,
            "end_logit": -8.296875,
            "text": "Herein, we show that dasatinib inhibits TCR-mediated signal",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": -8.2578125,
            "text": "that dasatinib inhibits TCR",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": -8.296875,
            "text": "that dasatinib inhibits TCR-mediated signal",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -8.234375,
            "text": "we show that dasatinib inhibits TCR-mediated signal transduction",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -8.234375,
            "text": "dasatinib inhibits TCR-mediated signal transduction",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -8.2578125,
            "text": "we show that dasatinib inhibits TCR",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -8.2578125,
            "text": "dasatinib inhibits TCR",
            "probability": 0.0
        }
    ],
    "56c85ed65795f9a73e000012_2": [
        {
            "start_logit": 8.3671875,
            "end_logit": 8.1953125,
            "text": "inhibits",
            "probability": 1.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 8.1953125,
            "text": "that dasatinib inhibits",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 8.1953125,
            "text": "Herein, we show that dasatinib inhibits",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3671875,
            "end_logit": -8.3515625,
            "text": "inhibits TCR-mediated signal transduction",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 8.1953125,
            "text": "we show that dasatinib inhibits",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1875,
            "end_logit": 8.1953125,
            "text": "dasatinib inhibits",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3671875,
            "end_logit": -8.3671875,
            "text": "inhibits TCR",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 8.1953125,
            "text": "show that dasatinib inhibits",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 8.1953125,
            "text": ", we show that dasatinib inhibits",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.015625,
            "end_logit": -8.3515625,
            "text": "that dasatinib inhibits TCR-mediated signal transduction",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": -8.3671875,
            "text": "that dasatinib inhibits TCR",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": -8.3515625,
            "text": "Herein, we show that dasatinib inhibits TCR-mediated signal transduction",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": -8.3671875,
            "text": "Herein, we show that dasatinib inhibits TCR",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -8.3515625,
            "text": "we show that dasatinib inhibits TCR-mediated signal transduction",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -8.3515625,
            "text": "dasatinib inhibits TCR-mediated signal transduction",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -8.3671875,
            "text": "we show that dasatinib inhibits TCR",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -8.3671875,
            "text": "dasatinib inhibits TCR",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -8.3515625,
            "text": "show that dasatinib inhibits TCR-mediated signal transduction",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -8.3671875,
            "text": "show that dasatinib inhibits TCR",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -8.3515625,
            "text": ", we show that dasatinib inhibits TCR-mediated signal transduction",
            "probability": 0.0
        }
    ],
    "56c85ed65795f9a73e000012_3": [
        {
            "start_logit": 8.5,
            "end_logit": 8.171875,
            "text": "inhibits",
            "probability": 1.0
        },
        {
            "start_logit": -7.8828125,
            "end_logit": 8.171875,
            "text": ", inhibits",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 8.171875,
            "text": "a small-molecule protein tyrosine kinase inhibitor, inhibits",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.15625,
            "end_logit": 8.171875,
            "text": ", a small-molecule protein tyrosine kinase inhibitor, inhibits",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 8.171875,
            "text": "Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.171875,
            "end_logit": 8.171875,
            "text": "protein tyrosine kinase inhibitor, inhibits",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 8.171875,
            "text": "small-molecule protein tyrosine kinase inhibitor, inhibits",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 8.171875,
            "text": "molecule protein tyrosine kinase inhibitor, inhibits",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.21875,
            "end_logit": 8.171875,
            "text": "inhibitor, inhibits",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.234375,
            "end_logit": 8.171875,
            "text": "-molecule protein tyrosine kinase inhibitor, inhibits",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.171875,
            "text": "atinib, a small-molecule protein tyrosine kinase inhibitor, inhibits",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1015625,
            "end_logit": -8.296875,
            "text": "a small-molecule protein tyrosine kinase",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": -8.34375,
            "text": "a small-molecule protein tyrosine",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": -8.296875,
            "text": ", a small-molecule protein tyrosine kinase",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -8.296875,
            "text": "Dasatinib, a small-molecule protein tyrosine kinase",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -8.296875,
            "text": "protein tyrosine kinase",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": -8.34375,
            "text": ", a small-molecule protein tyrosine",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -8.34375,
            "text": "Dasatinib, a small-molecule protein tyrosine",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -8.296875,
            "text": "small-molecule protein tyrosine kinase",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -8.296875,
            "text": "molecule protein tyrosine kinase",
            "probability": 0.0
        }
    ],
    "56c85ed65795f9a73e000012_4": [
        {
            "start_logit": 8.59375,
            "end_logit": 8.15625,
            "text": "inhibits",
            "probability": 1.0
        },
        {
            "start_logit": -7.88671875,
            "end_logit": 8.15625,
            "text": ", inhibits",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.15625,
            "end_logit": 8.15625,
            "text": "a small-molecule protein tyrosine kinase inhibitor, inhibits",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 8.15625,
            "text": "Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 8.15625,
            "text": ", a small-molecule protein tyrosine kinase inhibitor, inhibits",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.234375,
            "end_logit": 8.15625,
            "text": "protein tyrosine kinase inhibitor, inhibits",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 8.15625,
            "text": "small-molecule protein tyrosine kinase inhibitor, inhibits",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.28125,
            "end_logit": 8.15625,
            "text": "molecule protein tyrosine kinase inhibitor, inhibits",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 8.15625,
            "text": "inhibitor, inhibits",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.15625,
            "text": "-molecule protein tyrosine kinase inhibitor, inhibits",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.15625,
            "end_logit": -8.1953125,
            "text": "a small-molecule protein tyrosine kinase",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -8.1953125,
            "text": "Dasatinib, a small-molecule protein tyrosine kinase",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": -8.1953125,
            "text": ", a small-molecule protein tyrosine kinase",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": -8.25,
            "text": "a small-molecule protein tyrosine",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -8.25,
            "text": "Dasatinib, a small-molecule protein tyrosine",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": -8.25,
            "text": ", a small-molecule protein tyrosine",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -8.1953125,
            "text": "protein tyrosine kinase",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -8.1953125,
            "text": "small-molecule protein tyrosine kinase",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": -8.1953125,
            "text": "molecule protein tyrosine kinase",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -8.25,
            "text": "protein tyrosine",
            "probability": 0.0
        }
    ],
    "56c85ed65795f9a73e000012_5": [
        {
            "start_logit": 8.4765625,
            "end_logit": 8.25,
            "text": "inhibits",
            "probability": 1.0
        },
        {
            "start_logit": -7.69921875,
            "end_logit": 8.25,
            "text": "Dasatinib inhibits",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -8.140625,
            "text": "inhibits the proliferation and function of CD4+CD25",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -8.1875,
            "text": "inhibits the proliferation and function of CD4+CD25+ regulatory T cells.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.34375,
            "end_logit": 8.25,
            "text": "atinib inhibits",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.09375,
            "end_logit": -8.1875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.69921875,
            "end_logit": -8.140625,
            "text": "Dasatinib inhibits the proliferation and function of CD4+CD25",
            "probability": 0.0
        },
        {
            "start_logit": -7.734375,
            "end_logit": -8.140625,
            "text": "of CD4+CD25",
            "probability": 0.0
        },
        {
            "start_logit": -7.69921875,
            "end_logit": -8.1875,
            "text": "Dasatinib inhibits the proliferation and function of CD4+CD25+ regulatory T cells.",
            "probability": 0.0
        },
        {
            "start_logit": -7.734375,
            "end_logit": -8.1875,
            "text": "of CD4+CD25+ regulatory T cells.",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": -8.140625,
            "text": "CD4+CD25",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": -8.1875,
            "text": "CD4+CD25+ regulatory T cells.",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -8.140625,
            "text": "the proliferation and function of CD4+CD25",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -8.1875,
            "text": "the proliferation and function of CD4+CD25+ regulatory T cells.",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -8.140625,
            "text": "function of CD4+CD25",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": -8.140625,
            "text": "proliferation and function of CD4+CD25",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -8.1875,
            "text": "function of CD4+CD25+ regulatory T cells.",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": -8.140625,
            "text": "and function of CD4+CD25",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": -8.140625,
            "text": "+CD25",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": -8.1875,
            "text": "proliferation and function of CD4+CD25+ regulatory T cells.",
            "probability": 0.0
        }
    ],
    "58f4b25e70f9fc6f0f000011_1": [
        {
            "start_logit": 8.2578125,
            "end_logit": 8.046875,
            "text": "Liver",
            "probability": 1.0
        },
        {
            "start_logit": 8.2578125,
            "end_logit": -8.140625,
            "text": "Liver Injury Network",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.2578125,
            "end_logit": -8.203125,
            "text": "Liver Injury",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.2578125,
            "end_logit": -8.3125,
            "text": "Liver Injury Network.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.125,
            "end_logit": 8.046875,
            "text": ", including the ongoing, prospective U.S. Drug-Induced Liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.15625,
            "end_logit": 8.046875,
            "text": ", prospective U.S. Drug-Induced Liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 8.046875,
            "text": "a case-fatality rate or need for transplant of 10% or higher has been validated in several large national registries, including the ongoing, prospective U.S. Drug-Induced Liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": 8.046875,
            "text": ". Drug-Induced Liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": 8.046875,
            "text": "in several large national registries, including the ongoing, prospective U.S. Drug-Induced Liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": 8.046875,
            "text": "for transplant of 10% or higher has been validated in several large national registries, including the ongoing, prospective U.S. Drug-Induced Liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 8.046875,
            "text": "prospective U.S. Drug-Induced Liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 8.046875,
            "text": "been validated in several large national registries, including the ongoing, prospective U.S. Drug-Induced Liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 8.046875,
            "text": "transplant of 10% or higher has been validated in several large national registries, including the ongoing, prospective U.S. Drug-Induced Liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.28125,
            "end_logit": 8.046875,
            "text": "rate or need for transplant of 10% or higher has been validated in several large national registries, including the ongoing, prospective U.S. Drug-Induced Liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 8.046875,
            "text": "induced hepatocellular jaundice causing a case-fatality rate or need for transplant of 10% or higher has been validated in several large national registries, including the ongoing, prospective U.S. Drug-Induced Liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 8.046875,
            "text": "several large national registries, including the ongoing, prospective U.S. Drug-Induced Liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 8.046875,
            "text": "or need for transplant of 10% or higher has been validated in several large national registries, including the ongoing, prospective U.S. Drug-Induced Liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 8.046875,
            "text": "-fatality rate or need for transplant of 10% or higher has been validated in several large national registries, including the ongoing, prospective U.S. Drug-Induced Liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.328125,
            "end_logit": 8.046875,
            "text": "Induced Liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.8671875,
            "end_logit": -8.3125,
            "text": ".",
            "probability": 0.0
        }
    ],
    "58f4b25e70f9fc6f0f000011_2": [
        {
            "start_logit": 8.2421875,
            "end_logit": 8.3671875,
            "text": "liver",
            "probability": 1.0
        },
        {
            "start_logit": -7.9296875,
            "end_logit": 8.3671875,
            "text": "with liver",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 8.3671875,
            "text": "associated with liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 8.3671875,
            "text": "alleles outside those associated with liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.2421875,
            "end_logit": -8.28125,
            "text": "liver injury patterns",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.2421875,
            "end_logit": -8.3203125,
            "text": "liver injury patterns were found to affect potential severity as measured by Hy's Law",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.2421875,
            "end_logit": -8.3515625,
            "text": "liver injury patterns were found to affect potential severity as measured by Hy's Law criteria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.2421875,
            "end_logit": -8.3515625,
            "text": "liver injury",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.2421875,
            "end_logit": -8.359375,
            "text": "liver injury patterns were found to affect potential severity as measured",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.2421875,
            "end_logit": -8.3671875,
            "text": "liver injury patterns were found to affect potential severity as measured by Hy'",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9296875,
            "end_logit": -8.28125,
            "text": "with liver injury patterns",
            "probability": 0.0
        },
        {
            "start_logit": -7.9296875,
            "end_logit": -8.3203125,
            "text": "with liver injury patterns were found to affect potential severity as measured by Hy's Law",
            "probability": 0.0
        },
        {
            "start_logit": -7.9296875,
            "end_logit": -8.3515625,
            "text": "with liver injury patterns were found to affect potential severity as measured by Hy's Law criteria",
            "probability": 0.0
        },
        {
            "start_logit": -7.9296875,
            "end_logit": -8.3515625,
            "text": "with liver injury",
            "probability": 0.0
        },
        {
            "start_logit": -7.9296875,
            "end_logit": -8.359375,
            "text": "with liver injury patterns were found to affect potential severity as measured",
            "probability": 0.0
        },
        {
            "start_logit": -7.9296875,
            "end_logit": -8.3671875,
            "text": "with liver injury patterns were found to affect potential severity as measured by Hy'",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -8.3203125,
            "text": "found to affect potential severity as measured by Hy's Law",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -8.3515625,
            "text": "found to affect potential severity as measured by Hy's Law criteria",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -8.359375,
            "text": "found to affect potential severity as measured",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -8.3671875,
            "text": "found to affect potential severity as measured by Hy'",
            "probability": 0.0
        }
    ],
    "58f4b25e70f9fc6f0f000011_3": [
        {
            "start_logit": 8.2734375,
            "end_logit": 8.375,
            "text": "liver",
            "probability": 1.0
        },
        {
            "start_logit": -6.96875,
            "end_logit": 8.375,
            "text": ".We conducted a retrospective cohort study of 15,353 Kaiser Permanente Northern California members diagnosed with DILI from 2004 through 2010, liver",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -8.078125,
            "end_logit": 8.375,
            "text": ", liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 8.375,
            "text": "of 15,353 Kaiser Permanente Northern California members diagnosed with DILI from 2004 through 2010, liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.234375,
            "end_logit": 8.375,
            "text": "validated the model in a separate sample.We conducted a retrospective cohort study of 15,353 Kaiser Permanente Northern California members diagnosed with DILI from 2004 through 2010, liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 8.375,
            "text": "of alanine aminotransferase or aspartate aminotransferase and total bilirubin, and validated the model in a separate sample.We conducted a retrospective cohort study of 15,353 Kaiser Permanente Northern California members diagnosed with DILI from 2004 through 2010, liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 8.375,
            "text": "on levels of alanine aminotransferase or aspartate aminotransferase and total bilirubin, and validated the model in a separate sample.We conducted a retrospective cohort study of 15,353 Kaiser Permanente Northern California members diagnosed with DILI from 2004 through 2010, liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 8.375,
            "text": "We conducted a retrospective cohort study of 15,353 Kaiser Permanente Northern California members diagnosed with DILI from 2004 through 2010, liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": 8.375,
            "text": "with DILI from 2004 through 2010, liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 8.375,
            "text": "and validated the model in a separate sample.We conducted a retrospective cohort study of 15,353 Kaiser Permanente Northern California members diagnosed with DILI from 2004 through 2010, liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 8.375,
            "text": "sample.We conducted a retrospective cohort study of 15,353 Kaiser Permanente Northern California members diagnosed with DILI from 2004 through 2010, liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.28125,
            "end_logit": 8.375,
            "text": "the model in a separate sample.We conducted a retrospective cohort study of 15,353 Kaiser Permanente Northern California members diagnosed with DILI from 2004 through 2010, liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.2734375,
            "end_logit": -8.2578125,
            "text": "liver aminotransferase",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.2734375,
            "end_logit": -8.2890625,
            "text": "liver aminotransferase levels above the upper limit of normal, and no pre-existing liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.2734375,
            "end_logit": -8.296875,
            "text": "liver aminotransferase levels above the upper limit of normal, and no pre",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.2734375,
            "end_logit": -8.296875,
            "text": "liver aminotransferase levels above the upper limit of normal, and no pre-existing liver disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.2734375,
            "end_logit": -8.3203125,
            "text": "liver aminotransferase levels above the upper limit",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.2734375,
            "end_logit": -8.328125,
            "text": "liver aminotransferase levels above the upper",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.96875,
            "end_logit": -8.234375,
            "text": ".We conducted a retrospective cohort study of 15",
            "probability": 0.0
        },
        {
            "start_logit": -6.96875,
            "end_logit": -8.2578125,
            "text": ".We conducted a retrospective cohort study of 15,353 Kaiser Permanente Northern California members diagnosed with DILI from 2004 through 2010, liver aminotransferase",
            "probability": 0.0
        }
    ],
    "58f4b25e70f9fc6f0f000011_4": [
        {
            "start_logit": 8.4453125,
            "end_logit": 8.2734375,
            "text": "Liver",
            "probability": 1.0
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -8.15625,
            "text": "Liver Failure",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -8.2421875,
            "text": "Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy's Law",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -8.2421875,
            "text": "Liver Failure in Patients With Drug-Induced Liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -8.2890625,
            "text": "Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy'",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -8.3125,
            "text": "Liver Failure in Patients With Drug-Induced Liver Injury",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -8.328125,
            "text": "Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -8.3359375,
            "text": "Liver Failure in Patients With Drug",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.234375,
            "end_logit": 8.2734375,
            "text": "Acute Liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 8.2734375,
            "text": "Risk of Acute Liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.234375,
            "end_logit": -8.15625,
            "text": "Acute Liver Failure",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -8.15625,
            "text": "Risk of Acute Liver Failure",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -8.2421875,
            "text": "Acute Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy's Law",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -8.2421875,
            "text": "Acute Liver Failure in Patients With Drug-Induced Liver",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -8.2421875,
            "text": "Risk of Acute Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy's Law",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -8.2421875,
            "text": "Risk of Acute Liver Failure in Patients With Drug-Induced Liver",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -8.2890625,
            "text": "Acute Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy'",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -8.3125,
            "text": "Acute Liver Failure in Patients With Drug-Induced Liver Injury",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -8.328125,
            "text": "Acute Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -8.3359375,
            "text": "Acute Liver Failure in Patients With Drug",
            "probability": 0.0
        }
    ],
    "58f4b25e70f9fc6f0f000011_5": [
        {
            "start_logit": 8.5859375,
            "end_logit": 8.1640625,
            "text": "liver",
            "probability": 1.0
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -8.3046875,
            "text": "liver injury (DILI) with jaundice indicates a serious reaction, is used widely to determine risk for acute liver failure (ALF)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -8.3203125,
            "text": "liver injury (DILI) with jaundice indicates a serious reaction, is used widely to determine risk for acute liver failure (ALF",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -8.3203125,
            "text": "liver injury (DILI) with jaundice indicates a serious reaction, is used widely to determine risk for acute liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -8.328125,
            "text": "liver injury (DILI) with jaundice indicates a serious reaction, is used widely to determine risk for acute liver failure",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -8.3359375,
            "text": "liver injury (DIL",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -8.34375,
            "text": "liver injury (DILI) with jaundice indicates a serious reaction, is used widely to determine risk for acute liver failure (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -8.3515625,
            "text": "liver injury",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -8.3671875,
            "text": "liver injury (DILI) with jaundice",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -8.375,
            "text": "liver injury (DILI)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -8.375,
            "text": "liver injury (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 8.1640625,
            "text": "that hepatocellular drug-induced liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 8.1640625,
            "text": "induced liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 8.1640625,
            "text": "states that hepatocellular drug-induced liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.359375,
            "end_logit": 8.1640625,
            "text": "-induced liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3671875,
            "end_logit": 8.1640625,
            "text": "drug-induced liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -8.3046875,
            "text": "that hepatocellular drug-induced liver injury (DILI) with jaundice indicates a serious reaction, is used widely to determine risk for acute liver failure (ALF)",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -8.3203125,
            "text": "that hepatocellular drug-induced liver injury (DILI) with jaundice indicates a serious reaction, is used widely to determine risk for acute liver failure (ALF",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -8.3203125,
            "text": "that hepatocellular drug-induced liver injury (DILI) with jaundice indicates a serious reaction, is used widely to determine risk for acute liver",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -8.328125,
            "text": "that hepatocellular drug-induced liver injury (DILI) with jaundice indicates a serious reaction, is used widely to determine risk for acute liver failure",
            "probability": 0.0
        }
    ],
    "58f4b25e70f9fc6f0f000011_6": [
        {
            "start_logit": 8.09375,
            "end_logit": 8.3671875,
            "text": "liver",
            "probability": 1.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": 8.3671875,
            "text": "identify drug-induced liver",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 8.3671875,
            "text": "induced liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 8.3671875,
            "text": "drug-induced liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 8.3671875,
            "text": "to identify drug-induced liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.09375,
            "end_logit": -8.078125,
            "text": "liver injury (DIL",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 8.3671875,
            "text": "Hy's law is a method used to identify drug-induced liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 8.3671875,
            "text": "used to identify drug-induced liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 8.3671875,
            "text": "-induced liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3671875,
            "end_logit": 8.3671875,
            "text": "method used to identify drug-induced liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.09375,
            "end_logit": -8.171875,
            "text": "liver injury",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.09375,
            "end_logit": -8.296875,
            "text": "liver injury (DILI",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.09375,
            "end_logit": -8.34375,
            "text": "liver injury (DILI)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.09375,
            "end_logit": -8.078125,
            "text": "identify drug-induced liver injury (DIL",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -8.078125,
            "text": "induced liver injury (DIL",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": -8.171875,
            "text": "identify drug-induced liver injury",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -8.171875,
            "text": "induced liver injury",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": -8.078125,
            "text": "(DIL",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": -8.078125,
            "text": "drug-induced liver injury (DIL",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": -8.296875,
            "text": "identify drug-induced liver injury (DILI",
            "probability": 0.0
        }
    ],
    "58f4b25e70f9fc6f0f000011_7": [
        {
            "start_logit": 8.1953125,
            "end_logit": 8.3984375,
            "text": "liver",
            "probability": 1.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 8.3984375,
            "text": "severe liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 8.3984375,
            "text": "Potential severe liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -8.28125,
            "text": "liver injury is identified in clinical trials by ALT>3 \u00d7 upper limits of normal (ULN) and total bilirubin>2 \u00d7 ULN, and termed 'Hy's Law",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -8.28125,
            "text": "liver injury is identified in clinical trials by ALT>3 \u00d7 upper limits of normal (ULN) and total bilirubin>2 \u00d7 ULN, and termed 'Hy's Law' by the US FDA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -8.3046875,
            "text": "liver injury is identified in clinical trials by ALT>3 \u00d7 upper limits of normal (ULN) and total bilirubin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -8.3125,
            "text": "liver injury is identified in clinical trials by ALT>3 \u00d7 upper limits of normal (ULN) and total bilirubin>2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -8.3203125,
            "text": "liver injury is identified in clinical trials by ALT>3 \u00d7 upper limits of normal (ULN) and total bilirubin>2 \u00d7 ULN, and termed 'Hy'",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -8.328125,
            "text": "liver injury is identified in clinical trials by ALT>3 \u00d7 upper limits of normal (ULN) and total bilirubin>2 \u00d7",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -8.328125,
            "text": "liver injury is identified in clinical trials by ALT",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -8.3359375,
            "text": "liver injury is identified in clinical trials by ALT>3 \u00d7 upper limits of normal",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -8.34375,
            "text": "liver injury is identified in clinical trials by ALT>3 \u00d7 upper limits of normal (ULN) and total bilirubin>2 \u00d7 ULN, and termed 'Hy's Law' by",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -8.34375,
            "text": "liver injury is identified in clinical trials by ALT>3 \u00d7 upper limits of normal (ULN) and total bilirubin>2 \u00d7 UL",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -8.3515625,
            "text": "liver injury is identified in clinical trials by ALT>3 \u00d7 upper limits of normal (ULN) and total bilirubin>2 \u00d7 ULN, and termed 'Hy's",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -8.3515625,
            "text": "liver injury is identified in clinical trials by ALT>3 \u00d7 upper limits",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -8.3515625,
            "text": "liver injury is identified in clinical trials by ALT>3 \u00d7 upper limits of normal (ULN) and total bilirubin>",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -8.359375,
            "text": "liver injury is identified in clinical trials by ALT>3 \u00d7 upper limits of normal (ULN",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.046875,
            "end_logit": -8.28125,
            "text": "(ULN) and total bilirubin>2 \u00d7 ULN, and termed 'Hy's Law",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": -8.28125,
            "text": "(ULN) and total bilirubin>2 \u00d7 ULN, and termed 'Hy's Law' by the US FDA",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": -8.3046875,
            "text": "(ULN) and total bilirubin",
            "probability": 0.0
        }
    ],
    "58f4b25e70f9fc6f0f000011_8": [
        {
            "start_logit": 8.171875,
            "end_logit": 8.4296875,
            "text": "liver",
            "probability": 1.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 8.4296875,
            "text": "Severe liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.171875,
            "end_logit": -8.0703125,
            "text": "liver injury is identified by the liver",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.171875,
            "end_logit": -8.1796875,
            "text": "liver injury is identified by the liver chemistry",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.171875,
            "end_logit": -8.1953125,
            "text": "liver injury is identified by the liver chemistry threshold of alanine aminotransferase",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.171875,
            "end_logit": -8.25,
            "text": "liver injury is identified by the liver chemistry threshold of alanine aminotransferase (ALT",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.171875,
            "end_logit": -8.2578125,
            "text": "liver injury is identified by the liver chemistry threshold of alanine aminotransferase (ALT)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.171875,
            "end_logit": -8.28125,
            "text": "liver injury is identified by the liver chemistry threshold",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.171875,
            "end_logit": -8.28125,
            "text": "liver injury is identified by the liver chemistry threshold of alanine aminotransferase (ALT)>3\u00d7 upper limit of normal (ULN) and bilirubin>2\u00d7 ULN, termed Hy's law by the Food and Drug Administration",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.171875,
            "end_logit": -8.28125,
            "text": "liver injury is identified by the liver chemistry threshold of alanine aminotransferase (ALT)>3\u00d7 upper limit of normal",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.171875,
            "end_logit": -8.28125,
            "text": "liver injury is identified by the liver chemistry threshold of alanine aminotransferase (ALT)>3\u00d7 upper limit of normal (ULN)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.171875,
            "end_logit": -8.28125,
            "text": "liver injury is identified by the liver chemistry threshold of alanine aminotransferase (ALT)>3\u00d7 upper limit of normal (ULN) and bilirubin>2\u00d7 ULN, termed Hy's law",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.171875,
            "end_logit": -8.2890625,
            "text": "liver injury is identified by the liver chemistry threshold of alanine aminotransferase (ALT)>3\u00d7 upper limit of normal (ULN",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.171875,
            "end_logit": -8.2890625,
            "text": "liver injury is identified by the liver chemistry threshold of alanine aminotransferase (ALT)>3\u00d7 upper limit of normal (ULN) and bilirubin>2\u00d7 ULN, termed Hy's law by the Food and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.171875,
            "end_logit": -8.2890625,
            "text": "liver injury is identified by the liver chemistry threshold of alanine aminotransferase (ALT)>3\u00d7 upper limit of normal (ULN) and bilirubin>2\u00d7 ULN, termed Hy's law by the Food and Drug",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.171875,
            "end_logit": -8.296875,
            "text": "liver injury is identified by the liver chemistry threshold of alanine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.171875,
            "end_logit": -8.296875,
            "text": "liver injury is identified by the liver chemistry threshold of alanine aminotransferase (ALT)>3\u00d7 upper limit of normal (ULN) and bilirubin>2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.171875,
            "end_logit": -8.3125,
            "text": "liver injury is identified by the liver chemistry threshold of alanine aminotransferase (ALT)>3\u00d7 upper limit of normal (ULN) and bilirubin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.171875,
            "end_logit": -8.3125,
            "text": "liver injury is identified by the liver chemistry threshold of alanine aminotransferase (ALT)>",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1328125,
            "end_logit": -8.0703125,
            "text": "Severe liver injury is identified by the liver",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_1": [
        {
            "start_logit": 8.5390625,
            "end_logit": 8.2890625,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -7.90625,
            "end_logit": 8.2890625,
            "text": ", dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 8.2890625,
            "text": ", idarucizumab for one of the DOACs i.e., dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.234375,
            "end_logit": 8.2890625,
            "text": "reversal agent has been approved by the Food and Drug Administration (FDA), idarucizumab for one of the DOACs i.e., dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 8.2890625,
            "text": "So far only one reversal agent has been approved by the Food and Drug Administration (FDA), idarucizumab for one of the DOACs i.e., dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.265625,
            "end_logit": 8.2890625,
            "text": "approved by the Food and Drug Administration (FDA), idarucizumab for one of the DOACs i.e., dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 8.2890625,
            "text": "has been approved by the Food and Drug Administration (FDA), idarucizumab for one of the DOACs i.e., dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.28125,
            "end_logit": 8.2890625,
            "text": "been approved by the Food and Drug Administration (FDA), idarucizumab for one of the DOACs i.e., dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 8.2890625,
            "text": "idarucizumab for one of the DOACs i.e., dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.2890625,
            "text": "agent has been approved by the Food and Drug Administration (FDA), idarucizumab for one of the DOACs i.e., dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.2890625,
            "text": "(FDA), idarucizumab for one of the DOACs i.e., dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 8.2890625,
            "text": "rucizumab for one of the DOACs i.e., dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 8.2890625,
            "text": "by the Food and Drug Administration (FDA), idarucizumab for one of the DOACs i.e., dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 8.2890625,
            "text": "far only one reversal agent has been approved by the Food and Drug Administration (FDA), idarucizumab for one of the DOACs i.e., dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.328125,
            "end_logit": 8.2890625,
            "text": "the Food and Drug Administration (FDA), idarucizumab for one of the DOACs i.e., dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.328125,
            "end_logit": 8.2890625,
            "text": "only one reversal agent has been approved by the Food and Drug Administration (FDA), idarucizumab for one of the DOACs i.e., dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -8.2734375,
            "text": ", idarucizumab for one of the DOACs i",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -8.2734375,
            "text": "reversal agent has been approved by the Food and Drug Administration (FDA), idarucizumab for one of the DOACs i",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -8.3046875,
            "text": ", idarucizumab for one",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -8.2734375,
            "text": "So far only one reversal agent has been approved by the Food and Drug Administration (FDA), idarucizumab for one of the DOACs i",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_2": [
        {
            "start_logit": 8.3359375,
            "end_logit": 8.4453125,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": 8.4453125,
            "text": ", or dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.046875,
            "end_logit": 8.4453125,
            "text": "or dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 8.4453125,
            "text": "oral anticoagulants such as apixaban, rivaroxaban, or dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 8.4453125,
            "text": ", rivaroxaban, or dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 8.4453125,
            "text": "such as apixaban, rivaroxaban, or dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": 8.4453125,
            "text": "as apixaban, rivaroxaban, or dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 8.4453125,
            "text": "apixaban, rivaroxaban, or dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 8.4453125,
            "text": "rivaroxaban, or dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.28125,
            "end_logit": 8.4453125,
            "text": "New oral anticoagulants such as apixaban, rivaroxaban, or dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3359375,
            "end_logit": -8.3046875,
            "text": "dabigatran may be preferred to vitamin K antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexane",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3359375,
            "end_logit": -8.359375,
            "text": "dabigatran may",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3359375,
            "end_logit": -8.3828125,
            "text": "dabigatran may be preferred to vitamin K antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andex",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3359375,
            "end_logit": -8.3828125,
            "text": "dabigatran may be preferred to vitamin K antagonists in patients without cancer or renal failure, more so after the development of reversal agents such",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3359375,
            "end_logit": -8.3984375,
            "text": "dabigatran may be preferred to vitamin K antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3359375,
            "end_logit": -8.3984375,
            "text": "dabigatran may be preferred to vitamin K antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3359375,
            "end_logit": -8.3984375,
            "text": "dabigatran may be preferred to vitamin K antagonists in patients without cancer or renal failure",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3359375,
            "end_logit": -8.40625,
            "text": "dabigatran may be preferred to vitamin K antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3359375,
            "end_logit": -8.4140625,
            "text": "dabigatran may be preferred to vitamin K antagonists in patients without cancer or renal failure, more so",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3359375,
            "end_logit": -8.4140625,
            "text": "dabigatran may be preferred to vitamin K",
            "probability": 5.960464477539063e-08
        }
    ],
    "5a7237672dc08e987e000008_3": [
        {
            "start_logit": 7.94921875,
            "end_logit": 8.78125,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -7.8515625,
            "end_logit": 8.78125,
            "text": "of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 8.78125,
            "text": "Idarucizumab resulted in immediate, complete and sustained reversal of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.1875,
            "end_logit": 8.78125,
            "text": "reversal of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.21875,
            "end_logit": 8.78125,
            "text": "immediate, complete and sustained reversal of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.25,
            "end_logit": 8.78125,
            "text": ", complete and sustained reversal of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.265625,
            "end_logit": 8.78125,
            "text": "in immediate, complete and sustained reversal of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.28125,
            "end_logit": 8.78125,
            "text": "sustained reversal of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3125,
            "end_logit": 8.78125,
            "text": "rucizumab resulted in immediate, complete and sustained reversal of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.94921875,
            "end_logit": -8.1640625,
            "text": "dabigatran anticoagulant",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.94921875,
            "end_logit": -8.28125,
            "text": "dabigatran anticoagulant activity",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.94921875,
            "end_logit": -8.359375,
            "text": "dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.94921875,
            "end_logit": -8.3671875,
            "text": "dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renal",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8515625,
            "end_logit": -8.1640625,
            "text": "of dabigatran anticoagulant",
            "probability": 0.0
        },
        {
            "start_logit": -7.8515625,
            "end_logit": -8.28125,
            "text": "of dabigatran anticoagulant activity",
            "probability": 0.0
        },
        {
            "start_logit": -7.8515625,
            "end_logit": -8.359375,
            "text": "of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally",
            "probability": 0.0
        },
        {
            "start_logit": -7.8515625,
            "end_logit": -8.3671875,
            "text": "of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renal",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": -8.1640625,
            "text": "Idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -8.1640625,
            "text": "reversal of dabigatran anticoagulant",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": -8.28125,
            "text": "Idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_4": [
        {
            "start_logit": 8.0703125,
            "end_logit": 8.6796875,
            "text": "Dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -7.78125,
            "end_logit": 8.6796875,
            "text": "of Dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.21875,
            "end_logit": 8.6796875,
            "text": "Reversal of Dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 8.6796875,
            "text": "Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 8.6796875,
            "text": "Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3125,
            "end_logit": 8.6796875,
            "text": "Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.328125,
            "end_logit": 8.6796875,
            "text": "Mediated Reversal of Dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.34375,
            "end_logit": 8.6796875,
            "text": "Idarucizumab-Mediated Reversal of Dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0703125,
            "end_logit": -8.2109375,
            "text": "Dabigatran Anticoagulant",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0703125,
            "end_logit": -8.328125,
            "text": "Dabigatran Anticoagulant Activity in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0703125,
            "end_logit": -8.34375,
            "text": "Dabigatran Anticoagulant Activity",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0703125,
            "end_logit": -8.3671875,
            "text": "Dabigatran Anticoagulant Activity in a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.78125,
            "end_logit": -8.2109375,
            "text": "of Dabigatran Anticoagulant",
            "probability": 0.0
        },
        {
            "start_logit": -7.78125,
            "end_logit": -8.328125,
            "text": "of Dabigatran Anticoagulant Activity in",
            "probability": 0.0
        },
        {
            "start_logit": -7.78125,
            "end_logit": -8.34375,
            "text": "of Dabigatran Anticoagulant Activity",
            "probability": 0.0
        },
        {
            "start_logit": -7.78125,
            "end_logit": -8.3671875,
            "text": "of Dabigatran Anticoagulant Activity in a",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.2109375,
            "text": "Reversal of Dabigatran Anticoagulant",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": -8.2109375,
            "text": "Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": -8.2109375,
            "text": "Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": -8.2109375,
            "text": "Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_5": [
        {
            "start_logit": 8.265625,
            "end_logit": 8.515625,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 8.515625,
            "text": "of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 8.515625,
            "text": "discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 8.515625,
            "text": "reversal of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1875,
            "end_logit": 8.515625,
            "text": "We also discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.21875,
            "end_logit": 8.515625,
            "text": "strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.234375,
            "end_logit": 8.515625,
            "text": "idarucizumab for the reversal of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.234375,
            "end_logit": 8.515625,
            "text": "reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.234375,
            "end_logit": 8.515625,
            "text": "of idarucizumab for the reversal of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.265625,
            "end_logit": -8.375,
            "text": "dabigatran and two agents, andexane",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.265625,
            "end_logit": -8.3828125,
            "text": "dabigatran and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.125,
            "end_logit": -8.375,
            "text": "of dabigatran and two agents, andexane",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -8.3828125,
            "text": "of dabigatran and",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -8.375,
            "text": "discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran and two agents, andexane",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -8.375,
            "text": "reversal of dabigatran and two agents, andexane",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -8.3828125,
            "text": "discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran and",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -8.3828125,
            "text": "discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -8.3828125,
            "text": "reversal of dabigatran and",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -8.3828125,
            "text": "reversal",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -8.375,
            "text": "We also discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran and two agents, andexane",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_6": [
        {
            "start_logit": 8.4609375,
            "end_logit": 8.359375,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -7.84375,
            "end_logit": 8.359375,
            "text": "of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 8.359375,
            "text": "anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 8.359375,
            "text": "reversal of the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.265625,
            "end_logit": 8.359375,
            "text": "is approved for the urgent reversal of the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.265625,
            "end_logit": 8.359375,
            "text": "urgent reversal of the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.359375,
            "text": "Idarucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.359375,
            "text": "approved for the urgent reversal of the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.359375,
            "text": "the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 8.359375,
            "text": "for the urgent reversal of the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 8.359375,
            "text": "the urgent reversal of the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.328125,
            "end_logit": 8.359375,
            "text": "that is approved for the urgent reversal of the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 8.359375,
            "text": "of the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 8.359375,
            "text": "reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 8.359375,
            "text": "agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.375,
            "end_logit": 8.359375,
            "text": "rucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -8.2421875,
            "text": "anticoagulant effects",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": -8.2421875,
            "text": "reversal of the anticoagulant effects",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": -8.2421875,
            "text": "is approved for the urgent reversal of the anticoagulant effects",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": -8.2421875,
            "text": "urgent reversal of the anticoagulant effects",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_7": [
        {
            "start_logit": 8.3359375,
            "end_logit": 8.4609375,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -7.1015625,
            "end_logit": 8.4609375,
            "text": "with dabigatran",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 8.4609375,
            "text": "for idarucizumab in treatment of bleeding associated with dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 8.4609375,
            "text": "The initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 8.4609375,
            "text": "initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.265625,
            "end_logit": 8.4609375,
            "text": "associated with dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.28125,
            "end_logit": 8.4609375,
            "text": "of bleeding associated with dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 8.4609375,
            "text": "idarucizumab in treatment of bleeding associated with dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 8.4609375,
            "text": "data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.4609375,
            "text": "role for idarucizumab in treatment of bleeding associated with dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.4609375,
            "text": "bleeding associated with dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 8.4609375,
            "text": "in treatment of bleeding associated with dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 8.4609375,
            "text": "treatment of bleeding associated with dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.328125,
            "end_logit": 8.4609375,
            "text": "rucizumab in treatment of bleeding associated with dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 8.4609375,
            "text": "suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 8.4609375,
            "text": ": The initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.359375,
            "end_logit": 8.4609375,
            "text": "a definite role for idarucizumab in treatment of bleeding associated with dabigatran",
            "probability": 5.960464477539063e-08
        }
    ],
    "5a7237672dc08e987e000008_8": [
        {
            "start_logit": 7.8359375,
            "end_logit": 8.8046875,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -7.4609375,
            "end_logit": 8.8046875,
            "text": "of dabigatran",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.69921875,
            "end_logit": 8.8046875,
            "text": "administration of 5 g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.79296875,
            "end_logit": 8.8046875,
            "text": "The administration of 5 g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 8.8046875,
            "text": "5 g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 8.8046875,
            "text": "anticoagulant activity of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 8.8046875,
            "text": "intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.03125,
            "end_logit": 8.8046875,
            "text": "the anticoagulant activity of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 8.8046875,
            "text": "of 5 g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0625,
            "end_logit": 8.8046875,
            "text": "completely reversed the anticoagulant activity of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.09375,
            "end_logit": 8.8046875,
            "text": "g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 8.8046875,
            "text": "promptly and completely reversed the anticoagulant activity of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 8.8046875,
            "text": "idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.8359375,
            "end_logit": -7.515625,
            "text": "dabigatran as assessed by routine and specific coagulation assays (aPTT from to 75 to 26 s, PT from 26 to 11 s and diluted thrombin time from 92 to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.8359375,
            "end_logit": -7.765625,
            "text": "dabigatran as assessed by routine and specific coagulation assays (aPTT from to 75 to 26 s, PT from 26 to 11 s and diluted thrombin time from 92 to 27 s).",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.8359375,
            "end_logit": -7.91796875,
            "text": "dabigatran as assessed by routine and specific coagulation assays (aPTT from to 75 to 26 s, PT from 26 to 11 s and diluted thrombin time from 92",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.8359375,
            "end_logit": -7.9765625,
            "text": "dabigatran as assessed by routine and specific coagulation assays (aPTT from to 75 to 26 s, PT from 26 to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.8359375,
            "end_logit": -8.0078125,
            "text": "dabigatran as assessed by routine and specific coagulation assays (aPTT from to 75 to 26 s, PT from 26 to 11 s and diluted thrombin time from 92 to 27",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.8359375,
            "end_logit": -8.140625,
            "text": "dabigatran as assessed by routine and specific coagulation assays (aPTT from to 75 to 26 s, PT from 26 to 11",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.8359375,
            "end_logit": -8.1640625,
            "text": "dabigatran as assessed by routine and specific coagulation assays (aPTT from to 75 to",
            "probability": 5.960464477539063e-08
        }
    ],
    "5a7237672dc08e987e000008_9": [
        {
            "start_logit": 8.4375,
            "end_logit": 8.3984375,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.1953125,
            "text": "dabigatran with high affinity, is in development as a specific antidote for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 8.3984375,
            "text": "binds dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.296875,
            "text": "dabigatran with high",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.3125,
            "text": "dabigatran with high affinity, is in development as a specific antidote",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.328125,
            "text": "dabigatran with high affinity",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 8.3984375,
            "text": "that binds dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3984375,
            "end_logit": 8.3984375,
            "text": ", a monoclonal antibody fragment that binds dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.40625,
            "end_logit": 8.3984375,
            "text": "Idarucizumab, a monoclonal antibody fragment that binds dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.4140625,
            "end_logit": 8.3984375,
            "text": "a monoclonal antibody fragment that binds dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1953125,
            "end_logit": -8.1953125,
            "text": "binds dabigatran with high affinity, is in development as a specific antidote for dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -8.1953125,
            "text": ", is in development as a specific antidote for dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": -8.1953125,
            "text": "development as a specific antidote for dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": -8.1953125,
            "text": "a specific antidote for dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": -8.1953125,
            "text": "as a specific antidote for dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": -8.296875,
            "text": "binds dabigatran with high",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": -8.3125,
            "text": "binds dabigatran with high affinity, is in development as a specific antidote",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": -8.1953125,
            "text": "in development as a specific antidote for dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": -8.1953125,
            "text": "is in development as a specific antidote for dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": -8.328125,
            "text": "binds dabigatran with high affinity",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_10": [
        {
            "start_logit": 8.3125,
            "end_logit": 8.484375,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -7.9296875,
            "end_logit": 8.484375,
            "text": "in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 8.484375,
            "text": "to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.03125,
            "end_logit": 8.484375,
            "text": "study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.15625,
            "end_logit": 8.484375,
            "text": "A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 8.484375,
            "text": "investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 8.484375,
            "text": "safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.21875,
            "end_logit": 8.484375,
            "text": "randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 8.484375,
            "text": "of idarucizumab, a specific antidote to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 8.484375,
            "text": ", a specific antidote to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": 8.484375,
            "text": "healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 8.484375,
            "text": "the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.265625,
            "end_logit": 8.484375,
            "text": "a specific antidote to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 8.484375,
            "text": "specific antidote to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 8.484375,
            "text": "tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.484375,
            "text": "to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9296875,
            "end_logit": -8.3359375,
            "text": "in healthy volunteers to investigate the safety, tolerability and pharmacokinetics",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": -8.3359375,
            "text": "study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": -8.3359375,
            "text": "A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -8.3359375,
            "text": "investigate the safety, tolerability and pharmacokinetics",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_11": [
        {
            "start_logit": 8.296875,
            "end_logit": 8.4921875,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 8.4921875,
            "text": "agent for the anticoagulant activity of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.265625,
            "end_logit": 8.4921875,
            "text": "the anticoagulant activity of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 8.4921875,
            "text": "To evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 8.4921875,
            "text": "anticoagulant activity of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.28125,
            "end_logit": 8.4921875,
            "text": "for the anticoagulant activity of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 8.4921875,
            "text": "reversal agent for the anticoagulant activity of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 8.4921875,
            "text": "of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3125,
            "end_logit": 8.4921875,
            "text": ", as a specific reversal agent for the anticoagulant activity of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3125,
            "end_logit": 8.4921875,
            "text": "evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.296875,
            "end_logit": -8.359375,
            "text": "dabigatran and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.265625,
            "end_logit": -8.3203125,
            "text": "agent for the anticoagulant",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": -8.3359375,
            "text": "agent for the anticoagulant activity",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": -8.3203125,
            "text": "the anticoagulant",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": -8.3359375,
            "text": "the anticoagulant activity",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -8.3203125,
            "text": "To evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -8.3203125,
            "text": "anticoagulant",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": -8.3203125,
            "text": "for the anticoagulant",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -8.3359375,
            "text": "To evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -8.3359375,
            "text": "anticoagulant activity",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_12": [
        {
            "start_logit": 8.546875,
            "end_logit": 8.296875,
            "text": "Dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": 8.546875,
            "end_logit": -7.96484375,
            "text": "Dabigatran etex",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.546875,
            "end_logit": -7.98046875,
            "text": "Dabigatran et",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.546875,
            "end_logit": -8.03125,
            "text": "Dabigatran etexila",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.546875,
            "end_logit": -8.0859375,
            "text": "Dabigatran etexilate is an oral thrombin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.546875,
            "end_logit": -8.09375,
            "text": "Dabigatran etexilate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.546875,
            "end_logit": -8.1953125,
            "text": "Dabigatran etexilate is an oral thrombin inhibitor that can be reversed",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.546875,
            "end_logit": -8.2109375,
            "text": "Dabigatran etexilate is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.546875,
            "end_logit": -8.21875,
            "text": "Dabigatran etexilate is an oral thrombin inhibitor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.546875,
            "end_logit": -8.2265625,
            "text": "Dabigatran etexilate is an oral thrombin inhibitor that can",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.546875,
            "end_logit": -8.265625,
            "text": "Dabigatran etexilate is an oral thrombin inhibitor that can be reversed by ida",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.546875,
            "end_logit": -8.265625,
            "text": "Dabigatran etexilate is an oral thrombin inhibitor that can be",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.546875,
            "end_logit": -8.2890625,
            "text": "Dabigatran etexilate is an oral thrombin inhibitor that",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.546875,
            "end_logit": -8.2890625,
            "text": "Dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idaruc",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.546875,
            "end_logit": -8.296875,
            "text": "Dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.546875,
            "end_logit": -8.3046875,
            "text": "Dabigatran etexilate is an",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": -8.0859375,
            "text": "oral thrombin",
            "probability": 0.0
        },
        {
            "start_logit": -8.390625,
            "end_logit": -7.96484375,
            "text": "etex",
            "probability": 0.0
        },
        {
            "start_logit": -8.390625,
            "end_logit": -7.98046875,
            "text": "et",
            "probability": 0.0
        },
        {
            "start_logit": -8.390625,
            "end_logit": -8.03125,
            "text": "etexila",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_13": [
        {
            "start_logit": 8.5625,
            "end_logit": 8.28125,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -7.6015625,
            "end_logit": 8.28125,
            "text": "to dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 8.28125,
            "text": "In ICH related to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.28125,
            "text": "related to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3125,
            "end_logit": 8.28125,
            "text": "ICH related to dabigatran",
            "probability": 5.960464477539063e-08
        }
    ],
    "5a7237672dc08e987e000008_14": [
        {
            "start_logit": 8.359375,
            "end_logit": 8.484375,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 8.484375,
            "text": "for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.046875,
            "text": "dabigatran etex",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.0703125,
            "text": "dabigatran etexilate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.078125,
            "text": "dabigatran etexila",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 8.484375,
            "text": "reversal agent for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 8.484375,
            "text": "Idarucizumab is a reversal agent for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 8.484375,
            "text": "agent for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.1953125,
            "text": "dabigatran et",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 8.484375,
            "text": "a reversal agent for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 8.484375,
            "text": "rucizumab is a reversal agent for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 8.484375,
            "text": "is a reversal agent for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0625,
            "end_logit": -8.046875,
            "text": "for dabigatran etex",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": -8.0703125,
            "text": "for dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": -8.078125,
            "text": "for dabigatran etexila",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": -8.1953125,
            "text": "for dabigatran et",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.046875,
            "text": "etex",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.0703125,
            "text": "etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.078125,
            "text": "etexila",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -8.046875,
            "text": "reversal agent for dabigatran etex",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_15": [
        {
            "start_logit": 8.234375,
            "end_logit": 8.5546875,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -7.5859375,
            "end_logit": 8.5546875,
            "text": "Idarucizumab completely reversed the anticoagulant effect of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.75390625,
            "end_logit": 8.5546875,
            "text": "of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.15625,
            "end_logit": 8.5546875,
            "text": "anticoagulant effect of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 8.5546875,
            "text": "rucizumab completely reversed the anticoagulant effect of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.234375,
            "end_logit": 8.5546875,
            "text": "effect of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 8.5546875,
            "text": "the anticoagulant effect of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3125,
            "end_logit": 8.5546875,
            "text": "izumab completely reversed the anticoagulant effect of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.234375,
            "end_logit": -8.046875,
            "text": "dabigatran within minutes",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.375,
            "end_logit": 8.5546875,
            "text": "reversed the anticoagulant effect of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.390625,
            "end_logit": 8.5546875,
            "text": "completely reversed the anticoagulant effect of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.234375,
            "end_logit": -8.3046875,
            "text": "dabigatran within",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5859375,
            "end_logit": -8.046875,
            "text": "Idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes",
            "probability": 0.0
        },
        {
            "start_logit": -7.75390625,
            "end_logit": -8.046875,
            "text": "of dabigatran within minutes",
            "probability": 0.0
        },
        {
            "start_logit": -7.5859375,
            "end_logit": -8.3046875,
            "text": "Idarucizumab completely reversed the anticoagulant effect of dabigatran within",
            "probability": 0.0
        },
        {
            "start_logit": -7.75390625,
            "end_logit": -8.3046875,
            "text": "of dabigatran within",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": -8.046875,
            "text": "within minutes",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": -8.046875,
            "text": "anticoagulant effect of dabigatran within minutes",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -8.046875,
            "text": "rucizumab completely reversed the anticoagulant effect of dabigatran within minutes",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -8.046875,
            "text": "effect of dabigatran within minutes",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_16": [
        {
            "start_logit": 8.546875,
            "end_logit": 8.296875,
            "text": "Dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": 8.546875,
            "end_logit": -7.96484375,
            "text": "Dabigatran etex",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.546875,
            "end_logit": -7.98046875,
            "text": "Dabigatran et",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.546875,
            "end_logit": -8.03125,
            "text": "Dabigatran etexila",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.546875,
            "end_logit": -8.0859375,
            "text": "Dabigatran etexilate is an oral thrombin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.546875,
            "end_logit": -8.09375,
            "text": "Dabigatran etexilate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.546875,
            "end_logit": -8.1953125,
            "text": "Dabigatran etexilate is an oral thrombin inhibitor that can be reversed",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.546875,
            "end_logit": -8.2109375,
            "text": "Dabigatran etexilate is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.546875,
            "end_logit": -8.21875,
            "text": "Dabigatran etexilate is an oral thrombin inhibitor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.546875,
            "end_logit": -8.2265625,
            "text": "Dabigatran etexilate is an oral thrombin inhibitor that can",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.546875,
            "end_logit": -8.265625,
            "text": "Dabigatran etexilate is an oral thrombin inhibitor that can be reversed by ida",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.546875,
            "end_logit": -8.265625,
            "text": "Dabigatran etexilate is an oral thrombin inhibitor that can be",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.546875,
            "end_logit": -8.2890625,
            "text": "Dabigatran etexilate is an oral thrombin inhibitor that",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.546875,
            "end_logit": -8.2890625,
            "text": "Dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idaruc",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.546875,
            "end_logit": -8.296875,
            "text": "Dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.546875,
            "end_logit": -8.3046875,
            "text": "Dabigatran etexilate is an",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": -8.0859375,
            "text": "oral thrombin",
            "probability": 0.0
        },
        {
            "start_logit": -8.390625,
            "end_logit": -7.96484375,
            "text": "etex",
            "probability": 0.0
        },
        {
            "start_logit": -8.390625,
            "end_logit": -7.98046875,
            "text": "et",
            "probability": 0.0
        },
        {
            "start_logit": -8.390625,
            "end_logit": -8.03125,
            "text": "etexila",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_17": [
        {
            "start_logit": 8.4375,
            "end_logit": 8.4140625,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 8.4140625,
            "text": "for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.0546875,
            "text": "dabigatran etex",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.0859375,
            "text": "dabigatran etexila",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.09375,
            "text": "dabigatran etexilate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.1796875,
            "text": "dabigatran et",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 8.4140625,
            "text": "reversal agent for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.28125,
            "end_logit": 8.4140625,
            "text": "agent for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 8.4140625,
            "text": "Idarucizumab is a reversal agent for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 8.4140625,
            "text": "INTRODUCTION Idarucizumab is a reversal agent for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.328125,
            "end_logit": 8.4140625,
            "text": "a reversal agent for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 8.4140625,
            "text": "rucizumab is a reversal agent for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3671875,
            "end_logit": 8.4140625,
            "text": "is a reversal agent for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3828125,
            "end_logit": 8.4140625,
            "text": "izumab is a reversal agent for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.015625,
            "end_logit": -8.0546875,
            "text": "for dabigatran etex",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": -8.0859375,
            "text": "for dabigatran etexila",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": -8.09375,
            "text": "for dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": -8.1796875,
            "text": "for dabigatran et",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -8.0546875,
            "text": "etex",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -8.0859375,
            "text": "etexila",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_18": [
        {
            "start_logit": 8.34375,
            "end_logit": 8.453125,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 8.453125,
            "text": "of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1875,
            "end_logit": 8.453125,
            "text": "anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 8.453125,
            "text": "the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.453125,
            "text": "reversal of the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 8.453125,
            "text": "Idarucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3125,
            "end_logit": 8.453125,
            "text": "of the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 8.453125,
            "text": "for reversal of the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.375,
            "end_logit": 8.453125,
            "text": "effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3828125,
            "end_logit": 8.453125,
            "text": "rucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.4375,
            "end_logit": 8.453125,
            "text": "izumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1875,
            "end_logit": -8.21875,
            "text": "anticoagulant effects",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -8.2421875,
            "text": "anticoagulant",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -8.21875,
            "text": "the anticoagulant effects",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -8.2421875,
            "text": "the anticoagulant",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": -8.21875,
            "text": "reversal of the anticoagulant effects",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": -8.2421875,
            "text": "reversal of the anticoagulant",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": -8.21875,
            "text": "Idarucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": -8.21875,
            "text": "of the anticoagulant effects",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": -8.2421875,
            "text": "Idarucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_19": [
        {
            "start_logit": 8.4140625,
            "end_logit": 8.4140625,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -7.80859375,
            "end_logit": 8.4140625,
            "text": "to dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.203125,
            "end_logit": 8.4140625,
            "text": "Idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 8.4140625,
            "text": "rucizumab is a monoclonal antibody fragment specifically targeted to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3828125,
            "end_logit": 8.4140625,
            "text": "izumab is a monoclonal antibody fragment specifically targeted to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.390625,
            "end_logit": 8.4140625,
            "text": "specifically targeted to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3984375,
            "end_logit": 8.4140625,
            "text": "a monoclonal antibody fragment specifically targeted to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3984375,
            "end_logit": 8.4140625,
            "text": "antibody fragment specifically targeted to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": -8.328125,
            "text": "Idarucizumab is a monoclonal",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -8.328125,
            "text": "Idarucizumab is a monoclonal antibody fragment",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -8.3359375,
            "text": "Idarucizumab is",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -8.3359375,
            "text": "Idarucizumab is a monoclonal antibody fragment specifically targeted",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": -8.328125,
            "text": "rucizumab is a monoclonal",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": -8.328125,
            "text": "rucizumab is a monoclonal antibody fragment",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": -8.3359375,
            "text": "rucizumab is",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": -8.3359375,
            "text": "rucizumab is a monoclonal antibody fragment specifically targeted",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": -8.328125,
            "text": "izumab is a monoclonal",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": -8.328125,
            "text": "izumab is a monoclonal antibody fragment",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": -8.3359375,
            "text": "izumab is",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": -8.3359375,
            "text": "izumab is a monoclonal antibody fragment specifically targeted",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_20": [
        {
            "start_logit": 8.4140625,
            "end_logit": 8.4140625,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -7.80859375,
            "end_logit": 8.4140625,
            "text": "to dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.203125,
            "end_logit": 8.4140625,
            "text": "Idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 8.4140625,
            "text": "rucizumab is a monoclonal antibody fragment specifically targeted to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3828125,
            "end_logit": 8.4140625,
            "text": "izumab is a monoclonal antibody fragment specifically targeted to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.390625,
            "end_logit": 8.4140625,
            "text": "specifically targeted to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3984375,
            "end_logit": 8.4140625,
            "text": "a monoclonal antibody fragment specifically targeted to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3984375,
            "end_logit": 8.4140625,
            "text": "antibody fragment specifically targeted to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": -8.328125,
            "text": "Idarucizumab is a monoclonal",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -8.328125,
            "text": "Idarucizumab is a monoclonal antibody fragment",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -8.3359375,
            "text": "Idarucizumab is",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -8.3359375,
            "text": "Idarucizumab is a monoclonal antibody fragment specifically targeted",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": -8.328125,
            "text": "rucizumab is a monoclonal",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": -8.328125,
            "text": "rucizumab is a monoclonal antibody fragment",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": -8.3359375,
            "text": "rucizumab is",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": -8.3359375,
            "text": "rucizumab is a monoclonal antibody fragment specifically targeted",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": -8.328125,
            "text": "izumab is a monoclonal",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": -8.328125,
            "text": "izumab is a monoclonal antibody fragment",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": -8.3359375,
            "text": "izumab is",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": -8.3359375,
            "text": "izumab is a monoclonal antibody fragment specifically targeted",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_21": [
        {
            "start_logit": 8.140625,
            "end_logit": 8.6484375,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 8.6484375,
            "text": ", directly binds dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 8.6484375,
            "text": "binds dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 8.6484375,
            "text": "Idarucizumab, a monoclonal antibody fragment, directly binds dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.328125,
            "end_logit": 8.6484375,
            "text": "directly binds dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.34375,
            "end_logit": 8.6484375,
            "text": "rucizumab, a monoclonal antibody fragment, directly binds dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.375,
            "end_logit": 8.6484375,
            "text": ", a monoclonal antibody fragment, directly binds dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.140625,
            "end_logit": -8.1640625,
            "text": "dabigatran etex",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.140625,
            "end_logit": -8.1796875,
            "text": "dabigatran etexilate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.140625,
            "end_logit": -8.1796875,
            "text": "dabigatran etexila",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.140625,
            "end_logit": -8.3125,
            "text": "dabigatran et",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.140625,
            "end_logit": -8.3515625,
            "text": "dabigatran etexilate and neutralizes its activity",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.140625,
            "end_logit": -8.359375,
            "text": "dabigatran etexilate and neutral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.125,
            "end_logit": -8.1640625,
            "text": "etex",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -8.1796875,
            "text": "etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -8.1796875,
            "text": "etexila",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -8.1640625,
            "text": ", directly binds dabigatran etex",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -8.1796875,
            "text": ", directly binds dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -8.1796875,
            "text": ", directly binds dabigatran etexila",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -8.1640625,
            "text": "binds dabigatran etex",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_22": [
        {
            "start_logit": 8.4765625,
            "end_logit": 8.3515625,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": 8.3515625,
            "text": "binds dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -8.3046875,
            "text": "dabigatran with high",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -8.3203125,
            "text": "dabigatran with high affinity",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.21875,
            "end_logit": 8.3515625,
            "text": "Idarucizumab is an antibody fragment that binds dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 8.3515625,
            "text": "that binds dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.359375,
            "end_logit": 8.3515625,
            "text": "rucizumab is an antibody fragment that binds dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.390625,
            "end_logit": 8.3515625,
            "text": "antibody fragment that binds dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.390625,
            "end_logit": 8.3515625,
            "text": "izumab is an antibody fragment that binds dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3984375,
            "end_logit": 8.3515625,
            "text": "an antibody fragment that binds dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.4140625,
            "end_logit": 8.3515625,
            "text": "fragment that binds dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.03125,
            "end_logit": -8.3046875,
            "text": "binds dabigatran with high",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": -8.3203125,
            "text": "binds dabigatran with high affinity",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.3046875,
            "text": "with high",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.3203125,
            "text": "with high affinity",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.3046875,
            "text": "Idarucizumab is an antibody fragment that binds dabigatran with high",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.3203125,
            "text": "Idarucizumab is an antibody fragment that binds dabigatran with high affinity",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.328125,
            "text": "Idarucizumab is an antibody fragment",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -8.3046875,
            "text": "that binds dabigatran with high",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -8.3203125,
            "text": "that binds dabigatran with high affinity",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_23": [
        {
            "start_logit": 8.359375,
            "end_logit": 8.4765625,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 8.4765625,
            "text": "of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 8.4765625,
            "text": "Reversal of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": 8.4765625,
            "text": "CONCLUSION Reversal of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.25,
            "text": "dabigatran et",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.296875,
            "text": "dabigatran etex",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.3046875,
            "text": "dabigatran etexila",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.3125,
            "text": "dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.328125,
            "text": "dabigatran etexilate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.3359375,
            "text": "dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.3515625,
            "text": "dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator interactions",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.3671875,
            "text": "dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -8.25,
            "text": "of dabigatran et",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -8.296875,
            "text": "of dabigatran etex",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -8.3046875,
            "text": "of dabigatran etexila",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -8.3125,
            "text": "of dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -8.328125,
            "text": "of dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -8.3359375,
            "text": "of dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -8.3515625,
            "text": "of dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator interactions",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -8.3671875,
            "text": "of dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_24": [
        {
            "start_logit": 8.4921875,
            "end_logit": 8.3125,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -7.78515625,
            "end_logit": 8.3125,
            "text": "to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.171875,
            "end_logit": 8.3125,
            "text": ", monoclonal antibody fragment that specifically binds to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.265625,
            "end_logit": 8.3125,
            "text": "that specifically binds to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 8.3125,
            "text": "Idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.3125,
            "text": "treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.3125,
            "text": "it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3125,
            "end_logit": 8.3125,
            "text": "binds to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 8.3125,
            "text": "option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 8.3125,
            "text": "specifically binds to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 8.3125,
            "text": "is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 8.3125,
            "text": "RESULTS Idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 8.3125,
            "text": "as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.359375,
            "end_logit": 8.3125,
            "text": "novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.375,
            "end_logit": 8.3125,
            "text": "rucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3828125,
            "end_logit": 8.3125,
            "text": "the only humanized, monoclonal antibody fragment that specifically binds to dabigatran",
            "probability": 5.960464477539063e-08
        }
    ],
    "5a7237672dc08e987e000008_25": [
        {
            "start_logit": 8.2421875,
            "end_logit": 8.546875,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 8.546875,
            "text": "of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 8.546875,
            "text": "anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 8.546875,
            "text": "reversal of anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.21875,
            "end_logit": 8.546875,
            "text": "In 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 8.546875,
            "text": ") reversal of anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.234375,
            "end_logit": 8.546875,
            "text": "of anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 8.546875,
            "text": "rapid (minutes) reversal of anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.265625,
            "end_logit": 8.546875,
            "text": "approved for rapid (minutes) reversal of anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.265625,
            "end_logit": 8.546875,
            "text": ", the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.28125,
            "end_logit": 8.546875,
            "text": "was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.28125,
            "end_logit": 8.546875,
            "text": "for rapid (minutes) reversal of anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.546875,
            "text": "(minutes) reversal of anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.546875,
            "text": "effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 8.546875,
            "text": "fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 8.546875,
            "text": "2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.265625,
            "text": "In 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -8.265625,
            "text": "rapid (minutes",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.3203125,
            "text": "In 2015, the humanized monoclonal antibody",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": -8.265625,
            "text": "approved for rapid (minutes",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_26": [
        {
            "start_logit": 8.390625,
            "end_logit": 8.4296875,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 8.4296875,
            "text": ", dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 8.4296875,
            "text": "reverse the direct thrombin inhibitor, dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 8.4296875,
            "text": "Idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 8.4296875,
            "text": "the direct thrombin inhibitor, dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3125,
            "end_logit": 8.4296875,
            "text": "to reverse the direct thrombin inhibitor, dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 8.4296875,
            "text": "direct thrombin inhibitor, dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 8.4296875,
            "text": "thrombin inhibitor, dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -7.90625,
            "text": "reverse the direct thrombin",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -7.90625,
            "text": "Idarucizumab is a specific antidote targeted to reverse the direct thrombin",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -7.90625,
            "text": "the direct thrombin",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": -7.90625,
            "text": "to reverse the direct thrombin",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": -7.90625,
            "text": "direct thrombin",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": -7.90625,
            "text": "thrombin",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -8.2578125,
            "text": "reverse the direct thrombin inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -8.2578125,
            "text": "Idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -8.2578125,
            "text": "the direct thrombin inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": -8.2578125,
            "text": "to reverse the direct thrombin inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": -8.2578125,
            "text": "direct thrombin inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -8.328125,
            "text": "Idarucizumab is",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_27": [
        {
            "start_logit": 8.375,
            "end_logit": 8.4375,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 8.4375,
            "text": "targeting dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.375,
            "end_logit": -8.2578125,
            "text": "dabigatran, is the first specific antidote for a NOAC to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 8.4375,
            "text": ", an antibody fragment targeting dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.375,
            "end_logit": -8.328125,
            "text": "dabigatran, is the first specific antidote for a NOAC to be approved, but real-world experience is limited",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.375,
            "end_logit": -8.328125,
            "text": "dabigatran, is the first specific antidote",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.375,
            "end_logit": -8.34375,
            "text": "dabigatran, is the first specific antidote for a NOAC",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.375,
            "end_logit": -8.3515625,
            "text": "dabigatran, is the first specific antid",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.05078125,
            "end_logit": -8.328125,
            "text": ", but real-world experience is limited",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -8.2578125,
            "text": "targeting dabigatran, is the first specific antidote for a NOAC to",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -8.328125,
            "text": "targeting dabigatran, is the first specific antidote for a NOAC to be approved, but real-world experience is limited",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -8.328125,
            "text": "targeting dabigatran, is the first specific antidote",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -8.34375,
            "text": "targeting dabigatran, is the first specific antidote for a NOAC",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -8.3515625,
            "text": "targeting dabigatran, is the first specific antid",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": -8.2578125,
            "text": ", is the first specific antidote for a NOAC to",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": -8.2578125,
            "text": "the first specific antidote for a NOAC to",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": -8.2578125,
            "text": "a NOAC to",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": -8.2578125,
            "text": "first specific antidote for a NOAC to",
            "probability": 0.0
        },
        {
            "start_logit": -8.3515625,
            "end_logit": -8.2578125,
            "text": "NOAC to",
            "probability": 0.0
        },
        {
            "start_logit": -8.3515625,
            "end_logit": -8.2578125,
            "text": "is the first specific antidote for a NOAC to",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_28": [
        {
            "start_logit": 8.4375,
            "end_logit": 8.359375,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": 8.4375,
            "end_logit": -7.95703125,
            "text": "dabigatran, and reversed the effects of the drug on coagulation variables",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9296875,
            "end_logit": 8.359375,
            "text": "of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.0625,
            "text": "dabigatran, and reversed the effects of the drug on coagulation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.21875,
            "text": "dabigatran, and reversed the effects of the drug on coagulation variables.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.140625,
            "end_logit": 8.359375,
            "text": "Idarucizumab neutralised plasma concentrations of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.328125,
            "text": "dabigatran, and reversed the effects of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 8.359375,
            "text": "concentrations of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 8.359375,
            "text": "plasma concentrations of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 8.359375,
            "text": "izumab neutralised plasma concentrations of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.34375,
            "end_logit": 8.359375,
            "text": "rucizumab neutralised plasma concentrations of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.390625,
            "end_logit": 8.359375,
            "text": "neutralised plasma concentrations of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.00390625,
            "end_logit": -8.21875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.9296875,
            "end_logit": -7.95703125,
            "text": "of dabigatran, and reversed the effects of the drug on coagulation variables",
            "probability": 0.0
        },
        {
            "start_logit": -7.9296875,
            "end_logit": -8.0625,
            "text": "of dabigatran, and reversed the effects of the drug on coagulation",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": -7.95703125,
            "text": "effects of the drug on coagulation variables",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": -7.95703125,
            "text": ", and reversed the effects of the drug on coagulation variables",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": -7.95703125,
            "text": "Idarucizumab neutralised plasma concentrations of dabigatran, and reversed the effects of the drug on coagulation variables",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -7.95703125,
            "text": "the effects of the drug on coagulation variables",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": -7.95703125,
            "text": "reversed the effects of the drug on coagulation variables",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_29": [
        {
            "start_logit": 8.375,
            "end_logit": 8.4296875,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -7.94921875,
            "end_logit": 8.4296875,
            "text": "of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.046875,
            "end_logit": 8.4296875,
            "text": "anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.15625,
            "end_logit": 8.4296875,
            "text": "the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 8.4296875,
            "text": "reverse the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 8.4296875,
            "text": "developed to reverse the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": 8.4296875,
            "text": "to reverse the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.4296875,
            "text": "Idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.4296875,
            "text": ", was developed to reverse the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 8.4296875,
            "text": "effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 8.4296875,
            "text": "was developed to reverse the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3671875,
            "end_logit": 8.4296875,
            "text": "rucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.40625,
            "end_logit": 8.4296875,
            "text": "izumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.4140625,
            "end_logit": 8.4296875,
            "text": ", an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.046875,
            "end_logit": -8.140625,
            "text": "anticoagulant effects",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": -8.140625,
            "text": "the anticoagulant effects",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": -8.28125,
            "text": "anticoagulant",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -8.140625,
            "text": "reverse the anticoagulant effects",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -8.140625,
            "text": "developed to reverse the anticoagulant effects",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -8.140625,
            "text": "to reverse the anticoagulant effects",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_30": [
        {
            "start_logit": 8.203125,
            "end_logit": 8.5390625,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -7.859375,
            "end_logit": 8.5390625,
            "text": "Idarucizumab also reversed the effects of dabigatran",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 8.5390625,
            "text": "of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 8.5390625,
            "text": "effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.203125,
            "end_logit": -7.9140625,
            "text": "dabigatran and, unlike PCCs, was not associated with over-correction of thrombin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.203125,
            "end_logit": -8.0078125,
            "text": "dabigatran and, unlike PCCs, was not associated with over-correction of thrombin generation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.34375,
            "end_logit": 8.5390625,
            "text": "rucizumab also reversed the effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 8.5390625,
            "text": "the effects of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.203125,
            "end_logit": -8.1484375,
            "text": "dabigatran and, unlike PCCs, was not associated with over-correction of thrombin generation.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.203125,
            "end_logit": -8.234375,
            "text": "dabigatran and, unlike PCCs, was not associated with over",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.203125,
            "end_logit": -8.25,
            "text": "dabigatran and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.203125,
            "end_logit": -8.2890625,
            "text": "dabigatran and, unlike PCC",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.203125,
            "end_logit": -8.296875,
            "text": "dabigatran and, unlike PCCs, was not associated with over-correction",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.828125,
            "end_logit": -8.1484375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.859375,
            "end_logit": -7.9140625,
            "text": "Idarucizumab also reversed the effects of dabigatran and, unlike PCCs, was not associated with over-correction of thrombin",
            "probability": 0.0
        },
        {
            "start_logit": -7.9140625,
            "end_logit": -7.9140625,
            "text": ", unlike PCCs, was not associated with over-correction of thrombin",
            "probability": 0.0
        },
        {
            "start_logit": -7.859375,
            "end_logit": -8.0078125,
            "text": "Idarucizumab also reversed the effects of dabigatran and, unlike PCCs, was not associated with over-correction of thrombin generation",
            "probability": 0.0
        },
        {
            "start_logit": -7.9140625,
            "end_logit": -8.0078125,
            "text": ", unlike PCCs, was not associated with over-correction of thrombin generation",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": -7.9140625,
            "text": ", was not associated with over-correction of thrombin",
            "probability": 0.0
        },
        {
            "start_logit": -7.859375,
            "end_logit": -8.1484375,
            "text": "Idarucizumab also reversed the effects of dabigatran and, unlike PCCs, was not associated with over-correction of thrombin generation.",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_31": [
        {
            "start_logit": 8.34375,
            "end_logit": 8.4765625,
            "text": "Dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": 8.34375,
            "end_logit": -7.99609375,
            "text": "Dabigatran etexilate (DE",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.34375,
            "end_logit": -8.109375,
            "text": "Dabigatran etexilate (DE) dose-dependently prolonged diluted thrombin time",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.34375,
            "end_logit": -8.1796875,
            "text": "Dabigatran etex",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.34375,
            "end_logit": -8.1796875,
            "text": "Dabigatran etexila",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.34375,
            "end_logit": -8.203125,
            "text": "Dabigatran etexilate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.34375,
            "end_logit": -8.21875,
            "text": "Dabigatran etexilate (DE) dose-dependently prolonged diluted thrombin time and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.34375,
            "end_logit": -8.234375,
            "text": "Dabigatran etexilate (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.34375,
            "end_logit": -8.265625,
            "text": "Dabigatran et",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.34375,
            "end_logit": -8.2890625,
            "text": "Dabigatran etexilate (DE) dose-dependently",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.34375,
            "end_logit": -8.3125,
            "text": "Dabigatran etexilate (DE) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.34375,
            "end_logit": -8.3203125,
            "text": "Dabigatran etexilate (DE) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.34375,
            "end_logit": -8.328125,
            "text": "Dabigatran etexilate (DE) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0703125,
            "end_logit": -8.109375,
            "text": "diluted thrombin time",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -7.99609375,
            "text": "etexilate (DE",
            "probability": 0.0
        },
        {
            "start_logit": -7.890625,
            "end_logit": -8.3203125,
            "text": ", which were reversed",
            "probability": 0.0
        },
        {
            "start_logit": -7.890625,
            "end_logit": -8.328125,
            "text": ", which were reversed by idarucizumab",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": -7.99609375,
            "text": "te (DE",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": -8.21875,
            "text": "diluted thrombin time and",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -8.109375,
            "text": "etexilate (DE) dose-dependently prolonged diluted thrombin time",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_32": [
        {
            "start_logit": 8.390625,
            "end_logit": 8.421875,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": 8.421875,
            "text": "article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.390625,
            "end_logit": -8.0234375,
            "text": "dabigatran.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 8.421875,
            "text": "this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 8.421875,
            "text": "of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.109375,
            "end_logit": 8.421875,
            "text": "In this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1875,
            "end_logit": 8.421875,
            "text": "effect of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.234375,
            "end_logit": 8.421875,
            "text": "we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 8.421875,
            "text": "discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 8.421875,
            "text": "efficacy for reversing effect of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.28125,
            "end_logit": 8.421875,
            "text": "safety, tolerability and its efficacy for reversing effect of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 8.421875,
            "text": "reversing effect of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.421875,
            "text": "for reversing effect of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.421875,
            "text": "the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.421875,
            "text": ", we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 8.421875,
            "text": "its efficacy for reversing effect of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.328125,
            "end_logit": 8.421875,
            "text": "tolerability and its efficacy for reversing effect of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.328125,
            "end_logit": 8.421875,
            "text": "evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.390625,
            "end_logit": -8.3359375,
            "text": "dabigatran..",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.03125,
            "end_logit": -8.0234375,
            "text": "article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran.",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_33": [
        {
            "start_logit": 8.578125,
            "end_logit": 8.265625,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -7.79296875,
            "end_logit": 8.265625,
            "text": "for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": 8.265625,
            "text": "reversal agent for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.265625,
            "end_logit": 8.265625,
            "text": "of idarucizumab, a potential reversal agent for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.28125,
            "end_logit": 8.265625,
            "text": "agent for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 8.265625,
            "text": "potential reversal agent for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 8.265625,
            "text": "Food and Drug Administration approval of idarucizumab, a potential reversal agent for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 8.265625,
            "text": ", a potential reversal agent for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.359375,
            "end_logit": 8.265625,
            "text": "recent The Food and Drug Administration approval of idarucizumab, a potential reversal agent for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3671875,
            "end_logit": 8.265625,
            "text": "The Food and Drug Administration approval of idarucizumab, a potential reversal agent for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3828125,
            "end_logit": 8.265625,
            "text": "approval of idarucizumab, a potential reversal agent for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3828125,
            "end_logit": 8.265625,
            "text": "a potential reversal agent for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.40625,
            "end_logit": 8.265625,
            "text": "idarucizumab, a potential reversal agent for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.421875,
            "end_logit": 8.265625,
            "text": "the recent The Food and Drug Administration approval of idarucizumab, a potential reversal agent for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.4296875,
            "end_logit": 8.265625,
            "text": "rucizumab, a potential reversal agent for dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": -8.2734375,
            "text": "reversal",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": -8.2734375,
            "text": "of idarucizumab, a potential reversal",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": -8.2734375,
            "text": "potential reversal",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": -8.25,
            "text": "Food and Drug Administration",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": -8.2734375,
            "text": "Food and Drug Administration approval of idarucizumab, a potential reversal",
            "probability": 0.0
        }
    ],
    "56c1d856ef6e394741000032_1": [
        {
            "start_logit": 9.984375,
            "end_logit": 9.5625,
            "text": "lectin complement pathway",
            "probability": 1.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -1.900390625,
            "text": "lectin",
            "probability": 1.055002212524414e-05
        },
        {
            "start_logit": -2.1953125,
            "end_logit": 9.5625,
            "text": "pathway",
            "probability": 5.125999450683594e-06
        },
        {
            "start_logit": -6.80078125,
            "end_logit": 9.5625,
            "text": "complement pathway",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.984375,
            "end_logit": -7.765625,
            "text": "lectin complement",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.35546875,
            "end_logit": 9.5625,
            "text": "the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.0625,
            "text": "lectin complement pathway and",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.1875,
            "text": "lectin complement pathway and SLE",
            "probability": 0.0
        },
        {
            "start_logit": -7.8046875,
            "end_logit": 9.5625,
            "text": "study aims to investigate whether an association exists between the ficolins that are part of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -7.91015625,
            "end_logit": 9.5625,
            "text": "This study aims to investigate whether an association exists between the ficolins that are part of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 9.5625,
            "text": "aims to investigate whether an association exists between the ficolins that are part of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.5625,
            "text": "association exists between the ficolins that are part of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.5625,
            "text": "ficolins that are part of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.5625,
            "text": "between the ficolins that are part of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.5625,
            "text": "whether an association exists between the ficolins that are part of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.5625,
            "text": "investigate whether an association exists between the ficolins that are part of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.5625,
            "text": "an association exists between the ficolins that are part of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": 9.5625,
            "text": "to investigate whether an association exists between the ficolins that are part of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.3671875,
            "end_logit": 9.5625,
            "text": "the ficolins that are part of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.390625,
            "end_logit": 9.5625,
            "text": "of the lectin complement pathway",
            "probability": 0.0
        }
    ],
    "56c1d856ef6e394741000032_2": [
        {
            "start_logit": 9.953125,
            "end_logit": 9.484375,
            "text": "lectin complement pathway",
            "probability": 1.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -1.978515625,
            "text": "lectin",
            "probability": 1.055002212524414e-05
        },
        {
            "start_logit": -2.37109375,
            "end_logit": 9.484375,
            "text": "pathway",
            "probability": 4.410743713378906e-06
        },
        {
            "start_logit": -6.546875,
            "end_logit": 9.484375,
            "text": "complement pathway",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.953125,
            "end_logit": -7.23828125,
            "text": "lectin complement pathway (LC",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.953125,
            "end_logit": -7.95703125,
            "text": "lectin complement",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.015625,
            "text": "lectin complement pathway (LCP",
            "probability": 0.0
        },
        {
            "start_logit": -7.6640625,
            "end_logit": 9.484375,
            "text": "the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.1484375,
            "text": "lectin complement pathway (LCP)",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.28125,
            "text": "lectin complement pathway (",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.2890625,
            "text": "lectin complement pathway (LCP), in",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.3046875,
            "text": "lectin complement pathway (LCP), in subarachnoid hemorrhage (SAH)",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.3046875,
            "text": "lectin complement pathway (LCP), in subarachnoid hemorrhage (SAH) pathology and",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.3203125,
            "text": "lectin complement pathway (LCP), in subarachnoid hemorrhage (",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.3515625,
            "text": "lectin complement pathway (LCP),",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.484375,
            "text": ", the main initiator of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.484375,
            "text": "To assess the involvement of ficolin-3, the main initiator of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.484375,
            "text": "involvement of ficolin-3, the main initiator of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.484375,
            "text": "assess the involvement of ficolin-3, the main initiator of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.484375,
            "text": "the main initiator of the lectin complement pathway",
            "probability": 0.0
        }
    ],
    "56c1d856ef6e394741000032_3": [
        {
            "start_logit": 9.890625,
            "end_logit": 9.3125,
            "text": "lectin complement pathway",
            "probability": 1.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -2.125,
            "text": "lectin",
            "probability": 1.0788440704345703e-05
        },
        {
            "start_logit": -2.677734375,
            "end_logit": 9.3125,
            "text": "pathway",
            "probability": 3.4570693969726562e-06
        },
        {
            "start_logit": -7.0,
            "end_logit": 9.3125,
            "text": "complement pathway",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.890625,
            "end_logit": -7.79296875,
            "text": "lectin complement",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.890625,
            "end_logit": -7.98046875,
            "text": "lectin complement pathway activation in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.1328125,
            "text": "lectin complement pathway activation",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.1796875,
            "text": "lectin complement pathway activation in patients with subarachnoid hemorrhage",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.1875,
            "text": "lectin complement pathway activation in patients",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.1875,
            "text": "lectin complement pathway activation in patients with subarachnoid",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 9.3125,
            "text": "Ficolin-3-mediated lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.3125,
            "text": "mediated lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.359375,
            "end_logit": 9.3125,
            "text": "-mediated lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.359375,
            "end_logit": 9.3125,
            "text": "olin-3-mediated lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": 9.3125,
            "text": "-3-mediated lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": -2.125,
            "text": "Ficolin-3-mediated lectin",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -2.125,
            "text": "mediated lectin",
            "probability": 0.0
        },
        {
            "start_logit": -8.359375,
            "end_logit": -2.125,
            "text": "-mediated lectin",
            "probability": 0.0
        },
        {
            "start_logit": -8.359375,
            "end_logit": -2.125,
            "text": "olin-3-mediated lectin",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": -2.125,
            "text": "-3-mediated lectin",
            "probability": 0.0
        }
    ],
    "56c1d856ef6e394741000032_4": [
        {
            "start_logit": 9.9375,
            "end_logit": 9.421875,
            "text": "lectin complement pathway",
            "probability": 1.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -1.955078125,
            "text": "lectin",
            "probability": 1.150369644165039e-05
        },
        {
            "start_logit": -2.40625,
            "end_logit": 9.421875,
            "text": "pathway",
            "probability": 4.351139068603516e-06
        },
        {
            "start_logit": 9.9375,
            "end_logit": -7.47265625,
            "text": "lectin complement",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.328125,
            "end_logit": 9.421875,
            "text": "complement pathway",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.0625,
            "text": "lectin complement pathway initiator",
            "probability": 0.0
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 9.421875,
            "text": "the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.421875,
            "text": "complement activating potential and is the only collagenase proteolytic resistant molecule among the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.421875,
            "text": "Ficolin-3 has a high complement activating potential and is the only collagenase proteolytic resistant molecule among the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.421875,
            "text": "potential and is the only collagenase proteolytic resistant molecule among the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.421875,
            "text": ", Ficolin-3 has a high complement activating potential and is the only collagenase proteolytic resistant molecule among the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.421875,
            "text": "a high complement activating potential and is the only collagenase proteolytic resistant molecule among the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.421875,
            "text": "among the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": 9.421875,
            "text": "is the only collagenase proteolytic resistant molecule among the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": 9.421875,
            "text": "high complement activating potential and is the only collagenase proteolytic resistant molecule among the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.359375,
            "end_logit": 9.421875,
            "text": "has a high complement activating potential and is the only collagenase proteolytic resistant molecule among the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.375,
            "end_logit": 9.421875,
            "text": "molecule among the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": 9.421875,
            "text": "and is the only collagenase proteolytic resistant molecule among the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.3984375,
            "end_logit": 9.421875,
            "text": "activating potential and is the only collagenase proteolytic resistant molecule among the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -7.8671875,
            "end_logit": -1.955078125,
            "text": "the lectin",
            "probability": 0.0
        }
    ],
    "56c1d856ef6e394741000032_5": [
        {
            "start_logit": 9.96875,
            "end_logit": 9.4609375,
            "text": "lectin complement pathway",
            "probability": 1.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -1.9150390625,
            "text": "lectin",
            "probability": 1.138448715209961e-05
        },
        {
            "start_logit": -2.384765625,
            "end_logit": 9.4609375,
            "text": "pathway",
            "probability": 4.291534423828125e-06
        },
        {
            "start_logit": -6.61328125,
            "end_logit": 9.4609375,
            "text": "the lectin complement pathway",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.9140625,
            "end_logit": 9.4609375,
            "text": "complement pathway",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.96875,
            "end_logit": -7.671875,
            "text": "lectin complement",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 9.4609375,
            "text": "in the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.4609375,
            "text": "Ficolin-3 (Hakata antigen or H-ficolin) is a soluble pattern recognition molecule in the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.4609375,
            "text": "-ficolin) is a soluble pattern recognition molecule in the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.4609375,
            "text": "or H-ficolin) is a soluble pattern recognition molecule in the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.4609375,
            "text": "antigen or H-ficolin) is a soluble pattern recognition molecule in the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.4609375,
            "text": "pattern recognition molecule in the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.4609375,
            "text": "molecule in the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 9.4609375,
            "text": "Hakata antigen or H-ficolin) is a soluble pattern recognition molecule in the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 9.4609375,
            "text": "ficolin) is a soluble pattern recognition molecule in the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": 9.4609375,
            "text": "(Hakata antigen or H-ficolin) is a soluble pattern recognition molecule in the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": 9.4609375,
            "text": "a soluble pattern recognition molecule in the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 9.4609375,
            "text": "soluble pattern recognition molecule in the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -6.61328125,
            "end_logit": -1.9150390625,
            "text": "the lectin",
            "probability": 0.0
        },
        {
            "start_logit": -7.97265625,
            "end_logit": -1.9150390625,
            "text": "in the lectin",
            "probability": 0.0
        }
    ],
    "56c1d856ef6e394741000032_6": [
        {
            "start_logit": 9.9296875,
            "end_logit": 9.4453125,
            "text": "lectin complement pathway",
            "probability": 1.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -2.02734375,
            "text": "lectin",
            "probability": 1.043081283569336e-05
        },
        {
            "start_logit": -2.41796875,
            "end_logit": 9.4453125,
            "text": "pathway",
            "probability": 4.351139068603516e-06
        },
        {
            "start_logit": -6.42578125,
            "end_logit": 9.4453125,
            "text": "complement pathway",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -7.67578125,
            "text": "lectin complement pathway and form complexes with serine proteases named MASP-1, -2 and -3 and two nonenzymatic proteins. MASP-2 is the main initiator of lectin pathway",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -7.86328125,
            "text": "lectin complement",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.50390625,
            "end_logit": 9.4453125,
            "text": "the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.125,
            "text": "lectin complement pathway and form complexes with serine proteases named MASP-1, -2 and -3 and two nonenzymatic proteins. MASP-2 is the main initiator of lectin",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.1875,
            "text": "lectin complement pathway and form complexes with serine proteases",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.21875,
            "text": "lectin complement pathway and form complexes with serine proteases named MASP-1, -2 and -3 and two nonenzymatic proteins. MASP-2 is the main initiator of lectin pathway activation, while ficolin",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.21875,
            "text": "lectin complement pathway and form complexes with serine proteases named MASP-1, -2 and -3 and two nonenzymatic proteins. MASP-2 is the main",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.2265625,
            "text": "lectin complement pathway and form complexes with serine",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.2265625,
            "text": "lectin complement pathway and form complexes with serine proteases named MASP-1",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.234375,
            "text": "lectin complement pathway and form complexes with serine proteases named MASP-1, -2 and -3 and two nonenzymatic proteins. MASP-2",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.25,
            "text": "lectin complement pathway and",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.25,
            "text": "lectin complement pathway and form complexes with serine proteases named",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.2578125,
            "text": "lectin complement pathway and form complexes with serine proteases named MASP",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.2578125,
            "text": "lectin complement pathway and form complexes with serine proteases named MASP-1, -2 and -3 and two nonenzymatic proteins. MASP-2 is the main initiator of lectin pathway activation",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.2578125,
            "text": "lectin complement pathway and form complexes with serine proteases named MASP-1, -2 and -3 and two nonenzymatic proteins. MASP-2 is the main initiator of lectin pathway activation, while fic",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.2578125,
            "text": "lectin complement pathway and form complexes with serine proteases named MASP-1, -2 and",
            "probability": 0.0
        }
    ],
    "5a7639419e632bc066000005_1": [
        {
            "start_logit": 9.9921875,
            "end_logit": 9.59375,
            "text": "DeepLoc",
            "probability": 1.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -1.8798828125,
            "text": "Deep",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": -2.1640625,
            "end_logit": 9.59375,
            "text": "c",
            "probability": 5.185604095458984e-06
        },
        {
            "start_logit": -6.0,
            "end_logit": 9.59375,
            "text": "Loc",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.1015625,
            "text": "DeepLo",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.296875,
            "text": "DeepLoc: prediction of protein subcellular localization",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.34375,
            "text": "DeepLoc: prediction of protein subcellular localization using",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.34375,
            "text": "DeepLoc: prediction of protein subcellular localization using deep learning",
            "probability": 0.0
        },
        {
            "start_logit": -2.1640625,
            "end_logit": -8.296875,
            "text": "c: prediction of protein subcellular localization",
            "probability": 0.0
        },
        {
            "start_logit": -2.1640625,
            "end_logit": -8.34375,
            "text": "c: prediction of protein subcellular localization using",
            "probability": 0.0
        },
        {
            "start_logit": -2.1640625,
            "end_logit": -8.34375,
            "text": "c: prediction of protein subcellular localization using deep learning",
            "probability": 0.0
        },
        {
            "start_logit": -6.0,
            "end_logit": -8.1015625,
            "text": "Lo",
            "probability": 0.0
        },
        {
            "start_logit": -6.0,
            "end_logit": -8.296875,
            "text": "Loc: prediction of protein subcellular localization",
            "probability": 0.0
        },
        {
            "start_logit": -6.0,
            "end_logit": -8.34375,
            "text": "Loc: prediction of protein subcellular localization using",
            "probability": 0.0
        },
        {
            "start_logit": -6.0,
            "end_logit": -8.34375,
            "text": "Loc: prediction of protein subcellular localization using deep learning",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": -8.296875,
            "text": "prediction of protein subcellular localization",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": -8.34375,
            "text": "prediction of protein subcellular localization using",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": -8.34375,
            "text": "prediction of protein subcellular localization using deep learning",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.296875,
            "text": "of protein subcellular localization",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -8.296875,
            "text": "protein subcellular localization",
            "probability": 0.0
        }
    ],
    "5a7639419e632bc066000005_2": [
        {
            "start_logit": 9.9921875,
            "end_logit": 9.59375,
            "text": "DeepLoc",
            "probability": 1.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -1.8798828125,
            "text": "Deep",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": -2.1640625,
            "end_logit": 9.59375,
            "text": "c",
            "probability": 5.185604095458984e-06
        },
        {
            "start_logit": -6.0,
            "end_logit": 9.59375,
            "text": "Loc",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.1015625,
            "text": "DeepLo",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.296875,
            "text": "DeepLoc: prediction of protein subcellular localization",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.34375,
            "text": "DeepLoc: prediction of protein subcellular localization using",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.34375,
            "text": "DeepLoc: prediction of protein subcellular localization using deep learning",
            "probability": 0.0
        },
        {
            "start_logit": -2.1640625,
            "end_logit": -8.296875,
            "text": "c: prediction of protein subcellular localization",
            "probability": 0.0
        },
        {
            "start_logit": -2.1640625,
            "end_logit": -8.34375,
            "text": "c: prediction of protein subcellular localization using",
            "probability": 0.0
        },
        {
            "start_logit": -2.1640625,
            "end_logit": -8.34375,
            "text": "c: prediction of protein subcellular localization using deep learning",
            "probability": 0.0
        },
        {
            "start_logit": -6.0,
            "end_logit": -8.1015625,
            "text": "Lo",
            "probability": 0.0
        },
        {
            "start_logit": -6.0,
            "end_logit": -8.296875,
            "text": "Loc: prediction of protein subcellular localization",
            "probability": 0.0
        },
        {
            "start_logit": -6.0,
            "end_logit": -8.34375,
            "text": "Loc: prediction of protein subcellular localization using",
            "probability": 0.0
        },
        {
            "start_logit": -6.0,
            "end_logit": -8.34375,
            "text": "Loc: prediction of protein subcellular localization using deep learning",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": -8.296875,
            "text": "prediction of protein subcellular localization",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": -8.34375,
            "text": "prediction of protein subcellular localization using",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": -8.34375,
            "text": "prediction of protein subcellular localization using deep learning",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.296875,
            "text": "of protein subcellular localization",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -8.296875,
            "text": "protein subcellular localization",
            "probability": 0.0
        }
    ],
    "54e0d7471388e8454a000015_1": [
        {
            "start_logit": 10.078125,
            "end_logit": 9.7890625,
            "text": "interleukin-17A",
            "probability": 1.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -1.6796875,
            "text": "interleukin",
            "probability": 1.0371208190917969e-05
        },
        {
            "start_logit": -1.6806640625,
            "end_logit": 9.7890625,
            "text": "17A",
            "probability": 7.748603820800781e-06
        },
        {
            "start_logit": -6.15234375,
            "end_logit": 9.7890625,
            "text": "-17A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.078125,
            "end_logit": -8.359375,
            "text": "interleukin-17A monoclonal",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 9.7890625,
            "text": "-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.7890625,
            "text": "human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.7890625,
            "text": "Secukinumab is a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.7890625,
            "text": "a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.7890625,
            "text": "anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.7890625,
            "text": "ukinumab is a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.7890625,
            "text": "fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": 9.7890625,
            "text": "ab is a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": 9.7890625,
            "text": "is a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.7890625,
            "text": "inumab is a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 9.7890625,
            "text": ": Secukinumab is a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": -1.6796875,
            "text": "-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -1.6796875,
            "text": "human anti-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": -1.6796875,
            "text": "Secukinumab is a fully human anti-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": -1.6796875,
            "text": "a fully human anti-interleukin",
            "probability": 0.0
        }
    ],
    "54e0d7471388e8454a000015_2": [
        {
            "start_logit": 10.0390625,
            "end_logit": 9.7421875,
            "text": "interleukin-17A",
            "probability": 1.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -1.775390625,
            "text": "interleukin",
            "probability": 9.953975677490234e-06
        },
        {
            "start_logit": -1.7978515625,
            "end_logit": 9.7421875,
            "text": "17A",
            "probability": 7.212162017822266e-06
        },
        {
            "start_logit": -6.0078125,
            "end_logit": 9.7421875,
            "text": "-17A",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.3984375,
            "text": "interleukin-17A monoclonal antibody, demonstrated efficacy and safety in moderate-to",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.7421875,
            "text": "-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.7421875,
            "text": "human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.4453125,
            "text": "interleukin-17A monoclonal",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.4453125,
            "text": "interleukin-17A monoclonal antibody, demonstrated efficacy and safety in moderate",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.7421875,
            "text": ", a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.7421875,
            "text": "a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.7421875,
            "text": "Secukinumab, a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.7421875,
            "text": "anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": -1.775390625,
            "text": "-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": -1.775390625,
            "text": "human anti-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -1.775390625,
            "text": ", a fully human anti-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -1.775390625,
            "text": "a fully human anti-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -1.775390625,
            "text": "Secukinumab, a fully human anti-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -1.775390625,
            "text": "anti-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -1.7978515625,
            "end_logit": -8.3984375,
            "text": "17A monoclonal antibody, demonstrated efficacy and safety in moderate-to",
            "probability": 0.0
        }
    ],
    "54e0d7471388e8454a000015_3": [
        {
            "start_logit": 10.046875,
            "end_logit": 9.7578125,
            "text": "interleukin-17A",
            "probability": 1.0
        },
        {
            "start_logit": 10.046875,
            "end_logit": -1.7646484375,
            "text": "interleukin",
            "probability": 9.834766387939453e-06
        },
        {
            "start_logit": -1.7529296875,
            "end_logit": 9.7578125,
            "text": "17A",
            "probability": 7.450580596923828e-06
        },
        {
            "start_logit": -6.02734375,
            "end_logit": 9.7578125,
            "text": "-17A",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.046875,
            "end_logit": -8.3515625,
            "text": "interleukin-17A monoclonal antibody, in patients with moderate-to",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": 9.7578125,
            "text": "evaluated secukinumab, a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": 9.7578125,
            "text": "-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.7578125,
            "text": "human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": 10.046875,
            "end_logit": -8.4140625,
            "text": "interleukin-17A monoclonal",
            "probability": 0.0
        },
        {
            "start_logit": 10.046875,
            "end_logit": -8.4296875,
            "text": "interleukin-17A monoclonal antibody, in patients with moderate",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.7578125,
            "text": ", a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 9.7578125,
            "text": "We evaluated secukinumab, a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.7578125,
            "text": "a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.7578125,
            "text": "fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.7578125,
            "text": "anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.7578125,
            "text": "secukinumab, a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": -1.7646484375,
            "text": "evaluated secukinumab, a fully human anti-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": -1.7646484375,
            "text": "-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": -1.7646484375,
            "text": "human anti-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -1.7646484375,
            "text": ", a fully human anti-interleukin",
            "probability": 0.0
        }
    ],
    "54e0d7471388e8454a000015_4": [
        {
            "start_logit": 10.0,
            "end_logit": 9.7109375,
            "text": "interleukin-17A",
            "probability": 1.0
        },
        {
            "start_logit": 10.0,
            "end_logit": -1.8955078125,
            "text": "interleukin",
            "probability": 9.000301361083984e-06
        },
        {
            "start_logit": -1.876953125,
            "end_logit": 9.7109375,
            "text": "17A",
            "probability": 6.9141387939453125e-06
        },
        {
            "start_logit": -6.16796875,
            "end_logit": 9.7109375,
            "text": "-17A",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.0,
            "end_logit": -8.375,
            "text": "interleukin-17A monoclonal",
            "probability": 0.0
        },
        {
            "start_logit": 10.0,
            "end_logit": -8.390625,
            "text": "interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind",
            "probability": 0.0
        },
        {
            "start_logit": 10.0,
            "end_logit": -8.390625,
            "text": "interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled",
            "probability": 0.0
        },
        {
            "start_logit": 10.0,
            "end_logit": -8.3984375,
            "text": "interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double",
            "probability": 0.0
        },
        {
            "start_logit": 10.0,
            "end_logit": -8.40625,
            "text": "interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.7109375,
            "text": "-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.7109375,
            "text": "Anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -1.8955078125,
            "text": "-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": -1.8955078125,
            "text": "Anti-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -1.876953125,
            "end_logit": -8.375,
            "text": "17A monoclonal",
            "probability": 0.0
        },
        {
            "start_logit": -1.876953125,
            "end_logit": -8.390625,
            "text": "17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind",
            "probability": 0.0
        },
        {
            "start_logit": -1.876953125,
            "end_logit": -8.390625,
            "text": "17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled",
            "probability": 0.0
        },
        {
            "start_logit": -1.876953125,
            "end_logit": -8.3984375,
            "text": "17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double",
            "probability": 0.0
        },
        {
            "start_logit": -1.876953125,
            "end_logit": -8.40625,
            "text": "17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo",
            "probability": 0.0
        },
        {
            "start_logit": -6.16796875,
            "end_logit": -8.375,
            "text": "-17A monoclonal",
            "probability": 0.0
        },
        {
            "start_logit": -6.16796875,
            "end_logit": -8.390625,
            "text": "-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind",
            "probability": 0.0
        }
    ],
    "54e0d7471388e8454a000015_5": [
        {
            "start_logit": 10.03125,
            "end_logit": 9.7109375,
            "text": "interleukin-17A",
            "probability": 1.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -1.81640625,
            "text": "interleukin",
            "probability": 9.834766387939453e-06
        },
        {
            "start_logit": -1.873046875,
            "end_logit": 9.7109375,
            "text": "17A",
            "probability": 6.67572021484375e-06
        },
        {
            "start_logit": -6.0859375,
            "end_logit": 9.7109375,
            "text": "-17A",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.3515625,
            "text": "interleukin-17A monoclonal antibody, in patients with moderate-to",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.3671875,
            "text": "interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.390625,
            "text": "interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.3984375,
            "text": "interleukin-17A monoclonal antibody, in patients with moderate",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.40625,
            "text": "interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": 9.7109375,
            "text": "-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.421875,
            "text": "interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.4296875,
            "text": "interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.4375,
            "text": "interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.7109375,
            "text": "human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": -1.81640625,
            "text": "-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": -1.81640625,
            "text": "human anti-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -1.873046875,
            "end_logit": -8.3515625,
            "text": "17A monoclonal antibody, in patients with moderate-to",
            "probability": 0.0
        },
        {
            "start_logit": -1.873046875,
            "end_logit": -8.3671875,
            "text": "17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week",
            "probability": 0.0
        },
        {
            "start_logit": -1.873046875,
            "end_logit": -8.390625,
            "text": "17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24",
            "probability": 0.0
        },
        {
            "start_logit": -1.873046875,
            "end_logit": -8.3984375,
            "text": "17A monoclonal antibody, in patients with moderate",
            "probability": 0.0
        }
    ],
    "54e0d7471388e8454a000015_6": [
        {
            "start_logit": 9.9609375,
            "end_logit": 9.625,
            "text": "interleukin-17A",
            "probability": 1.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -1.9912109375,
            "text": "interleukin",
            "probability": 8.940696716308594e-06
        },
        {
            "start_logit": -2.056640625,
            "end_logit": 9.625,
            "text": "17A",
            "probability": 6.020069122314453e-06
        },
        {
            "start_logit": -6.22265625,
            "end_logit": 9.625,
            "text": "-17A",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.03125,
            "end_logit": 9.625,
            "text": "targeted interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.4375,
            "text": "interleukin-17A blockade, in patients with noninfect",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.453125,
            "text": "interleukin-17A blockade, in patients with noninfectious uveitis",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.4609375,
            "text": "interleukin-17A blockade, in patients with noninfe",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.625,
            "text": "human monoclonal antibody for targeted interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.625,
            "text": "safety of different doses of secukinumab, a fully human monoclonal antibody for targeted interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.625,
            "text": "efficacy and safety of different doses of secukinumab, a fully human monoclonal antibody for targeted interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.625,
            "text": "a fully human monoclonal antibody for targeted interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.625,
            "text": ", a fully human monoclonal antibody for targeted interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.625,
            "text": "for targeted interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.625,
            "text": "of different doses of secukinumab, a fully human monoclonal antibody for targeted interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.625,
            "text": "different doses of secukinumab, a fully human monoclonal antibody for targeted interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.625,
            "text": "fully human monoclonal antibody for targeted interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": -1.9912109375,
            "text": "targeted interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -1.9912109375,
            "text": "human monoclonal antibody for targeted interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": -1.9912109375,
            "text": "safety of different doses of secukinumab, a fully human monoclonal antibody for targeted interleukin",
            "probability": 0.0
        }
    ],
    "54e0d7471388e8454a000015_7": [
        {
            "start_logit": 9.9921875,
            "end_logit": 9.671875,
            "text": "interleukin-17A",
            "probability": 1.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -1.908203125,
            "text": "interleukin",
            "probability": 9.417533874511719e-06
        },
        {
            "start_logit": -1.970703125,
            "end_logit": 9.671875,
            "text": "17A",
            "probability": 6.4373016357421875e-06
        },
        {
            "start_logit": -6.30859375,
            "end_logit": 9.671875,
            "text": "-17A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.390625,
            "text": "interleukin-17A-",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.40625,
            "text": "interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.40625,
            "text": "interleukin-17A-blocking",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.40625,
            "text": "interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.671875,
            "text": "the interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -1.908203125,
            "text": "the interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -1.970703125,
            "end_logit": -8.390625,
            "text": "17A-",
            "probability": 0.0
        },
        {
            "start_logit": -1.970703125,
            "end_logit": -8.40625,
            "text": "17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label",
            "probability": 0.0
        },
        {
            "start_logit": -1.970703125,
            "end_logit": -8.40625,
            "text": "17A-blocking",
            "probability": 0.0
        },
        {
            "start_logit": -1.970703125,
            "end_logit": -8.40625,
            "text": "17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel",
            "probability": 0.0
        },
        {
            "start_logit": -6.30859375,
            "end_logit": -8.390625,
            "text": "-17A-",
            "probability": 0.0
        },
        {
            "start_logit": -6.30859375,
            "end_logit": -8.40625,
            "text": "-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label",
            "probability": 0.0
        },
        {
            "start_logit": -6.30859375,
            "end_logit": -8.40625,
            "text": "-17A-blocking",
            "probability": 0.0
        },
        {
            "start_logit": -6.30859375,
            "end_logit": -8.40625,
            "text": "-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -8.40625,
            "text": "an open-label",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -8.40625,
            "text": "an open-label, parallel",
            "probability": 0.0
        }
    ],
    "54e0d7471388e8454a000015_8": [
        {
            "start_logit": 10.046875,
            "end_logit": 9.75,
            "text": "interleukin-17A",
            "probability": 1.0
        },
        {
            "start_logit": 10.046875,
            "end_logit": -1.779296875,
            "text": "interleukin",
            "probability": 9.834766387939453e-06
        },
        {
            "start_logit": -1.7783203125,
            "end_logit": 9.75,
            "text": "17A",
            "probability": 7.271766662597656e-06
        },
        {
            "start_logit": -6.08203125,
            "end_logit": 9.75,
            "text": "-17A",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.046875,
            "end_logit": -8.140625,
            "text": "interleukin-17A (IL-17A",
            "probability": 0.0
        },
        {
            "start_logit": 10.046875,
            "end_logit": -8.171875,
            "text": "interleukin-17A (IL",
            "probability": 0.0
        },
        {
            "start_logit": 10.046875,
            "end_logit": -8.2734375,
            "text": "interleukin-17A (IL-",
            "probability": 0.0
        },
        {
            "start_logit": 10.046875,
            "end_logit": -8.3359375,
            "text": "interleukin-17A (IL-17A) monoclonal antibody (MAb",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 9.75,
            "text": "-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": 10.046875,
            "end_logit": -8.375,
            "text": "interleukin-17A (IL-17A) monoclonal",
            "probability": 0.0
        },
        {
            "start_logit": 10.046875,
            "end_logit": -8.3828125,
            "text": "interleukin-17A (IL-17A) monoclonal antibody",
            "probability": 0.0
        },
        {
            "start_logit": 10.046875,
            "end_logit": -8.3828125,
            "text": "interleukin-17A (IL-17A) monoclonal antibody (MAb) sec",
            "probability": 0.0
        },
        {
            "start_logit": 10.046875,
            "end_logit": -8.3984375,
            "text": "interleukin-17A (IL-17A) monoclonal antibody (",
            "probability": 0.0
        },
        {
            "start_logit": 10.046875,
            "end_logit": -8.4140625,
            "text": "interleukin-17A (IL-17A)",
            "probability": 0.0
        },
        {
            "start_logit": 10.046875,
            "end_logit": -8.421875,
            "text": "interleukin-17A (IL-17A) monoclonal antibody (MAb)",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.75,
            "text": "subjects exposed to the anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.75,
            "text": "the anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.75,
            "text": "evaluate the efficacy of influenza and meningococcal vaccinations in healthy subjects exposed to the anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.75,
            "text": "in healthy subjects exposed to the anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.75,
            "text": "to the anti-interleukin-17A",
            "probability": 0.0
        }
    ],
    "58b6978822d300530900000a_1": [
        {
            "start_logit": 9.671875,
            "end_logit": 9.640625,
            "text": "Alzheimer's disease",
            "probability": 1.0
        },
        {
            "start_logit": -2.001953125,
            "end_logit": 9.640625,
            "text": "disease",
            "probability": 8.52346420288086e-06
        },
        {
            "start_logit": 9.671875,
            "end_logit": -2.42578125,
            "text": "Alzheimer",
            "probability": 5.781650543212891e-06
        },
        {
            "start_logit": -6.36328125,
            "end_logit": 9.640625,
            "text": "'s disease",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.8671875,
            "end_logit": 9.640625,
            "text": "s disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.671875,
            "end_logit": -7.7890625,
            "text": "Alzheimer's",
            "probability": 0.0
        },
        {
            "start_logit": 9.671875,
            "end_logit": -7.96875,
            "text": "Alzheimer'",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 9.640625,
            "text": "the Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": 9.671875,
            "end_logit": -8.109375,
            "text": "Alzheimer's disease mouse",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.640625,
            "text": "paper offers new insight into cognitive dysfunctions of the Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 9.640625,
            "text": "this paper offers new insight into cognitive dysfunctions of the Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.640625,
            "text": "new insight into cognitive dysfunctions of the Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.640625,
            "text": "The novel approach to study the transgenic mice cognitive abilities presented in this paper offers new insight into cognitive dysfunctions of the Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.640625,
            "text": "approach to study the transgenic mice cognitive abilities presented in this paper offers new insight into cognitive dysfunctions of the Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.640625,
            "text": "insight into cognitive dysfunctions of the Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.640625,
            "text": "in this paper offers new insight into cognitive dysfunctions of the Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.640625,
            "text": "study the transgenic mice cognitive abilities presented in this paper offers new insight into cognitive dysfunctions of the Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.640625,
            "text": "the transgenic mice cognitive abilities presented in this paper offers new insight into cognitive dysfunctions of the Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.640625,
            "text": "novel approach to study the transgenic mice cognitive abilities presented in this paper offers new insight into cognitive dysfunctions of the Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.640625,
            "text": "of the Alzheimer's disease",
            "probability": 0.0
        }
    ],
    "58b6978822d300530900000a_2": [
        {
            "start_logit": 9.890625,
            "end_logit": 9.671875,
            "text": "Alzheimer's disease",
            "probability": 1.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -2.134765625,
            "text": "Alzheimer",
            "probability": 7.450580596923828e-06
        },
        {
            "start_logit": -1.966796875,
            "end_logit": 9.671875,
            "text": "disease",
            "probability": 7.092952728271484e-06
        },
        {
            "start_logit": -6.24609375,
            "end_logit": 9.671875,
            "text": "'s disease",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.3359375,
            "end_logit": 9.671875,
            "text": "s disease",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.890625,
            "end_logit": -7.7109375,
            "text": "Alzheimer's disease (",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -7.99609375,
            "text": "Alzheimer's disease (AD)",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.0703125,
            "text": "Alzheimer'",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.1875,
            "text": "Alzheimer's",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.2109375,
            "text": "Alzheimer's disease (AD) is the massive loss of synapses that occurs at an early clinical stage of the disease. In this study, we characterize alterations in spine density",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.2265625,
            "text": "Alzheimer's disease (AD",
            "probability": 0.0
        },
        {
            "start_logit": -1.966796875,
            "end_logit": -7.7109375,
            "text": "disease (",
            "probability": 0.0
        },
        {
            "start_logit": -1.966796875,
            "end_logit": -7.99609375,
            "text": "disease (AD)",
            "probability": 0.0
        },
        {
            "start_logit": -1.966796875,
            "end_logit": -8.2109375,
            "text": "disease (AD) is the massive loss of synapses that occurs at an early clinical stage of the disease. In this study, we characterize alterations in spine density",
            "probability": 0.0
        },
        {
            "start_logit": -1.966796875,
            "end_logit": -8.2265625,
            "text": "disease (AD",
            "probability": 0.0
        },
        {
            "start_logit": -6.24609375,
            "end_logit": -7.7109375,
            "text": "'s disease (",
            "probability": 0.0
        },
        {
            "start_logit": -6.32421875,
            "end_logit": -7.7109375,
            "text": ". A similar reduction of 42%",
            "probability": 0.0
        },
        {
            "start_logit": -6.3359375,
            "end_logit": -7.7109375,
            "text": "s disease (",
            "probability": 0.0
        },
        {
            "start_logit": -6.32421875,
            "end_logit": -7.8046875,
            "text": ". The density of mushroom-type spines was reduced by 34%",
            "probability": 0.0
        },
        {
            "start_logit": -6.24609375,
            "end_logit": -7.99609375,
            "text": "'s disease (AD)",
            "probability": 0.0
        }
    ],
    "58b6978822d300530900000a_3": [
        {
            "start_logit": 9.765625,
            "end_logit": 9.6015625,
            "text": "Alzheimer's disease",
            "probability": 1.0
        },
        {
            "start_logit": -2.154296875,
            "end_logit": 9.6015625,
            "text": "disease",
            "probability": 6.616115570068359e-06
        },
        {
            "start_logit": 9.765625,
            "end_logit": -2.353515625,
            "text": "Alzheimer",
            "probability": 6.377696990966797e-06
        },
        {
            "start_logit": 9.765625,
            "end_logit": -5.71484375,
            "text": "Alzheimer's disease.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.02734375,
            "end_logit": 9.6015625,
            "text": "onset Alzheimer's disease",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.46484375,
            "end_logit": 9.6015625,
            "text": "'s disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.69921875,
            "end_logit": 9.6015625,
            "text": "with early-onset Alzheimer's disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.796875,
            "end_logit": 9.6015625,
            "text": "s disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.765625,
            "end_logit": -7.8125,
            "text": "Alzheimer'",
            "probability": 0.0
        },
        {
            "start_logit": 9.765625,
            "end_logit": -7.87109375,
            "text": "Alzheimer's",
            "probability": 0.0
        },
        {
            "start_logit": -7.734375,
            "end_logit": 9.6015625,
            "text": "in two Italian families with early-onset Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.765625,
            "end_logit": 9.6015625,
            "text": "mutation (Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.82421875,
            "end_logit": 9.6015625,
            "text": "The London APP mutation (Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.8828125,
            "end_logit": 9.6015625,
            "text": "with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.88671875,
            "end_logit": 9.6015625,
            "text": "two Italian families with early-onset Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 9.6015625,
            "text": "-onset Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.96875,
            "end_logit": 9.6015625,
            "text": "London APP mutation (Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 9.6015625,
            "text": "associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.6015625,
            "text": "families with early-onset Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.6015625,
            "text": "Italian families with early-onset Alzheimer's disease",
            "probability": 0.0
        }
    ],
    "58b6978822d300530900000a_4": [
        {
            "start_logit": 8.9609375,
            "end_logit": 7.65625,
            "text": "AD",
            "probability": 1.0
        },
        {
            "start_logit": 8.9609375,
            "end_logit": -7.05859375,
            "text": "AD in 3 out of 7 siblings and it is also present in a fourth sibling who has only shown signs of executive dysfunction so far. Two subjects of the other family with AD diagnosis were carriers of the same mutation.",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.9609375,
            "end_logit": -7.05859375,
            "text": "AD in 3 out of 7 siblings and it is also present in a fourth sibling who has only shown signs of executive dysfunction so far.",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.9609375,
            "end_logit": -7.7265625,
            "text": "AD in 3 out",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.9609375,
            "end_logit": -7.765625,
            "text": "AD in",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.9609375,
            "end_logit": -8.0078125,
            "text": "AD in 3 out of 7 siblings and it is also present in a fourth sibling who has only shown signs of executive dysfunction so",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.9609375,
            "end_logit": -8.03125,
            "text": "AD in 3 out of 7 siblings and it is also present in a fourth sibling who has only shown signs of executive dysfunction so far. Two subjects of the other family with AD",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.9609375,
            "end_logit": -8.1640625,
            "text": "AD in 3 out of",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9609375,
            "end_logit": -8.2265625,
            "text": "AD in 3 out of 7 siblings and it is also present in a fourth sibling who has only shown signs of executive dysfunction so far. Two subjects of the other family with AD diagnosis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9609375,
            "end_logit": -8.2421875,
            "text": "AD in 3 out of 7 siblings and it is",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9609375,
            "end_logit": -8.25,
            "text": "AD in 3 out of 7 siblings and it is also present in a fourth sibling who has only",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9609375,
            "end_logit": -8.2578125,
            "text": "AD in 3 out of 7 siblings and it is also present in a",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9609375,
            "end_logit": -8.2578125,
            "text": "AD in 3",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9609375,
            "end_logit": -8.2578125,
            "text": "AD in 3 out of 7",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9609375,
            "end_logit": -8.265625,
            "text": "AD in 3 out of 7 siblings and it is also present in a fourth sibling who has only shown signs of executive dysfunction so far",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9609375,
            "end_logit": -8.265625,
            "text": "AD in 3 out of 7 siblings and it is also present in a fourth sibling who has only shown signs",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9609375,
            "end_logit": -8.28125,
            "text": "AD in 3 out of 7 siblings and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.30078125,
            "end_logit": 7.65625,
            "text": "for AD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.58203125,
            "end_logit": 7.65625,
            "text": "In 1 family, this mutation was responsible for AD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.640625,
            "end_logit": 7.65625,
            "text": ", this mutation was responsible for AD",
            "probability": 5.960464477539063e-08
        }
    ],
    "58b6978822d300530900000a_5": [
        {
            "start_logit": 8.5625,
            "end_logit": 8.1328125,
            "text": "AD",
            "probability": 1.0
        },
        {
            "start_logit": 8.5625,
            "end_logit": -7.6640625,
            "text": "AD patient is extracellular amyloid plaques formed by accumulated beta-amyloid protein (Abeta), a metabolic product of amyloid precursor protein (APP).",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5625,
            "end_logit": -7.74609375,
            "text": "AD patient is extracellular amyloid plaques formed by accumulated beta-amyloid protein (Abeta), a metabolic product of amyloid precursor protein (APP). Studies have revealed a strong genetic linkage in the early-onset familial form (<60 years old) of AD",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.5625,
            "end_logit": 8.1328125,
            "text": "an AD",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0,
            "end_logit": 8.1328125,
            "text": "of an AD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.3984375,
            "end_logit": -7.6640625,
            "text": ". Studies have revealed a strong genetic linkage in the early-onset familial form (<60 years old) of AD. For example, some mutant APPs are transmitted dominantly and are segregated with inheritance of early onset AD.",
            "probability": 0.0
        },
        {
            "start_logit": -6.3984375,
            "end_logit": -7.6640625,
            "text": ". Studies have revealed a strong genetic linkage in the early-onset familial form (<60 years old) of AD.",
            "probability": 0.0
        },
        {
            "start_logit": -6.3984375,
            "end_logit": -7.6640625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.3984375,
            "end_logit": -7.6640625,
            "text": ". For example, some mutant APPs are transmitted dominantly and are segregated with inheritance of early onset AD.",
            "probability": 0.0
        },
        {
            "start_logit": -6.3984375,
            "end_logit": -7.6640625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.3984375,
            "end_logit": -7.6640625,
            "text": ". These mutants facilitate Abeta production. The \"Swedish\" mutations (APP(SW)) and the \"London\" mutation (APP(LON)) are examples of these mutants.",
            "probability": 0.0
        },
        {
            "start_logit": -6.3984375,
            "end_logit": -7.6640625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.3984375,
            "end_logit": -7.6640625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.3984375,
            "end_logit": -7.74609375,
            "text": ". Studies have revealed a strong genetic linkage in the early-onset familial form (<60 years old) of AD",
            "probability": 0.0
        },
        {
            "start_logit": -6.3984375,
            "end_logit": -7.89453125,
            "text": ". For example, some mutant APPs are transmitted dominantly and are segregated with inheritance of early onset AD. These mutants facilitate Abeta production. The \"Swedish\" mutations (APP(SW)) and the \"London\" mutation (APP(LON",
            "probability": 0.0
        },
        {
            "start_logit": -6.3984375,
            "end_logit": -7.89453125,
            "text": ". These mutants facilitate Abeta production. The \"Swedish\" mutations (APP(SW)) and the \"London\" mutation (APP(LON",
            "probability": 0.0
        },
        {
            "start_logit": -6.3984375,
            "end_logit": -7.94921875,
            "text": ". Studies have revealed a strong genetic linkage in the early-onset familial form (<60 years old) of AD. For example, some mutant APPs are transmitted dominant",
            "probability": 0.0
        },
        {
            "start_logit": -6.3984375,
            "end_logit": -7.94921875,
            "text": ". For example, some mutant APPs are transmitted dominant",
            "probability": 0.0
        },
        {
            "start_logit": -6.3984375,
            "end_logit": -8.0078125,
            "text": ". Studies have revealed a strong genetic linkage in the early-onset familial form (<60 years old) of AD. For example, some mutant APPs are transmitted dominantly and are segregated with inheritance of early onset AD. These mutants facilitate Abeta production",
            "probability": 0.0
        },
        {
            "start_logit": -6.3984375,
            "end_logit": -8.0078125,
            "text": ". For example, some mutant APPs are transmitted dominantly and are segregated with inheritance of early onset AD. These mutants facilitate Abeta production",
            "probability": 0.0
        }
    ],
    "58b6978822d300530900000a_6": [
        {
            "start_logit": 8.734375,
            "end_logit": 7.796875,
            "text": "AD",
            "probability": 1.0
        },
        {
            "start_logit": 8.734375,
            "end_logit": -7.54296875,
            "text": "AD development",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.734375,
            "end_logit": -8.125,
            "text": "AD development.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.70703125,
            "end_logit": 7.796875,
            "text": "in AD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 7.796875,
            "text": "study may be useful in both in vivo and in vitro studies to investigate the pathophysiological role of APP(SW) and APP(LON) in AD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 7.796875,
            "text": "this study may be useful in both in vivo and in vitro studies to investigate the pathophysiological role of APP(SW) and APP(LON) in AD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 7.796875,
            "text": "both in vivo and in vitro studies to investigate the pathophysiological role of APP(SW) and APP(LON) in AD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 7.796875,
            "text": "studies to investigate the pathophysiological role of APP(SW) and APP(LON) in AD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 7.796875,
            "text": "The sequences that are effective to silence APP(SW) and APP(LON) as identified in this study may be useful in both in vivo and in vitro studies to investigate the pathophysiological role of APP(SW) and APP(LON) in AD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.140625,
            "end_logit": 7.796875,
            "text": "in vivo and in vitro studies to investigate the pathophysiological role of APP(SW) and APP(LON) in AD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.140625,
            "end_logit": 7.796875,
            "text": "ence APP(SW) and APP(LON) as identified in this study may be useful in both in vivo and in vitro studies to investigate the pathophysiological role of APP(SW) and APP(LON) in AD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.15625,
            "end_logit": 7.796875,
            "text": "be useful in both in vivo and in vitro studies to investigate the pathophysiological role of APP(SW) and APP(LON) in AD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.171875,
            "end_logit": 7.796875,
            "text": "identified in this study may be useful in both in vivo and in vitro studies to investigate the pathophysiological role of APP(SW) and APP(LON) in AD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1875,
            "end_logit": 7.796875,
            "text": "may be useful in both in vivo and in vitro studies to investigate the pathophysiological role of APP(SW) and APP(LON) in AD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1875,
            "end_logit": 7.796875,
            "text": "and in vitro studies to investigate the pathophysiological role of APP(SW) and APP(LON) in AD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.21875,
            "end_logit": 7.796875,
            "text": "in this study may be useful in both in vivo and in vitro studies to investigate the pathophysiological role of APP(SW) and APP(LON) in AD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 7.796875,
            "text": "sequences that are effective to silence APP(SW) and APP(LON) as identified in this study may be useful in both in vivo and in vitro studies to investigate the pathophysiological role of APP(SW) and APP(LON) in AD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.59765625,
            "end_logit": -8.125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.70703125,
            "end_logit": -7.54296875,
            "text": "in AD development",
            "probability": 0.0
        },
        {
            "start_logit": -7.7890625,
            "end_logit": -7.54296875,
            "text": "development",
            "probability": 0.0
        }
    ],
    "58b6978822d300530900000a_7": [
        {
            "start_logit": 9.6953125,
            "end_logit": 9.609375,
            "text": "Alzheimer's disease",
            "probability": 1.0
        },
        {
            "start_logit": -2.1640625,
            "end_logit": 9.609375,
            "text": "disease",
            "probability": 7.033348083496094e-06
        },
        {
            "start_logit": 9.6953125,
            "end_logit": -2.494140625,
            "text": "Alzheimer",
            "probability": 5.4836273193359375e-06
        },
        {
            "start_logit": -6.53515625,
            "end_logit": 9.609375,
            "text": "'s disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.72265625,
            "end_logit": 9.609375,
            "text": "s disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6953125,
            "end_logit": -7.98046875,
            "text": "Alzheimer's",
            "probability": 0.0
        },
        {
            "start_logit": 9.6953125,
            "end_logit": -8.046875,
            "text": "Alzheimer'",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.609375,
            "text": "familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": 9.6953125,
            "end_logit": -8.1953125,
            "text": "Alzheimer's disease using two reporter alleles encoding the Photinus and Renilla luciferase genes and carrying mutant and wild-type allelic sequences in their 3'",
            "probability": 0.0
        },
        {
            "start_logit": 9.6953125,
            "end_logit": -8.21875,
            "text": "Alzheimer's disease using two reporter alleles encoding the Photinus",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 9.609375,
            "text": "to familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": 9.6953125,
            "end_logit": -8.25,
            "text": "Alzheimer's disease using",
            "probability": 0.0
        },
        {
            "start_logit": 9.6953125,
            "end_logit": -8.2578125,
            "text": "Alzheimer's disease using two",
            "probability": 0.0
        },
        {
            "start_logit": 9.6953125,
            "end_logit": -8.2578125,
            "text": "Alzheimer's disease using two reporter alleles encoding the Photinus and Renilla luciferase genes and carrying mutant and wild",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.609375,
            "text": "Here, we show ASP-RNAi against the Swedish- and London-type amyloid precursor protein (APP) variants related to familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.609375,
            "text": "type amyloid precursor protein (APP) variants related to familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.609375,
            "text": "related to familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.609375,
            "text": "we show ASP-RNAi against the Swedish- and London-type amyloid precursor protein (APP) variants related to familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.609375,
            "text": "variants related to familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.609375,
            "text": "amyloid precursor protein (APP) variants related to familial Alzheimer's disease",
            "probability": 0.0
        }
    ],
    "58b6978822d300530900000a_8": [
        {
            "start_logit": 9.78125,
            "end_logit": 9.6171875,
            "text": "Alzheimer's disease",
            "probability": 1.0
        },
        {
            "start_logit": -2.134765625,
            "end_logit": 9.6171875,
            "text": "disease",
            "probability": 6.616115570068359e-06
        },
        {
            "start_logit": 9.78125,
            "end_logit": -2.365234375,
            "text": "Alzheimer",
            "probability": 6.198883056640625e-06
        },
        {
            "start_logit": -6.42578125,
            "end_logit": 9.6171875,
            "text": "s disease",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.43359375,
            "end_logit": 9.6171875,
            "text": "'s disease",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.1796875,
            "end_logit": 9.6171875,
            "text": "with Alzheimer's disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.78125,
            "end_logit": -7.66796875,
            "text": "Alzheimer's disease (V642",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.78125,
            "end_logit": -7.69140625,
            "text": "Alzheimer's disease (V64",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.78125,
            "end_logit": -7.8984375,
            "text": "Alzheimer's disease (V",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -7.91015625,
            "text": "Alzheimer'",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.0390625,
            "text": "Alzheimer's disease (V642I, so-called London mutation, hereafter APPLd2) and wild-type controls were",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.046875,
            "text": "Alzheimer's",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.09375,
            "text": "Alzheimer's disease (V642I, so-called London mutation, hereafter APPLd2) and",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.1171875,
            "text": "Alzheimer's disease (V642I, so-called London mutation, hereafter APPLd2) and wild-type controls were studied at age periods",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.1328125,
            "text": "Alzheimer's disease (V642I",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.140625,
            "text": "Alzheimer's disease (V642I, so-called London mutation, hereafter APPLd2)",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.1640625,
            "text": "Alzheimer's disease (V642I, so-called London mutation, hereafter APPLd2) and wild-type controls were studied at age periods (3 and 10 months) prior",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.1796875,
            "text": "Alzheimer's disease (V642I, so-called London",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.1796875,
            "text": "Alzheimer's disease (V642I, so-called London mutation, hereafter APPLd2) and wild-type controls were studied at age",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.1875,
            "text": "Alzheimer's disease (V642I, so-called London mutation, hereafter APPLd2) and wild-type controls were studied at age periods (3 and 10 months) prior to the overt development of neuritic amyloid plaques",
            "probability": 0.0
        }
    ],
    "58b6978822d300530900000a_9": [
        {
            "start_logit": 9.8671875,
            "end_logit": 9.6015625,
            "text": "Alzheimer's disease",
            "probability": 1.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -2.166015625,
            "text": "Alzheimer",
            "probability": 7.748603820800781e-06
        },
        {
            "start_logit": -2.17578125,
            "end_logit": 9.6015625,
            "text": "disease",
            "probability": 5.841255187988281e-06
        },
        {
            "start_logit": -6.68359375,
            "end_logit": 9.6015625,
            "text": "'s disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.7890625,
            "end_logit": 9.6015625,
            "text": "s disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.796875,
            "text": "Alzheimer'",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.9921875,
            "text": "Alzheimer's",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.171875,
            "text": "Alzheimer's disease genes",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.203125,
            "text": "Alzheimer's disease genes: the amyloid precursor",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.234375,
            "text": "Alzheimer's disease genes: the amyloid precursor protein",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.6015625,
            "text": "of Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.6015625,
            "text": "Allele-specific silencing of Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -2.17578125,
            "end_logit": -8.171875,
            "text": "disease genes",
            "probability": 0.0
        },
        {
            "start_logit": -2.17578125,
            "end_logit": -8.203125,
            "text": "disease genes: the amyloid precursor",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -2.166015625,
            "text": "of Alzheimer",
            "probability": 0.0
        },
        {
            "start_logit": -2.17578125,
            "end_logit": -8.234375,
            "text": "disease genes: the amyloid precursor protein",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": -2.166015625,
            "text": "Allele-specific silencing of Alzheimer",
            "probability": 0.0
        },
        {
            "start_logit": -6.68359375,
            "end_logit": -7.796875,
            "text": "'",
            "probability": 0.0
        },
        {
            "start_logit": -6.68359375,
            "end_logit": -7.9921875,
            "text": "'s",
            "probability": 0.0
        },
        {
            "start_logit": -6.7890625,
            "end_logit": -7.9921875,
            "text": "s",
            "probability": 0.0
        }
    ],
    "58b6978822d300530900000a_10": [
        {
            "start_logit": 9.828125,
            "end_logit": 9.546875,
            "text": "Alzheimers disease (",
            "probability": 1.0
        },
        {
            "start_logit": -0.89111328125,
            "end_logit": 9.546875,
            "text": "(",
            "probability": 2.2113323211669922e-05
        },
        {
            "start_logit": 9.828125,
            "end_logit": -1.693359375,
            "text": "Alzheimer",
            "probability": 1.3113021850585938e-05
        },
        {
            "start_logit": 9.828125,
            "end_logit": -2.08203125,
            "text": "Alzheimers disease (AD).",
            "probability": 8.940696716308594e-06
        },
        {
            "start_logit": 9.828125,
            "end_logit": -2.08203125,
            "text": "Alzheimers disease (AD).We describe 2 Italian families showing the missense mutation in exon 17 of the amyloid precursor protein gene on chromosome 21 (Val717Ile), known as London mutation.",
            "probability": 8.940696716308594e-06
        },
        {
            "start_logit": 9.828125,
            "end_logit": -2.228515625,
            "text": "Alzheimers disease (AD)",
            "probability": 7.68899917602539e-06
        },
        {
            "start_logit": 9.828125,
            "end_logit": -4.5390625,
            "text": "Alzheimers disease",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 9.828125,
            "end_logit": -4.97265625,
            "text": "Alzheimers disease (AD).We describe 2 Italian families showing the missense mutation in exon 17 of the amyloid precursor protein gene on chromosome 21 (Val717",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.828125,
            "end_logit": -5.17578125,
            "text": "Alzheimers disease (AD",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 9.828125,
            "end_logit": -5.453125,
            "text": "Alzheimers disease (AD).We describe 2 Italian families showing the missense mutation in exon 17 of the amyloid precursor protein gene on chromosome 21 (Val717Ile), known as London mutation.In 1 family, this mutation was responsible for AD",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.828125,
            "end_logit": -5.94140625,
            "text": "Alzheimers disease (AD).We describe 2 Italian families showing the missense mutation in exon 17 of the amyloid precursor protein gene on chromosome 21 (Val71",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.8203125,
            "end_logit": 9.546875,
            "text": "of Alzheimers disease (",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.34765625,
            "end_logit": 9.546875,
            "text": "Mutations in the amyloid precursor protein gene were the first to be recognized as a cause of Alzheimers disease (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.828125,
            "end_logit": -6.703125,
            "text": "Alzheimers",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.828125,
            "end_logit": -6.74609375,
            "text": "Alzheimers disease (AD).We describe 2 Italian families showing the missense mutation in exon 17 of the amyloid precursor protein gene on chromosome 21 (Val717Ile",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.828125,
            "end_logit": -7.20703125,
            "text": "Alzheimers disease (AD).We describe 2 Italian families showing the missense mutation in exon 17 of the amyloid precursor protein gene on chromosome 21 (Val717Ile), known as London mutation.In 1 family, this mutation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.828125,
            "end_logit": -7.375,
            "text": "Alzheimers disease (AD).We describe 2 Italian families showing the missense mutation in exon 17 of the amyloid precursor protein gene on chromosome 21 (Val717Ile)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.21484375,
            "end_logit": 9.546875,
            "text": "first to be recognized as a cause of Alzheimers disease (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.89111328125,
            "end_logit": -2.08203125,
            "text": "(AD).",
            "probability": 0.0
        },
        {
            "start_logit": -0.89111328125,
            "end_logit": -2.08203125,
            "text": "(AD).We describe 2 Italian families showing the missense mutation in exon 17 of the amyloid precursor protein gene on chromosome 21 (Val717Ile), known as London mutation.",
            "probability": 0.0
        }
    ],
    "58b6978822d300530900000a_11": [
        {
            "start_logit": -3.38671875,
            "end_logit": -2.693359375,
            "text": "mutation (Val717Ile",
            "probability": 0.1600341796875
        },
        {
            "start_logit": -3.38671875,
            "end_logit": -2.97265625,
            "text": "mutation (Val717Ile) associated with early shifting abilities and behavioral changes",
            "probability": 0.12078857421875
        },
        {
            "start_logit": -3.38671875,
            "end_logit": -2.98828125,
            "text": "mutation (Val717Ile) associated with early shifting abilities and behavioral",
            "probability": 0.118896484375
        },
        {
            "start_logit": -3.38671875,
            "end_logit": -3.087890625,
            "text": "mutation (Val717Ile) associated with early shifting abilities",
            "probability": 0.107421875
        },
        {
            "start_logit": -3.38671875,
            "end_logit": -3.337890625,
            "text": "mutation (Val717",
            "probability": 0.08367919921875
        },
        {
            "start_logit": -3.38671875,
            "end_logit": -3.69140625,
            "text": "mutation (Val717Ile) associated with early shifting",
            "probability": 0.058868408203125
        },
        {
            "start_logit": -3.38671875,
            "end_logit": -3.76171875,
            "text": "mutation (Val71",
            "probability": 0.05487060546875
        },
        {
            "start_logit": -3.38671875,
            "end_logit": -3.916015625,
            "text": "mutation (Val717Ile) associated with early shifting abilities and behavioral changes in",
            "probability": 0.046905517578125
        },
        {
            "start_logit": -3.38671875,
            "end_logit": -3.923828125,
            "text": "mutation (Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimers disease",
            "probability": 0.04656982421875
        },
        {
            "start_logit": -5.296875,
            "end_logit": -2.693359375,
            "text": "London APP mutation (Val717Ile",
            "probability": 0.023590087890625
        },
        {
            "start_logit": -3.38671875,
            "end_logit": -4.72265625,
            "text": "mutation (Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families",
            "probability": 0.02099609375
        },
        {
            "start_logit": -5.296875,
            "end_logit": -2.923828125,
            "text": "London APP",
            "probability": 0.0188140869140625
        },
        {
            "start_logit": -3.38671875,
            "end_logit": -4.84375,
            "text": "mutation (Val717Ile)",
            "probability": 0.018524169921875
        },
        {
            "start_logit": -5.5390625,
            "end_logit": -2.693359375,
            "text": "The London APP mutation (Val717Ile",
            "probability": 0.018524169921875
        },
        {
            "start_logit": -3.38671875,
            "end_logit": -4.87890625,
            "text": "mutation (Val717Ile) associated with early shifting abilities and",
            "probability": 0.0179443359375
        },
        {
            "start_logit": -5.296875,
            "end_logit": -2.97265625,
            "text": "London APP mutation (Val717Ile) associated with early shifting abilities and behavioral changes",
            "probability": 0.0179443359375
        },
        {
            "start_logit": -5.296875,
            "end_logit": -2.98828125,
            "text": "London APP mutation (Val717Ile) associated with early shifting abilities and behavioral",
            "probability": 0.017669677734375
        },
        {
            "start_logit": -5.296875,
            "end_logit": -3.087890625,
            "text": "London APP mutation (Val717Ile) associated with early shifting abilities",
            "probability": 0.015960693359375
        },
        {
            "start_logit": -5.41015625,
            "end_logit": -2.97265625,
            "text": "early shifting abilities and behavioral changes",
            "probability": 0.015960693359375
        },
        {
            "start_logit": -5.41015625,
            "end_logit": -2.98828125,
            "text": "early shifting abilities and behavioral",
            "probability": 0.015716552734375
        }
    ],
    "58b6978822d300530900000a_12": [
        {
            "start_logit": 9.8671875,
            "end_logit": 9.6015625,
            "text": "Alzheimer's disease",
            "probability": 1.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -2.166015625,
            "text": "Alzheimer",
            "probability": 7.748603820800781e-06
        },
        {
            "start_logit": -2.17578125,
            "end_logit": 9.6015625,
            "text": "disease",
            "probability": 5.841255187988281e-06
        },
        {
            "start_logit": -6.68359375,
            "end_logit": 9.6015625,
            "text": "'s disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.7890625,
            "end_logit": 9.6015625,
            "text": "s disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.796875,
            "text": "Alzheimer'",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.9921875,
            "text": "Alzheimer's",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.171875,
            "text": "Alzheimer's disease genes",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.203125,
            "text": "Alzheimer's disease genes: the amyloid precursor",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.234375,
            "text": "Alzheimer's disease genes: the amyloid precursor protein",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.6015625,
            "text": "of Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.6015625,
            "text": "Allele-specific silencing of Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -2.17578125,
            "end_logit": -8.171875,
            "text": "disease genes",
            "probability": 0.0
        },
        {
            "start_logit": -2.17578125,
            "end_logit": -8.203125,
            "text": "disease genes: the amyloid precursor",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -2.166015625,
            "text": "of Alzheimer",
            "probability": 0.0
        },
        {
            "start_logit": -2.17578125,
            "end_logit": -8.234375,
            "text": "disease genes: the amyloid precursor protein",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": -2.166015625,
            "text": "Allele-specific silencing of Alzheimer",
            "probability": 0.0
        },
        {
            "start_logit": -6.68359375,
            "end_logit": -7.796875,
            "text": "'",
            "probability": 0.0
        },
        {
            "start_logit": -6.68359375,
            "end_logit": -7.9921875,
            "text": "'s",
            "probability": 0.0
        },
        {
            "start_logit": -6.7890625,
            "end_logit": -7.9921875,
            "text": "s",
            "probability": 0.0
        }
    ],
    "58b6978822d300530900000a_13": [
        {
            "start_logit": 9.765625,
            "end_logit": 9.6015625,
            "text": "Alzheimer's disease",
            "probability": 1.0
        },
        {
            "start_logit": -2.154296875,
            "end_logit": 9.6015625,
            "text": "disease",
            "probability": 6.616115570068359e-06
        },
        {
            "start_logit": 9.765625,
            "end_logit": -2.353515625,
            "text": "Alzheimer",
            "probability": 6.377696990966797e-06
        },
        {
            "start_logit": 9.765625,
            "end_logit": -5.71484375,
            "text": "Alzheimer's disease.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.02734375,
            "end_logit": 9.6015625,
            "text": "onset Alzheimer's disease",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.46484375,
            "end_logit": 9.6015625,
            "text": "'s disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.69921875,
            "end_logit": 9.6015625,
            "text": "with early-onset Alzheimer's disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.796875,
            "end_logit": 9.6015625,
            "text": "s disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.765625,
            "end_logit": -7.8125,
            "text": "Alzheimer'",
            "probability": 0.0
        },
        {
            "start_logit": 9.765625,
            "end_logit": -7.87109375,
            "text": "Alzheimer's",
            "probability": 0.0
        },
        {
            "start_logit": -7.734375,
            "end_logit": 9.6015625,
            "text": "in two Italian families with early-onset Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.765625,
            "end_logit": 9.6015625,
            "text": "mutation (Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.82421875,
            "end_logit": 9.6015625,
            "text": "The London APP mutation (Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.8828125,
            "end_logit": 9.6015625,
            "text": "with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.88671875,
            "end_logit": 9.6015625,
            "text": "two Italian families with early-onset Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 9.6015625,
            "text": "-onset Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.96875,
            "end_logit": 9.6015625,
            "text": "London APP mutation (Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 9.6015625,
            "text": "associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.6015625,
            "text": "families with early-onset Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.6015625,
            "text": "Italian families with early-onset Alzheimer's disease",
            "probability": 0.0
        }
    ],
    "52fe58f82059c6d71c00007a_1": [
        {
            "start_logit": 8.796875,
            "end_logit": 8.015625,
            "text": "multiple",
            "probability": 1.0
        },
        {
            "start_logit": 8.796875,
            "end_logit": -6.703125,
            "text": "multiple origins",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.796875,
            "end_logit": -7.61328125,
            "text": "multiple origins.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.1640625,
            "end_logit": 8.015625,
            "text": ", whereas most archaea and all eukaryotes replicate using multiple",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 8.015625,
            "text": "using multiple",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 8.015625,
            "text": "whereas most archaea and all eukaryotes replicate using multiple",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 8.015625,
            "text": "from single origins, whereas most archaea and all eukaryotes replicate using multiple",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 8.015625,
            "text": "Bacteria and some archaea replicate from single origins, whereas most archaea and all eukaryotes replicate using multiple",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 8.015625,
            "text": "single origins, whereas most archaea and all eukaryotes replicate using multiple",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1875,
            "end_logit": 8.015625,
            "text": "replicate using multiple",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 8.015625,
            "text": "archaea replicate from single origins, whereas most archaea and all eukaryotes replicate using multiple",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 8.015625,
            "text": "archaea and all eukaryotes replicate using multiple",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.234375,
            "end_logit": 8.015625,
            "text": "replicate from single origins, whereas most archaea and all eukaryotes replicate using multiple",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 8.015625,
            "text": "some archaea replicate from single origins, whereas most archaea and all eukaryotes replicate using multiple",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3125,
            "end_logit": 8.015625,
            "text": "and all eukaryotes replicate using multiple",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.359375,
            "end_logit": 8.015625,
            "text": "most archaea and all eukaryotes replicate using multiple",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1640625,
            "end_logit": -6.703125,
            "text": ", whereas most archaea and all eukaryotes replicate using multiple origins",
            "probability": 0.0
        },
        {
            "start_logit": -7.97265625,
            "end_logit": -6.703125,
            "text": "using multiple origins",
            "probability": 0.0
        },
        {
            "start_logit": -7.9921875,
            "end_logit": -6.703125,
            "text": "whereas most archaea and all eukaryotes replicate using multiple origins",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -6.703125,
            "text": "from single origins, whereas most archaea and all eukaryotes replicate using multiple origins",
            "probability": 0.0
        }
    ],
    "52fe58f82059c6d71c00007a_2": [
        {
            "start_logit": 8.1796875,
            "end_logit": 8.53125,
            "text": "multiple",
            "probability": 1.0
        },
        {
            "start_logit": 8.1796875,
            "end_logit": -7.75,
            "text": "multiple DNA replication",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1796875,
            "end_logit": -8.0703125,
            "text": "multiple DNA replication origins are a hallmark of Eukaryotes and some Archaea",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1796875,
            "end_logit": -8.09375,
            "text": "multiple DNA replication origins",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.546875,
            "end_logit": -7.75,
            "text": "DNA replication",
            "probability": 0.0
        },
        {
            "start_logit": -7.546875,
            "end_logit": -8.0703125,
            "text": "DNA replication origins are a hallmark of Eukaryotes and some Archaea",
            "probability": 0.0
        },
        {
            "start_logit": -7.546875,
            "end_logit": -8.09375,
            "text": "DNA replication origins",
            "probability": 0.0
        },
        {
            "start_logit": -8.453125,
            "end_logit": -7.75,
            "text": "replication",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": -8.0703125,
            "text": "of Eukaryotes and some Archaea",
            "probability": 0.0
        },
        {
            "start_logit": -8.3984375,
            "end_logit": -8.0703125,
            "text": "some Archaea",
            "probability": 0.0
        },
        {
            "start_logit": -8.4140625,
            "end_logit": -8.0703125,
            "text": "a hallmark of Eukaryotes and some Archaea",
            "probability": 0.0
        },
        {
            "start_logit": -8.4375,
            "end_logit": -8.0703125,
            "text": "are a hallmark of Eukaryotes and some Archaea",
            "probability": 0.0
        },
        {
            "start_logit": -8.4375,
            "end_logit": -8.0703125,
            "text": "origins are a hallmark of Eukaryotes and some Archaea",
            "probability": 0.0
        },
        {
            "start_logit": -8.4453125,
            "end_logit": -8.0703125,
            "text": "and some Archaea",
            "probability": 0.0
        },
        {
            "start_logit": -8.4375,
            "end_logit": -8.09375,
            "text": "origins",
            "probability": 0.0
        },
        {
            "start_logit": -8.453125,
            "end_logit": -8.0703125,
            "text": "replication origins are a hallmark of Eukaryotes and some Archaea",
            "probability": 0.0
        },
        {
            "start_logit": -8.453125,
            "end_logit": -8.09375,
            "text": "replication origins",
            "probability": 0.0
        }
    ],
    "52fe58f82059c6d71c00007a_3": [
        {
            "start_logit": 8.15625,
            "end_logit": 8.578125,
            "text": "Multiple",
            "probability": 1.0
        },
        {
            "start_logit": 8.15625,
            "end_logit": -7.5625,
            "text": "Multiple orc/cdc6-associated replication origins were predicted in all of the analyzed haloarchaeal genome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.15625,
            "end_logit": -7.93359375,
            "text": "Multiple orc/cdc6-associated replication origins were predicted in all",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.15625,
            "end_logit": -8.078125,
            "text": "Multiple orc/cdc6-associated replication origins were predicted in all of the analyzed haloarchaea",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.15625,
            "end_logit": -8.078125,
            "text": "Multiple orc",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.15625,
            "end_logit": -8.1171875,
            "text": "Multiple orc/cdc6-associated replication origins were predicted in all of the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.15625,
            "end_logit": -8.1171875,
            "text": "Multiple orc/cdc6",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.15625,
            "end_logit": -8.1328125,
            "text": "Multiple orc/cdc6-associated replication origins were predicted in all of the analyzed haloarch",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.15625,
            "end_logit": -8.1640625,
            "text": "Multiple orc/cdc",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.890625,
            "end_logit": -7.5625,
            "text": "in all of the analyzed haloarchaeal genome",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": -7.5625,
            "text": "replication origins were predicted in all of the analyzed haloarchaeal genome",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -7.5625,
            "text": "of the analyzed haloarchaeal genome",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -7.5625,
            "text": "associated replication origins were predicted in all of the analyzed haloarchaeal genome",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -7.5625,
            "text": "the analyzed haloarchaeal genome",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -7.5625,
            "text": "predicted in all of the analyzed haloarchaeal genome",
            "probability": 0.0
        },
        {
            "start_logit": -7.890625,
            "end_logit": -7.93359375,
            "text": "in all",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": -7.5625,
            "text": "origins were predicted in all of the analyzed haloarchaeal genome",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": -7.5625,
            "text": "orc/cdc6-associated replication origins were predicted in all of the analyzed haloarchaeal genome",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": -7.5625,
            "text": "haloarchaeal genome",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": -7.5625,
            "text": "all of the analyzed haloarchaeal genome",
            "probability": 0.0
        }
    ],
    "52fe58f82059c6d71c00007a_4": [
        {
            "start_logit": 7.84765625,
            "end_logit": 8.8203125,
            "text": "multiple",
            "probability": 1.0
        },
        {
            "start_logit": 7.84765625,
            "end_logit": -5.61328125,
            "text": "multiple replication origins serve purposes other than simply shortening the time required for replication",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.69921875,
            "end_logit": 8.8203125,
            "text": "the multiple",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.84765625,
            "end_logit": -6.7578125,
            "text": "multiple replication origins serve",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.73828125,
            "end_logit": 8.8203125,
            "text": "that the multiple",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.9140625,
            "end_logit": 8.8203125,
            "text": "Sulfolobus chromosome implies that the multiple",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.94921875,
            "end_logit": 8.8203125,
            "text": "the Sulfolobus chromosome implies that the multiple",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 8.8203125,
            "text": "chromosome implies that the multiple",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.15625,
            "end_logit": 8.8203125,
            "text": "The strong replication-biased structuring of the Sulfolobus chromosome implies that the multiple",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.84765625,
            "end_logit": -7.25390625,
            "text": "multiple replication",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.84765625,
            "end_logit": -7.31640625,
            "text": "multiple replication origins serve purposes other than simply shortening the time required",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 8.8203125,
            "text": "s chromosome implies that the multiple",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.3125,
            "end_logit": 8.8203125,
            "text": "lobus chromosome implies that the multiple",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 8.8203125,
            "text": "bus chromosome implies that the multiple",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.84765625,
            "end_logit": -7.39453125,
            "text": "multiple replication origins serve purposes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.84765625,
            "end_logit": -7.43359375,
            "text": "multiple replication origins serve purposes other than simply shortening the time required for",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.84765625,
            "end_logit": -7.4375,
            "text": "multiple replication origins serve purposes other than",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.84765625,
            "end_logit": -7.51171875,
            "text": "multiple replication origins serve purposes other",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.84765625,
            "end_logit": -7.625,
            "text": "multiple replication origins",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.84765625,
            "end_logit": -7.7421875,
            "text": "multiple replication origins serve purposes other than simply shortening the time",
            "probability": 5.960464477539063e-08
        }
    ],
    "52fe58f82059c6d71c00007a_5": [
        {
            "start_logit": 8.171875,
            "end_logit": 8.5234375,
            "text": "multiple",
            "probability": 1.0
        },
        {
            "start_logit": -7.68359375,
            "end_logit": 8.5234375,
            "text": "the multiple",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.171875,
            "end_logit": -7.76171875,
            "text": "multiple replication",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.171875,
            "end_logit": -7.83203125,
            "text": "multiple replication origin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.171875,
            "end_logit": -7.88671875,
            "text": "multiple replication origin paradigm",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.171875,
            "end_logit": -7.88671875,
            "text": "multiple replication origin paradigm has also been demonstrated within the archaeal domain of life",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.171875,
            "end_logit": -7.94921875,
            "text": "multiple replication origin paradigm has also been demonstrated within the archaeal domain",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.171875,
            "end_logit": -7.984375,
            "text": "multiple replication origin paradigm has also been demonstrated within the archaeal domain of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.171875,
            "end_logit": -8.0390625,
            "text": "multiple replication origin paradigm has also been demonstrated within the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.171875,
            "end_logit": -8.078125,
            "text": "multiple replication origin paradigm has also been demonstrated",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.171875,
            "end_logit": -8.0859375,
            "text": "multiple replication origin paradigm has also been demonstrated within",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.68359375,
            "end_logit": -7.76171875,
            "text": "the multiple replication",
            "probability": 0.0
        },
        {
            "start_logit": -7.68359375,
            "end_logit": -7.83203125,
            "text": "the multiple replication origin",
            "probability": 0.0
        },
        {
            "start_logit": -7.68359375,
            "end_logit": -7.88671875,
            "text": "the multiple replication origin paradigm",
            "probability": 0.0
        },
        {
            "start_logit": -7.68359375,
            "end_logit": -7.88671875,
            "text": "the multiple replication origin paradigm has also been demonstrated within the archaeal domain of life",
            "probability": 0.0
        },
        {
            "start_logit": -7.68359375,
            "end_logit": -7.94921875,
            "text": "the multiple replication origin paradigm has also been demonstrated within the archaeal domain",
            "probability": 0.0
        },
        {
            "start_logit": -7.68359375,
            "end_logit": -7.984375,
            "text": "the multiple replication origin paradigm has also been demonstrated within the archaeal domain of",
            "probability": 0.0
        },
        {
            "start_logit": -7.68359375,
            "end_logit": -8.0390625,
            "text": "the multiple replication origin paradigm has also been demonstrated within the",
            "probability": 0.0
        },
        {
            "start_logit": -7.68359375,
            "end_logit": -8.078125,
            "text": "the multiple replication origin paradigm has also been demonstrated",
            "probability": 0.0
        },
        {
            "start_logit": -7.68359375,
            "end_logit": -8.0859375,
            "text": "the multiple replication origin paradigm has also been demonstrated within",
            "probability": 0.0
        }
    ],
    "52fe58f82059c6d71c00007a_6": [
        {
            "start_logit": 8.15625,
            "end_logit": 8.59375,
            "text": "multiple",
            "probability": 1.0
        },
        {
            "start_logit": 8.15625,
            "end_logit": -8.0078125,
            "text": "multiple chromosome replication",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.15625,
            "end_logit": -8.0546875,
            "text": "multiple chromosome replication origins in Sulfolobus species has added yet another eukaryotic trait to the archaea",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.15625,
            "end_logit": -8.125,
            "text": "multiple chromosome replication origins in Sulfolobus species has added yet another",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.15625,
            "end_logit": -8.1484375,
            "text": "multiple chromosome replication origins in Sulfolobus species",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.15625,
            "end_logit": -8.1484375,
            "text": "multiple chromosome replication origins in Sulfolobus species has added yet",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.15625,
            "end_logit": -8.1484375,
            "text": "multiple chromosome replication origins in Sulfolobus species has added yet another eukaryotic trait to the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.15625,
            "end_logit": -8.15625,
            "text": "multiple chromosome replication origins in Sulfolobus species has added yet another eukaryotic trait to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.15625,
            "end_logit": -8.15625,
            "text": "multiple chromosome replication origins in Sulfolobu",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.15625,
            "end_logit": -8.1640625,
            "text": "multiple chromosome replication origins in Sulfolobus species has added yet another eukaryotic trait",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.15625,
            "end_logit": -8.1640625,
            "text": "multiple chromosome replication origins",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.15625,
            "end_logit": -8.171875,
            "text": "multiple chromosome replication origins in Sulfolobus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.15625,
            "end_logit": -8.1796875,
            "text": "multiple chromosome replication origins in Sulfolo",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.15625,
            "end_logit": -8.1796875,
            "text": "multiple chromosome replication origins in Sulfo",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.82421875,
            "end_logit": -8.0078125,
            "text": "chromosome replication",
            "probability": 0.0
        },
        {
            "start_logit": -7.82421875,
            "end_logit": -8.0546875,
            "text": "chromosome replication origins in Sulfolobus species has added yet another eukaryotic trait to the archaea",
            "probability": 0.0
        },
        {
            "start_logit": -7.82421875,
            "end_logit": -8.125,
            "text": "chromosome replication origins in Sulfolobus species has added yet another",
            "probability": 0.0
        },
        {
            "start_logit": -7.82421875,
            "end_logit": -8.1484375,
            "text": "chromosome replication origins in Sulfolobus species",
            "probability": 0.0
        },
        {
            "start_logit": -7.82421875,
            "end_logit": -8.1484375,
            "text": "chromosome replication origins in Sulfolobus species has added yet",
            "probability": 0.0
        },
        {
            "start_logit": -7.82421875,
            "end_logit": -8.1484375,
            "text": "chromosome replication origins in Sulfolobus species has added yet another eukaryotic trait to the",
            "probability": 0.0
        }
    ],
    "52fe58f82059c6d71c00007a_7": [
        {
            "start_logit": 7.98828125,
            "end_logit": 8.6640625,
            "text": "multiple",
            "probability": 1.0
        },
        {
            "start_logit": -7.984375,
            "end_logit": 8.6640625,
            "text": "In addition, the potential multiple",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 8.6640625,
            "text": ", the potential multiple",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.234375,
            "end_logit": 8.6640625,
            "text": "potential multiple",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 8.6640625,
            "text": "the potential multiple",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.98828125,
            "end_logit": -7.703125,
            "text": "multiple replication origins of the archaeon Sulfolobus solfataricus are suggested by the analysis based on the Z curve method",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.98828125,
            "end_logit": -7.91015625,
            "text": "multiple replication origins of the archaeon Sulfolobus solfataricus are suggested by the analysis based on the Z curve",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.98828125,
            "end_logit": -8.1328125,
            "text": "multiple replication",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.984375,
            "end_logit": -7.703125,
            "text": "In addition, the potential multiple replication origins of the archaeon Sulfolobus solfataricus are suggested by the analysis based on the Z curve method",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": -7.703125,
            "text": "analysis based on the Z curve method",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": -7.703125,
            "text": "the Z curve method",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": -7.703125,
            "text": "based on the Z curve method",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": -7.703125,
            "text": "replication origins of the archaeon Sulfolobus solfataricus are suggested by the analysis based on the Z curve method",
            "probability": 0.0
        },
        {
            "start_logit": -7.984375,
            "end_logit": -7.91015625,
            "text": "In addition, the potential multiple replication origins of the archaeon Sulfolobus solfataricus are suggested by the analysis based on the Z curve",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -7.703125,
            "text": "on the Z curve method",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -7.703125,
            "text": ", the potential multiple replication origins of the archaeon Sulfolobus solfataricus are suggested by the analysis based on the Z curve method",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": -7.91015625,
            "text": "analysis based on the Z curve",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -7.703125,
            "text": "potential multiple replication origins of the archaeon Sulfolobus solfataricus are suggested by the analysis based on the Z curve method",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": -7.91015625,
            "text": "the Z curve",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": -7.91015625,
            "text": "based on the Z curve",
            "probability": 0.0
        }
    ],
    "52fe58f82059c6d71c00007a_8": [
        {
            "start_logit": 8.2890625,
            "end_logit": 8.4375,
            "text": "multiple",
            "probability": 1.0
        },
        {
            "start_logit": 8.2890625,
            "end_logit": -6.09375,
            "text": "multiple replication origins have been observed in archaea, considerably less is known about their evolutionary processes.",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.0234375,
            "end_logit": 8.4375,
            "text": "While multiple",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.2890625,
            "end_logit": -7.46484375,
            "text": "multiple replication origins have",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.2890625,
            "end_logit": -7.5234375,
            "text": "multiple replication origins",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.2890625,
            "end_logit": -7.5390625,
            "text": "multiple replication origins have been observed",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.2890625,
            "end_logit": -7.5390625,
            "text": "multiple replication origins have been",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.2890625,
            "end_logit": -7.59375,
            "text": "multiple replication origins have been observed in archaea, considerably less is known about their evolutionary",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.2890625,
            "end_logit": -7.6796875,
            "text": "multiple replication",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.2890625,
            "end_logit": -7.69140625,
            "text": "multiple replication origins have been observed in archaea, considerably less is known",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.2890625,
            "end_logit": -7.6953125,
            "text": "multiple replication origins have been observed in archaea, considerably less is known about their evolutionary processes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.2890625,
            "end_logit": -7.703125,
            "text": "multiple replication origins have been observed in archaea",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.2890625,
            "end_logit": -7.7265625,
            "text": "multiple replication origins have been observed in archaea, considerably less is known about their",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.90234375,
            "end_logit": -6.09375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.0234375,
            "end_logit": -6.09375,
            "text": "While multiple replication origins have been observed in archaea, considerably less is known about their evolutionary processes.",
            "probability": 0.0
        },
        {
            "start_logit": -7.40234375,
            "end_logit": -6.09375,
            "text": "replication origins have been observed in archaea, considerably less is known about their evolutionary processes.",
            "probability": 0.0
        },
        {
            "start_logit": -7.73046875,
            "end_logit": -6.09375,
            "text": "in archaea, considerably less is known about their evolutionary processes.",
            "probability": 0.0
        },
        {
            "start_logit": -7.765625,
            "end_logit": -6.09375,
            "text": ", considerably less is known about their evolutionary processes.",
            "probability": 0.0
        },
        {
            "start_logit": -7.87109375,
            "end_logit": -6.09375,
            "text": "observed in archaea, considerably less is known about their evolutionary processes.",
            "probability": 0.0
        },
        {
            "start_logit": -7.94921875,
            "end_logit": -6.09375,
            "text": "been observed in archaea, considerably less is known about their evolutionary processes.",
            "probability": 0.0
        }
    ],
    "52fe58f82059c6d71c00007a_9": [
        {
            "start_logit": 8.1171875,
            "end_logit": 8.625,
            "text": "multiple",
            "probability": 1.0
        },
        {
            "start_logit": 8.1171875,
            "end_logit": -7.7890625,
            "text": "multiple orc/cdc6-associated replication origins in haloarchaeal genomes",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1171875,
            "end_logit": -8.046875,
            "text": "multiple orc/cdc6-associated replication origins in haloarchaea",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1171875,
            "end_logit": -8.1171875,
            "text": "multiple orc",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1171875,
            "end_logit": -8.125,
            "text": "multiple orc/cdc6-associated replication origins in haloarch",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1171875,
            "end_logit": -8.203125,
            "text": "multiple orc/cdc",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1171875,
            "end_logit": -8.203125,
            "text": "multiple or",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1171875,
            "end_logit": -8.203125,
            "text": "multiple orc/cdc6",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.140625,
            "end_logit": -7.7890625,
            "text": "replication origins in haloarchaeal genomes",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -7.7890625,
            "text": "in haloarchaeal genomes",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": -7.7890625,
            "text": "origins in haloarchaeal genomes",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": -7.7890625,
            "text": "associated replication origins in haloarchaeal genomes",
            "probability": 0.0
        },
        {
            "start_logit": -8.3515625,
            "end_logit": -7.7890625,
            "text": "-associated replication origins in haloarchaeal genomes",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": -7.7890625,
            "text": "l genomes",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": -8.046875,
            "text": "replication origins in haloarchaea",
            "probability": 0.0
        },
        {
            "start_logit": -8.421875,
            "end_logit": -7.7890625,
            "text": "haloarchaeal genomes",
            "probability": 0.0
        },
        {
            "start_logit": -8.421875,
            "end_logit": -7.7890625,
            "text": "orc/cdc6-associated replication origins in haloarchaeal genomes",
            "probability": 0.0
        },
        {
            "start_logit": -8.4296875,
            "end_logit": -7.7890625,
            "text": "/cdc6-associated replication origins in haloarchaeal genomes",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": -8.125,
            "text": "replication origins in haloarch",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -8.046875,
            "text": "in haloarchaea",
            "probability": 0.0
        }
    ],
    "5fe31317a43ad31278000044_1": [
        {
            "start_logit": 10.109375,
            "end_logit": 9.5703125,
            "text": "IL-1\u03b2",
            "probability": 1.0
        },
        {
            "start_logit": 10.109375,
            "end_logit": -1.587890625,
            "text": "IL",
            "probability": 1.4185905456542969e-05
        },
        {
            "start_logit": -2.130859375,
            "end_logit": 9.5703125,
            "text": "1\u03b2",
            "probability": 4.76837158203125e-06
        },
        {
            "start_logit": -6.08984375,
            "end_logit": 9.5703125,
            "text": "-1\u03b2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.109375,
            "end_logit": -8.3671875,
            "text": "IL-1\u03b2, IL",
            "probability": 0.0
        },
        {
            "start_logit": 10.109375,
            "end_logit": -8.390625,
            "text": "IL-1\u03b2, IL-6",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.5703125,
            "text": "(IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 9.5703125,
            "text": "human adipose tissue biopsies to study the relationship of MAP3K8 expression with markers of obesity and expression of pro-inflammatory cytokines (IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.5703125,
            "text": "of pro-inflammatory cytokines (IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 9.5703125,
            "text": "relationship of MAP3K8 expression with markers of obesity and expression of pro-inflammatory cytokines (IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.5703125,
            "text": "used human adipose tissue biopsies to study the relationship of MAP3K8 expression with markers of obesity and expression of pro-inflammatory cytokines (IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.5703125,
            "text": "We used human adipose tissue biopsies to study the relationship of MAP3K8 expression with markers of obesity and expression of pro-inflammatory cytokines (IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.5703125,
            "text": "study the relationship of MAP3K8 expression with markers of obesity and expression of pro-inflammatory cytokines (IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.5703125,
            "text": "of MAP3K8 expression with markers of obesity and expression of pro-inflammatory cytokines (IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.5703125,
            "text": "the relationship of MAP3K8 expression with markers of obesity and expression of pro-inflammatory cytokines (IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": -1.587890625,
            "text": "(IL",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -1.587890625,
            "text": "human adipose tissue biopsies to study the relationship of MAP3K8 expression with markers of obesity and expression of pro-inflammatory cytokines (IL",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": -1.587890625,
            "text": "of pro-inflammatory cytokines (IL",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": -1.587890625,
            "text": "relationship of MAP3K8 expression with markers of obesity and expression of pro-inflammatory cytokines (IL",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -1.587890625,
            "text": "used human adipose tissue biopsies to study the relationship of MAP3K8 expression with markers of obesity and expression of pro-inflammatory cytokines (IL",
            "probability": 0.0
        }
    ],
    "5fe31317a43ad31278000044_2": [
        {
            "start_logit": 10.1171875,
            "end_logit": 9.7421875,
            "text": "IL-1\u03b2",
            "probability": 1.0
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -1.5537109375,
            "text": "IL",
            "probability": 1.239776611328125e-05
        },
        {
            "start_logit": -1.806640625,
            "end_logit": 9.7421875,
            "text": "1\u03b2",
            "probability": 6.616115570068359e-06
        },
        {
            "start_logit": -5.81640625,
            "end_logit": 9.7421875,
            "text": "-1\u03b2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -8.2890625,
            "text": "IL-1\u03b2 and",
            "probability": 0.0
        },
        {
            "start_logit": -7.9375,
            "end_logit": 9.7421875,
            "text": "Together, the data in both human and mouse show that MAP3K8 is involved in local adipose tissue inflammation, specifically for IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -8.3359375,
            "text": "IL-1\u03b2 and its responsive cytokines IL-6 and IL-8, but",
            "probability": 0.0
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 9.7421875,
            "text": "for IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -8.359375,
            "text": "IL-1\u03b2 and its responsive cytokines IL-6 and IL",
            "probability": 0.0
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -8.375,
            "text": "IL-1\u03b2 and its responsive",
            "probability": 0.0
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -8.3828125,
            "text": "IL-1\u03b2 and its responsive cytokines IL",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.7421875,
            "text": "the data in both human and mouse show that MAP3K8 is involved in local adipose tissue inflammation, specifically for IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.7421875,
            "text": ", the data in both human and mouse show that MAP3K8 is involved in local adipose tissue inflammation, specifically for IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.7421875,
            "text": "data in both human and mouse show that MAP3K8 is involved in local adipose tissue inflammation, specifically for IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.7421875,
            "text": "in both human and mouse show that MAP3K8 is involved in local adipose tissue inflammation, specifically for IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 9.7421875,
            "text": "human and mouse show that MAP3K8 is involved in local adipose tissue inflammation, specifically for IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 9.7421875,
            "text": "MAP3K8 is involved in local adipose tissue inflammation, specifically for IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 9.7421875,
            "text": "that MAP3K8 is involved in local adipose tissue inflammation, specifically for IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.7421875,
            "text": "both human and mouse show that MAP3K8 is involved in local adipose tissue inflammation, specifically for IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -7.9375,
            "end_logit": -1.5537109375,
            "text": "Together, the data in both human and mouse show that MAP3K8 is involved in local adipose tissue inflammation, specifically for IL",
            "probability": 0.0
        }
    ],
    "5fe31317a43ad31278000044_3": [
        {
            "start_logit": 10.09375,
            "end_logit": 9.6015625,
            "text": "IL-1\u03b2",
            "probability": 1.0
        },
        {
            "start_logit": 10.09375,
            "end_logit": -1.630859375,
            "text": "IL",
            "probability": 1.329183578491211e-05
        },
        {
            "start_logit": -2.099609375,
            "end_logit": 9.6015625,
            "text": "1\u03b2",
            "probability": 5.066394805908203e-06
        },
        {
            "start_logit": -5.71875,
            "end_logit": 9.6015625,
            "text": "-1\u03b2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.92578125,
            "end_logit": 9.6015625,
            "text": ", IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.6015625,
            "text": ", also known as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 9.6015625,
            "text": "also known as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.6015625,
            "text": "as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.6015625,
            "text": "the production of TNF\u03b1, IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.6015625,
            "text": "known as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 9.6015625,
            "text": "kinase tumor progression locus 2 (Tpl2, also known as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.6015625,
            "text": "tumor progression locus 2 (Tpl2, also known as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.6015625,
            "text": ") is a potent inflammatory mediator that drives the production of TNF\u03b1, IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.6015625,
            "text": "that drives the production of TNF\u03b1, IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.6015625,
            "text": "(Tpl2, also known as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.6015625,
            "text": "locus 2 (Tpl2, also known as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -7.92578125,
            "end_logit": -1.630859375,
            "text": ", IL",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": -1.630859375,
            "text": ", also known as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -1.630859375,
            "text": "also known as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -1.630859375,
            "text": "as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL",
            "probability": 0.0
        }
    ],
    "5fe31317a43ad31278000044_4": [
        {
            "start_logit": 10.1015625,
            "end_logit": 9.609375,
            "text": "IL-1\u03b2",
            "probability": 1.0
        },
        {
            "start_logit": 10.1015625,
            "end_logit": -1.611328125,
            "text": "IL",
            "probability": 1.329183578491211e-05
        },
        {
            "start_logit": -2.064453125,
            "end_logit": 9.609375,
            "text": "1\u03b2",
            "probability": 5.185604095458984e-06
        },
        {
            "start_logit": -5.7421875,
            "end_logit": 9.609375,
            "text": "-1\u03b2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.88671875,
            "end_logit": 9.609375,
            "text": ", IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 10.1015625,
            "end_logit": -8.390625,
            "text": "IL-1\u03b2, and IFN\u03b3",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.609375,
            "text": ", also known as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 9.609375,
            "text": "also known as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.609375,
            "text": "as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.609375,
            "text": "the production of TNF\u03b1, IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.609375,
            "text": "known as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.609375,
            "text": "kinase tumor progression locus 2 (Tpl2, also known as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.609375,
            "text": "tumor progression locus 2 (Tpl2, also known as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.609375,
            "text": "(Tpl2, also known as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.609375,
            "text": "that drives the production of TNF\u03b1, IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.609375,
            "text": "of TNF\u03b1, IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.609375,
            "text": "locus 2 (Tpl2, also known as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -7.88671875,
            "end_logit": -1.611328125,
            "text": ", IL",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": -1.611328125,
            "text": ", also known as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -1.611328125,
            "text": "also known as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL",
            "probability": 0.0
        }
    ],
    "5fe31317a43ad31278000044_5": [
        {
            "start_logit": 10.078125,
            "end_logit": 9.6015625,
            "text": "IL-1\u03b2",
            "probability": 1.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -1.68359375,
            "text": "IL",
            "probability": 1.239776611328125e-05
        },
        {
            "start_logit": -2.130859375,
            "end_logit": 9.6015625,
            "text": "1\u03b2",
            "probability": 4.947185516357422e-06
        },
        {
            "start_logit": -5.92578125,
            "end_logit": 9.6015625,
            "text": "-1\u03b2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.34765625,
            "end_logit": 9.6015625,
            "text": "induced IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -8.3203125,
            "text": "IL-1\u03b2 reporter",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": 9.6015625,
            "text": "for EPAC and TPL2 reduced AR agonist-induced IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.6015625,
            "text": "-induced IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.6015625,
            "text": "that inhibitors for EPAC and TPL2 reduced AR agonist-induced IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.6015625,
            "text": "exchange protein directly activated by cAMP) and TPL2 (tumor progression locus 2, MAP3K8) and found that inhibitors for EPAC and TPL2 reduced AR agonist-induced IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.6015625,
            "text": "by cAMP) and TPL2 (tumor progression locus 2, MAP3K8) and found that inhibitors for EPAC and TPL2 reduced AR agonist-induced IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 9.6015625,
            "text": "involvement of EPAC (exchange protein directly activated by cAMP) and TPL2 (tumor progression locus 2, MAP3K8) and found that inhibitors for EPAC and TPL2 reduced AR agonist-induced IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 9.6015625,
            "text": "examined the involvement of EPAC (exchange protein directly activated by cAMP) and TPL2 (tumor progression locus 2, MAP3K8) and found that inhibitors for EPAC and TPL2 reduced AR agonist-induced IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.6015625,
            "text": "We further examined the involvement of EPAC (exchange protein directly activated by cAMP) and TPL2 (tumor progression locus 2, MAP3K8) and found that inhibitors for EPAC and TPL2 reduced AR agonist-induced IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.6015625,
            "text": "found that inhibitors for EPAC and TPL2 reduced AR agonist-induced IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.6015625,
            "text": "protein directly activated by cAMP) and TPL2 (tumor progression locus 2, MAP3K8) and found that inhibitors for EPAC and TPL2 reduced AR agonist-induced IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.6015625,
            "text": "(exchange protein directly activated by cAMP) and TPL2 (tumor progression locus 2, MAP3K8) and found that inhibitors for EPAC and TPL2 reduced AR agonist-induced IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.6015625,
            "text": "(tumor progression locus 2, MAP3K8) and found that inhibitors for EPAC and TPL2 reduced AR agonist-induced IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -7.34765625,
            "end_logit": -1.68359375,
            "text": "induced IL",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": -1.68359375,
            "text": "for EPAC and TPL2 reduced AR agonist-induced IL",
            "probability": 0.0
        }
    ],
    "5fe31317a43ad31278000044_6": [
        {
            "start_logit": 10.1328125,
            "end_logit": 9.7578125,
            "text": "IL-1\u03b2",
            "probability": 1.0
        },
        {
            "start_logit": 10.1328125,
            "end_logit": -1.533203125,
            "text": "IL",
            "probability": 1.2516975402832031e-05
        },
        {
            "start_logit": -1.734375,
            "end_logit": 9.7578125,
            "text": "1\u03b2",
            "probability": 7.033348083496094e-06
        },
        {
            "start_logit": -5.86328125,
            "end_logit": 9.7578125,
            "text": "-1\u03b2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.1328125,
            "end_logit": -7.93359375,
            "text": "IL-1\u03b2, IL-6 and IL-8, but not TNF -\u03b1, in human adipose tissue",
            "probability": 0.0
        },
        {
            "start_logit": 10.1328125,
            "end_logit": -8.265625,
            "text": "IL-1\u03b2, IL",
            "probability": 0.0
        },
        {
            "start_logit": 10.1328125,
            "end_logit": -8.2890625,
            "text": "IL-1\u03b2, IL-6 and IL-8, but not TNF -\u03b1, in human adipose",
            "probability": 0.0
        },
        {
            "start_logit": -7.9140625,
            "end_logit": 9.7578125,
            "text": "of IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 10.1328125,
            "end_logit": -8.296875,
            "text": "IL-1\u03b2, IL-6 and IL-8, but",
            "probability": 0.0
        },
        {
            "start_logit": 10.1328125,
            "end_logit": -8.3125,
            "text": "IL-1\u03b2, IL-6 and IL-8, but not TNF",
            "probability": 0.0
        },
        {
            "start_logit": 10.1328125,
            "end_logit": -8.3203125,
            "text": "IL-1\u03b2, IL-6",
            "probability": 0.0
        },
        {
            "start_logit": 10.1328125,
            "end_logit": -8.328125,
            "text": "IL-1\u03b2, IL-6 and IL-8, but not TNF -\u03b1, in human adipose tissue were",
            "probability": 0.0
        },
        {
            "start_logit": 10.1328125,
            "end_logit": -8.34375,
            "text": "IL-1\u03b2, IL-6 and IL-8, but not TNF -\u03b1, in human adipose tissue were associated with higher expression of MAP3K8",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.7578125,
            "text": ", high mRNA expression levels of IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 9.7578125,
            "text": "high mRNA expression levels of IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.7578125,
            "text": "levels of IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.7578125,
            "text": "Additionally, high mRNA expression levels of IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.7578125,
            "text": "mRNA expression levels of IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -7.9140625,
            "end_logit": -1.533203125,
            "text": "of IL",
            "probability": 0.0
        },
        {
            "start_logit": -1.734375,
            "end_logit": -7.93359375,
            "text": "1\u03b2, IL-6 and IL-8, but not TNF -\u03b1, in human adipose tissue",
            "probability": 0.0
        }
    ],
    "5fe31317a43ad31278000044_7": [
        {
            "start_logit": 10.140625,
            "end_logit": 9.765625,
            "text": "IL-1\u03b2",
            "probability": 1.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -1.5205078125,
            "text": "IL",
            "probability": 1.2516975402832031e-05
        },
        {
            "start_logit": -1.7177734375,
            "end_logit": 9.765625,
            "text": "1\u03b2",
            "probability": 7.092952728271484e-06
        },
        {
            "start_logit": -5.6015625,
            "end_logit": 9.765625,
            "text": "-1\u03b2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.484375,
            "end_logit": 9.765625,
            "text": ", yet displayed lower mRNA expression levels of IL-1\u03b2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.1640625,
            "text": "IL-1\u03b2, IL-6 and CXCL1 in adipose tissue",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1171875,
            "end_logit": 9.765625,
            "text": "of IL-1\u03b2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.140625,
            "end_logit": -8.0234375,
            "text": "IL-1\u03b2, IL-6 and CXCL1 in adipose tissue in response to the HFD as",
            "probability": 0.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -8.0859375,
            "text": "IL-1\u03b2, IL-6 and CXCL1 in adipose tissue in response to the HFD as compared",
            "probability": 0.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -8.1015625,
            "text": "IL-1\u03b2, IL-6 and CXCL1 in adipose",
            "probability": 0.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -8.1796875,
            "text": "IL-1\u03b2, IL-6 and CXCL1 in adipose tissue in response to the HFD",
            "probability": 0.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -8.21875,
            "text": "IL-1\u03b2,",
            "probability": 0.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -8.21875,
            "text": "IL-1\u03b2, IL",
            "probability": 0.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -8.2265625,
            "text": "IL-1\u03b2, IL-6 and CXCL1",
            "probability": 0.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -8.2421875,
            "text": "IL-1\u03b2, IL-6 and CXCL1 in adipose tissue in response to the HFD as compared to WT animals",
            "probability": 0.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -8.2421875,
            "text": "IL-1\u03b2, IL-6 and CXCL1 in adipose tissue in response to the HFD as compared to",
            "probability": 0.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -8.25,
            "text": "IL-1\u03b2, IL-6",
            "probability": 0.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -8.3046875,
            "text": "IL-1\u03b2, IL-",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.765625,
            "text": "lower mRNA expression levels of IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.765625,
            "text": "displayed lower mRNA expression levels of IL-1\u03b2",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_1": [
        {
            "start_logit": 3.658203125,
            "end_logit": -4.15234375,
            "text": "antivirals against virus",
            "probability": 0.4482421875
        },
        {
            "start_logit": -1.669921875,
            "end_logit": 0.65625,
            "text": "SARS-CoV-2.",
            "probability": 0.2666015625
        },
        {
            "start_logit": 3.658203125,
            "end_logit": -5.4453125,
            "text": "antiviral",
            "probability": 0.123046875
        },
        {
            "start_logit": 3.658203125,
            "end_logit": -6.1875,
            "text": "antivirals",
            "probability": 0.058563232421875
        },
        {
            "start_logit": 3.658203125,
            "end_logit": -6.66796875,
            "text": "antivirals against",
            "probability": 0.036224365234375
        },
        {
            "start_logit": -4.1171875,
            "end_logit": 0.65625,
            "text": ".",
            "probability": 0.0230865478515625
        },
        {
            "start_logit": -4.71484375,
            "end_logit": 0.65625,
            "text": "In the COVID-19 era, there has been a race for drugs to be effective against SARS-CoV-2.",
            "probability": 0.01268768310546875
        },
        {
            "start_logit": -5.66796875,
            "end_logit": 0.65625,
            "text": "drugs to be effective against SARS-CoV-2.",
            "probability": 0.00490570068359375
        },
        {
            "start_logit": -5.69140625,
            "end_logit": 0.65625,
            "text": "race for drugs to be effective against SARS-CoV-2.",
            "probability": 0.004787445068359375
        },
        {
            "start_logit": -5.82421875,
            "end_logit": 0.65625,
            "text": "a race for drugs to be effective against SARS-CoV-2.",
            "probability": 0.004192352294921875
        },
        {
            "start_logit": -5.98046875,
            "end_logit": 0.65625,
            "text": ", there has been a race for drugs to be effective against SARS-CoV-2.",
            "probability": 0.0035877227783203125
        },
        {
            "start_logit": -6.05859375,
            "end_logit": 0.65625,
            "text": "the COVID-19 era, there has been a race for drugs to be effective against SARS-CoV-2.",
            "probability": 0.00331878662109375
        },
        {
            "start_logit": -6.21875,
            "end_logit": 0.65625,
            "text": "against SARS-CoV-2.",
            "probability": 0.00281524658203125
        },
        {
            "start_logit": -1.669921875,
            "end_logit": -4.15234375,
            "text": "SARS-CoV-2. There are reports about the uses of Remdesivir and Favipiravir as existing antivirals against virus",
            "probability": 0.0021762847900390625
        },
        {
            "start_logit": -6.76171875,
            "end_logit": 0.65625,
            "text": "for drugs to be effective against SARS-CoV-2.",
            "probability": 0.0016431808471679688
        },
        {
            "start_logit": -1.669921875,
            "end_logit": -4.83984375,
            "text": "SARS-CoV-2",
            "probability": 0.0010938644409179688
        },
        {
            "start_logit": -1.669921875,
            "end_logit": -4.9296875,
            "text": "SARS-CoV",
            "probability": 0.0009965896606445312
        },
        {
            "start_logit": -7.3359375,
            "end_logit": 0.65625,
            "text": "been a race for drugs to be effective against SARS-CoV-2.",
            "probability": 0.0009207725524902344
        },
        {
            "start_logit": -1.669921875,
            "end_logit": -5.4453125,
            "text": "SARS-CoV-2. There are reports about the uses of Remdesivir and Favipiravir as existing antiviral",
            "probability": 0.0005946159362792969
        },
        {
            "start_logit": -1.669921875,
            "end_logit": -6.16796875,
            "text": "SARS",
            "probability": 0.0002899169921875
        }
    ],
    "621ebb733a8413c65300005c_2": [
        {
            "start_logit": 7.0703125,
            "end_logit": 5.4765625,
            "text": "COVID-19",
            "probability": 1.0
        },
        {
            "start_logit": 7.0703125,
            "end_logit": -4.79296875,
            "text": "COV",
            "probability": 3.4809112548828125e-05
        },
        {
            "start_logit": 7.0703125,
            "end_logit": -5.67578125,
            "text": "COVID-19 (lopinavir, ritonavir, ivermectin, remdesivir and favipiravir)",
            "probability": 1.430511474609375e-05
        },
        {
            "start_logit": 7.0703125,
            "end_logit": -6.2734375,
            "text": "COVID-",
            "probability": 7.867813110351562e-06
        },
        {
            "start_logit": -5.3125,
            "end_logit": 5.4765625,
            "text": "to treat COVID-19",
            "probability": 4.172325134277344e-06
        },
        {
            "start_logit": -5.51171875,
            "end_logit": 5.4765625,
            "text": "treat COVID-19",
            "probability": 3.4570693969726562e-06
        },
        {
            "start_logit": 7.0703125,
            "end_logit": -7.37109375,
            "text": "COVID-19 (",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": 7.0703125,
            "end_logit": -7.55078125,
            "text": "COVID",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": 7.0703125,
            "end_logit": -7.7890625,
            "text": "COVID-19 (lopinavir, ritonavir",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": 7.0703125,
            "end_logit": -7.79296875,
            "text": "COVID-19 (lopin",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": 7.0703125,
            "end_logit": -7.8125,
            "text": "COVID-19 (lopinavir, ritonavir, ivermectin, remdesivir and favipiravir),",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": 7.0703125,
            "end_logit": -7.8828125,
            "text": "COVID-19 (lopinavir, ritonavir, ivermectin",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": 7.0703125,
            "end_logit": -7.9140625,
            "text": "COVID-19 (lo",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": 7.0703125,
            "end_logit": -7.94921875,
            "text": "COVID-19 (lopinavir",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": 7.0703125,
            "end_logit": -7.9609375,
            "text": "COVID-19 (lopinavir, ritonavir, ivermectin, remdesivir",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 7.0703125,
            "end_logit": -8.03125,
            "text": "COVID-19 (lopinavir, ritonavir, ivermectin, remdes",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": -6.51171875,
            "end_logit": 5.4765625,
            "text": "19",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -6.95703125,
            "end_logit": 5.4765625,
            "text": "ID-19",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -7.34375,
            "end_logit": 5.4765625,
            "text": "repurposed drugs advocated to treat COVID-19",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.6875,
            "end_logit": 5.4765625,
            "text": "key repurposed drugs advocated to treat COVID-19",
            "probability": 4.172325134277344e-07
        }
    ],
    "621ebb733a8413c65300005c_3": [
        {
            "start_logit": 8.7734375,
            "end_logit": 6.15625,
            "text": "COVID-19",
            "probability": 1.0
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -3.41796875,
            "text": "COV",
            "probability": 6.920099258422852e-05
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -4.0390625,
            "text": "COVID-19 patients",
            "probability": 3.737211227416992e-05
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -5.7265625,
            "text": "COVID-",
            "probability": 6.9141387939453125e-06
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -7.06640625,
            "text": "COVID",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": -5.98046875,
            "end_logit": 6.15625,
            "text": "treat COVID-19",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.1015625,
            "end_logit": 6.15625,
            "text": "19",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.18359375,
            "end_logit": 6.15625,
            "text": ") to treat COVID-19",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.3046875,
            "end_logit": 6.15625,
            "text": "ID-19",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.3828125,
            "end_logit": 6.15625,
            "text": "(Arbidol) to treat COVID-19",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.48828125,
            "end_logit": 6.15625,
            "text": "compare the efficacy and safety of favipiravir and umifenovir (Arbidol) to treat COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.60546875,
            "end_logit": 6.15625,
            "text": "to treat COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.69140625,
            "end_logit": 6.15625,
            "text": "To compare the efficacy and safety of favipiravir and umifenovir (Arbidol) to treat COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.73046875,
            "end_logit": 6.15625,
            "text": "efficacy and safety of favipiravir and umifenovir (Arbidol) to treat COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.875,
            "end_logit": 6.15625,
            "text": "the efficacy and safety of favipiravir and umifenovir (Arbidol) to treat COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9375,
            "end_logit": 6.15625,
            "text": "Arbidol) to treat COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 6.15625,
            "text": "and umifenovir (Arbidol) to treat COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0,
            "end_logit": 6.15625,
            "text": "safety of favipiravir and umifenovir (Arbidol) to treat COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 6.15625,
            "text": "of favipiravir and umifenovir (Arbidol) to treat COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.09375,
            "end_logit": 6.15625,
            "text": "and safety of favipiravir and umifenovir (Arbidol) to treat COVID-19",
            "probability": 5.960464477539063e-08
        }
    ],
    "621ebb733a8413c65300005c_4": [
        {
            "start_logit": 8.65625,
            "end_logit": 7.13671875,
            "text": "COVID-19",
            "probability": 1.0
        },
        {
            "start_logit": 8.65625,
            "end_logit": -3.7421875,
            "text": "COV",
            "probability": 1.8775463104248047e-05
        },
        {
            "start_logit": 8.65625,
            "end_logit": -5.40625,
            "text": "COVID-19 treatments",
            "probability": 3.5762786865234375e-06
        },
        {
            "start_logit": 8.65625,
            "end_logit": -6.64453125,
            "text": "COVID-",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -5.26953125,
            "end_logit": 7.13671875,
            "text": "19",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -5.4453125,
            "end_logit": 7.13671875,
            "text": "possible COVID-19",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -7.53125,
            "text": "COVID",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.890625,
            "end_logit": 7.13671875,
            "text": "ID-19",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.953125,
            "end_logit": 7.13671875,
            "text": "Favipiravir (FPV) and hydroxychloroquine (HCQ) are considered possible COVID-19",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.3359375,
            "end_logit": 7.13671875,
            "text": "considered possible COVID-19",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.7421875,
            "end_logit": 7.13671875,
            "text": ") and hydroxychloroquine (HCQ) are considered possible COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.74609375,
            "end_logit": 7.13671875,
            "text": "(HCQ) are considered possible COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.85546875,
            "end_logit": 7.13671875,
            "text": ") are considered possible COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.078125,
            "end_logit": 7.13671875,
            "text": "hydroxychloroquine (HCQ) are considered possible COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.140625,
            "end_logit": 7.13671875,
            "text": "-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.15625,
            "end_logit": 7.13671875,
            "text": "are considered possible COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.4453125,
            "end_logit": -3.7421875,
            "text": "possible COV",
            "probability": 0.0
        },
        {
            "start_logit": -5.26953125,
            "end_logit": -5.40625,
            "text": "19 treatments",
            "probability": 0.0
        },
        {
            "start_logit": -6.953125,
            "end_logit": -3.7421875,
            "text": "Favipiravir (FPV) and hydroxychloroquine (HCQ) are considered possible COV",
            "probability": 0.0
        },
        {
            "start_logit": -5.4453125,
            "end_logit": -5.40625,
            "text": "possible COVID-19 treatments",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_5": [
        {
            "start_logit": 8.921875,
            "end_logit": 6.88671875,
            "text": "Favipiravir (FVP) has been used for treatment of COVID-19 in many countries.",
            "probability": 0.9560546875
        },
        {
            "start_logit": 8.921875,
            "end_logit": 3.275390625,
            "text": "Favipiravir (FVP) has been used for treatment of COVID-19 in",
            "probability": 0.0256805419921875
        },
        {
            "start_logit": 4.6328125,
            "end_logit": 6.88671875,
            "text": "COVID-19 in many countries.",
            "probability": 0.0130157470703125
        },
        {
            "start_logit": 8.921875,
            "end_logit": 1.6201171875,
            "text": "Favipiravir (FVP) has been used for treatment of COVID-19",
            "probability": 0.004901885986328125
        },
        {
            "start_logit": 4.6328125,
            "end_logit": 3.275390625,
            "text": "COVID-19 in",
            "probability": 0.0003521442413330078
        },
        {
            "start_logit": 8.921875,
            "end_logit": -1.763671875,
            "text": "Fav",
            "probability": 0.00016641616821289062
        },
        {
            "start_logit": 0.0022830963134765625,
            "end_logit": 6.88671875,
            "text": ".",
            "probability": 0.00012755393981933594
        },
        {
            "start_logit": 4.6328125,
            "end_logit": 1.6201171875,
            "text": "COVID-19",
            "probability": 6.723403930664062e-05
        },
        {
            "start_logit": -2.216796875,
            "end_logit": 6.88671875,
            "text": "treatment of COVID-19 in many countries.",
            "probability": 1.3828277587890625e-05
        },
        {
            "start_logit": 8.921875,
            "end_logit": -5.03515625,
            "text": "Favipiravir (FVP) has been used for treatment of COVID-19 in many countries",
            "probability": 6.318092346191406e-06
        },
        {
            "start_logit": 8.921875,
            "end_logit": -5.47265625,
            "text": "Favipiravir (FVP) has been used for treatment of COVID-19 in many",
            "probability": 4.112720489501953e-06
        },
        {
            "start_logit": 8.921875,
            "end_logit": -6.13671875,
            "text": "Favipiravir (FVP) has been used for treatment of COV",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": 8.921875,
            "end_logit": -6.1484375,
            "text": "Favipiravir (FVP) has been used for treatment of COVID-",
            "probability": 2.0265579223632812e-06
        },
        {
            "start_logit": -4.48046875,
            "end_logit": 6.88671875,
            "text": "of COVID-19 in many countries.",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -4.8828125,
            "end_logit": 6.88671875,
            "text": "ipiravir (FVP) has been used for treatment of COVID-19 in many countries.",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.1171875,
            "text": "Favipiravir (FVP) has been used for treatment of COVID",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -5.36328125,
            "end_logit": 6.88671875,
            "text": "iravir (FVP) has been used for treatment of COVID-19 in many countries.",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -5.36328125,
            "end_logit": 6.88671875,
            "text": "for treatment of COVID-19 in many countries.",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -5.40234375,
            "end_logit": 6.88671875,
            "text": "used for treatment of COVID-19 in many countries.",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.6328125,
            "text": "Favipiravir (FV",
            "probability": 4.76837158203125e-07
        }
    ],
    "621ebb733a8413c65300005c_6": [
        {
            "start_logit": 9.7109375,
            "end_logit": 9.4140625,
            "text": "COVID-19 infection",
            "probability": 1.0
        },
        {
            "start_logit": 9.7109375,
            "end_logit": -2.072265625,
            "text": "COV",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": -2.255859375,
            "end_logit": 9.4140625,
            "text": "infection",
            "probability": 6.318092346191406e-06
        },
        {
            "start_logit": -4.2578125,
            "end_logit": 9.4140625,
            "text": "severe COVID-19 infection",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -4.5859375,
            "end_logit": 9.4140625,
            "text": "with severe COVID-19 infection",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 9.7109375,
            "end_logit": -5.90625,
            "text": "COVID-19 infection.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.7109375,
            "end_logit": -6.3828125,
            "text": "COVID-19",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.39453125,
            "end_logit": 9.4140625,
            "text": "ID-19 infection",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.90234375,
            "end_logit": 9.4140625,
            "text": "patients with severe COVID-19 infection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.0546875,
            "end_logit": 9.4140625,
            "text": "treating patients with severe COVID-19 infection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7109375,
            "end_logit": -7.37890625,
            "text": "COVID-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.28515625,
            "end_logit": 9.4140625,
            "text": "-19 infection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7109375,
            "end_logit": -7.66015625,
            "text": "COVID",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.78515625,
            "end_logit": 9.4140625,
            "text": "in treating patients with severe COVID-19 infection",
            "probability": 0.0
        },
        {
            "start_logit": -7.80078125,
            "end_logit": 9.4140625,
            "text": "19 infection",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": 9.4140625,
            "text": "assess the efficacy of Favipiravir compared to the standard therapy in treating patients with severe COVID-19 infection",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.4140625,
            "text": "Favipiravir compared to the standard therapy in treating patients with severe COVID-19 infection",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.4140625,
            "text": "To assess the efficacy of Favipiravir compared to the standard therapy in treating patients with severe COVID-19 infection",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.4140625,
            "text": "therapy in treating patients with severe COVID-19 infection",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.4140625,
            "text": "the efficacy of Favipiravir compared to the standard therapy in treating patients with severe COVID-19 infection",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_7": [
        {
            "start_logit": 5.6640625,
            "end_logit": 8.4765625,
            "text": "COVID-19 infections",
            "probability": 1.0
        },
        {
            "start_logit": -3.58984375,
            "end_logit": 8.4765625,
            "text": "infections",
            "probability": 9.608268737792969e-05
        },
        {
            "start_logit": -4.5390625,
            "end_logit": 8.4765625,
            "text": "with severe COVID-19 infections",
            "probability": 3.707408905029297e-05
        },
        {
            "start_logit": -5.3203125,
            "end_logit": 8.4765625,
            "text": "in patients with severe COVID-19 infections",
            "probability": 1.6987323760986328e-05
        },
        {
            "start_logit": -6.0,
            "end_logit": 8.4765625,
            "text": "severe COVID-19 infections",
            "probability": 8.58306884765625e-06
        },
        {
            "start_logit": -6.32421875,
            "end_logit": 8.4765625,
            "text": "patients with severe COVID-19 infections",
            "probability": 6.258487701416016e-06
        },
        {
            "start_logit": -6.6484375,
            "end_logit": 8.4765625,
            "text": "ID-19 infections",
            "probability": 4.470348358154297e-06
        },
        {
            "start_logit": -7.5234375,
            "end_logit": 8.4765625,
            "text": "-19 infections",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": 5.6640625,
            "end_logit": -5.140625,
            "text": "COVID-19",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -7.984375,
            "end_logit": 8.4765625,
            "text": "Favipiravir versus standard of care in patients with severe COVID-19 infections",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 8.4765625,
            "text": "care in patients with severe COVID-19 infections",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 8.4765625,
            "text": "19 infections",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 5.6640625,
            "end_logit": -6.01171875,
            "text": "COV",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 5.6640625,
            "end_logit": -7.0703125,
            "text": "COVID-",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 5.6640625,
            "end_logit": -7.71484375,
            "text": "COVID",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -4.5390625,
            "end_logit": -5.140625,
            "text": "with severe COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -5.3203125,
            "end_logit": -5.140625,
            "text": "in patients with severe COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -4.5390625,
            "end_logit": -6.01171875,
            "text": "with severe COV",
            "probability": 0.0
        },
        {
            "start_logit": -6.0,
            "end_logit": -5.140625,
            "text": "severe COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -5.3203125,
            "end_logit": -6.01171875,
            "text": "in patients with severe COV",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_8": [
        {
            "start_logit": 3.5859375,
            "end_logit": -0.09735107421875,
            "text": "COVID-19",
            "probability": 0.53076171875
        },
        {
            "start_logit": 3.5859375,
            "end_logit": -0.244873046875,
            "text": "COVID-19.",
            "probability": 0.45849609375
        },
        {
            "start_logit": 3.5859375,
            "end_logit": -5.3125,
            "text": "COVID-",
            "probability": 0.0028858184814453125
        },
        {
            "start_logit": -1.755859375,
            "end_logit": -0.09735107421875,
            "text": "of COVID-19",
            "probability": 0.002536773681640625
        },
        {
            "start_logit": -1.755859375,
            "end_logit": -0.244873046875,
            "text": "of COVID-19.",
            "probability": 0.0021953582763671875
        },
        {
            "start_logit": 3.5859375,
            "end_logit": -6.65234375,
            "text": "COV",
            "probability": 0.0007557868957519531
        },
        {
            "start_logit": 3.5859375,
            "end_logit": -6.75390625,
            "text": "COVID",
            "probability": 0.0006823539733886719
        },
        {
            "start_logit": -3.314453125,
            "end_logit": -0.09735107421875,
            "text": "treatment of COVID-19",
            "probability": 0.0005354881286621094
        },
        {
            "start_logit": -3.314453125,
            "end_logit": -0.244873046875,
            "text": "treatment of COVID-19.",
            "probability": 0.0004620552062988281
        },
        {
            "start_logit": -4.74609375,
            "end_logit": -0.244873046875,
            "text": ".",
            "probability": 0.00010973215103149414
        },
        {
            "start_logit": -5.36328125,
            "end_logit": -0.09735107421875,
            "text": "the treatment of COVID-19",
            "probability": 6.866455078125e-05
        },
        {
            "start_logit": -5.36328125,
            "end_logit": -0.244873046875,
            "text": "the treatment of COVID-19.",
            "probability": 5.9664249420166016e-05
        },
        {
            "start_logit": -5.60546875,
            "end_logit": -0.09735107421875,
            "text": "in the treatment of COVID-19",
            "probability": 5.429983139038086e-05
        },
        {
            "start_logit": -5.60546875,
            "end_logit": -0.244873046875,
            "text": "in the treatment of COVID-19.",
            "probability": 4.64320182800293e-05
        },
        {
            "start_logit": -6.73046875,
            "end_logit": -0.09735107421875,
            "text": "Molnupiravir/Favipiravir in the treatment of COVID-19",
            "probability": 1.7642974853515625e-05
        },
        {
            "start_logit": -6.73046875,
            "end_logit": -0.244873046875,
            "text": "Molnupiravir/Favipiravir in the treatment of COVID-19.",
            "probability": 1.5079975128173828e-05
        },
        {
            "start_logit": -6.9296875,
            "end_logit": -0.09735107421875,
            "text": "Favipiravir in the treatment of COVID-19",
            "probability": 1.4424324035644531e-05
        },
        {
            "start_logit": -1.755859375,
            "end_logit": -5.3125,
            "text": "of COVID-",
            "probability": 1.3709068298339844e-05
        },
        {
            "start_logit": -6.9296875,
            "end_logit": -0.244873046875,
            "text": "Favipiravir in the treatment of COVID-19.",
            "probability": 1.239776611328125e-05
        },
        {
            "start_logit": -7.2578125,
            "end_logit": -0.09735107421875,
            "text": "ID-19",
            "probability": 1.0371208190917969e-05
        }
    ],
    "621ebb733a8413c65300005c_9": [
        {
            "start_logit": 8.6796875,
            "end_logit": 5.2265625,
            "text": "influenza",
            "probability": 0.9990234375
        },
        {
            "start_logit": 8.6796875,
            "end_logit": -2.04296875,
            "text": "influenza infections",
            "probability": 0.0006961822509765625
        },
        {
            "start_logit": 8.6796875,
            "end_logit": -2.794921875,
            "text": "influenza infections, has been suggested to be effective against SARS-CoV-2, although this is not yet fully validated.",
            "probability": 0.0003273487091064453
        },
        {
            "start_logit": 8.6796875,
            "end_logit": -7.58203125,
            "text": "influenza infections, has been suggested to be effective against SARS-CoV",
            "probability": 2.7418136596679688e-06
        },
        {
            "start_logit": 8.6796875,
            "end_logit": -7.76171875,
            "text": "influenza infections, has been suggested to be effective against SARS-CoV-2",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": 8.6796875,
            "end_logit": -7.8359375,
            "text": "influenza infections, has been suggested to be effective against SARS",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": 8.6796875,
            "end_logit": -8.0,
            "text": "influenza infections, has been suggested to",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 8.6796875,
            "end_logit": -8.0234375,
            "text": "influenza infections, has been suggested to be effective against SARS-CoV-",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 8.6796875,
            "end_logit": -8.0625,
            "text": "influenza infections, has been suggested to be effective against SARS-CoV-2, although",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": 8.6796875,
            "end_logit": -8.09375,
            "text": "influenza infections, has been suggested to be effective against SARS-CoV-2, although this is not yet",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": 8.6796875,
            "end_logit": -8.1015625,
            "text": "influenza infections, has been suggested to be effective against SARS-",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": 8.6796875,
            "end_logit": -8.109375,
            "text": "influenza infections, has been suggested",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": 8.6796875,
            "end_logit": -8.15625,
            "text": "influenza infections, has",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": 8.6796875,
            "end_logit": -8.203125,
            "text": "influenza infections, has been suggested to be effective against SARS-CoV-2,",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": -6.125,
            "end_logit": 5.2265625,
            "text": "Favipiravir, indicated for the treatment of new and re-emerging influenza",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.55859375,
            "end_logit": 5.2265625,
            "text": "emerging influenza",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.73046875,
            "end_logit": 5.2265625,
            "text": "treatment of new and re-emerging influenza",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.1484375,
            "end_logit": 5.2265625,
            "text": "of new and re-emerging influenza",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 5.2265625,
            "text": "indicated for the treatment of new and re-emerging influenza",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.39453125,
            "end_logit": 5.2265625,
            "text": "new and re-emerging influenza",
            "probability": 1.1920928955078125e-07
        }
    ],
    "621ebb733a8413c65300005c_10": [
        {
            "start_logit": 8.9140625,
            "end_logit": 7.921875,
            "text": "COVID-19",
            "probability": 1.0
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -1.724609375,
            "text": "COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir.",
            "probability": 6.401538848876953e-05
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -2.66796875,
            "text": "COVID-19 patients",
            "probability": 2.5093555450439453e-05
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -3.42578125,
            "text": "COV",
            "probability": 1.1682510375976562e-05
        },
        {
            "start_logit": -4.46484375,
            "end_logit": 7.921875,
            "text": "19",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -6.37890625,
            "text": "COVID-",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -5.51953125,
            "end_logit": 7.921875,
            "text": "moderate COVID-19",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -6.83203125,
            "text": "COVID-19 patients treated",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -7.29296875,
            "text": "COVID-19 patients treated with hydroxychlor",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -7.30859375,
            "text": "COVID-19 patients treated with hydroxychloroquine",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -7.421875,
            "text": "COVID-19 patients treated with",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -7.43359375,
            "text": "COVID",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -7.6640625,
            "text": "COVID-19 patients treated with hydroxychloroquine, favipiravir",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -7.7265625,
            "text": "COVID-19 patients treated with hydroxychloroquine, favipiravir,",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -7.734375,
            "text": "COVID-19 patients treated with hydroxych",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -7.73828125,
            "text": "COVID-19 patients treated with hydroxychloroquine, favipira",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.875,
            "end_logit": 7.921875,
            "text": "ID-19",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.9921875,
            "end_logit": 7.921875,
            "text": "of mild/moderate COVID-19",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.05078125,
            "end_logit": 7.921875,
            "text": "Comparing ICU admission rates of mild/moderate COVID-19",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.6640625,
            "end_logit": 7.921875,
            "text": "ICU admission rates of mild/moderate COVID-19",
            "probability": 5.960464477539063e-08
        }
    ],
    "621ebb733a8413c65300005c_11": [
        {
            "start_logit": 5.01953125,
            "end_logit": -2.3359375,
            "text": "influenza",
            "probability": 0.62158203125
        },
        {
            "start_logit": 5.01953125,
            "end_logit": -3.75,
            "text": "influenza A/California/04/2009 (H1N1",
            "probability": 0.151123046875
        },
        {
            "start_logit": 5.01953125,
            "end_logit": -4.29296875,
            "text": "influenza A/California/04/2009 (H1N1)",
            "probability": 0.0877685546875
        },
        {
            "start_logit": 5.01953125,
            "end_logit": -5.0078125,
            "text": "influenza A",
            "probability": 0.04296875
        },
        {
            "start_logit": 5.01953125,
            "end_logit": -5.54296875,
            "text": "influenza A/California/04/2009 (H1N1) virus infections",
            "probability": 0.025146484375
        },
        {
            "start_logit": 5.01953125,
            "end_logit": -5.59765625,
            "text": "influenza A/California/04/2009 (H1N1) virus",
            "probability": 0.0238189697265625
        },
        {
            "start_logit": 5.01953125,
            "end_logit": -6.5546875,
            "text": "influenza A/California/04/2009",
            "probability": 0.00914764404296875
        },
        {
            "start_logit": 5.01953125,
            "end_logit": -6.7578125,
            "text": "influenza A/California",
            "probability": 0.0074615478515625
        },
        {
            "start_logit": 5.01953125,
            "end_logit": -6.9765625,
            "text": "influenza A/California/04/2009 (H1N1) virus infections in mice.",
            "probability": 0.0059967041015625
        },
        {
            "start_logit": 5.01953125,
            "end_logit": -7.35546875,
            "text": "influenza A/California/04/",
            "probability": 0.0041046142578125
        },
        {
            "start_logit": 5.01953125,
            "end_logit": -7.3828125,
            "text": "influenza A/California/04/2009 (H1N1) virus infections in mice",
            "probability": 0.003993988037109375
        },
        {
            "start_logit": 5.01953125,
            "end_logit": -7.39453125,
            "text": "influenza A/California/",
            "probability": 0.003948211669921875
        },
        {
            "start_logit": 5.01953125,
            "end_logit": -7.43359375,
            "text": "influenza A/California/04",
            "probability": 0.0037975311279296875
        },
        {
            "start_logit": 5.01953125,
            "end_logit": -7.53125,
            "text": "influenza A/",
            "probability": 0.003444671630859375
        },
        {
            "start_logit": 5.01953125,
            "end_logit": -7.5625,
            "text": "influenza A/California/04/2009 (",
            "probability": 0.003337860107421875
        },
        {
            "start_logit": 5.01953125,
            "end_logit": -7.76171875,
            "text": "influenza A/California/04/2009 (H1N1) virus infections in",
            "probability": 0.002735137939453125
        },
        {
            "start_logit": -7.43359375,
            "end_logit": -2.3359375,
            "text": "of pandemic influenza",
            "probability": 2.4437904357910156e-06
        },
        {
            "start_logit": -7.6953125,
            "end_logit": -2.3359375,
            "text": "treatment of pandemic influenza",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": -7.703125,
            "end_logit": -2.3359375,
            "text": "pandemic influenza",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": -8.046875,
            "end_logit": -2.3359375,
            "text": "the treatment of pandemic influenza",
            "probability": 1.3113021850585938e-06
        }
    ],
    "621ebb733a8413c65300005c_12": [
        {
            "start_logit": 1.498046875,
            "end_logit": 6.31640625,
            "text": "Favipiravir possesses high utility for treating patients with COVID-19.",
            "probability": 0.82568359375
        },
        {
            "start_logit": -0.75634765625,
            "end_logit": 6.31640625,
            "text": "with COVID-19.",
            "probability": 0.086669921875
        },
        {
            "start_logit": -1.1181640625,
            "end_logit": 6.31640625,
            "text": ".",
            "probability": 0.060546875
        },
        {
            "start_logit": -2.544921875,
            "end_logit": 6.31640625,
            "text": "COVID-19.",
            "probability": 0.0145416259765625
        },
        {
            "start_logit": -3.63671875,
            "end_logit": 6.31640625,
            "text": "for treating patients with COVID-19.",
            "probability": 0.00487518310546875
        },
        {
            "start_logit": -3.673828125,
            "end_logit": 6.31640625,
            "text": "treating patients with COVID-19.",
            "probability": 0.0046844482421875
        },
        {
            "start_logit": -4.8359375,
            "end_logit": 6.31640625,
            "text": "patients with COVID-19.",
            "probability": 0.001468658447265625
        },
        {
            "start_logit": -6.203125,
            "end_logit": 6.31640625,
            "text": "utility for treating patients with COVID-19.",
            "probability": 0.0003743171691894531
        },
        {
            "start_logit": -6.234375,
            "end_logit": 6.31640625,
            "text": "high utility for treating patients with COVID-19.",
            "probability": 0.00036263465881347656
        },
        {
            "start_logit": -6.5703125,
            "end_logit": 6.31640625,
            "text": "ipiravir possesses high utility for treating patients with COVID-19.",
            "probability": 0.00026035308837890625
        },
        {
            "start_logit": -6.94921875,
            "end_logit": 6.31640625,
            "text": "ID-19.",
            "probability": 0.00017750263214111328
        },
        {
            "start_logit": -7.19140625,
            "end_logit": 6.31640625,
            "text": "vir possesses high utility for treating patients with COVID-19.",
            "probability": 0.00013935565948486328
        },
        {
            "start_logit": -7.20703125,
            "end_logit": 6.31640625,
            "text": "iravir possesses high utility for treating patients with COVID-19.",
            "probability": 0.00013709068298339844
        },
        {
            "start_logit": -7.74609375,
            "end_logit": 6.31640625,
            "text": "BACKGROUND: Favipiravir possesses high utility for treating patients with COVID-19.",
            "probability": 7.998943328857422e-05
        },
        {
            "start_logit": -7.84375,
            "end_logit": 6.31640625,
            "text": "possesses high utility for treating patients with COVID-19.",
            "probability": 7.224082946777344e-05
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 6.31640625,
            "text": "-19.",
            "probability": 6.085634231567383e-05
        },
        {
            "start_logit": 1.498046875,
            "end_logit": -3.3359375,
            "text": "Favipiravir possesses high utility for treating patients with COVID-19",
            "probability": 5.328655242919922e-05
        },
        {
            "start_logit": -8.171875,
            "end_logit": 6.31640625,
            "text": ": Favipiravir possesses high utility for treating patients with COVID-19.",
            "probability": 5.2034854888916016e-05
        },
        {
            "start_logit": 1.498046875,
            "end_logit": -5.50390625,
            "text": "Favipiravir possesses high utility for treating patients with COVID-",
            "probability": 6.079673767089844e-06
        },
        {
            "start_logit": -0.75634765625,
            "end_logit": -3.3359375,
            "text": "with COVID-19",
            "probability": 5.543231964111328e-06
        }
    ],
    "621ebb733a8413c65300005c_13": [
        {
            "start_logit": 8.4296875,
            "end_logit": 2.138671875,
            "text": "influenza",
            "probability": 0.9111328125
        },
        {
            "start_logit": 8.4296875,
            "end_logit": -0.1934814453125,
            "text": "influenza viruses",
            "probability": 0.088134765625
        },
        {
            "start_logit": 8.4296875,
            "end_logit": -6.5,
            "text": "influenza viruses, including A(H1N1)pdm09, A(H5N1) and the recently emerged A(H7N9) avian virus.",
            "probability": 0.00016105175018310547
        },
        {
            "start_logit": 8.4296875,
            "end_logit": -7.7265625,
            "text": "influenza viruses, including A(H1N1",
            "probability": 4.7266483306884766e-05
        },
        {
            "start_logit": 8.4296875,
            "end_logit": -7.86328125,
            "text": "influenza viruses, including A(H1N1)pdm09, A(H5N1) and the recently emerged A(H7",
            "probability": 4.1365623474121094e-05
        },
        {
            "start_logit": 8.4296875,
            "end_logit": -7.8828125,
            "text": "influenza viruses, including A(H1N1)pdm09, A(H5N1) and the recently emerged A(H7N",
            "probability": 4.0411949157714844e-05
        },
        {
            "start_logit": 8.4296875,
            "end_logit": -7.8828125,
            "text": "influenza viruses,",
            "probability": 4.0411949157714844e-05
        },
        {
            "start_logit": 8.4296875,
            "end_logit": -7.91796875,
            "text": "influenza viruses, including A(H1N1)pd",
            "probability": 3.886222839355469e-05
        },
        {
            "start_logit": 8.4296875,
            "end_logit": -7.9453125,
            "text": "influenza viruses, including A(H1N1)pdm09",
            "probability": 3.796815872192383e-05
        },
        {
            "start_logit": 8.4296875,
            "end_logit": -7.97265625,
            "text": "influenza viruses, including A(H1N1)pdm09, A(H5N1) and the recently emerged A(H7N9",
            "probability": 3.707408905029297e-05
        },
        {
            "start_logit": 8.4296875,
            "end_logit": -7.9765625,
            "text": "influenza viruses, including A(H1N1)pdm",
            "probability": 3.6776065826416016e-05
        },
        {
            "start_logit": 8.4296875,
            "end_logit": -7.98046875,
            "text": "influenza viruses, including A(H1N1)",
            "probability": 3.647804260253906e-05
        },
        {
            "start_logit": 8.4296875,
            "end_logit": -7.984375,
            "text": "influenza viruses, including A(H1N1)pdm09, A(H5N1",
            "probability": 3.647804260253906e-05
        },
        {
            "start_logit": 8.4296875,
            "end_logit": -7.99609375,
            "text": "influenza viruses, including A",
            "probability": 3.594160079956055e-05
        },
        {
            "start_logit": 8.4296875,
            "end_logit": -8.046875,
            "text": "influenza viruses, including A(H1N1)pdm09, A(H5N1) and the recently emerged A(H7N9) avian virus",
            "probability": 3.427267074584961e-05
        },
        {
            "start_logit": -6.18359375,
            "end_logit": 2.138671875,
            "text": "Favipiravir is active against a broad range of influenza",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.7578125,
            "end_logit": 2.138671875,
            "text": "of influenza",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 2.138671875,
            "text": "ipiravir is active against a broad range of influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 2.138671875,
            "text": "iravir is active against a broad range of influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.28125,
            "end_logit": 2.138671875,
            "text": "against a broad range of influenza",
            "probability": 5.960464477539063e-08
        }
    ],
    "621ebb733a8413c65300005c_14": [
        {
            "start_logit": 9.53125,
            "end_logit": 9.046875,
            "text": "influenza virus infections",
            "probability": 1.0
        },
        {
            "start_logit": 9.53125,
            "end_logit": -2.556640625,
            "text": "influenza",
            "probability": 9.179115295410156e-06
        },
        {
            "start_logit": -2.98046875,
            "end_logit": 9.046875,
            "text": "infections",
            "probability": 3.6954879760742188e-06
        },
        {
            "start_logit": 9.53125,
            "end_logit": -4.64453125,
            "text": "influenza virus infections and has shown promise against other highly pathogenic RNA viruses including CCHFV with demonstrated efficacy in the type I interferon deficient mouse model.",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -5.05078125,
            "end_logit": 9.046875,
            "text": "Favipiravir is approved in Japan for the treatment of influenza virus infections",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -5.25390625,
            "end_logit": 9.046875,
            "text": "of influenza virus infections",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.53125,
            "end_logit": -6.02734375,
            "text": "influenza virus infections and has shown promise against other highly pathogenic RNA viruses",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -5.69921875,
            "end_logit": 9.046875,
            "text": "treatment of influenza virus infections",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.53125,
            "end_logit": -6.765625,
            "text": "influenza virus infections and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.53125,
            "end_logit": -7.01171875,
            "text": "influenza virus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.53125,
            "end_logit": -7.49609375,
            "text": "influenza virus infections and has shown promise against other highly pathogenic RNA viruses including",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.53125,
            "end_logit": -7.49609375,
            "text": "influenza virus infections and has shown promise against other highly pathogenic RNA viruses including CCH",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.53125,
            "end_logit": -7.51171875,
            "text": "influenza virus infections and has shown promise against other highly pathogenic RNA viruses including CCHFV with",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.53125,
            "end_logit": -7.5625,
            "text": "influenza virus infections and has shown promise against other highly pathogenic RNA viruses including CCHFV with demonstrated efficacy in the type I interferon",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.53125,
            "end_logit": -7.625,
            "text": "influenza virus infections and has shown promise against other highly pathogenic RNA viruses including CCHFV",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.234375,
            "end_logit": 9.046875,
            "text": "virus infections",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.359375,
            "end_logit": 9.046875,
            "text": "the treatment of influenza virus infections",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.53125,
            "end_logit": -7.859375,
            "text": "influenza virus infections and has shown promise against other highly pathogenic RNA viruses including CCHFV with demonstrated efficacy in the type I interferon deficient",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.41015625,
            "end_logit": 9.046875,
            "text": "approved in Japan for the treatment of influenza virus infections",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.44140625,
            "end_logit": 9.046875,
            "text": "for the treatment of influenza virus infections",
            "probability": 5.960464477539063e-08
        }
    ],
    "621ebb733a8413c65300005c_15": [
        {
            "start_logit": 6.69140625,
            "end_logit": -0.3271484375,
            "text": "antiviral drug, is being used for COVID-19 treatment, and we currently have limited information regarding its efficacy and safety.",
            "probability": 0.8828125
        },
        {
            "start_logit": 6.69140625,
            "end_logit": -3.43359375,
            "text": "antiviral",
            "probability": 0.03955078125
        },
        {
            "start_logit": 6.69140625,
            "end_logit": -3.55078125,
            "text": "antiviral drug",
            "probability": 0.035186767578125
        },
        {
            "start_logit": 6.69140625,
            "end_logit": -3.59375,
            "text": "antiviral drug,",
            "probability": 0.03369140625
        },
        {
            "start_logit": 6.69140625,
            "end_logit": -6.6796875,
            "text": "antiviral drug, is being used for COVID-19",
            "probability": 0.0015401840209960938
        },
        {
            "start_logit": 6.69140625,
            "end_logit": -6.69921875,
            "text": "antiviral drug, is being used for COVID-19 treatment,",
            "probability": 0.0015096664428710938
        },
        {
            "start_logit": 6.69140625,
            "end_logit": -7.21875,
            "text": "antiviral drug, is being used for COVID-19 treatment",
            "probability": 0.0008983612060546875
        },
        {
            "start_logit": 6.69140625,
            "end_logit": -7.6875,
            "text": "antiviral drug, is being used for COVID-",
            "probability": 0.0005617141723632812
        },
        {
            "start_logit": 6.69140625,
            "end_logit": -7.81640625,
            "text": "antiviral drug, is being used for COVID",
            "probability": 0.0004940032958984375
        },
        {
            "start_logit": 6.69140625,
            "end_logit": -7.82421875,
            "text": "antiviral drug, is being used for COV",
            "probability": 0.0004901885986328125
        },
        {
            "start_logit": 6.69140625,
            "end_logit": -7.8984375,
            "text": "antiviral drug, is being used for COVID-19 treatment, and",
            "probability": 0.0004551410675048828
        },
        {
            "start_logit": 6.69140625,
            "end_logit": -8.0859375,
            "text": "antiviral drug, is being",
            "probability": 0.00037741661071777344
        },
        {
            "start_logit": 6.69140625,
            "end_logit": -8.1171875,
            "text": "antiviral drug, is being used for COVID-19 treatment, and we currently",
            "probability": 0.0003654956817626953
        },
        {
            "start_logit": 6.69140625,
            "end_logit": -8.140625,
            "text": "antiviral drug, is",
            "probability": 0.0003571510314941406
        },
        {
            "start_logit": 6.69140625,
            "end_logit": -8.1484375,
            "text": "antiviral drug, is being used",
            "probability": 0.00035452842712402344
        },
        {
            "start_logit": 6.69140625,
            "end_logit": -8.1875,
            "text": "antiviral drug, is being used for COVID-19 treatment, and we",
            "probability": 0.0003407001495361328
        },
        {
            "start_logit": 6.69140625,
            "end_logit": -8.1953125,
            "text": "antiviral drug, is being used for COVID-19 treatment, and we currently have limited information regarding",
            "probability": 0.0003383159637451172
        },
        {
            "start_logit": 6.69140625,
            "end_logit": -8.1953125,
            "text": "antiviral drug, is being used for COVID-19 treatment, and we currently have limited information regarding its efficacy and",
            "probability": 0.0003383159637451172
        },
        {
            "start_logit": -2.7734375,
            "end_logit": -0.3271484375,
            "text": "Favipiravir, an antiviral drug, is being used for COVID-19 treatment, and we currently have limited information regarding its efficacy and safety.",
            "probability": 6.818771362304688e-05
        },
        {
            "start_logit": -4.11328125,
            "end_logit": -0.3271484375,
            "text": ".",
            "probability": 1.7940998077392578e-05
        }
    ],
    "621ebb733a8413c65300005c_16": [
        {
            "start_logit": 8.921875,
            "end_logit": 7.546875,
            "text": "influenza",
            "probability": 1.0
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.8828125,
            "text": "influenza in Japan in 2014 and has shown potent in vitro activity against severe acute respiratory syndrome coronavirus-2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.88671875,
            "text": "influenza in Japan in 2014 and has shown potent in vitro activity against severe acute respiratory syndrome coronavirus",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -8.0,
            "text": "influenza in Japan",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -8.015625,
            "text": "influenza in Japan in 2014 and has shown potent in vitro activity against severe acute respiratory syndrome coronavirus-2.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -8.0703125,
            "text": "influenza in Japan in 2014 and has shown potent in vitro activity against severe acute respiratory",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -8.09375,
            "text": "influenza in",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -8.1015625,
            "text": "influenza in Japan in 2014 and",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -8.1171875,
            "text": "influenza in Japan in 2014 and has shown potent in vitro activity against severe acute respiratory syndrome coronavirus-",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -8.15625,
            "text": "influenza in Japan in 2014 and has shown potent in vitro activity against severe acute respiratory syndrome",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -8.15625,
            "text": "influenza in Japan in 2014",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -8.1640625,
            "text": "influenza in Japan in 2014 and has shown potent in vitro",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 7.546875,
            "text": "approved for new and reemerging pandemic influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": 7.546875,
            "text": "drug that was approved for new and reemerging pandemic influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 7.546875,
            "text": "Favipiravir is one such oral drug that was approved for new and reemerging pandemic influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 7.546875,
            "text": "was approved for new and reemerging pandemic influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 7.546875,
            "text": "pandemic influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3125,
            "end_logit": 7.546875,
            "text": "for new and reemerging pandemic influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.4140625,
            "end_logit": 7.546875,
            "text": "ging pandemic influenza",
            "probability": 0.0
        },
        {
            "start_logit": -7.13671875,
            "end_logit": -8.015625,
            "text": ".",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_17": [
        {
            "start_logit": 9.3125,
            "end_logit": 6.56640625,
            "text": "influenza",
            "probability": 1.0
        },
        {
            "start_logit": 9.3125,
            "end_logit": -1.74609375,
            "text": "influenza and Ebola, which has shown some promise in early trials for treatment of COVID-19.",
            "probability": 0.0002453327178955078
        },
        {
            "start_logit": 9.3125,
            "end_logit": -5.13671875,
            "text": "influenza and Ebola,",
            "probability": 8.285045623779297e-06
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.34765625,
            "text": "influenza and Ebola",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.546875,
            "text": "influenza and Ebola, which",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.62109375,
            "text": "influenza and Ebola, which has shown some promise in early trials for treatment of COVID-19",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.80078125,
            "text": "influenza and Ebola, which has shown some",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.8125,
            "text": "influenza and Ebola, which has shown some promise",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.85546875,
            "text": "influenza and Ebola, which has",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -5.16015625,
            "end_logit": 6.56640625,
            "text": "Favipiravir is an antiviral previously indicated for influenza",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.9765625,
            "text": "influenza and Ebola, which has shown some promise in early",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.98046875,
            "text": "influenza and",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.984375,
            "text": "influenza and Ebola, which has shown some promise in early trials",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.99609375,
            "text": "influenza and Ebola, which has shown some promise in early trials for treatment of COV",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.3125,
            "end_logit": -8.0078125,
            "text": "influenza and Ebola, which has shown some promise in early trials for treatment of COVID",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.3125,
            "end_logit": -8.015625,
            "text": "influenza and Ebola, which has shown some promise in early trials for treatment of COVID-",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.3125,
            "end_logit": -8.0625,
            "text": "influenza and Ebola, which has shown",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.234375,
            "end_logit": 6.56640625,
            "text": "for influenza",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.65625,
            "end_logit": 6.56640625,
            "text": "previously indicated for influenza",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.78515625,
            "end_logit": 6.56640625,
            "text": "antiviral previously indicated for influenza",
            "probability": 1.1920928955078125e-07
        }
    ],
    "621ebb733a8413c65300005c_18": [
        {
            "start_logit": 9.859375,
            "end_logit": 9.265625,
            "text": "Ebola virus infection",
            "probability": 1.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -2.138671875,
            "text": "Ebola",
            "probability": 1.1146068572998047e-05
        },
        {
            "start_logit": -2.763671875,
            "end_logit": 9.265625,
            "text": "infection",
            "probability": 3.2782554626464844e-06
        },
        {
            "start_logit": -6.1484375,
            "end_logit": 9.265625,
            "text": "influenza, now has been demonstrated to have a curative effect in treating Ebola virus infection",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.859375,
            "end_logit": -7.16796875,
            "text": "Ebola virus infection.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.73046875,
            "end_logit": 9.265625,
            "text": "antiviral drug which was mainly used for the treatment of influenza, now has been demonstrated to have a curative effect in treating Ebola virus infection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.92578125,
            "end_logit": 9.265625,
            "text": "treating Ebola virus infection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.859375,
            "end_logit": -7.5859375,
            "text": "Ebola virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.0859375,
            "end_logit": 9.265625,
            "text": "virus infection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.171875,
            "end_logit": 9.265625,
            "text": "of influenza, now has been demonstrated to have a curative effect in treating Ebola virus infection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1953125,
            "end_logit": 9.265625,
            "text": "drug which was mainly used for the treatment of influenza, now has been demonstrated to have a curative effect in treating Ebola virus infection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.203125,
            "end_logit": 9.265625,
            "text": "novel antiviral drug which was mainly used for the treatment of influenza, now has been demonstrated to have a curative effect in treating Ebola virus infection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.23046875,
            "end_logit": 9.265625,
            "text": "treatment of influenza, now has been demonstrated to have a curative effect in treating Ebola virus infection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.30078125,
            "end_logit": 9.265625,
            "text": "was mainly used for the treatment of influenza, now has been demonstrated to have a curative effect in treating Ebola virus infection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.46875,
            "end_logit": 9.265625,
            "text": "in treating Ebola virus infection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.53515625,
            "end_logit": 9.265625,
            "text": "demonstrated to have a curative effect in treating Ebola virus infection",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.203125,
            "text": "Ebola virus infection. I",
            "probability": 0.0
        },
        {
            "start_logit": -7.62109375,
            "end_logit": 9.265625,
            "text": "the treatment of influenza, now has been demonstrated to have a curative effect in treating Ebola virus infection",
            "probability": 0.0
        },
        {
            "start_logit": -7.69140625,
            "end_logit": 9.265625,
            "text": "avipiravir, a novel antiviral drug which was mainly used for the treatment of influenza, now has been demonstrated to have a curative effect in treating Ebola virus infection",
            "probability": 0.0
        },
        {
            "start_logit": -7.7265625,
            "end_logit": 9.265625,
            "text": "been demonstrated to have a curative effect in treating Ebola virus infection",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_19": [
        {
            "start_logit": 9.0546875,
            "end_logit": 7.75390625,
            "text": "influenza virus",
            "probability": 1.0
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -3.40234375,
            "text": "influenza",
            "probability": 1.430511474609375e-05
        },
        {
            "start_logit": -4.46875,
            "end_logit": 7.75390625,
            "text": "virus",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -6.49609375,
            "text": "influenza virus]",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -6.7265625,
            "text": "influenza virus] inhibits in vitro murine norovirus replication.",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -5.62109375,
            "end_logit": 7.75390625,
            "text": "infections with the influenza virus",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -5.71484375,
            "end_logit": 7.75390625,
            "text": "the influenza virus",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.53515625,
            "text": "influenza virus] inhibits in vitro murine norovirus replication",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.57421875,
            "text": "influenza virus] inhibits in vitro murine norovirus",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.36328125,
            "end_logit": 7.75390625,
            "text": "of infections with the influenza virus",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.47265625,
            "end_logit": 7.75390625,
            "text": "treatment of infections with the influenza virus",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.5703125,
            "end_logit": 7.75390625,
            "text": "with the influenza virus",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.91015625,
            "text": "influenza virus] inhibits in vitro murine nor",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -8.0078125,
            "text": "influenza virus] inhibits in vitro",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -8.1484375,
            "text": "influenza virus] inhibits",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.1015625,
            "end_logit": 7.75390625,
            "text": "drug in advanced clinical development for the treatment of infections with the influenza virus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.2421875,
            "end_logit": 7.75390625,
            "text": ", a drug in advanced clinical development for the treatment of infections with the influenza virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.42578125,
            "end_logit": 7.75390625,
            "text": "the treatment of infections with the influenza virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 7.75390625,
            "text": "clinical development for the treatment of infections with the influenza virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.68359375,
            "end_logit": 7.75390625,
            "text": "development for the treatment of infections with the influenza virus",
            "probability": 5.960464477539063e-08
        }
    ],
    "621ebb733a8413c65300005c_20": [
        {
            "start_logit": 0.86083984375,
            "end_logit": 1.943359375,
            "text": "COVID-19",
            "probability": 0.64794921875
        },
        {
            "start_logit": 0.243896484375,
            "end_logit": 1.943359375,
            "text": "with COVID-19",
            "probability": 0.349609375
        },
        {
            "start_logit": 0.86083984375,
            "end_logit": -5.40625,
            "text": "COVID-",
            "probability": 0.00041604042053222656
        },
        {
            "start_logit": -7.03125,
            "end_logit": 1.943359375,
            "text": "patients with COVID-19",
            "probability": 0.00024259090423583984
        },
        {
            "start_logit": 0.243896484375,
            "end_logit": -5.40625,
            "text": "with COVID-",
            "probability": 0.0002243518829345703
        },
        {
            "start_logit": -7.140625,
            "end_logit": 1.943359375,
            "text": "for patients with COVID-19",
            "probability": 0.000217437744140625
        },
        {
            "start_logit": -7.31640625,
            "end_logit": 1.943359375,
            "text": "ID-19",
            "probability": 0.00018167495727539062
        },
        {
            "start_logit": -7.6171875,
            "end_logit": 1.943359375,
            "text": "Favipiravir might be a treatment option for patients with COVID-19",
            "probability": 0.00013494491577148438
        },
        {
            "start_logit": 0.86083984375,
            "end_logit": -6.67578125,
            "text": "COVID",
            "probability": 0.0001163482666015625
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 1.943359375,
            "text": "combination therapy of Lopinavir/Ritonavir plus Favipiravir might be a treatment option for patients with COVID-19",
            "probability": 0.00010675191879272461
        },
        {
            "start_logit": -7.890625,
            "end_logit": 1.943359375,
            "text": "of Lopinavir/Ritonavir plus Favipiravir might be a treatment option for patients with COVID-19",
            "probability": 0.00010269880294799805
        },
        {
            "start_logit": -7.91015625,
            "end_logit": 1.943359375,
            "text": "The combination therapy of Lopinavir/Ritonavir plus Favipiravir might be a treatment option for patients with COVID-19",
            "probability": 0.00010025501251220703
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 1.943359375,
            "text": "treatment option for patients with COVID-19",
            "probability": 9.28044319152832e-05
        },
        {
            "start_logit": -8.140625,
            "end_logit": 1.943359375,
            "text": "therapy of Lopinavir/Ritonavir plus Favipiravir might be a treatment option for patients with COVID-19",
            "probability": 7.998943328857422e-05
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 1.943359375,
            "text": "plus Favipiravir might be a treatment option for patients with COVID-19",
            "probability": 7.933378219604492e-05
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 1.943359375,
            "text": "Lopinavir/Ritonavir plus Favipiravir might be a treatment option for patients with COVID-19",
            "probability": 7.814168930053711e-05
        },
        {
            "start_logit": -8.234375,
            "end_logit": 1.943359375,
            "text": "vir might be a treatment option for patients with COVID-19",
            "probability": 7.283687591552734e-05
        },
        {
            "start_logit": -8.25,
            "end_logit": 1.943359375,
            "text": "ipiravir might be a treatment option for patients with COVID-19",
            "probability": 7.170438766479492e-05
        },
        {
            "start_logit": -8.265625,
            "end_logit": 1.943359375,
            "text": "19",
            "probability": 7.05718994140625e-05
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 1.943359375,
            "text": "option for patients with COVID-19",
            "probability": 7.003545761108398e-05
        }
    ],
    "621ebb733a8413c65300005c_21": [
        {
            "start_logit": 1.4697265625,
            "end_logit": 2.0546875,
            "text": "COVID-19.",
            "probability": 0.96044921875
        },
        {
            "start_logit": -2.4375,
            "end_logit": 2.0546875,
            "text": "vir, Favipiravir and Ribavirin might be a safer therapeutic option for COVID-19.",
            "probability": 0.019317626953125
        },
        {
            "start_logit": -2.986328125,
            "end_logit": 2.0546875,
            "text": ".",
            "probability": 0.0111846923828125
        },
        {
            "start_logit": 1.4697265625,
            "end_logit": -3.33203125,
            "text": "COVID-19",
            "probability": 0.004398345947265625
        },
        {
            "start_logit": -4.6640625,
            "end_logit": 2.0546875,
            "text": "for COVID-19.",
            "probability": 0.0020847320556640625
        },
        {
            "start_logit": -6.16796875,
            "end_logit": 2.0546875,
            "text": "Favipiravir and Ribavirin might be a safer therapeutic option for COVID-19.",
            "probability": 0.00046324729919433594
        },
        {
            "start_logit": 1.4697265625,
            "end_logit": -5.7109375,
            "text": "COV",
            "probability": 0.0004074573516845703
        },
        {
            "start_logit": 1.4697265625,
            "end_logit": -6.38671875,
            "text": "COVID",
            "probability": 0.00020802021026611328
        },
        {
            "start_logit": -7.125,
            "end_logit": 2.0546875,
            "text": ", Favipiravir and Ribavirin might be a safer therapeutic option for COVID-19.",
            "probability": 0.0001779794692993164
        },
        {
            "start_logit": -7.15234375,
            "end_logit": 2.0546875,
            "text": "safer therapeutic option for COVID-19.",
            "probability": 0.00017249584197998047
        },
        {
            "start_logit": -7.2734375,
            "end_logit": 2.0546875,
            "text": "therapeutic option for COVID-19.",
            "probability": 0.00015342235565185547
        },
        {
            "start_logit": 1.4697265625,
            "end_logit": -6.69921875,
            "text": "COVID-",
            "probability": 0.00015223026275634766
        },
        {
            "start_logit": -7.5078125,
            "end_logit": 2.0546875,
            "text": "option for COVID-19.",
            "probability": 0.00012135505676269531
        },
        {
            "start_logit": -7.79296875,
            "end_logit": 2.0546875,
            "text": "ipiravir and Ribavirin might be a safer therapeutic option for COVID-19.",
            "probability": 9.083747863769531e-05
        },
        {
            "start_logit": -2.4375,
            "end_logit": -3.33203125,
            "text": "vir, Favipiravir and Ribavirin might be a safer therapeutic option for COVID-19",
            "probability": 8.809566497802734e-05
        },
        {
            "start_logit": -7.87109375,
            "end_logit": 2.0546875,
            "text": "ID-19.",
            "probability": 8.404254913330078e-05
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 2.0546875,
            "text": "and Ribavirin might be a safer therapeutic option for COVID-19.",
            "probability": 8.213520050048828e-05
        },
        {
            "start_logit": -7.90625,
            "end_logit": 2.0546875,
            "text": "a safer therapeutic option for COVID-19.",
            "probability": 8.147954940795898e-05
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 2.0546875,
            "text": "Ribavirin might be a safer therapeutic option for COVID-19.",
            "probability": 7.832050323486328e-05
        },
        {
            "start_logit": -7.94921875,
            "end_logit": 2.0546875,
            "text": "be a safer therapeutic option for COVID-19.",
            "probability": 7.772445678710938e-05
        }
    ],
    "621ebb733a8413c65300005c_22": [
        {
            "start_logit": 4.50390625,
            "end_logit": 2.49609375,
            "text": "Covid-19",
            "probability": 0.9951171875
        },
        {
            "start_logit": 4.50390625,
            "end_logit": -3.322265625,
            "text": "Covid-19: A Retrospective Study.",
            "probability": 0.0029506683349609375
        },
        {
            "start_logit": -2.4296875,
            "end_logit": 2.49609375,
            "text": "of Covid-19",
            "probability": 0.0009698867797851562
        },
        {
            "start_logit": 4.50390625,
            "end_logit": -5.796875,
            "text": "Covid-",
            "probability": 0.00024819374084472656
        },
        {
            "start_logit": 4.50390625,
            "end_logit": -6.2578125,
            "text": "Cov",
            "probability": 0.0001577138900756836
        },
        {
            "start_logit": 4.50390625,
            "end_logit": -6.96875,
            "text": "Covid",
            "probability": 7.68899917602539e-05
        },
        {
            "start_logit": 4.50390625,
            "end_logit": -7.41796875,
            "text": "Covid-19:",
            "probability": 4.9233436584472656e-05
        },
        {
            "start_logit": 4.50390625,
            "end_logit": -7.9375,
            "text": "Covid-19: A Retrospective",
            "probability": 2.9206275939941406e-05
        },
        {
            "start_logit": 4.50390625,
            "end_logit": -8.3671875,
            "text": "Covid-19: A",
            "probability": 1.913309097290039e-05
        },
        {
            "start_logit": -6.4453125,
            "end_logit": 2.49609375,
            "text": "Management of Covid-19",
            "probability": 1.7464160919189453e-05
        },
        {
            "start_logit": -6.96484375,
            "end_logit": 2.49609375,
            "text": "Effectiveness and Safety of Favipiravir Compared to Hydroxychloroquine for Management of Covid-19",
            "probability": 1.0371208190917969e-05
        },
        {
            "start_logit": -7.359375,
            "end_logit": 2.49609375,
            "text": "id-19",
            "probability": 7.033348083496094e-06
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 2.49609375,
            "text": "Safety of Favipiravir Compared to Hydroxychloroquine for Management of Covid-19",
            "probability": 5.7220458984375e-06
        },
        {
            "start_logit": -7.6171875,
            "end_logit": 2.49609375,
            "text": "for Management of Covid-19",
            "probability": 5.424022674560547e-06
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 2.49609375,
            "text": "Favipiravir Compared to Hydroxychloroquine for Management of Covid-19",
            "probability": 5.066394805908203e-06
        },
        {
            "start_logit": -7.73046875,
            "end_logit": 2.49609375,
            "text": "to Hydroxychloroquine for Management of Covid-19",
            "probability": 4.887580871582031e-06
        },
        {
            "start_logit": -7.859375,
            "end_logit": 2.49609375,
            "text": "Hydroxychloroquine for Management of Covid-19",
            "probability": 4.291534423828125e-06
        },
        {
            "start_logit": -8.015625,
            "end_logit": 2.49609375,
            "text": "of Favipiravir Compared to Hydroxychloroquine for Management of Covid-19",
            "probability": 3.6954879760742188e-06
        },
        {
            "start_logit": -8.09375,
            "end_logit": 2.49609375,
            "text": "vir Compared to Hydroxychloroquine for Management of Covid-19",
            "probability": 3.3974647521972656e-06
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 2.49609375,
            "text": "19",
            "probability": 3.2186508178710938e-06
        }
    ],
    "621ebb733a8413c65300005c_23": [
        {
            "start_logit": 8.7578125,
            "end_logit": 7.6328125,
            "text": "influenza",
            "probability": 1.0
        },
        {
            "start_logit": 8.7578125,
            "end_logit": -7.796875,
            "text": "influenza inf",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.7578125,
            "end_logit": -7.98828125,
            "text": "influenza infec",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 7.6328125,
            "text": "of influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 7.6328125,
            "text": "treatment of influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.234375,
            "end_logit": 7.6328125,
            "text": "the treatment of influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": 7.6328125,
            "text": "Favipiravir and oseltamivir are antiviral compounds used for the treatment of influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 7.6328125,
            "text": "for the treatment of influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3671875,
            "end_logit": 7.6328125,
            "text": "antiviral compounds used for the treatment of influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3671875,
            "end_logit": 7.6328125,
            "text": "used for the treatment of influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.390625,
            "end_logit": 7.6328125,
            "text": "ipiravir and oseltamivir are antiviral compounds used for the treatment of influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3984375,
            "end_logit": 7.6328125,
            "text": "vir are antiviral compounds used for the treatment of influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3984375,
            "end_logit": 7.6328125,
            "text": ": Favipiravir and oseltamivir are antiviral compounds used for the treatment of influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.40625,
            "end_logit": 7.6328125,
            "text": "iravir and oseltamivir are antiviral compounds used for the treatment of influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.40625,
            "end_logit": 7.6328125,
            "text": "are antiviral compounds used for the treatment of influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.40625,
            "end_logit": 7.6328125,
            "text": "and oseltamivir are antiviral compounds used for the treatment of influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.421875,
            "end_logit": 7.6328125,
            "text": "vir and oseltamivir are antiviral compounds used for the treatment of influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6328125,
            "end_logit": -7.796875,
            "text": "of influenza inf",
            "probability": 0.0
        },
        {
            "start_logit": -7.6328125,
            "end_logit": -7.98828125,
            "text": "of influenza infec",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -7.796875,
            "text": "treatment of influenza inf",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_24": [
        {
            "start_logit": 5.9921875,
            "end_logit": 3.3359375,
            "text": "coronavirus disease 2019",
            "probability": 0.998046875
        },
        {
            "start_logit": 5.9921875,
            "end_logit": -3.859375,
            "text": "coronavirus disease",
            "probability": 0.0007486343383789062
        },
        {
            "start_logit": 5.9921875,
            "end_logit": -4.25,
            "text": "coronavirus disease 2019 (COVID-19)",
            "probability": 0.0005064010620117188
        },
        {
            "start_logit": 5.9921875,
            "end_logit": -5.2890625,
            "text": "coronavirus",
            "probability": 0.00017917156219482422
        },
        {
            "start_logit": 5.9921875,
            "end_logit": -5.3515625,
            "text": "coronavirus disease 2019 (COVID-19",
            "probability": 0.00016832351684570312
        },
        {
            "start_logit": 5.9921875,
            "end_logit": -6.00390625,
            "text": "coronavirus disease 2019 (COV",
            "probability": 8.732080459594727e-05
        },
        {
            "start_logit": 5.9921875,
            "end_logit": -6.66015625,
            "text": "coronavirus disease 2019 (",
            "probability": 4.5359134674072266e-05
        },
        {
            "start_logit": 5.9921875,
            "end_logit": -6.7578125,
            "text": "coronavirus disease 2019 (COVID",
            "probability": 4.13060188293457e-05
        },
        {
            "start_logit": 5.9921875,
            "end_logit": -7.41796875,
            "text": "coronavirus disease 2019 (COVID-",
            "probability": 2.1398067474365234e-05
        },
        {
            "start_logit": -6.890625,
            "end_logit": 3.3359375,
            "text": "managing coronavirus disease 2019",
            "probability": 2.562999725341797e-06
        },
        {
            "start_logit": -7.67578125,
            "end_logit": 3.3359375,
            "text": "2019",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -7.80859375,
            "end_logit": 3.3359375,
            "text": "Favipiravir is a promising treatment candidate for managing coronavirus disease 2019",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -8.0625,
            "end_logit": 3.3359375,
            "text": "WHAT IS KNOWN AND OBJECTIVE: Favipiravir is a promising treatment candidate for managing coronavirus disease 2019",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -8.109375,
            "end_logit": 3.3359375,
            "text": "for managing coronavirus disease 2019",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 3.3359375,
            "text": "treatment candidate for managing coronavirus disease 2019",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 3.3359375,
            "text": "OBJECTIVE: Favipiravir is a promising treatment candidate for managing coronavirus disease 2019",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -8.171875,
            "end_logit": 3.3359375,
            "text": ": Favipiravir is a promising treatment candidate for managing coronavirus disease 2019",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -8.171875,
            "end_logit": 3.3359375,
            "text": "IS KNOWN AND OBJECTIVE: Favipiravir is a promising treatment candidate for managing coronavirus disease 2019",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 3.3359375,
            "text": "AND OBJECTIVE: Favipiravir is a promising treatment candidate for managing coronavirus disease 2019",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -8.234375,
            "end_logit": 3.3359375,
            "text": "candidate for managing coronavirus disease 2019",
            "probability": 6.556510925292969e-07
        }
    ],
    "621ebb733a8413c65300005c_25": [
        {
            "start_logit": 9.1015625,
            "end_logit": 7.36328125,
            "text": "influenza",
            "probability": 1.0
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -7.91796875,
            "text": "influenza, the next pandemic influenza strain, and other severe RNA virus infections for which standard treatments are not available.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -7.94140625,
            "text": "influenza, the next pandemic influenza",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -8.015625,
            "text": "influenza, the next pandemic influenza strain, and other severe RNA virus infections",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -8.0546875,
            "text": "influenza, the next pandemic influenza strain, and other severe RNA virus infections for which standard treatments are",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -8.109375,
            "text": "influenza, the next pandemic influenza strain, and other severe RNA virus infections for which standard treatments are not available",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.4375,
            "end_logit": 7.36328125,
            "text": "Favipiravir is expected to be an important therapeutic agent for severe influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 7.36328125,
            "text": "severe influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.171875,
            "end_logit": 7.36328125,
            "text": "ipiravir is expected to be an important therapeutic agent for severe influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 7.36328125,
            "text": "iravir is expected to be an important therapeutic agent for severe influenza",
            "probability": 0.0
        },
        {
            "start_logit": -7.046875,
            "end_logit": -7.91796875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.4375,
            "end_logit": -7.91796875,
            "text": "Favipiravir is expected to be an important therapeutic agent for severe influenza, the next pandemic influenza strain, and other severe RNA virus infections for which standard treatments are not available.",
            "probability": 0.0
        },
        {
            "start_logit": -7.4375,
            "end_logit": -7.94140625,
            "text": "Favipiravir is expected to be an important therapeutic agent for severe influenza, the next pandemic influenza",
            "probability": 0.0
        },
        {
            "start_logit": -7.4375,
            "end_logit": -8.015625,
            "text": "Favipiravir is expected to be an important therapeutic agent for severe influenza, the next pandemic influenza strain, and other severe RNA virus infections",
            "probability": 0.0
        },
        {
            "start_logit": -7.4375,
            "end_logit": -8.0546875,
            "text": "Favipiravir is expected to be an important therapeutic agent for severe influenza, the next pandemic influenza strain, and other severe RNA virus infections for which standard treatments are",
            "probability": 0.0
        },
        {
            "start_logit": -7.4375,
            "end_logit": -8.109375,
            "text": "Favipiravir is expected to be an important therapeutic agent for severe influenza, the next pandemic influenza strain, and other severe RNA virus infections for which standard treatments are not available",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": -7.91796875,
            "text": "severe influenza, the next pandemic influenza strain, and other severe RNA virus infections for which standard treatments are not available.",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": -7.94140625,
            "text": "severe influenza, the next pandemic influenza",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": -7.91796875,
            "text": ", and other severe RNA virus infections for which standard treatments are not available.",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": -8.015625,
            "text": "severe influenza, the next pandemic influenza strain, and other severe RNA virus infections",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_26": [
        {
            "start_logit": 9.640625,
            "end_logit": 9.0,
            "text": "influenza virus infections",
            "probability": 1.0
        },
        {
            "start_logit": 9.640625,
            "end_logit": -2.373046875,
            "text": "influenza",
            "probability": 1.150369644165039e-05
        },
        {
            "start_logit": -3.15625,
            "end_logit": 9.0,
            "text": "infections",
            "probability": 2.7418136596679688e-06
        },
        {
            "start_logit": 9.640625,
            "end_logit": -7.11328125,
            "text": "influenza virus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.54296875,
            "end_logit": 9.0,
            "text": "treat pandemic influenza virus infections",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.640625,
            "end_logit": -7.90625,
            "text": "influenza virus infections.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.53125,
            "end_logit": 9.0,
            "text": "pandemic influenza virus infections",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.546875,
            "end_logit": 9.0,
            "text": "virus infections",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8828125,
            "end_logit": 9.0,
            "text": "Favipiravir, also known as T-705, is an antiviral drug that has been approved in 2014 in Japan to treat pandemic influenza virus infections",
            "probability": 0.0
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 9.0,
            "text": "drug that has been approved in 2014 in Japan to treat pandemic influenza virus infections",
            "probability": 0.0
        },
        {
            "start_logit": -8.0,
            "end_logit": 9.0,
            "text": "to treat pandemic influenza virus infections",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.0,
            "text": "approved in 2014 in Japan to treat pandemic influenza virus infections",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.0,
            "text": "antiviral drug that has been approved in 2014 in Japan to treat pandemic influenza virus infections",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.0,
            "text": "as T-705, is an antiviral drug that has been approved in 2014 in Japan to treat pandemic influenza virus infections",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.0,
            "text": "has been approved in 2014 in Japan to treat pandemic influenza virus infections",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.0,
            "text": "also known as T-705, is an antiviral drug that has been approved in 2014 in Japan to treat pandemic influenza virus infections",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 9.0,
            "text": "been approved in 2014 in Japan to treat pandemic influenza virus infections",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 9.0,
            "text": "known as T-705, is an antiviral drug that has been approved in 2014 in Japan to treat pandemic influenza virus infections",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.0,
            "text": "T-705, is an antiviral drug that has been approved in 2014 in Japan to treat pandemic influenza virus infections",
            "probability": 0.0
        },
        {
            "start_logit": -6.54296875,
            "end_logit": -2.373046875,
            "text": "treat pandemic influenza",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_27": [
        {
            "start_logit": 9.03125,
            "end_logit": 7.4765625,
            "text": "influenza",
            "probability": 1.0
        },
        {
            "start_logit": 9.03125,
            "end_logit": -8.015625,
            "text": "influenza strains;",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.03125,
            "end_logit": -8.1015625,
            "text": "influenza strains",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.03125,
            "end_logit": -8.1640625,
            "text": "influenza strains; and several phase 2 and 3 clinical trials are",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.03125,
            "end_logit": -8.1640625,
            "text": "influenza strains; and several phase 2 and 3 clinical trials are ongoing in the United States and Europe",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.03125,
            "end_logit": -8.171875,
            "text": "influenza strains; and several phase 2 and 3 clinical trials are ongoing in the United States and Europe.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.296875,
            "end_logit": 7.4765625,
            "text": "use in Japan against emerging influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3125,
            "end_logit": 7.4765625,
            "text": "in Japan against emerging influenza",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 7.4765625,
            "text": "emerging influenza",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 7.4765625,
            "text": "against emerging influenza",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 7.4765625,
            "text": "a purine analogue antiviral approved for use in Japan against emerging influenza",
            "probability": 0.0
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 7.4765625,
            "text": "antiviral approved for use in Japan against emerging influenza",
            "probability": 0.0
        },
        {
            "start_logit": -6.80859375,
            "end_logit": -8.171875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": -8.015625,
            "text": "use in Japan against emerging influenza strains;",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": -8.015625,
            "text": "in Japan against emerging influenza strains;",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": -8.015625,
            "text": "emerging influenza strains;",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": -8.015625,
            "text": "against emerging influenza strains;",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": -8.015625,
            "text": "a purine analogue antiviral approved for use in Japan against emerging influenza strains;",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -8.1640625,
            "text": "phase 2 and 3 clinical trials are",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -8.1640625,
            "text": "phase 2 and 3 clinical trials are ongoing in the United States and Europe",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_28": [
        {
            "start_logit": 9.234375,
            "end_logit": 7.12890625,
            "text": "influenza",
            "probability": 1.0
        },
        {
            "start_logit": 9.234375,
            "end_logit": -7.6953125,
            "text": "influenza and many other RNA viral diseases",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.234375,
            "end_logit": -7.76171875,
            "text": "influenza and many other RNA viral diseases for which there are no approved therapies.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.234375,
            "end_logit": -7.98046875,
            "text": "influenza and many other RNA viral",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.234375,
            "end_logit": -8.125,
            "text": "influenza and",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.234375,
            "end_logit": -8.140625,
            "text": "influenza and many other RNA viral diseases for which there are no",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.234375,
            "end_logit": -8.15625,
            "text": "influenza and many other RNA viral diseases for which there are",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.234375,
            "end_logit": -8.203125,
            "text": "influenza and many other RNA viral diseases for which there",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.9375,
            "end_logit": 7.12890625,
            "text": "for influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 7.12890625,
            "text": "drug candidate for influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1875,
            "end_logit": 7.12890625,
            "text": "favipiravir is a promising drug candidate for influenza",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 7.12890625,
            "text": "With its unique mechanism of action and broad range of antiviral activity, favipiravir is a promising drug candidate for influenza",
            "probability": 0.0
        },
        {
            "start_logit": -8.359375,
            "end_logit": 7.12890625,
            "text": "of antiviral activity, favipiravir is a promising drug candidate for influenza",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": 7.12890625,
            "text": "antiviral activity, favipiravir is a promising drug candidate for influenza",
            "probability": 0.0
        },
        {
            "start_logit": -8.390625,
            "end_logit": 7.12890625,
            "text": "its unique mechanism of action and broad range of antiviral activity, favipiravir is a promising drug candidate for influenza",
            "probability": 0.0
        },
        {
            "start_logit": -8.3984375,
            "end_logit": 7.12890625,
            "text": ", favipiravir is a promising drug candidate for influenza",
            "probability": 0.0
        },
        {
            "start_logit": -7.23828125,
            "end_logit": -7.76171875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.9375,
            "end_logit": -7.6953125,
            "text": "for influenza and many other RNA viral diseases",
            "probability": 0.0
        },
        {
            "start_logit": -7.9375,
            "end_logit": -7.76171875,
            "text": "for influenza and many other RNA viral diseases for which there are no approved therapies.",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": -7.6953125,
            "text": "other RNA viral diseases",
            "probability": 0.0
        }
    ],
    "5e48bf5ed14c9f295d000019_1": [
        {
            "start_logit": 9.9140625,
            "end_logit": 9.53125,
            "text": "Nonconvulsive Status Epilepticus",
            "probability": 1.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -2.103515625,
            "text": "Noncon",
            "probability": 8.940696716308594e-06
        },
        {
            "start_logit": -2.291015625,
            "end_logit": 9.53125,
            "text": "Epilepticus",
            "probability": 5.066394805908203e-06
        },
        {
            "start_logit": -5.97265625,
            "end_logit": 9.53125,
            "text": "vulsive Status Epilepticus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.26171875,
            "end_logit": 9.53125,
            "text": "ulsive Status Epilepticus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.65625,
            "end_logit": 9.53125,
            "text": "Status Epilepticus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.765625,
            "end_logit": 9.53125,
            "text": "With Nonconvulsive Status Epilepticus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -7.515625,
            "text": "Nonconvulsive Status",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -7.7421875,
            "text": "Nonconvulsive Status Epilepticus by",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -7.97265625,
            "text": "Nonconvulsive Status Epilepticus by Using Salzburg Consensus Criteria",
            "probability": 0.0
        },
        {
            "start_logit": -7.9140625,
            "end_logit": 9.53125,
            "text": "Patients With Nonconvulsive Status Epilepticus",
            "probability": 0.0
        },
        {
            "start_logit": -7.921875,
            "end_logit": 9.53125,
            "text": "Ill Patients With Nonconvulsive Status Epilepticus",
            "probability": 0.0
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 9.53125,
            "text": "Reevaluation of the Critically Ill Patients With Nonconvulsive Status Epilepticus",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.375,
            "text": "Nonconvulsive",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.390625,
            "text": "Nonconvulsive Status Epilepticus by Using Salzburg Consensus",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 9.53125,
            "text": "Critically Ill Patients With Nonconvulsive Status Epilepticus",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": 9.53125,
            "text": "ation of the Critically Ill Patients With Nonconvulsive Status Epilepticus",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.53125,
            "text": "the Critically Ill Patients With Nonconvulsive Status Epilepticus",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.53125,
            "text": "of the Critically Ill Patients With Nonconvulsive Status Epilepticus",
            "probability": 0.0
        },
        {
            "start_logit": -6.765625,
            "end_logit": -2.103515625,
            "text": "With Noncon",
            "probability": 0.0
        }
    ],
    "5e48bf5ed14c9f295d000019_2": [
        {
            "start_logit": 9.9296875,
            "end_logit": 9.46875,
            "text": "nonconvulsive status epilepticus",
            "probability": 1.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -2.037109375,
            "text": "noncon",
            "probability": 9.953975677490234e-06
        },
        {
            "start_logit": -2.38671875,
            "end_logit": 9.46875,
            "text": "epilepticus",
            "probability": 4.410743713378906e-06
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -5.04296875,
            "text": "nonconvulsive status epilepticus (NCS",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -5.109375,
            "text": "nonconvulsive status epilepticus (NCSE)",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -4.76171875,
            "end_logit": 9.46875,
            "text": "with nonconvulsive status epilepticus",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.28515625,
            "end_logit": 9.46875,
            "text": "vulsive status epilepticus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -6.91015625,
            "text": "nonconvulsive status epilepticus (NCSE",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.4921875,
            "end_logit": 9.46875,
            "text": "ulsive status epilepticus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.82421875,
            "end_logit": 9.46875,
            "text": "status epilepticus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -7.48828125,
            "text": "nonconvulsive status",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.09375,
            "text": "nonconvulsive",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.328125,
            "text": "nonconvulsive status epilepticus (",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.390625,
            "text": "nonconv",
            "probability": 0.0
        },
        {
            "start_logit": -7.9296875,
            "end_logit": 9.46875,
            "text": "patients with nonconvulsive status epilepticus",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.46875,
            "text": "ill patients with nonconvulsive status epilepticus",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": 9.46875,
            "text": "prognosis of critically ill patients with nonconvulsive status epilepticus",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 9.46875,
            "text": "We aimed to assess the usefulness of the Salzburg Consensus Criteria (SCC) for determining the prognosis of critically ill patients with nonconvulsive status epilepticus",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.46875,
            "text": "the prognosis of critically ill patients with nonconvulsive status epilepticus",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.46875,
            "text": "assess the usefulness of the Salzburg Consensus Criteria (SCC) for determining the prognosis of critically ill patients with nonconvulsive status epilepticus",
            "probability": 0.0
        }
    ],
    "5e48bf5ed14c9f295d000019_3": [
        {
            "start_logit": 9.9453125,
            "end_logit": 9.546875,
            "text": "Nonconvulsive Status Epilepticus",
            "probability": 1.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -2.04296875,
            "text": "Noncon",
            "probability": 9.238719940185547e-06
        },
        {
            "start_logit": -2.29296875,
            "end_logit": 9.546875,
            "text": "Epilepticus",
            "probability": 4.76837158203125e-06
        },
        {
            "start_logit": -5.9140625,
            "end_logit": 9.546875,
            "text": "vulsive Status Epilepticus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.4453125,
            "end_logit": 9.546875,
            "text": "ulsive Status Epilepticus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.4921875,
            "end_logit": 9.546875,
            "text": "Status Epilepticus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -7.734375,
            "text": "Nonconvulsive Status",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.0234375,
            "text": "Nonconvulsive Status Epilepticus: Validating the Salzburg Criteria Against an Expert EEG",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.1484375,
            "text": "Nonconvulsive Status Epilepticus: Validating the Salzburg Criteria",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.1796875,
            "text": "Nonconvulsive",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.2109375,
            "text": "Nonconvulsive Status Epilepticus: Validating the Salzburg Criteria Against",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.265625,
            "text": "Nonconvulsive Status Epilepticus: Validating the Salzburg Criteria Against an Expert EEG Examiner",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.2890625,
            "text": "Nonconvulsive Status Epilepticus:",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.34375,
            "text": "Nonconvulsive Status Epilepticus: Validating the Salzburg Criteria Against an",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.3828125,
            "text": "Nonconvulsive Status Epilepticus: Validating the Salzburg",
            "probability": 0.0
        },
        {
            "start_logit": -2.29296875,
            "end_logit": -8.0234375,
            "text": "Epilepticus: Validating the Salzburg Criteria Against an Expert EEG",
            "probability": 0.0
        },
        {
            "start_logit": -2.29296875,
            "end_logit": -8.1484375,
            "text": "Epilepticus: Validating the Salzburg Criteria",
            "probability": 0.0
        },
        {
            "start_logit": -2.29296875,
            "end_logit": -8.2109375,
            "text": "Epilepticus: Validating the Salzburg Criteria Against",
            "probability": 0.0
        },
        {
            "start_logit": -2.29296875,
            "end_logit": -8.265625,
            "text": "Epilepticus: Validating the Salzburg Criteria Against an Expert EEG Examiner",
            "probability": 0.0
        },
        {
            "start_logit": -2.29296875,
            "end_logit": -8.2890625,
            "text": "Epilepticus:",
            "probability": 0.0
        }
    ],
    "5e48bf5ed14c9f295d000019_4": [
        {
            "start_logit": 9.921875,
            "end_logit": 9.3984375,
            "text": "nonconvulsive status epilepticus",
            "probability": 1.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -2.076171875,
            "text": "noncon",
            "probability": 1.043081283569336e-05
        },
        {
            "start_logit": -2.52734375,
            "end_logit": 9.3984375,
            "text": "epilepticus",
            "probability": 3.993511199951172e-06
        },
        {
            "start_logit": 9.921875,
            "end_logit": -5.421875,
            "text": "nonconvulsive status epilepticus (NCSE)",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.921875,
            "end_logit": -6.3515625,
            "text": "nonconvulsive status epilepticus (NCS",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -5.87109375,
            "end_logit": 9.3984375,
            "text": "vulsive status epilepticus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.375,
            "end_logit": 9.3984375,
            "text": "ulsive status epilepticus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.58203125,
            "end_logit": 9.3984375,
            "text": "status epilepticus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.921875,
            "end_logit": -7.55859375,
            "text": "nonconvulsive status epilepticus (NCSE",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.921875,
            "end_logit": -7.79296875,
            "text": "nonconvulsive status",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.921875,
            "end_logit": -7.984375,
            "text": "nonconvulsive status epilepticus (",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.140625,
            "text": "nonconvulsive status epilepticus (NCSE), external validation",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.1640625,
            "text": "nonconvulsive status epilepticus (NCSE), external validation of the recently proposed Salzburg criteria is paramount",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.1875,
            "text": "nonconvulsive",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.1875,
            "text": "nonconvulsive status epilepticus (NCSE), external validation of the recently proposed Salzburg criteria is",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.1875,
            "text": "nonconvulsive status epilepticus (NCSE), external validation of the recently",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.2421875,
            "text": "nonconvulsive status epilepticus (NCSE), external validation of the recently proposed Salzburg criteria",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.3671875,
            "text": "nonconvulsive status epilepticus (NCSE), external validation of the recently proposed",
            "probability": 0.0
        },
        {
            "start_logit": -7.9375,
            "end_logit": 9.3984375,
            "text": "To improve the diagnostic accuracy of electroencephalography (EEG) criteria for nonconvulsive status epilepticus",
            "probability": 0.0
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 9.3984375,
            "text": "for nonconvulsive status epilepticus",
            "probability": 0.0
        }
    ],
    "5e48bf5ed14c9f295d000019_5": [
        {
            "start_logit": 9.921875,
            "end_logit": 9.3984375,
            "text": "nonconvulsive status epilepticus",
            "probability": 1.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -2.076171875,
            "text": "noncon",
            "probability": 1.043081283569336e-05
        },
        {
            "start_logit": -2.52734375,
            "end_logit": 9.3984375,
            "text": "epilepticus",
            "probability": 3.993511199951172e-06
        },
        {
            "start_logit": 9.921875,
            "end_logit": -5.421875,
            "text": "nonconvulsive status epilepticus (NCSE)",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.921875,
            "end_logit": -6.3515625,
            "text": "nonconvulsive status epilepticus (NCS",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -5.87109375,
            "end_logit": 9.3984375,
            "text": "vulsive status epilepticus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.375,
            "end_logit": 9.3984375,
            "text": "ulsive status epilepticus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.58203125,
            "end_logit": 9.3984375,
            "text": "status epilepticus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.921875,
            "end_logit": -7.55859375,
            "text": "nonconvulsive status epilepticus (NCSE",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.921875,
            "end_logit": -7.79296875,
            "text": "nonconvulsive status",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.921875,
            "end_logit": -7.984375,
            "text": "nonconvulsive status epilepticus (",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.140625,
            "text": "nonconvulsive status epilepticus (NCSE), external validation",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.1640625,
            "text": "nonconvulsive status epilepticus (NCSE), external validation of the recently proposed Salzburg criteria is paramount",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.1875,
            "text": "nonconvulsive",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.1875,
            "text": "nonconvulsive status epilepticus (NCSE), external validation of the recently proposed Salzburg criteria is",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.1875,
            "text": "nonconvulsive status epilepticus (NCSE), external validation of the recently",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.2421875,
            "text": "nonconvulsive status epilepticus (NCSE), external validation of the recently proposed Salzburg criteria",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.3671875,
            "text": "nonconvulsive status epilepticus (NCSE), external validation of the recently proposed",
            "probability": 0.0
        },
        {
            "start_logit": -7.9375,
            "end_logit": 9.3984375,
            "text": "To improve the diagnostic accuracy of electroencephalography (EEG) criteria for nonconvulsive status epilepticus",
            "probability": 0.0
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 9.3984375,
            "text": "for nonconvulsive status epilepticus",
            "probability": 0.0
        }
    ],
    "623e02e0f0baec9a1b000005_1": [
        {
            "start_logit": 8.828125,
            "end_logit": 7.45703125,
            "text": "ER retention sequence",
            "probability": 1.0
        },
        {
            "start_logit": 8.828125,
            "end_logit": -3.28515625,
            "text": "ER retention sequence (KDEL)",
            "probability": 2.1755695343017578e-05
        },
        {
            "start_logit": 8.828125,
            "end_logit": -3.70703125,
            "text": "ER",
            "probability": 1.430511474609375e-05
        },
        {
            "start_logit": 8.828125,
            "end_logit": -5.9453125,
            "text": "ER retention sequence (",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": -4.765625,
            "end_logit": 7.45703125,
            "text": "sequence",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 8.828125,
            "end_logit": -7.140625,
            "text": "ER retention sequence (KDEL",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.828125,
            "end_logit": -7.30078125,
            "text": "ER retention sequence (KD",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.828125,
            "end_logit": -7.80078125,
            "text": "ER retention",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.171875,
            "end_logit": 7.45703125,
            "text": "retention sequence",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -4.765625,
            "end_logit": -3.28515625,
            "text": "sequence (KDEL)",
            "probability": 0.0
        },
        {
            "start_logit": -7.171875,
            "end_logit": -3.28515625,
            "text": "retention sequence (KDEL)",
            "probability": 0.0
        },
        {
            "start_logit": -4.765625,
            "end_logit": -5.9453125,
            "text": "sequence (",
            "probability": 0.0
        },
        {
            "start_logit": -4.765625,
            "end_logit": -7.140625,
            "text": "sequence (KDEL",
            "probability": 0.0
        },
        {
            "start_logit": -4.765625,
            "end_logit": -7.30078125,
            "text": "sequence (KD",
            "probability": 0.0
        },
        {
            "start_logit": -7.171875,
            "end_logit": -5.9453125,
            "text": "retention sequence (",
            "probability": 0.0
        },
        {
            "start_logit": -7.171875,
            "end_logit": -7.140625,
            "text": "retention sequence (KDEL",
            "probability": 0.0
        },
        {
            "start_logit": -7.171875,
            "end_logit": -7.30078125,
            "text": "retention sequence (KD",
            "probability": 0.0
        },
        {
            "start_logit": -7.171875,
            "end_logit": -7.80078125,
            "text": "retention",
            "probability": 0.0
        }
    ],
    "53617eeb7d100faa0900000a_1": [
        {
            "start_logit": 9.6640625,
            "end_logit": 8.8515625,
            "text": "Anorexia Athletica",
            "probability": 1.0
        },
        {
            "start_logit": 9.6640625,
            "end_logit": -2.529296875,
            "text": "Anorexia",
            "probability": 1.138448715209961e-05
        },
        {
            "start_logit": -3.275390625,
            "end_logit": 8.8515625,
            "text": "a",
            "probability": 2.384185791015625e-06
        },
        {
            "start_logit": -5.6953125,
            "end_logit": 8.8515625,
            "text": "developing Anorexia Athletica",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.6640625,
            "end_logit": -7.21875,
            "text": "Anorexia Athletic",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.6640625,
            "end_logit": -7.64453125,
            "text": "Anorexia Athletica.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.90234375,
            "end_logit": 8.8515625,
            "text": "Athletica",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.58203125,
            "end_logit": 8.8515625,
            "text": "to developing Anorexia Athletica",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.86328125,
            "end_logit": 8.8515625,
            "text": "are prone to developing Anorexia Athletica",
            "probability": 0.0
        },
        {
            "start_logit": -7.953125,
            "end_logit": 8.8515625,
            "text": "they are prone to developing Anorexia Athletica",
            "probability": 0.0
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 8.8515625,
            "text": "Elite Rhythmic Gymnasts (RGs) constitute a unique metabolic model and they are prone to developing Anorexia Athletica",
            "probability": 0.0
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 8.8515625,
            "text": "(RGs) constitute a unique metabolic model and they are prone to developing Anorexia Athletica",
            "probability": 0.0
        },
        {
            "start_logit": -8.0,
            "end_logit": 8.8515625,
            "text": "and they are prone to developing Anorexia Athletica",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 8.8515625,
            "text": "prone to developing Anorexia Athletica",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 8.8515625,
            "text": "Rhythmic Gymnasts (RGs) constitute a unique metabolic model and they are prone to developing Anorexia Athletica",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 8.8515625,
            "text": "metabolic model and they are prone to developing Anorexia Athletica",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 8.8515625,
            "text": "a unique metabolic model and they are prone to developing Anorexia Athletica",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 8.8515625,
            "text": ") constitute a unique metabolic model and they are prone to developing Anorexia Athletica",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 8.8515625,
            "text": "model and they are prone to developing Anorexia Athletica",
            "probability": 0.0
        },
        {
            "start_logit": -5.6953125,
            "end_logit": -2.529296875,
            "text": "developing Anorexia",
            "probability": 0.0
        }
    ],
    "53617eeb7d100faa0900000a_2": [
        {
            "start_logit": 9.671875,
            "end_logit": 9.0234375,
            "text": "anorexia athletica",
            "probability": 1.0
        },
        {
            "start_logit": 9.671875,
            "end_logit": -2.5390625,
            "text": "anorexia",
            "probability": 9.59634780883789e-06
        },
        {
            "start_logit": -3.091796875,
            "end_logit": 9.0234375,
            "text": "a",
            "probability": 2.86102294921875e-06
        },
        {
            "start_logit": 9.671875,
            "end_logit": -7.45703125,
            "text": "anorexia athletic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.671875,
            "end_logit": -7.55859375,
            "text": "anorexia athletica (AA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.078125,
            "end_logit": 9.0234375,
            "text": "athletica",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.671875,
            "end_logit": -8.0078125,
            "text": "anorexia athletica (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6953125,
            "end_logit": 9.0234375,
            "text": "with anorexia athletica",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 9.0234375,
            "text": "female juvenile elite gymnasts with anorexia athletica",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.0234375,
            "text": "studied 13 female juvenile elite gymnasts with anorexia athletica",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.0234375,
            "text": "We studied 13 female juvenile elite gymnasts with anorexia athletica",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.0234375,
            "text": "elite gymnasts with anorexia athletica",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.0234375,
            "text": "juvenile elite gymnasts with anorexia athletica",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.0234375,
            "text": "gymnasts with anorexia athletica",
            "probability": 0.0
        },
        {
            "start_logit": -7.6953125,
            "end_logit": -2.5390625,
            "text": "with anorexia",
            "probability": 0.0
        },
        {
            "start_logit": -3.091796875,
            "end_logit": -7.55859375,
            "text": "a (AA",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": -2.5390625,
            "text": "female juvenile elite gymnasts with anorexia",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": -2.5390625,
            "text": "studied 13 female juvenile elite gymnasts with anorexia",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -2.5390625,
            "text": "We studied 13 female juvenile elite gymnasts with anorexia",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -2.5390625,
            "text": "elite gymnasts with anorexia",
            "probability": 0.0
        }
    ],
    "5c900b9eecadf2e73f000004_1": [
        {
            "start_logit": 9.9921875,
            "end_logit": 9.6171875,
            "text": "Alnylam Pharmaceuticals",
            "probability": 1.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -1.849609375,
            "text": "Al",
            "probability": 1.043081283569336e-05
        },
        {
            "start_logit": -1.9951171875,
            "end_logit": 9.6171875,
            "text": "Pharmaceuticals",
            "probability": 6.258487701416016e-06
        },
        {
            "start_logit": -6.46875,
            "end_logit": 9.6171875,
            "text": "am Pharmaceuticals",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -7.11328125,
            "text": "Alnyl",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.9375,
            "end_logit": 9.6171875,
            "text": "ylam Pharmaceuticals",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.0,
            "end_logit": 9.6171875,
            "text": "nylam Pharmaceuticals",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -7.4765625,
            "text": "Alnylam",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -7.72265625,
            "text": "Aln",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -7.8359375,
            "text": "Alnylam Pharmaceuticals; it was recently approved in the USA",
            "probability": 0.0
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 9.6171875,
            "text": "Patisiran has been developed by Alnylam Pharmaceuticals",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.0390625,
            "text": "Alnylam Pharmaceuticals; it was recently approved in the USA for the treatment of the polyneuropathy of hereditary TTR",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.125,
            "text": "Alnylam Pharmaceuticals;",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.171875,
            "text": "Alnylam Pharmaceuticals; it was recently approved in the USA for the treatment of the polyneuropathy of hereditary TTR-mediated amyloidosis (",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.203125,
            "text": "Alnylam Pharmaceuticals; it was recently approved in the USA for the treatment of the polyneuropathy of hereditary TTR-mediated amyloidosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.2265625,
            "text": "Alnylam Pharmaceuticals; it was recently approved in the USA for the treatment of the polyneuropathy of hereditary TTR-mediated amyloidosis (hATTR) in adults and",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.2421875,
            "text": "Alnylam Pharmaceuticals; it was recently approved in the USA for the treatment of the polyneuropathy of hereditary TTR-mediated amyloidosis (hAT",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.2421875,
            "text": "Alnylam Pharmaceuticals; it was recently approved in the USA for the treatment of the polyneuropathy of hereditary TTR-mediated amyloidosis (hATTR",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.2421875,
            "text": "Alnylam Pharmaceuticals; it was recently approved in the USA for the treatment of the polyneuropathy of hereditary TTR-mediated amyloidosis (hATTR) in",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.2421875,
            "text": "Alnylam Pharmaceuticals; it was recently approved in the USA for the treatment of the polyneuropathy of hereditary TTR-mediated",
            "probability": 0.0
        }
    ],
    "58c27b7102b8c60953000021_1": [
        {
            "start_logit": 9.796875,
            "end_logit": 9.34375,
            "text": "Enhancer Sharing",
            "probability": 1.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -2.318359375,
            "text": "Enhancer",
            "probability": 8.58306884765625e-06
        },
        {
            "start_logit": -2.6484375,
            "end_logit": 9.34375,
            "text": "Sharing",
            "probability": 3.933906555175781e-06
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.078125,
            "text": "Enhancer Sharing Promotes",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.2578125,
            "text": "Enhancer Sharing Promotes Neighborhoods of Transcriptional Regulation Across",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.328125,
            "text": "Enhancer Sharing Promotes Neighborhoods of Transcriptional Regulation Across Eukaryotes",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.3671875,
            "text": "Enhancer Sharing Promotes Neighborhoods of Transcriptional Regulation",
            "probability": 0.0
        },
        {
            "start_logit": -2.6484375,
            "end_logit": -8.078125,
            "text": "Sharing Promotes",
            "probability": 0.0
        },
        {
            "start_logit": -2.6484375,
            "end_logit": -8.2578125,
            "text": "Sharing Promotes Neighborhoods of Transcriptional Regulation Across",
            "probability": 0.0
        },
        {
            "start_logit": -2.6484375,
            "end_logit": -8.328125,
            "text": "Sharing Promotes Neighborhoods of Transcriptional Regulation Across Eukaryotes",
            "probability": 0.0
        },
        {
            "start_logit": -2.6484375,
            "end_logit": -8.3671875,
            "text": "Sharing Promotes Neighborhoods of Transcriptional Regulation",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": -8.2578125,
            "text": "Neighborhoods of Transcriptional Regulation Across",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": -8.328125,
            "text": "Neighborhoods of Transcriptional Regulation Across Eukaryotes",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": -8.2578125,
            "text": "Transcriptional Regulation Across",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": -8.2578125,
            "text": "of Transcriptional Regulation Across",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": -8.3671875,
            "text": "Neighborhoods of Transcriptional Regulation",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": -8.328125,
            "text": "Transcriptional Regulation Across Eukaryotes",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": -8.328125,
            "text": "of Transcriptional Regulation Across Eukaryotes",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": -8.3671875,
            "text": "Transcriptional Regulation",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": -8.3671875,
            "text": "of Transcriptional Regulation",
            "probability": 0.0
        }
    ],
    "58c27b7102b8c60953000021_2": [
        {
            "start_logit": 9.859375,
            "end_logit": 9.6328125,
            "text": "enhancer sharing",
            "probability": 1.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -2.158203125,
            "text": "enhancer",
            "probability": 7.510185241699219e-06
        },
        {
            "start_logit": -1.9697265625,
            "end_logit": 9.6328125,
            "text": "sharing",
            "probability": 7.212162017822266e-06
        },
        {
            "start_logit": 9.859375,
            "end_logit": -7.55078125,
            "text": "enhancer sharing is commonplace among eukaryotes, and that EP distance",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.859375,
            "end_logit": -7.69140625,
            "text": "enhancer sharing is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 9.6328125,
            "text": "that enhancer sharing",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -7.7421875,
            "text": "enhancer sharing is commonplace among eukaryotes, and that EP distance is",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.0234375,
            "text": "enhancer sharing is commonplace among eukaryotes, and that EP distance is an important layer of information in gene regulation",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.046875,
            "text": "enhancer sharing is commonplace among eukaryotes, and that EP distance is an",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.0703125,
            "text": "enhancer sharing is commonplace among eukaryotes, and that EP distance is an important",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.078125,
            "text": "enhancer sharing is commonplace among eukaryotes, and that EP distance is an important layer",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.0859375,
            "text": "enhancer sharing is commonplace",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.125,
            "text": "enhancer sharing is common",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.1796875,
            "text": "enhancer sharing is commonplace among eukaryotes, and that EP distance is an important layer of information",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.203125,
            "text": "enhancer sharing is commonplace among eukaryotes",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.2421875,
            "text": "enhancer sharing is commonplace among eukaryotes, and that EP distance is an important layer of information in gene",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": 9.6328125,
            "text": "We propose that enhancer sharing",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 9.6328125,
            "text": "propose that enhancer sharing",
            "probability": 0.0
        },
        {
            "start_logit": -1.9697265625,
            "end_logit": -7.55078125,
            "text": "sharing is commonplace among eukaryotes, and that EP distance",
            "probability": 0.0
        },
        {
            "start_logit": -7.49609375,
            "end_logit": -2.158203125,
            "text": "that enhancer",
            "probability": 0.0
        }
    ],
    "58c27b7102b8c60953000021_3": [
        {
            "start_logit": 9.875,
            "end_logit": 9.40625,
            "text": "Enhancer Sharing",
            "probability": 1.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -2.142578125,
            "text": "Enhancer",
            "probability": 9.655952453613281e-06
        },
        {
            "start_logit": -2.52734375,
            "end_logit": 9.40625,
            "text": "Sharing",
            "probability": 4.112720489501953e-06
        },
        {
            "start_logit": 9.875,
            "end_logit": -7.96875,
            "text": "Enhancer Sharing Promotes",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.125,
            "text": "Enhancer Sharing Promotes Neighborhoods of Transcriptional Regulation Across",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.234375,
            "text": "Enhancer Sharing Promotes Neighborhoods of Transcriptional Regulation Across Eukaryotes",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.28125,
            "text": "Enhancer Sharing Promotes Neighborhoods of Transcriptional Regulation",
            "probability": 0.0
        },
        {
            "start_logit": -2.52734375,
            "end_logit": -7.96875,
            "text": "Sharing Promotes",
            "probability": 0.0
        },
        {
            "start_logit": -2.52734375,
            "end_logit": -8.125,
            "text": "Sharing Promotes Neighborhoods of Transcriptional Regulation Across",
            "probability": 0.0
        },
        {
            "start_logit": -2.52734375,
            "end_logit": -8.234375,
            "text": "Sharing Promotes Neighborhoods of Transcriptional Regulation Across Eukaryotes",
            "probability": 0.0
        },
        {
            "start_logit": -2.52734375,
            "end_logit": -8.28125,
            "text": "Sharing Promotes Neighborhoods of Transcriptional Regulation",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -8.125,
            "text": "Neighborhoods of Transcriptional Regulation Across",
            "probability": 0.0
        },
        {
            "start_logit": -8.375,
            "end_logit": -7.96875,
            "text": "Promotes",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -8.234375,
            "text": "Neighborhoods of Transcriptional Regulation Across Eukaryotes",
            "probability": 0.0
        },
        {
            "start_logit": -8.359375,
            "end_logit": -8.125,
            "text": "of Transcriptional Regulation Across",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -8.28125,
            "text": "Neighborhoods of Transcriptional Regulation",
            "probability": 0.0
        },
        {
            "start_logit": -8.3671875,
            "end_logit": -8.125,
            "text": "Transcriptional Regulation Across",
            "probability": 0.0
        },
        {
            "start_logit": -8.375,
            "end_logit": -8.125,
            "text": "Promotes Neighborhoods of Transcriptional Regulation Across",
            "probability": 0.0
        },
        {
            "start_logit": -8.4296875,
            "end_logit": -8.125,
            "text": "Regulation Across",
            "probability": 0.0
        },
        {
            "start_logit": -8.359375,
            "end_logit": -8.234375,
            "text": "of Transcriptional Regulation Across Eukaryotes",
            "probability": 0.0
        }
    ],
    "5c8973f3d558e5f232000007_1": [
        {
            "start_logit": 9.9921875,
            "end_logit": 9.71875,
            "text": "Alipogene tiparvovec",
            "probability": 1.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -1.9130859375,
            "text": "Ali",
            "probability": 8.821487426757812e-06
        },
        {
            "start_logit": -1.8740234375,
            "end_logit": 9.71875,
            "text": "c",
            "probability": 6.973743438720703e-06
        },
        {
            "start_logit": -6.09375,
            "end_logit": 9.71875,
            "text": "pogene tiparvovec",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.44140625,
            "end_logit": 9.71875,
            "text": "tiparvovec",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.52734375,
            "end_logit": 9.71875,
            "text": "arvovec",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.5625,
            "end_logit": 9.71875,
            "text": "gene tiparvovec",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.734375,
            "end_logit": 9.71875,
            "text": "vovec",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -7.25390625,
            "text": "Alipogene tiparvove",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.98046875,
            "end_logit": 9.71875,
            "text": "vec",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -7.80078125,
            "text": "Alipogene tiparvo",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -7.97265625,
            "text": "Alipogene tiparvovec (Glybera",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -7.97265625,
            "text": "Alipogene tiparvovec (Glybera\u00ae) is the first gene therapy to receive Marketing Authorization in the European Union; GENIALL (GENetherapy In the MAnagement of Lipoprotein Lipase",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -7.99609375,
            "text": "Alipogene tiparvovec (Glybera\u00ae)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.0078125,
            "text": "Alipogene tiparvovec (Glyber",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.09375,
            "text": "Alipogene tiparvovec (Glybera\u00ae) is the first gene therapy to receive Marketing Authorization in the European Union; GENIALL (GENetherapy In the MAnagement of Lipoprotein Lipase Deficiency",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.140625,
            "text": "Alipogene tiparvovec (Glybera\u00ae",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.140625,
            "text": "Alipogene",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.171875,
            "text": "Alipogene tip",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.2421875,
            "text": "Alipogene tiparvovec (Glybera\u00ae) is",
            "probability": 0.0
        }
    ],
    "5c929094ecadf2e73f000019_1": [
        {
            "start_logit": 9.0625,
            "end_logit": 7.62890625,
            "text": "activation",
            "probability": 1.0
        },
        {
            "start_logit": 9.0625,
            "end_logit": -7.171875,
            "text": "activation of retrotransposons.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.0625,
            "end_logit": -7.34375,
            "text": "activation of retrotransposons",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.234375,
            "end_logit": 7.62890625,
            "text": "to the activation",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.0625,
            "end_logit": -7.71484375,
            "text": "activation of retrotransp",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.0625,
            "end_logit": -7.81640625,
            "text": "activation of retrotranspos",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.38671875,
            "end_logit": 7.62890625,
            "text": "the activation",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.984375,
            "end_logit": 7.62890625,
            "text": ". These include the loss of DNA-nuclear lamina interactions, the distension of centromeres, and changes in chromatin composition that can lead to the activation",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.15625,
            "end_logit": 7.62890625,
            "text": "Senescent cells undergo dramatic alterations to their chromatin landscape that affect genome accessibility and their transcriptional program. These include the loss of DNA-nuclear lamina interactions, the distension of centromeres, and changes in chromatin composition that can lead to the activation",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.79296875,
            "end_logit": 7.62890625,
            "text": ", and changes in chromatin composition that can lead to the activation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.890625,
            "end_logit": 7.62890625,
            "text": "cells undergo dramatic alterations to their chromatin landscape that affect genome accessibility and their transcriptional program. These include the loss of DNA-nuclear lamina interactions, the distension of centromeres, and changes in chromatin composition that can lead to the activation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 7.62890625,
            "text": "can lead to the activation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 7.62890625,
            "text": "lead to the activation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.078125,
            "end_logit": 7.62890625,
            "text": "that can lead to the activation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.109375,
            "end_logit": 7.62890625,
            "text": "and changes in chromatin composition that can lead to the activation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 7.62890625,
            "text": "of centromeres, and changes in chromatin composition that can lead to the activation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 7.62890625,
            "text": "changes in chromatin composition that can lead to the activation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3125,
            "end_logit": 7.62890625,
            "text": "loss of DNA-nuclear lamina interactions, the distension of centromeres, and changes in chromatin composition that can lead to the activation",
            "probability": 0.0
        },
        {
            "start_logit": -6.234375,
            "end_logit": -7.171875,
            "text": "to the activation of retrotransposons.",
            "probability": 0.0
        },
        {
            "start_logit": -6.38671875,
            "end_logit": -7.171875,
            "text": "the activation of retrotransposons.",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_1": [
        {
            "start_logit": 9.9140625,
            "end_logit": 9.9296875,
            "text": "28 joints",
            "probability": 1.0
        },
        {
            "start_logit": -1.173828125,
            "end_logit": 9.9296875,
            "text": "joints",
            "probability": 1.531839370727539e-05
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -2.0390625,
            "text": "28",
            "probability": 6.318092346191406e-06
        },
        {
            "start_logit": -7.875,
            "end_logit": 9.9296875,
            "text": "in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.0,
            "text": "28 joints (",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.21875,
            "text": "28 joints (DAS",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.9296875,
            "text": "Disease activity score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -1.173828125,
            "end_logit": -8.0,
            "text": "joints (",
            "probability": 0.0
        },
        {
            "start_logit": -1.173828125,
            "end_logit": -8.21875,
            "text": "joints (DAS",
            "probability": 0.0
        },
        {
            "start_logit": -7.875,
            "end_logit": -2.0390625,
            "text": "in 28",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": -2.0390625,
            "text": "Disease activity score in 28",
            "probability": 0.0
        },
        {
            "start_logit": -7.875,
            "end_logit": -8.0,
            "text": "in 28 joints (",
            "probability": 0.0
        },
        {
            "start_logit": -7.875,
            "end_logit": -8.21875,
            "text": "in 28 joints (DAS",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": -8.0,
            "text": "Disease activity score in 28 joints (",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": -8.21875,
            "text": "Disease activity score in 28 joints (DAS",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_2": [
        {
            "start_logit": 9.9296875,
            "end_logit": 9.9375,
            "text": "28 joints",
            "probability": 1.0
        },
        {
            "start_logit": -1.1494140625,
            "end_logit": 9.9375,
            "text": "joints",
            "probability": 1.531839370727539e-05
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -1.9912109375,
            "text": "28",
            "probability": 6.556510925292969e-06
        },
        {
            "start_logit": -6.5234375,
            "end_logit": 9.9375,
            "text": "in 28 joints",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7578125,
            "end_logit": 9.9375,
            "text": "ter 7 years, apart from routine clinical follow-up, treating rheumatologists were asked to complete a questionnaire designed specifically for the present study to evaluate the current therapy with infliximab, the level of disease activity (Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 9.9375,
            "text": "(Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 9.9375,
            "text": ", apart from routine clinical follow-up, treating rheumatologists were asked to complete a questionnaire designed specifically for the present study to evaluate the current therapy with infliximab, the level of disease activity (Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 9.9375,
            "text": "from routine clinical follow-up, treating rheumatologists were asked to complete a questionnaire designed specifically for the present study to evaluate the current therapy with infliximab, the level of disease activity (Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.9375,
            "text": "the level of disease activity (Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.9375,
            "text": "treating rheumatologists were asked to complete a questionnaire designed specifically for the present study to evaluate the current therapy with infliximab, the level of disease activity (Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.9375,
            "text": "present study to evaluate the current therapy with infliximab, the level of disease activity (Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 9.9375,
            "text": "Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.9375,
            "text": "study to evaluate the current therapy with infliximab, the level of disease activity (Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.9375,
            "text": "level of disease activity (Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.2109375,
            "text": "28 joints [DAS28",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.25,
            "text": "28 joints [DAS28]",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.3046875,
            "text": "28 joints [DAS",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.3125,
            "text": "28 joints [",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.359375,
            "text": "28 joints [DAS28]) and",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.3671875,
            "text": "28 joints [DAS28])",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_3": [
        {
            "start_logit": 9.9453125,
            "end_logit": 9.953125,
            "text": "28 Joints",
            "probability": 1.0
        },
        {
            "start_logit": -1.166015625,
            "end_logit": 9.953125,
            "text": "Joints",
            "probability": 1.4841556549072266e-05
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -1.9658203125,
            "text": "28",
            "probability": 6.616115570068359e-06
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 9.953125,
            "text": "in 28 Joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -7.9765625,
            "text": "28 Joints (",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.953125,
            "text": "Disease Activity Score in 28 Joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.953125,
            "text": ": Disease Activity Score in 28 Joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.265625,
            "text": "28 Joints (DAS",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.296875,
            "text": "28 Joints (DAS28)",
            "probability": 0.0
        },
        {
            "start_logit": -1.166015625,
            "end_logit": -7.9765625,
            "text": "Joints (",
            "probability": 0.0
        },
        {
            "start_logit": -1.166015625,
            "end_logit": -8.265625,
            "text": "Joints (DAS",
            "probability": 0.0
        },
        {
            "start_logit": -1.166015625,
            "end_logit": -8.296875,
            "text": "Joints (DAS28)",
            "probability": 0.0
        },
        {
            "start_logit": -7.56640625,
            "end_logit": -1.9658203125,
            "text": "in 28",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": -1.9658203125,
            "text": "Disease Activity Score in 28",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": -1.9658203125,
            "text": ": Disease Activity Score in 28",
            "probability": 0.0
        },
        {
            "start_logit": -7.56640625,
            "end_logit": -7.9765625,
            "text": "in 28 Joints (",
            "probability": 0.0
        },
        {
            "start_logit": -7.56640625,
            "end_logit": -8.265625,
            "text": "in 28 Joints (DAS",
            "probability": 0.0
        },
        {
            "start_logit": -7.56640625,
            "end_logit": -8.296875,
            "text": "in 28 Joints (DAS28)",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": -7.9765625,
            "text": "Disease Activity Score in 28 Joints (",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": -7.9765625,
            "text": ": Disease Activity Score in 28 Joints (",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_4": [
        {
            "start_logit": 9.8828125,
            "end_logit": 9.859375,
            "text": "28 joints",
            "probability": 1.0
        },
        {
            "start_logit": -1.4169921875,
            "end_logit": 9.859375,
            "text": "joints",
            "probability": 1.233816146850586e-05
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -2.09765625,
            "text": "28",
            "probability": 6.318092346191406e-06
        },
        {
            "start_logit": -6.69921875,
            "end_logit": 9.859375,
            "text": "in 28 joints",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.859375,
            "end_logit": 9.859375,
            "text": "a Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 9.859375,
            "text": ", according to American College of Rheumatology guidelines, in patients with active rheumatoid arthritis (RA) as defined by a Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.859375,
            "text": "Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.859375,
            "text": ", in patients with active rheumatoid arthritis (RA) as defined by a Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.25,
            "text": "28 joints (",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.859375,
            "text": "by a Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.859375,
            "text": "to American College of Rheumatology guidelines, in patients with active rheumatoid arthritis (RA) as defined by a Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.859375,
            "text": "Antirheumatic treatment is frequently not appropriately modified, according to American College of Rheumatology guidelines, in patients with active rheumatoid arthritis (RA) as defined by a Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.28125,
            "text": "28 joints (DAS28) score greater",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.859375,
            "text": "patients with active rheumatoid arthritis (RA) as defined by a Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.859375,
            "text": "according to American College of Rheumatology guidelines, in patients with active rheumatoid arthritis (RA) as defined by a Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.3125,
            "text": "28 joints (DAS28)",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.3515625,
            "text": "28 joints (DAS",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.3828125,
            "text": "28 joints (DAS28",
            "probability": 0.0
        },
        {
            "start_logit": -6.69921875,
            "end_logit": -2.09765625,
            "text": "in 28",
            "probability": 0.0
        },
        {
            "start_logit": -1.4169921875,
            "end_logit": -8.25,
            "text": "joints (",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_5": [
        {
            "start_logit": 9.9609375,
            "end_logit": 9.9453125,
            "text": "28 joints",
            "probability": 1.0
        },
        {
            "start_logit": -1.1875,
            "end_logit": 9.9453125,
            "text": "joints",
            "probability": 1.4424324035644531e-05
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -1.9287109375,
            "text": "28",
            "probability": 6.973743438720703e-06
        },
        {
            "start_logit": -6.28125,
            "end_logit": 9.9453125,
            "text": "on 28 joints",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -7.72265625,
            "text": "28 joints (",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 9.9453125,
            "text": "based on 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.9453125,
            "text": "The Disease Activity Score based on 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.2109375,
            "text": "28 joints (DAS28) has been increasingly used in clinical practice",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.21875,
            "text": "28 joints (DAS",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.9453125,
            "text": "Disease Activity Score based on 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.25,
            "text": "28 joints (DAS28) has been increasingly used in clinical practice and research studies",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.25,
            "text": "28 joints (DAS28)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.2578125,
            "text": "28 joints (DAS28) has",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.2734375,
            "text": "28 joints (DAS28) has been increasingly used in clinical practice and research",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.2734375,
            "text": "28 joints (DAS28) has been increasingly",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.296875,
            "text": "28 joints (DAS28) has been",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.296875,
            "text": "28 joints (DAS28",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.3125,
            "text": "28 joints (DAS28) has been increasingly used in clinical practice and research studies of",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.328125,
            "text": "28 joints (DAS28) has been increasingly used in clinical practice and",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.34375,
            "text": "28 joints (DAS28) has been increasingly used in clinical practice and research studies of rheumatoid",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_6": [
        {
            "start_logit": 9.953125,
            "end_logit": 9.9453125,
            "text": "28 joints",
            "probability": 1.0
        },
        {
            "start_logit": -1.19140625,
            "end_logit": 9.9453125,
            "text": "joints",
            "probability": 1.430511474609375e-05
        },
        {
            "start_logit": 9.953125,
            "end_logit": -1.9423828125,
            "text": "28",
            "probability": 6.794929504394531e-06
        },
        {
            "start_logit": -6.29296875,
            "end_logit": 9.9453125,
            "text": "on 28 joints",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.953125,
            "end_logit": -7.73828125,
            "text": "28 joints (",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.9453125,
            "text": "based on 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 9.9453125,
            "text": "The Disease Activity Score based on 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.21875,
            "text": "28 joints (DAS",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.9453125,
            "text": "Disease Activity Score based on 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.2265625,
            "text": "28 joints (DAS28) has been widely used in clinical practice",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.2578125,
            "text": "28 joints (DAS28) has been widely",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.2578125,
            "text": "28 joints (DAS28)",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.265625,
            "text": "28 joints (DAS28) has been widely used in clinical practice and research studies",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.28125,
            "text": "28 joints (DAS28) has been widely used in clinical practice and research",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.3046875,
            "text": "28 joints (DAS28",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.3125,
            "text": "28 joints (DAS28) has",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": 9.9453125,
            "text": ": The Disease Activity Score based on 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.328125,
            "text": "28 joints (DAS28) has been widely used in clinical practice and research studies of",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.3359375,
            "text": "28 joints (DAS28) has been",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.34375,
            "text": "28 joints (DAS28) has been widely used in clinical practice and",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_7": [
        {
            "start_logit": 9.9296875,
            "end_logit": 9.9296875,
            "text": "28 joints",
            "probability": 1.0
        },
        {
            "start_logit": -1.2294921875,
            "end_logit": 9.9296875,
            "text": "joints",
            "probability": 1.430511474609375e-05
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -2.005859375,
            "text": "28",
            "probability": 6.556510925292969e-06
        },
        {
            "start_logit": -7.70703125,
            "end_logit": 9.9296875,
            "text": "in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -7.984375,
            "end_logit": 9.9296875,
            "text": "The Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.9296875,
            "text": "Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.203125,
            "text": "28 joints (",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.28125,
            "text": "28 joints (DAS28)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.3203125,
            "text": "28 joints (DAS28), used to assess disease activity in rheumatoid arthritis",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.3671875,
            "text": "28 joints (DAS28), used to assess disease activity in rheumatoid arthritis (",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.3671875,
            "text": "28 joints (DAS28), used to assess disease activity",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.375,
            "text": "28 joints (DAS28), used to assess disease activity in",
            "probability": 0.0
        },
        {
            "start_logit": -1.2294921875,
            "end_logit": -8.203125,
            "text": "joints (",
            "probability": 0.0
        },
        {
            "start_logit": -1.2294921875,
            "end_logit": -8.28125,
            "text": "joints (DAS28)",
            "probability": 0.0
        },
        {
            "start_logit": -1.2294921875,
            "end_logit": -8.3203125,
            "text": "joints (DAS28), used to assess disease activity in rheumatoid arthritis",
            "probability": 0.0
        },
        {
            "start_logit": -1.2294921875,
            "end_logit": -8.3671875,
            "text": "joints (DAS28), used to assess disease activity in rheumatoid arthritis (",
            "probability": 0.0
        },
        {
            "start_logit": -1.2294921875,
            "end_logit": -8.3671875,
            "text": "joints (DAS28), used to assess disease activity",
            "probability": 0.0
        },
        {
            "start_logit": -1.2294921875,
            "end_logit": -8.375,
            "text": "joints (DAS28), used to assess disease activity in",
            "probability": 0.0
        },
        {
            "start_logit": -7.70703125,
            "end_logit": -2.005859375,
            "text": "in 28",
            "probability": 0.0
        },
        {
            "start_logit": -7.984375,
            "end_logit": -2.005859375,
            "text": "The Disease Activity Score in 28",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_8": [
        {
            "start_logit": 9.8984375,
            "end_logit": 9.96875,
            "text": "28 joints",
            "probability": 1.0
        },
        {
            "start_logit": -1.0234375,
            "end_logit": 9.96875,
            "text": "joints",
            "probability": 1.7940998077392578e-05
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -2.048828125,
            "text": "28",
            "probability": 6.020069122314453e-06
        },
        {
            "start_logit": -6.8046875,
            "end_logit": 9.96875,
            "text": "in 28 joints",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.82421875,
            "end_logit": 9.96875,
            "text": "better reflects joint synovitis, i.e., the 2-component Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -7.8515625,
            "end_logit": 9.96875,
            "text": "reflects joint synovitis, i.e., the 2-component Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -7.890625,
            "text": "28 joints (",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": 9.96875,
            "text": "joint synovitis, i.e., the 2-component Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.96875,
            "text": "using a reweighted disease activity score that better reflects joint synovitis, i.e., the 2-component Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.96875,
            "text": "To determine whether using a reweighted disease activity score that better reflects joint synovitis, i.e., the 2-component Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.96875,
            "text": "whether using a reweighted disease activity score that better reflects joint synovitis, i.e., the 2-component Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.96875,
            "text": "a reweighted disease activity score that better reflects joint synovitis, i.e., the 2-component Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.96875,
            "text": ", the 2-component Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.15625,
            "text": "28 joints (DAS28",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.25,
            "text": "28 joints (DAS28) (based on swollen joint count and C-reactive protein level), produces more clinically relevant treatment outcome trajectories compared to the standard 4",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.265625,
            "text": "28 joints (DAS28)",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.2890625,
            "text": "28 joints (DAS",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.3046875,
            "text": "28 joints (DAS28) (based on swollen joint",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.3046875,
            "text": "28 joints (DAS28) (based on swollen joint count and C-reactive protein level), produces more clinically relevant treatment outcome trajectories compared",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.328125,
            "text": "28 joints (DAS28) (based on swollen joint count",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_9": [
        {
            "start_logit": 9.9296875,
            "end_logit": 9.9453125,
            "text": "28 joints",
            "probability": 1.0
        },
        {
            "start_logit": -1.1845703125,
            "end_logit": 9.9453125,
            "text": "joints",
            "probability": 1.4841556549072266e-05
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -2.0,
            "text": "28",
            "probability": 6.496906280517578e-06
        },
        {
            "start_logit": -7.81640625,
            "end_logit": 9.9453125,
            "text": "in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.1171875,
            "text": "28 joints (",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.9453125,
            "text": "The Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.9453125,
            "text": "Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.3515625,
            "text": "28 joints (DAS",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.3515625,
            "text": "28 joints (DAS28) is a key measure in clinical practice",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.3671875,
            "text": "28 joints (DAS28) is",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.375,
            "text": "28 joints (DAS28) is a",
            "probability": 0.0
        },
        {
            "start_logit": -1.1845703125,
            "end_logit": -8.1171875,
            "text": "joints (",
            "probability": 0.0
        },
        {
            "start_logit": -1.1845703125,
            "end_logit": -8.3515625,
            "text": "joints (DAS",
            "probability": 0.0
        },
        {
            "start_logit": -1.1845703125,
            "end_logit": -8.3515625,
            "text": "joints (DAS28) is a key measure in clinical practice",
            "probability": 0.0
        },
        {
            "start_logit": -1.1845703125,
            "end_logit": -8.3671875,
            "text": "joints (DAS28) is",
            "probability": 0.0
        },
        {
            "start_logit": -1.1845703125,
            "end_logit": -8.375,
            "text": "joints (DAS28) is a",
            "probability": 0.0
        },
        {
            "start_logit": -7.81640625,
            "end_logit": -2.0,
            "text": "in 28",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -2.0,
            "text": "The Disease Activity Score in 28",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -2.0,
            "text": "Disease Activity Score in 28",
            "probability": 0.0
        },
        {
            "start_logit": -7.81640625,
            "end_logit": -8.1171875,
            "text": "in 28 joints (",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_10": [
        {
            "start_logit": 9.921875,
            "end_logit": 9.9375,
            "text": "28 Joints",
            "probability": 1.0
        },
        {
            "start_logit": -1.212890625,
            "end_logit": 9.9375,
            "text": "Joints",
            "probability": 1.4603137969970703e-05
        },
        {
            "start_logit": 9.921875,
            "end_logit": -2.015625,
            "text": "28",
            "probability": 6.4373016357421875e-06
        },
        {
            "start_logit": -7.76953125,
            "end_logit": 9.9375,
            "text": "in 28 Joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.0703125,
            "text": "28 Joints (",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.9375,
            "text": "Disease Activity Score in 28 Joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.2109375,
            "text": "28 Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.9375,
            "text": ": Disease Activity Score in 28 Joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.2734375,
            "text": "28 Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid arth",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.34375,
            "text": "28 Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.359375,
            "text": "28 Joints (DAS",
            "probability": 0.0
        },
        {
            "start_logit": -1.212890625,
            "end_logit": -8.0703125,
            "text": "Joints (",
            "probability": 0.0
        },
        {
            "start_logit": -1.212890625,
            "end_logit": -8.2109375,
            "text": "Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid",
            "probability": 0.0
        },
        {
            "start_logit": -1.212890625,
            "end_logit": -8.2734375,
            "text": "Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid arth",
            "probability": 0.0
        },
        {
            "start_logit": -1.212890625,
            "end_logit": -8.34375,
            "text": "Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in",
            "probability": 0.0
        },
        {
            "start_logit": -1.212890625,
            "end_logit": -8.359375,
            "text": "Joints (DAS",
            "probability": 0.0
        },
        {
            "start_logit": -7.76953125,
            "end_logit": -2.015625,
            "text": "in 28",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -2.015625,
            "text": "Disease Activity Score in 28",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": -2.015625,
            "text": ": Disease Activity Score in 28",
            "probability": 0.0
        },
        {
            "start_logit": -7.76953125,
            "end_logit": -8.0703125,
            "text": "in 28 Joints (",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_11": [
        {
            "start_logit": 9.9609375,
            "end_logit": 10.015625,
            "text": "28 joints",
            "probability": 1.0
        },
        {
            "start_logit": -0.94189453125,
            "end_logit": 10.015625,
            "text": "joints",
            "probability": 1.8477439880371094e-05
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -1.9248046875,
            "text": "28",
            "probability": 6.616115570068359e-06
        },
        {
            "start_logit": -7.3671875,
            "end_logit": 10.015625,
            "text": "in 28 joints",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 10.015625,
            "text": "Comparison of Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -7.96484375,
            "text": "28 joints with ESR",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.25,
            "text": "28 joints with ESR (DAS28), Clinical Disease Activity Index (CDAI), Health Assessment Questionnaire Disability Index (HAQ-DI) & Routine Assessment of Patient Index Data with 3 measures (RAPID3",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.2578125,
            "text": "28 joints with ESR (DAS28), Clinical Disease Activity Index (CDAI), Health Assessment Questionnaire Disability Index (HAQ-DI) & Routine Assessment of Patient Index Data with 3 measures (RAPID3) for assessing disease activity in",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.2734375,
            "text": "28 joints with ESR (DAS28), Clinical Disease Activity Index (",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.2890625,
            "text": "28 joints with ESR (DAS28), Clinical Disease Activity Index (CDAI), Health Assessment Questionnaire Disability Index (HAQ-DI) & Routine Assessment of Patient Index Data with 3 measures (RAPID3) for assessing disease activity",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.2890625,
            "text": "28 joints with",
            "probability": 0.0
        },
        {
            "start_logit": -0.94189453125,
            "end_logit": -7.96484375,
            "text": "joints with ESR",
            "probability": 0.0
        },
        {
            "start_logit": -0.94189453125,
            "end_logit": -8.25,
            "text": "joints with ESR (DAS28), Clinical Disease Activity Index (CDAI), Health Assessment Questionnaire Disability Index (HAQ-DI) & Routine Assessment of Patient Index Data with 3 measures (RAPID3",
            "probability": 0.0
        },
        {
            "start_logit": -0.94189453125,
            "end_logit": -8.2578125,
            "text": "joints with ESR (DAS28), Clinical Disease Activity Index (CDAI), Health Assessment Questionnaire Disability Index (HAQ-DI) & Routine Assessment of Patient Index Data with 3 measures (RAPID3) for assessing disease activity in",
            "probability": 0.0
        },
        {
            "start_logit": -0.94189453125,
            "end_logit": -8.2734375,
            "text": "joints with ESR (DAS28), Clinical Disease Activity Index (",
            "probability": 0.0
        },
        {
            "start_logit": -0.94189453125,
            "end_logit": -8.2890625,
            "text": "joints with ESR (DAS28), Clinical Disease Activity Index (CDAI), Health Assessment Questionnaire Disability Index (HAQ-DI) & Routine Assessment of Patient Index Data with 3 measures (RAPID3) for assessing disease activity",
            "probability": 0.0
        },
        {
            "start_logit": -0.94189453125,
            "end_logit": -8.2890625,
            "text": "joints with",
            "probability": 0.0
        },
        {
            "start_logit": -7.3671875,
            "end_logit": -1.9248046875,
            "text": "in 28",
            "probability": 0.0
        },
        {
            "start_logit": -7.97265625,
            "end_logit": -1.9248046875,
            "text": "Comparison of Disease Activity Score in 28",
            "probability": 0.0
        },
        {
            "start_logit": -7.3671875,
            "end_logit": -7.96484375,
            "text": "in 28 joints with ESR",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_12": [
        {
            "start_logit": 9.953125,
            "end_logit": 9.90625,
            "text": "28 joints",
            "probability": 1.0
        },
        {
            "start_logit": -1.2861328125,
            "end_logit": 9.90625,
            "text": "joints",
            "probability": 1.3113021850585938e-05
        },
        {
            "start_logit": 9.953125,
            "end_logit": -1.9384765625,
            "text": "28",
            "probability": 7.212162017822266e-06
        },
        {
            "start_logit": -6.53515625,
            "end_logit": 9.90625,
            "text": "in 28 joints",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 9.90625,
            "text": "the Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.0859375,
            "text": "28 joints (",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.1875,
            "text": "28 joints (DAS28) were",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.1875,
            "text": "28 joints (DAS28)",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.1953125,
            "text": "28 joints (DAS28",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.90625,
            "text": "Clinical Disease Activity Index (CDAI) scores, and the Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.265625,
            "text": "28 joints (DAS",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 9.90625,
            "text": "and the Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.90625,
            "text": "Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.90625,
            "text": "(CDAI) scores, and the Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.90625,
            "text": "scores, and the Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.90625,
            "text": "Simplified Disease Activity Index (SDAI) scores, Clinical Disease Activity Index (CDAI) scores, and the Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.3515625,
            "text": "28 joints (DAS28) were calculated using data from tocilizumab trials in patients with RA in whom disease had remained active despite treatment with disease-modifying antirheu",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.359375,
            "text": "28 joints (DAS28) were calculated using data from tocilizumab trials in patients with RA",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.3671875,
            "text": "28 joints (DAS28) were calculated using data from tocilizumab trials in patients with RA in whom disease had remained active despite treatment with disease-modifying antirheumatic",
            "probability": 0.0
        },
        {
            "start_logit": -6.53515625,
            "end_logit": -1.9384765625,
            "text": "in 28",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_13": [
        {
            "start_logit": 9.9140625,
            "end_logit": 9.9375,
            "text": "28 joints",
            "probability": 1.0
        },
        {
            "start_logit": -1.18359375,
            "end_logit": 9.9375,
            "text": "joints",
            "probability": 1.519918441772461e-05
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -2.044921875,
            "text": "28",
            "probability": 6.318092346191406e-06
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -7.875,
            "text": "28 joints (",
            "probability": 0.0
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 9.9375,
            "text": "in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -7.94921875,
            "text": "28 joints (DAS",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.0078125,
            "text": "28 joints (DAS28",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.0546875,
            "text": "28 joints (DAS28)-remission has not",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.0546875,
            "text": "28 joints (DAS28)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.0703125,
            "text": "28 joints (DAS28)-remission",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.1015625,
            "text": "28 joints (DAS28)-remission has not been included among American College of Rheumatology/European League Against Rheumatism definitions, because of its association with significant residual disease activity, partly",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.140625,
            "text": "28 joints (DAS28)-remission has not been included among American College of Rheumatology/European League Against Rheumatism definitions, because of its association with significant residual disease activity, partly due to high weighting of acute-phase reactants (",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.140625,
            "text": "28 joints (DAS28)-remission has not been included among",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.1484375,
            "text": "28 joints (DAS28)-remission has not been included among American College of Rheumatology/European League Against Rheumatism definitions, because of its association with significant residual disease activity, partly due to high weighting of acute-phase",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.15625,
            "text": "28 joints (DAS28)-remission has not been included among American College of Rheumatology/European League Against Rheumatism definitions, because of its association with significant residual disease activity, partly due to high weighting of acute-phase reactants (APR",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.1640625,
            "text": "28 joints (DAS28)-remission has not been included among American College of Rheumatology/European League Against Rheumatism definitions, because of its association with significant residual disease activity, partly due to high weighting of acute-phase reactants",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.171875,
            "text": "28 joints (DAS28)-remission has not been included among American College of Rheumatology/European League Against Rheumatism definitions, because of its association with significant residual disease activity, partly due",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.171875,
            "text": "28 joints (DAS28)-remission has not been included",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.1875,
            "text": "28 joints (DAS28)-remission has not been included among American College of Rheumatology/European League Against Rheumatism definitions",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.1875,
            "text": "28 joints (DAS28)-remission has not been included among American College of Rheumatology/European League Against Rheumatism definitions, because of its association with significant residual disease activity",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_14": [
        {
            "start_logit": 9.9609375,
            "end_logit": 9.9765625,
            "text": "28 joints",
            "probability": 1.0
        },
        {
            "start_logit": -1.03515625,
            "end_logit": 9.9765625,
            "text": "joints",
            "probability": 1.6689300537109375e-05
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -1.93359375,
            "text": "28",
            "probability": 6.735324859619141e-06
        },
        {
            "start_logit": -7.7109375,
            "end_logit": 9.9765625,
            "text": "of 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -7.77734375,
            "text": "28 joints with C-reactive protein (DAS)28",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.015625,
            "text": "28 joints with C-reactive protein (DAS",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.078125,
            "text": "28 joints with C-reactive protein (DAS)28-CRP",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.9765625,
            "text": "(bDMARDs) and in low or moderate Disease Activity Score of 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.9765625,
            "text": "moderate Disease Activity Score of 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.9765625,
            "text": ") and in low or moderate Disease Activity Score of 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.25,
            "text": "28 joints with C-reactive protein (DAS)28-CRP)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.2578125,
            "text": "28 joints with",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.9765625,
            "text": "patients were na\u00efve to biological disease-modifying anti-rheumatic drugs (bDMARDs) and in low or moderate Disease Activity Score of 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.265625,
            "text": "28 joints with C-reactive protein (DAS)28-",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.9765625,
            "text": "were na\u00efve to biological disease-modifying anti-rheumatic drugs (bDMARDs) and in low or moderate Disease Activity Score of 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.9765625,
            "text": "in low or moderate Disease Activity Score of 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.9765625,
            "text": "All patients were na\u00efve to biological disease-modifying anti-rheumatic drugs (bDMARDs) and in low or moderate Disease Activity Score of 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.9765625,
            "text": "to biological disease-modifying anti-rheumatic drugs (bDMARDs) and in low or moderate Disease Activity Score of 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.9765625,
            "text": "or moderate Disease Activity Score of 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.34375,
            "text": "28 joints with C-reactive",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_15": [
        {
            "start_logit": 9.9296875,
            "end_logit": 9.9375,
            "text": "28 Joints",
            "probability": 1.0
        },
        {
            "start_logit": -1.2080078125,
            "end_logit": 9.9375,
            "text": "Joints",
            "probability": 1.4424324035644531e-05
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -2.0078125,
            "text": "28",
            "probability": 6.4373016357421875e-06
        },
        {
            "start_logit": -7.734375,
            "end_logit": 9.9375,
            "text": "in 28 Joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.0859375,
            "text": "28 Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid art",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.0859375,
            "text": "28 Joints (",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.9375,
            "text": "Disease Activity Score in 28 Joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.21875,
            "text": "28 Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.9375,
            "text": ": Disease Activity Score in 28 Joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.375,
            "text": "28 Joints (DAS",
            "probability": 0.0
        },
        {
            "start_logit": -1.2080078125,
            "end_logit": -8.0859375,
            "text": "Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid art",
            "probability": 0.0
        },
        {
            "start_logit": -1.2080078125,
            "end_logit": -8.0859375,
            "text": "Joints (",
            "probability": 0.0
        },
        {
            "start_logit": -1.2080078125,
            "end_logit": -8.21875,
            "text": "Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid",
            "probability": 0.0
        },
        {
            "start_logit": -1.2080078125,
            "end_logit": -8.375,
            "text": "Joints (DAS",
            "probability": 0.0
        },
        {
            "start_logit": -7.734375,
            "end_logit": -2.0078125,
            "text": "in 28",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -2.0078125,
            "text": "Disease Activity Score in 28",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -2.0078125,
            "text": ": Disease Activity Score in 28",
            "probability": 0.0
        },
        {
            "start_logit": -7.734375,
            "end_logit": -8.0859375,
            "text": "in 28 Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid art",
            "probability": 0.0
        },
        {
            "start_logit": -7.734375,
            "end_logit": -8.0859375,
            "text": "in 28 Joints (",
            "probability": 0.0
        },
        {
            "start_logit": -7.734375,
            "end_logit": -8.21875,
            "text": "in 28 Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_16": [
        {
            "start_logit": 9.9296875,
            "end_logit": 9.9375,
            "text": "28 joints",
            "probability": 1.0
        },
        {
            "start_logit": -1.205078125,
            "end_logit": 9.9375,
            "text": "joints",
            "probability": 1.4483928680419922e-05
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -2.001953125,
            "text": "28",
            "probability": 6.496906280517578e-06
        },
        {
            "start_logit": -7.90234375,
            "end_logit": 9.9375,
            "text": "in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.140625,
            "text": "28 joints (",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.9375,
            "text": "The Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.9375,
            "text": "Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.328125,
            "text": "28 joints (DAS",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.3671875,
            "text": "28 joints (DAS28)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.3671875,
            "text": "28 joints (DAS28) is",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.3671875,
            "text": "28 joints (DAS28",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.3671875,
            "text": "28 joints (DAS28) is a key measure in clinical practice and",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.375,
            "text": "28 joints (DAS28) is a key measure in clinical practice",
            "probability": 0.0
        },
        {
            "start_logit": -1.205078125,
            "end_logit": -8.140625,
            "text": "joints (",
            "probability": 0.0
        },
        {
            "start_logit": -1.205078125,
            "end_logit": -8.328125,
            "text": "joints (DAS",
            "probability": 0.0
        },
        {
            "start_logit": -1.205078125,
            "end_logit": -8.3671875,
            "text": "joints (DAS28)",
            "probability": 0.0
        },
        {
            "start_logit": -1.205078125,
            "end_logit": -8.3671875,
            "text": "joints (DAS28) is",
            "probability": 0.0
        },
        {
            "start_logit": -1.205078125,
            "end_logit": -8.3671875,
            "text": "joints (DAS28",
            "probability": 0.0
        },
        {
            "start_logit": -1.205078125,
            "end_logit": -8.3671875,
            "text": "joints (DAS28) is a key measure in clinical practice and",
            "probability": 0.0
        },
        {
            "start_logit": -1.205078125,
            "end_logit": -8.375,
            "text": "joints (DAS28) is a key measure in clinical practice",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_17": [
        {
            "start_logit": 9.9375,
            "end_logit": 9.9296875,
            "text": "28 joints",
            "probability": 1.0
        },
        {
            "start_logit": -1.236328125,
            "end_logit": 9.9296875,
            "text": "joints",
            "probability": 1.3947486877441406e-05
        },
        {
            "start_logit": 9.9375,
            "end_logit": -1.9853515625,
            "text": "28",
            "probability": 6.616115570068359e-06
        },
        {
            "start_logit": -7.63671875,
            "end_logit": 9.9296875,
            "text": "including 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.9296875,
            "text": "The Disease Activity Score including 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 9.9296875,
            "text": "Disease Activity Score including 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.28125,
            "text": "28 joints (DAS28) and the Clinical Disease Activity Index (CDAI) were developed in order to provide a quantifiable measure of rheumatoid arthritis",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.296875,
            "text": "28 joints (",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.3046875,
            "text": "28 joints (DAS28) and the Clinical Disease Activity Index (CDAI) were developed in order to provide a quantifiable measure of rheumatoid arthritis (RA",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.328125,
            "text": "28 joints (DAS28) and the Clinical Disease Activity Index (CDAI) were",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.3671875,
            "text": "28 joints (DAS28)",
            "probability": 0.0
        },
        {
            "start_logit": -1.236328125,
            "end_logit": -8.28125,
            "text": "joints (DAS28) and the Clinical Disease Activity Index (CDAI) were developed in order to provide a quantifiable measure of rheumatoid arthritis",
            "probability": 0.0
        },
        {
            "start_logit": -1.236328125,
            "end_logit": -8.296875,
            "text": "joints (",
            "probability": 0.0
        },
        {
            "start_logit": -1.236328125,
            "end_logit": -8.3046875,
            "text": "joints (DAS28) and the Clinical Disease Activity Index (CDAI) were developed in order to provide a quantifiable measure of rheumatoid arthritis (RA",
            "probability": 0.0
        },
        {
            "start_logit": -1.236328125,
            "end_logit": -8.328125,
            "text": "joints (DAS28) and the Clinical Disease Activity Index (CDAI) were",
            "probability": 0.0
        },
        {
            "start_logit": -1.236328125,
            "end_logit": -8.3671875,
            "text": "joints (DAS28)",
            "probability": 0.0
        },
        {
            "start_logit": -7.63671875,
            "end_logit": -1.9853515625,
            "text": "including 28",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -1.9853515625,
            "text": "The Disease Activity Score including 28",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -1.9853515625,
            "text": "Disease Activity Score including 28",
            "probability": 0.0
        },
        {
            "start_logit": -7.63671875,
            "end_logit": -8.28125,
            "text": "including 28 joints (DAS28) and the Clinical Disease Activity Index (CDAI) were developed in order to provide a quantifiable measure of rheumatoid arthritis",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_18": [
        {
            "start_logit": 9.9609375,
            "end_logit": 9.9453125,
            "text": "28 joints",
            "probability": 1.0
        },
        {
            "start_logit": -1.18359375,
            "end_logit": 9.9453125,
            "text": "joints",
            "probability": 1.4483928680419922e-05
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -1.9208984375,
            "text": "28",
            "probability": 7.033348083496094e-06
        },
        {
            "start_logit": -6.2578125,
            "end_logit": 9.9453125,
            "text": "on 28 joints",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -7.6484375,
            "text": "28 joints (",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": 9.9453125,
            "text": "based on 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.9453125,
            "text": "The Disease Activity Score based on 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.15625,
            "text": "28 joints (DAS28) has been increasingly used in clinical practice and research studies of",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.1640625,
            "text": "28 joints (DAS28) has been increasingly used in clinical practice",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.171875,
            "text": "28 joints (DAS28) has been increasingly used in clinical practice and research studies of rheumatoid",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.1875,
            "text": "28 joints (DAS",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.203125,
            "text": "28 joints (DAS28)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.203125,
            "text": "28 joints (DAS28) has",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.203125,
            "text": "28 joints (DAS28) has been increasingly used in clinical practice and research studies of rheumatoid arth",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.9453125,
            "text": "Disease Activity Score based on 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.2265625,
            "text": "28 joints (DAS28) has been increasingly used in clinical practice and research studies",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.2265625,
            "text": "28 joints (DAS28) has been increasingly",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.265625,
            "text": "28 joints (DAS28) has been",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.265625,
            "text": "28 joints (DAS28",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.265625,
            "text": "28 joints (DAS28) has been increasingly used in clinical practice and research",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_19": [
        {
            "start_logit": 9.9765625,
            "end_logit": 9.9375,
            "text": "28 joints",
            "probability": 1.0
        },
        {
            "start_logit": -1.2080078125,
            "end_logit": 9.9375,
            "text": "joints",
            "probability": 1.3947486877441406e-05
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -1.890625,
            "text": "28",
            "probability": 7.331371307373047e-06
        },
        {
            "start_logit": -6.8984375,
            "end_logit": 9.9375,
            "text": "including 28 joints",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.046875,
            "text": "28 joints (",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.1796875,
            "text": "28 joints (DAS28) compared with the Clinical Disease Activity Index (CD",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.1796875,
            "text": "28 joints (DAS28) compared",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 9.9375,
            "text": "the Disease Activity Score including 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.2734375,
            "text": "28 joints (DAS28",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.2890625,
            "text": "28 joints (DAS28) compared with the Clinical Disease Activity Index (CDAI)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.2890625,
            "text": "28 joints (DAS28) compared with the Clinical Disease Activity",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.9375,
            "text": "reliability and congruency of the Disease Activity Score including 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.3046875,
            "text": "28 joints (DAS",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.9375,
            "text": "of the Disease Activity Score including 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.9375,
            "text": "and congruency of the Disease Activity Score including 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.9375,
            "text": "congruency of the Disease Activity Score including 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": 9.9375,
            "text": "ency of the Disease Activity Score including 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -6.8984375,
            "end_logit": -1.890625,
            "text": "including 28",
            "probability": 0.0
        },
        {
            "start_logit": -1.2080078125,
            "end_logit": -8.046875,
            "text": "joints (",
            "probability": 0.0
        },
        {
            "start_logit": -1.2080078125,
            "end_logit": -8.1796875,
            "text": "joints (DAS28) compared with the Clinical Disease Activity Index (CD",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_20": [
        {
            "start_logit": 9.9375,
            "end_logit": 10.0234375,
            "text": "28 joints",
            "probability": 1.0
        },
        {
            "start_logit": -0.91259765625,
            "end_logit": 10.0234375,
            "text": "joints",
            "probability": 1.9252300262451172e-05
        },
        {
            "start_logit": 9.9375,
            "end_logit": -1.9912109375,
            "text": "28",
            "probability": 6.020069122314453e-06
        },
        {
            "start_logit": -7.72265625,
            "end_logit": 10.0234375,
            "text": "in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 10.0234375,
            "text": "Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.21875,
            "text": "28 joints calculated",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.265625,
            "text": "28 joints calculated with C-reactive protein (DAS28",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.265625,
            "text": "28 joints calculated with C-reactive protein (DAS28-CRP) is used instead of erythrocyte sedimentation rate (DAS28-ESR) to assess rheumatoid arthritis disease activity; however, values for remission and low disease activity (LDA) for DAS28",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.2734375,
            "text": "28 joints calculated with C-reactive protein (DAS28-CRP) is used instead of erythrocyte sedimentation rate (DAS28-ESR) to assess rheumatoid arthritis disease activity; however, values for remission and low disease activity (LDA)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.28125,
            "text": "28 joints calculated with C-reactive protein (DAS28-CRP) is used instead",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.28125,
            "text": "28 joints calculated with C-reactive protein (DAS28-CRP) is used instead of erythrocyte sedimentation rate (DAS28-ESR) to assess rheumatoid arthritis disease activity; however, values for remission and low disease activity (LDA) for DAS",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.2890625,
            "text": "28 joints calculated with C-reactive protein (DAS28-CRP) is used instead of erythrocyte sedimentation rate (DAS28-ESR) to assess rheumatoid arthritis disease activity",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.3046875,
            "text": "28 joints calculated with C-reactive protein (DAS28-CRP) is used instead of erythrocyte sedimentation rate (DAS28-ESR) to assess rheumatoid arthritis disease activity; however, values for remission and low disease activity (",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.3046875,
            "text": "28 joints calculated with C-reactive protein (DAS28-CRP) is used instead of erythrocyte sedimentation rate (DAS28-ESR) to assess rheumatoid arthritis disease activity; however, values for remission and low disease activity",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.3125,
            "text": "28 joints calculated with C-reactive protein (DAS28-CRP) is used instead of erythrocyte sedimentation rate (DAS28-ESR) to assess rheumatoid arthritis disease activity; however, values for remission and low disease",
            "probability": 0.0
        },
        {
            "start_logit": -0.91259765625,
            "end_logit": -8.21875,
            "text": "joints calculated",
            "probability": 0.0
        },
        {
            "start_logit": -0.91259765625,
            "end_logit": -8.265625,
            "text": "joints calculated with C-reactive protein (DAS28",
            "probability": 0.0
        },
        {
            "start_logit": -0.91259765625,
            "end_logit": -8.265625,
            "text": "joints calculated with C-reactive protein (DAS28-CRP) is used instead of erythrocyte sedimentation rate (DAS28-ESR) to assess rheumatoid arthritis disease activity; however, values for remission and low disease activity (LDA) for DAS28",
            "probability": 0.0
        },
        {
            "start_logit": -0.91259765625,
            "end_logit": -8.2734375,
            "text": "joints calculated with C-reactive protein (DAS28-CRP) is used instead of erythrocyte sedimentation rate (DAS28-ESR) to assess rheumatoid arthritis disease activity; however, values for remission and low disease activity (LDA)",
            "probability": 0.0
        },
        {
            "start_logit": -0.91259765625,
            "end_logit": -8.28125,
            "text": "joints calculated with C-reactive protein (DAS28-CRP) is used instead",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_21": [
        {
            "start_logit": 9.890625,
            "end_logit": 10.0,
            "text": "28 joints",
            "probability": 1.0
        },
        {
            "start_logit": -0.95703125,
            "end_logit": 10.0,
            "text": "joints",
            "probability": 1.9550323486328125e-05
        },
        {
            "start_logit": 9.890625,
            "end_logit": -2.078125,
            "text": "28",
            "probability": 5.662441253662109e-06
        },
        {
            "start_logit": -7.33984375,
            "end_logit": 10.0,
            "text": "in 28 joints",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 10.0,
            "text": "To optimize use of the Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 10.0,
            "text": "optimize use of the Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": 10.0,
            "text": "use of the Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.0625,
            "text": "28 joints (DAS28) in",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 10.0,
            "text": "Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.078125,
            "text": "28 joints (",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 10.0,
            "text": "the Disease Activity Score in 28 joints",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.171875,
            "text": "28 joints (DAS28",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.2265625,
            "text": "28 joints (DAS",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.25,
            "text": "28 joints (DAS28) in early rheumatoid arthritis (RA) by",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.28125,
            "text": "28 joints (DAS28) in early rheumatoid arthritis (RA) by adding the \"squeeze test\" of forefeet.METHODS: The squeeze test is used to examine bilateral compression pain (BCP) across the metatarsophal",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.28125,
            "text": "28 joints (DAS28) in early rheumatoid arthritis (RA) by adding the \"squeeze test\" of forefeet",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.28125,
            "text": "28 joints (DAS28)",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.296875,
            "text": "28 joints (DAS28) in early rheumatoid arthritis",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.296875,
            "text": "28 joints (DAS28) in early rheumatoid arthritis (RA) by adding the \"squeeze test\" of forefeet.METHODS: The squeeze test is used to examine bilateral compression pain (BCP) across the metatarsoph",
            "probability": 0.0
        },
        {
            "start_logit": -0.95703125,
            "end_logit": -8.0625,
            "text": "joints (DAS28) in",
            "probability": 0.0
        }
    ],
    "5710a592cf1c32585100002a_1": [
        {
            "start_logit": 8.140625,
            "end_logit": 8.578125,
            "text": "CO2",
            "probability": 1.0
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 8.578125,
            "text": "/CO2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 8.578125,
            "text": "Upon infection of a mammalian host, Bacillus anthracis responds to host cues, and particularly to elevated temperature (37\u00b0C) and bicarbonate/CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 8.578125,
            "text": "temperature (37\u00b0C) and bicarbonate/CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 8.578125,
            "text": "elevated temperature (37\u00b0C) and bicarbonate/CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 8.578125,
            "text": "Bacillus anthracis responds to host cues, and particularly to elevated temperature (37\u00b0C) and bicarbonate/CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 8.578125,
            "text": "to elevated temperature (37\u00b0C) and bicarbonate/CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 8.578125,
            "text": ", and particularly to elevated temperature (37\u00b0C) and bicarbonate/CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 8.578125,
            "text": "infection of a mammalian host, Bacillus anthracis responds to host cues, and particularly to elevated temperature (37\u00b0C) and bicarbonate/CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.21875,
            "end_logit": 8.578125,
            "text": "to host cues, and particularly to elevated temperature (37\u00b0C) and bicarbonate/CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 8.578125,
            "text": "and bicarbonate/CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.234375,
            "end_logit": 8.578125,
            "text": "a mammalian host, Bacillus anthracis responds to host cues, and particularly to elevated temperature (37\u00b0C) and bicarbonate/CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 8.578125,
            "text": ") and bicarbonate/CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": 8.578125,
            "text": "host cues, and particularly to elevated temperature (37\u00b0C) and bicarbonate/CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 8.578125,
            "text": "of a mammalian host, Bacillus anthracis responds to host cues, and particularly to elevated temperature (37\u00b0C) and bicarbonate/CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.265625,
            "end_logit": 8.578125,
            "text": "(37\u00b0C) and bicarbonate/CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.140625,
            "end_logit": -8.3203125,
            "text": "CO2 concentrations, with increased expression of virulence factors that include the anthrax toxins and extracellular capsular layer.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.140625,
            "end_logit": -8.3515625,
            "text": "CO2 concentrations, with increased expression of virulence factors that include the anthrax toxins and extracellular capsular",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.140625,
            "end_logit": -8.3515625,
            "text": "CO2 concentrations, with increased expression of virulence factors that include the anthrax toxins and extracellular capsular layer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.140625,
            "end_logit": -8.3515625,
            "text": "CO2 concentrations, with increased expression of virulence factors that",
            "probability": 5.960464477539063e-08
        }
    ],
    "5710a592cf1c32585100002a_2": [
        {
            "start_logit": 8.5625,
            "end_logit": 8.203125,
            "text": "bicarbonate",
            "probability": 1.0
        },
        {
            "start_logit": 8.5625,
            "end_logit": -7.6953125,
            "text": "bicarbonate exhibited increased AtxA dimer/monomer ratios and increased AtxA activity, relative to cultures grown without added CO(2) /bicarbonate, suggesting that this host-associated signal enhances AtxA function by shifting the dimer/monomer equilibrium towards the dimeric state",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5625,
            "end_logit": -7.78515625,
            "text": "bicarbonate exhibited increased AtxA dimer/monomer ratios and increased AtxA activity, relative to cultures grown without added CO(2) /bicarbonate, suggesting that this host-associated signal enhances AtxA function by shifting the dimer/monomer equilibrium towards the dimeric",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5625,
            "end_logit": -7.80078125,
            "text": "bicarbonate exhibited increased AtxA dimer/monomer ratios and increased AtxA activity, relative to cultures grown without added CO(2) /bicarbonate, suggesting that this host-associated signal enhances AtxA function by",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5625,
            "end_logit": -7.83984375,
            "text": "bicarbonate exhibited increased AtxA dimer/monomer ratios and increased AtxA activity, relative to cultures grown without added CO(2) /bicarbonate, suggesting that this host-associated signal enhances AtxA function by shifting the dimer/monomer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5625,
            "end_logit": -7.859375,
            "text": "bicarbonate exhibited increased AtxA dimer/monomer ratios and increased AtxA activity, relative to cultures grown without added CO(2) /bicarbonate, suggesting that this host-associated signal enhances AtxA function by shifting the dimer/monomer equilibrium towards",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5625,
            "end_logit": -7.875,
            "text": "bicarbonate exhibited increased AtxA dimer/monomer ratios and increased AtxA activity, relative to cultures grown without added CO(2) /bicarbonate, suggesting that this host-associated signal enhances AtxA function",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5625,
            "end_logit": -7.91796875,
            "text": "bicarbonate exhibited increased AtxA dimer/monomer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5625,
            "end_logit": -7.93359375,
            "text": "bicarbonate exhibited increased AtxA dimer/monomer ratios and increased AtxA activity, relative to cultures grown without added CO(2) /bicarbonate, suggesting that this host-associated signal enhances AtxA function by shifting the dimer/monomer equilibrium",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5625,
            "end_logit": -7.953125,
            "text": "bicarbonate exhibited",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5625,
            "end_logit": -7.97265625,
            "text": "bicarbonate exhibited increased AtxA dimer/monomer ratios and increased AtxA activity, relative to cultures grown without added CO(2) /bicarbonate, suggesting that this host-associated signal enhances AtxA function by shifting the dimer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5625,
            "end_logit": -7.98828125,
            "text": "bicarbonate exhibited increased AtxA dimer/monomer ratios and increased AtxA activity, relative to cultures grown without added CO(2) /bicarbonate",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5625,
            "end_logit": -7.98828125,
            "text": "bicarbonate exhibited increased AtxA dimer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5625,
            "end_logit": -8.0,
            "text": "bicarbonate exhibited increased AtxA dimer/monomer ratios and increased AtxA activity, relative to cultures grown without added CO(2)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5625,
            "end_logit": -8.015625,
            "text": "bicarbonate exhibited increased AtxA dimer/monomer ratios and increased AtxA activity, relative to cultures grown without added CO(2) /bicarbonate,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.21875,
            "end_logit": 8.203125,
            "text": "CO(2) /bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3125,
            "end_logit": 8.203125,
            "text": "/bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 8.203125,
            "text": "elevated CO(2) /bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.4375,
            "end_logit": 8.203125,
            "text": "grown with elevated CO(2) /bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.46875,
            "end_logit": 8.203125,
            "text": "cultures grown with elevated CO(2) /bicarbonate",
            "probability": 5.960464477539063e-08
        }
    ],
    "5710a592cf1c32585100002a_3": [
        {
            "start_logit": 8.484375,
            "end_logit": 8.3359375,
            "text": "CO2",
            "probability": 1.0
        },
        {
            "start_logit": -7.52734375,
            "end_logit": 8.3359375,
            "text": "by CO2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.484375,
            "end_logit": -8.0546875,
            "text": "CO2, a signal",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.484375,
            "end_logit": -8.078125,
            "text": "CO2, a signal mimicking the host environment",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.484375,
            "end_logit": -8.1953125,
            "text": "CO2, a signal mimicking",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.484375,
            "end_logit": -8.2109375,
            "text": "CO2, a signal mimicking the host",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.484375,
            "end_logit": -8.2109375,
            "text": "CO2, a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 8.3359375,
            "text": "Transcription of the major Bacillus anthracis virulence genes is triggered by CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 8.3359375,
            "text": "virulence genes is triggered by CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 8.3359375,
            "text": "Bacillus anthracis virulence genes is triggered by CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3828125,
            "end_logit": 8.3359375,
            "text": "genes is triggered by CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.390625,
            "end_logit": 8.3359375,
            "text": "of the major Bacillus anthracis virulence genes is triggered by CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.40625,
            "end_logit": 8.3359375,
            "text": "major Bacillus anthracis virulence genes is triggered by CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.421875,
            "end_logit": 8.3359375,
            "text": "the major Bacillus anthracis virulence genes is triggered by CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.52734375,
            "end_logit": -8.0546875,
            "text": "by CO2, a signal",
            "probability": 0.0
        },
        {
            "start_logit": -7.52734375,
            "end_logit": -8.078125,
            "text": "by CO2, a signal mimicking the host environment",
            "probability": 0.0
        },
        {
            "start_logit": -7.52734375,
            "end_logit": -8.1953125,
            "text": "by CO2, a signal mimicking",
            "probability": 0.0
        },
        {
            "start_logit": -7.52734375,
            "end_logit": -8.2109375,
            "text": "by CO2, a signal mimicking the host",
            "probability": 0.0
        },
        {
            "start_logit": -7.52734375,
            "end_logit": -8.2109375,
            "text": "by CO2, a",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -8.0546875,
            "text": "Transcription of the major Bacillus anthracis virulence genes is triggered by CO2, a signal",
            "probability": 0.0
        }
    ],
    "5710a592cf1c32585100002a_4": [
        {
            "start_logit": 8.3515625,
            "end_logit": 8.453125,
            "text": "CO2",
            "probability": 1.0
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 8.453125,
            "text": "of CO2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 8.453125,
            "text": "presence of CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.109375,
            "end_logit": 8.453125,
            "text": "in presence of CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1875,
            "end_logit": 8.453125,
            "text": "in vitro in presence of CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": 8.453125,
            "text": ", in vitro in presence of CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -8.21875,
            "text": "CO2 and in vivo, AtxA is part of the sap and eag regulatory",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -8.234375,
            "text": "CO2 and in vivo, AtxA is part",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.34375,
            "end_logit": 8.453125,
            "text": "vitro in presence of CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -8.25,
            "text": "CO2 and in vivo, AtxA is part of the sap and eag regulatory network",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -8.25,
            "text": "CO2 and in vivo, AtxA is part of the sap",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -8.2734375,
            "text": "CO2 and in vivo, AtxA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6796875,
            "end_logit": -8.21875,
            "text": "of CO2 and in vivo, AtxA is part of the sap and eag regulatory",
            "probability": 0.0
        },
        {
            "start_logit": -7.6796875,
            "end_logit": -8.234375,
            "text": "of CO2 and in vivo, AtxA is part",
            "probability": 0.0
        },
        {
            "start_logit": -7.6796875,
            "end_logit": -8.25,
            "text": "of CO2 and in vivo, AtxA is part of the sap and eag regulatory network",
            "probability": 0.0
        },
        {
            "start_logit": -7.6796875,
            "end_logit": -8.25,
            "text": "of CO2 and in vivo, AtxA is part of the sap",
            "probability": 0.0
        },
        {
            "start_logit": -7.6796875,
            "end_logit": -8.2734375,
            "text": "of CO2 and in vivo, AtxA",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": -8.21875,
            "text": "presence of CO2 and in vivo, AtxA is part of the sap and eag regulatory",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": -8.234375,
            "text": "presence of CO2 and in vivo, AtxA is part",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": -8.25,
            "text": "presence of CO2 and in vivo, AtxA is part of the sap and eag regulatory network",
            "probability": 0.0
        }
    ],
    "5710a592cf1c32585100002a_5": [
        {
            "start_logit": 8.015625,
            "end_logit": 8.6328125,
            "text": "CO2",
            "probability": 1.0
        },
        {
            "start_logit": -7.08203125,
            "end_logit": 8.6328125,
            "text": "not CO2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.6953125,
            "end_logit": 8.6328125,
            "text": "temperature, not CO2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 8.6328125,
            "text": ", not CO2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.015625,
            "end_logit": -7.62890625,
            "text": "CO2/bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.359375,
            "end_logit": 8.6328125,
            "text": ": temperature, not CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3984375,
            "end_logit": 8.6328125,
            "text": "Bacillus anthracis: temperature, not CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.40625,
            "end_logit": 8.6328125,
            "text": "anthrax toxin activator gene (atxA) expression in Bacillus anthracis: temperature, not CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.40625,
            "end_logit": 8.6328125,
            "text": "in Bacillus anthracis: temperature, not CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.015625,
            "end_logit": -7.9921875,
            "text": "CO2/bicarbonate, affects AtxA synthesis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.015625,
            "end_logit": -7.9921875,
            "text": "CO2/bicarbonate, affects AtxA synthesis.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.015625,
            "end_logit": -8.09375,
            "text": "CO2/bicarbonate, affects AtxA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.015625,
            "end_logit": -8.15625,
            "text": "CO2/bicarbonate, affects At",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.08203125,
            "end_logit": -7.62890625,
            "text": "not CO2/bicarbonate",
            "probability": 0.0
        },
        {
            "start_logit": -7.03125,
            "end_logit": -7.9921875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.08203125,
            "end_logit": -7.9921875,
            "text": "not CO2/bicarbonate, affects AtxA synthesis",
            "probability": 0.0
        },
        {
            "start_logit": -7.08203125,
            "end_logit": -7.9921875,
            "text": "not CO2/bicarbonate, affects AtxA synthesis.",
            "probability": 0.0
        },
        {
            "start_logit": -7.08203125,
            "end_logit": -8.09375,
            "text": "not CO2/bicarbonate, affects AtxA",
            "probability": 0.0
        },
        {
            "start_logit": -7.08203125,
            "end_logit": -8.15625,
            "text": "not CO2/bicarbonate, affects At",
            "probability": 0.0
        },
        {
            "start_logit": -7.6953125,
            "end_logit": -7.62890625,
            "text": "temperature, not CO2/bicarbonate",
            "probability": 0.0
        }
    ],
    "5710a592cf1c32585100002a_6": [
        {
            "start_logit": 8.0625,
            "end_logit": 8.6484375,
            "text": "CO2",
            "probability": 1.0
        },
        {
            "start_logit": -8.0,
            "end_logit": 8.6484375,
            "text": "In atxA+ strains, expression of the toxin genes (pag, lef, and cya) is enhanced by two physiologically significant signals: elevated CO2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0,
            "end_logit": 8.6484375,
            "text": ", and cya) is enhanced by two physiologically significant signals: elevated CO2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.0625,
            "end_logit": -7.6171875,
            "text": "CO2/bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 8.6484375,
            "text": "elevated CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.21875,
            "end_logit": 8.6484375,
            "text": "by two physiologically significant signals: elevated CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": 8.6484375,
            "text": ", expression of the toxin genes (pag, lef, and cya) is enhanced by two physiologically significant signals: elevated CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3125,
            "end_logit": 8.6484375,
            "text": "enhanced by two physiologically significant signals: elevated CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.328125,
            "end_logit": 8.6484375,
            "text": "two physiologically significant signals: elevated CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.34375,
            "end_logit": 8.6484375,
            "text": ") is enhanced by two physiologically significant signals: elevated CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 8.6484375,
            "text": "atxA+ strains, expression of the toxin genes (pag, lef, and cya) is enhanced by two physiologically significant signals: elevated CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.359375,
            "end_logit": 8.6484375,
            "text": "expression of the toxin genes (pag, lef, and cya) is enhanced by two physiologically significant signals: elevated CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3984375,
            "end_logit": 8.6484375,
            "text": ", lef, and cya) is enhanced by two physiologically significant signals: elevated CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.40625,
            "end_logit": 8.6484375,
            "text": "of the toxin genes (pag, lef, and cya) is enhanced by two physiologically significant signals: elevated CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.421875,
            "end_logit": 8.6484375,
            "text": "physiologically significant signals: elevated CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0625,
            "end_logit": -8.078125,
            "text": "CO2/bicarbonate and temperature.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.05859375,
            "end_logit": -8.078125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -8.0,
            "end_logit": -7.6171875,
            "text": "In atxA+ strains, expression of the toxin genes (pag, lef, and cya) is enhanced by two physiologically significant signals: elevated CO2/bicarbonate",
            "probability": 0.0
        },
        {
            "start_logit": -8.0,
            "end_logit": -7.6171875,
            "text": ", and cya) is enhanced by two physiologically significant signals: elevated CO2/bicarbonate",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -7.6171875,
            "text": "elevated CO2/bicarbonate",
            "probability": 0.0
        }
    ],
    "5710a592cf1c32585100002a_7": [
        {
            "start_logit": 8.1015625,
            "end_logit": 8.609375,
            "text": "CO2",
            "probability": 1.0
        },
        {
            "start_logit": 8.1015625,
            "end_logit": -7.4375,
            "text": "CO2/bicarbonate",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 8.609375,
            "text": "by CO2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 8.609375,
            "text": "Our data indicate that atxA expression is not influenced by CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.234375,
            "end_logit": 8.609375,
            "text": "that atxA expression is not influenced by CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1015625,
            "end_logit": -7.80078125,
            "text": "CO2/bicarbonate levels. However, the steady-state level of atxA mRNA in cells grown in elevated CO2/bicarbonate at 37 degrees C is five",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1015625,
            "end_logit": -7.875,
            "text": "CO2/bicarbonate levels. However, the steady-state level of atxA mRNA in cells grown in elevated CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1015625,
            "end_logit": -7.875,
            "text": "CO2/bicarbonate levels. However, the steady-state level of atxA mRNA in cells grown in elevated CO2/bicarbonate at 37 degrees C is five- to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1015625,
            "end_logit": -7.91796875,
            "text": "CO2/bicarbonate levels. However, the steady-state level of atxA mRNA in cells grown in elevated CO2/bicarbonate at 37 degrees C is five- to sixfold higher than that observed",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1015625,
            "end_logit": -7.94921875,
            "text": "CO2/bicarbonate levels",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1015625,
            "end_logit": -7.98046875,
            "text": "CO2/bicarbonate levels. However, the steady-state level of atxA mRNA in cells grown in elevated CO2/bicarbonate at 37 degrees C is five- to sixfold higher than that observed in cells grown in the same conditions at 28 degrees C.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1015625,
            "end_logit": -7.98046875,
            "text": "CO2/bicarbonate levels.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1015625,
            "end_logit": -8.046875,
            "text": "CO2/bicarbonate levels. However, the steady-state level of atxA mRNA in cells grown in elevated CO2/bicarbonate at 37 degrees C is five- to six",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1015625,
            "end_logit": -8.0625,
            "text": "CO2/bicarbonate levels. However, the steady-state level of atxA mRNA in cells grown in elevated CO2/bicarbonate at 37 degrees C is five- to sixfold",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1015625,
            "end_logit": -8.0703125,
            "text": "CO2/bicarbonate levels. However, the steady-state level of atxA mRNA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1015625,
            "end_logit": -8.0859375,
            "text": "CO2/bicarbonate levels. However, the steady-state level of atxA mRNA in cells grown in elevated CO2/bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1015625,
            "end_logit": -8.09375,
            "text": "CO2/bicarbonate levels. However, the steady-state level of atxA mRNA in cells grown in elevated CO2/bicarbonate at 37 degrees C is five- to sixfold higher",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1015625,
            "end_logit": -8.09375,
            "text": "CO2/bicarbonate levels. However, the steady-state level of atxA mRNA in cells grown in elevated CO2/bicarbonate at 37 degrees C is five- to sixfold higher than that observed in cells grown in the same conditions",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1015625,
            "end_logit": -8.1015625,
            "text": "CO2/bicarbonate levels. However, the steady-state level of atxA mRNA in cells grown in elevated CO2/bicarbonate at 37 degrees C is five- to sixfold higher than that observed in cells grown in the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1015625,
            "end_logit": -8.1484375,
            "text": "CO2/bicarbonate levels. However, the steady-state",
            "probability": 5.960464477539063e-08
        }
    ],
    "5710a592cf1c32585100002a_8": [
        {
            "start_logit": -3.39453125,
            "end_logit": 8.4375,
            "text": "CO2",
            "probability": 0.8984375
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 8.4375,
            "text": ", CO2",
            "probability": 0.00850677490234375
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 8.4375,
            "text": ", can be viewed as a regulon, in which transcription of all three genes is activated in trans by the same regulatory gene, atxA, in response to the same signal, CO2",
            "probability": 0.00774383544921875
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 8.4375,
            "text": "viewed as a regulon, in which transcription of all three genes is activated in trans by the same regulatory gene, atxA, in response to the same signal, CO2",
            "probability": 0.00762176513671875
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 8.4375,
            "text": "which transcription of all three genes is activated in trans by the same regulatory gene, atxA, in response to the same signal, CO2",
            "probability": 0.00762176513671875
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 8.4375,
            "text": "transcription of all three genes is activated in trans by the same regulatory gene, atxA, in response to the same signal, CO2",
            "probability": 0.007389068603515625
        },
        {
            "start_logit": -8.21875,
            "end_logit": 8.4375,
            "text": "be viewed as a regulon, in which transcription of all three genes is activated in trans by the same regulatory gene, atxA, in response to the same signal, CO2",
            "probability": 0.0072174072265625
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 8.4375,
            "text": "to the same signal, CO2",
            "probability": 0.007160186767578125
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 8.4375,
            "text": "can be viewed as a regulon, in which transcription of all three genes is activated in trans by the same regulatory gene, atxA, in response to the same signal, CO2",
            "probability": 0.007045745849609375
        },
        {
            "start_logit": -8.25,
            "end_logit": 8.4375,
            "text": "the same signal, CO2",
            "probability": 0.006992340087890625
        },
        {
            "start_logit": -8.25,
            "end_logit": 8.4375,
            "text": "the same regulatory gene, atxA, in response to the same signal, CO2",
            "probability": 0.006992340087890625
        },
        {
            "start_logit": -8.265625,
            "end_logit": 8.4375,
            "text": "response to the same signal, CO2",
            "probability": 0.006885528564453125
        },
        {
            "start_logit": -8.265625,
            "end_logit": 8.4375,
            "text": "same signal, CO2",
            "probability": 0.006885528564453125
        },
        {
            "start_logit": -8.28125,
            "end_logit": 8.4375,
            "text": ", in which transcription of all three genes is activated in trans by the same regulatory gene, atxA, in response to the same signal, CO2",
            "probability": 0.006778717041015625
        },
        {
            "start_logit": -8.28125,
            "end_logit": 8.4375,
            "text": ", atxA, in response to the same signal, CO2",
            "probability": 0.006778717041015625
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -8.3203125,
            "text": ", can be viewed as a regulon, in which transcription of all three",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -8.328125,
            "text": ", can be viewed as a regulon, in which transcription of all three genes is activated in trans by the same regulatory gene, atxA, in response to the same signal",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -8.3203125,
            "text": "viewed as a regulon, in which transcription of all three",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -8.3203125,
            "text": "which transcription of all three",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -8.328125,
            "text": "viewed as a regulon, in which transcription of all three genes is activated in trans by the same regulatory gene, atxA, in response to the same signal",
            "probability": 0.0
        }
    ],
    "5710a592cf1c32585100002a_9": [
        {
            "start_logit": 8.171875,
            "end_logit": 8.609375,
            "text": "CO2",
            "probability": 1.0
        },
        {
            "start_logit": 8.171875,
            "end_logit": -7.52734375,
            "text": "CO2 and the toxin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.1875,
            "end_logit": 8.609375,
            "text": "Comparison of the resulting protein patterns indicated that synthesis of non-toxin proteins is influenced by growth in elevated CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 8.609375,
            "text": "elevated CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.609375,
            "text": "in elevated CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3125,
            "end_logit": 8.609375,
            "text": "protein patterns indicated that synthesis of non-toxin proteins is influenced by growth in elevated CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.328125,
            "end_logit": 8.609375,
            "text": "of the resulting protein patterns indicated that synthesis of non-toxin proteins is influenced by growth in elevated CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 8.609375,
            "text": "toxin proteins is influenced by growth in elevated CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.171875,
            "end_logit": -7.9296875,
            "text": "CO2 and the toxin gene",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.375,
            "end_logit": 8.609375,
            "text": "-toxin proteins is influenced by growth in elevated CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3984375,
            "end_logit": 8.609375,
            "text": "the resulting protein patterns indicated that synthesis of non-toxin proteins is influenced by growth in elevated CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.4140625,
            "end_logit": 8.609375,
            "text": "growth in elevated CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.4296875,
            "end_logit": 8.609375,
            "text": "of non-toxin proteins is influenced by growth in elevated CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.4375,
            "end_logit": 8.609375,
            "text": "non-toxin proteins is influenced by growth in elevated CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.4453125,
            "end_logit": 8.609375,
            "text": "resulting protein patterns indicated that synthesis of non-toxin proteins is influenced by growth in elevated CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.453125,
            "end_logit": 8.609375,
            "text": "proteins is influenced by growth in elevated CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.171875,
            "end_logit": -8.0390625,
            "text": "CO2 and the toxin gene regulator",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.171875,
            "end_logit": -8.09375,
            "text": "CO2 and the toxin gene regulator, atxA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.171875,
            "end_logit": -8.15625,
            "text": "CO2 and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.171875,
            "end_logit": -8.171875,
            "text": "CO2 and the toxin gene regulator, at",
            "probability": 5.960464477539063e-08
        }
    ],
    "5710a592cf1c32585100002a_10": [
        {
            "start_logit": 8.84375,
            "end_logit": 7.98828125,
            "text": "bicarbonate",
            "probability": 1.0
        },
        {
            "start_logit": -7.73046875,
            "end_logit": 7.98828125,
            "text": "by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.21875,
            "end_logit": 7.98828125,
            "text": "appeared to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.21875,
            "end_logit": 7.98828125,
            "text": "Transcription initiated from P1 and P2 was activated by both atxA and acpA, and activation appeared to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": 7.98828125,
            "text": "activation appeared to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.265625,
            "end_logit": 7.98828125,
            "text": "and activation appeared to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 7.98828125,
            "text": ", and activation appeared to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 7.98828125,
            "text": "from P1 and P2 was activated by both atxA and acpA, and activation appeared to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3125,
            "end_logit": 7.98828125,
            "text": "stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 7.98828125,
            "text": "both atxA and acpA, and activation appeared to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3671875,
            "end_logit": 7.98828125,
            "text": "atxA and acpA, and activation appeared to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.375,
            "end_logit": 7.98828125,
            "text": "and acpA, and activation appeared to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.375,
            "end_logit": 7.98828125,
            "text": "to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.390625,
            "end_logit": 7.98828125,
            "text": "A, and activation appeared to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.390625,
            "end_logit": 7.98828125,
            "text": "be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.1484375,
            "text": "Transcription initiated from P1 and",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.171875,
            "text": "Transcription initiated from P1 and P2 was",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.171875,
            "text": "Transcription initiated from P1",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.1875,
            "text": "Transcription initiated",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.203125,
            "text": "appeared to",
            "probability": 0.0
        }
    ],
    "5710a592cf1c32585100002a_11": [
        {
            "start_logit": 8.2890625,
            "end_logit": 8.46875,
            "text": "CO2",
            "probability": 1.0
        },
        {
            "start_logit": -7.35546875,
            "end_logit": 8.46875,
            "text": "to CO2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.2890625,
            "end_logit": -7.72265625,
            "text": "CO2 through an AtxA-dependent mechanism",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.2890625,
            "end_logit": -7.96875,
            "text": "CO2 through an AtxA-dependent",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 8.46875,
            "text": "Transcriptome analysis identifies Bacillus anthracis genes that respond to CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 8.46875,
            "text": "identifies Bacillus anthracis genes that respond to CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.2890625,
            "end_logit": -8.0625,
            "text": "CO2 through an AtxA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3125,
            "end_logit": 8.46875,
            "text": "analysis identifies Bacillus anthracis genes that respond to CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3125,
            "end_logit": 8.46875,
            "text": "Bacillus anthracis genes that respond to CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.2890625,
            "end_logit": -8.1640625,
            "text": "CO2 through",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.34375,
            "end_logit": 8.46875,
            "text": "respond to CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 8.46875,
            "text": "genes that respond to CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.390625,
            "end_logit": 8.46875,
            "text": "that respond to CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.35546875,
            "end_logit": -7.72265625,
            "text": "to CO2 through an AtxA-dependent mechanism",
            "probability": 0.0
        },
        {
            "start_logit": -7.35546875,
            "end_logit": -7.96875,
            "text": "to CO2 through an AtxA-dependent",
            "probability": 0.0
        },
        {
            "start_logit": -7.35546875,
            "end_logit": -8.0625,
            "text": "to CO2 through an AtxA",
            "probability": 0.0
        },
        {
            "start_logit": -7.35546875,
            "end_logit": -8.1640625,
            "text": "to CO2 through",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -7.72265625,
            "text": "Transcriptome analysis identifies Bacillus anthracis genes that respond to CO2 through an AtxA-dependent mechanism",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -7.72265625,
            "text": "identifies Bacillus anthracis genes that respond to CO2 through an AtxA-dependent mechanism",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": -7.72265625,
            "text": "analysis identifies Bacillus anthracis genes that respond to CO2 through an AtxA-dependent mechanism",
            "probability": 0.0
        }
    ],
    "5710a592cf1c32585100002a_12": [
        {
            "start_logit": 8.84375,
            "end_logit": 7.98828125,
            "text": "bicarbonate",
            "probability": 1.0
        },
        {
            "start_logit": -7.73046875,
            "end_logit": 7.98828125,
            "text": "by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.21875,
            "end_logit": 7.98828125,
            "text": "appeared to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.21875,
            "end_logit": 7.98828125,
            "text": "Transcription initiated from P1 and P2 was activated by both atxA and acpA, and activation appeared to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": 7.98828125,
            "text": "activation appeared to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.265625,
            "end_logit": 7.98828125,
            "text": "and activation appeared to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 7.98828125,
            "text": ", and activation appeared to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 7.98828125,
            "text": "from P1 and P2 was activated by both atxA and acpA, and activation appeared to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3125,
            "end_logit": 7.98828125,
            "text": "stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 7.98828125,
            "text": "both atxA and acpA, and activation appeared to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3671875,
            "end_logit": 7.98828125,
            "text": "atxA and acpA, and activation appeared to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.375,
            "end_logit": 7.98828125,
            "text": "and acpA, and activation appeared to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.375,
            "end_logit": 7.98828125,
            "text": "to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.390625,
            "end_logit": 7.98828125,
            "text": "A, and activation appeared to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.390625,
            "end_logit": 7.98828125,
            "text": "be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.1484375,
            "text": "Transcription initiated from P1 and",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.171875,
            "text": "Transcription initiated from P1 and P2 was",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.171875,
            "text": "Transcription initiated from P1",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.1875,
            "text": "Transcription initiated",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.203125,
            "text": "appeared to",
            "probability": 0.0
        }
    ],
    "5710a592cf1c32585100002a_13": [
        {
            "start_logit": 8.4609375,
            "end_logit": 8.34375,
            "text": "CO2",
            "probability": 1.0
        },
        {
            "start_logit": -6.7265625,
            "end_logit": 8.34375,
            "text": "to CO2",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -7.76171875,
            "text": "CO2 through an AtxA-dependent",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -7.8125,
            "text": "CO2 through an AtxA-dependent mechanism",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -7.890625,
            "text": "CO2 through an AtxA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -8.1328125,
            "text": "CO2 through an AtxA-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -8.15625,
            "text": "CO2 through an At",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.078125,
            "end_logit": 8.34375,
            "text": "Transcriptome analysis identifies Bacillus anthracis genes that respond to CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.265625,
            "end_logit": 8.34375,
            "text": "identifies Bacillus anthracis genes that respond to CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.34375,
            "text": "Bacillus anthracis genes that respond to CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.328125,
            "end_logit": 8.34375,
            "text": "genes that respond to CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 8.34375,
            "text": "analysis identifies Bacillus anthracis genes that respond to CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3671875,
            "end_logit": 8.34375,
            "text": "respond to CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.390625,
            "end_logit": 8.34375,
            "text": "that respond to CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.7265625,
            "end_logit": -7.76171875,
            "text": "to CO2 through an AtxA-dependent",
            "probability": 0.0
        },
        {
            "start_logit": -6.7265625,
            "end_logit": -7.8125,
            "text": "to CO2 through an AtxA-dependent mechanism",
            "probability": 0.0
        },
        {
            "start_logit": -6.7265625,
            "end_logit": -7.890625,
            "text": "to CO2 through an AtxA",
            "probability": 0.0
        },
        {
            "start_logit": -6.7265625,
            "end_logit": -8.1328125,
            "text": "to CO2 through an AtxA-",
            "probability": 0.0
        },
        {
            "start_logit": -6.7265625,
            "end_logit": -8.15625,
            "text": "to CO2 through an At",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": -7.76171875,
            "text": "Transcriptome analysis identifies Bacillus anthracis genes that respond to CO2 through an AtxA-dependent",
            "probability": 0.0
        }
    ],
    "5710a592cf1c32585100002a_14": [
        {
            "start_logit": 8.4453125,
            "end_logit": 8.3828125,
            "text": "CO2",
            "probability": 1.0
        },
        {
            "start_logit": -7.4375,
            "end_logit": 8.3828125,
            "text": "of CO2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 8.3828125,
            "text": "levels of CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.171875,
            "end_logit": 8.3828125,
            "text": "under elevated levels of CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 8.3828125,
            "text": "growth under elevated levels of CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 8.3828125,
            "text": "elevated levels of CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 8.3828125,
            "text": "during growth under elevated levels of CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.28125,
            "end_logit": 8.3828125,
            "text": "toxin genes by B. anthracis is enhanced during growth under elevated levels of CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.328125,
            "end_logit": 8.3828125,
            "text": "Expression of the toxin genes by B. anthracis is enhanced during growth under elevated levels of CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 8.3828125,
            "text": "enhanced during growth under elevated levels of CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.4296875,
            "end_logit": 8.3828125,
            "text": "the toxin genes by B. anthracis is enhanced during growth under elevated levels of CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -8.0390625,
            "text": "levels",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -8.0390625,
            "text": "under elevated levels",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": -8.0390625,
            "text": "growth under elevated levels",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -8.0390625,
            "text": "elevated levels",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -8.0390625,
            "text": "during growth under elevated levels",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": -8.0390625,
            "text": "toxin genes by B. anthracis is enhanced during growth under elevated levels",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -8.1953125,
            "text": "under elevated",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": -8.0390625,
            "text": "Expression of the toxin genes by B. anthracis is enhanced during growth under elevated levels",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": -8.0390625,
            "text": "enhanced during growth under elevated levels",
            "probability": 0.0
        }
    ],
    "5710a592cf1c32585100002a_15": [
        {
            "start_logit": 8.359375,
            "end_logit": 8.4296875,
            "text": "CO2",
            "probability": 1.0
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.015625,
            "text": "CO2 effect",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.03125,
            "text": "CO2 effect is observed only in the presence of another pXO1 gene, atxA, which encodes a transactivator of anthrax toxin synthesis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.0625,
            "text": "CO2 effect is observed only in the presence of another pXO1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.1171875,
            "text": "CO2 effect is observed only in the presence of another pXO1 gene, atxA, which encodes a transactivator of anthrax toxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.140625,
            "text": "CO2 effect is observed only in the presence of another pX",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 8.4296875,
            "text": "This CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.1640625,
            "text": "CO2 effect is observed only in the presence of another pXO1 gene, atxA, which encodes a trans",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.171875,
            "text": "CO2 effect is observed",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.171875,
            "text": "CO2 effect is observed only in the presence of another pXO1 gene, atxA, which encodes a transactivator",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.1875,
            "text": "CO2 effect is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.1953125,
            "text": "CO2 effect is observed only in the presence of another pXO1 gene",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.2109375,
            "text": "CO2 effect is observed only",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.2109375,
            "text": "CO2 effect is observed only in the presence of another pXO1 gene, atxA, which encodes a transactivator of anthrax",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.21875,
            "text": "CO2 effect is observed only in the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.359375,
            "end_logit": -8.21875,
            "text": "CO2 effect is observed only in the presence of another pXO1 gene, atxA, which encodes a transactivator of anthr",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.125,
            "end_logit": -8.015625,
            "text": "effect",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -8.03125,
            "text": "effect is observed only in the presence of another pXO1 gene, atxA, which encodes a transactivator of anthrax toxin synthesis",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -8.0625,
            "text": "effect is observed only in the presence of another pXO1",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -8.015625,
            "text": "This CO2 effect",
            "probability": 0.0
        }
    ],
    "5710a592cf1c32585100002a_16": [
        {
            "start_logit": 8.3046875,
            "end_logit": 8.5078125,
            "text": "CO2",
            "probability": 1.0
        },
        {
            "start_logit": -7.5546875,
            "end_logit": 8.5078125,
            "text": "% CO2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.9140625,
            "end_logit": 8.5078125,
            "text": "Here we show that transcription of atxA does not appear to differ in cells grown in 5% CO2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 8.5078125,
            "text": "in 5% CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -7.953125,
            "text": "CO2 compared with cells grown in air",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.234375,
            "end_logit": 8.5078125,
            "text": "cells grown in 5% CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 8.5078125,
            "text": "in cells grown in 5% CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 8.5078125,
            "text": "5% CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 8.5078125,
            "text": "grown in 5% CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 8.5078125,
            "text": "of atxA does not appear to differ in cells grown in 5% CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 8.5078125,
            "text": "we show that transcription of atxA does not appear to differ in cells grown in 5% CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.359375,
            "end_logit": 8.5078125,
            "text": "that transcription of atxA does not appear to differ in cells grown in 5% CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -8.1640625,
            "text": "CO2 compared with cells grown",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -8.2109375,
            "text": "CO2 compared with cells grown in air.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.19921875,
            "end_logit": -8.2109375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.5546875,
            "end_logit": -7.953125,
            "text": "% CO2 compared with cells grown in air",
            "probability": 0.0
        },
        {
            "start_logit": -7.5546875,
            "end_logit": -8.1640625,
            "text": "% CO2 compared with cells grown",
            "probability": 0.0
        },
        {
            "start_logit": -7.5546875,
            "end_logit": -8.2109375,
            "text": "% CO2 compared with cells grown in air.",
            "probability": 0.0
        },
        {
            "start_logit": -7.9140625,
            "end_logit": -7.953125,
            "text": "Here we show that transcription of atxA does not appear to differ in cells grown in 5% CO2 compared with cells grown in air",
            "probability": 0.0
        },
        {
            "start_logit": -7.9140625,
            "end_logit": -8.125,
            "text": "Here we show that transcription of atxA does not appear to differ",
            "probability": 0.0
        }
    ],
    "5710a592cf1c32585100002a_17": [
        {
            "start_logit": 8.921875,
            "end_logit": 7.87890625,
            "text": "bicarbonate",
            "probability": 1.0
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.34375,
            "text": "bicarbonate. Deletion analysis of the upstream region of the cap promoter revealed",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.56640625,
            "text": "bicarbonate. Deletion analysis of the upstream region of the cap promoter revealed that activation by both atxA and acpA required a DNA segment of 70 bp",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.83203125,
            "text": "bicarbonate. Deletion analysis of the upstream region of the cap promoter revealed that activation by both atxA and acpA required a DNA segment of 70 bp extending upstream of the P1",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.89453125,
            "text": "bicarbonate. Deletion analysis of the upstream region of the cap promoter revealed that activation by both atxA and acpA required a DNA segment of 70",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.9453125,
            "text": "bicarbonate. Deletion analysis of the upstream region of the cap promoter",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -8.015625,
            "text": "bicarbonate. Deletion analysis of the upstream region of the cap promoter revealed that activation by both atxA and acpA required a DNA segment of 70 bp extending upstream",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -8.0234375,
            "text": "bicarbonate. Deletion analysis of the upstream region of the cap promoter revealed that activation by both atxA and acpA required a DNA segment of 70 bp extending upstream of the P1 site",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -8.1015625,
            "text": "bicarbonate. Deletion analysis of the upstream region of the cap",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -8.1015625,
            "text": "bicarbonate. Deletion analysis of the upstream region of the cap promoter revealed that activation by both atxA and acpA required",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -8.15625,
            "text": "bicarbonate. Deletion analysis of the upstream region of the cap promoter revealed that activation by both atxA and acpA required a DNA segment",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -8.1796875,
            "text": "bicarbonate. Deletion analysis of the upstream region of the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -8.1796875,
            "text": "bicarbonate. Deletion analysis of the upstream",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -8.1953125,
            "text": "bicarbonate. Deletion analysis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -8.1953125,
            "text": "bicarbonate. Deletion analysis of the upstream region of",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -8.203125,
            "text": "bicarbonate. Deletion analysis of the upstream region of the cap promoter revealed that activation by both atxA and acpA required a DNA segment of 70 bp extending upstream of the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -8.21875,
            "text": "bicarbonate. Deletion analysis of the upstream region of the cap promoter revealed that activation",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.71484375,
            "end_logit": 7.87890625,
            "text": "by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 7.87890625,
            "text": "appeared to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 7.87890625,
            "text": "Transcription initiated from P1 and P2 was activated by both atxA and acpA, and activation appeared to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        }
    ],
    "5710a592cf1c32585100002a_18": [
        {
            "start_logit": 8.734375,
            "end_logit": 8.078125,
            "text": "bicarbonate",
            "probability": 1.0
        },
        {
            "start_logit": -7.12109375,
            "end_logit": 8.078125,
            "text": ". Transcription initiated from P1 and P2 was activated by both atxA and acpA, and activation appeared to be stimulated by bicarbonate",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.54296875,
            "end_logit": 8.078125,
            "text": "by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 8.078125,
            "text": "appeared to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.171875,
            "end_logit": 8.078125,
            "text": "to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1875,
            "end_logit": 8.078125,
            "text": "and activation appeared to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 8.078125,
            "text": ", and activation appeared to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 8.078125,
            "text": ", upstream of the translation-initiation codon of capB. Transcription initiated from P1 and P2 was activated by both atxA and acpA, and activation appeared to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 8.078125,
            "text": "activation appeared to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 8.078125,
            "text": "positions 731 bp and 625 bp, respectively, upstream of the translation-initiation codon of capB. Transcription initiated from P1 and P2 was activated by both atxA and acpA, and activation appeared to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.28125,
            "end_logit": 8.078125,
            "text": ", located at positions 731 bp and 625 bp, respectively, upstream of the translation-initiation codon of capB. Transcription initiated from P1 and P2 was activated by both atxA and acpA, and activation appeared to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 8.078125,
            "text": "and 625 bp, respectively, upstream of the translation-initiation codon of capB. Transcription initiated from P1 and P2 was activated by both atxA and acpA, and activation appeared to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.078125,
            "text": ", respectively, upstream of the translation-initiation codon of capB. Transcription initiated from P1 and P2 was activated by both atxA and acpA, and activation appeared to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.12109375,
            "end_logit": -8.1484375,
            "text": ". Transcription initiated from P1",
            "probability": 0.0
        },
        {
            "start_logit": -7.12109375,
            "end_logit": -8.1484375,
            "text": ". Transcription initiated from P1 and P2",
            "probability": 0.0
        },
        {
            "start_logit": -7.12109375,
            "end_logit": -8.1796875,
            "text": ". Transcription initiated from P1 and P2 was activated by both atxA",
            "probability": 0.0
        },
        {
            "start_logit": -7.12109375,
            "end_logit": -8.1875,
            "text": ". Transcription initiated from P1 and P2 was activated by both atxA and acpA, and activation appeared to be stimulated",
            "probability": 0.0
        },
        {
            "start_logit": -7.12109375,
            "end_logit": -8.203125,
            "text": ". Transcription initiated from P1 and",
            "probability": 0.0
        },
        {
            "start_logit": -7.12109375,
            "end_logit": -8.2109375,
            "text": ". Transcription",
            "probability": 0.0
        },
        {
            "start_logit": -7.12109375,
            "end_logit": -8.21875,
            "text": ". Transcription initiated from P1 and P2 was",
            "probability": 0.0
        }
    ],
    "5710a592cf1c32585100002a_19": [
        {
            "start_logit": 8.84375,
            "end_logit": 7.98828125,
            "text": "bicarbonate",
            "probability": 1.0
        },
        {
            "start_logit": -7.73046875,
            "end_logit": 7.98828125,
            "text": "by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.21875,
            "end_logit": 7.98828125,
            "text": "appeared to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.21875,
            "end_logit": 7.98828125,
            "text": "Transcription initiated from P1 and P2 was activated by both atxA and acpA, and activation appeared to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": 7.98828125,
            "text": "activation appeared to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.265625,
            "end_logit": 7.98828125,
            "text": "and activation appeared to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 7.98828125,
            "text": ", and activation appeared to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 7.98828125,
            "text": "from P1 and P2 was activated by both atxA and acpA, and activation appeared to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3125,
            "end_logit": 7.98828125,
            "text": "stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 7.98828125,
            "text": "both atxA and acpA, and activation appeared to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3671875,
            "end_logit": 7.98828125,
            "text": "atxA and acpA, and activation appeared to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.375,
            "end_logit": 7.98828125,
            "text": "and acpA, and activation appeared to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.375,
            "end_logit": 7.98828125,
            "text": "to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.390625,
            "end_logit": 7.98828125,
            "text": "A, and activation appeared to be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.390625,
            "end_logit": 7.98828125,
            "text": "be stimulated by bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.1484375,
            "text": "Transcription initiated from P1 and",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.171875,
            "text": "Transcription initiated from P1 and P2 was",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.171875,
            "text": "Transcription initiated from P1",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.1875,
            "text": "Transcription initiated",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.203125,
            "text": "appeared to",
            "probability": 0.0
        }
    ],
    "5710a592cf1c32585100002a_20": [
        {
            "start_logit": 8.015625,
            "end_logit": 8.6328125,
            "text": "CO2",
            "probability": 1.0
        },
        {
            "start_logit": -7.08203125,
            "end_logit": 8.6328125,
            "text": "not CO2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.6953125,
            "end_logit": 8.6328125,
            "text": "temperature, not CO2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 8.6328125,
            "text": ", not CO2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.015625,
            "end_logit": -7.62890625,
            "text": "CO2/bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.359375,
            "end_logit": 8.6328125,
            "text": ": temperature, not CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3984375,
            "end_logit": 8.6328125,
            "text": "Bacillus anthracis: temperature, not CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.40625,
            "end_logit": 8.6328125,
            "text": "anthrax toxin activator gene (atxA) expression in Bacillus anthracis: temperature, not CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.40625,
            "end_logit": 8.6328125,
            "text": "in Bacillus anthracis: temperature, not CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.015625,
            "end_logit": -7.9921875,
            "text": "CO2/bicarbonate, affects AtxA synthesis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.015625,
            "end_logit": -7.9921875,
            "text": "CO2/bicarbonate, affects AtxA synthesis.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.015625,
            "end_logit": -8.09375,
            "text": "CO2/bicarbonate, affects AtxA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.015625,
            "end_logit": -8.15625,
            "text": "CO2/bicarbonate, affects At",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.08203125,
            "end_logit": -7.62890625,
            "text": "not CO2/bicarbonate",
            "probability": 0.0
        },
        {
            "start_logit": -7.03125,
            "end_logit": -7.9921875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.08203125,
            "end_logit": -7.9921875,
            "text": "not CO2/bicarbonate, affects AtxA synthesis",
            "probability": 0.0
        },
        {
            "start_logit": -7.08203125,
            "end_logit": -7.9921875,
            "text": "not CO2/bicarbonate, affects AtxA synthesis.",
            "probability": 0.0
        },
        {
            "start_logit": -7.08203125,
            "end_logit": -8.09375,
            "text": "not CO2/bicarbonate, affects AtxA",
            "probability": 0.0
        },
        {
            "start_logit": -7.08203125,
            "end_logit": -8.15625,
            "text": "not CO2/bicarbonate, affects At",
            "probability": 0.0
        },
        {
            "start_logit": -7.6953125,
            "end_logit": -7.62890625,
            "text": "temperature, not CO2/bicarbonate",
            "probability": 0.0
        }
    ],
    "5a87ea1861bb38fb2400000d_1": [
        {
            "start_logit": 9.8671875,
            "end_logit": 9.3046875,
            "text": "circularized oligodeoxynucleotides",
            "probability": 1.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -2.15625,
            "text": "circular",
            "probability": 1.055002212524414e-05
        },
        {
            "start_logit": -2.66015625,
            "end_logit": 9.3046875,
            "text": "otides",
            "probability": 3.635883331298828e-06
        },
        {
            "start_logit": -4.98046875,
            "end_logit": 9.3046875,
            "text": "oligodeoxynucleotides",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -5.515625,
            "end_logit": 9.3046875,
            "text": "ized oligodeoxynucleotides",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -6.58984375,
            "text": "circularized oligodeoxynucleotides (coligos)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.1328125,
            "end_logit": 9.3046875,
            "text": "ynucleotides",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.453125,
            "text": "circularized oligodeoxynucleotides (coligo",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.609375,
            "text": "circularized oligodeoxynucleotides (coli",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.7109375,
            "text": "circularized oligodeoxynucleotides (coligos",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.875,
            "text": "circularized oligodeoxynucleotides (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.66015625,
            "end_logit": -6.58984375,
            "text": "otides (coligos)",
            "probability": 0.0
        },
        {
            "start_logit": -2.66015625,
            "end_logit": -7.453125,
            "text": "otides (coligo",
            "probability": 0.0
        },
        {
            "start_logit": -2.66015625,
            "end_logit": -7.609375,
            "text": "otides (coli",
            "probability": 0.0
        },
        {
            "start_logit": -2.66015625,
            "end_logit": -7.7109375,
            "text": "otides (coligos",
            "probability": 0.0
        },
        {
            "start_logit": -2.66015625,
            "end_logit": -7.875,
            "text": "otides (",
            "probability": 0.0
        },
        {
            "start_logit": -4.98046875,
            "end_logit": -6.58984375,
            "text": "oligodeoxynucleotides (coligos)",
            "probability": 0.0
        },
        {
            "start_logit": -5.515625,
            "end_logit": -6.58984375,
            "text": "ized oligodeoxynucleotides (coligos)",
            "probability": 0.0
        },
        {
            "start_logit": -4.98046875,
            "end_logit": -7.453125,
            "text": "oligodeoxynucleotides (coligo",
            "probability": 0.0
        },
        {
            "start_logit": -4.98046875,
            "end_logit": -7.609375,
            "text": "oligodeoxynucleotides (coli",
            "probability": 0.0
        }
    ],
    "530cf4e0c8a0b4a00c000006_1": [
        {
            "start_logit": 9.7890625,
            "end_logit": 9.4375,
            "text": "hypertrophic cardiomyopathy",
            "probability": 1.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -2.326171875,
            "text": "hypertrophic",
            "probability": 7.808208465576172e-06
        },
        {
            "start_logit": -2.447265625,
            "end_logit": 9.4375,
            "text": "cardiomyopathy",
            "probability": 4.887580871582031e-06
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -8.109375,
            "text": "hypertrophic cardiomyopathy (30",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -8.1484375,
            "text": "hypertrophic cardiomyopathy (30 %",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -8.34375,
            "text": "hypertrophic cardiomyopathy (30 %), followed by coronary artery anomalies (9",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -8.34375,
            "text": "hypertrophic cardiomyopathy (30 %), followed by coronary artery anomalies (9 %",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -8.34375,
            "text": "hypertrophic cardiomyopathy (30 %), followed by coronary artery anomalies (9 %), and myocarditis (9 %",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -8.3515625,
            "text": "hypertrophic cardiomyopathy (30 %), followed by coronary artery",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -8.3671875,
            "text": "hypertrophic cardiomyopathy (30 %), followed by coronary artery anomalies",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -8.375,
            "text": "hypertrophic cardiomyopathy (30 %), followed by coronary artery anomalies (9 %), and myocarditis (9",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -8.3828125,
            "text": "hypertrophic cardiomyopathy (30 %)",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -8.3828125,
            "text": "hypertrophic cardiomyopathy (30 %), followed by coronary artery anomalies (9 %)",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -8.390625,
            "text": "hypertrophic cardiomyopathy (30 %), followed by coronary artery anomalies (9 %), and myocarditis (9 %)",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -8.3984375,
            "text": "hypertrophic cardiomyopathy (30 %), followed by coronary artery anomalies (",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -8.3984375,
            "text": "hypertrophic cardiomyopathy (30 %), followed by coronary artery anomalies (9 %), and myocarditis",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.4375,
            "text": "was hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 9.4375,
            "text": "death was hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -2.326171875,
            "text": "was hypertrophic",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -2.326171875,
            "text": "death was hypertrophic",
            "probability": 0.0
        }
    ],
    "530cf4e0c8a0b4a00c000006_2": [
        {
            "start_logit": 9.828125,
            "end_logit": 9.4453125,
            "text": "hypertrophic cardiomyopathy",
            "probability": 1.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -2.2421875,
            "text": "hypertrophic",
            "probability": 8.344650268554688e-06
        },
        {
            "start_logit": -2.4375,
            "end_logit": 9.4453125,
            "text": "cardiomyopathy",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.0390625,
            "text": "hypertrophic cardiomyopathy (HCM)",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.09375,
            "text": "hypertrophic cardiomyopathy (HCM",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.15625,
            "text": "hypertrophic cardiomyopathy (HCM), is a genetic disorder responsible for more than a third",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.2578125,
            "text": "hypertrophic cardiomyopathy (HCM), is a genetic disorder responsible for more than a",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.28125,
            "text": "hypertrophic cardiomyopathy (",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.3515625,
            "text": "hypertrophic cardiomyopathy (HCM),",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.359375,
            "text": "hypertrophic cardiomyopathy (HCM), is a genetic disorder responsible for more than",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.3671875,
            "text": "hypertrophic cardiomyopathy (HCM), is a genetic disorder responsible for more than a third of cases",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.390625,
            "text": "hypertrophic cardiomyopathy (HCM), is a genetic disorder responsible for more than a third of cases and",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.390625,
            "text": "hypertrophic cardiomyopathy (HCM), is a genetic disorder responsible for more than a third of cases and is manageable",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 9.4453125,
            "text": ", hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.4453125,
            "text": "The most common cause of this, hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -2.2421875,
            "text": ", hypertrophic",
            "probability": 0.0
        },
        {
            "start_logit": -2.4375,
            "end_logit": -8.0390625,
            "text": "cardiomyopathy (HCM)",
            "probability": 0.0
        },
        {
            "start_logit": -2.4375,
            "end_logit": -8.09375,
            "text": "cardiomyopathy (HCM",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": -2.2421875,
            "text": "The most common cause of this, hypertrophic",
            "probability": 0.0
        },
        {
            "start_logit": -2.4375,
            "end_logit": -8.15625,
            "text": "cardiomyopathy (HCM), is a genetic disorder responsible for more than a third",
            "probability": 0.0
        }
    ],
    "530cf4e0c8a0b4a00c000006_3": [
        {
            "start_logit": 9.84375,
            "end_logit": 9.3671875,
            "text": "Hypertrophic cardiomyopathy",
            "probability": 1.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -2.21875,
            "text": "Hypertrophic",
            "probability": 9.238719940185547e-06
        },
        {
            "start_logit": -2.5703125,
            "end_logit": 9.3671875,
            "text": "cardiomyopathy",
            "probability": 4.0531158447265625e-06
        },
        {
            "start_logit": 9.84375,
            "end_logit": -7.9609375,
            "text": "Hypertrophic cardiomyopathy (HCM)",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.0546875,
            "text": "Hypertrophic cardiomyopathy (HCM",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.328125,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.3359375,
            "text": "Hypertrophic cardiomyopathy (",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.359375,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac death (SCD",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.375,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac death (SCD)",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.3828125,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac death",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.390625,
            "text": "Hypertrophic cardiomyopathy (HCM) is",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.3984375,
            "text": "Hypertrophic cardiomyopathy (HCM) is the",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.4140625,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac death (SCD) in",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.421875,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac death (SCD) in young",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.4296875,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.4375,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.4375,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most",
            "probability": 0.0
        },
        {
            "start_logit": -2.5703125,
            "end_logit": -7.9609375,
            "text": "cardiomyopathy (HCM)",
            "probability": 0.0
        },
        {
            "start_logit": -2.5703125,
            "end_logit": -8.0546875,
            "text": "cardiomyopathy (HCM",
            "probability": 0.0
        },
        {
            "start_logit": -2.5703125,
            "end_logit": -8.328125,
            "text": "cardiomyopathy (HCM) is the most common cause",
            "probability": 0.0
        }
    ],
    "530cf4e0c8a0b4a00c000006_4": [
        {
            "start_logit": 9.84375,
            "end_logit": 9.375,
            "text": "Hypertrophic cardiomyopathy",
            "probability": 1.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -2.228515625,
            "text": "Hypertrophic",
            "probability": 9.179115295410156e-06
        },
        {
            "start_logit": -2.564453125,
            "end_logit": 9.375,
            "text": "cardiomyopathy",
            "probability": 4.112720489501953e-06
        },
        {
            "start_logit": 9.84375,
            "end_logit": -7.86328125,
            "text": "Hypertrophic cardiomyopathy (HCM)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.84375,
            "end_logit": -7.99609375,
            "text": "Hypertrophic cardiomyopathy (HCM",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.2734375,
            "text": "Hypertrophic cardiomyopathy (",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.2890625,
            "text": "Hypertrophic cardiomyopathy (HCM) is regarded as the",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.2890625,
            "text": "Hypertrophic cardiomyopathy (HCM) is regarded as the most common cause",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.3359375,
            "text": "Hypertrophic cardiomyopathy (HCM) is regarded as the most",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.375,
            "text": "Hypertrophic cardiomyopathy (HCM) is regarded as",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.375,
            "text": "Hypertrophic cardiomyopathy (HCM) is regarded as the most common",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.40625,
            "text": "Hypertrophic cardiomyopathy (HCM) is",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.421875,
            "text": "Hypertrophic cardiomyopathy (HCM) is regarded as the most common cause of sudden cardiac death in",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.421875,
            "text": "Hypertrophic cardiomyopathy (HCM) is regarded as the most common cause of sudden cardiac death in young people (including trained athletes)",
            "probability": 0.0
        },
        {
            "start_logit": -2.564453125,
            "end_logit": -7.86328125,
            "text": "cardiomyopathy (HCM)",
            "probability": 0.0
        },
        {
            "start_logit": -2.564453125,
            "end_logit": -7.99609375,
            "text": "cardiomyopathy (HCM",
            "probability": 0.0
        },
        {
            "start_logit": -2.564453125,
            "end_logit": -8.2734375,
            "text": "cardiomyopathy (",
            "probability": 0.0
        },
        {
            "start_logit": -2.564453125,
            "end_logit": -8.2890625,
            "text": "cardiomyopathy (HCM) is regarded as the",
            "probability": 0.0
        },
        {
            "start_logit": -2.564453125,
            "end_logit": -8.2890625,
            "text": "cardiomyopathy (HCM) is regarded as the most common cause",
            "probability": 0.0
        },
        {
            "start_logit": -2.564453125,
            "end_logit": -8.3359375,
            "text": "cardiomyopathy (HCM) is regarded as the most",
            "probability": 0.0
        }
    ],
    "530cf4e0c8a0b4a00c000006_5": [
        {
            "start_logit": 9.84375,
            "end_logit": 9.3671875,
            "text": "Hypertrophic cardiomyopathy",
            "probability": 1.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -2.216796875,
            "text": "Hypertrophic",
            "probability": 9.238719940185547e-06
        },
        {
            "start_logit": -2.580078125,
            "end_logit": 9.3671875,
            "text": "cardiomyopathy",
            "probability": 3.993511199951172e-06
        },
        {
            "start_logit": 9.84375,
            "end_logit": -7.8203125,
            "text": "Hypertrophic cardiomyopathy (HCM)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.84375,
            "end_logit": -7.98828125,
            "text": "Hypertrophic cardiomyopathy (HCM",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.3125,
            "text": "Hypertrophic cardiomyopathy (",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.328125,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.3671875,
            "text": "Hypertrophic cardiomyopathy (HCM) is the",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.375,
            "text": "Hypertrophic cardiomyopathy (HCM) is",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.4140625,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.421875,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common",
            "probability": 0.0
        },
        {
            "start_logit": -2.580078125,
            "end_logit": -7.8203125,
            "text": "cardiomyopathy (HCM)",
            "probability": 0.0
        },
        {
            "start_logit": -2.580078125,
            "end_logit": -7.98828125,
            "text": "cardiomyopathy (HCM",
            "probability": 0.0
        },
        {
            "start_logit": -2.580078125,
            "end_logit": -8.3125,
            "text": "cardiomyopathy (",
            "probability": 0.0
        },
        {
            "start_logit": -2.580078125,
            "end_logit": -8.328125,
            "text": "cardiomyopathy (HCM) is the most common cause",
            "probability": 0.0
        },
        {
            "start_logit": -2.580078125,
            "end_logit": -8.3671875,
            "text": "cardiomyopathy (HCM) is the",
            "probability": 0.0
        },
        {
            "start_logit": -2.580078125,
            "end_logit": -8.375,
            "text": "cardiomyopathy (HCM) is",
            "probability": 0.0
        },
        {
            "start_logit": -2.580078125,
            "end_logit": -8.4140625,
            "text": "cardiomyopathy (HCM) is the most",
            "probability": 0.0
        },
        {
            "start_logit": -2.580078125,
            "end_logit": -8.421875,
            "text": "cardiomyopathy (HCM) is the most common",
            "probability": 0.0
        },
        {
            "start_logit": -7.9765625,
            "end_logit": -7.8203125,
            "text": "(HCM)",
            "probability": 0.0
        }
    ],
    "530cf4e0c8a0b4a00c000006_6": [
        {
            "start_logit": 9.8046875,
            "end_logit": 9.359375,
            "text": "Hypertrophic cardiomyopathy",
            "probability": 1.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -2.3046875,
            "text": "Hypertrophic",
            "probability": 8.64267349243164e-06
        },
        {
            "start_logit": -2.615234375,
            "end_logit": 9.359375,
            "text": "cardiomyopathy",
            "probability": 4.0531158447265625e-06
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.328125,
            "text": "Hypertrophic cardiomyopathy is regarded as the most common cause",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.375,
            "text": "Hypertrophic cardiomyopathy is regarded as the",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.3984375,
            "text": "Hypertrophic cardiomyopathy is regarded as the most",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.40625,
            "text": "Hypertrophic cardiomyopathy is regarded as",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.421875,
            "text": "Hypertrophic cardiomyopathy is regarded as the most common",
            "probability": 0.0
        },
        {
            "start_logit": -2.615234375,
            "end_logit": -8.328125,
            "text": "cardiomyopathy is regarded as the most common cause",
            "probability": 0.0
        },
        {
            "start_logit": -2.615234375,
            "end_logit": -8.375,
            "text": "cardiomyopathy is regarded as the",
            "probability": 0.0
        },
        {
            "start_logit": -2.615234375,
            "end_logit": -8.3984375,
            "text": "cardiomyopathy is regarded as the most",
            "probability": 0.0
        },
        {
            "start_logit": -2.615234375,
            "end_logit": -8.40625,
            "text": "cardiomyopathy is regarded as",
            "probability": 0.0
        },
        {
            "start_logit": -2.615234375,
            "end_logit": -8.421875,
            "text": "cardiomyopathy is regarded as the most common",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -8.328125,
            "text": "is regarded as the most common cause",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -8.328125,
            "text": "regarded as the most common cause",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -8.375,
            "text": "is regarded as the",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -8.3984375,
            "text": "is regarded as the most",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -8.375,
            "text": "regarded as the",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -8.40625,
            "text": "is regarded as",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -8.3984375,
            "text": "regarded as the most",
            "probability": 0.0
        }
    ],
    "530cf4e0c8a0b4a00c000006_7": [
        {
            "start_logit": 9.8046875,
            "end_logit": 9.375,
            "text": "hypertrophic cardiomyopathy",
            "probability": 1.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -2.2890625,
            "text": "hypertrophic",
            "probability": 8.52346420288086e-06
        },
        {
            "start_logit": -2.5703125,
            "end_logit": 9.375,
            "text": "cardiomyopathy",
            "probability": 4.172325134277344e-06
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.375,
            "text": "is hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 9.375,
            "text": "The most common cause of sudden cardiac death in athletes is hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.375,
            "text": "sudden cardiac death in athletes is hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.375,
            "text": "of sudden cardiac death in athletes is hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.375,
            "text": "cardiac death in athletes is hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.375,
            "text": "in athletes is hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.375,
            "text": "cause of sudden cardiac death in athletes is hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.375,
            "text": "common cause of sudden cardiac death in athletes is hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.375,
            "text": "athletes is hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.375,
            "text": "death in athletes is hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": -2.2890625,
            "text": "is hypertrophic",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -2.2890625,
            "text": "The most common cause of sudden cardiac death in athletes is hypertrophic",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -2.2890625,
            "text": "sudden cardiac death in athletes is hypertrophic",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -2.2890625,
            "text": "of sudden cardiac death in athletes is hypertrophic",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -2.2890625,
            "text": "cardiac death in athletes is hypertrophic",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -2.2890625,
            "text": "in athletes is hypertrophic",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -2.2890625,
            "text": "cause of sudden cardiac death in athletes is hypertrophic",
            "probability": 0.0
        }
    ],
    "530cf4e0c8a0b4a00c000006_8": [
        {
            "start_logit": 9.8203125,
            "end_logit": 9.296875,
            "text": "Hypertrophic cardiomyopathy",
            "probability": 1.0
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -2.287109375,
            "text": "Hypertrophic",
            "probability": 9.238719940185547e-06
        },
        {
            "start_logit": -2.720703125,
            "end_logit": 9.296875,
            "text": "cardiomyopathy",
            "probability": 3.5762786865234375e-06
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -8.0234375,
            "text": "Hypertrophic cardiomyopathy (HCM)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -8.078125,
            "text": "Hypertrophic cardiomyopathy (HCM",
            "probability": 0.0
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -8.2109375,
            "text": "Hypertrophic cardiomyopathy (HCM) is one",
            "probability": 0.0
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -8.3203125,
            "text": "Hypertrophic cardiomyopathy (HCM) is one of the most common inherited primary cardiac disorders and the",
            "probability": 0.0
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -8.328125,
            "text": "Hypertrophic cardiomyopathy (",
            "probability": 0.0
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -8.3359375,
            "text": "Hypertrophic cardiomyopathy (HCM) is one of the most",
            "probability": 0.0
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -8.359375,
            "text": "Hypertrophic cardiomyopathy (HCM) is one of the most common inherited primary cardiac disorders",
            "probability": 0.0
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -8.3671875,
            "text": "Hypertrophic cardiomyopathy (HCM) is one of the most common inherited primary cardiac disorders and the most",
            "probability": 0.0
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -8.375,
            "text": "Hypertrophic cardiomyopathy (HCM) is one of the most common inherited primary cardiac disorders and the most common cause",
            "probability": 0.0
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -8.390625,
            "text": "Hypertrophic cardiomyopathy (HCM) is one of",
            "probability": 0.0
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -8.390625,
            "text": "Hypertrophic cardiomyopathy (HCM) is one of the most common inherited primary cardiac",
            "probability": 0.0
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -8.3984375,
            "text": "Hypertrophic cardiomyopathy (HCM) is one of the",
            "probability": 0.0
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -8.3984375,
            "text": "Hypertrophic cardiomyopathy (HCM) is one of the most common inherited primary cardiac disorders and",
            "probability": 0.0
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -8.421875,
            "text": "Hypertrophic cardiomyopathy (HCM) is one of the most common inherited primary cardiac disorders and the most common cause of sudden cardiac death",
            "probability": 0.0
        },
        {
            "start_logit": -2.720703125,
            "end_logit": -8.0234375,
            "text": "cardiomyopathy (HCM)",
            "probability": 0.0
        },
        {
            "start_logit": -2.720703125,
            "end_logit": -8.078125,
            "text": "cardiomyopathy (HCM",
            "probability": 0.0
        },
        {
            "start_logit": -2.720703125,
            "end_logit": -8.2109375,
            "text": "cardiomyopathy (HCM) is one",
            "probability": 0.0
        }
    ],
    "530cf4e0c8a0b4a00c000006_9": [
        {
            "start_logit": 9.765625,
            "end_logit": 9.2109375,
            "text": "hypertrophic cardiomyopathy",
            "probability": 1.0
        },
        {
            "start_logit": 9.765625,
            "end_logit": -2.40234375,
            "text": "hypertrophic",
            "probability": 9.059906005859375e-06
        },
        {
            "start_logit": -2.892578125,
            "end_logit": 9.2109375,
            "text": "cardiomyopathy",
            "probability": 3.2186508178710938e-06
        },
        {
            "start_logit": 9.765625,
            "end_logit": -7.7578125,
            "text": "hypertrophic cardiomyopathy (HCM)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.765625,
            "end_logit": -8.0078125,
            "text": "hypertrophic cardiomyopathy (HCM",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.765625,
            "end_logit": -8.15625,
            "text": "hypertrophic cardiomyopathy (",
            "probability": 0.0
        },
        {
            "start_logit": -7.953125,
            "end_logit": 9.2109375,
            "text": ", including competitive athletes, is the inherited disorder hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.2109375,
            "text": "disorder hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 9.2109375,
            "text": "individuals aged less than 35 years, including competitive athletes, is the inherited disorder hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.2109375,
            "text": "in individuals aged less than 35 years, including competitive athletes, is the inherited disorder hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.2109375,
            "text": "The most common cause of sudden cardiac death in individuals aged less than 35 years, including competitive athletes, is the inherited disorder hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.2109375,
            "text": "aged less than 35 years, including competitive athletes, is the inherited disorder hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.2109375,
            "text": "competitive athletes, is the inherited disorder hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 9.2109375,
            "text": ", is the inherited disorder hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.2109375,
            "text": "sudden cardiac death in individuals aged less than 35 years, including competitive athletes, is the inherited disorder hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.2109375,
            "text": "including competitive athletes, is the inherited disorder hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.2109375,
            "text": "than 35 years, including competitive athletes, is the inherited disorder hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.2109375,
            "text": "years, including competitive athletes, is the inherited disorder hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.2109375,
            "text": "of sudden cardiac death in individuals aged less than 35 years, including competitive athletes, is the inherited disorder hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -7.953125,
            "end_logit": -2.40234375,
            "text": ", including competitive athletes, is the inherited disorder hypertrophic",
            "probability": 0.0
        }
    ],
    "530cf4e0c8a0b4a00c000006_10": [
        {
            "start_logit": 9.84375,
            "end_logit": 9.3671875,
            "text": "Hypertrophic cardiomyopathy",
            "probability": 1.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -2.23046875,
            "text": "Hypertrophic",
            "probability": 9.059906005859375e-06
        },
        {
            "start_logit": -2.595703125,
            "end_logit": 9.3671875,
            "text": "cardiomyopathy",
            "probability": 3.933906555175781e-06
        },
        {
            "start_logit": 9.84375,
            "end_logit": -7.96875,
            "text": "Hypertrophic cardiomyopathy (HCM)",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.0546875,
            "text": "Hypertrophic cardiomyopathy (HCM",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.3828125,
            "text": "Hypertrophic cardiomyopathy (HCM) is the",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.3828125,
            "text": "Hypertrophic cardiomyopathy (",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.390625,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.40625,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of death in the",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.4453125,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.4453125,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.453125,
            "text": "Hypertrophic cardiomyopathy (HCM) is",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.453125,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of death in the young, particularly",
            "probability": 0.0
        },
        {
            "start_logit": -2.595703125,
            "end_logit": -7.96875,
            "text": "cardiomyopathy (HCM)",
            "probability": 0.0
        },
        {
            "start_logit": -2.595703125,
            "end_logit": -8.0546875,
            "text": "cardiomyopathy (HCM",
            "probability": 0.0
        },
        {
            "start_logit": -2.595703125,
            "end_logit": -8.3828125,
            "text": "cardiomyopathy (HCM) is the",
            "probability": 0.0
        },
        {
            "start_logit": -2.595703125,
            "end_logit": -8.3828125,
            "text": "cardiomyopathy (",
            "probability": 0.0
        },
        {
            "start_logit": -2.595703125,
            "end_logit": -8.390625,
            "text": "cardiomyopathy (HCM) is the most common cause",
            "probability": 0.0
        },
        {
            "start_logit": -2.595703125,
            "end_logit": -8.40625,
            "text": "cardiomyopathy (HCM) is the most common cause of death in the",
            "probability": 0.0
        },
        {
            "start_logit": -2.595703125,
            "end_logit": -8.4453125,
            "text": "cardiomyopathy (HCM) is the most common cause of",
            "probability": 0.0
        }
    ],
    "530cf4e0c8a0b4a00c000006_11": [
        {
            "start_logit": 9.8359375,
            "end_logit": 9.4140625,
            "text": "Hypertrophic cardiomyopathy",
            "probability": 1.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -2.228515625,
            "text": "Hypertrophic",
            "probability": 8.821487426757812e-06
        },
        {
            "start_logit": -2.5078125,
            "end_logit": 9.4140625,
            "text": "cardiomyopathy",
            "probability": 4.351139068603516e-06
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -8.2421875,
            "text": "Hypertrophic cardiomyopathy (HC",
            "probability": 0.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -8.3125,
            "text": "Hypertrophic cardiomyopathy (HC)",
            "probability": 0.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -8.3984375,
            "text": "Hypertrophic cardiomyopathy (HC) is probably the most common cause",
            "probability": 0.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -8.4375,
            "text": "Hypertrophic cardiomyopathy (",
            "probability": 0.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -8.4453125,
            "text": "Hypertrophic cardiomyopathy (HC) is probably the most common cause of sudden cardiac death in youthful athletes, and this diagnosis has represented a contraindication",
            "probability": 0.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -8.4453125,
            "text": "Hypertrophic cardiomyopathy (HC) is",
            "probability": 0.0
        },
        {
            "start_logit": -2.5078125,
            "end_logit": -8.2421875,
            "text": "cardiomyopathy (HC",
            "probability": 0.0
        },
        {
            "start_logit": -2.5078125,
            "end_logit": -8.3125,
            "text": "cardiomyopathy (HC)",
            "probability": 0.0
        },
        {
            "start_logit": -2.5078125,
            "end_logit": -8.3984375,
            "text": "cardiomyopathy (HC) is probably the most common cause",
            "probability": 0.0
        },
        {
            "start_logit": -2.5078125,
            "end_logit": -8.4375,
            "text": "cardiomyopathy (",
            "probability": 0.0
        },
        {
            "start_logit": -2.5078125,
            "end_logit": -8.4453125,
            "text": "cardiomyopathy (HC) is probably the most common cause of sudden cardiac death in youthful athletes, and this diagnosis has represented a contraindication",
            "probability": 0.0
        },
        {
            "start_logit": -2.5078125,
            "end_logit": -8.4453125,
            "text": "cardiomyopathy (HC) is",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -8.2421875,
            "text": "(HC",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -8.3125,
            "text": "(HC)",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -8.3984375,
            "text": "(HC) is probably the most common cause",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -8.3984375,
            "text": "probably the most common cause",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -8.4375,
            "text": "(",
            "probability": 0.0
        }
    ],
    "5e4601293f54159529000002_1": [
        {
            "start_logit": 9.7734375,
            "end_logit": 9.6328125,
            "text": "multiple sclerosis",
            "probability": 1.0
        },
        {
            "start_logit": -2.1015625,
            "end_logit": 9.6328125,
            "text": "sclerosis",
            "probability": 6.973743438720703e-06
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -2.33984375,
            "text": "multiple",
            "probability": 6.318092346191406e-06
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.6328125,
            "text": "for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.6328125,
            "text": "Diagnostic performance of central vein sign for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 9.6328125,
            "text": "of central vein sign for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.6328125,
            "text": "performance of central vein sign for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.6328125,
            "text": "central vein sign for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": -2.33984375,
            "text": "for multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -2.33984375,
            "text": "Diagnostic performance of central vein sign for multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -2.33984375,
            "text": "of central vein sign for multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -2.33984375,
            "text": "performance of central vein sign for multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -2.33984375,
            "text": "central vein sign for multiple",
            "probability": 0.0
        }
    ],
    "5e4601293f54159529000002_2": [
        {
            "start_logit": 9.84375,
            "end_logit": 9.5390625,
            "text": "multiple sclerosis",
            "probability": 1.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -2.193359375,
            "text": "multiple",
            "probability": 8.046627044677734e-06
        },
        {
            "start_logit": -2.28515625,
            "end_logit": 9.5390625,
            "text": "sclerosis",
            "probability": 5.424022674560547e-06
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.015625,
            "text": "multiple sclerosis (MS)",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.046875,
            "text": "multiple sclerosis (MS",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.1015625,
            "text": "multiple sclerosis (",
            "probability": 0.0
        },
        {
            "start_logit": -7.8828125,
            "end_logit": 9.5390625,
            "text": "for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.5390625,
            "text": "on FLAIR* magnetic resonance imaging (MRI) is highly specific and sensitive for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.5390625,
            "text": "magnetic resonance imaging (MRI) is highly specific and sensitive for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 9.5390625,
            "text": "\"central vein sign\" (CVS) on FLAIR* magnetic resonance imaging (MRI) is highly specific and sensitive for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.5390625,
            "text": "Detection of a \"central vein sign\" (CVS) on FLAIR* magnetic resonance imaging (MRI) is highly specific and sensitive for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.5390625,
            "text": "a \"central vein sign\" (CVS) on FLAIR* magnetic resonance imaging (MRI) is highly specific and sensitive for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.5390625,
            "text": "(MRI) is highly specific and sensitive for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.5390625,
            "text": "central vein sign\" (CVS) on FLAIR* magnetic resonance imaging (MRI) is highly specific and sensitive for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.5390625,
            "text": "* magnetic resonance imaging (MRI) is highly specific and sensitive for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.5390625,
            "text": "\" (CVS) on FLAIR* magnetic resonance imaging (MRI) is highly specific and sensitive for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.5390625,
            "text": "of a \"central vein sign\" (CVS) on FLAIR* magnetic resonance imaging (MRI) is highly specific and sensitive for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 9.5390625,
            "text": "vein sign\" (CVS) on FLAIR* magnetic resonance imaging (MRI) is highly specific and sensitive for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.359375,
            "end_logit": 9.5390625,
            "text": ": Detection of a \"central vein sign\" (CVS) on FLAIR* magnetic resonance imaging (MRI) is highly specific and sensitive for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -7.8828125,
            "end_logit": -2.193359375,
            "text": "for multiple",
            "probability": 0.0
        }
    ],
    "5e4601293f54159529000002_3": [
        {
            "start_logit": 9.8046875,
            "end_logit": 9.6171875,
            "text": "Multiple Sclerosis",
            "probability": 1.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -2.283203125,
            "text": "Multiple",
            "probability": 6.794929504394531e-06
        },
        {
            "start_logit": -2.125,
            "end_logit": 9.6171875,
            "text": "Sclerosis",
            "probability": 6.616115570068359e-06
        },
        {
            "start_logit": -7.90625,
            "end_logit": 9.6171875,
            "text": "Central vein sign differentiates Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.1015625,
            "text": "Multiple Sclerosis from central nervous system inflammatory vascul",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.109375,
            "text": "Multiple Sclerosis from central nervous system",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.15625,
            "text": "Multiple Sclerosis from central nervous system inflammatory vasculopathies",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.265625,
            "text": "Multiple Sclerosis from central nervous system inflammatory",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.2890625,
            "text": "Multiple Sclerosis from central nervous",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.6171875,
            "text": "s Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.6171875,
            "text": "vein sign differentiates Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.390625,
            "end_logit": 9.6171875,
            "text": "differentiates Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.3984375,
            "end_logit": 9.6171875,
            "text": "sign differentiates Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -7.90625,
            "end_logit": -2.283203125,
            "text": "Central vein sign differentiates Multiple",
            "probability": 0.0
        },
        {
            "start_logit": -2.125,
            "end_logit": -8.1015625,
            "text": "Sclerosis from central nervous system inflammatory vascul",
            "probability": 0.0
        },
        {
            "start_logit": -2.125,
            "end_logit": -8.109375,
            "text": "Sclerosis from central nervous system",
            "probability": 0.0
        },
        {
            "start_logit": -2.125,
            "end_logit": -8.15625,
            "text": "Sclerosis from central nervous system inflammatory vasculopathies",
            "probability": 0.0
        },
        {
            "start_logit": -2.125,
            "end_logit": -8.265625,
            "text": "Sclerosis from central nervous system inflammatory",
            "probability": 0.0
        },
        {
            "start_logit": -2.125,
            "end_logit": -8.2890625,
            "text": "Sclerosis from central nervous",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": -2.283203125,
            "text": "s Multiple",
            "probability": 0.0
        }
    ],
    "5e4601293f54159529000002_4": [
        {
            "start_logit": 9.84375,
            "end_logit": 9.5,
            "text": "multiple sclerosis",
            "probability": 1.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -2.1796875,
            "text": "multiple",
            "probability": 8.463859558105469e-06
        },
        {
            "start_logit": -2.326171875,
            "end_logit": 9.5,
            "text": "sclerosis",
            "probability": 5.185604095458984e-06
        },
        {
            "start_logit": -7.0859375,
            "end_logit": 9.5,
            "text": "between multiple sclerosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.1015625,
            "text": "multiple sclerosis (MS)",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.109375,
            "text": "multiple sclerosis (MS",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.1328125,
            "text": "multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NM",
            "probability": 0.0
        },
        {
            "start_logit": -7.8046875,
            "end_logit": 9.5,
            "text": "distinguish between multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.171875,
            "text": "multiple sclerosis (",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.2109375,
            "text": "multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOS",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.2421875,
            "text": "multiple sclerosis (MS) and neuromyelitis optic",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.2734375,
            "text": "multiple sclerosis (MS) and neuromyelitis optica",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.28125,
            "text": "multiple sclerosis (MS) and neuromyelitis optica spectrum",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.3125,
            "text": "multiple sclerosis (MS) and neuromyelitis",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.3125,
            "text": "multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD)",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.3203125,
            "text": "multiple sclerosis (MS) and",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 9.5,
            "text": "the central vein sign (CVS) on a clinical 3T scanner to distinguish between multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 9.5,
            "text": "central vein sign (CVS) on a clinical 3T scanner to distinguish between multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.5,
            "text": "to distinguish between multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.5,
            "text": "clinical 3T scanner to distinguish between multiple sclerosis",
            "probability": 0.0
        }
    ],
    "5e4601293f54159529000002_5": [
        {
            "start_logit": 9.8125,
            "end_logit": 9.7109375,
            "text": "Multiple Sclerosis",
            "probability": 1.0
        },
        {
            "start_logit": -1.9169921875,
            "end_logit": 9.7109375,
            "text": "Sclerosis",
            "probability": 7.987022399902344e-06
        },
        {
            "start_logit": 9.8125,
            "end_logit": -2.279296875,
            "text": "Multiple",
            "probability": 6.139278411865234e-06
        },
        {
            "start_logit": -7.48828125,
            "end_logit": 9.7109375,
            "text": "in Multiple Sclerosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.7109375,
            "text": "Diagnostic Imaging Biomarker in Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.7109375,
            "text": "Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.7109375,
            "text": "Imaging Biomarker in Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.7109375,
            "text": "Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.7109375,
            "text": "the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.7109375,
            "text": "a Diagnostic Imaging Biomarker in Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": 9.7109375,
            "text": "of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.7109375,
            "text": "Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.359375,
            "end_logit": 9.7109375,
            "text": "Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -7.48828125,
            "end_logit": -2.279296875,
            "text": "in Multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -2.279296875,
            "text": "Diagnostic Imaging Biomarker in Multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -2.279296875,
            "text": "Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": -2.279296875,
            "text": "Imaging Biomarker in Multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": -2.279296875,
            "text": "Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": -2.279296875,
            "text": "the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": -2.279296875,
            "text": "a Diagnostic Imaging Biomarker in Multiple",
            "probability": 0.0
        }
    ],
    "5e4601293f54159529000002_6": [
        {
            "start_logit": 9.8125,
            "end_logit": 9.6328125,
            "text": "multiple sclerosis",
            "probability": 1.0
        },
        {
            "start_logit": -2.078125,
            "end_logit": 9.6328125,
            "text": "sclerosis",
            "probability": 6.9141387939453125e-06
        },
        {
            "start_logit": 9.8125,
            "end_logit": -2.275390625,
            "text": "multiple",
            "probability": 6.794929504394531e-06
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.0859375,
            "text": "multiple sclerosis (MS",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.1015625,
            "text": "multiple sclerosis (MS)",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.234375,
            "text": "multiple sclerosis (MS) and not MS, mainly based on findings from ultrahigh-field magnetic resonance imaging (MRI)",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.234375,
            "text": "multiple sclerosis (MS) and not MS, mainly based on findings from ultrahigh-field magnetic resonance imaging (",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.6328125,
            "text": "between multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.2578125,
            "text": "multiple sclerosis (MS) and not MS, mainly based on findings from ultrahigh-field magnetic resonance imaging",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.265625,
            "text": "multiple sclerosis (MS) and",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.265625,
            "text": "multiple sclerosis (MS) and not MS, mainly based on findings from ultrahigh-field magnetic resonance",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.2734375,
            "text": "multiple sclerosis (MS) and not MS, mainly based on findings from ultrahigh-field magnetic resonance imaging (MRI",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.296875,
            "text": "multiple sclerosis (",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.6328125,
            "text": "The central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.6328125,
            "text": "Importance  The central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.6328125,
            "text": "central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.6328125,
            "text": "imaging biomarker for distinguishing between multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -2.078125,
            "end_logit": -8.0859375,
            "text": "sclerosis (MS",
            "probability": 0.0
        },
        {
            "start_logit": -2.078125,
            "end_logit": -8.1015625,
            "text": "sclerosis (MS)",
            "probability": 0.0
        },
        {
            "start_logit": -2.078125,
            "end_logit": -8.234375,
            "text": "sclerosis (MS) and not MS, mainly based on findings from ultrahigh-field magnetic resonance imaging (MRI)",
            "probability": 0.0
        }
    ],
    "5e4601293f54159529000002_7": [
        {
            "start_logit": 9.8515625,
            "end_logit": 9.65625,
            "text": "multiple sclerosis",
            "probability": 1.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -2.185546875,
            "text": "multiple",
            "probability": 7.212162017822266e-06
        },
        {
            "start_logit": -2.03515625,
            "end_logit": 9.65625,
            "text": "sclerosis",
            "probability": 6.973743438720703e-06
        },
        {
            "start_logit": -7.87109375,
            "end_logit": 9.65625,
            "text": "for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.65625,
            "text": "central vein sign is a promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.65625,
            "text": "The central vein sign is a promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.65625,
            "text": "PURPOSE  The central vein sign is a promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.65625,
            "text": "vein sign is a promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.65625,
            "text": "sign is a promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.65625,
            "text": "imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.65625,
            "text": "MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.65625,
            "text": "promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.65625,
            "text": "a promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.65625,
            "text": "is a promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 9.65625,
            "text": "diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -7.87109375,
            "end_logit": -2.185546875,
            "text": "for multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -2.185546875,
            "text": "central vein sign is a promising MR imaging diagnostic biomarker for multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -2.185546875,
            "text": "The central vein sign is a promising MR imaging diagnostic biomarker for multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": -2.185546875,
            "text": "PURPOSE  The central vein sign is a promising MR imaging diagnostic biomarker for multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": -2.185546875,
            "text": "vein sign is a promising MR imaging diagnostic biomarker for multiple",
            "probability": 0.0
        }
    ],
    "5e4601293f54159529000002_8": [
        {
            "start_logit": 9.8515625,
            "end_logit": 9.65625,
            "text": "multiple sclerosis",
            "probability": 1.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -2.185546875,
            "text": "multiple",
            "probability": 7.212162017822266e-06
        },
        {
            "start_logit": -2.03515625,
            "end_logit": 9.65625,
            "text": "sclerosis",
            "probability": 6.973743438720703e-06
        },
        {
            "start_logit": -7.87109375,
            "end_logit": 9.65625,
            "text": "for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.65625,
            "text": "central vein sign is a promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.65625,
            "text": "The central vein sign is a promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.65625,
            "text": "PURPOSE The central vein sign is a promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.65625,
            "text": "vein sign is a promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.65625,
            "text": "sign is a promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.65625,
            "text": "imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.65625,
            "text": "MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.65625,
            "text": "promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.65625,
            "text": "a promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.65625,
            "text": "is a promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 9.65625,
            "text": "diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -7.87109375,
            "end_logit": -2.185546875,
            "text": "for multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -2.185546875,
            "text": "central vein sign is a promising MR imaging diagnostic biomarker for multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -2.185546875,
            "text": "The central vein sign is a promising MR imaging diagnostic biomarker for multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": -2.185546875,
            "text": "PURPOSE The central vein sign is a promising MR imaging diagnostic biomarker for multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": -2.185546875,
            "text": "vein sign is a promising MR imaging diagnostic biomarker for multiple",
            "probability": 0.0
        }
    ],
    "5e4601293f54159529000002_9": [
        {
            "start_logit": 9.8046875,
            "end_logit": 9.7890625,
            "text": "Multiple Sclerosis",
            "probability": 1.0
        },
        {
            "start_logit": -1.7451171875,
            "end_logit": 9.7890625,
            "text": "Sclerosis",
            "probability": 9.655952453613281e-06
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -2.2578125,
            "text": "Multiple",
            "probability": 5.841255187988281e-06
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.73828125,
            "text": "Multiple Sclerosis Lesions Is Present Irrespective of the T2* Sequence at 3 T. BACKGROUND AND PURPOSE Previous T2*-weighted magnetic resonance imaging (MRI) studies have used white matter lesion (WM",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.75390625,
            "text": "Multiple Sclerosis Lesions Is Present Irrespective of the T2* Sequence at 3 T. BACKGROUND AND PURPOSE Previous T2*-weighted magnetic resonance imaging (MRI) studies have used white matter lesion (WML) central veins to distinguish multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.81640625,
            "text": "Multiple Sclerosis Lesions Is Present Irrespective of the T2* Sequence at 3 T. BACKGROUND AND PURPOSE Previous T2*-weighted magnetic resonance imaging (MRI) studies have used white matter lesion (WML) central veins to distinguish multiple sclerosis (",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.9296875,
            "text": "Multiple Sclerosis Lesions Is Present Irrespective of the T2* Sequence at 3 T. BACKGROUND AND PURPOSE Previous T2*-weighted magnetic resonance imaging (MRI) studies have used white matter lesion (WML) central veins to distinguish multiple sclerosis (MS",
            "probability": 0.0
        },
        {
            "start_logit": -7.92578125,
            "end_logit": 9.7890625,
            "text": "in Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.953125,
            "text": "Multiple Sclerosis Lesions",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.984375,
            "text": "Multiple Sclerosis Lesions Is Present Irrespective of the T2* Sequence at 3 T. BACKGROUND AND PURPOSE Previous T2*-weighted magnetic resonance imaging (MRI) studies have used white matter lesion (WML) central veins to distinguish multiple sclerosis (MS) from",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.015625,
            "text": "Multiple Sclerosis Lesions Is Present Irrespective of the T2* Sequence at 3 T. BACKGROUND AND PURPOSE Previous T2*-weighted magnetic resonance imaging (MRI) studies have used white matter lesion",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.0546875,
            "text": "Multiple Sclerosis Lesions Is Present Irrespective of the T2* Sequence at 3 T. BACKGROUND AND PURPOSE Previous T2*-weighted magnetic resonance imaging (MRI) studies have used white matter lesion (WML) central veins to distinguish multiple sclerosis (MS)",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.109375,
            "text": "Multiple Sclerosis Lesions Is Present Irrespective of the T2* Sequence at 3 T. BACKGROUND AND PURPOSE Previous T2*-weighted magnetic resonance imaging (MRI) studies have used white matter lesion (",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.1171875,
            "text": "Multiple Sclerosis Lesions Is Present Irrespective of the T2* Sequence at 3 T. BACKGROUND AND PURPOSE Previous T2*-weighted magnetic resonance imaging (MRI) studies have used white matter lesion (WML) central",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.125,
            "text": "Multiple Sclerosis Lesions Is Present Irrespective of the T2* Sequence at 3 T. BACKGROUND AND PURPOSE Previous T2*-weighted magnetic resonance imaging (MRI) studies have used white matter lesion (WML",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.140625,
            "text": "Multiple Sclerosis Lesions Is Present Irrespective of the T2* Sequence at 3 T. BACKGROUND AND PURPOSE Previous T2*-weighted magnetic resonance imaging (MRI) studies have used white matter",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.140625,
            "text": "Multiple Sclerosis Lesions Is Present Irrespective of the T2* Sequence at 3 T. BACKGROUND AND PURPOSE Previous T2*-weighted magnetic resonance imaging (MRI) studies have used white matter lesion (WML) central veins to distinguish multiple",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.15625,
            "text": "Multiple Sclerosis Lesions Is Present Irrespective of the T2* Sequence at 3 T. BACKGROUND AND PURPOSE Previous T2*-weighted magnetic resonance imaging (MRI) studies have used white matter lesion (WML) central veins",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.15625,
            "text": "Multiple Sclerosis Lesions Is Present Irrespective of the T2* Sequence at 3 T. BACKGROUND AND PURPOSE Previous T2*-weighted magnetic resonance imaging (MRI) studies have used white matter lesion (WML)",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.15625,
            "text": "Multiple Sclerosis Lesions Is Present Irrespective of the T2* Sequence at 3 T. BACKGROUND AND PURPOSE Previous T2*-weighted magnetic resonance imaging (",
            "probability": 0.0
        }
    ],
    "5c8fe7cb0101eac87000000c_1": [
        {
            "start_logit": 9.921875,
            "end_logit": 9.2578125,
            "text": "Runt related factor-2",
            "probability": 1.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -2.025390625,
            "text": "Run",
            "probability": 1.2516975402832031e-05
        },
        {
            "start_logit": -2.66796875,
            "end_logit": 9.2578125,
            "text": "2",
            "probability": 3.3974647521972656e-06
        },
        {
            "start_logit": -6.1875,
            "end_logit": 9.2578125,
            "text": "t related factor-2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.921875,
            "end_logit": -7.25,
            "text": "Runt related factor-2 (Runx2)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.83984375,
            "end_logit": 9.2578125,
            "text": "factor-2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.921875,
            "end_logit": -7.53515625,
            "text": "Runt related factor-2 (Runx2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.875,
            "end_logit": 9.2578125,
            "text": "related factor-2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.921875,
            "end_logit": -7.796875,
            "text": "Runt related factor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.15625,
            "end_logit": 9.2578125,
            "text": "-2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.921875,
            "end_logit": -7.94140625,
            "text": "Runt related factor-2 (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.2421875,
            "text": "Runt related",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.2421875,
            "text": "Runt related factor-",
            "probability": 0.0
        },
        {
            "start_logit": -2.66796875,
            "end_logit": -7.25,
            "text": "2 (Runx2)",
            "probability": 0.0
        },
        {
            "start_logit": -2.66796875,
            "end_logit": -7.53515625,
            "text": "2 (Runx2",
            "probability": 0.0
        },
        {
            "start_logit": -2.66796875,
            "end_logit": -7.94140625,
            "text": "2 (",
            "probability": 0.0
        },
        {
            "start_logit": -6.1875,
            "end_logit": -7.25,
            "text": "t related factor-2 (Runx2)",
            "probability": 0.0
        },
        {
            "start_logit": -6.1875,
            "end_logit": -7.53515625,
            "text": "t related factor-2 (Runx2",
            "probability": 0.0
        },
        {
            "start_logit": -6.1875,
            "end_logit": -7.796875,
            "text": "t related factor",
            "probability": 0.0
        },
        {
            "start_logit": -6.83984375,
            "end_logit": -7.25,
            "text": "factor-2 (Runx2)",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_1": [
        {
            "start_logit": 10.015625,
            "end_logit": 9.5,
            "text": "calcitonin gene-related peptide",
            "probability": 1.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -1.853515625,
            "text": "calcitonin",
            "probability": 1.1742115020751953e-05
        },
        {
            "start_logit": -2.365234375,
            "end_logit": 9.5,
            "text": "peptide",
            "probability": 4.172325134277344e-06
        },
        {
            "start_logit": -6.453125,
            "end_logit": 9.5,
            "text": "gene-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.015625,
            "end_logit": -7.6328125,
            "text": "calcitonin gene-related",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1171875,
            "end_logit": 9.5,
            "text": "-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.35546875,
            "end_logit": 9.5,
            "text": "related peptide",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.0703125,
            "text": "calcitonin gene-related peptide receptor occupancy",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.1015625,
            "text": "calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.2265625,
            "text": "calcitonin gene",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.2734375,
            "text": "calcitonin gene-",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.2734375,
            "text": "calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.2890625,
            "text": "calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.3046875,
            "text": "calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.3125,
            "text": "calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.328125,
            "text": "calcitonin gene-related peptide receptor occupancy by tel",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.3359375,
            "text": "calcitonin gene-related peptide receptor occupancy by telca",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.3515625,
            "text": "calcitonin gene-related peptide receptor occupancy by telcagepant in",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.3671875,
            "text": "calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK-42",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.3671875,
            "text": "calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK-4232",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_2": [
        {
            "start_logit": 9.9140625,
            "end_logit": 9.515625,
            "text": "calcitonin gene-related peptide",
            "probability": 1.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -2.087890625,
            "text": "calcitonin",
            "probability": 9.059906005859375e-06
        },
        {
            "start_logit": -2.345703125,
            "end_logit": 9.515625,
            "text": "peptide",
            "probability": 4.708766937255859e-06
        },
        {
            "start_logit": -6.3828125,
            "end_logit": 9.515625,
            "text": "gene-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.85546875,
            "end_logit": 9.515625,
            "text": "-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1171875,
            "end_logit": 9.515625,
            "text": "related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -7.5546875,
            "text": "calcitonin gene-related",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.015625,
            "text": "calcitonin gene-related peptide (CGRP",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.171875,
            "text": "calcitonin gene",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.2109375,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist currently undergoing clinical trials for migraine (http://www.merck.com",
            "probability": 0.0
        },
        {
            "start_logit": -7.84375,
            "end_logit": 9.515625,
            "text": "novel calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.28125,
            "text": "calcitonin gene-",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.3125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist currently undergoing clinical trials for migraine (http://www.merck.com/research/pipeline",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.3203125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist currently undergoing clinical trials for migraine (http://www.merck.com/research/pipeline/home.",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.3203125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist currently undergoing clinical trials for migraine (http://www.merck",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.3203125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist currently undergoing clinical trials for migraine (http://www.merck.com/research/pipeline/home",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.3359375,
            "text": "calcitonin gene-related peptide (",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.34375,
            "text": "calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.34375,
            "text": "calcitonin gene-related peptide (CGRP)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.34375,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist currently undergoing clinical trials for migraine (http://www.merck.",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_3": [
        {
            "start_logit": 9.9921875,
            "end_logit": 9.5390625,
            "text": "calcitonin gene-related peptide",
            "probability": 1.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -1.908203125,
            "text": "calcitonin",
            "probability": 1.0728836059570312e-05
        },
        {
            "start_logit": -2.291015625,
            "end_logit": 9.5390625,
            "text": "peptide",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": -6.3203125,
            "end_logit": 9.5390625,
            "text": "gene-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.97265625,
            "end_logit": 9.5390625,
            "text": "-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -7.62890625,
            "text": "calcitonin gene-related",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1953125,
            "end_logit": 9.5390625,
            "text": "related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -7.828125,
            "text": "calcitonin gene-related peptide (CGRP",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.140625,
            "text": "calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.1640625,
            "text": "calcitonin gene",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.2265625,
            "text": "calcitonin gene-related peptide (",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.265625,
            "text": "calcitonin gene-related peptide (CGRP)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.28125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist being evaluated for acute migraine",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.3203125,
            "text": "calcitonin gene-",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.5390625,
            "text": "a calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.359375,
            "end_logit": 9.5390625,
            "text": "is a calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -2.291015625,
            "end_logit": -7.828125,
            "text": "peptide (CGRP",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -1.908203125,
            "text": "a calcitonin",
            "probability": 0.0
        },
        {
            "start_logit": -8.359375,
            "end_logit": -1.908203125,
            "text": "is a calcitonin",
            "probability": 0.0
        },
        {
            "start_logit": -2.291015625,
            "end_logit": -8.140625,
            "text": "peptide (CGRP) receptor",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_4": [
        {
            "start_logit": 9.9609375,
            "end_logit": 9.421875,
            "text": "Calcitonin gene-related peptide",
            "probability": 1.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -1.9755859375,
            "text": "Calcitonin",
            "probability": 1.1324882507324219e-05
        },
        {
            "start_logit": -2.51171875,
            "end_logit": 9.421875,
            "text": "peptide",
            "probability": 3.874301910400391e-06
        },
        {
            "start_logit": -6.42578125,
            "end_logit": 9.421875,
            "text": "gene-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -7.60546875,
            "text": "Calcitonin gene-related",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.08984375,
            "end_logit": 9.421875,
            "text": "-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.34375,
            "end_logit": 9.421875,
            "text": "related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.1484375,
            "text": "Calcitonin gene",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.265625,
            "text": "Calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.2734375,
            "text": "Calcitonin gene-related peptide receptor antagonists, such as telcagepant, may be useful for acute migraine",
            "probability": 0.0
        },
        {
            "start_logit": -2.51171875,
            "end_logit": -8.265625,
            "text": "peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -2.51171875,
            "end_logit": -8.2734375,
            "text": "peptide receptor antagonists, such as telcagepant, may be useful for acute migraine",
            "probability": 0.0
        },
        {
            "start_logit": -6.42578125,
            "end_logit": -7.60546875,
            "text": "gene-related",
            "probability": 0.0
        },
        {
            "start_logit": -6.42578125,
            "end_logit": -8.1484375,
            "text": "gene",
            "probability": 0.0
        },
        {
            "start_logit": -6.42578125,
            "end_logit": -8.265625,
            "text": "gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.08984375,
            "end_logit": -7.60546875,
            "text": "-related",
            "probability": 0.0
        },
        {
            "start_logit": -6.42578125,
            "end_logit": -8.2734375,
            "text": "gene-related peptide receptor antagonists, such as telcagepant, may be useful for acute migraine",
            "probability": 0.0
        },
        {
            "start_logit": -7.34375,
            "end_logit": -7.60546875,
            "text": "related",
            "probability": 0.0
        },
        {
            "start_logit": -7.08984375,
            "end_logit": -8.265625,
            "text": "-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.08984375,
            "end_logit": -8.2734375,
            "text": "-related peptide receptor antagonists, such as telcagepant, may be useful for acute migraine",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_5": [
        {
            "start_logit": 9.96875,
            "end_logit": 9.375,
            "text": "calcitonin gene-related peptide",
            "probability": 1.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -1.962890625,
            "text": "calcitonin",
            "probability": 1.1920928955078125e-05
        },
        {
            "start_logit": -2.625,
            "end_logit": 9.375,
            "text": "peptide",
            "probability": 3.3974647521972656e-06
        },
        {
            "start_logit": -6.296875,
            "end_logit": 9.375,
            "text": "gene-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.84375,
            "end_logit": 9.375,
            "text": "-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.08203125,
            "end_logit": 9.375,
            "text": "related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.96875,
            "end_logit": -7.95703125,
            "text": "calcitonin gene-related",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.0859375,
            "text": "calcitonin gene-related peptide (CGRP",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.25,
            "text": "calcitonin gene",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.328125,
            "text": "calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.34375,
            "text": "calcitonin gene-related peptide (CGRP)",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.375,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonists (gepants)-olcegepant (BIBN 4096 BS), telcagepant (MK-09",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.3828125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonists (gepants)-olcegepant (BIBN 40",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.390625,
            "text": "calcitonin gene-related peptide (",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.40625,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonists (gepants)-olcegepant (BIBN 4096 BS), telcagepant (MK-0974)",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.40625,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonists (gepants)-olcegepant (BIBN 4096 BS), telcagepant (",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.4140625,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonists (gepants)-olcegepant (BIBN 4096 BS), telca",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.421875,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonists (gepants)-olcegepant (BIBN 4096 BS), telcagepant (MK-0974), MK3207, and BI 44",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.4296875,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonists (gepants)-olcegepant (BIBN 4096 BS), telcagepant",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.4296875,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonists (gepants)-olcegepant (BIBN 4096 BS), telcagepan",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_6": [
        {
            "start_logit": 10.015625,
            "end_logit": 9.59375,
            "text": "calcitonin gene-related peptide",
            "probability": 1.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -1.8486328125,
            "text": "calcitonin",
            "probability": 1.0728836059570312e-05
        },
        {
            "start_logit": -2.166015625,
            "end_logit": 9.59375,
            "text": "peptide",
            "probability": 5.125999450683594e-06
        },
        {
            "start_logit": -6.45703125,
            "end_logit": 9.59375,
            "text": "gene-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.015625,
            "end_logit": -7.2421875,
            "text": "calcitonin gene-related",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1328125,
            "end_logit": 9.59375,
            "text": "-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4609375,
            "end_logit": 9.59375,
            "text": "related peptide",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.0546875,
            "text": "calcitonin gene",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.0546875,
            "text": "calcitonin gene-",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.0859375,
            "text": "calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.3671875,
            "text": "calcitonin gene-related peptide receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.59375,
            "text": "a calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.59375,
            "text": ", a calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": -1.8486328125,
            "text": "a calcitonin",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -1.8486328125,
            "text": ", a calcitonin",
            "probability": 0.0
        },
        {
            "start_logit": -2.166015625,
            "end_logit": -8.0859375,
            "text": "peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -2.166015625,
            "end_logit": -8.3671875,
            "text": "peptide receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": -6.45703125,
            "end_logit": -7.2421875,
            "text": "gene-related",
            "probability": 0.0
        },
        {
            "start_logit": -7.1328125,
            "end_logit": -7.2421875,
            "text": "-related",
            "probability": 0.0
        },
        {
            "start_logit": -6.45703125,
            "end_logit": -8.0546875,
            "text": "gene",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_7": [
        {
            "start_logit": 9.9765625,
            "end_logit": 9.484375,
            "text": "calcitonin gene-related peptide",
            "probability": 1.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -1.943359375,
            "text": "calcitonin",
            "probability": 1.0788440704345703e-05
        },
        {
            "start_logit": -2.41015625,
            "end_logit": 9.484375,
            "text": "peptide",
            "probability": 4.172325134277344e-06
        },
        {
            "start_logit": -6.39453125,
            "end_logit": 9.484375,
            "text": "gene-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -7.48046875,
            "text": "calcitonin gene-related",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.12109375,
            "end_logit": 9.484375,
            "text": "-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.26171875,
            "end_logit": 9.484375,
            "text": "related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.1328125,
            "text": "calcitonin gene",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.1953125,
            "text": "calcitonin gene-",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.265625,
            "text": "calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.3828125,
            "text": "calcitonin gene-related peptide receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.390625,
            "text": "calcitonin gene-related peptide receptor antagonist, tel",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 9.484375,
            "text": "potent calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.484375,
            "text": "The potent calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -1.943359375,
            "text": "potent calcitonin",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -1.943359375,
            "text": "The potent calcitonin",
            "probability": 0.0
        },
        {
            "start_logit": -2.41015625,
            "end_logit": -8.265625,
            "text": "peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -2.41015625,
            "end_logit": -8.3828125,
            "text": "peptide receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": -2.41015625,
            "end_logit": -8.390625,
            "text": "peptide receptor antagonist, tel",
            "probability": 0.0
        },
        {
            "start_logit": -6.39453125,
            "end_logit": -7.48046875,
            "text": "gene-related",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_8": [
        {
            "start_logit": 9.984375,
            "end_logit": 9.5390625,
            "text": "calcitonin gene-related peptide",
            "probability": 1.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -1.939453125,
            "text": "calcitonin",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": -2.28515625,
            "end_logit": 9.5390625,
            "text": "peptide",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": -6.21875,
            "end_logit": 9.5390625,
            "text": "gene-related peptide",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.640625,
            "end_logit": 9.5390625,
            "text": "-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.078125,
            "end_logit": 9.5390625,
            "text": "related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.984375,
            "end_logit": -7.78125,
            "text": "calcitonin gene-related",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.09375,
            "text": "calcitonin gene-related peptide (CGRP",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.2265625,
            "text": "calcitonin gene",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.3203125,
            "text": "calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.3203125,
            "text": "calcitonin gene-related peptide (CGRP)",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.359375,
            "text": "calcitonin gene-related peptide (",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.375,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist, telcagepant, on the haemodynamic response to sublingual nitroglycerin (",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.3828125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist, telcagepant, on the haemodynamic response to sublingual nitroglycerin (NTG)",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.421875,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist, tel",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.5390625,
            "text": "assess the effect of the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.5390625,
            "text": "effect of the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.5390625,
            "text": "the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.5390625,
            "text": "To assess the effect of the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -1.939453125,
            "text": "assess the effect of the calcitonin",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_9": [
        {
            "start_logit": 10.0390625,
            "end_logit": 9.5390625,
            "text": "calcitonin gene-related peptide",
            "probability": 1.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -1.7841796875,
            "text": "calcitonin",
            "probability": 1.2099742889404297e-05
        },
        {
            "start_logit": -2.302734375,
            "end_logit": 9.5390625,
            "text": "peptide",
            "probability": 4.351139068603516e-06
        },
        {
            "start_logit": -6.3828125,
            "end_logit": 9.5390625,
            "text": "gene-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -7.296875,
            "text": "calcitonin gene-related",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.94140625,
            "end_logit": 9.5390625,
            "text": "-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4140625,
            "end_logit": 9.5390625,
            "text": "related peptide",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.0703125,
            "text": "calcitonin gene",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.2265625,
            "text": "calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 9.5390625,
            "text": "oral calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.5390625,
            "text": "an oral calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -7.96484375,
            "end_logit": -1.7841796875,
            "text": "oral calcitonin",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -1.7841796875,
            "text": "an oral calcitonin",
            "probability": 0.0
        },
        {
            "start_logit": -2.302734375,
            "end_logit": -8.2265625,
            "text": "peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -6.3828125,
            "end_logit": -7.296875,
            "text": "gene-related",
            "probability": 0.0
        },
        {
            "start_logit": -6.94140625,
            "end_logit": -7.296875,
            "text": "-related",
            "probability": 0.0
        },
        {
            "start_logit": -6.3828125,
            "end_logit": -8.0703125,
            "text": "gene",
            "probability": 0.0
        },
        {
            "start_logit": -6.3828125,
            "end_logit": -8.2265625,
            "text": "gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.4140625,
            "end_logit": -7.296875,
            "text": "related",
            "probability": 0.0
        },
        {
            "start_logit": -6.94140625,
            "end_logit": -8.2265625,
            "text": "-related peptide receptor",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_10": [
        {
            "start_logit": 9.9296875,
            "end_logit": 9.421875,
            "text": "calcitonin gene-related peptide",
            "probability": 1.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -2.05859375,
            "text": "calcitonin",
            "probability": 1.043081283569336e-05
        },
        {
            "start_logit": -2.5390625,
            "end_logit": 9.421875,
            "text": "peptide",
            "probability": 3.874301910400391e-06
        },
        {
            "start_logit": -6.2734375,
            "end_logit": 9.421875,
            "text": "gene-related peptide",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.84765625,
            "end_logit": 9.421875,
            "text": "-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.08984375,
            "end_logit": 9.421875,
            "text": "related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -7.79296875,
            "text": "calcitonin gene-related",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.046875,
            "text": "calcitonin gene-related peptide (CGRP",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.25,
            "text": "calcitonin gene",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.2578125,
            "text": "calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.3046875,
            "text": "calcitonin gene-related peptide (",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.3046875,
            "text": "calcitonin gene-related peptide (CGRP)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.375,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonists olce",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.375,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonists ol",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.421875,
            "text": "The calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.421875,
            "text": ": The calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": -2.05859375,
            "text": "The calcitonin",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": -2.05859375,
            "text": ": The calcitonin",
            "probability": 0.0
        },
        {
            "start_logit": -2.5390625,
            "end_logit": -8.046875,
            "text": "peptide (CGRP",
            "probability": 0.0
        },
        {
            "start_logit": -2.5390625,
            "end_logit": -8.2578125,
            "text": "peptide (CGRP) receptor",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_11": [
        {
            "start_logit": 9.96875,
            "end_logit": 9.3984375,
            "text": "Calcitonin gene-related peptide",
            "probability": 1.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -1.9716796875,
            "text": "Calcitonin",
            "probability": 1.150369644165039e-05
        },
        {
            "start_logit": -2.56640625,
            "end_logit": 9.3984375,
            "text": "peptide",
            "probability": 3.5762786865234375e-06
        },
        {
            "start_logit": -6.05078125,
            "end_logit": 9.3984375,
            "text": "gene-related peptide",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.88671875,
            "end_logit": 9.3984375,
            "text": "-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.96484375,
            "end_logit": 9.3984375,
            "text": "related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.96875,
            "end_logit": -7.96875,
            "text": "Calcitonin gene-related peptide (CGRP",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.015625,
            "text": "Calcitonin gene-related",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.25,
            "text": "Calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.2890625,
            "text": "Calcitonin gene-related peptide (CGRP)",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.3203125,
            "text": "Calcitonin gene-related peptide (CGRP) receptor antagonists are another promising nonvasoconstrictor approach to treating acute migraine. Olce",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.3515625,
            "text": "Calcitonin gene-related peptide (CGRP) receptor antagonists are another promising nonvasoconstr",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.3515625,
            "text": "Calcitonin gene-related peptide (CGRP) receptor antagonists are another promising nonvasoconstrictor approach to treating acute migraine. Olcegepant (BIBN4096",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.3515625,
            "text": "Calcitonin gene-related peptide (CGRP) receptor antagonists are another promising nonvasoconstrictor approach to treating acute migraine. Olcegepant (BIBN409",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.359375,
            "text": "Calcitonin gene-related peptide (CGRP) receptor antagonists are another promising nonvasoconstrictor approach to treating acute migraine. Ol",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.3671875,
            "text": "Calcitonin gene-related peptide (",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.375,
            "text": "Calcitonin gene-related peptide (CGRP) receptor antagonists are another promising nonvas",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.375,
            "text": "Calcitonin gene-related peptide (CGRP) receptor antagonists are another promising nonvasoconstrictor approach to treating acute migraine. Olcegepant (BIBN4",
            "probability": 0.0
        },
        {
            "start_logit": -2.56640625,
            "end_logit": -7.96875,
            "text": "peptide (CGRP",
            "probability": 0.0
        },
        {
            "start_logit": -2.56640625,
            "end_logit": -8.25,
            "text": "peptide (CGRP) receptor",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_12": [
        {
            "start_logit": 10.0234375,
            "end_logit": 9.4921875,
            "text": "calcitonin gene-related peptide",
            "probability": 1.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -1.8388671875,
            "text": "calcitonin",
            "probability": 1.2040138244628906e-05
        },
        {
            "start_logit": -2.388671875,
            "end_logit": 9.4921875,
            "text": "peptide",
            "probability": 4.0531158447265625e-06
        },
        {
            "start_logit": -6.2265625,
            "end_logit": 9.4921875,
            "text": "gene-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.69921875,
            "end_logit": 9.4921875,
            "text": "-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.13671875,
            "end_logit": 9.4921875,
            "text": "related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -7.67578125,
            "text": "calcitonin gene-related",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -7.75390625,
            "text": "calcitonin gene-related peptide (CGRP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.1875,
            "text": "calcitonin gene",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.203125,
            "text": "calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.25,
            "text": "calcitonin gene-related peptide (CGRP)",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.28125,
            "text": "calcitonin gene-related peptide (",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 9.4921875,
            "text": "a calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.4921875,
            "text": "- Telcagepant is a calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": -1.8388671875,
            "text": "a calcitonin",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": -1.8388671875,
            "text": "- Telcagepant is a calcitonin",
            "probability": 0.0
        },
        {
            "start_logit": -2.388671875,
            "end_logit": -7.75390625,
            "text": "peptide (CGRP",
            "probability": 0.0
        },
        {
            "start_logit": -2.388671875,
            "end_logit": -8.203125,
            "text": "peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -2.388671875,
            "end_logit": -8.25,
            "text": "peptide (CGRP)",
            "probability": 0.0
        },
        {
            "start_logit": -2.388671875,
            "end_logit": -8.28125,
            "text": "peptide (",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_13": [
        {
            "start_logit": 9.9609375,
            "end_logit": 9.4375,
            "text": "calcitonin gene-related peptide",
            "probability": 1.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -1.9765625,
            "text": "calcitonin",
            "probability": 1.0967254638671875e-05
        },
        {
            "start_logit": -2.494140625,
            "end_logit": 9.4375,
            "text": "peptide",
            "probability": 3.874301910400391e-06
        },
        {
            "start_logit": -6.48046875,
            "end_logit": 9.4375,
            "text": "gene-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -7.390625,
            "text": "calcitonin gene-related",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.19140625,
            "end_logit": 9.4375,
            "text": "-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.33984375,
            "end_logit": 9.4375,
            "text": "related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.109375,
            "text": "calcitonin gene",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.1640625,
            "text": "calcitonin gene-",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.4140625,
            "text": "calcitonin gene-related peptide antagonist",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.4296875,
            "text": "calcitonin gene-related peptide antagonist telcagepant 300",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.4375,
            "text": "calcitonin gene-related peptide antagonist telcagepant 300 mg orally had",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.4453125,
            "text": "calcitonin gene-related peptide antagonist tel",
            "probability": 0.0
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 9.4375,
            "text": "3 randomized clinical trials (n = 1585) the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": 9.4375,
            "text": "the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 9.4375,
            "text": "In 3 randomized clinical trials (n = 1585) the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 9.4375,
            "text": "clinical trials (n = 1585) the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 9.4375,
            "text": "(n = 1585) the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": 9.4375,
            "text": "trials (n = 1585) the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.4375,
            "text": "randomized clinical trials (n = 1585) the calcitonin gene-related peptide",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_14": [
        {
            "start_logit": 9.9765625,
            "end_logit": 9.46875,
            "text": "calcitonin gene-related peptide",
            "probability": 1.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -1.935546875,
            "text": "calcitonin",
            "probability": 1.1205673217773438e-05
        },
        {
            "start_logit": -2.447265625,
            "end_logit": 9.46875,
            "text": "peptide",
            "probability": 4.0531158447265625e-06
        },
        {
            "start_logit": -6.3359375,
            "end_logit": 9.46875,
            "text": "gene-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.875,
            "end_logit": 9.46875,
            "text": "-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -7.49609375,
            "text": "calcitonin gene-related",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 9.46875,
            "text": "related peptide",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.21875,
            "text": "calcitonin gene",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.3671875,
            "text": "calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 9.46875,
            "text": "oral calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.46875,
            "text": "an oral calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.46875,
            "text": "is an oral calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.46875,
            "text": "t is an oral calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -7.9765625,
            "end_logit": -1.935546875,
            "text": "oral calcitonin",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -1.935546875,
            "text": "an oral calcitonin",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -1.935546875,
            "text": "is an oral calcitonin",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -1.935546875,
            "text": "t is an oral calcitonin",
            "probability": 0.0
        },
        {
            "start_logit": -2.447265625,
            "end_logit": -8.3671875,
            "text": "peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -6.3359375,
            "end_logit": -7.49609375,
            "text": "gene-related",
            "probability": 0.0
        },
        {
            "start_logit": -6.875,
            "end_logit": -7.49609375,
            "text": "-related",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_15": [
        {
            "start_logit": 9.9609375,
            "end_logit": 9.453125,
            "text": "calcitonin gene-related peptide",
            "probability": 1.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -1.974609375,
            "text": "calcitonin",
            "probability": 1.0967254638671875e-05
        },
        {
            "start_logit": -2.470703125,
            "end_logit": 9.453125,
            "text": "peptide",
            "probability": 4.0531158447265625e-06
        },
        {
            "start_logit": -6.2890625,
            "end_logit": 9.453125,
            "text": "gene-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.765625,
            "end_logit": 9.453125,
            "text": "-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1640625,
            "end_logit": 9.453125,
            "text": "related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -7.953125,
            "text": "calcitonin gene-related",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.140625,
            "text": "calcitonin gene-related peptide (CGRP",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.1953125,
            "text": "calcitonin gene",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.2890625,
            "text": "calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.2890625,
            "text": "calcitonin gene-related peptide (CGRP)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.390625,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant (tablet formulation) for treatment of a migraine",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.40625,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.40625,
            "text": "calcitonin gene-related peptide (",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.453125,
            "text": "study evaluated the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.453125,
            "text": "evaluated the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.453125,
            "text": "This study evaluated the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 9.453125,
            "text": "the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": -1.974609375,
            "text": "study evaluated the calcitonin",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": -1.974609375,
            "text": "evaluated the calcitonin",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_16": [
        {
            "start_logit": 9.890625,
            "end_logit": 9.40625,
            "text": "calcitonin gene-related peptide",
            "probability": 1.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -2.1484375,
            "text": "calcitonin",
            "probability": 9.59634780883789e-06
        },
        {
            "start_logit": -2.568359375,
            "end_logit": 9.40625,
            "text": "peptide",
            "probability": 3.874301910400391e-06
        },
        {
            "start_logit": -6.515625,
            "end_logit": 9.40625,
            "text": "gene-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.23046875,
            "end_logit": 9.40625,
            "text": "related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.890625,
            "end_logit": -7.74609375,
            "text": "calcitonin gene-related",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.42578125,
            "end_logit": 9.40625,
            "text": "-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.203125,
            "text": "calcitonin gene",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.2109375,
            "text": "calcitonin gene-related peptide (CGRP",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.2890625,
            "text": "calcitonin gene-related peptide (CGRP)",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.3046875,
            "text": "calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.859375,
            "end_logit": 9.40625,
            "text": "of the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.375,
            "text": "calcitonin gene-related peptide (",
            "probability": 0.0
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 9.40625,
            "text": "the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.453125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.40625,
            "text": "trial of the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.40625,
            "text": "analysis of patient-level data from a previous randomized, placebo-controlled trial of the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.40625,
            "text": "composite efficacy-plus-tolerability endpoints based on a post-hoc analysis of patient-level data from a previous randomized, placebo-controlled trial of the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.40625,
            "text": "study was to evaluate new composite efficacy-plus-tolerability endpoints based on a post-hoc analysis of patient-level data from a previous randomized, placebo-controlled trial of the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.40625,
            "text": "on a post-hoc analysis of patient-level data from a previous randomized, placebo-controlled trial of the calcitonin gene-related peptide",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_17": [
        {
            "start_logit": 9.9453125,
            "end_logit": 9.515625,
            "text": "calcitonin gene-related peptide",
            "probability": 1.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -2.015625,
            "text": "calcitonin",
            "probability": 9.715557098388672e-06
        },
        {
            "start_logit": -2.34375,
            "end_logit": 9.515625,
            "text": "peptide",
            "probability": 4.589557647705078e-06
        },
        {
            "start_logit": -6.32421875,
            "end_logit": 9.515625,
            "text": "gene-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.8671875,
            "end_logit": 9.515625,
            "text": "-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.109375,
            "end_logit": 9.515625,
            "text": "related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -7.75,
            "text": "calcitonin gene-related",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -7.90625,
            "text": "calcitonin gene-related peptide (CGRP",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.09375,
            "text": "calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.125,
            "text": "calcitonin gene-related peptide (CGRP)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.1796875,
            "text": "calcitonin gene-related peptide (",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.2109375,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.21875,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist tel",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.234375,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist telca",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.25,
            "text": "calcitonin gene",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.2578125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human cranial arteries",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.3125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist telcage",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.3125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.3125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human cranial",
            "probability": 0.0
        },
        {
            "start_logit": -8.359375,
            "end_logit": 9.515625,
            "text": "Effect of the calcitonin gene-related peptide",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_18": [
        {
            "start_logit": 9.96875,
            "end_logit": 9.5234375,
            "text": "calcitonin gene-related peptide",
            "probability": 1.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -1.9580078125,
            "text": "calcitonin",
            "probability": 1.0192394256591797e-05
        },
        {
            "start_logit": -2.322265625,
            "end_logit": 9.5234375,
            "text": "peptide",
            "probability": 4.589557647705078e-06
        },
        {
            "start_logit": -6.41015625,
            "end_logit": 9.5234375,
            "text": "gene-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.96875,
            "end_logit": -7.4453125,
            "text": "calcitonin gene-related",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.12109375,
            "end_logit": 9.5234375,
            "text": "-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.31640625,
            "end_logit": 9.5234375,
            "text": "related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.1484375,
            "text": "calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.25,
            "text": "calcitonin gene",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.265625,
            "text": "calcitonin gene-",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.3046875,
            "text": "calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.3046875,
            "text": "calcitonin gene-related peptide receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.3203125,
            "text": "calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in human isolated coronary",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.328125,
            "text": "calcitonin gene-related peptide receptor antagonist tel",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.3359375,
            "text": "calcitonin gene-related peptide receptor antagonist telca",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.3515625,
            "text": "calcitonin gene-related peptide receptor antagonist telcagepant",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.5234375,
            "text": "the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.5234375,
            "text": "Characterization of the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.5234375,
            "text": "of the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -1.9580078125,
            "text": "the calcitonin",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_19": [
        {
            "start_logit": 10.0234375,
            "end_logit": 9.5859375,
            "text": "calcitonin gene-related peptide",
            "probability": 1.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -1.81640625,
            "text": "calcitonin",
            "probability": 1.1146068572998047e-05
        },
        {
            "start_logit": -2.19140625,
            "end_logit": 9.5859375,
            "text": "peptide",
            "probability": 4.947185516357422e-06
        },
        {
            "start_logit": -6.625,
            "end_logit": 9.5859375,
            "text": "gene-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -7.20703125,
            "text": "calcitonin gene-related",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.18359375,
            "end_logit": 9.5859375,
            "text": "-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 9.5859375,
            "text": "related peptide",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -7.9140625,
            "text": "calcitonin gene",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.0,
            "text": "calcitonin gene-",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.046875,
            "text": "calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.3515625,
            "text": "calcitonin gene-related peptide receptor blockers",
            "probability": 0.0
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 9.5859375,
            "text": "the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.5859375,
            "text": "of antimigraine drug-the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.5859375,
            "text": "-the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 9.5859375,
            "text": "drug-the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": 9.5859375,
            "text": "a new class of antimigraine drug-the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.3671875,
            "end_logit": 9.5859375,
            "text": "represents a new class of antimigraine drug-the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": 9.5859375,
            "text": "Telcagepant represents a new class of antimigraine drug-the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.3984375,
            "end_logit": 9.5859375,
            "text": "cagepant represents a new class of antimigraine drug-the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.3984375,
            "end_logit": 9.5859375,
            "text": "pant represents a new class of antimigraine drug-the calcitonin gene-related peptide",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_20": [
        {
            "start_logit": 9.9765625,
            "end_logit": 9.5546875,
            "text": "calcitonin gene-related peptide",
            "probability": 1.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -1.9326171875,
            "text": "calcitonin",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": -2.265625,
            "end_logit": 9.5546875,
            "text": "peptide",
            "probability": 4.827976226806641e-06
        },
        {
            "start_logit": -6.53125,
            "end_logit": 9.5546875,
            "text": "gene-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -7.34375,
            "text": "calcitonin gene-related",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.10546875,
            "end_logit": 9.5546875,
            "text": "-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.2734375,
            "end_logit": 9.5546875,
            "text": "related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.640625,
            "end_logit": 9.5546875,
            "text": "oral calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.1953125,
            "text": "calcitonin gene-",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.1953125,
            "text": "calcitonin gene",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.2578125,
            "text": "calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.5546875,
            "text": ", an oral calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.5546875,
            "text": "an oral calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 9.5546875,
            "text": "tolerability of telcagepant, an oral calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.5546875,
            "text": "of telcagepant, an oral calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.5546875,
            "text": "dose pharmacokinetics and tolerability of telcagepant, an oral calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.5546875,
            "text": "-dose pharmacokinetics and tolerability of telcagepant, an oral calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.5546875,
            "text": "multiple-dose pharmacokinetics and tolerability of telcagepant, an oral calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -7.640625,
            "end_logit": -1.9326171875,
            "text": "oral calcitonin",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -1.9326171875,
            "text": ", an oral calcitonin",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_21": [
        {
            "start_logit": 9.953125,
            "end_logit": 9.5078125,
            "text": "calcitonin gene-related peptide",
            "probability": 1.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -2.0,
            "text": "calcitonin",
            "probability": 9.953975677490234e-06
        },
        {
            "start_logit": -2.35546875,
            "end_logit": 9.5078125,
            "text": "peptide",
            "probability": 4.470348358154297e-06
        },
        {
            "start_logit": -6.4921875,
            "end_logit": 9.5078125,
            "text": "gene-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.953125,
            "end_logit": -7.2578125,
            "text": "calcitonin gene-related",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.109375,
            "end_logit": 9.5078125,
            "text": "-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.40625,
            "end_logit": 9.5078125,
            "text": "related peptide",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.1171875,
            "text": "calcitonin gene-",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.1796875,
            "text": "calcitonin gene",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.2890625,
            "text": "calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.2890625,
            "text": "calcitonin gene-related peptide receptor antagonist being developed for acute treatment of migraine with and",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.3828125,
            "text": "calcitonin gene-related peptide receptor antagonist being developed for acute treatment of migraine with and without aura",
            "probability": 0.0
        },
        {
            "start_logit": -7.9375,
            "end_logit": 9.5078125,
            "text": "selective calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.390625,
            "text": "calcitonin gene-related peptide receptor antagonist being developed for acute treatment of migraine with and without",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.5078125,
            "text": ", and selective calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 9.5078125,
            "text": "and selective calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.5078125,
            "text": ", orally active, and selective calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 9.5078125,
            "text": "active, and selective calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 9.5078125,
            "text": "orally active, and selective calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.5078125,
            "text": "novel, orally active, and selective calcitonin gene-related peptide",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_22": [
        {
            "start_logit": 9.9453125,
            "end_logit": 9.5390625,
            "text": "calcitonin gene-related peptide",
            "probability": 1.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -2.021484375,
            "text": "calcitonin",
            "probability": 9.5367431640625e-06
        },
        {
            "start_logit": -2.2890625,
            "end_logit": 9.5390625,
            "text": "peptide",
            "probability": 4.887580871582031e-06
        },
        {
            "start_logit": -6.19140625,
            "end_logit": 9.5390625,
            "text": "gene-related peptide",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.8359375,
            "end_logit": 9.5390625,
            "text": "-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -7.51953125,
            "text": "calcitonin gene-related",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1640625,
            "end_logit": 9.5390625,
            "text": "related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -7.78515625,
            "text": "calcitonin gene-related peptide (CGRP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.1484375,
            "text": "calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.171875,
            "text": "calcitonin gene-related peptide (CGRP)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.203125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant and to compare its coronary vasoconstrictive",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.2109375,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant and to compare its coronary vasoconstrict",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.2109375,
            "text": "calcitonin gene-related peptide (",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.2578125,
            "text": "calcitonin gene",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.28125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant and to compare its coronary vasoconstr",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.2890625,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.3125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist tel",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.3125,
            "text": "calcitonin gene-",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.3359375,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist telca",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.3359375,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant and to compare its coronary vasoconstrictive potential to that of zolmitri",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_23": [
        {
            "start_logit": 9.953125,
            "end_logit": 9.5703125,
            "text": "calcitonin gene-related peptide",
            "probability": 1.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -1.9970703125,
            "text": "calcitonin",
            "probability": 9.357929229736328e-06
        },
        {
            "start_logit": -2.232421875,
            "end_logit": 9.5703125,
            "text": "peptide",
            "probability": 5.066394805908203e-06
        },
        {
            "start_logit": -6.33984375,
            "end_logit": 9.5703125,
            "text": "gene-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.93359375,
            "end_logit": 9.5703125,
            "text": "-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.16015625,
            "end_logit": 9.5703125,
            "text": "related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.953125,
            "end_logit": -7.5625,
            "text": "calcitonin gene-related",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.953125,
            "end_logit": -7.8671875,
            "text": "calcitonin gene-related peptide (CGRP",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.125,
            "text": "calcitonin gene",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.1328125,
            "text": "calcitonin gene-related peptide (",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.1640625,
            "text": "calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.2109375,
            "text": "calcitonin gene-",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.28125,
            "text": "calcitonin gene-related peptide (CGRP)",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.3515625,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist and",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.3671875,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist and is currently under clinical",
            "probability": 0.0
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 9.5703125,
            "text": "oral calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.5703125,
            "text": "novel oral calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.5703125,
            "text": "a novel oral calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.5703125,
            "text": "is a novel oral calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.5703125,
            "text": "-0974) is a novel oral calcitonin gene-related peptide",
            "probability": 0.0
        }
    ],
    "5c6ab4c17c78d6947100001d_1": [
        {
            "start_logit": 9.953125,
            "end_logit": 9.6953125,
            "text": "MATLAB",
            "probability": 1.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -1.935546875,
            "text": "MAT",
            "probability": 8.821487426757812e-06
        },
        {
            "start_logit": -1.896484375,
            "end_logit": 9.6953125,
            "text": "LAB",
            "probability": 7.092952728271484e-06
        },
        {
            "start_logit": -6.5546875,
            "end_logit": 9.6953125,
            "text": ". Moreover, the validity of the method is not restricted to a particular type of kinetics. The tool offers total flexibility regarding network topology, kinetics and parameterization, as well as simulation options.Availability and implementation: SELANSI runs under the MATLAB",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.5546875,
            "end_logit": 9.6953125,
            "text": ". The tool offers total flexibility regarding network topology, kinetics and parameterization, as well as simulation options.Availability and implementation: SELANSI runs under the MATLAB",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.953125,
            "end_logit": -7.84375,
            "text": "MATLAB environment",
            "probability": 0.0
        },
        {
            "start_logit": -7.79296875,
            "end_logit": 9.6953125,
            "text": "the MATLAB",
            "probability": 0.0
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 9.6953125,
            "text": "under the MATLAB",
            "probability": 0.0
        },
        {
            "start_logit": -7.87109375,
            "end_logit": 9.6953125,
            "text": "SELANSI runs under the MATLAB",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.1953125,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.com",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.203125,
            "text": "MATLAB environment, and is available under GPLv3 licens",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.2109375,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.2109375,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.com/view",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.2265625,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.",
            "probability": 0.0
        },
        {
            "start_logit": -7.984375,
            "end_logit": 9.6953125,
            "text": "runs under the MATLAB",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.2734375,
            "text": "MATLAB environment, and is available under GPLv3",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.28125,
            "text": "MATLAB environment, and is available under GPLv3 license",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.6953125,
            "text": "I runs under the MATLAB",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.3125,
            "text": "MATLAB environment, and is available under GPLv",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.3203125,
            "text": "MATLAB environment, and is available under GPLv3 license at https:/",
            "probability": 0.0
        }
    ],
    "5c6ab4c17c78d6947100001d_2": [
        {
            "start_logit": 9.90625,
            "end_logit": 9.5390625,
            "text": "MATLAB",
            "probability": 1.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -2.0546875,
            "text": "MAT",
            "probability": 9.298324584960938e-06
        },
        {
            "start_logit": -2.27734375,
            "end_logit": 9.5390625,
            "text": "LAB",
            "probability": 5.185604095458984e-06
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.15625,
            "text": "MATLAB environment, and is available under GPLv3 licens",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.1640625,
            "text": "MATLAB environment",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.1796875,
            "text": "MATLAB environment, and is available under GPLv3 license",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.2109375,
            "text": "MATLAB environment, and is available under GPLv",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.2265625,
            "text": "MATLAB environment, and is available under GPLv3",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.25,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.28125,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.com",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.28125,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.com/view",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.28125,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.2890625,
            "text": "MATLAB environment, and is available under GP",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.3046875,
            "text": "MATLAB environment, and is available under GPLv3 license at https:/",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.328125,
            "text": "MATLAB environment, and is available under GPLv3 license at https:",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.3515625,
            "text": "MATLAB environment, and is",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.3515625,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.359375,
            "text": "MATLAB environment, and",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.359375,
            "text": "MATLAB environment, and is available under GPLv3 license at https",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.359375,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.",
            "probability": 0.0
        }
    ],
    "5c6ab4c17c78d6947100001d_3": [
        {
            "start_logit": 9.8828125,
            "end_logit": 9.46875,
            "text": "MATLAB",
            "probability": 1.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -2.103515625,
            "text": "MAT",
            "probability": 9.5367431640625e-06
        },
        {
            "start_logit": -2.40625,
            "end_logit": 9.46875,
            "text": "LAB",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": -6.421875,
            "end_logit": 9.46875,
            "text": ".<br><b>Availability and implementation</b>: SELANSI runs under the MATLAB",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.1328125,
            "text": "MATLAB environment",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.3671875,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.375,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.com",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.390625,
            "text": "MATLAB environment, and is available under GPLv3 licens",
            "probability": 0.0
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 9.46875,
            "text": "the MATLAB",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.3984375,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.com/view/selansi.<br><b>Contact</b>: antonio@iim.cs",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.40625,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.4140625,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.com/view",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.4140625,
            "text": "MATLAB environment, and is available under GPLv",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.4140625,
            "text": "MATLAB environment, and is available under GPLv3 license",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.421875,
            "text": "MATLAB environment, and is available under GPLv3 license at https:",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.4296875,
            "text": "MATLAB environment,",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.4296875,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.com/view/selansi.",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 9.46875,
            "text": "under the MATLAB",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.46875,
            "text": "runs under the MATLAB",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.46875,
            "text": "implementation</b>: SELANSI runs under the MATLAB",
            "probability": 0.0
        }
    ],
    "5c6ab4c17c78d6947100001d_4": [
        {
            "start_logit": 9.90625,
            "end_logit": 9.5,
            "text": "MATLAB",
            "probability": 1.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -2.068359375,
            "text": "MAT",
            "probability": 9.417533874511719e-06
        },
        {
            "start_logit": -2.365234375,
            "end_logit": 9.5,
            "text": "LAB",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.015625,
            "text": "MATLAB environment",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.2109375,
            "text": "MATLAB environment, and is available under GPLv3 licens",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.2109375,
            "text": "MATLAB environment, and is available under GPLv",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.2265625,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.234375,
            "text": "MATLAB environment, and is available under GPLv3 license",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.25,
            "text": "MATLAB environment, and is available under GPLv3",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.2578125,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.2578125,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.com",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.28125,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.com/view",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.296875,
            "text": "MATLAB environment, and is available under GP",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.3125,
            "text": "MATLAB environment, and",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.328125,
            "text": "MATLAB environment, and is",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.3359375,
            "text": "MATLAB environment, and is available under GPLv3 license at https:/",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.3515625,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.3515625,
            "text": "MATLAB environment, and is available under GPLv3 license at https:",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.3515625,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.com/view/selans",
            "probability": 0.0
        },
        {
            "start_logit": -7.984375,
            "end_logit": 9.5,
            "text": "SELANSI runs under the MATLAB",
            "probability": 0.0
        }
    ],
    "5a992b371d1251d03b00000a_1": [
        {
            "start_logit": 9.8671875,
            "end_logit": 9.65625,
            "text": "Metagenomics of the Human Intestinal Tract",
            "probability": 1.0
        },
        {
            "start_logit": -1.7724609375,
            "end_logit": 9.65625,
            "text": "Tract",
            "probability": 8.761882781982422e-06
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -2.109375,
            "text": "Metagen",
            "probability": 7.68899917602539e-06
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -5.109375,
            "text": "Metagenomics of the Human Intestinal Tract (MetaHIT) project",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -5.359375,
            "end_logit": 9.65625,
            "text": "and Metagenomics of the Human Intestinal Tract",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -6.1484375,
            "text": "Metagenomics of the Human Intestinal Tract (MetaHIT)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.16796875,
            "end_logit": 9.65625,
            "text": "omics of the Human Intestinal Tract",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.3828125,
            "end_logit": 9.65625,
            "text": "Human Intestinal Tract",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.44921875,
            "end_logit": 9.65625,
            "text": "the Human Intestinal Tract",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.07421875,
            "text": "Metagenomics of the Human Intestinal Tract (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.8984375,
            "end_logit": 9.65625,
            "text": "Intestinal Tract",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.1484375,
            "text": "Metagenomics of the Human Intestinal Tract (MetaHIT) project are focusing mainly on the human microbiome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.25390625,
            "text": "Metagenomics of the Human Intestinal Tract (Meta",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.31640625,
            "text": "Metagenomics of the Human Intestinal Tract (MetaHIT) project are focusing mainly on the human microbiome.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1953125,
            "end_logit": 9.65625,
            "text": "of the Human Intestinal Tract",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.4609375,
            "text": "Metagenomics of the Human Intestinal Tract (MetaHIT",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.50390625,
            "text": "Metagenomics of the Human Intestinal Tract (MetaHI",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.52734375,
            "text": "Metagenomics of the Human Intestinal",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -7.6875,
            "text": "Metagenomics of",
            "probability": 0.0
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 9.65625,
            "text": "consortia like the Human Microbiome project (HMP) and Metagenomics of the Human Intestinal Tract",
            "probability": 0.0
        }
    ],
    "530c7f52970c65fa6b000010_1": [
        {
            "start_logit": 10.2890625,
            "end_logit": 9.953125,
            "text": "Oxantel disrupts polymicrobial biofilm",
            "probability": 1.0
        },
        {
            "start_logit": 10.2890625,
            "end_logit": -1.025390625,
            "text": "Oxa",
            "probability": 1.6987323760986328e-05
        },
        {
            "start_logit": -0.9169921875,
            "end_logit": 9.953125,
            "text": "biofilm",
            "probability": 1.3530254364013672e-05
        },
        {
            "start_logit": 10.2890625,
            "end_logit": -4.9765625,
            "text": "Oxantel disrupts polymicrobial biofilm development",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 10.2890625,
            "end_logit": -5.359375,
            "text": "Oxantel disrupts polymicrobial biofilm development of periodontal",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 10.2890625,
            "end_logit": -5.57421875,
            "text": "Oxantel",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 10.2890625,
            "end_logit": -5.75,
            "text": "Oxantel disrupts polymicrobial biofilm development of periodontal pathogens",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.98828125,
            "end_logit": 9.953125,
            "text": "ntel disrupts polymicrobial biofilm",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.2890625,
            "end_logit": -6.79296875,
            "text": "Oxantel disrupts",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.2890625,
            "end_logit": -7.10546875,
            "text": "Oxantel disrupts polym",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.2890625,
            "end_logit": -7.33203125,
            "text": "Oxantel disrupts polymicrobial biofilm development of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.046875,
            "end_logit": 9.953125,
            "text": "polymicrobial biofilm",
            "probability": 0.0
        },
        {
            "start_logit": -7.13671875,
            "end_logit": 9.953125,
            "text": "ial biofilm",
            "probability": 0.0
        },
        {
            "start_logit": 10.2890625,
            "end_logit": -7.84765625,
            "text": "Oxantel disrupts polymicrobial",
            "probability": 0.0
        },
        {
            "start_logit": -7.8125,
            "end_logit": 9.953125,
            "text": "disrupts polymicrobial biofilm",
            "probability": 0.0
        },
        {
            "start_logit": -7.859375,
            "end_logit": 9.953125,
            "text": "robial biofilm",
            "probability": 0.0
        },
        {
            "start_logit": -7.875,
            "end_logit": 9.953125,
            "text": "icrobial biofilm",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.953125,
            "text": "el disrupts polymicrobial biofilm",
            "probability": 0.0
        },
        {
            "start_logit": -0.9169921875,
            "end_logit": -4.9765625,
            "text": "biofilm development",
            "probability": 0.0
        },
        {
            "start_logit": -0.9169921875,
            "end_logit": -5.359375,
            "text": "biofilm development of periodontal",
            "probability": 0.0
        }
    ],
    "5540fbce234c5a7c75000001_1": [
        {
            "start_logit": 10.1796875,
            "end_logit": 9.53125,
            "text": "Chaperone-mediated autophagy (CMA)",
            "probability": 1.0
        },
        {
            "start_logit": 10.1796875,
            "end_logit": -1.431640625,
            "text": "Chaperone",
            "probability": 1.722574234008789e-05
        },
        {
            "start_logit": -2.27734375,
            "end_logit": 9.53125,
            "text": ")",
            "probability": 3.874301910400391e-06
        },
        {
            "start_logit": -6.11328125,
            "end_logit": 9.53125,
            "text": "autophagy (CMA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.36328125,
            "end_logit": 9.53125,
            "text": "mediated autophagy (CMA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.4296875,
            "end_logit": 9.53125,
            "text": "-mediated autophagy (CMA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.59765625,
            "end_logit": 9.53125,
            "text": "(CMA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1796875,
            "end_logit": -7.50390625,
            "text": "Chaperone-mediated autophagy (CMA) is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1796875,
            "end_logit": -7.703125,
            "text": "Chaperone-mediated autophagy (CMA) is a selective form of lysosomal",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1796875,
            "end_logit": -7.75390625,
            "text": "Chaperone-mediated autophagy (CMA) is a selective form of lysosomal degradation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1796875,
            "end_logit": -7.796875,
            "text": "Chaperone-mediated autophagy (",
            "probability": 0.0
        },
        {
            "start_logit": -7.171875,
            "end_logit": 9.53125,
            "text": "CMA)",
            "probability": 0.0
        },
        {
            "start_logit": 10.1796875,
            "end_logit": -7.83203125,
            "text": "Chaperone-mediated autophagy (CMA) is a",
            "probability": 0.0
        },
        {
            "start_logit": 10.1796875,
            "end_logit": -7.91796875,
            "text": "Chaperone-mediated autophagy (CMA",
            "probability": 0.0
        },
        {
            "start_logit": 10.1796875,
            "end_logit": -8.0078125,
            "text": "Chaperone-mediated autophagy (CMA) is a selective form",
            "probability": 0.0
        },
        {
            "start_logit": 10.1796875,
            "end_logit": -8.0859375,
            "text": "Chaperone-mediated autophagy (CMA) is a selective",
            "probability": 0.0
        },
        {
            "start_logit": 10.1796875,
            "end_logit": -8.109375,
            "text": "Chaperone-mediated autophagy (CMA) is a selective form of lysosomal degradation targeting proteins carrying",
            "probability": 0.0
        },
        {
            "start_logit": 10.1796875,
            "end_logit": -8.1484375,
            "text": "Chaperone-mediated autophagy (CMA) is a selective form of lysosomal degradation targeting proteins carrying the KFERQ motif",
            "probability": 0.0
        },
        {
            "start_logit": 10.1796875,
            "end_logit": -8.1796875,
            "text": "Chaperone-mediated autophagy (CMA) is a selective form of lysosomal degradation targeting proteins carrying the KFERQ motif.",
            "probability": 0.0
        },
        {
            "start_logit": 10.1796875,
            "end_logit": -8.1796875,
            "text": "Chaperone-mediated autophagy (CMA) is a selective form of lysosomal degradation targeting proteins carrying the",
            "probability": 0.0
        }
    ],
    "5540fbce234c5a7c75000001_2": [
        {
            "start_logit": 10.1796875,
            "end_logit": 9.53125,
            "text": "Chaperone-mediated autophagy (CMA)",
            "probability": 1.0
        },
        {
            "start_logit": 10.1796875,
            "end_logit": -1.431640625,
            "text": "Chaperone",
            "probability": 1.722574234008789e-05
        },
        {
            "start_logit": -2.27734375,
            "end_logit": 9.53125,
            "text": ")",
            "probability": 3.874301910400391e-06
        },
        {
            "start_logit": -6.11328125,
            "end_logit": 9.53125,
            "text": "autophagy (CMA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.36328125,
            "end_logit": 9.53125,
            "text": "mediated autophagy (CMA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.4296875,
            "end_logit": 9.53125,
            "text": "-mediated autophagy (CMA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.59765625,
            "end_logit": 9.53125,
            "text": "(CMA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1796875,
            "end_logit": -7.50390625,
            "text": "Chaperone-mediated autophagy (CMA) is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1796875,
            "end_logit": -7.703125,
            "text": "Chaperone-mediated autophagy (CMA) is a selective form of lysosomal",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1796875,
            "end_logit": -7.75390625,
            "text": "Chaperone-mediated autophagy (CMA) is a selective form of lysosomal degradation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1796875,
            "end_logit": -7.796875,
            "text": "Chaperone-mediated autophagy (",
            "probability": 0.0
        },
        {
            "start_logit": -7.171875,
            "end_logit": 9.53125,
            "text": "CMA)",
            "probability": 0.0
        },
        {
            "start_logit": 10.1796875,
            "end_logit": -7.83203125,
            "text": "Chaperone-mediated autophagy (CMA) is a",
            "probability": 0.0
        },
        {
            "start_logit": 10.1796875,
            "end_logit": -7.91796875,
            "text": "Chaperone-mediated autophagy (CMA",
            "probability": 0.0
        },
        {
            "start_logit": 10.1796875,
            "end_logit": -8.0078125,
            "text": "Chaperone-mediated autophagy (CMA) is a selective form",
            "probability": 0.0
        },
        {
            "start_logit": 10.1796875,
            "end_logit": -8.0859375,
            "text": "Chaperone-mediated autophagy (CMA) is a selective",
            "probability": 0.0
        },
        {
            "start_logit": 10.1796875,
            "end_logit": -8.109375,
            "text": "Chaperone-mediated autophagy (CMA) is a selective form of lysosomal degradation targeting proteins carrying",
            "probability": 0.0
        },
        {
            "start_logit": 10.1796875,
            "end_logit": -8.1484375,
            "text": "Chaperone-mediated autophagy (CMA) is a selective form of lysosomal degradation targeting proteins carrying the KFERQ motif",
            "probability": 0.0
        },
        {
            "start_logit": 10.1796875,
            "end_logit": -8.1796875,
            "text": "Chaperone-mediated autophagy (CMA) is a selective form of lysosomal degradation targeting proteins carrying the KFERQ motif.",
            "probability": 0.0
        },
        {
            "start_logit": 10.1796875,
            "end_logit": -8.1796875,
            "text": "Chaperone-mediated autophagy (CMA) is a selective form of lysosomal degradation targeting proteins carrying the",
            "probability": 0.0
        }
    ],
    "5540fbce234c5a7c75000001_3": [
        {
            "start_logit": 10.1640625,
            "end_logit": 9.53125,
            "text": "Chaperone-mediated autophagy (CMA)",
            "probability": 1.0
        },
        {
            "start_logit": 10.1640625,
            "end_logit": -1.4765625,
            "text": "Chaperone",
            "probability": 1.6689300537109375e-05
        },
        {
            "start_logit": -2.30078125,
            "end_logit": 9.53125,
            "text": ")",
            "probability": 3.933906555175781e-06
        },
        {
            "start_logit": -6.0625,
            "end_logit": 9.53125,
            "text": "autophagy (CMA)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.296875,
            "end_logit": 9.53125,
            "text": "mediated autophagy (CMA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.31640625,
            "end_logit": 9.53125,
            "text": "-mediated autophagy (CMA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.4375,
            "end_logit": 9.53125,
            "text": "(CMA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1640625,
            "end_logit": -7.57421875,
            "text": "Chaperone-mediated autophagy (CMA) is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.0546875,
            "end_logit": 9.53125,
            "text": "CMA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1640625,
            "end_logit": -7.921875,
            "text": "Chaperone-mediated autophagy (CMA) is a",
            "probability": 0.0
        },
        {
            "start_logit": 10.1640625,
            "end_logit": -7.94140625,
            "text": "Chaperone-mediated autophagy (CMA",
            "probability": 0.0
        },
        {
            "start_logit": 10.1640625,
            "end_logit": -7.984375,
            "text": "Chaperone-mediated autophagy (",
            "probability": 0.0
        },
        {
            "start_logit": 10.1640625,
            "end_logit": -8.1171875,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble cytosolic proteins bearing the",
            "probability": 0.0
        },
        {
            "start_logit": 10.1640625,
            "end_logit": -8.140625,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism",
            "probability": 0.0
        },
        {
            "start_logit": 10.1640625,
            "end_logit": -8.1484375,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble cytosolic proteins bearing",
            "probability": 0.0
        },
        {
            "start_logit": 10.1640625,
            "end_logit": -8.15625,
            "text": "Chaperone-mediated autophagy (CMA) is a selective",
            "probability": 0.0
        },
        {
            "start_logit": 10.1640625,
            "end_logit": -8.1796875,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble cytosolic proteins bearing the sequence KFERQ",
            "probability": 0.0
        },
        {
            "start_logit": 10.1640625,
            "end_logit": -8.2265625,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble",
            "probability": 0.0
        },
        {
            "start_logit": 10.1640625,
            "end_logit": -8.234375,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble cytosolic proteins bearing the sequence KFER",
            "probability": 0.0
        },
        {
            "start_logit": 10.1640625,
            "end_logit": -8.2578125,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble cytosolic proteins",
            "probability": 0.0
        }
    ],
    "5540fbce234c5a7c75000001_4": [
        {
            "start_logit": 10.203125,
            "end_logit": 9.4765625,
            "text": "chaperone-mediated autophagy (CMA)",
            "probability": 1.0
        },
        {
            "start_logit": 10.203125,
            "end_logit": -1.3515625,
            "text": "chaperone",
            "probability": 1.9669532775878906e-05
        },
        {
            "start_logit": -2.361328125,
            "end_logit": 9.4765625,
            "text": ")",
            "probability": 3.4570693969726562e-06
        },
        {
            "start_logit": -4.77734375,
            "end_logit": 9.4765625,
            "text": "by chaperone-mediated autophagy (CMA)",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -5.71484375,
            "end_logit": 9.4765625,
            "text": "autophagy (CMA)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.09765625,
            "end_logit": 9.4765625,
            "text": "mediated autophagy (CMA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.1796875,
            "end_logit": 9.4765625,
            "text": "-mediated autophagy (CMA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.3671875,
            "end_logit": 9.4765625,
            "text": "(CMA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.203125,
            "end_logit": -7.59765625,
            "text": "chaperone-mediated autophagy (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.203125,
            "end_logit": -7.63671875,
            "text": "chaperone-mediated autophagy (CMA),",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.203125,
            "end_logit": -7.66015625,
            "text": "chaperone-mediated autophagy (CMA), in which Hsc70 (Heat shock cognate 70)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.203125,
            "end_logit": -7.75,
            "text": "chaperone-mediated autophagy (CMA), in which Hsc70 (Heat shock cognate 70) selectively binds proteins with exposed KFERQ motifs",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.078125,
            "end_logit": 9.4765625,
            "text": "CMA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.203125,
            "end_logit": -7.96875,
            "text": "chaperone-mediated autophagy (CMA), in which Hsc70 (Heat shock cognate 70) selectively binds proteins with exposed KFERQ motifs and pushes them inside lysosomes through the LAMP-2A (Lysosome-associated membrane protein type",
            "probability": 0.0
        },
        {
            "start_logit": 10.203125,
            "end_logit": -7.97265625,
            "text": "chaperone-mediated autophagy (CMA), in which Hsc70 (Heat shock cognate 70) selectively binds proteins with exposed KFERQ motifs and",
            "probability": 0.0
        },
        {
            "start_logit": 10.203125,
            "end_logit": -7.9921875,
            "text": "chaperone-mediated autophagy (CMA), in which Hsc70 (Heat shock cognate 70) selectively binds proteins with exposed KFERQ motifs and pushes them inside lysosomes through the LAMP-2A (Lysosome-associated membrane protein type 2A",
            "probability": 0.0
        },
        {
            "start_logit": 10.203125,
            "end_logit": -8.0078125,
            "text": "chaperone-mediated autophagy (CMA), in which Hsc70 (Heat shock cognate 70) selectively binds proteins with exposed KFERQ motifs and pushes them inside lysosomes through the LAMP-2A (Lysosome-associated membrane protein type 2A)",
            "probability": 0.0
        },
        {
            "start_logit": 10.203125,
            "end_logit": -8.03125,
            "text": "chaperone-mediated autophagy (CMA), in which Hsc70",
            "probability": 0.0
        },
        {
            "start_logit": 10.203125,
            "end_logit": -8.03125,
            "text": "chaperone-mediated autophagy (CMA), in which Hsc70 (Heat shock cognate 70) selectively binds proteins with exposed KFERQ",
            "probability": 0.0
        },
        {
            "start_logit": 10.203125,
            "end_logit": -8.03125,
            "text": "chaperone-mediated autophagy (CMA",
            "probability": 0.0
        }
    ],
    "5540fbce234c5a7c75000001_5": [
        {
            "start_logit": 10.203125,
            "end_logit": 9.4765625,
            "text": "chaperone-mediated autophagy (CMA)",
            "probability": 1.0
        },
        {
            "start_logit": 10.203125,
            "end_logit": -1.3515625,
            "text": "chaperone",
            "probability": 1.9669532775878906e-05
        },
        {
            "start_logit": -2.361328125,
            "end_logit": 9.4765625,
            "text": ")",
            "probability": 3.4570693969726562e-06
        },
        {
            "start_logit": -4.77734375,
            "end_logit": 9.4765625,
            "text": "by chaperone-mediated autophagy (CMA)",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -5.71484375,
            "end_logit": 9.4765625,
            "text": "autophagy (CMA)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.09765625,
            "end_logit": 9.4765625,
            "text": "mediated autophagy (CMA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.1796875,
            "end_logit": 9.4765625,
            "text": "-mediated autophagy (CMA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.3671875,
            "end_logit": 9.4765625,
            "text": "(CMA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.203125,
            "end_logit": -7.59765625,
            "text": "chaperone-mediated autophagy (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.203125,
            "end_logit": -7.63671875,
            "text": "chaperone-mediated autophagy (CMA),",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.203125,
            "end_logit": -7.66015625,
            "text": "chaperone-mediated autophagy (CMA), in which Hsc70 (Heat shock cognate 70)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.203125,
            "end_logit": -7.75,
            "text": "chaperone-mediated autophagy (CMA), in which Hsc70 (Heat shock cognate 70) selectively binds proteins with exposed KFERQ motifs",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.078125,
            "end_logit": 9.4765625,
            "text": "CMA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.203125,
            "end_logit": -7.96875,
            "text": "chaperone-mediated autophagy (CMA), in which Hsc70 (Heat shock cognate 70) selectively binds proteins with exposed KFERQ motifs and pushes them inside lysosomes through the LAMP-2A (Lysosome-associated membrane protein type",
            "probability": 0.0
        },
        {
            "start_logit": 10.203125,
            "end_logit": -7.97265625,
            "text": "chaperone-mediated autophagy (CMA), in which Hsc70 (Heat shock cognate 70) selectively binds proteins with exposed KFERQ motifs and",
            "probability": 0.0
        },
        {
            "start_logit": 10.203125,
            "end_logit": -7.9921875,
            "text": "chaperone-mediated autophagy (CMA), in which Hsc70 (Heat shock cognate 70) selectively binds proteins with exposed KFERQ motifs and pushes them inside lysosomes through the LAMP-2A (Lysosome-associated membrane protein type 2A",
            "probability": 0.0
        },
        {
            "start_logit": 10.203125,
            "end_logit": -8.0078125,
            "text": "chaperone-mediated autophagy (CMA), in which Hsc70 (Heat shock cognate 70) selectively binds proteins with exposed KFERQ motifs and pushes them inside lysosomes through the LAMP-2A (Lysosome-associated membrane protein type 2A)",
            "probability": 0.0
        },
        {
            "start_logit": 10.203125,
            "end_logit": -8.03125,
            "text": "chaperone-mediated autophagy (CMA), in which Hsc70",
            "probability": 0.0
        },
        {
            "start_logit": 10.203125,
            "end_logit": -8.03125,
            "text": "chaperone-mediated autophagy (CMA), in which Hsc70 (Heat shock cognate 70) selectively binds proteins with exposed KFERQ",
            "probability": 0.0
        },
        {
            "start_logit": 10.203125,
            "end_logit": -8.03125,
            "text": "chaperone-mediated autophagy (CMA",
            "probability": 0.0
        }
    ],
    "5540fbce234c5a7c75000001_6": [
        {
            "start_logit": 10.1875,
            "end_logit": 9.546875,
            "text": "Chaperone-mediated autophagy (CMA)",
            "probability": 1.0
        },
        {
            "start_logit": 10.1875,
            "end_logit": -1.431640625,
            "text": "Chaperone",
            "probability": 1.710653305053711e-05
        },
        {
            "start_logit": -2.26953125,
            "end_logit": 9.546875,
            "text": ")",
            "probability": 3.933906555175781e-06
        },
        {
            "start_logit": -6.046875,
            "end_logit": 9.546875,
            "text": "autophagy (CMA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.28515625,
            "end_logit": 9.546875,
            "text": "(CMA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.37109375,
            "end_logit": 9.546875,
            "text": "mediated autophagy (CMA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.375,
            "end_logit": 9.546875,
            "text": "-mediated autophagy (CMA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.890625,
            "end_logit": 9.546875,
            "text": "CMA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1875,
            "end_logit": -7.6328125,
            "text": "Chaperone-mediated autophagy (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1875,
            "end_logit": -7.85546875,
            "text": "Chaperone-mediated autophagy (CMA) is",
            "probability": 0.0
        },
        {
            "start_logit": 10.1875,
            "end_logit": -8.0,
            "text": "Chaperone-mediated autophagy (CMA) is a",
            "probability": 0.0
        },
        {
            "start_logit": 10.1875,
            "end_logit": -8.15625,
            "text": "Chaperone-mediated autophagy (CMA",
            "probability": 0.0
        },
        {
            "start_logit": 10.1875,
            "end_logit": -8.1875,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble cytosolic proteins bearing the sequence KFERQ",
            "probability": 0.0
        },
        {
            "start_logit": 10.1875,
            "end_logit": -8.1875,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble cytosolic proteins bearing the",
            "probability": 0.0
        },
        {
            "start_logit": 10.1875,
            "end_logit": -8.2109375,
            "text": "Chaperone-mediated autophagy (CMA) is a selective",
            "probability": 0.0
        },
        {
            "start_logit": 10.1875,
            "end_logit": -8.2109375,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble cytosolic proteins bearing",
            "probability": 0.0
        },
        {
            "start_logit": 10.1875,
            "end_logit": -8.234375,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble cytosolic proteins bearing the sequence KFER",
            "probability": 0.0
        },
        {
            "start_logit": 10.1875,
            "end_logit": -8.2421875,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism",
            "probability": 0.0
        },
        {
            "start_logit": 10.1875,
            "end_logit": -8.2421875,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble",
            "probability": 0.0
        },
        {
            "start_logit": 10.1875,
            "end_logit": -8.25,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of",
            "probability": 0.0
        }
    ],
    "5540fbce234c5a7c75000001_7": [
        {
            "start_logit": 10.1171875,
            "end_logit": 9.5,
            "text": "Chaperone-mediated autophagy (CMA)",
            "probability": 1.0
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -1.603515625,
            "text": "Chaperone",
            "probability": 1.4960765838623047e-05
        },
        {
            "start_logit": -2.353515625,
            "end_logit": 9.5,
            "text": ")",
            "probability": 3.814697265625e-06
        },
        {
            "start_logit": -6.08203125,
            "end_logit": 9.5,
            "text": "autophagy (CMA)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.36328125,
            "end_logit": 9.5,
            "text": "mediated autophagy (CMA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.4140625,
            "end_logit": 9.5,
            "text": "(CMA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.43359375,
            "end_logit": 9.5,
            "text": "-mediated autophagy (CMA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.203125,
            "end_logit": 9.5,
            "text": "CMA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -7.8828125,
            "text": "Chaperone-mediated autophagy (CMA) is",
            "probability": 0.0
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -7.96484375,
            "text": "Chaperone-mediated autophagy (CMA",
            "probability": 0.0
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -8.046875,
            "text": "Chaperone-mediated autophagy (CMA) is a",
            "probability": 0.0
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -8.125,
            "text": "Chaperone-mediated autophagy (",
            "probability": 0.0
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -8.1796875,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble cytosolic proteins bearing the",
            "probability": 0.0
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -8.1953125,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble cytosolic proteins bearing the sequence KFERQ",
            "probability": 0.0
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -8.1953125,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble cytosolic proteins bearing",
            "probability": 0.0
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -8.2109375,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism",
            "probability": 0.0
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -8.234375,
            "text": "Chaperone-mediated autophagy (CMA) is a selective",
            "probability": 0.0
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -8.2734375,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble cytosolic proteins bearing the sequence KFER",
            "probability": 0.0
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -8.2890625,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble",
            "probability": 0.0
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -8.3203125,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble cytosolic proteins",
            "probability": 0.0
        }
    ],
    "5540fbce234c5a7c75000001_8": [
        {
            "start_logit": 10.1640625,
            "end_logit": 9.4375,
            "text": "chaperone-mediated autophagy (CMA)",
            "probability": 1.0
        },
        {
            "start_logit": 10.1640625,
            "end_logit": -1.4599609375,
            "text": "chaperone",
            "probability": 1.8656253814697266e-05
        },
        {
            "start_logit": -2.46484375,
            "end_logit": 9.4375,
            "text": ")",
            "probability": 3.2782554626464844e-06
        },
        {
            "start_logit": -5.25,
            "end_logit": 9.4375,
            "text": "by chaperone-mediated autophagy (CMA)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.69140625,
            "end_logit": 9.4375,
            "text": "autophagy (CMA)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.1171875,
            "end_logit": 9.4375,
            "text": "mediated autophagy (CMA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.18359375,
            "end_logit": 9.4375,
            "text": "-mediated autophagy (CMA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.2421875,
            "end_logit": 9.4375,
            "text": "(CMA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1640625,
            "end_logit": -7.82421875,
            "text": "chaperone-mediated autophagy (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1328125,
            "end_logit": 9.4375,
            "text": "CMA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1640625,
            "end_logit": -7.9296875,
            "text": "chaperone-mediated autophagy (CMA),",
            "probability": 0.0
        },
        {
            "start_logit": 10.1640625,
            "end_logit": -8.0078125,
            "text": "chaperone-mediated autophagy (CMA), in which Hsc70 (Heat shock cognate 70) selectively binds proteins with exposed KFERQ motifs",
            "probability": 0.0
        },
        {
            "start_logit": 10.1640625,
            "end_logit": -8.0234375,
            "text": "chaperone-mediated autophagy (CMA), in which Hsc70 (Heat shock cognate 70)",
            "probability": 0.0
        },
        {
            "start_logit": 10.1640625,
            "end_logit": -8.0859375,
            "text": "chaperone-mediated autophagy (CMA), in which Hsc70 (Heat shock cognate 70) selectively binds proteins with exposed KFERQ motifs and pushes them inside lysosomes through the LAMP-2A (Lysosome-associated membrane protein type 2A",
            "probability": 0.0
        },
        {
            "start_logit": 10.1640625,
            "end_logit": -8.109375,
            "text": "chaperone-mediated autophagy (CMA), in which Hsc70 (Heat shock cognate 70) selectively binds proteins with exposed KFERQ motifs and pushes them inside lysosomes through the LAMP-2A (Lysosome-associated membrane protein type",
            "probability": 0.0
        },
        {
            "start_logit": 10.1640625,
            "end_logit": -8.1171875,
            "text": "chaperone-mediated autophagy (CMA",
            "probability": 0.0
        },
        {
            "start_logit": 10.1640625,
            "end_logit": -8.1171875,
            "text": "chaperone-mediated autophagy (CMA), in which Hsc70 (Heat shock cognate 70) selectively binds proteins with exposed KFERQ motifs and",
            "probability": 0.0
        },
        {
            "start_logit": 10.1640625,
            "end_logit": -8.1328125,
            "text": "chaperone-mediated autophagy (CMA), in which Hsc70 (Heat shock cognate 70) selectively binds proteins with exposed KFERQ",
            "probability": 0.0
        },
        {
            "start_logit": 10.1640625,
            "end_logit": -8.1328125,
            "text": "chaperone-mediated autophagy (CMA), in which Hsc70",
            "probability": 0.0
        },
        {
            "start_logit": 10.1640625,
            "end_logit": -8.1640625,
            "text": "chaperone-mediated autophagy (CMA), in which Hsc70 (Heat shock cognate 70) selectively binds proteins with exposed KFERQ motifs and pushes them inside lysosomes through the LAMP-2A",
            "probability": 0.0
        }
    ],
    "5ac138aa95d0062724000001_1": [
        {
            "start_logit": 10.5078125,
            "end_logit": 0.321044921875,
            "text": "Nar",
            "probability": 0.60693359375
        },
        {
            "start_logit": 1.072265625,
            "end_logit": 8.5078125,
            "text": ".",
            "probability": 0.1739501953125
        },
        {
            "start_logit": 10.5078125,
            "end_logit": -1.1708984375,
            "text": "Nardilysin (N-arginine dibasic convertase; Nrdc) is a metalloendopeptidase of the M16 family",
            "probability": 0.136474609375
        },
        {
            "start_logit": 10.5078125,
            "end_logit": -3.283203125,
            "text": "Nardilysin (N-arginine dibasic convertase; Nrdc) is a metalloendopeptidase of the M16 family that promotes ectodomain shedding of the precursor forms of various growth factors and cytokines by",
            "probability": 0.0165557861328125
        },
        {
            "start_logit": 10.5078125,
            "end_logit": -3.646484375,
            "text": "Nardilysin (N-arginine dibasic convertase; Nrdc) is a metalloendopeptidase of the M1",
            "probability": 0.01146697998046875
        },
        {
            "start_logit": 10.5078125,
            "end_logit": -3.765625,
            "text": "Nardilysin (N-arginine dibasic convertase; Nrdc) is a metalloendopeptidase of the M16",
            "probability": 0.01020050048828125
        },
        {
            "start_logit": 10.5078125,
            "end_logit": -3.998046875,
            "text": "Nardilysin (N-arginine dibasic convertase; Nrdc) is a metalloendopeptidase of the M16 family that",
            "probability": 0.0080718994140625
        },
        {
            "start_logit": 10.5078125,
            "end_logit": -4.2734375,
            "text": "Nardilysin (N-arginine dibasic convertase; Nrdc",
            "probability": 0.00614166259765625
        },
        {
            "start_logit": 10.5078125,
            "end_logit": -4.5078125,
            "text": "Nardilysin (N-arginine dibasic convertase; Nrdc) is a metalloendopeptidase of the M16 family that promotes ectodomain shedding of the precursor forms of various growth factors and cytokines by enhancing the protease",
            "probability": 0.004856109619140625
        },
        {
            "start_logit": 10.5078125,
            "end_logit": -4.55078125,
            "text": "Nardilysin (N-arginine dibasic convertase; Nrdc) is a metalloendopeptidase of the M16 family that promotes ectodomain shedding of the precursor forms of various growth factors and cytokines by enhancing the protease activities",
            "probability": 0.004650115966796875
        },
        {
            "start_logit": 10.5078125,
            "end_logit": -4.69921875,
            "text": "Nardilysin (N-arginine dibasic convertase; Nrdc) is a metalloendopeptidase of the M16 family that promotes",
            "probability": 0.004009246826171875
        },
        {
            "start_logit": 10.5078125,
            "end_logit": -5.1796875,
            "text": "Nardilysin (N-arginine dibasic convertase; Nrdc) is a metalloendopeptidase of the M16 family that promotes ectodomain shedding",
            "probability": 0.00247955322265625
        },
        {
            "start_logit": 10.5078125,
            "end_logit": -5.20703125,
            "text": "Nardilysin (N-arginine dibasic convertase; Nrdc) is a metalloendopeptidase of the M16 family that promotes ectodomain shedding of the precursor forms of various growth factors and cytokines",
            "probability": 0.0024127960205078125
        },
        {
            "start_logit": 10.5078125,
            "end_logit": -5.21484375,
            "text": "Nardilysin (N-arginine dibasic convertase; Nr",
            "probability": 0.0023937225341796875
        },
        {
            "start_logit": -3.234375,
            "end_logit": 8.5078125,
            "text": "; Nrdc) is a metalloendopeptidase of the M16 family that promotes ectodomain shedding of the precursor forms of various growth factors and cytokines by enhancing the protease activities of a disintegrin and metalloproteinase (ADAM) proteins.",
            "probability": 0.002349853515625
        },
        {
            "start_logit": 10.5078125,
            "end_logit": -5.24609375,
            "text": "Nardilysin (N-arginine dibasic convertase; Nrdc) is a metalloendopeptidase of the M16 family that promotes ectodomain shedding of the precursor",
            "probability": 0.0023212432861328125
        },
        {
            "start_logit": 10.5078125,
            "end_logit": -5.29296875,
            "text": "Nardilysin (N-arginine dibasic convertase; Nrdc) is a metalloendopeptidase of the M16 family that promotes ectodomain shedding of the precursor forms of various growth factors and cytokines by enhancing",
            "probability": 0.0022144317626953125
        },
        {
            "start_logit": -3.98828125,
            "end_logit": 8.5078125,
            "text": "of a disintegrin and metalloproteinase (ADAM) proteins.",
            "probability": 0.0011053085327148438
        },
        {
            "start_logit": -4.64453125,
            "end_logit": 8.5078125,
            "text": "ectodomain shedding of the precursor forms of various growth factors and cytokines by enhancing the protease activities of a disintegrin and metalloproteinase (ADAM) proteins.",
            "probability": 0.0005731582641601562
        },
        {
            "start_logit": -4.68359375,
            "end_logit": 8.5078125,
            "text": "a metalloendopeptidase of the M16 family that promotes ectodomain shedding of the precursor forms of various growth factors and cytokines by enhancing the protease activities of a disintegrin and metalloproteinase (ADAM) proteins.",
            "probability": 0.0005512237548828125
        }
    ],
    "5708a845cf1c32585100000f_1": [
        {
            "start_logit": 9.9921875,
            "end_logit": 9.65625,
            "text": "Wnt signaling",
            "probability": 1.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -1.876953125,
            "text": "Wnt",
            "probability": 9.715557098388672e-06
        },
        {
            "start_logit": -1.9521484375,
            "end_logit": 9.65625,
            "text": "signaling",
            "probability": 6.4373016357421875e-06
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.078125,
            "text": "Wnt signaling is",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.1796875,
            "text": "Wnt signaling is known to be important for diverse embryonic and post-natal cellular events and be regulated by the proteins Dishevelled and Axin. Although Dishevelled is activated by Wnt and involved in signal transduction, it is not clear",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.2265625,
            "text": "Wnt signaling is known to be important for diverse embryonic and post-natal cellular events",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.234375,
            "text": "Wnt signaling is known to be important for diverse embryonic and post-natal cellular events and be regulated by the proteins Dishevelled and Axin. Although Dishevelled is activated by Wnt and involved in signal transduction",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.25,
            "text": "Wnt signaling is known to be important for diverse embryonic and post-natal cellular events and be regulated by the proteins Dishevelled and Axin. Although Dishevelled is activated by Wnt",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.25,
            "text": "Wnt signaling is known to be important for diverse embryonic and post-natal cellular events and be regulated by the proteins Dishevelled and Axin. Although Dishevelled is",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.265625,
            "text": "Wnt signaling is known to be important for diverse embryonic and post-natal cellular events and be regulated by the proteins Dishevelled and Axin. Although Dishevelled",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.28125,
            "text": "Wnt signaling is known",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.2890625,
            "text": "Wnt signaling is known to be important for diverse embryonic and post-natal cellular events and be regulated by the proteins Dishevelled",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.296875,
            "text": "Wnt signaling is known to be important for diverse embryonic and post-natal cellular events and be regulated by the proteins Dishevelled and Axin. Although Dishevelled is activated",
            "probability": 0.0
        },
        {
            "start_logit": -1.9521484375,
            "end_logit": -8.078125,
            "text": "signaling is",
            "probability": 0.0
        },
        {
            "start_logit": -1.9521484375,
            "end_logit": -8.1796875,
            "text": "signaling is known to be important for diverse embryonic and post-natal cellular events and be regulated by the proteins Dishevelled and Axin. Although Dishevelled is activated by Wnt and involved in signal transduction, it is not clear",
            "probability": 0.0
        },
        {
            "start_logit": -1.9521484375,
            "end_logit": -8.2265625,
            "text": "signaling is known to be important for diverse embryonic and post-natal cellular events",
            "probability": 0.0
        },
        {
            "start_logit": -1.9521484375,
            "end_logit": -8.234375,
            "text": "signaling is known to be important for diverse embryonic and post-natal cellular events and be regulated by the proteins Dishevelled and Axin. Although Dishevelled is activated by Wnt and involved in signal transduction",
            "probability": 0.0
        },
        {
            "start_logit": -1.9521484375,
            "end_logit": -8.2421875,
            "text": "signaling is known to be important for diverse embryonic and post-natal cellular events and be regulated by the proteins Dishevelled and Axin. Although Dishevelled is activated by Wnt and involved in signal transduction, it is not clear how Dishevelled",
            "probability": 0.0
        },
        {
            "start_logit": -1.9521484375,
            "end_logit": -8.25,
            "text": "signaling is known to be important for diverse embryonic and post-natal cellular events and be regulated by the proteins Dishevelled and Axin. Although Dishevelled is activated by Wnt",
            "probability": 0.0
        },
        {
            "start_logit": -1.9521484375,
            "end_logit": -8.25,
            "text": "signaling is known to be important for diverse embryonic and post-natal cellular events and be regulated by the proteins Dishevelled and Axin. Although Dishevelled is",
            "probability": 0.0
        }
    ],
    "5708a845cf1c32585100000f_2": [
        {
            "start_logit": 10.0703125,
            "end_logit": 9.5625,
            "text": "Wnt signaling",
            "probability": 1.0
        },
        {
            "start_logit": 10.0703125,
            "end_logit": -1.6630859375,
            "text": "Wnt",
            "probability": 1.341104507446289e-05
        },
        {
            "start_logit": -2.16015625,
            "end_logit": 9.5625,
            "text": "signaling",
            "probability": 4.947185516357422e-06
        },
        {
            "start_logit": -6.6015625,
            "end_logit": 9.5625,
            "text": ". Intriguingly, within the same tissues where Xenopus Dishevelled (Xdsh) controls cell fate via canonical Wnt signaling",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0703125,
            "end_logit": -8.3671875,
            "text": "Wnt signaling,",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.5625,
            "text": ", within the same tissues where Xenopus Dishevelled (Xdsh) controls cell fate via canonical Wnt signaling",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.5625,
            "text": "cell fate via canonical Wnt signaling",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.5625,
            "text": "via canonical Wnt signaling",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.5625,
            "text": "biological processes. Intriguingly, within the same tissues where Xenopus Dishevelled (Xdsh) controls cell fate via canonical Wnt signaling",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.5625,
            "text": "canonical Wnt signaling",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.5625,
            "text": "diverse biological processes. Intriguingly, within the same tissues where Xenopus Dishevelled (Xdsh) controls cell fate via canonical Wnt signaling",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.5625,
            "text": "several diverse biological processes. Intriguingly, within the same tissues where Xenopus Dishevelled (Xdsh) controls cell fate via canonical Wnt signaling",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.5625,
            "text": "The Dishevelled protein mediates several diverse biological processes. Intriguingly, within the same tissues where Xenopus Dishevelled (Xdsh) controls cell fate via canonical Wnt signaling",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.5625,
            "text": "processes. Intriguingly, within the same tissues where Xenopus Dishevelled (Xdsh) controls cell fate via canonical Wnt signaling",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": 9.5625,
            "text": ") controls cell fate via canonical Wnt signaling",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.5625,
            "text": "Dishevelled protein mediates several diverse biological processes. Intriguingly, within the same tissues where Xenopus Dishevelled (Xdsh) controls cell fate via canonical Wnt signaling",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.5625,
            "text": "ly, within the same tissues where Xenopus Dishevelled (Xdsh) controls cell fate via canonical Wnt signaling",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.5625,
            "text": "controls cell fate via canonical Wnt signaling",
            "probability": 0.0
        },
        {
            "start_logit": -6.6015625,
            "end_logit": -1.6630859375,
            "text": ". Intriguingly, within the same tissues where Xenopus Dishevelled (Xdsh) controls cell fate via canonical Wnt",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -1.6630859375,
            "text": ", within the same tissues where Xenopus Dishevelled (Xdsh) controls cell fate via canonical Wnt",
            "probability": 0.0
        }
    ],
    "5708a845cf1c32585100000f_3": [
        {
            "start_logit": 10.0703125,
            "end_logit": 9.5546875,
            "text": "Wnt signaling",
            "probability": 1.0
        },
        {
            "start_logit": 10.0703125,
            "end_logit": -1.6591796875,
            "text": "Wnt",
            "probability": 1.3530254364013672e-05
        },
        {
            "start_logit": -2.193359375,
            "end_logit": 9.5546875,
            "text": "signaling",
            "probability": 4.708766937255859e-06
        },
        {
            "start_logit": 10.0703125,
            "end_logit": -8.2890625,
            "text": "Wnt signaling pathways",
            "probability": 0.0
        },
        {
            "start_logit": -7.89453125,
            "end_logit": 9.5546875,
            "text": "al Wnt signaling",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 9.5546875,
            "text": "which have been identified in humans, are highly conserved components of canonical and noncanonical Wnt signaling",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.5546875,
            "text": "been identified in humans, are highly conserved components of canonical and noncanonical Wnt signaling",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.5546875,
            "text": ", are highly conserved components of canonical and noncanonical Wnt signaling",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.5546875,
            "text": "humans, are highly conserved components of canonical and noncanonical Wnt signaling",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.5546875,
            "text": "have been identified in humans, are highly conserved components of canonical and noncanonical Wnt signaling",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.5546875,
            "text": "conserved components of canonical and noncanonical Wnt signaling",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.5546875,
            "text": "identified in humans, are highly conserved components of canonical and noncanonical Wnt signaling",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.5546875,
            "text": "of which have been identified in humans, are highly conserved components of canonical and noncanonical Wnt signaling",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.5546875,
            "text": "are highly conserved components of canonical and noncanonical Wnt signaling",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.5546875,
            "text": "components of canonical and noncanonical Wnt signaling",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.5546875,
            "text": "three of which have been identified in humans, are highly conserved components of canonical and noncanonical Wnt signaling",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.5546875,
            "text": ", three of which have been identified in humans, are highly conserved components of canonical and noncanonical Wnt signaling",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.5546875,
            "text": "and noncanonical Wnt signaling",
            "probability": 0.0
        },
        {
            "start_logit": -7.89453125,
            "end_logit": -1.6591796875,
            "text": "al Wnt",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": -1.6591796875,
            "text": "which have been identified in humans, are highly conserved components of canonical and noncanonical Wnt",
            "probability": 0.0
        }
    ],
    "5acf74460340b9f058000013_1": [
        {
            "start_logit": 9.9765625,
            "end_logit": 9.5234375,
            "text": "ABCC11",
            "probability": 1.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -1.943359375,
            "text": "ABC",
            "probability": 1.043081283569336e-05
        },
        {
            "start_logit": -2.341796875,
            "end_logit": 9.5234375,
            "text": "1",
            "probability": 4.470348358154297e-06
        },
        {
            "start_logit": -6.5078125,
            "end_logit": 9.5234375,
            "text": "C11",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -7.91796875,
            "text": "ABCC1",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.296875,
            "text": "ABCC11 affects the cerume",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.3203125,
            "text": "ABCC11 affects the cerumen",
            "probability": 0.0
        },
        {
            "start_logit": -7.8828125,
            "end_logit": 9.5234375,
            "text": "in ABCC11",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.3515625,
            "text": "ABCC11 affects the cerumen VOC profiles",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.3515625,
            "text": "ABCC11 affects the cerumen VOC profiles of individuals from African, Caucasian, and Asian descent",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.359375,
            "text": "ABCC11 affects the cerumen VOC",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.390625,
            "text": "ABCC11 affects the cerumen VOC profiles of",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.4375,
            "text": "ABCC11 affects the cerumen VOC profiles of individuals from",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.453125,
            "text": "ABCC11 affects the cerumen VOC profiles of individuals from African",
            "probability": 0.0
        },
        {
            "start_logit": -8.0,
            "end_logit": 9.5234375,
            "text": "A single nucleotide polymorphism (SNP) in ABCC11",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 9.5234375,
            "text": "single nucleotide polymorphism (SNP) in ABCC11",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.5234375,
            "text": "SNP) in ABCC11",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.5234375,
            "text": "(SNP) in ABCC11",
            "probability": 0.0
        },
        {
            "start_logit": -7.8828125,
            "end_logit": -1.943359375,
            "text": "in ABC",
            "probability": 0.0
        },
        {
            "start_logit": -8.0,
            "end_logit": -1.943359375,
            "text": "A single nucleotide polymorphism (SNP) in ABC",
            "probability": 0.0
        }
    ],
    "5acf74460340b9f058000013_2": [
        {
            "start_logit": 9.984375,
            "end_logit": 9.5859375,
            "text": "ABCC11",
            "probability": 1.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -1.9033203125,
            "text": "ABC",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": -2.177734375,
            "end_logit": 9.5859375,
            "text": "1",
            "probability": 5.245208740234375e-06
        },
        {
            "start_logit": -6.015625,
            "end_logit": 9.5859375,
            "text": "C11",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.015625,
            "text": "ABCC1",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.0546875,
            "text": "ABCC11 genotype alone does not predict the type and relative levels of volatiles found in human cerumen, and suggest that other biochemical pathways must",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.09375,
            "text": "ABCC11 genotype alone",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.1015625,
            "text": "ABCC11 genotype alone does not predict the type and relative levels of volatiles found in human cerumen, and suggest that other biochemical pathways",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.1328125,
            "text": "ABCC11 genotype alone does not predict the type and relative levels of volatiles found in human cerumen, and suggest that other",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.1796875,
            "text": "ABCC11 genotype alone does not predict the type and relative levels of volatiles found in human cerumen, and suggest that other biochemical pathways must be",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.1875,
            "text": "ABCC11 genotype alone does not predict the type and relative levels of volatiles found in human cerumen,",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.1875,
            "text": "ABCC11 genotype alone does not predict the type and relative",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.203125,
            "text": "ABCC11 genotype alone does not predict the type and relative levels of volatiles found in human cerumen, and suggest that other biochemical pathways must be involved",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.21875,
            "text": "ABCC11 genotype alone does not predict the type and relative levels of volatiles found in human cerumen, and",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.2265625,
            "text": "ABCC11 genotype alone does not predict the type and relative levels of volatiles found in human cerume",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.234375,
            "text": "ABCC11 genotype alone does not predict the type and relative levels of volatiles found in human cerumen, and suggest that other biochemical",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.2421875,
            "text": "ABCC11 genotype",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.2421875,
            "text": "ABCC11 genotype alone does not predict the type and relative levels of volatiles",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.25,
            "text": "ABCC11 genotype alone does not predict the type and relative levels of volatiles found in human cerumen, and suggest",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.25,
            "text": "ABCC11 genotype alone does",
            "probability": 0.0
        }
    ],
    "5acf74460340b9f058000013_3": [
        {
            "start_logit": 10.0078125,
            "end_logit": 9.609375,
            "text": "ABCC11",
            "probability": 1.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -1.8876953125,
            "text": "ABC",
            "probability": 1.0073184967041016e-05
        },
        {
            "start_logit": -2.15625,
            "end_logit": 9.609375,
            "text": "1",
            "probability": 5.185604095458984e-06
        },
        {
            "start_logit": -6.23828125,
            "end_logit": 9.609375,
            "text": "C11",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.015625,
            "text": "ABCC1",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.1015625,
            "text": "ABCC11 encodes an ATP-driven efflux pump",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.125,
            "text": "ABCC11 encodes an ATP-driven efflux pump protein that plays an important function in cerumin",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.1328125,
            "text": "ABCC11 encodes an ATP-driven",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.15625,
            "text": "ABCC11 encodes an ATP-driven efflux pump protein that plays an important function in ceruminous apocrine glands",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.1953125,
            "text": "ABCC11 encodes an ATP-driven efflux pump protein that plays an important function in ceruminous apocrine glands of the auditory canal",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.2109375,
            "text": "ABCC11 encodes an ATP-driven efflux pump protein that plays an important function in ceruminous",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.2109375,
            "text": "ABCC11 encodes an ATP-driven efflux",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.2109375,
            "text": "ABCC11 encodes an ATP-driven efflux pump protein that plays an important function in ceruminous apoc",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.21875,
            "text": "ABCC11 encodes an ATP",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.21875,
            "text": "ABCC11 encodes an ATP-driven efflux pump protein that plays an important function in ceruminous apocrine",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.2265625,
            "text": "ABCC11 encodes",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.234375,
            "text": "ABCC11 encodes an ATP-driven efflux pump protein that plays an important function in ceruminous apocrine glands of",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.234375,
            "text": "ABCC11 encodes an ATP-driven efflux pump protein that",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.2421875,
            "text": "ABCC11 encodes an ATP-driven efflux pump protein that plays an",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.2421875,
            "text": "ABCC11 encodes an ATP-driven efflux pump protein",
            "probability": 0.0
        }
    ],
    "5acf74460340b9f058000013_4": [
        {
            "start_logit": 10.0078125,
            "end_logit": 9.7578125,
            "text": "ABCC11",
            "probability": 1.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -1.85546875,
            "text": "ABC",
            "probability": 9.059906005859375e-06
        },
        {
            "start_logit": -1.7421875,
            "end_logit": 9.7578125,
            "text": "1",
            "probability": 7.867813110351562e-06
        },
        {
            "start_logit": -6.0625,
            "end_logit": 9.7578125,
            "text": "C11",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.10546875,
            "end_logit": 9.7578125,
            "text": "(ABCC11",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -7.83203125,
            "text": "ABCC1",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -7.91015625,
            "text": "ABCC11)",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -7.9765625,
            "text": "ABCC11) to",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.0546875,
            "text": "ABCC11) to the production of different types of axillary odorants and cerumen",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.1171875,
            "text": "ABCC11) to the production of different types of axillary odorants",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.140625,
            "text": "ABCC11) to the production of different types of axillary odorants and cerume",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.234375,
            "text": "ABCC11) to the production of different types of axillary odor",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": 9.7578125,
            "text": "the adenosine triphosphate (ATP) binding cassette, sub-family C, member 11 gene (ABCC11",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.7578125,
            "text": "adenosine triphosphate (ATP) binding cassette, sub-family C, member 11 gene (ABCC11",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 9.7578125,
            "text": "Recent studies link a single nucleotide polymorphism (SNP) in the adenosine triphosphate (ATP) binding cassette, sub-family C, member 11 gene (ABCC11",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 9.7578125,
            "text": "(SNP) in the adenosine triphosphate (ATP) binding cassette, sub-family C, member 11 gene (ABCC11",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.7578125,
            "text": "link a single nucleotide polymorphism (SNP) in the adenosine triphosphate (ATP) binding cassette, sub-family C, member 11 gene (ABCC11",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.7578125,
            "text": "in the adenosine triphosphate (ATP) binding cassette, sub-family C, member 11 gene (ABCC11",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.7578125,
            "text": "studies link a single nucleotide polymorphism (SNP) in the adenosine triphosphate (ATP) binding cassette, sub-family C, member 11 gene (ABCC11",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.7578125,
            "text": "a single nucleotide polymorphism (SNP) in the adenosine triphosphate (ATP) binding cassette, sub-family C, member 11 gene (ABCC11",
            "probability": 0.0
        }
    ],
    "62265b4a3a8413c653000083_1": [
        {
            "start_logit": 9.0078125,
            "end_logit": 6.38671875,
            "text": "Runt-related transcription factor 1 (RUNX1T1) isoforms are involved in adipogenesis.",
            "probability": 0.98828125
        },
        {
            "start_logit": 9.0078125,
            "end_logit": 1.875,
            "text": "Runt-related transcription factor 1",
            "probability": 0.010894775390625
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -2.427734375,
            "text": "Runt-related transcription factor 1 (RUNX1T1) isoforms are involved in adipogenesis",
            "probability": 0.00014722347259521484
        },
        {
            "start_logit": -0.262451171875,
            "end_logit": 6.38671875,
            "text": ".",
            "probability": 9.351968765258789e-05
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -3.37109375,
            "text": "Run",
            "probability": 5.7637691497802734e-05
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -5.6640625,
            "text": "Runt-related transcription factor 1 (RUNX1T1)",
            "probability": 5.781650543212891e-06
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -5.94921875,
            "text": "Runt-related transcription factor",
            "probability": 4.351139068603516e-06
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -6.71875,
            "text": "Runt-related transcription factor 1 (RUNX1T1",
            "probability": 2.0265579223632812e-06
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -6.83203125,
            "text": "Runt-related transcription factor 1 (RUNX1T1) isoforms",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -6.984375,
            "text": "Runt-related transcription factor 1 (RUNX1T1) isoforms are",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -7.12890625,
            "text": "Runt-related transcription factor 1 (",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -7.41796875,
            "text": "Runt-related transcription factor 1 (RUNX1",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -7.578125,
            "text": "Runt-related transcription factor 1 (RUNX1T1) isoforms are involved in",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -7.59765625,
            "text": "Runt-related transcription",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -7.70703125,
            "text": "Runt-related",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -7.78515625,
            "text": "Runt-related transcription factor 1 (RUN",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -7.83984375,
            "text": "Runt",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -5.50390625,
            "end_logit": 6.38671875,
            "text": "(RUNX1T1) isoforms are involved in adipogenesis.",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -8.171875,
            "text": "Runt-related transcription factor 1 (RUNX1T1) isoforms are involved",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -5.890625,
            "end_logit": 6.38671875,
            "text": "in adipogenesis.",
            "probability": 3.5762786865234375e-07
        }
    ],
    "54e8c7220fc566b149000002_1": [
        {
            "start_logit": -3.216796875,
            "end_logit": 8.484375,
            "text": "nucleus",
            "probability": 0.98193359375
        },
        {
            "start_logit": -8.078125,
            "end_logit": 8.484375,
            "text": "S100A4 interacts with p53 in the nucleus",
            "probability": 0.0076141357421875
        },
        {
            "start_logit": -8.3984375,
            "end_logit": 8.484375,
            "text": "with p53 in the nucleus",
            "probability": 0.005527496337890625
        },
        {
            "start_logit": -8.40625,
            "end_logit": 8.484375,
            "text": "interacts with p53 in the nucleus",
            "probability": 0.005481719970703125
        },
        {
            "start_logit": -8.078125,
            "end_logit": -7.72265625,
            "text": "S100A4 interacts with p53",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": -7.9453125,
            "text": "S100A4 interacts with p53 in the",
            "probability": 0.0
        },
        {
            "start_logit": -8.3984375,
            "end_logit": -7.72265625,
            "text": "with p53",
            "probability": 0.0
        },
        {
            "start_logit": -8.40625,
            "end_logit": -7.72265625,
            "text": "interacts with p53",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": -8.1015625,
            "text": "S100A4 interacts with p53 in",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": -8.2734375,
            "text": "S100A4 interacts",
            "probability": 0.0
        },
        {
            "start_logit": -8.3984375,
            "end_logit": -7.9453125,
            "text": "with p53 in the",
            "probability": 0.0
        },
        {
            "start_logit": -8.40625,
            "end_logit": -7.9453125,
            "text": "interacts with p53 in the",
            "probability": 0.0
        },
        {
            "start_logit": -8.3984375,
            "end_logit": -8.1015625,
            "text": "with p53 in",
            "probability": 0.0
        },
        {
            "start_logit": -8.40625,
            "end_logit": -8.1015625,
            "text": "interacts with p53 in",
            "probability": 0.0
        },
        {
            "start_logit": -8.40625,
            "end_logit": -8.2734375,
            "text": "interacts",
            "probability": 0.0
        }
    ],
    "54e8c7220fc566b149000002_2": [
        {
            "start_logit": 8.609375,
            "end_logit": 8.1171875,
            "text": "nucleus",
            "probability": 1.0
        },
        {
            "start_logit": -7.65625,
            "end_logit": 8.1171875,
            "text": "using proximity ligation assay, we show that the interaction takes place in the cell nucleus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.609375,
            "end_logit": -8.1640625,
            "text": "nucleus.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.828125,
            "end_logit": 8.1171875,
            "text": "proximity ligation assay, we show that the interaction takes place in the cell nucleus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 8.1171875,
            "text": ", we show that the interaction takes place in the cell nucleus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 8.1171875,
            "text": "interaction takes place in the cell nucleus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.15625,
            "end_logit": 8.1171875,
            "text": "the interaction takes place in the cell nucleus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.15625,
            "end_logit": 8.1171875,
            "text": "we show that the interaction takes place in the cell nucleus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1875,
            "end_logit": 8.1171875,
            "text": "cell nucleus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 8.1171875,
            "text": "that the interaction takes place in the cell nucleus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 8.1171875,
            "text": "takes place in the cell nucleus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.359375,
            "end_logit": 8.1171875,
            "text": "assay, we show that the interaction takes place in the cell nucleus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3671875,
            "end_logit": 8.1171875,
            "text": "show that the interaction takes place in the cell nucleus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.484375,
            "end_logit": 8.1171875,
            "text": "place in the cell nucleus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.65625,
            "end_logit": -7.49609375,
            "text": "using proximity ligation assay",
            "probability": 0.0
        },
        {
            "start_logit": -7.06640625,
            "end_logit": -8.1640625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.828125,
            "end_logit": -7.49609375,
            "text": "proximity ligation assay",
            "probability": 0.0
        },
        {
            "start_logit": -7.65625,
            "end_logit": -7.71484375,
            "text": "using proximity ligation assay, we show that the interaction takes place",
            "probability": 0.0
        },
        {
            "start_logit": -7.828125,
            "end_logit": -7.71484375,
            "text": "proximity ligation assay, we show that the interaction takes place",
            "probability": 0.0
        },
        {
            "start_logit": -7.65625,
            "end_logit": -7.9609375,
            "text": "using proximity ligation",
            "probability": 0.0
        }
    ],
    "58f0b0c070f9fc6f0f000006_1": [
        {
            "start_logit": 10.5,
            "end_logit": 8.4453125,
            "text": "Valbenazine granted breakthrough drug status for treating tardive dyskinesia.",
            "probability": 0.9990234375
        },
        {
            "start_logit": 10.5,
            "end_logit": 1.3935546875,
            "text": "Val",
            "probability": 0.0008692741394042969
        },
        {
            "start_logit": 0.908203125,
            "end_logit": 8.4453125,
            "text": "benazine granted breakthrough drug status for treating tardive dyskinesia.",
            "probability": 6.860494613647461e-05
        },
        {
            "start_logit": 0.74365234375,
            "end_logit": 8.4453125,
            "text": ".",
            "probability": 5.823373794555664e-05
        },
        {
            "start_logit": -1.1025390625,
            "end_logit": 8.4453125,
            "text": "nazine granted breakthrough drug status for treating tardive dyskinesia.",
            "probability": 9.238719940185547e-06
        },
        {
            "start_logit": -2.0625,
            "end_logit": 8.4453125,
            "text": "ine granted breakthrough drug status for treating tardive dyskinesia.",
            "probability": 3.516674041748047e-06
        },
        {
            "start_logit": -2.64453125,
            "end_logit": 8.4453125,
            "text": "zine granted breakthrough drug status for treating tardive dyskinesia.",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": 10.5,
            "end_logit": -5.12890625,
            "text": "Valbenazine granted breakthrough drug status for treating tardive dyskinesia",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 10.5,
            "end_logit": -5.30859375,
            "text": "Valbenazine granted breakthrough drug status for treating tard",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 10.5,
            "end_logit": -5.83984375,
            "text": "Valbenazine granted breakthrough drug status",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -3.943359375,
            "end_logit": 8.4453125,
            "text": "ed breakthrough drug status for treating tardive dyskinesia.",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -4.04296875,
            "end_logit": 8.4453125,
            "text": "breakthrough drug status for treating tardive dyskinesia.",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 10.5,
            "end_logit": -6.35546875,
            "text": "Valbenazine grant",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 10.5,
            "end_logit": -6.40625,
            "text": "Valbenazine granted breakthrough drug status for",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 10.5,
            "end_logit": -6.56640625,
            "text": "Valbenazine granted breakthrough drug status for treating tardive",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 10.5,
            "end_logit": -6.87890625,
            "text": "Valbenazine granted breakthrough drug status for treating",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 10.5,
            "end_logit": -6.9375,
            "text": "Valbenazine granted breakthrough",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 10.5,
            "end_logit": -6.984375,
            "text": "Valbe",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.12890625,
            "end_logit": 8.4453125,
            "text": "for treating tardive dyskinesia.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 10.5,
            "end_logit": -7.26953125,
            "text": "Valbenazine granted breakthrough drug",
            "probability": 1.7881393432617188e-07
        }
    ],
    "5aae6499fcf456587200000c_1": [
        {
            "start_logit": 10.1953125,
            "end_logit": 9.5859375,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus",
            "probability": 1.0
        },
        {
            "start_logit": 10.1953125,
            "end_logit": -1.3837890625,
            "text": "Borderline",
            "probability": 1.722574234008789e-05
        },
        {
            "start_logit": -2.123046875,
            "end_logit": 9.5859375,
            "text": "aureus",
            "probability": 4.470348358154297e-06
        },
        {
            "start_logit": -5.4375,
            "end_logit": 9.5859375,
            "text": "oxacillin-resistant Staphylococcus aureus",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.828125,
            "end_logit": 9.5859375,
            "text": "Staphylococcus aureus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.19921875,
            "end_logit": 9.5859375,
            "text": "cillin-resistant Staphylococcus aureus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.52734375,
            "end_logit": 9.5859375,
            "text": "lin-resistant Staphylococcus aureus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1953125,
            "end_logit": -7.16796875,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BOR",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1953125,
            "end_logit": -7.328125,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.7578125,
            "end_logit": 9.5859375,
            "text": "resistant Staphylococcus aureus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.87109375,
            "end_logit": 9.5859375,
            "text": "-resistant Staphylococcus aureus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1953125,
            "end_logit": -7.6484375,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1953125,
            "end_logit": -7.796875,
            "text": "Borderline oxacillin-resistant",
            "probability": 0.0
        },
        {
            "start_logit": 10.1953125,
            "end_logit": -7.9765625,
            "text": "Borderline oxacillin",
            "probability": 0.0
        },
        {
            "start_logit": -2.123046875,
            "end_logit": -7.16796875,
            "text": "aureus (BOR",
            "probability": 0.0
        },
        {
            "start_logit": -2.123046875,
            "end_logit": -7.328125,
            "text": "aureus (BORSA)",
            "probability": 0.0
        },
        {
            "start_logit": -2.123046875,
            "end_logit": -7.6484375,
            "text": "aureus (BORSA",
            "probability": 0.0
        },
        {
            "start_logit": -5.4375,
            "end_logit": -7.16796875,
            "text": "oxacillin-resistant Staphylococcus aureus (BOR",
            "probability": 0.0
        },
        {
            "start_logit": -5.4375,
            "end_logit": -7.328125,
            "text": "oxacillin-resistant Staphylococcus aureus (BORSA)",
            "probability": 0.0
        },
        {
            "start_logit": -5.828125,
            "end_logit": -7.16796875,
            "text": "Staphylococcus aureus (BOR",
            "probability": 0.0
        }
    ],
    "5aae6499fcf456587200000c_2": [
        {
            "start_logit": 10.15625,
            "end_logit": 9.5546875,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus",
            "probability": 1.0
        },
        {
            "start_logit": 10.15625,
            "end_logit": -1.4873046875,
            "text": "Borderline",
            "probability": 1.5914440155029297e-05
        },
        {
            "start_logit": -2.171875,
            "end_logit": 9.5546875,
            "text": "aureus",
            "probability": 4.410743713378906e-06
        },
        {
            "start_logit": -5.60546875,
            "end_logit": 9.5546875,
            "text": "oxacillin-resistant Staphylococcus aureus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -5.7109375,
            "end_logit": 9.5546875,
            "text": "Staphylococcus aureus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.34765625,
            "end_logit": 9.5546875,
            "text": "cillin-resistant Staphylococcus aureus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.15625,
            "end_logit": -7.19921875,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) may be misidentified as intrinsically methicillin-resistant Staphylococcus aureus (MRSA) in the clinical laboratory.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.15625,
            "end_logit": -7.203125,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BOR",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.15625,
            "end_logit": -7.27734375,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.68359375,
            "end_logit": 9.5546875,
            "text": "lin-resistant Staphylococcus aureus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.15625,
            "end_logit": -7.38671875,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) may be misidentified as intrinsically methicillin-resistant Staphylococcus aureus (MRSA) in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.15625,
            "end_logit": -7.453125,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.15625,
            "end_logit": -7.45703125,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) may be misidentified as intrinsically methicillin-resistant Staphylococcus aureus (MRSA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.15625,
            "end_logit": -7.50390625,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) may",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.15625,
            "end_logit": -7.51171875,
            "text": "Borderline oxacillin-resistant",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.9453125,
            "end_logit": 9.5546875,
            "text": "resistant Staphylococcus aureus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.98046875,
            "end_logit": 9.5546875,
            "text": "-resistant Staphylococcus aureus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.15625,
            "end_logit": -7.609375,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) may be misidentified as intrinsically methicillin-resistant Staphylococcus aureus (MRSA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.15625,
            "end_logit": -7.62109375,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) may be misidentified as intrinsically methicillin-resistant Staphylococcus aureus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.15625,
            "end_logit": -7.7578125,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) may be misidentified as intrinsically methicillin-resistant Staphylococcus",
            "probability": 5.960464477539063e-08
        }
    ],
    "5aae6499fcf456587200000c_3": [
        {
            "start_logit": 10.0546875,
            "end_logit": 9.3984375,
            "text": "borderline oxacillin-resistant Staphylococcus aureus",
            "probability": 1.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -1.7666015625,
            "text": "borderline",
            "probability": 1.4185905456542969e-05
        },
        {
            "start_logit": -2.486328125,
            "end_logit": 9.3984375,
            "text": "aureus",
            "probability": 3.5762786865234375e-06
        },
        {
            "start_logit": -5.45703125,
            "end_logit": 9.3984375,
            "text": "oxacillin-resistant Staphylococcus aureus",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -6.26171875,
            "text": "borderline oxacillin-resistant Staphylococcus aureus (BORSA)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.1875,
            "end_logit": 9.3984375,
            "text": "Staphylococcus aureus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -6.9765625,
            "text": "borderline oxacillin-resistant Staphylococcus aureus (BOR",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.421875,
            "end_logit": 9.3984375,
            "text": "cillin-resistant Staphylococcus aureus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.62890625,
            "end_logit": 9.3984375,
            "text": "lin-resistant Staphylococcus aureus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.6328125,
            "end_logit": 9.3984375,
            "text": "resistant Staphylococcus aureus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -7.33203125,
            "text": "borderline oxacillin-resistant Staphylococcus aureus (BORSA) with oxacillin MICs \u2265",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -7.359375,
            "text": "borderline oxacillin-resistant Staphylococcus aureus (BORSA) with oxacillin MICs \u22654",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.96875,
            "end_logit": 9.3984375,
            "text": "-resistant Staphylococcus aureus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -7.6875,
            "text": "borderline oxacillin-resistant Staphylococcus aureus (BORSA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -7.70703125,
            "text": "borderline oxacillin-resistant Staphylococcus aureus (BORSA) with oxacillin MICs \u22654 mg/L",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -7.71484375,
            "text": "borderline oxacillin-resistant Staphylococcus aureus (BORSA) with oxacillin MICs \u22654 mg",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -7.82421875,
            "text": "borderline oxacillin-resistant",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -7.90625,
            "text": "borderline oxacillin-resistant Staphylococcus aureus (BORSA) with oxacillin MICs \u22654 mg/",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -8.0390625,
            "text": "borderline oxacillin-resistant Staphylococcus aureus (BORSA) with oxacillin MICs \u22654 mg/L, the in vitro bactericidal activity and pharmacodynamic effect of oxacillin against clinical BOR",
            "probability": 0.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -8.046875,
            "text": "borderline oxacillin",
            "probability": 0.0
        }
    ],
    "5aae6499fcf456587200000c_4": [
        {
            "start_logit": 10.140625,
            "end_logit": 9.5390625,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus",
            "probability": 1.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -1.5283203125,
            "text": "Borderline",
            "probability": 1.5437602996826172e-05
        },
        {
            "start_logit": -2.220703125,
            "end_logit": 9.5390625,
            "text": "aureus",
            "probability": 4.231929779052734e-06
        },
        {
            "start_logit": -5.5234375,
            "end_logit": 9.5390625,
            "text": "oxacillin-resistant Staphylococcus aureus",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.05859375,
            "end_logit": 9.5390625,
            "text": "Staphylococcus aureus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.203125,
            "end_logit": 9.5390625,
            "text": "cillin-resistant Staphylococcus aureus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.0078125,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) represents a quite poorly understood and inadequately defined phenotype of methicillin resistance.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.0859375,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BOR",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.515625,
            "end_logit": 9.5390625,
            "text": "lin-resistant Staphylococcus aureus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.5390625,
            "end_logit": 9.5390625,
            "text": "resistant Staphylococcus aureus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.41796875,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.8203125,
            "end_logit": 9.5390625,
            "text": "-resistant Staphylococcus aureus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.47265625,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) represents a quite poorly understood and inadequately defined phenotype of methicillin resistance",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.55859375,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.5703125,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) represents",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.7265625,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) represents a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.7890625,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) represents a quite poorly understood",
            "probability": 0.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.796875,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) represents a quite poorly understood and inadequately defined phenotype",
            "probability": 0.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.84765625,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) represents a quite poorly understood and inadequate",
            "probability": 0.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.875,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) represents a quite poorly",
            "probability": 0.0
        }
    ],
    "5aae6499fcf456587200000c_5": [
        {
            "start_logit": 10.140625,
            "end_logit": 9.578125,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus",
            "probability": 1.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -1.5478515625,
            "text": "Borderline",
            "probability": 1.4722347259521484e-05
        },
        {
            "start_logit": -2.1328125,
            "end_logit": 9.578125,
            "text": "aureus",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": 10.140625,
            "end_logit": -6.01953125,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) exhibit oxacillin MIC values of 1-8 microg ml(-1), but lack mecA, which encodes the low-affinity penicillin-binding protein (PBP)2a.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.85546875,
            "end_logit": 9.578125,
            "text": "Staphylococcus aureus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -5.88671875,
            "end_logit": 9.578125,
            "text": "oxacillin-resistant Staphylococcus aureus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.140625,
            "end_logit": -6.8046875,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) exhibit oxacillin MIC values of 1-8 microg ml(-1), but lack mecA, which encodes the low-affinity penicillin-binding protein (PBP)2a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.140625,
            "end_logit": -6.96484375,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) exhibit oxacillin MIC values of 1-8 microg ml(-1), but lack mecA, which encodes the low-affinity penicillin-binding protein (PBP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.52734375,
            "end_logit": 9.578125,
            "text": "cillin-resistant Staphylococcus aureus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.15234375,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) exhibit oxacillin MIC values of 1-8 microg ml(-1), but lack mecA, which encodes the low-affinity penicillin-binding protein (PBP)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.59765625,
            "end_logit": 9.578125,
            "text": "resistant Staphylococcus aureus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.64453125,
            "end_logit": 9.578125,
            "text": "lin-resistant Staphylococcus aureus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.25,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) exhibit oxacillin MIC values of 1-8 microg ml(-1), but lack mecA, which encodes the low-affinity penicillin-binding protein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.83203125,
            "end_logit": 9.578125,
            "text": "-resistant Staphylococcus aureus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.43359375,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.515625,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) exhibit oxacillin MIC values",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.515625,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) exhibit oxacillin MIC values of 1-8 microg ml(-1), but lack mecA, which encodes the low-affinity penicillin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.5234375,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BOR",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.54296875,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) exhibit oxacillin MIC values of 1-8 microg ml(-1), but lack mecA, which encodes the low-affinity penicillin-binding",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.640625,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) exhibit oxacillin MIC values of 1-8 microg ml(-1), but",
            "probability": 5.960464477539063e-08
        }
    ],
    "5aae6499fcf456587200000c_6": [
        {
            "start_logit": 10.1875,
            "end_logit": 9.59375,
            "text": "borderline oxacillin resistant Staphylococcus aureus",
            "probability": 1.0
        },
        {
            "start_logit": 10.1875,
            "end_logit": -1.4169921875,
            "text": "borderline",
            "probability": 1.6570091247558594e-05
        },
        {
            "start_logit": -2.103515625,
            "end_logit": 9.59375,
            "text": "aureus",
            "probability": 4.589557647705078e-06
        },
        {
            "start_logit": -5.453125,
            "end_logit": 9.59375,
            "text": "oxacillin resistant Staphylococcus aureus",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.79296875,
            "end_logit": 9.59375,
            "text": "Staphylococcus aureus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.1875,
            "end_logit": 9.59375,
            "text": "cillin resistant Staphylococcus aureus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.296875,
            "end_logit": 9.59375,
            "text": "lin resistant Staphylococcus aureus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.35546875,
            "end_logit": 9.59375,
            "text": "resistant Staphylococcus aureus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1875,
            "end_logit": -7.16015625,
            "text": "borderline oxacillin resistant Staphylococcus aureus (BOR",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1875,
            "end_logit": -7.36328125,
            "text": "borderline oxacillin resistant Staphylococcus aureus (BORSA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1875,
            "end_logit": -7.671875,
            "text": "borderline oxacillin resistant Staphylococcus aureus (BORSA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1875,
            "end_logit": -8.09375,
            "text": "borderline oxacillin",
            "probability": 0.0
        },
        {
            "start_logit": 10.1875,
            "end_logit": -8.171875,
            "text": "borderline oxacillin resistant",
            "probability": 0.0
        },
        {
            "start_logit": -2.103515625,
            "end_logit": -7.16015625,
            "text": "aureus (BOR",
            "probability": 0.0
        },
        {
            "start_logit": -2.103515625,
            "end_logit": -7.36328125,
            "text": "aureus (BORSA)",
            "probability": 0.0
        },
        {
            "start_logit": -2.103515625,
            "end_logit": -7.671875,
            "text": "aureus (BORSA",
            "probability": 0.0
        },
        {
            "start_logit": -5.453125,
            "end_logit": -7.16015625,
            "text": "oxacillin resistant Staphylococcus aureus (BOR",
            "probability": 0.0
        },
        {
            "start_logit": -5.453125,
            "end_logit": -7.36328125,
            "text": "oxacillin resistant Staphylococcus aureus (BORSA)",
            "probability": 0.0
        },
        {
            "start_logit": -5.79296875,
            "end_logit": -7.16015625,
            "text": "Staphylococcus aureus (BOR",
            "probability": 0.0
        },
        {
            "start_logit": -5.453125,
            "end_logit": -7.671875,
            "text": "oxacillin resistant Staphylococcus aureus (BORSA",
            "probability": 0.0
        }
    ],
    "5aae6499fcf456587200000c_7": [
        {
            "start_logit": 10.1953125,
            "end_logit": 9.5859375,
            "text": "borderline oxacillin-resistant Staphylococcus aureus",
            "probability": 1.0
        },
        {
            "start_logit": 10.1953125,
            "end_logit": -1.3837890625,
            "text": "borderline",
            "probability": 1.722574234008789e-05
        },
        {
            "start_logit": -2.123046875,
            "end_logit": 9.5859375,
            "text": "aureus",
            "probability": 4.470348358154297e-06
        },
        {
            "start_logit": -5.4375,
            "end_logit": 9.5859375,
            "text": "oxacillin-resistant Staphylococcus aureus",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.828125,
            "end_logit": 9.5859375,
            "text": "Staphylococcus aureus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.19921875,
            "end_logit": 9.5859375,
            "text": "cillin-resistant Staphylococcus aureus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.52734375,
            "end_logit": 9.5859375,
            "text": "lin-resistant Staphylococcus aureus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1953125,
            "end_logit": -7.16796875,
            "text": "borderline oxacillin-resistant Staphylococcus aureus (BOR",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1953125,
            "end_logit": -7.328125,
            "text": "borderline oxacillin-resistant Staphylococcus aureus (BORSA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.7578125,
            "end_logit": 9.5859375,
            "text": "resistant Staphylococcus aureus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.87109375,
            "end_logit": 9.5859375,
            "text": "-resistant Staphylococcus aureus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1953125,
            "end_logit": -7.6484375,
            "text": "borderline oxacillin-resistant Staphylococcus aureus (BORSA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1953125,
            "end_logit": -7.796875,
            "text": "borderline oxacillin-resistant",
            "probability": 0.0
        },
        {
            "start_logit": 10.1953125,
            "end_logit": -7.9765625,
            "text": "borderline oxacillin",
            "probability": 0.0
        },
        {
            "start_logit": -2.123046875,
            "end_logit": -7.16796875,
            "text": "aureus (BOR",
            "probability": 0.0
        },
        {
            "start_logit": -2.123046875,
            "end_logit": -7.328125,
            "text": "aureus (BORSA)",
            "probability": 0.0
        },
        {
            "start_logit": -2.123046875,
            "end_logit": -7.6484375,
            "text": "aureus (BORSA",
            "probability": 0.0
        },
        {
            "start_logit": -5.4375,
            "end_logit": -7.16796875,
            "text": "oxacillin-resistant Staphylococcus aureus (BOR",
            "probability": 0.0
        },
        {
            "start_logit": -5.4375,
            "end_logit": -7.328125,
            "text": "oxacillin-resistant Staphylococcus aureus (BORSA)",
            "probability": 0.0
        },
        {
            "start_logit": -5.828125,
            "end_logit": -7.16796875,
            "text": "Staphylococcus aureus (BOR",
            "probability": 0.0
        }
    ],
    "5aae6499fcf456587200000c_8": [
        {
            "start_logit": 10.203125,
            "end_logit": 9.5390625,
            "text": "borderline oxacillin-resistant Staphylococcus aureus",
            "probability": 1.0
        },
        {
            "start_logit": 10.203125,
            "end_logit": -1.3447265625,
            "text": "borderline",
            "probability": 1.8656253814697266e-05
        },
        {
            "start_logit": -2.2421875,
            "end_logit": 9.5390625,
            "text": "aureus",
            "probability": 3.933906555175781e-06
        },
        {
            "start_logit": -5.26953125,
            "end_logit": 9.5390625,
            "text": "oxacillin-resistant Staphylococcus aureus",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.58984375,
            "end_logit": 9.5390625,
            "text": "Staphylococcus aureus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.125,
            "end_logit": 9.5390625,
            "text": "cillin-resistant Staphylococcus aureus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.203125,
            "end_logit": -6.87109375,
            "text": "borderline oxacillin-resistant Staphylococcus aureus (BOR",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.44140625,
            "end_logit": 9.5390625,
            "text": "lin-resistant Staphylococcus aureus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.203125,
            "end_logit": -7.18359375,
            "text": "borderline oxacillin-resistant Staphylococcus aureus (BORSA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.73828125,
            "end_logit": 9.5390625,
            "text": "resistant Staphylococcus aureus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.77734375,
            "end_logit": 9.5390625,
            "text": "-resistant Staphylococcus aureus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.203125,
            "end_logit": -7.4765625,
            "text": "borderline oxacillin-resistant Staphylococcus aureus (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.203125,
            "end_logit": -7.8203125,
            "text": "borderline oxacillin-resistant",
            "probability": 0.0
        },
        {
            "start_logit": 10.203125,
            "end_logit": -8.0703125,
            "text": "borderline oxacillin",
            "probability": 0.0
        },
        {
            "start_logit": -2.2421875,
            "end_logit": -6.87109375,
            "text": "aureus (BOR",
            "probability": 0.0
        },
        {
            "start_logit": -2.2421875,
            "end_logit": -7.18359375,
            "text": "aureus (BORSA",
            "probability": 0.0
        },
        {
            "start_logit": -2.2421875,
            "end_logit": -7.4765625,
            "text": "aureus (",
            "probability": 0.0
        },
        {
            "start_logit": -5.26953125,
            "end_logit": -6.87109375,
            "text": "oxacillin-resistant Staphylococcus aureus (BOR",
            "probability": 0.0
        },
        {
            "start_logit": -5.26953125,
            "end_logit": -7.18359375,
            "text": "oxacillin-resistant Staphylococcus aureus (BORSA",
            "probability": 0.0
        },
        {
            "start_logit": -5.58984375,
            "end_logit": -6.87109375,
            "text": "Staphylococcus aureus (BOR",
            "probability": 0.0
        }
    ],
    "5e46eb7a3f5415952900000d_1": [
        {
            "start_logit": 9.8671875,
            "end_logit": 9.59375,
            "text": "Essential Tremor",
            "probability": 1.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -2.16796875,
            "text": "Essential",
            "probability": 7.748603820800781e-06
        },
        {
            "start_logit": -2.1640625,
            "end_logit": 9.59375,
            "text": "Tremor",
            "probability": 5.900859832763672e-06
        },
        {
            "start_logit": -7.55078125,
            "end_logit": 9.59375,
            "text": "for Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.265625,
            "text": "Essential Tremor Questionnaire (QUE",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.28125,
            "text": "Essential Tremor Questionnaire",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.3125,
            "text": "Essential Tremor Questionnaire (QUEST) were",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.59375,
            "text": "study visit, the Fahn-Tolosa-Marin (FTM) scale, the Unified Parkinson's Disease Rating Scale, and the Quality of Life for Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": 9.59375,
            "text": "the Unified Parkinson's Disease Rating Scale, and the Quality of Life for Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.59375,
            "text": "During each study visit, the Fahn-Tolosa-Marin (FTM) scale, the Unified Parkinson's Disease Rating Scale, and the Quality of Life for Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.3828125,
            "text": "Essential Tremor Questionnaire (QUEST) were administered along with kinematic assessment of the treated limb",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.3828125,
            "text": "Essential Tremor Questionnaire (",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.390625,
            "text": "Essential Tremor Questionnaire (QUEST",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.59375,
            "text": "Unified Parkinson's Disease Rating Scale, and the Quality of Life for Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.59375,
            "text": "the Quality of Life for Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.4140625,
            "text": "Essential Tremor Questionnaire (QUEST)",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 9.59375,
            "text": "each study visit, the Fahn-Tolosa-Marin (FTM) scale, the Unified Parkinson's Disease Rating Scale, and the Quality of Life for Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 9.59375,
            "text": "visit, the Fahn-Tolosa-Marin (FTM) scale, the Unified Parkinson's Disease Rating Scale, and the Quality of Life for Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.59375,
            "text": ", and the Quality of Life for Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -7.55078125,
            "end_logit": -2.16796875,
            "text": "for Essential",
            "probability": 0.0
        }
    ],
    "5e46eb7a3f5415952900000d_2": [
        {
            "start_logit": 9.859375,
            "end_logit": 9.578125,
            "text": "essential tremor",
            "probability": 1.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -2.18359375,
            "text": "essential",
            "probability": 7.748603820800781e-06
        },
        {
            "start_logit": -2.181640625,
            "end_logit": 9.578125,
            "text": "tremor",
            "probability": 5.900859832763672e-06
        },
        {
            "start_logit": -7.86328125,
            "end_logit": 9.578125,
            "text": "for essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.234375,
            "text": "essential tremor (ET)",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.2421875,
            "text": "essential tremor (ET), but its anchors for ratings from 0 to 4 of upper limb tremor",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.25,
            "text": "essential tremor (ET",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.2578125,
            "text": "essential tremor (ET), but its anchors for ratings from 0 to",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.3359375,
            "text": "essential tremor (",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.3515625,
            "text": "essential tremor (ET), but its anchor",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.3671875,
            "text": "essential tremor (ET), but its anchors for ratings from 0 to 4 of upper limb tremor are probably too low for patients with severe tremor (tremor",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.3828125,
            "text": "essential tremor (ET), but its anchors for ratings from 0 to 4 of upper limb tremor are probably too low for patients with severe tremor (tremor amplitude",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.3828125,
            "text": "essential tremor (ET), but its anchors for ratings from 0 to 4 of upper limb tremor are probably too low",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.390625,
            "text": "essential tremor (ET), but its anchors",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.390625,
            "text": "essential tremor (ET), but its anchors for ratings from 0 to 4 of upper limb tremor are",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.40625,
            "text": "essential tremor (ET), but its anchors for ratings from 0 to 4 of upper limb tremor are probably too low for patients with severe tremor",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.4140625,
            "text": "essential tremor (ET), but its anchors for ratings from 0 to 4 of upper limb",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.578125,
            "text": "in large trials for essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.578125,
            "text": "for Tremor (FTM) has been used in large trials for essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.578125,
            "text": "been used in large trials for essential tremor",
            "probability": 0.0
        }
    ],
    "5e46eb7a3f5415952900000d_3": [
        {
            "start_logit": 9.6015625,
            "end_logit": 9.6015625,
            "text": "Essential Tremor",
            "probability": 1.0
        },
        {
            "start_logit": -1.9990234375,
            "end_logit": 9.6015625,
            "text": "Tremor",
            "probability": 9.179115295410156e-06
        },
        {
            "start_logit": 9.6015625,
            "end_logit": -2.58984375,
            "text": "Essential",
            "probability": 5.066394805908203e-06
        },
        {
            "start_logit": -7.30078125,
            "end_logit": 9.6015625,
            "text": "of Essential Tremor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6015625,
            "end_logit": -7.8828125,
            "text": "Essential Tremor Rating Scale, and the Tremor Research Group Essential Tremor Rating Assessment Scale), one ADL/disability scale (the Bain and Findley Tremor ADL Scale), one quality-of-life scale (the Quality of Life in Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 9.6015625,
            "text": "Study of Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -7.984375,
            "end_logit": 9.6015625,
            "text": "Clinical Tremor Rating Scale, the Bain and Findley Spirography Scale, the Washington Heights-Inwood Genetic Study of Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.0,
            "end_logit": 9.6015625,
            "text": "the Fahn-Tolosa-Marin Tremor Rating Scale, the Bain and Findley Clinical Tremor Rating Scale, the Bain and Findley Spirography Scale, the Washington Heights-Inwood Genetic Study of Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.0,
            "end_logit": 9.6015625,
            "text": "the Washington Heights-Inwood Genetic Study of Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.0,
            "end_logit": 9.6015625,
            "text": "ley Clinical Tremor Rating Scale, the Bain and Findley Spirography Scale, the Washington Heights-Inwood Genetic Study of Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": 9.6015625,
            "end_logit": -8.0234375,
            "text": "Essential Tremor Rating Scale, and the Tremor Research Group Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": 9.6015625,
            "end_logit": -8.28125,
            "text": "Essential Tremor Rating Scale, and the Tremor Research Group Essential Tremor Rating Assessment Scale)",
            "probability": 0.0
        },
        {
            "start_logit": 9.6015625,
            "end_logit": -8.3359375,
            "text": "Essential Tremor Rating Scale, and the Tremor Research",
            "probability": 0.0
        },
        {
            "start_logit": -1.9990234375,
            "end_logit": -7.8828125,
            "text": "Tremor Rating Scale, and the Tremor Research Group Essential Tremor Rating Assessment Scale), one ADL/disability scale (the Bain and Findley Tremor ADL Scale), one quality-of-life scale (the Quality of Life in Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -7.30078125,
            "end_logit": -2.58984375,
            "text": "of Essential",
            "probability": 0.0
        },
        {
            "start_logit": -1.9990234375,
            "end_logit": -8.0234375,
            "text": "Tremor Rating Scale, and the Tremor Research Group Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -1.9990234375,
            "end_logit": -8.28125,
            "text": "Tremor Rating Scale, and the Tremor Research Group Essential Tremor Rating Assessment Scale)",
            "probability": 0.0
        },
        {
            "start_logit": -1.9990234375,
            "end_logit": -8.3125,
            "text": "Tremor Rating Scale, and the Tremor Research Group Essential Tremor Rating Assessment Scale), one ADL/disability scale (the Bain and Findley Tremor ADL Scale), one quality-of-life scale (the Quality of Life in Essential Tremor Questionnaire)",
            "probability": 0.0
        },
        {
            "start_logit": -1.9990234375,
            "end_logit": -8.3359375,
            "text": "Tremor Rating Scale, and the Tremor Research",
            "probability": 0.0
        },
        {
            "start_logit": -7.9453125,
            "end_logit": -2.58984375,
            "text": "Study of Essential",
            "probability": 0.0
        }
    ],
    "5e46eb7a3f5415952900000d_4": [
        {
            "start_logit": 9.875,
            "end_logit": 9.5703125,
            "text": "essential tremor",
            "probability": 1.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -2.1484375,
            "text": "essential",
            "probability": 8.225440979003906e-06
        },
        {
            "start_logit": -2.138671875,
            "end_logit": 9.5703125,
            "text": "tremor",
            "probability": 6.079673767089844e-06
        },
        {
            "start_logit": 9.875,
            "end_logit": -6.62890625,
            "text": "essential tremor (ET)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.875,
            "end_logit": -6.83984375,
            "text": "essential tremor (ET",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.125,
            "text": "essential tremor (",
            "probability": 0.0
        },
        {
            "start_logit": -7.875,
            "end_logit": 9.5703125,
            "text": "in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 9.5703125,
            "text": "The purpose of this study was to evaluate interrater and intrarater reliability of the Fahn-Tolosa-Marin Tremor Rating Scale (TRS) in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 9.5703125,
            "text": "study was to evaluate interrater and intrarater reliability of the Fahn-Tolosa-Marin Tremor Rating Scale (TRS) in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 9.5703125,
            "text": "evaluate interrater and intrarater reliability of the Fahn-Tolosa-Marin Tremor Rating Scale (TRS) in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.5703125,
            "text": "interrater and intrarater reliability of the Fahn-Tolosa-Marin Tremor Rating Scale (TRS) in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.5703125,
            "text": "this study was to evaluate interrater and intrarater reliability of the Fahn-Tolosa-Marin Tremor Rating Scale (TRS) in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.5703125,
            "text": "to evaluate interrater and intrarater reliability of the Fahn-Tolosa-Marin Tremor Rating Scale (TRS) in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.5703125,
            "text": "purpose of this study was to evaluate interrater and intrarater reliability of the Fahn-Tolosa-Marin Tremor Rating Scale (TRS) in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.5703125,
            "text": "was to evaluate interrater and intrarater reliability of the Fahn-Tolosa-Marin Tremor Rating Scale (TRS) in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.5703125,
            "text": "of this study was to evaluate interrater and intrarater reliability of the Fahn-Tolosa-Marin Tremor Rating Scale (TRS) in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.5703125,
            "text": "the Fahn-Tolosa-Marin Tremor Rating Scale (TRS) in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.5703125,
            "text": "and intrarater reliability of the Fahn-Tolosa-Marin Tremor Rating Scale (TRS) in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.5703125,
            "text": "of the Fahn-Tolosa-Marin Tremor Rating Scale (TRS) in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -2.138671875,
            "end_logit": -6.62890625,
            "text": "tremor (ET)",
            "probability": 0.0
        }
    ],
    "5e46eb7a3f5415952900000d_5": [
        {
            "start_logit": 9.8671875,
            "end_logit": 9.6328125,
            "text": "essential tremor",
            "probability": 1.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -2.162109375,
            "text": "essential",
            "probability": 7.510185241699219e-06
        },
        {
            "start_logit": -2.046875,
            "end_logit": 9.6328125,
            "text": "tremor",
            "probability": 6.67572021484375e-06
        },
        {
            "start_logit": -7.83203125,
            "end_logit": 9.6328125,
            "text": "in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.6328125,
            "text": "Assessment of interrater and intrarater reliability of the Fahn-Tolosa-Marin Tremor Rating Scale in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.6328125,
            "text": "interrater and intrarater reliability of the Fahn-Tolosa-Marin Tremor Rating Scale in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 9.6328125,
            "text": "the Fahn-Tolosa-Marin Tremor Rating Scale in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.6328125,
            "text": "of the Fahn-Tolosa-Marin Tremor Rating Scale in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.6328125,
            "text": "and intrarater reliability of the Fahn-Tolosa-Marin Tremor Rating Scale in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.6328125,
            "text": "of interrater and intrarater reliability of the Fahn-Tolosa-Marin Tremor Rating Scale in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.6328125,
            "text": "Fahn-Tolosa-Marin Tremor Rating Scale in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.6328125,
            "text": "reliability of the Fahn-Tolosa-Marin Tremor Rating Scale in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.6328125,
            "text": "-Tolosa-Marin Tremor Rating Scale in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.6328125,
            "text": "Scale in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -7.83203125,
            "end_logit": -2.162109375,
            "text": "in essential",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": -2.162109375,
            "text": "Assessment of interrater and intrarater reliability of the Fahn-Tolosa-Marin Tremor Rating Scale in essential",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -2.162109375,
            "text": "interrater and intrarater reliability of the Fahn-Tolosa-Marin Tremor Rating Scale in essential",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": -2.162109375,
            "text": "the Fahn-Tolosa-Marin Tremor Rating Scale in essential",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -2.162109375,
            "text": "of the Fahn-Tolosa-Marin Tremor Rating Scale in essential",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -2.162109375,
            "text": "and intrarater reliability of the Fahn-Tolosa-Marin Tremor Rating Scale in essential",
            "probability": 0.0
        }
    ],
    "5e46eb7a3f5415952900000d_6": [
        {
            "start_logit": 9.90625,
            "end_logit": 9.5703125,
            "text": "Essential Tremor",
            "probability": 1.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -2.056640625,
            "text": "Essential",
            "probability": 9.000301361083984e-06
        },
        {
            "start_logit": -2.197265625,
            "end_logit": 9.5703125,
            "text": "Tremor",
            "probability": 5.602836608886719e-06
        },
        {
            "start_logit": -7.91015625,
            "end_logit": 9.5703125,
            "text": "the Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.359375,
            "text": "Essential Tremor Rating",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.5703125,
            "text": "Comparison of the Fahn-Tolosa-Marin Clinical Rating Scale and the Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.5703125,
            "text": "and the Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.5703125,
            "text": "Rating Scale and the Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.5703125,
            "text": "Clinical Rating Scale and the Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.5703125,
            "text": "the Fahn-Tolosa-Marin Clinical Rating Scale and the Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.5703125,
            "text": "Fahn-Tolosa-Marin Clinical Rating Scale and the Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": 9.5703125,
            "text": "Scale and the Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.5703125,
            "text": "of the Fahn-Tolosa-Marin Clinical Rating Scale and the Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -7.91015625,
            "end_logit": -2.056640625,
            "text": "the Essential",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -2.056640625,
            "text": "Comparison of the Fahn-Tolosa-Marin Clinical Rating Scale and the Essential",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -2.056640625,
            "text": "and the Essential",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": -2.056640625,
            "text": "Rating Scale and the Essential",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": -2.056640625,
            "text": "Clinical Rating Scale and the Essential",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": -2.056640625,
            "text": "the Fahn-Tolosa-Marin Clinical Rating Scale and the Essential",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": -2.056640625,
            "text": "Fahn-Tolosa-Marin Clinical Rating Scale and the Essential",
            "probability": 0.0
        }
    ],
    "58f4b1a170f9fc6f0f000010_1": [
        {
            "start_logit": 10.0234375,
            "end_logit": 9.5625,
            "text": "Amanita phalloides",
            "probability": 1.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -1.7939453125,
            "text": "Am",
            "probability": 1.1563301086425781e-05
        },
        {
            "start_logit": -2.232421875,
            "end_logit": 9.5625,
            "text": "ides",
            "probability": 4.708766937255859e-06
        },
        {
            "start_logit": -6.17578125,
            "end_logit": 9.5625,
            "text": "anita phalloides",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.54296875,
            "end_logit": 9.5625,
            "text": "phalloides",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -7.3984375,
            "text": "Amanita",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.03515625,
            "end_logit": 9.5625,
            "text": "in Amanita phalloides",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1484375,
            "end_logit": 9.5625,
            "text": "loides",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1796875,
            "end_logit": 9.5625,
            "text": "ta phalloides",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -7.69140625,
            "text": "Amanita phalloides poisoning",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -7.77734375,
            "text": "Amanita phallo",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -7.796875,
            "text": "Amanita phal",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.3359375,
            "text": "Amani",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.5625,
            "text": "liver transplantation improves patients' short-term post liver transplantation survival in Amanita phalloides",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.5625,
            "text": "term post liver transplantation survival in Amanita phalloides",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 9.5625,
            "text": "-term post liver transplantation survival in Amanita phalloides",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.5625,
            "text": "survival in Amanita phalloides",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.5625,
            "text": "improves patients' short-term post liver transplantation survival in Amanita phalloides",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.5625,
            "text": "short-term post liver transplantation survival in Amanita phalloides",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.5625,
            "text": "post liver transplantation survival in Amanita phalloides",
            "probability": 0.0
        }
    ],
    "58aa0c6f396a458e50000008_1": [
        {
            "start_logit": 8.6875,
            "end_logit": 8.1171875,
            "text": "oxytocin",
            "probability": 1.0
        },
        {
            "start_logit": 8.6875,
            "end_logit": -7.89453125,
            "text": "oxytocin (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.6875,
            "end_logit": -7.93359375,
            "text": "oxytocin (OXT)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.6875,
            "end_logit": -8.0234375,
            "text": "oxytocin (OX",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.6875,
            "end_logit": -8.0390625,
            "text": "oxytocin (OXT) and its receptor (OXTR) have critical roles in the regulation of pro-social behaviors, including social recognition, pair bonding, parental behavior, and stress-related",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.6875,
            "end_logit": -8.1015625,
            "text": "oxytocin (OXT",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.6875,
            "end_logit": -8.1328125,
            "text": "oxytocin (OXT) and its receptor (OXTR) have critical roles in the regulation of pro-social behaviors, including social recognition, pair bonding, parental behavior, and stress-related responses",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6875,
            "end_logit": -8.2109375,
            "text": "oxytocin (OXT) and its receptor (OXTR",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6875,
            "end_logit": -8.2265625,
            "text": "oxytocin (OXT) and its receptor (OXTR) have critical roles in the regulation of pro-social behaviors, including social recognition, pair bonding, parental behavior, and stress-related responses.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6875,
            "end_logit": -8.2265625,
            "text": "oxytocin (OXT) and its receptor (OXTR)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6875,
            "end_logit": -8.234375,
            "text": "oxytocin (OXT) and its receptor (OXTR) have critical roles in the regulation of pro-social behaviors, including social recognition",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6875,
            "end_logit": -8.234375,
            "text": "oxytocin (OXT) and its receptor (OXTR) have critical roles in the regulation of pro-social behaviors, including social recognition, pair bonding",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6875,
            "end_logit": -8.2421875,
            "text": "oxytocin (OXT) and its receptor (OXTR) have critical roles in the regulation of pro",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6875,
            "end_logit": -8.2421875,
            "text": "oxytocin (OXT) and its receptor (OXTR) have critical roles in the regulation of pro-social behaviors, including social recognition, pair bonding, parental behavior, and stress-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6875,
            "end_logit": -8.25,
            "text": "oxytocin (OXT) and its receptor (OXTR) have critical roles in the regulation of pro-social behaviors, including social recognition, pair bonding, parental behavior, and stress",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.265625,
            "end_logit": 8.1171875,
            "text": "hormone oxytocin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.328125,
            "end_logit": 8.1171875,
            "text": "neurohypophysial hormone oxytocin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.359375,
            "end_logit": 8.1171875,
            "text": "The neurohypophysial hormone oxytocin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.12890625,
            "end_logit": -8.2265625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.92578125,
            "end_logit": -7.89453125,
            "text": "(",
            "probability": 0.0
        }
    ],
    "58aa0c6f396a458e50000008_2": [
        {
            "start_logit": 8.5703125,
            "end_logit": 8.2578125,
            "text": "oxytocin",
            "probability": 1.0
        },
        {
            "start_logit": 8.5703125,
            "end_logit": -8.078125,
            "text": "oxytocin has roles",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5703125,
            "end_logit": -8.0859375,
            "text": "oxytocin has roles in social bonding, energy metabolism, and wound healing contributing to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5703125,
            "end_logit": -8.0859375,
            "text": "oxytocin has roles in social bonding, energy metabolism, and wound healing",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5703125,
            "end_logit": -8.09375,
            "text": "oxytocin has roles in social bonding, energy metabolism",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5703125,
            "end_logit": -8.09375,
            "text": "oxytocin has roles in social bonding, energy metabolism, and wound healing contributing",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5703125,
            "end_logit": -8.1328125,
            "text": "oxytocin has roles in social bonding, energy metabolism, and wound healing contributing to good physical, mental and social health.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5703125,
            "end_logit": -8.15625,
            "text": "oxytocin has roles in social bonding,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5703125,
            "end_logit": -8.15625,
            "text": "oxytocin has roles in social bonding, energy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5703125,
            "end_logit": -8.1796875,
            "text": "oxytocin has",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5703125,
            "end_logit": -8.1796875,
            "text": "oxytocin has roles in social bonding",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5703125,
            "end_logit": -8.21875,
            "text": "oxytocin has roles in social bonding, energy metabolism, and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5703125,
            "end_logit": -8.21875,
            "text": "oxytocin has roles in social bonding, energy metabolism, and wound",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5703125,
            "end_logit": -8.2421875,
            "text": "oxytocin has roles in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5703125,
            "end_logit": -8.2578125,
            "text": "oxytocin has roles in social bonding, energy metabolism, and wound healing contributing to good",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 8.2578125,
            "text": "hormone oxytocin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3828125,
            "end_logit": 8.2578125,
            "text": "Neuropeptide hormone oxytocin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.25,
            "end_logit": -8.1328125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.98046875,
            "end_logit": -8.0859375,
            "text": "social bonding, energy metabolism, and wound healing contributing to",
            "probability": 0.0
        },
        {
            "start_logit": -7.98046875,
            "end_logit": -8.0859375,
            "text": "social bonding, energy metabolism, and wound healing",
            "probability": 0.0
        }
    ],
    "58aa0c6f396a458e50000008_3": [
        {
            "start_logit": 8.6015625,
            "end_logit": 8.2109375,
            "text": "Oxytocin",
            "probability": 1.0
        },
        {
            "start_logit": 8.6015625,
            "end_logit": -7.32421875,
            "text": "Oxytocin is known as the 'love hormone' due its role in promoting mother-child and pair bonding.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.6015625,
            "end_logit": -7.65625,
            "text": "Oxytocin is known as the 'love hormone",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.6015625,
            "end_logit": -7.75,
            "text": "Oxytocin is known as the 'love hormone' due its role in promoting mother-child",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.6015625,
            "end_logit": -7.75390625,
            "text": "Oxytocin is known",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.6015625,
            "end_logit": -7.8046875,
            "text": "Oxytocin is known as the 'lov",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.6015625,
            "end_logit": -7.8515625,
            "text": "Oxytocin is known as the 'love hormone' due its role in promoting mother-child and pair bonding",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.6015625,
            "end_logit": -7.86328125,
            "text": "Oxytocin is known as the 'love hormone'",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.6015625,
            "end_logit": -7.92578125,
            "text": "Oxytocin is known as the 'love hormone' due its role in promoting mother-child and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.6015625,
            "end_logit": -7.96875,
            "text": "Oxytocin is known as the 'love hormone' due",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.6015625,
            "end_logit": -8.0,
            "text": "Oxytocin is known as the 'love",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.6015625,
            "end_logit": -8.0078125,
            "text": "Oxytocin is known as the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.6015625,
            "end_logit": -8.015625,
            "text": "Oxytocin is known as the 'love hormone' due its role in promoting mother",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.6015625,
            "end_logit": -8.0703125,
            "text": "Oxytocin is known as",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6015625,
            "end_logit": -8.1171875,
            "text": "Oxytocin is known as the 'love hormone' due its role in promoting mother-child and pair",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6015625,
            "end_logit": -8.1328125,
            "text": "Oxytocin is known as the 'love hormone' due its role in promoting mother-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6015625,
            "end_logit": -8.171875,
            "text": "Oxytocin is known as the 'love hormone' due its",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.41796875,
            "end_logit": -7.32421875,
            "text": "is known as the 'love hormone' due its role in promoting mother-child and pair bonding.",
            "probability": 0.0
        },
        {
            "start_logit": -7.44921875,
            "end_logit": -7.32421875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.41796875,
            "end_logit": -7.65625,
            "text": "is known as the 'love hormone",
            "probability": 0.0
        }
    ],
    "58aa0c6f396a458e50000008_4": [
        {
            "start_logit": 8.5859375,
            "end_logit": 8.1796875,
            "text": "oxytocin",
            "probability": 1.0
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -7.546875,
            "text": "oxytocin (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -7.63671875,
            "text": "oxytocin (OT",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -7.65625,
            "text": "oxytocin (OT)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -7.99609375,
            "text": "oxytocin (OT) hormone pathway is involved in numerous physiological processes, and one of its receptor genes (OXTR) has been implicated in pair bonding behavior in mammalian lineages.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -8.015625,
            "text": "oxytocin (OT) hormone",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -8.0546875,
            "text": "oxytocin (OT) hormone pathway",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -8.09375,
            "text": "oxytocin (OT) hormone pathway is involved in numerous physiological processes, and one of its receptor genes (OXTR",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -8.109375,
            "text": "oxytocin (OT) hormone pathway is involved in numerous physiological processes",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -8.125,
            "text": "oxytocin (OT) hormone pathway is involved in numerous physiological processes, and one of its receptor genes (OXTR) has been implicated in pair bonding behavior in mammalian lineages",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -8.1484375,
            "text": "oxytocin (OT) hormone pathway is involved in numerous physiological processes, and one of its receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -8.1484375,
            "text": "oxytocin (OT) hormone pathway is involved in numerous physiological processes, and one of its receptor genes (OXTR) has been implicated in pair bonding behavior in mammalian",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -8.15625,
            "text": "oxytocin (OT) hormone pathway is involved in numerous physiological processes, and one of its receptor genes (OX",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -8.1796875,
            "text": "oxytocin (OT) hormone pathway is involved in numerous physiological processes, and one of its receptor genes (OXTR) has been implicated in pair bonding behavior",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -8.1796875,
            "text": "oxytocin (OT) hormone pathway is involved in numerous physiological processes,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -8.1875,
            "text": "oxytocin (OT) hormone pathway is involved in numerous physiological processes, and one of its receptor genes",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -8.1953125,
            "text": "oxytocin (OT) hormone pathway is involved in numerous physiological processes, and one of its",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -8.1953125,
            "text": "oxytocin (OT) hormone pathway is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.328125,
            "end_logit": 8.1796875,
            "text": "The oxytocin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.08984375,
            "end_logit": -7.99609375,
            "text": ".",
            "probability": 0.0
        }
    ],
    "58aa0c6f396a458e50000008_5": [
        {
            "start_logit": 8.671875,
            "end_logit": 8.1484375,
            "text": "oxytocin",
            "probability": 1.0
        },
        {
            "start_logit": 8.671875,
            "end_logit": -7.37109375,
            "text": "oxytocin, a hormone involved in parent-offspring",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.671875,
            "end_logit": -7.63671875,
            "text": "oxytocin, a hormone involved in parent-offspring bonding",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.671875,
            "end_logit": -7.8671875,
            "text": "oxytocin, a",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.671875,
            "end_logit": -7.87109375,
            "text": "oxytocin, a hormone involved in parent",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.671875,
            "end_logit": -8.03125,
            "text": "oxytocin, a hormone involved in parent-",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.671875,
            "end_logit": -8.03125,
            "text": "oxytocin, a hormone",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.671875,
            "end_logit": -8.1328125,
            "text": "oxytocin, a hormone involved",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -7.37109375,
            "text": "parent-offspring",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": -7.37109375,
            "text": "in parent-offspring",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -7.37109375,
            "text": "a hormone involved in parent-offspring",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -7.37109375,
            "text": ", a hormone involved in parent-offspring",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -7.63671875,
            "text": "parent-offspring bonding",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": -7.37109375,
            "text": "hormone involved in parent-offspring",
            "probability": 0.0
        },
        {
            "start_logit": -8.3515625,
            "end_logit": -7.37109375,
            "text": "involved in parent-offspring",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": -7.63671875,
            "text": "in parent-offspring bonding",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -7.63671875,
            "text": "a hormone involved in parent-offspring bonding",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -7.63671875,
            "text": ", a hormone involved in parent-offspring bonding",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -7.87109375,
            "text": "parent",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": -7.63671875,
            "text": "hormone involved in parent-offspring bonding",
            "probability": 0.0
        }
    ],
    "58a5b1fe60087bc10a000024_1": [
        {
            "start_logit": 10.140625,
            "end_logit": 9.7109375,
            "text": "SUMO-conjugating enzyme",
            "probability": 1.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -1.5341796875,
            "text": "SUMO",
            "probability": 1.3232231140136719e-05
        },
        {
            "start_logit": -1.7841796875,
            "end_logit": 9.7109375,
            "text": "enzyme",
            "probability": 6.616115570068359e-06
        },
        {
            "start_logit": -6.1171875,
            "end_logit": 9.7109375,
            "text": "conjugating enzyme",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.23828125,
            "end_logit": 9.7109375,
            "text": "-conjugating enzyme",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.51171875,
            "end_logit": 9.7109375,
            "text": ". SUMO-conjugating enzyme",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.09375,
            "text": "SUMO-conjugating enzyme (Ubc9) is an important conjunction enzyme in the SUMO pathway.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.69921875,
            "end_logit": 9.7109375,
            "text": "ating enzyme",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.265625,
            "text": "SUMO-conjugating enzyme (Ubc9) is an important conjunction enzyme in the SUMO pathway",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.38671875,
            "text": "SUMO-conjugating enzyme (Ubc9)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.484375,
            "text": "SUMO-conjugating enzyme (Ubc9) is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.55078125,
            "text": "SUMO-conjugating enzyme (Ub",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.69140625,
            "text": "SUMO-conjugating enzyme (Ubc9) is an",
            "probability": 0.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.76171875,
            "text": "SUMO-conjugating enzyme (Ubc",
            "probability": 0.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.80078125,
            "text": "SUMO-conjugating enzyme (",
            "probability": 0.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.81640625,
            "text": "SUMO-conjugating enzyme (Ubc9) is an important conjunction enzyme",
            "probability": 0.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.828125,
            "text": "SUMO-conjugating enzyme (Ubc9",
            "probability": 0.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.8515625,
            "text": "SUMO-conjugating enzyme (Ubc9) is an important",
            "probability": 0.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.8515625,
            "text": "SUMO-conjugating enzyme (Ubc9) is an important conjunction",
            "probability": 0.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.86328125,
            "text": "SUMO-conjugating",
            "probability": 0.0
        }
    ],
    "58a5b1fe60087bc10a000024_2": [
        {
            "start_logit": 10.0546875,
            "end_logit": 9.8125,
            "text": "SUMO-conjugating enzyme",
            "probability": 1.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -1.72265625,
            "text": "SUMO",
            "probability": 9.655952453613281e-06
        },
        {
            "start_logit": -1.5576171875,
            "end_logit": 9.8125,
            "text": "enzyme",
            "probability": 9.000301361083984e-06
        },
        {
            "start_logit": -6.25390625,
            "end_logit": 9.8125,
            "text": "-conjugating enzyme",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.32421875,
            "end_logit": 9.8125,
            "text": "conjugating enzyme",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.0390625,
            "end_logit": 9.8125,
            "text": "ating enzyme",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -7.41796875,
            "text": "SUMO-conjugating",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.22265625,
            "end_logit": 9.8125,
            "text": "the SUMO-conjugating enzyme",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -7.98828125,
            "text": "SUMO-conjugating enzyme UB",
            "probability": 0.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -8.03125,
            "text": "SUMO-conjugating enzyme UBC9 and",
            "probability": 0.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -8.1171875,
            "text": "SUMO-conjugating enzyme UBC9 and is a novel target for sumoylation.",
            "probability": 0.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -8.1875,
            "text": "SUMO-conjugating enzyme UBC",
            "probability": 0.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -8.1953125,
            "text": "SUMO-conjug",
            "probability": 0.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -8.1953125,
            "text": "SUMO-conjugating enzyme UBC9 and is a novel target for sumoylation",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": 9.8125,
            "text": "RAP80 interacts with the SUMO-conjugating enzyme",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.8125,
            "text": "with the SUMO-conjugating enzyme",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.8125,
            "text": "80 interacts with the SUMO-conjugating enzyme",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.8125,
            "text": "interacts with the SUMO-conjugating enzyme",
            "probability": 0.0
        },
        {
            "start_logit": -7.22265625,
            "end_logit": -1.72265625,
            "text": "the SUMO",
            "probability": 0.0
        },
        {
            "start_logit": -1.5576171875,
            "end_logit": -7.98828125,
            "text": "enzyme UB",
            "probability": 0.0
        }
    ],
    "58a5b1fe60087bc10a000024_3": [
        {
            "start_logit": 9.7109375,
            "end_logit": 9.6953125,
            "text": "SUMO-conjugating enzyme",
            "probability": 1.0
        },
        {
            "start_logit": -1.8388671875,
            "end_logit": 9.6953125,
            "text": "enzyme",
            "probability": 9.655952453613281e-06
        },
        {
            "start_logit": 9.7109375,
            "end_logit": -2.4921875,
            "text": "SUMO",
            "probability": 5.066394805908203e-06
        },
        {
            "start_logit": -6.4296875,
            "end_logit": 9.6953125,
            "text": "-conjugating enzyme",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.89453125,
            "end_logit": 9.6953125,
            "text": "conjugating enzyme",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7109375,
            "end_logit": -7.26953125,
            "text": "SUMO-conjugating enzyme Ub",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.30078125,
            "end_logit": 9.6953125,
            "text": "E2 SUMO-conjugating enzyme",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7109375,
            "end_logit": -7.40625,
            "text": "SUMO-conjugating enzyme Ubc9 and a E3 SUMO ligase, PIASy, can enhance Ets-1 sumoylation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.40234375,
            "end_logit": 9.6953125,
            "text": "ating enzyme",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7109375,
            "end_logit": -7.48828125,
            "text": "SUMO-conjugating",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7109375,
            "end_logit": -7.53515625,
            "text": "SUMO-conjugating enzyme Ubc9 and a E3 SUMO ligase, PIASy, can enhance Ets-1 sumo",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7109375,
            "end_logit": -7.796875,
            "text": "SUMO-conjugating enzyme Ubc",
            "probability": 0.0
        },
        {
            "start_logit": 9.7109375,
            "end_logit": -7.82421875,
            "text": "SUMO-conjugating enzyme Ubc9 and a E3 SUMO ligase, PIASy, can enhance",
            "probability": 0.0
        },
        {
            "start_logit": 9.7109375,
            "end_logit": -7.85546875,
            "text": "SUMO-conjugating enzyme Ubc9 and a E3 SUMO ligase, PIASy, can enhance Ets",
            "probability": 0.0
        },
        {
            "start_logit": -7.8515625,
            "end_logit": 9.6953125,
            "text": "demonstrated that the E2 SUMO-conjugating enzyme",
            "probability": 0.0
        },
        {
            "start_logit": 9.7109375,
            "end_logit": -7.87890625,
            "text": "SUMO-conjugating enzyme Ubc9 and",
            "probability": 0.0
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 9.6953125,
            "text": "we further demonstrated that the E2 SUMO-conjugating enzyme",
            "probability": 0.0
        },
        {
            "start_logit": -7.90234375,
            "end_logit": 9.6953125,
            "text": "(Ets-1 K15R/K227R), as well as WT or mutant proteins of the SUMO pathway, we further demonstrated that the E2 SUMO-conjugating enzyme",
            "probability": 0.0
        },
        {
            "start_logit": 9.7109375,
            "end_logit": -7.921875,
            "text": "SUMO-conjugating enzyme Ubc9",
            "probability": 0.0
        },
        {
            "start_logit": -7.953125,
            "end_logit": 9.6953125,
            "text": "sumoylation deficient version (Ets-1 K15R/K227R), as well as WT or mutant proteins of the SUMO pathway, we further demonstrated that the E2 SUMO-conjugating enzyme",
            "probability": 0.0
        }
    ],
    "58a5b1fe60087bc10a000024_4": [
        {
            "start_logit": 9.234375,
            "end_logit": 9.6953125,
            "text": "SUMO-conjugating enzyme",
            "probability": 1.0
        },
        {
            "start_logit": -1.7607421875,
            "end_logit": 9.6953125,
            "text": "enzyme",
            "probability": 1.6689300537109375e-05
        },
        {
            "start_logit": 9.234375,
            "end_logit": -3.24609375,
            "text": "SUMO",
            "probability": 2.384185791015625e-06
        },
        {
            "start_logit": -6.70703125,
            "end_logit": 9.6953125,
            "text": "conjugating enzyme",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.828125,
            "end_logit": 9.6953125,
            "text": "-conjugating enzyme",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.1484375,
            "end_logit": 9.6953125,
            "text": "SUMO modification is required for stimuli-induced p100 phosphorylation and that blocking SUMOylation of p100, either by site-directed mutation or by short interfering RNA-targeted diminution of E2 SUMO-conjugating enzyme",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.23828125,
            "end_logit": 9.6953125,
            "text": "ating enzyme",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.69921875,
            "end_logit": 9.6953125,
            "text": "results show that basal SUMO modification is required for stimuli-induced p100 phosphorylation and that blocking SUMOylation of p100, either by site-directed mutation or by short interfering RNA-targeted diminution of E2 SUMO-conjugating enzyme",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7109375,
            "end_logit": 9.6953125,
            "text": "blocking SUMOylation of p100, either by site-directed mutation or by short interfering RNA-targeted diminution of E2 SUMO-conjugating enzyme",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7265625,
            "end_logit": 9.6953125,
            "text": "The results show that basal SUMO modification is required for stimuli-induced p100 phosphorylation and that blocking SUMOylation of p100, either by site-directed mutation or by short interfering RNA-targeted diminution of E2 SUMO-conjugating enzyme",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7890625,
            "end_logit": 9.6953125,
            "text": "E2 SUMO-conjugating enzyme",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8203125,
            "end_logit": 9.6953125,
            "text": "of E2 SUMO-conjugating enzyme",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.91015625,
            "end_logit": 9.6953125,
            "text": "that blocking SUMOylation of p100, either by site-directed mutation or by short interfering RNA-targeted diminution of E2 SUMO-conjugating enzyme",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.984375,
            "end_logit": 9.6953125,
            "text": "by short interfering RNA-targeted diminution of E2 SUMO-conjugating enzyme",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 9.6953125,
            "text": "mutation or by short interfering RNA-targeted diminution of E2 SUMO-conjugating enzyme",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.03125,
            "end_logit": 9.6953125,
            "text": "by site-directed mutation or by short interfering RNA-targeted diminution of E2 SUMO-conjugating enzyme",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 9.6953125,
            "text": "diminution of E2 SUMO-conjugating enzyme",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.234375,
            "end_logit": -7.5859375,
            "text": "SUMO-conjugating enzyme Ub",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.234375,
            "end_logit": -7.8828125,
            "text": "SUMO-conjugating",
            "probability": 0.0
        },
        {
            "start_logit": 9.234375,
            "end_logit": -7.921875,
            "text": "SUMO-conjugating enzyme Ubc9, inhibits various physiological stimuli-induced p100 processing and ultimate activation of the alternative NF-kappaB",
            "probability": 0.0
        }
    ],
    "58a5b1fe60087bc10a000024_5": [
        {
            "start_logit": 10.03125,
            "end_logit": 9.7109375,
            "text": "SUMO-conjugating enzyme",
            "probability": 1.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -1.833984375,
            "text": "SUMO",
            "probability": 9.59634780883789e-06
        },
        {
            "start_logit": -1.8310546875,
            "end_logit": 9.7109375,
            "text": "enzyme",
            "probability": 6.973743438720703e-06
        },
        {
            "start_logit": -6.2421875,
            "end_logit": 9.7109375,
            "text": "-conjugating enzyme",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.51953125,
            "end_logit": 9.7109375,
            "text": "conjugating enzyme",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.03125,
            "end_logit": -6.890625,
            "text": "SUMO-conjugating enzyme E2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.03125,
            "end_logit": -7.296875,
            "text": "SUMO-conjugating enzyme E2 UBC9 mediates viral immediate-early protein SUMOylation in crayfish to facilitate reproduction of white spot syndrome virus.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.98828125,
            "end_logit": 9.7109375,
            "text": "ating enzyme",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.03125,
            "end_logit": -7.40625,
            "text": "SUMO-conjugating enzyme E2 UBC9 mediates viral immediate-early protein SUMOylation in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.03125,
            "end_logit": -7.66796875,
            "text": "SUMO-conjugating",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -7.92578125,
            "text": "SUMO-conjugating enzyme E2 UBC9 mediates viral immediate-early protein SUMOylation",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -7.94921875,
            "text": "SUMO-conjugating enzyme E2 UB",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.0,
            "text": "SUMO-conjugating enzyme E2 UBC9 mediates viral immediate-early protein SUMOylation in cr",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.0703125,
            "text": "SUMO-conjugating enzyme E2 UBC9 mediates viral immediate-early protein SUMOylation in crayfish",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.0859375,
            "text": "SUMO-conjugating enzyme E2 UBC9 mediates",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.1015625,
            "text": "SUMO-conjugating enzyme E2 UBC9 mediates viral immediate-early protein SUMOylation in crayfish to",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.1171875,
            "text": "SUMO-conjugating enzyme E2 UBC",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.125,
            "text": "SUMO-conjugating enzyme E2 UBC9",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.1328125,
            "text": "SUMO-conjugating enzyme E2 UBC9 mediates viral immediate-early protein SUMOylation in crayfish to facilitate reproduction of white spot",
            "probability": 0.0
        },
        {
            "start_logit": -1.8310546875,
            "end_logit": -6.890625,
            "text": "enzyme E2",
            "probability": 0.0
        }
    ],
    "58a5b1fe60087bc10a000024_6": [
        {
            "start_logit": 10.015625,
            "end_logit": 9.6953125,
            "text": "SUMO-conjugating enzyme",
            "probability": 1.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -1.857421875,
            "text": "SUMO",
            "probability": 9.5367431640625e-06
        },
        {
            "start_logit": -1.8974609375,
            "end_logit": 9.6953125,
            "text": "enzyme",
            "probability": 6.616115570068359e-06
        },
        {
            "start_logit": -6.09765625,
            "end_logit": 9.6953125,
            "text": "conjugating enzyme",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.44140625,
            "end_logit": 9.6953125,
            "text": "-conjugating enzyme",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.8984375,
            "end_logit": 9.6953125,
            "text": "E2 SUMO-conjugating enzyme",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.90625,
            "end_logit": 9.6953125,
            "text": "ating enzyme",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 9.6953125,
            "text": "study, we revisited the role of Tax SUMOylation using a strategy based on the targeting of Ubc9, the unique E2 SUMO-conjugating enzyme",
            "probability": 0.0
        },
        {
            "start_logit": -7.640625,
            "end_logit": 9.6953125,
            "text": "this study, we revisited the role of Tax SUMOylation using a strategy based on the targeting of Ubc9, the unique E2 SUMO-conjugating enzyme",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -7.98046875,
            "text": "SUMO-conjugating enzyme.",
            "probability": 0.0
        },
        {
            "start_logit": -7.70703125,
            "end_logit": 9.6953125,
            "text": "SUMOylation using a strategy based on the targeting of Ubc9, the unique E2 SUMO-conjugating enzyme",
            "probability": 0.0
        },
        {
            "start_logit": -7.70703125,
            "end_logit": 9.6953125,
            "text": "In this study, we revisited the role of Tax SUMOylation using a strategy based on the targeting of Ubc9, the unique E2 SUMO-conjugating enzyme",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.03125,
            "text": "SUMO-conjugating",
            "probability": 0.0
        },
        {
            "start_logit": -7.78515625,
            "end_logit": 9.6953125,
            "text": ", we revisited the role of Tax SUMOylation using a strategy based on the targeting of Ubc9, the unique E2 SUMO-conjugating enzyme",
            "probability": 0.0
        },
        {
            "start_logit": -8.0,
            "end_logit": 9.6953125,
            "text": "we revisited the role of Tax SUMOylation using a strategy based on the targeting of Ubc9, the unique E2 SUMO-conjugating enzyme",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.6953125,
            "text": "Tax SUMOylation using a strategy based on the targeting of Ubc9, the unique E2 SUMO-conjugating enzyme",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.6953125,
            "text": "the role of Tax SUMOylation using a strategy based on the targeting of Ubc9, the unique E2 SUMO-conjugating enzyme",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.6953125,
            "text": "revisited the role of Tax SUMOylation using a strategy based on the targeting of Ubc9, the unique E2 SUMO-conjugating enzyme",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 9.6953125,
            "text": "the targeting of Ubc9, the unique E2 SUMO-conjugating enzyme",
            "probability": 0.0
        },
        {
            "start_logit": -6.8984375,
            "end_logit": -1.857421875,
            "text": "E2 SUMO",
            "probability": 0.0
        }
    ],
    "5c011057133db5eb78000025_1": [
        {
            "start_logit": 9.9140625,
            "end_logit": 9.65625,
            "text": "phase II",
            "probability": 1.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -1.94921875,
            "text": "phase",
            "probability": 9.238719940185547e-06
        },
        {
            "start_logit": -1.712890625,
            "end_logit": 9.65625,
            "text": "II",
            "probability": 9.000301361083984e-06
        },
        {
            "start_logit": -6.8125,
            "end_logit": 9.65625,
            "text": ", while several other novel compounds (AZD5847, PA-824, SQ109 and sutezolid) have been evaluated in phase II",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.125,
            "end_logit": 9.65625,
            "text": "in phase II",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -7.52734375,
            "text": "phase II clinical trials",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.65625,
            "text": "evaluated in phase II",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.65625,
            "text": "the treatment of drug-resistant tuberculosis, while several other novel compounds (AZD5847, PA-824, SQ109 and sutezolid) have been evaluated in phase II",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.65625,
            "text": "been evaluated in phase II",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.65625,
            "text": "of drug-resistant tuberculosis, while several other novel compounds (AZD5847, PA-824, SQ109 and sutezolid) have been evaluated in phase II",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.65625,
            "text": ") have been evaluated in phase II",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.65625,
            "text": "for the treatment of drug-resistant tuberculosis, while several other novel compounds (AZD5847, PA-824, SQ109 and sutezolid) have been evaluated in phase II",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.65625,
            "text": "approved for the treatment of drug-resistant tuberculosis, while several other novel compounds (AZD5847, PA-824, SQ109 and sutezolid) have been evaluated in phase II",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.65625,
            "text": "treatment of drug-resistant tuberculosis, while several other novel compounds (AZD5847, PA-824, SQ109 and sutezolid) have been evaluated in phase II",
            "probability": 0.0
        },
        {
            "start_logit": -6.8125,
            "end_logit": -1.94921875,
            "text": ", while several other novel compounds (AZD5847, PA-824, SQ109 and sutezolid) have been evaluated in phase",
            "probability": 0.0
        },
        {
            "start_logit": -7.125,
            "end_logit": -1.94921875,
            "text": "in phase",
            "probability": 0.0
        },
        {
            "start_logit": -1.712890625,
            "end_logit": -7.52734375,
            "text": "II clinical trials",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": -1.94921875,
            "text": "evaluated in phase",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": -1.94921875,
            "text": "the treatment of drug-resistant tuberculosis, while several other novel compounds (AZD5847, PA-824, SQ109 and sutezolid) have been evaluated in phase",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": -1.94921875,
            "text": "been evaluated in phase",
            "probability": 0.0
        }
    ],
    "601bfa531cb411341a000008_1": [
        {
            "start_logit": 9.9140625,
            "end_logit": 9.4296875,
            "text": "primary microcephaly",
            "probability": 1.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -2.107421875,
            "text": "primary",
            "probability": 9.715557098388672e-06
        },
        {
            "start_logit": -2.51171875,
            "end_logit": 9.4296875,
            "text": "y",
            "probability": 4.0531158447265625e-06
        },
        {
            "start_logit": -6.44921875,
            "end_logit": 9.4296875,
            "text": "microcephaly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.67578125,
            "end_logit": 9.4296875,
            "text": "ephaly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -7.83203125,
            "text": "primary microcephal",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -7.87109375,
            "text": "primary microcephaly and define",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.0078125,
            "text": "primary microcephaly and define a novel",
            "probability": 0.0
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 9.4296875,
            "text": "Heterozygous lamin B1 and lamin B2 variants cause primary microcephaly",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.0703125,
            "text": "primary microcephaly and define a",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.078125,
            "text": "primary microcephaly and define a novel lamin",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.15625,
            "text": "primary microcephaly and define a novel laminopathy",
            "probability": 0.0
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 9.4296875,
            "text": "cause primary microcephaly",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.4296875,
            "text": "lamin B1 and lamin B2 variants cause primary microcephaly",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.4296875,
            "text": "variants cause primary microcephaly",
            "probability": 0.0
        },
        {
            "start_logit": -8.390625,
            "end_logit": 9.4296875,
            "text": "lamin B2 variants cause primary microcephaly",
            "probability": 0.0
        },
        {
            "start_logit": -8.421875,
            "end_logit": 9.4296875,
            "text": "and lamin B2 variants cause primary microcephaly",
            "probability": 0.0
        },
        {
            "start_logit": -7.57421875,
            "end_logit": -2.107421875,
            "text": "Heterozygous lamin B1 and lamin B2 variants cause primary",
            "probability": 0.0
        },
        {
            "start_logit": -7.9921875,
            "end_logit": -2.107421875,
            "text": "cause primary",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": -2.107421875,
            "text": "lamin B1 and lamin B2 variants cause primary",
            "probability": 0.0
        }
    ],
    "601bfa531cb411341a000008_2": [
        {
            "start_logit": 9.8828125,
            "end_logit": 9.21875,
            "text": "primary microcephaly",
            "probability": 1.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -2.15234375,
            "text": "primary",
            "probability": 1.1682510375976562e-05
        },
        {
            "start_logit": -2.890625,
            "end_logit": 9.21875,
            "text": "y",
            "probability": 2.86102294921875e-06
        },
        {
            "start_logit": -5.95703125,
            "end_logit": 9.21875,
            "text": "microcephaly",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.5546875,
            "end_logit": 9.21875,
            "text": ".CONCLUSION: We identify dominant pathogenic variants in LMNB1 and LMNB2 as a genetic cause of primary microcephaly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.5703125,
            "end_logit": 9.21875,
            "text": "ephaly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.6171875,
            "text": "primary microcephal",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.0546875,
            "end_logit": 9.21875,
            "text": "of primary microcephaly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.1171875,
            "text": "primary microcephaly, implicating a major structural component of the nuclear envelope in its etiology and defining a new form of laminopathy. The distinct nature of this lamin B-associated phenotype highlights the strikingly different developmental requirements for lamin paralogs and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.15625,
            "text": "primary microcephaly, implicating a major structural component of the nuclear envelope in its etiology and defining a new form of laminopathy. The distinct nature of this lamin B",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.21875,
            "text": "primary microcephaly, implicating a major structural component of the nuclear envelope in",
            "probability": 0.0
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 9.21875,
            "text": "identify dominant pathogenic variants in LMNB1 and LMNB2 as a genetic cause of primary microcephaly",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": 9.21875,
            "text": "lamin \u0251-helical rod domain, likely disrupting interactions required for higher-order assembly of lamin filaments.CONCLUSION: We identify dominant pathogenic variants in LMNB1 and LMNB2 as a genetic cause of primary microcephaly",
            "probability": 0.0
        },
        {
            "start_logit": -6.5546875,
            "end_logit": -2.15234375,
            "text": ".CONCLUSION: We identify dominant pathogenic variants in LMNB1 and LMNB2 as a genetic cause of primary",
            "probability": 0.0
        },
        {
            "start_logit": -7.0546875,
            "end_logit": -2.15234375,
            "text": "of primary",
            "probability": 0.0
        },
        {
            "start_logit": -7.96484375,
            "end_logit": -2.15234375,
            "text": "identify dominant pathogenic variants in LMNB1 and LMNB2 as a genetic cause of primary",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": -2.15234375,
            "text": "lamin \u0251-helical rod domain, likely disrupting interactions required for higher-order assembly of lamin filaments.CONCLUSION: We identify dominant pathogenic variants in LMNB1 and LMNB2 as a genetic cause of primary",
            "probability": 0.0
        },
        {
            "start_logit": -2.890625,
            "end_logit": -8.1171875,
            "text": "y, implicating a major structural component of the nuclear envelope in its etiology and defining a new form of laminopathy. The distinct nature of this lamin B-associated phenotype highlights the strikingly different developmental requirements for lamin paralogs and",
            "probability": 0.0
        },
        {
            "start_logit": -2.890625,
            "end_logit": -8.140625,
            "text": "y, implicating a major structural component of the nuclear envelope in its etiology and defining a new form of laminopathy. The distinct nature of this lamin B-associated phenotype highlights the strikingly different developmental requirements for lamin paralogs and suggests a novel mechanism",
            "probability": 0.0
        },
        {
            "start_logit": -2.890625,
            "end_logit": -8.15625,
            "text": "y, implicating a major structural component of the nuclear envelope in its etiology and defining a new form of laminopathy. The distinct nature of this lamin B",
            "probability": 0.0
        }
    ],
    "601bfa531cb411341a000008_3": [
        {
            "start_logit": 9.8046875,
            "end_logit": 9.34375,
            "text": "primary microcephaly",
            "probability": 1.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -2.326171875,
            "text": "primary",
            "probability": 8.463859558105469e-06
        },
        {
            "start_logit": -2.6875,
            "end_logit": 9.34375,
            "text": "y",
            "probability": 3.7550926208496094e-06
        },
        {
            "start_logit": -6.4609375,
            "end_logit": 9.34375,
            "text": "microcephaly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.77734375,
            "end_logit": 9.34375,
            "text": "ephaly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.8515625,
            "text": "primary microcephaly and define",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.85546875,
            "text": "primary microcephal",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -7.98046875,
            "text": "primary microcephaly and define a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.0078125,
            "text": "primary microcephaly and define a novel",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.109375,
            "text": "primary microcephaly and define a novel laminopathy",
            "probability": 0.0
        },
        {
            "start_logit": 9.8046875,
            "end_logit": -8.125,
            "text": "primary microcephaly and define a novel lamin",
            "probability": 0.0
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 9.34375,
            "text": "Heterozygous lamin B1 and lamin B2 variants cause primary microcephaly",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.34375,
            "text": "cause primary microcephaly",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.34375,
            "text": "lamin B1 and lamin B2 variants cause primary microcephaly",
            "probability": 0.0
        },
        {
            "start_logit": -8.359375,
            "end_logit": 9.34375,
            "text": "variants cause primary microcephaly",
            "probability": 0.0
        },
        {
            "start_logit": -8.4375,
            "end_logit": 9.34375,
            "text": "lamin B2 variants cause primary microcephaly",
            "probability": 0.0
        },
        {
            "start_logit": -7.93359375,
            "end_logit": -2.326171875,
            "text": "Heterozygous lamin B1 and lamin B2 variants cause primary",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": -2.326171875,
            "text": "cause primary",
            "probability": 0.0
        },
        {
            "start_logit": -2.6875,
            "end_logit": -7.8515625,
            "text": "y and define",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -2.326171875,
            "text": "lamin B1 and lamin B2 variants cause primary",
            "probability": 0.0
        }
    ],
    "601bfa531cb411341a000008_4": [
        {
            "start_logit": 9.875,
            "end_logit": 9.3671875,
            "text": "primary microcephaly",
            "probability": 1.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -2.203125,
            "text": "primary",
            "probability": 9.357929229736328e-06
        },
        {
            "start_logit": -2.646484375,
            "end_logit": 9.3671875,
            "text": "y",
            "probability": 3.635883331298828e-06
        },
        {
            "start_logit": -6.4375,
            "end_logit": 9.3671875,
            "text": "microcephaly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.79296875,
            "end_logit": 9.3671875,
            "text": "ephaly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.875,
            "end_logit": -7.91796875,
            "text": "primary microcephal",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.875,
            "end_logit": -7.94921875,
            "text": "primary microcephaly, implicating a major structural component of the nuclear envelope",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.875,
            "end_logit": -7.98046875,
            "text": "primary microcephaly, implicating a major structural component of the nuclear envelope in",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.09375,
            "text": "primary microcephaly, implicating a major structural component of the nuclear",
            "probability": 0.0
        },
        {
            "start_logit": -7.5859375,
            "end_logit": 9.3671875,
            "text": "of primary microcephaly",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.1640625,
            "text": "primary microcephaly, implicating a major structural component of the nuclear envelope in its etiology",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.1875,
            "text": "primary microcephaly, implicating a major structural component of the nuclear envelope in its etiology and",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.2109375,
            "text": "primary microcephaly, implicating a major",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.2265625,
            "text": "primary microcephaly, implicating a major structural component of the nuclear envelope in its etiology and defining a new form of lamin",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.234375,
            "text": "primary microcephaly, implicating a major structural component of the nuclear envelope in its etiology and defining a new",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.234375,
            "text": "primary microcephaly, implicating a major structural",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.2421875,
            "text": "primary microcephaly, implicating a major structural component",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.2421875,
            "text": "primary microcephaly, implicating a major structural component of the nuclear envelope in its etiology and defining a new form of laminopathy",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.2578125,
            "text": "primary microcephaly, implicating a major structural component of the nuclear envelope in its",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -8.28125,
            "text": "primary microcephaly, implicating a major structural component of the nuclear envelope in its etiology and defining",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_1": [
        {
            "start_logit": 8.734375,
            "end_logit": 8.0390625,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.734375,
            "end_logit": -8.1171875,
            "text": "malaria infection (CHMI) using homologous parasites (same P. falciparum strain as in the vaccine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.734375,
            "end_logit": -8.125,
            "text": "malaria infection (CH",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.734375,
            "end_logit": -8.1796875,
            "text": "malaria infection (CHMI) using homologous parasites (same P",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.734375,
            "end_logit": -8.1875,
            "text": "malaria infection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.734375,
            "end_logit": -8.2109375,
            "text": "malaria infection (CHMI) using homologous parasites (same P. falciparum",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.734375,
            "end_logit": -8.21875,
            "text": "malaria infection (CHMI",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.734375,
            "end_logit": -8.2421875,
            "text": "malaria infection (CHMI) using homologous parasites (same P. falciparum strain as",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.734375,
            "end_logit": -8.25,
            "text": "malaria infection (CHMI) using homologous parasites (same P.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.734375,
            "end_logit": -8.2578125,
            "text": "malaria infection (CHMI) using homologous parasites (same P. falciparum strain as in the vaccine)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.734375,
            "end_logit": -8.328125,
            "text": "malaria infection (CHMI) using homologous parasites (same P. falciparum strain",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.734375,
            "end_logit": -8.328125,
            "text": "malaria infection (CHMI)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.734375,
            "end_logit": -8.328125,
            "text": "malaria infection (CHMI) using homologous parasites",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 8.0390625,
            "text": "human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.03125,
            "end_logit": 8.0390625,
            "text": "shown up to 100% protection against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 8.0390625,
            "text": "to 100% protection against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.09375,
            "end_logit": 8.0390625,
            "text": "against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.15625,
            "end_logit": 8.0390625,
            "text": "has shown up to 100% protection against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 8.0390625,
            "text": "(PfSPZ Vaccine) has shown up to 100% protection against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1875,
            "end_logit": 8.0390625,
            "text": "attenuated Plasmodium falciparum sporozoite (SPZ) vaccine (PfSPZ Vaccine) has shown up to 100% protection against controlled human malaria",
            "probability": 5.960464477539063e-08
        }
    ],
    "61f7d745882a024a10000038_2": [
        {
            "start_logit": 9.015625,
            "end_logit": 7.328125,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 9.015625,
            "end_logit": -7.94921875,
            "text": "malaria infection (CH",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.015625,
            "end_logit": -8.140625,
            "text": "malaria infection (CHMI",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.90625,
            "end_logit": 7.328125,
            "text": "100% against homologous controlled human malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.640625,
            "end_logit": 7.328125,
            "text": "of 100% against homologous controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.65625,
            "end_logit": 7.328125,
            "text": "shown vaccine efficacies (VEs) of 100% against homologous controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.75,
            "end_logit": 7.328125,
            "text": "(VEs) of 100% against homologous controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9140625,
            "end_logit": 7.328125,
            "text": "human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 7.328125,
            "text": "cryopreserved PfSPZ administered to subjects taking weekly chloroquine chemoprophylaxis) have shown vaccine efficacies (VEs) of 100% against homologous controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 7.328125,
            "text": "taking weekly chloroquine chemoprophylaxis) have shown vaccine efficacies (VEs) of 100% against homologous controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 7.328125,
            "text": ", aseptic, purified, cryopreserved PfSPZ administered to subjects taking weekly chloroquine chemoprophylaxis) have shown vaccine efficacies (VEs) of 100% against homologous controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 7.328125,
            "text": ", cryopreserved PfSPZ administered to subjects taking weekly chloroquine chemoprophylaxis) have shown vaccine efficacies (VEs) of 100% against homologous controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 7.328125,
            "text": "vaccine efficacies (VEs) of 100% against homologous controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.90625,
            "end_logit": -6.8125,
            "text": "100",
            "probability": 0.0
        },
        {
            "start_logit": -6.90625,
            "end_logit": -7.2578125,
            "text": "100%",
            "probability": 0.0
        },
        {
            "start_logit": -7.640625,
            "end_logit": -6.8125,
            "text": "of 100",
            "probability": 0.0
        },
        {
            "start_logit": -7.65625,
            "end_logit": -6.8125,
            "text": "shown vaccine efficacies (VEs) of 100",
            "probability": 0.0
        },
        {
            "start_logit": -7.75,
            "end_logit": -6.8125,
            "text": "(VEs) of 100",
            "probability": 0.0
        },
        {
            "start_logit": -7.94140625,
            "end_logit": -6.8125,
            "text": ", cryopreserved PfSPZ) and PfSPZ-CVac (infectious, aseptic, purified, cryopreserved PfSPZ administered to subjects taking weekly chloroquine chemoprophylaxis) have shown vaccine efficacies (VEs) of 100",
            "probability": 0.0
        },
        {
            "start_logit": -7.95703125,
            "end_logit": -6.8125,
            "text": ", purified, cryopreserved PfSPZ) and PfSPZ-CVac (infectious, aseptic, purified, cryopreserved PfSPZ administered to subjects taking weekly chloroquine chemoprophylaxis) have shown vaccine efficacies (VEs) of 100",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_3": [
        {
            "start_logit": 8.40625,
            "end_logit": 8.3359375,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.40625,
            "end_logit": -7.51953125,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.40625,
            "end_logit": -7.73046875,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.40625,
            "end_logit": -7.8828125,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.90625,
            "end_logit": 8.3359375,
            "text": ") malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.40625,
            "end_logit": -8.1015625,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 8.3359375,
            "text": ") sporozoite (SPZ) malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 8.3359375,
            "text": "attenuated Plasmodium falciparum (Pf) sporozoite (SPZ) malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.40625,
            "end_logit": -8.1796875,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.40625,
            "end_logit": -8.1953125,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria infection (CHMI",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.40625,
            "end_logit": -8.203125,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.40625,
            "end_logit": -8.203125,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria infection (CH",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.40625,
            "end_logit": -8.3046875,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.40625,
            "end_logit": -8.3046875,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria infection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.40625,
            "end_logit": -8.3046875,
            "text": "malaria vaccine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.40625,
            "end_logit": -8.3125,
            "text": "malaria vaccine, PfSP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.40625,
            "end_logit": -8.3203125,
            "text": "malaria vaccine, PfSPZ",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.40625,
            "end_logit": -8.328125,
            "text": "malaria vaccine, PfSPZ Vaccine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.40625,
            "end_logit": -8.359375,
            "text": "malaria vaccine, PfS",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.40625,
            "end_logit": -8.359375,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6",
            "probability": 5.960464477539063e-08
        }
    ],
    "61f7d745882a024a10000038_4": [
        {
            "start_logit": 8.734375,
            "end_logit": 8.0546875,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.734375,
            "end_logit": -8.21875,
            "text": "malaria vaccines, (1) a recombinant protein with adjuvant vaccine aimed at Plasmodium falciparum (Pf) pre-erythrocytic stages of the parasite cycle (RTS,S/AS01), (2) whole sporozoite",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.734375,
            "end_logit": -8.2578125,
            "text": "malaria vaccines, (1) a recombinant protein with adjuvant vaccine aimed at Plasmodium falciparum (Pf) pre-erythrocytic stages of the parasite cycle",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.734375,
            "end_logit": -8.2578125,
            "text": "malaria vaccines, (1) a recombinant protein with adjuvant vaccine aimed at Plasmodium falciparum (Pf) pre-erythrocytic stages of the parasite cycle (RTS,S/AS01), (2) whole sporozoite vaccines aimed at Pf pre",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.734375,
            "end_logit": -8.296875,
            "text": "malaria vaccines, (1) a recombinant protein with",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.734375,
            "end_logit": -8.3046875,
            "text": "malaria vaccines, (1) a recombinant protein with adjuvant vaccine aimed at Plasmodium falciparum (Pf) pre",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 8.0546875,
            "text": "review, we focus on four approaches to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 8.0546875,
            "text": "this limited review, we focus on four approaches to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.125,
            "end_logit": 8.0546875,
            "text": "we focus on four approaches to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 8.0546875,
            "text": "In this limited review, we focus on four approaches to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 8.0546875,
            "text": "limited review, we focus on four approaches to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.71484375,
            "end_logit": -8.25,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": -8.2578125,
            "text": "review, we focus on four approaches to malaria vaccines, (1) a recombinant protein with adjuvant vaccine aimed at Plasmodium falciparum (Pf) pre-erythrocytic stages of the parasite cycle",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": -8.21875,
            "text": ") whole sporozoite",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": -8.296875,
            "text": "review, we focus on four approaches to malaria vaccines, (1) a recombinant protein with",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": -8.3046875,
            "text": "review, we focus on four",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": -8.3046875,
            "text": "review, we focus on four approaches to malaria vaccines, (1) a recombinant protein with adjuvant vaccine aimed at Plasmodium falciparum (Pf) pre",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": -8.2578125,
            "text": ") whole sporozoite vaccines aimed at Pf pre",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": -8.2578125,
            "text": "this limited review, we focus on four approaches to malaria vaccines, (1) a recombinant protein with adjuvant vaccine aimed at Plasmodium falciparum (Pf) pre-erythrocytic stages of the parasite cycle",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": -8.25,
            "text": ", but also asexual erythrocytic stages, and (4) recombinant protein with adjuvant vaccines aimed at Pf and Plasmodium vivax sexual erythrocytic and mosquito stages.",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_5": [
        {
            "start_logit": 8.734375,
            "end_logit": 8.0546875,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.734375,
            "end_logit": -8.21875,
            "text": "malaria vaccines, (1) a recombinant protein with adjuvant vaccine aimed at Plasmodium falciparum (Pf) pre-erythrocytic stages of the parasite cycle (RTS,S/AS01), (2) whole sporozoite",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.734375,
            "end_logit": -8.2578125,
            "text": "malaria vaccines, (1) a recombinant protein with adjuvant vaccine aimed at Plasmodium falciparum (Pf) pre-erythrocytic stages of the parasite cycle",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.734375,
            "end_logit": -8.2578125,
            "text": "malaria vaccines, (1) a recombinant protein with adjuvant vaccine aimed at Plasmodium falciparum (Pf) pre-erythrocytic stages of the parasite cycle (RTS,S/AS01), (2) whole sporozoite vaccines aimed at Pf pre",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.734375,
            "end_logit": -8.296875,
            "text": "malaria vaccines, (1) a recombinant protein with",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.734375,
            "end_logit": -8.3046875,
            "text": "malaria vaccines, (1) a recombinant protein with adjuvant vaccine aimed at Plasmodium falciparum (Pf) pre",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 8.0546875,
            "text": "review, we focus on four approaches to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 8.0546875,
            "text": "this limited review, we focus on four approaches to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.125,
            "end_logit": 8.0546875,
            "text": "we focus on four approaches to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 8.0546875,
            "text": "In this limited review, we focus on four approaches to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 8.0546875,
            "text": "limited review, we focus on four approaches to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.71484375,
            "end_logit": -8.25,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": -8.2578125,
            "text": "review, we focus on four approaches to malaria vaccines, (1) a recombinant protein with adjuvant vaccine aimed at Plasmodium falciparum (Pf) pre-erythrocytic stages of the parasite cycle",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": -8.21875,
            "text": ") whole sporozoite",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": -8.296875,
            "text": "review, we focus on four approaches to malaria vaccines, (1) a recombinant protein with",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": -8.3046875,
            "text": "review, we focus on four",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": -8.3046875,
            "text": "review, we focus on four approaches to malaria vaccines, (1) a recombinant protein with adjuvant vaccine aimed at Plasmodium falciparum (Pf) pre",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": -8.2578125,
            "text": ") whole sporozoite vaccines aimed at Pf pre",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": -8.2578125,
            "text": "this limited review, we focus on four approaches to malaria vaccines, (1) a recombinant protein with adjuvant vaccine aimed at Plasmodium falciparum (Pf) pre-erythrocytic stages of the parasite cycle",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": -8.25,
            "text": ", but also asexual erythrocytic stages, and (4) recombinant protein with adjuvant vaccines aimed at Pf and Plasmodium vivax sexual erythrocytic and mosquito stages.",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_6": [
        {
            "start_logit": 8.453125,
            "end_logit": 8.3125,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.453125,
            "end_logit": -7.921875,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria infection (CHMI) with Plasmodium falciparum (Pf) parasites homologous to the vaccine strain up to 14 mo after final vaccination. No injectable malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.453125,
            "end_logit": -7.96875,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria infection (CHMI) with Plasmodium falciparum (Pf) parasites homologous to the vaccine strain up",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.453125,
            "end_logit": -8.0546875,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria infection (CHMI) with Plasmodium falciparum (Pf) parasites homologous to the vaccine strain up to 14 mo",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.453125,
            "end_logit": -8.140625,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.453125,
            "end_logit": -8.140625,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria infection (CHMI) with Plasmodium falciparum (Pf) parasites homologous to the vaccine strain up to 14 mo after final vaccination. No",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.453125,
            "end_logit": -8.140625,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria infection (CHMI) with Plasmodium falciparum (Pf) parasites homologous to the vaccine strain up to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.453125,
            "end_logit": -8.1796875,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria infection (CHMI) with Plasmodium falciparum (Pf) parasites homologous to the vaccine strain up to 14 mo after final vaccination.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.453125,
            "end_logit": -8.1953125,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 8.3125,
            "text": "attenuated malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.453125,
            "end_logit": -8.203125,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.453125,
            "end_logit": -8.203125,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria infection (CH",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.453125,
            "end_logit": -8.203125,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria infection (CHMI) with Plasmodium falciparum",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.453125,
            "end_logit": -8.2109375,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.453125,
            "end_logit": -8.2109375,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria infection (CHMI) with Plasmodium falciparum (Pf) parasites homologous to the vaccine strain up to 14",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1875,
            "end_logit": 8.3125,
            "text": "A live-attenuated malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": 8.3125,
            "text": "-attenuated malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.6796875,
            "end_logit": -7.921875,
            "text": ". No injectable malaria",
            "probability": 0.0
        },
        {
            "start_logit": -6.6796875,
            "end_logit": -8.0546875,
            "text": ". No injectable malaria vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -6.6796875,
            "end_logit": -8.1015625,
            "text": ". No injectable malaria vaccine has demonstrated long",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_7": [
        {
            "start_logit": 9.078125,
            "end_logit": 7.640625,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 9.078125,
            "end_logit": -8.1328125,
            "text": "malaria, but the features of the antibody response induced by this treatment remain",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.078125,
            "end_logit": -8.1328125,
            "text": "malaria, but the features of the antibody response",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.078125,
            "end_logit": -8.1484375,
            "text": "malaria, but the features of the antibody response induced",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.078125,
            "end_logit": -8.2265625,
            "text": "malaria, but the features of the antibody response induced by this treatment remain unclear. T",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.078125,
            "end_logit": -8.265625,
            "text": "malaria, but the features",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.078125,
            "end_logit": -8.2734375,
            "text": "malaria, but the features of the antibody response induced by this treatment remain unclear.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.62109375,
            "end_logit": 7.640625,
            "text": "against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.046875,
            "end_logit": 7.640625,
            "text": "shown to be protective against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.125,
            "end_logit": 7.640625,
            "text": "Immunization with attenuated Plasmodium falciparum sporozoites (PfSPZs) has been shown to be protective against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 7.640625,
            "text": "attenuated Plasmodium falciparum sporozoites (PfSPZs) has been shown to be protective against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 7.640625,
            "text": "be protective against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 7.640625,
            "text": "been shown to be protective against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 7.640625,
            "text": "protective against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.234375,
            "end_logit": 7.640625,
            "text": "with attenuated Plasmodium falciparum sporozoites (PfSPZs) has been shown to be protective against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.28125,
            "end_logit": 7.640625,
            "text": "to be protective against malaria",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 7.640625,
            "text": "(PfSPZs) has been shown to be protective against malaria",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 7.640625,
            "text": ") has been shown to be protective against malaria",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 7.640625,
            "text": "has been shown to be protective against malaria",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 7.640625,
            "text": "sporozoites (PfSPZs) has been shown to be protective against malaria",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_8": [
        {
            "start_logit": 8.6875,
            "end_logit": 8.125,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.6875,
            "end_logit": -8.125,
            "text": "malaria vaccines, which is based on human malaria sporozoites and called PfSPZ Vaccine, has been shown to protect a significant proportion of vaccine recipients from getting malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6875,
            "end_logit": -8.1328125,
            "text": "malaria vaccines, which is based on human malaria sporozoites and called PfSPZ Vaccine, has been shown to protect a significant",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6875,
            "end_logit": -8.1953125,
            "text": "malaria vaccines, which is based on human malaria sporozoites and called PfSPZ Vaccine, has been shown to protect a significant proportion of vaccine recipients from",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6875,
            "end_logit": -8.2421875,
            "text": "malaria vaccines",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6875,
            "end_logit": -8.2578125,
            "text": "malaria vaccines, which is based on human malaria sporozoites",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6875,
            "end_logit": -8.2578125,
            "text": "malaria vaccines, which is based on human malaria sporozoites and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6875,
            "end_logit": -8.265625,
            "text": "malaria vaccines, which is based on human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6875,
            "end_logit": -8.296875,
            "text": "malaria vaccines, which is based on human malaria spor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.125,
            "text": "human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.109375,
            "end_logit": -8.125,
            "text": "getting malaria",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": -8.125,
            "text": "shown to protect a significant proportion of vaccine recipients from getting malaria",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": -8.1328125,
            "text": "shown to protect a significant",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": -8.1953125,
            "text": "shown to protect a significant proportion of vaccine recipients from",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -8.125,
            "text": ", has been shown to protect a significant proportion of vaccine recipients from getting malaria",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -8.1328125,
            "text": ", has been shown to protect a significant",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -8.125,
            "text": "of vaccine recipients from getting malaria",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -8.125,
            "text": "protect a significant proportion of vaccine recipients from getting malaria",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -8.1328125,
            "text": "protect a significant",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -8.125,
            "text": "called PfSPZ Vaccine, has been shown to protect a significant proportion of vaccine recipients from getting malaria",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_9": [
        {
            "start_logit": 8.6640625,
            "end_logit": 8.0859375,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.6640625,
            "end_logit": -8.1640625,
            "text": "malaria infection (CH",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6640625,
            "end_logit": -8.2421875,
            "text": "malaria infection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6640625,
            "end_logit": -8.265625,
            "text": "malaria infection (CHMI) using homologous parasites (sa",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6640625,
            "end_logit": -8.28125,
            "text": "malaria infection (CHMI",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6640625,
            "end_logit": -8.3203125,
            "text": "malaria infection (CHMI) using homologous parasites (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6640625,
            "end_logit": -8.3828125,
            "text": "malaria infection (CHMI) using homologous parasites",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6640625,
            "end_logit": -8.390625,
            "text": "malaria infection (CHMI)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.921875,
            "end_logit": 8.0859375,
            "text": "human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 8.0859375,
            "text": "shown up to 100% protection against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 8.0859375,
            "text": "(PfSPZ Vaccine) has shown up to 100% protection against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.078125,
            "end_logit": 8.0859375,
            "text": "against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 8.0859375,
            "text": "to 100% protection against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 8.0859375,
            "text": "has shown up to 100% protection against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.15625,
            "end_logit": 8.0859375,
            "text": "attenuated Plasmodium falciparum sporozoite (SPZ) vaccine (PfSPZ Vaccine) has shown up to 100% protection against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.171875,
            "end_logit": 8.0859375,
            "text": ") has shown up to 100% protection against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 8.0859375,
            "text": "-attenuated Plasmodium falciparum sporozoite (SPZ) vaccine (PfSPZ Vaccine) has shown up to 100% protection against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 8.0859375,
            "text": "controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 8.0859375,
            "text": "up to 100% protection against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": 8.0859375,
            "text": "Plasmodium falciparum sporozoite (SPZ) vaccine (PfSPZ Vaccine) has shown up to 100% protection against controlled human malaria",
            "probability": 5.960464477539063e-08
        }
    ],
    "61f7d745882a024a10000038_10": [
        {
            "start_logit": 8.671875,
            "end_logit": 8.0390625,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.671875,
            "end_logit": -8.1171875,
            "text": "malaria infection (CH",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.671875,
            "end_logit": -8.2109375,
            "text": "malaria infection (CHMI",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.671875,
            "end_logit": -8.2109375,
            "text": "malaria infection (CHMI) 3 weeks after immunization, but the durability of protection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.671875,
            "end_logit": -8.2421875,
            "text": "malaria infection (CHMI) 3 weeks after immunization, but the durability of protection is unknown",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.671875,
            "end_logit": -8.2578125,
            "text": "malaria infection (CHMI) 3 weeks after immunization, but the durability of protection is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.671875,
            "end_logit": -8.28125,
            "text": "malaria infection (CHMI) 3 weeks after immunization, but the durability of protection is unknown. We ass",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.671875,
            "end_logit": -8.296875,
            "text": "malaria infection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.671875,
            "end_logit": -8.3203125,
            "text": "malaria infection (CHMI) 3 weeks",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 8.0390625,
            "text": "human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.078125,
            "end_logit": 8.0390625,
            "text": ", PfSPZ Vaccine, is highly protective against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.15625,
            "end_logit": 8.0390625,
            "text": ", is highly protective against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.21875,
            "end_logit": 8.0390625,
            "text": "against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.234375,
            "end_logit": 8.0390625,
            "text": "(SPZ) vaccine, PfSPZ Vaccine, is highly protective against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 8.0390625,
            "text": "controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.265625,
            "end_logit": 8.0390625,
            "text": "An attenuated Plasmodium falciparum (Pf) sporozoite (SPZ) vaccine, PfSPZ Vaccine, is highly protective against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.265625,
            "end_logit": 8.0390625,
            "text": "attenuated Plasmodium falciparum (Pf) sporozoite (SPZ) vaccine, PfSPZ Vaccine, is highly protective against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.73828125,
            "end_logit": -8.28125,
            "text": ". We ass",
            "probability": 0.0
        },
        {
            "start_logit": -7.96484375,
            "end_logit": -8.1171875,
            "text": "(CH",
            "probability": 0.0
        },
        {
            "start_logit": -7.96484375,
            "end_logit": -8.2109375,
            "text": "(CHMI",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_11": [
        {
            "start_logit": 7.640625,
            "end_logit": 7.29296875,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": -5.0703125,
            "end_logit": 7.29296875,
            "text": "malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria",
            "probability": 2.9802322387695312e-06
        },
        {
            "start_logit": 7.640625,
            "end_logit": -7.24609375,
            "text": "malaria infection in malaria-naive",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.640625,
            "end_logit": -7.4609375,
            "text": "malaria infection in malaria",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.640625,
            "end_logit": -7.78125,
            "text": "malaria infection in malaria-naive ind",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.640625,
            "end_logit": -7.921875,
            "text": "malaria infection",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.640625,
            "end_logit": -8.0859375,
            "text": "malaria infection in malaria-",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.640625,
            "end_logit": -8.1015625,
            "text": "malaria infection in",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.76953125,
            "end_logit": 7.29296875,
            "text": "whole malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.76953125,
            "end_logit": 7.29296875,
            "text": ", whole malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.953125,
            "end_logit": 7.29296875,
            "text": ", non-replicating, whole malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 7.29296875,
            "text": "human malaria",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 7.29296875,
            "text": "safe and protective against P falciparum controlled human malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 7.29296875,
            "text": "-replicating, whole malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.21875,
            "end_logit": 7.29296875,
            "text": "replicating, whole malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 7.29296875,
            "text": "reported to be safe and protective against P falciparum controlled human malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 7.29296875,
            "text": "been reported to be safe and protective against P falciparum controlled human malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.265625,
            "end_logit": 7.29296875,
            "text": "Plasmodium falciparum sporozite (PfSPZ) Vaccine is a metabolically active, non-replicating, whole malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 7.29296875,
            "text": "has been reported to be safe and protective against P falciparum controlled human malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.3125,
            "end_logit": 7.29296875,
            "text": "active, non-replicating, whole malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria",
            "probability": 1.1920928955078125e-07
        }
    ],
    "61f7d745882a024a10000038_12": [
        {
            "start_logit": 8.6015625,
            "end_logit": 8.171875,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.6015625,
            "end_logit": -8.0859375,
            "text": "malaria by chemoattenuated",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6015625,
            "end_logit": -8.140625,
            "text": "malaria by chemoat",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6015625,
            "end_logit": -8.171875,
            "text": "malaria by chemoatten",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6015625,
            "end_logit": -8.1796875,
            "text": "malaria by chemoattenuated PfSPZ vaccine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6015625,
            "end_logit": -8.3125,
            "text": "malaria by chemoattenuated PfSPZ",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0625,
            "end_logit": 8.171875,
            "text": "human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 8.171875,
            "text": "Sterile protection against human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.265625,
            "end_logit": 8.171875,
            "text": "protection against human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.171875,
            "text": "against human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0625,
            "end_logit": -8.0859375,
            "text": "human malaria by chemoattenuated",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": -8.140625,
            "text": "human malaria by chemoat",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": -8.171875,
            "text": "human malaria by chemoatten",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": -8.1796875,
            "text": "human malaria by chemoattenuated PfSPZ vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -8.0859375,
            "text": "Sterile protection against human malaria by chemoattenuated",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -8.140625,
            "text": "Sterile protection against human malaria by chemoat",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": -8.0859375,
            "text": "chemoattenuated",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": -8.0859375,
            "text": "protection against human malaria by chemoattenuated",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": -8.3125,
            "text": "human malaria by chemoattenuated PfSPZ",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -8.171875,
            "text": "Sterile protection against human malaria by chemoatten",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_13": [
        {
            "start_logit": 8.921875,
            "end_logit": 7.83984375,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 7.83984375,
            "text": "(DVI) for maximal efficacy against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 7.83984375,
            "text": ", cryopreserved Plasmodium falciparum sporozoites, is administered by direct venous inoculation (DVI) for maximal efficacy against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.078125,
            "end_logit": 7.83984375,
            "text": ", aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, is administered by direct venous inoculation (DVI) for maximal efficacy against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 7.83984375,
            "text": ", purified, cryopreserved Plasmodium falciparum sporozoites, is administered by direct venous inoculation (DVI) for maximal efficacy against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 7.83984375,
            "text": ", is administered by direct venous inoculation (DVI) for maximal efficacy against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 7.83984375,
            "text": "of radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, is administered by direct venous inoculation (DVI) for maximal efficacy against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 7.83984375,
            "text": "cryopreserved Plasmodium falciparum sporozoites, is administered by direct venous inoculation (DVI) for maximal efficacy against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.21875,
            "end_logit": 7.83984375,
            "text": "administered by direct venous inoculation (DVI) for maximal efficacy against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 7.83984375,
            "text": "against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": 7.83984375,
            "text": "-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, is administered by direct venous inoculation (DVI) for maximal efficacy against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": 7.83984375,
            "text": "PfSPZ Vaccine, composed of radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, is administered by direct venous inoculation (DVI) for maximal efficacy against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 7.83984375,
            "text": ", composed of radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, is administered by direct venous inoculation (DVI) for maximal efficacy against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 7.83984375,
            "text": "Plasmodium falciparum sporozoites, is administered by direct venous inoculation (DVI) for maximal efficacy against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9765625,
            "end_logit": -8.328125,
            "text": "(DV",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": -8.25,
            "text": ", cryopreserved Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": -8.25,
            "text": ", aseptic, purified, cryopreserved Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": -8.25,
            "text": ", purified, cryopreserved Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": -8.328125,
            "text": ", cryopreserved Plasmodium falciparum sporozoites, is administered by direct venous inoculation (DV",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": -8.328125,
            "text": ", aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, is administered by direct venous inoculation (DV",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_14": [
        {
            "start_logit": 8.7265625,
            "end_logit": 8.03125,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -8.1953125,
            "text": "malaria vaccines because of its unpara",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -8.2265625,
            "text": "malaria vaccines because of its unparall",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -8.234375,
            "text": "malaria vaccines because of its unp",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -8.265625,
            "text": "malaria vaccines because of its unparalleled",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -8.2890625,
            "text": "malaria vaccines because",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.09375,
            "end_logit": 8.03125,
            "text": "for malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.265625,
            "end_logit": 8.03125,
            "text": "considered the gold standard for malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.03125,
            "text": "been considered the gold standard for malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 8.03125,
            "text": "the gold standard for malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.375,
            "end_logit": 8.03125,
            "text": "gold standard for malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3828125,
            "end_logit": 8.03125,
            "text": "has been considered the gold standard for malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.390625,
            "end_logit": 8.03125,
            "text": "PfSPZ) vaccine has been considered the gold standard for malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3984375,
            "end_logit": 8.03125,
            "text": "attenuated sporozoite (PfSPZ) vaccine has been considered the gold standard for malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3984375,
            "end_logit": 8.03125,
            "text": "(PfSPZ) vaccine has been considered the gold standard for malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.40625,
            "end_logit": 8.03125,
            "text": "sporozoite (PfSPZ) vaccine has been considered the gold standard for malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.4140625,
            "end_logit": 8.03125,
            "text": "The radiation attenuated sporozoite (PfSPZ) vaccine has been considered the gold standard for malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.4140625,
            "end_logit": 8.03125,
            "text": "radiation attenuated sporozoite (PfSPZ) vaccine has been considered the gold standard for malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.09375,
            "end_logit": -8.1953125,
            "text": "for malaria vaccines because of its unpara",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": -8.2265625,
            "text": "for malaria vaccines because of its unparall",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_15": [
        {
            "start_logit": 8.4375,
            "end_logit": 8.296875,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.4375,
            "end_logit": -7.76953125,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4375,
            "end_logit": -7.96484375,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4375,
            "end_logit": -7.97265625,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 8.296875,
            "text": ") malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.125,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.125,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria infection (CHMI",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.1328125,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria infection (CH",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 8.296875,
            "text": "attenuated Plasmodium falciparum (Pf) sporozoite (SPZ) malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.2265625,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.109375,
            "end_logit": 8.296875,
            "text": ") sporozoite (SPZ) malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.2578125,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.28125,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria infection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.3046875,
            "text": "malaria vaccine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 8.296875,
            "text": "(SPZ) malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.3203125,
            "text": "malaria vaccine, PfSP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.328125,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.328125,
            "text": "malaria vaccine, PfSPZ",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.3359375,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria infection (CHMI)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.3359375,
            "text": "malaria vaccine, PfSPZ Vaccine",
            "probability": 5.960464477539063e-08
        }
    ],
    "61f7d745882a024a10000038_16": [
        {
            "start_logit": 8.8046875,
            "end_logit": 7.875,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.8046875,
            "end_logit": -8.046875,
            "text": "malaria chemoprop",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8046875,
            "end_logit": -8.0859375,
            "text": "malaria chemoprophylax",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8046875,
            "end_logit": -8.1328125,
            "text": "malaria chemoprophylaxis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8046875,
            "end_logit": -8.140625,
            "text": "malaria chemoprophy",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8046875,
            "end_logit": -8.15625,
            "text": "malaria chemoprophyla",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8046875,
            "end_logit": -8.1796875,
            "text": "malaria chemoprophylaxis.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8046875,
            "end_logit": -8.203125,
            "text": "malaria chemo",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.54296875,
            "end_logit": 7.875,
            "text": "on malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 7.875,
            "text": "(IV) inoculation of radiation-attenuated PfSPZ or in those who were exposed to live PfSPZ while on malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 7.875,
            "text": "of volunteers after intravenous (IV) inoculation of radiation-attenuated PfSPZ or in those who were exposed to live PfSPZ while on malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.046875,
            "end_logit": 7.875,
            "text": "of radiation-attenuated PfSPZ or in those who were exposed to live PfSPZ while on malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.046875,
            "end_logit": 7.875,
            "text": "in a small number of volunteers after intravenous (IV) inoculation of radiation-attenuated PfSPZ or in those who were exposed to live PfSPZ while on malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 7.875,
            "text": "in those who were exposed to live PfSPZ while on malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.09375,
            "end_logit": 7.875,
            "text": "a small number of volunteers after intravenous (IV) inoculation of radiation-attenuated PfSPZ or in those who were exposed to live PfSPZ while on malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 7.875,
            "text": ") inoculation of radiation-attenuated PfSPZ or in those who were exposed to live PfSPZ while on malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 7.875,
            "text": "after intravenous (IV) inoculation of radiation-attenuated PfSPZ or in those who were exposed to live PfSPZ while on malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.140625,
            "end_logit": 7.875,
            "text": "demonstrated in a small number of volunteers after intravenous (IV) inoculation of radiation-attenuated PfSPZ or in those who were exposed to live PfSPZ while on malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 7.875,
            "text": "who were exposed to live PfSPZ while on malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 7.875,
            "text": "those who were exposed to live PfSPZ while on malaria",
            "probability": 5.960464477539063e-08
        }
    ],
    "61f7d745882a024a10000038_17": [
        {
            "start_logit": 8.984375,
            "end_logit": 7.7265625,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.984375,
            "end_logit": -8.359375,
            "text": "malaria (mAbs 580 and 663). RTS,S mA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -8.390625,
            "text": "malaria (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -8.390625,
            "text": "malaria (mAbs 580",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -8.390625,
            "text": "malaria (mAbs 580 and 66",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.5390625,
            "end_logit": 7.7265625,
            "text": "to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.171875,
            "end_logit": 7.7265625,
            "text": "individuals exposed to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.171875,
            "end_logit": 7.7265625,
            "text": "an irradiated whole sporozoite vaccine PfSPZ (mAbs CIS43 and MGG4); or individuals exposed to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 7.7265625,
            "text": "/AS01 (mAbs 317 and 311); an irradiated whole sporozoite vaccine PfSPZ (mAbs CIS43 and MGG4); or individuals exposed to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 7.7265625,
            "text": "a recombinant CSP vaccine RTS,S/AS01 (mAbs 317 and 311); an irradiated whole sporozoite vaccine PfSPZ (mAbs CIS43 and MGG4); or individuals exposed to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 7.7265625,
            "text": "of a recombinant CSP vaccine RTS,S/AS01 (mAbs 317 and 311); an irradiated whole sporozoite vaccine PfSPZ (mAbs CIS43 and MGG4); or individuals exposed to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 7.7265625,
            "text": "); or individuals exposed to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 7.7265625,
            "text": "irradiated whole sporozoite vaccine PfSPZ (mAbs CIS43 and MGG4); or individuals exposed to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.234375,
            "end_logit": 7.7265625,
            "text": "and MGG4); or individuals exposed to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.234375,
            "end_logit": 7.7265625,
            "text": "; or individuals exposed to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 7.7265625,
            "text": "human recipients of a recombinant CSP vaccine RTS,S/AS01 (mAbs 317 and 311); an irradiated whole sporozoite vaccine PfSPZ (mAbs CIS43 and MGG4); or individuals exposed to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 7.7265625,
            "text": "exposed to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": 7.7265625,
            "text": "sporozoite vaccine PfSPZ (mAbs CIS43 and MGG4); or individuals exposed to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 7.7265625,
            "text": "whole sporozoite vaccine PfSPZ (mAbs CIS43 and MGG4); or individuals exposed to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 7.7265625,
            "text": ",S/AS01 (mAbs 317 and 311); an irradiated whole sporozoite vaccine PfSPZ (mAbs CIS43 and MGG4); or individuals exposed to malaria",
            "probability": 5.960464477539063e-08
        }
    ],
    "61f7d745882a024a10000038_18": [
        {
            "start_logit": 8.8203125,
            "end_logit": 7.953125,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -8.140625,
            "text": "malaria by a simple chemoattenuated",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -8.1875,
            "text": "malaria by a simple chemoatten",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -8.1875,
            "text": "malaria by a simple chemoattenuated PfSPZ vaccine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -8.2265625,
            "text": "malaria by a simple chemoat",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -8.28125,
            "text": "malaria by a simple chemoattenuated PfSPZ vaccine regimen",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -8.28125,
            "text": "malaria by a simple chemoattenuated PfSPZ",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.984375,
            "end_logit": 7.953125,
            "text": "against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3125,
            "end_logit": 7.953125,
            "text": "Heterologous protection against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.390625,
            "end_logit": 7.953125,
            "text": "protection against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.984375,
            "end_logit": -8.140625,
            "text": "against malaria by a simple chemoattenuated",
            "probability": 0.0
        },
        {
            "start_logit": -7.984375,
            "end_logit": -8.1875,
            "text": "against malaria by a simple chemoatten",
            "probability": 0.0
        },
        {
            "start_logit": -7.984375,
            "end_logit": -8.1875,
            "text": "against malaria by a simple chemoattenuated PfSPZ vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -7.984375,
            "end_logit": -8.2265625,
            "text": "against malaria by a simple chemoat",
            "probability": 0.0
        },
        {
            "start_logit": -7.984375,
            "end_logit": -8.28125,
            "text": "against malaria by a simple chemoattenuated PfSPZ vaccine regimen",
            "probability": 0.0
        },
        {
            "start_logit": -7.984375,
            "end_logit": -8.28125,
            "text": "against malaria by a simple chemoattenuated PfSPZ",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": -8.140625,
            "text": "a simple chemoattenuated",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": -8.140625,
            "text": "chemoattenuated",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": -8.1875,
            "text": "a simple chemoatten",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": -8.1875,
            "text": "a simple chemoattenuated PfSPZ vaccine",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_19": [
        {
            "start_logit": 9.0,
            "end_logit": 7.7890625,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 9.0,
            "end_logit": -8.1640625,
            "text": "malaria at",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0,
            "end_logit": -8.1640625,
            "text": "malaria at 1 year and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0,
            "end_logit": -8.171875,
            "text": "malaria at 1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0,
            "end_logit": -8.1875,
            "text": "malaria at 1 year and immune correlates",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0,
            "end_logit": -8.1875,
            "text": "malaria at 1 year",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0,
            "end_logit": -8.2578125,
            "text": "malaria at 1 year and immune correlates following PfSPZ vaccination",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0,
            "end_logit": -8.265625,
            "text": "malaria at 1 year and immune",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.21875,
            "end_logit": 7.7890625,
            "text": "against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3828125,
            "end_logit": 7.7890625,
            "text": "Protection against malaria",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.1640625,
            "text": "against malaria at",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.1640625,
            "text": "against malaria at 1 year and",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.171875,
            "text": "against malaria at 1",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.1875,
            "text": "against malaria at 1 year and immune correlates",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.1875,
            "text": "against malaria at 1 year",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.2578125,
            "text": "against malaria at 1 year and immune correlates following PfSPZ vaccination",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.265625,
            "text": "against malaria at 1 year and immune",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -8.2578125,
            "text": "following PfSPZ vaccination",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": -8.1640625,
            "text": "Protection against malaria at",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": -8.1640625,
            "text": "Protection against malaria at 1 year and",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_20": [
        {
            "start_logit": 8.75,
            "end_logit": 8.03125,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.75,
            "end_logit": -8.1953125,
            "text": "malaria infection",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0,
            "end_logit": 8.03125,
            "text": "human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": 8.03125,
            "text": "Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.28125,
            "end_logit": 8.03125,
            "text": "controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.34375,
            "end_logit": 8.03125,
            "text": "durable protection against heterologous controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.34375,
            "end_logit": 8.03125,
            "text": "against heterologous controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 8.03125,
            "text": "-transcending T cells and durable protection against heterologous controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 8.03125,
            "text": "heterologous controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.375,
            "end_logit": 8.03125,
            "text": "PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.375,
            "end_logit": 8.03125,
            "text": "and durable protection against heterologous controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3828125,
            "end_logit": 8.03125,
            "text": "strain-transcending T cells and durable protection against heterologous controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.390625,
            "end_logit": 8.03125,
            "text": "induces strain-transcending T cells and durable protection against heterologous controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0,
            "end_logit": -8.1953125,
            "text": "human malaria infection",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -8.1953125,
            "text": "Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": -8.1953125,
            "text": "controlled human malaria infection",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -8.2578125,
            "text": "Attenuated PfSPZ",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": -8.1953125,
            "text": "infection",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -8.2734375,
            "text": "Attenuated PfSP",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": -8.1953125,
            "text": "durable protection against heterologous controlled human malaria infection",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_21": [
        {
            "start_logit": 8.078125,
            "end_logit": 8.640625,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": -0.55224609375,
            "end_logit": 8.640625,
            "text": "Plasmodium falciparum malaria",
            "probability": 0.00017821788787841797
        },
        {
            "start_logit": -7.828125,
            "end_logit": 8.640625,
            "text": "Protection against Plasmodium falciparum malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.83203125,
            "end_logit": 8.640625,
            "text": "falciparum malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 8.640625,
            "text": "against Plasmodium falciparum malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.078125,
            "end_logit": -7.96484375,
            "text": "malaria by",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.078125,
            "end_logit": -8.09375,
            "text": "malaria by PfSPZ Vaccine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.078125,
            "end_logit": -8.1796875,
            "text": "malaria by PfS",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.078125,
            "end_logit": -8.203125,
            "text": "malaria by PfSP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.078125,
            "end_logit": -8.2109375,
            "text": "malaria by PfSPZ",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.55224609375,
            "end_logit": -6.6328125,
            "text": "Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -0.55224609375,
            "end_logit": -7.96484375,
            "text": "Plasmodium falciparum malaria by",
            "probability": 0.0
        },
        {
            "start_logit": -0.55224609375,
            "end_logit": -8.09375,
            "text": "Plasmodium falciparum malaria by PfSPZ Vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -0.55224609375,
            "end_logit": -8.1796875,
            "text": "Plasmodium falciparum malaria by PfS",
            "probability": 0.0
        },
        {
            "start_logit": -0.55224609375,
            "end_logit": -8.203125,
            "text": "Plasmodium falciparum malaria by PfSP",
            "probability": 0.0
        },
        {
            "start_logit": -0.55224609375,
            "end_logit": -8.2109375,
            "text": "Plasmodium falciparum malaria by PfSPZ",
            "probability": 0.0
        },
        {
            "start_logit": -7.828125,
            "end_logit": -6.6328125,
            "text": "Protection against Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -7.83203125,
            "end_logit": -6.6328125,
            "text": "falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -6.6328125,
            "text": "against Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -7.828125,
            "end_logit": -7.96484375,
            "text": "Protection against Plasmodium falciparum malaria by",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_22": [
        {
            "start_logit": 8.765625,
            "end_logit": 8.03125,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.765625,
            "end_logit": -8.0859375,
            "text": "malaria by chemoat",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.765625,
            "end_logit": -8.09375,
            "text": "malaria by chemoattenuated",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.765625,
            "end_logit": -8.125,
            "text": "malaria by chemoattenuated PfSPZ vaccine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.765625,
            "end_logit": -8.125,
            "text": "malaria by chemoatten",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.765625,
            "end_logit": -8.2109375,
            "text": "malaria by",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.765625,
            "end_logit": -8.265625,
            "text": "malaria by chemoattenuated PfSPZ",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 8.03125,
            "text": "human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": 8.03125,
            "text": "Sterile protection against human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 8.03125,
            "text": "protection against human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3125,
            "end_logit": 8.03125,
            "text": "against human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9921875,
            "end_logit": -8.0859375,
            "text": "human malaria by chemoat",
            "probability": 0.0
        },
        {
            "start_logit": -7.9921875,
            "end_logit": -8.09375,
            "text": "human malaria by chemoattenuated",
            "probability": 0.0
        },
        {
            "start_logit": -7.9921875,
            "end_logit": -8.125,
            "text": "human malaria by chemoattenuated PfSPZ vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -7.9921875,
            "end_logit": -8.125,
            "text": "human malaria by chemoatten",
            "probability": 0.0
        },
        {
            "start_logit": -7.9921875,
            "end_logit": -8.2109375,
            "text": "human malaria by",
            "probability": 0.0
        },
        {
            "start_logit": -7.9921875,
            "end_logit": -8.265625,
            "text": "human malaria by chemoattenuated PfSPZ",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -8.0859375,
            "text": "Sterile protection against human malaria by chemoat",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -8.09375,
            "text": "Sterile protection against human malaria by chemoattenuated",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -8.0859375,
            "text": "protection against human malaria by chemoat",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_23": [
        {
            "start_logit": 8.84375,
            "end_logit": 7.94140625,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.84375,
            "end_logit": -8.2734375,
            "text": "malaria in infants in western Kenya",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.84375,
            "end_logit": -8.296875,
            "text": "malaria in infants in western",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.84375,
            "end_logit": -8.3203125,
            "text": "malaria in infants in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.84375,
            "end_logit": -8.3203125,
            "text": "malaria in infants in western Kenya: a double-blind",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 7.94140625,
            "text": "against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3125,
            "end_logit": 7.94140625,
            "text": "Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.34375,
            "end_logit": 7.94140625,
            "text": "PfSPZ Vaccine against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 7.94140625,
            "text": "efficacy of PfSPZ Vaccine against malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": -8.2734375,
            "text": "against malaria in infants in western Kenya",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -8.296875,
            "text": "against malaria in infants in western",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -8.3203125,
            "text": "against malaria in infants in",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -8.3203125,
            "text": "against malaria in infants in western Kenya: a double-blind",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": -8.2734375,
            "text": "Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": -8.2734375,
            "text": "in infants in western Kenya",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": -8.296875,
            "text": "Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": -8.2734375,
            "text": "infants in western Kenya",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": -8.3203125,
            "text": "a double-blind",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": -8.3046875,
            "text": "Safety,",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": -8.3203125,
            "text": "Safety, immunogenicity and",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_24": [
        {
            "start_logit": 8.671875,
            "end_logit": 8.140625,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.671875,
            "end_logit": -8.328125,
            "text": "malaria infection (CHMI) by direct venous inoculation (DVI) of cryopreserved, infectious Plasmodium falciparum (Pf) sporozoites (SPZ) (PfSPZ Challenge) to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.671875,
            "end_logit": -8.328125,
            "text": "malaria infection (CHMI) by direct venous inoculation (DVI) of cryopreserved, infectious Plasmodium falciparum (Pf) sporozoites (SP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.671875,
            "end_logit": -8.3359375,
            "text": "malaria infection (CH",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.671875,
            "end_logit": -8.3515625,
            "text": "malaria infection (CHMI) by direct venous inoculation (DV",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.671875,
            "end_logit": -8.359375,
            "text": "malaria infection (CHMI",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.671875,
            "end_logit": -8.3671875,
            "text": "malaria infection (CHMI) by direct venous inoculation (DVI) of cryopreserved, infectious Plasmodium falciparum (Pf",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.671875,
            "end_logit": -8.375,
            "text": "malaria infection (CHMI) by direct venous inoculation (DVI) of cryopreserved, infectious Plasmodium falciparum",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.671875,
            "end_logit": -8.375,
            "text": "malaria infection (CHMI) by direct venous inoculation (DVI) of cryopreserved, infectious Plasmodium falciparum (Pf) sporozoites (SPZ",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.671875,
            "end_logit": -8.3828125,
            "text": "malaria infection (CHMI) by direct venous inoculation (DVI) of cryopreserved, infectious Plasmodium falciparum (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.671875,
            "end_logit": -8.390625,
            "text": "malaria infection (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.671875,
            "end_logit": -8.390625,
            "text": "malaria infection (CHMI) by direct venous inoculation (DVI) of cryopreserved, infectious Plasmodium falciparum (Pf) sporozoites (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.671875,
            "end_logit": -8.390625,
            "text": "malaria infection (CHMI) by direct venous inoculation (DVI) of cryopreserved, infectious Plasmodium falciparum (Pf) sporozoites (SPZ) (PfSPZ Challenge) to try to reduce time and costs of developing PfSPZ Vaccine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.671875,
            "end_logit": -8.390625,
            "text": "malaria infection (CHMI) by direct venous inoculation (DVI) of cryopreserved, infectious Plasmodium falciparum (Pf) sporozoites (SPZ) (PfS",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.671875,
            "end_logit": -8.3984375,
            "text": "malaria infection (CHMI) by direct venous inoculation (DVI) of cryopreserved, infectious Plasmodium falciparum (Pf) sporozoites (SPZ) (PfSPZ Challenge) to try to reduce time and costs of developing PfSP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.671875,
            "end_logit": -8.3984375,
            "text": "malaria infection (CHMI) by direct venous inoculation (DVI) of cryopreserved, infectious Plasmodium falciparum (Pf) sporozoites (SPZ) (PfSPZ Challenge) to try to reduce time and costs of developing PfS",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.671875,
            "end_logit": -8.3984375,
            "text": "malaria infection (CHMI)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.671875,
            "end_logit": -8.40625,
            "text": "malaria infection (CHMI) by direct",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 8.140625,
            "text": "human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 8.140625,
            "text": "We are using controlled human malaria",
            "probability": 5.960464477539063e-08
        }
    ],
    "61f7d745882a024a10000038_25": [
        {
            "start_logit": 8.765625,
            "end_logit": 7.9453125,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.765625,
            "end_logit": -8.0625,
            "text": "malaria infection (CH",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.765625,
            "end_logit": -8.15625,
            "text": "malaria infection (CHMI",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.765625,
            "end_logit": -8.1796875,
            "text": "malaria infection (CHMI) 3 weeks after immunization, but the durability of protection",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.765625,
            "end_logit": -8.2578125,
            "text": "malaria infection (CHMI) 3 weeks after immunization, but the durability of protection is unknown",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.765625,
            "end_logit": -8.2578125,
            "text": "malaria infection",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.765625,
            "end_logit": -8.28125,
            "text": "malaria infection (CHMI) 3 weeks after immunization, but the durability of protection is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.765625,
            "end_logit": -8.3046875,
            "text": "malaria infection (CHMI)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.765625,
            "end_logit": -8.3046875,
            "text": "malaria infection (CHMI) 3 weeks",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 7.9453125,
            "text": "human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.078125,
            "end_logit": 7.9453125,
            "text": ", PfSPZ Vaccine, is highly protective against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1875,
            "end_logit": 7.9453125,
            "text": ", is highly protective against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1875,
            "end_logit": 7.9453125,
            "text": "(SPZ) vaccine, PfSPZ Vaccine, is highly protective against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 7.9453125,
            "text": "against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": 7.9453125,
            "text": "An attenuated Plasmodium falciparum (Pf) sporozoite (SPZ) vaccine, PfSPZ Vaccine, is highly protective against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": 7.9453125,
            "text": "controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 7.9453125,
            "text": "attenuated Plasmodium falciparum (Pf) sporozoite (SPZ) vaccine, PfSPZ Vaccine, is highly protective against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.90234375,
            "end_logit": -8.0625,
            "text": "(CH",
            "probability": 0.0
        },
        {
            "start_logit": -7.90234375,
            "end_logit": -8.15625,
            "text": "(CHMI",
            "probability": 0.0
        },
        {
            "start_logit": -7.90234375,
            "end_logit": -8.1796875,
            "text": "(CHMI) 3 weeks after immunization, but the durability of protection",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_26": [
        {
            "start_logit": 8.9296875,
            "end_logit": 7.796875,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -8.1953125,
            "text": "malaria through long-lived tissue-resident T cells and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -8.25,
            "text": "malaria through long-lived tissue-resident T cells and that administration of higher doses may further enhance protection",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -8.25,
            "text": "malaria through long-lived tissue-resident T cells and that administration of higher doses may further",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -8.2578125,
            "text": "malaria through long-lived",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -8.2578125,
            "text": "malaria through long-lived tissue-resident",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -8.265625,
            "text": "malaria through long-lived tissue-resident T cells and that administration of higher doses may",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -8.265625,
            "text": "malaria through long-lived tissue",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -8.265625,
            "text": "malaria through long-lived tissue-resident T cells",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.21875,
            "end_logit": 7.796875,
            "text": "Our findings suggest that PfSPZ Vaccine conferred durable protection to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 7.796875,
            "text": "to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 7.796875,
            "text": "PfSPZ Vaccine conferred durable protection to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 7.796875,
            "text": "that PfSPZ Vaccine conferred durable protection to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.328125,
            "end_logit": 7.796875,
            "text": "findings suggest that PfSPZ Vaccine conferred durable protection to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 7.796875,
            "text": "suggest that PfSPZ Vaccine conferred durable protection to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3828125,
            "end_logit": 7.796875,
            "text": "durable protection to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3828125,
            "end_logit": 7.796875,
            "text": "Z Vaccine conferred durable protection to malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.1953125,
            "text": "Our findings suggest that PfSPZ Vaccine conferred durable protection to malaria through long-lived tissue-resident T cells and",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -8.1953125,
            "text": "to malaria through long-lived tissue-resident T cells and",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.25,
            "text": "Our findings suggest that PfSPZ Vaccine conferred durable protection to malaria through long-lived tissue-resident T cells and that administration of higher doses may further enhance protection",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_27": [
        {
            "start_logit": 8.5546875,
            "end_logit": 8.21875,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -8.0859375,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria infection (CHMI) with Plasmodium falciparum (Pf) parasites homologous to the vaccine strain up",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -8.125,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria infection (CHMI) with Plasmodium falciparum (Pf) parasites homologous to the vaccine strain up to 14 mo",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -8.171875,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -8.1875,
            "text": "malaria vaccine, Plasmodium falciparum",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -8.1953125,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -8.2109375,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria infection (CHMI) with Plasmodium falciparum",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -8.2109375,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -8.21875,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria infection (CHMI) with Plasmodium falciparum (Pf) parasites homologous to the vaccine strain up to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -8.234375,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -8.2421875,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria infection (CHMI) with Plasmodium falciparum (Pf) parasites homologous to the vaccine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -8.25,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria infection (CHMI) with Plasmodium falciparum (Pf",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -8.25,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria infection (CH",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -8.25,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria infection (CHMI) with Plasmodium falciparum (Pf) parasites homologous to the vaccine strain up to 14",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -8.25,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfS",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -8.2734375,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria infection (CHMI",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -8.2734375,
            "text": "malaria vaccine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -8.28125,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -8.28125,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria infection (CHMI) with Plasmodium falciparum (Pf) parasites homologous",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -8.28125,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria infection (CHMI) with Plasmodium falciparum (Pf) parasites",
            "probability": 5.960464477539063e-08
        }
    ],
    "61f7d745882a024a10000038_28": [
        {
            "start_logit": 8.8828125,
            "end_logit": 7.8359375,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": -6.77734375,
            "end_logit": 7.8359375,
            "text": ". PfSPZ Vaccine showed significant protection in African adults against P falciparum infection throughout an entire malaria",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.8828125,
            "end_logit": -8.1796875,
            "text": "malaria season.FUNDING: US National In",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8828125,
            "end_logit": -8.2109375,
            "text": "malaria season",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8828125,
            "end_logit": -8.2265625,
            "text": "malaria season.FUNDING: US National",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8828125,
            "end_logit": -8.234375,
            "text": "malaria season.FUNDING",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8828125,
            "end_logit": -8.3046875,
            "text": "malaria season.FUNDING: US",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.203125,
            "end_logit": 7.8359375,
            "text": "in African adults against P falciparum infection throughout an entire malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 7.8359375,
            "text": "entire malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.21875,
            "end_logit": 7.8359375,
            "text": "against P falciparum infection throughout an entire malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.234375,
            "end_logit": 7.8359375,
            "text": "significant protection in African adults against P falciparum infection throughout an entire malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 7.8359375,
            "text": "safe. PfSPZ Vaccine showed significant protection in African adults against P falciparum infection throughout an entire malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 7.8359375,
            "text": "African adults against P falciparum infection throughout an entire malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.28125,
            "end_logit": 7.8359375,
            "text": "and safe. PfSPZ Vaccine showed significant protection in African adults against P falciparum infection throughout an entire malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 7.8359375,
            "text": "well tolerated and safe. PfSPZ Vaccine showed significant protection in African adults against P falciparum infection throughout an entire malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3125,
            "end_logit": 7.8359375,
            "text": "tolerated and safe. PfSPZ Vaccine showed significant protection in African adults against P falciparum infection throughout an entire malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 7.8359375,
            "text": "adults against P falciparum infection throughout an entire malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.328125,
            "end_logit": 7.8359375,
            "text": "P falciparum infection throughout an entire malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 7.8359375,
            "text": "protection in African adults against P falciparum infection throughout an entire malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.34375,
            "end_logit": 7.8359375,
            "text": ": PfSPZ Vaccine was well tolerated and safe. PfSPZ Vaccine showed significant protection in African adults against P falciparum infection throughout an entire malaria",
            "probability": 5.960464477539063e-08
        }
    ],
    "61f7d745882a024a10000038_29": [
        {
            "start_logit": 8.4921875,
            "end_logit": 8.25,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.4921875,
            "end_logit": -7.31640625,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.4921875,
            "end_logit": -7.40234375,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.4921875,
            "end_logit": -7.76953125,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4921875,
            "end_logit": -8.0234375,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4921875,
            "end_logit": -8.03125,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4921875,
            "end_logit": -8.0859375,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria infection (CHMI",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.86328125,
            "end_logit": 8.25,
            "text": ") malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4921875,
            "end_logit": -8.109375,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria infection (CH",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4921875,
            "end_logit": -8.140625,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4921875,
            "end_logit": -8.2109375,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria infection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 8.25,
            "text": ") sporozoite (SPZ) malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4921875,
            "end_logit": -8.2578125,
            "text": "malaria vaccine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4921875,
            "end_logit": -8.265625,
            "text": "malaria vaccine, PfSPZ",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4921875,
            "end_logit": -8.265625,
            "text": "malaria vaccine, PfSP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4921875,
            "end_logit": -8.265625,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 8.25,
            "text": "attenuated Plasmodium falciparum (Pf) sporozoite (SPZ) malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4921875,
            "end_logit": -8.2890625,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4921875,
            "end_logit": -8.2890625,
            "text": "malaria vaccine, PfSPZ Vaccine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4921875,
            "end_logit": -8.3046875,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf",
            "probability": 5.960464477539063e-08
        }
    ],
    "61f7d745882a024a10000038_30": [
        {
            "start_logit": 7.53515625,
            "end_logit": 7.078125,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": -5.8828125,
            "end_logit": 7.078125,
            "text": "malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": 7.53515625,
            "end_logit": -7.40625,
            "text": "malaria infection in malaria",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.53515625,
            "end_logit": -7.6328125,
            "text": "malaria infection in malaria-naive",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.53515625,
            "end_logit": -7.9765625,
            "text": "malaria infection",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.53515625,
            "end_logit": -8.03125,
            "text": "malaria infection in",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.53515625,
            "end_logit": -8.2109375,
            "text": "malaria infection in malaria-",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.78125,
            "end_logit": 7.078125,
            "text": ", whole malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.87109375,
            "end_logit": 7.078125,
            "text": "whole malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 7.078125,
            "text": ", non-replicating, whole malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 7.078125,
            "text": "human malaria",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.09375,
            "end_logit": 7.078125,
            "text": "-replicating, whole malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 7.078125,
            "text": "safe and protective against P falciparum controlled human malaria",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.203125,
            "end_logit": 7.078125,
            "text": "replicating, whole malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 7.078125,
            "text": "been reported to be safe and protective against P falciparum controlled human malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.25,
            "end_logit": 7.078125,
            "text": "reported to be safe and protective against P falciparum controlled human malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.25,
            "end_logit": 7.078125,
            "text": "has been reported to be safe and protective against P falciparum controlled human malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 7.078125,
            "text": "active, non-replicating, whole malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.296875,
            "end_logit": 7.078125,
            "text": "a metabolically active, non-replicating, whole malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 7.078125,
            "text": "Plasmodium falciparum sporozite (PfSPZ) Vaccine is a metabolically active, non-replicating, whole malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria",
            "probability": 1.1920928955078125e-07
        }
    ],
    "61f7d745882a024a10000038_31": [
        {
            "start_logit": 8.65625,
            "end_logit": 8.1015625,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 8.65625,
            "end_logit": -8.0703125,
            "text": "malaria infection ten",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -8.125,
            "text": "malaria infection ten weeks after the last dose (group III",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -8.171875,
            "text": "malaria infection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.65625,
            "end_logit": -8.25,
            "text": "malaria infection ten weeks after the last dose",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.65625,
            "end_logit": -8.265625,
            "text": "malaria infection ten weeks",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.046875,
            "end_logit": 8.1015625,
            "text": "doses of 5.12 \u00d7 104 PfSPZ of PfSPZ Challenge at 28-day intervals were well tolerated and safe, and prevented infection in 9 out of 9 (100%) volunteers who underwent controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 8.1015625,
            "text": "Three doses of 5.12 \u00d7 104 PfSPZ of PfSPZ Challenge at 28-day intervals were well tolerated and safe, and prevented infection in 9 out of 9 (100%) volunteers who underwent controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 8.1015625,
            "text": "of 5.12 \u00d7 104 PfSPZ of PfSPZ Challenge at 28-day intervals were well tolerated and safe, and prevented infection in 9 out of 9 (100%) volunteers who underwent controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 8.1015625,
            "text": "human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 8.1015625,
            "text": "(100%) volunteers who underwent controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.21875,
            "end_logit": 8.1015625,
            "text": ") volunteers who underwent controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 8.1015625,
            "text": "controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 8.1015625,
            "text": "in 9 out of 9 (100%) volunteers who underwent controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.28125,
            "end_logit": 8.1015625,
            "text": ", and prevented infection in 9 out of 9 (100%) volunteers who underwent controlled human malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.046875,
            "end_logit": -8.03125,
            "text": "doses of 5.12 \u00d7 104 PfSPZ of PfSPZ Challenge at 28-day intervals were well tolerated and safe, and prevented infection in 9 out of 9 (100%",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": -8.0546875,
            "text": "doses of 5.12 \u00d7 104 PfSPZ of PfSPZ Challenge at 28-day intervals were well tolerated and safe, and prevented infection in 9 out of 9 (100",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -8.03125,
            "text": "Three doses of 5.12 \u00d7 104 PfSPZ of PfSPZ Challenge at 28-day intervals were well tolerated and safe, and prevented infection in 9 out of 9 (100%",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -8.0546875,
            "text": "Three doses of 5.12 \u00d7 104 PfSPZ of PfSPZ Challenge at 28-day intervals were well tolerated and safe, and prevented infection in 9 out of 9 (100",
            "probability": 0.0
        },
        {
            "start_logit": -8.0,
            "end_logit": -8.125,
            "text": "after the last dose (group III",
            "probability": 0.0
        }
    ],
    "622d1ed13a8413c6530000a3_1": [
        {
            "start_logit": 10.328125,
            "end_logit": 8.171875,
            "text": "The daughterless (da) gene in Drosophila encodes a broadly expressed transcriptional regulator whose specific functions in the control of sex determination and neurogenesis have been extensively examined.",
            "probability": 0.9990234375
        },
        {
            "start_logit": 10.328125,
            "end_logit": -0.343505859375,
            "text": "The",
            "probability": 0.00020003318786621094
        },
        {
            "start_logit": 10.328125,
            "end_logit": -0.4013671875,
            "text": "The daughterless (da) gene in Drosophila",
            "probability": 0.0001894235610961914
        },
        {
            "start_logit": 1.13671875,
            "end_logit": 8.171875,
            "text": ".",
            "probability": 0.00010216236114501953
        },
        {
            "start_logit": -0.59326171875,
            "end_logit": 8.171875,
            "text": "daughterless (da) gene in Drosophila encodes a broadly expressed transcriptional regulator whose specific functions in the control of sex determination and neurogenesis have been extensively examined.",
            "probability": 1.806020736694336e-05
        },
        {
            "start_logit": 10.328125,
            "end_logit": -3.06640625,
            "text": "The daughterless (da) gene in Drosophila encodes a broadly expressed transcriptional regulator",
            "probability": 1.3232231140136719e-05
        },
        {
            "start_logit": 10.328125,
            "end_logit": -3.70703125,
            "text": "The daughterless (da) gene in Drosophila encodes a broadly",
            "probability": 6.973743438720703e-06
        },
        {
            "start_logit": 10.328125,
            "end_logit": -4.39453125,
            "text": "The daughterless (da) gene in Drosophila encodes a broadly expressed transcriptional regulator whose specific functions in the control of sex determination",
            "probability": 3.516674041748047e-06
        },
        {
            "start_logit": 10.328125,
            "end_logit": -4.61328125,
            "text": "The daughterless (da",
            "probability": 2.8014183044433594e-06
        },
        {
            "start_logit": 10.328125,
            "end_logit": -4.98046875,
            "text": "The daughterless (da) gene in Drosophila encodes a broadly expressed transcriptional regulator whose specific functions in the control of sex determination and neurogenesis",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": 10.328125,
            "end_logit": -5.30078125,
            "text": "The daughterless (da) gene in Drosophila encodes a broadly expressed transcriptional",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 10.328125,
            "end_logit": -5.43359375,
            "text": "The daughterless (da) gene in Drosophila encodes a",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 10.328125,
            "end_logit": -5.46875,
            "text": "The daughterless (da) gene in Drosophila encodes a broadly expressed transcriptional regulator whose specific functions in the control of sex determination and neurogenesis have",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 10.328125,
            "end_logit": -5.48828125,
            "text": "The daughterless (da) gene in Drosophila encodes a broadly expressed",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 10.328125,
            "end_logit": -5.6796875,
            "text": "The daughterless (da) gene in Drosophila encodes",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 10.328125,
            "end_logit": -6.00390625,
            "text": "The daughterless (da) gene in Drosophila encodes a broadly expressed transcriptional regulator whose",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 10.328125,
            "end_logit": -6.0390625,
            "text": "The daughterless (da) gene in Drosophila encodes a broadly expressed transcriptional regulator whose specific functions in the control of sex",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -4.1640625,
            "end_logit": 8.171875,
            "text": "in Drosophila encodes a broadly expressed transcriptional regulator whose specific functions in the control of sex determination and neurogenesis have been extensively examined.",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 10.328125,
            "end_logit": -6.56640625,
            "text": "The daughterless (da)",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -4.5859375,
            "end_logit": 8.171875,
            "text": "(da) gene in Drosophila encodes a broadly expressed transcriptional regulator whose specific functions in the control of sex determination and neurogenesis have been extensively examined.",
            "probability": 3.5762786865234375e-07
        }
    ],
    "56bc9268ac7ad1001900001b_1": [
        {
            "start_logit": 10.078125,
            "end_logit": 9.796875,
            "text": "interleukin-17",
            "probability": 1.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -1.69140625,
            "text": "interleukin",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": -1.6611328125,
            "end_logit": 9.796875,
            "text": "17",
            "probability": 7.927417755126953e-06
        },
        {
            "start_logit": -6.33984375,
            "end_logit": 9.796875,
            "text": "-17",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.078125,
            "end_logit": -8.34375,
            "text": "interleukin-17 receptor",
            "probability": 0.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -8.3984375,
            "text": "interleukin-17 receptor A",
            "probability": 0.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -8.421875,
            "text": "interleukin-17 receptor A monoclonal antibody bro",
            "probability": 0.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -8.421875,
            "text": "interleukin-17 receptor A monoclonal",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.796875,
            "text": "-interleukin-17",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.796875,
            "text": "that the anti-interleukin-17",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.796875,
            "text": "suggested that the anti-interleukin-17",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.796875,
            "text": "clinical studies suggested that the anti-interleukin-17",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.796875,
            "text": "studies suggested that the anti-interleukin-17",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.796875,
            "text": "Early clinical studies suggested that the anti-interleukin-17",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.796875,
            "text": "anti-interleukin-17",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.796875,
            "text": "the anti-interleukin-17",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -1.69140625,
            "text": "-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -1.69140625,
            "text": "that the anti-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": -1.69140625,
            "text": "suggested that the anti-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": -1.69140625,
            "text": "clinical studies suggested that the anti-interleukin",
            "probability": 0.0
        }
    ],
    "56bc9268ac7ad1001900001b_2": [
        {
            "start_logit": 10.0703125,
            "end_logit": 9.7734375,
            "text": "interleukin-17",
            "probability": 1.0
        },
        {
            "start_logit": 10.0703125,
            "end_logit": -1.7021484375,
            "text": "interleukin",
            "probability": 1.0371208190917969e-05
        },
        {
            "start_logit": -1.7275390625,
            "end_logit": 9.7734375,
            "text": "17",
            "probability": 7.510185241699219e-06
        },
        {
            "start_logit": -6.28125,
            "end_logit": 9.7734375,
            "text": "-17",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0703125,
            "end_logit": -8.296875,
            "text": "interleukin-17-receptor",
            "probability": 0.0
        },
        {
            "start_logit": 10.0703125,
            "end_logit": -8.3671875,
            "text": "interleukin-17-",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.7734375,
            "text": "-interleukin-17",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.7734375,
            "text": "an anti-interleukin-17",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.7734375,
            "text": ", an anti-interleukin-17",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.7734375,
            "text": "anti-interleukin-17",
            "probability": 0.0
        },
        {
            "start_logit": -8.359375,
            "end_logit": 9.7734375,
            "text": "Brodalumab, an anti-interleukin-17",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": -1.7021484375,
            "text": "-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -1.7021484375,
            "text": "an anti-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -1.7021484375,
            "text": ", an anti-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": -1.7021484375,
            "text": "anti-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -1.7275390625,
            "end_logit": -8.296875,
            "text": "17-receptor",
            "probability": 0.0
        },
        {
            "start_logit": -8.359375,
            "end_logit": -1.7021484375,
            "text": "Brodalumab, an anti-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -1.7275390625,
            "end_logit": -8.3671875,
            "text": "17-",
            "probability": 0.0
        },
        {
            "start_logit": -6.28125,
            "end_logit": -8.296875,
            "text": "-17-receptor",
            "probability": 0.0
        },
        {
            "start_logit": -6.28125,
            "end_logit": -8.3671875,
            "text": "-17-",
            "probability": 0.0
        }
    ],
    "56c3184050c68dd416000003_1": [
        {
            "start_logit": 8.8984375,
            "end_logit": 7.8515625,
            "text": "hypertension",
            "probability": 1.0
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -8.3671875,
            "text": "hypertension (WHO classification",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -8.3671875,
            "text": "hypertension (WHO classification I",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 7.8515625,
            "text": "- 0.63 mg twice daily) in combination with bopindolol (1.16 +/- 0.12 mg once daily; n = 30) administered for 3 years to patients with essential hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 7.8515625,
            "text": "patients with essential hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 7.8515625,
            "text": ") in combination with bopindolol (1.16 +/- 0.12 mg once daily; n = 30) administered for 3 years to patients with essential hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 7.8515625,
            "text": "; n = 30) administered for 3 years to patients with essential hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 7.8515625,
            "text": "with essential hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 7.8515625,
            "text": "essential hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 7.8515625,
            "text": "to patients with essential hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 7.8515625,
            "text": "5 +/- 0.63 mg twice daily) in combination with bopindolol (1.16 +/- 0.12 mg once daily; n = 30) administered for 3 years to patients with essential hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -8.265625,
            "text": ", 4.55 +/- 0.56 mg twice daily; n = 11) or isradipine (7.5 +/- 0.63",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -8.3203125,
            "text": ", 4.55 +/- 0.56",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -8.328125,
            "text": ", 4.55 +/- 0.56 mg twice daily; n = 11) or isradipine (7.5 +/- 0",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -8.3359375,
            "text": ", 4.55 +/- 0",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -8.359375,
            "text": ", 4.55 +/- 0.56 mg twice daily; n = 11",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -8.3671875,
            "text": ", 4.55 +/- 0.56 mg twice daily; n = 11) or isradipine (7.5 +/- 0.63 mg twice daily) in combination with bopindolol (1.16",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -8.375,
            "text": ", 4.55 +/- 0.56 mg twice daily; n = 11) or isradipine (7.5 +/- 0.63 mg twice daily) in combination with bopindolol (1",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -8.375,
            "text": ", 4.55",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -8.390625,
            "text": ", 4.55 +/- 0.56 mg twice daily; n =",
            "probability": 0.0
        }
    ],
    "56c3184050c68dd416000003_2": [
        {
            "start_logit": 8.7734375,
            "end_logit": 8.0078125,
            "text": "hypertension",
            "probability": 1.0
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -8.1328125,
            "text": "hypertension, resulting in regression of left ventricular wall thickness and mass and augmentation of fractional shortening per 100 g left ventricular",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -8.15625,
            "text": "hypertension, resulting in regression of left ventricular wall thickness and mass and augmentation of fractional shortening per 100 g left ventricular mass",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -8.1640625,
            "text": "hypertension, resulting in regression of left ventricular wall thickness and mass and augmentation of fractional shortening per 100",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.1875,
            "end_logit": 8.0078125,
            "text": "Isradipine monotherapy was an effective antihypertensive drug in blacks with essential hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 8.0078125,
            "text": "with essential hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.28125,
            "end_logit": 8.0078125,
            "text": "dipine monotherapy was an effective antihypertensive drug in blacks with essential hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.328125,
            "end_logit": 8.0078125,
            "text": "pine monotherapy was an effective antihypertensive drug in blacks with essential hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 8.0078125,
            "text": "essential hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 8.0078125,
            "text": "effective antihypertensive drug in blacks with essential hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 8.0078125,
            "text": "in blacks with essential hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3671875,
            "end_logit": 8.0078125,
            "text": "antihypertensive drug in blacks with essential hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.375,
            "end_logit": 8.0078125,
            "text": "drug in blacks with essential hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3828125,
            "end_logit": 8.0078125,
            "text": "blacks with essential hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1875,
            "end_logit": -8.1328125,
            "text": "Isradipine monotherapy was an effective antihypertensive drug in blacks with essential hypertension, resulting in regression of left ventricular wall thickness and mass and augmentation of fractional shortening per 100 g left ventricular",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": -8.1328125,
            "text": "with essential hypertension, resulting in regression of left ventricular wall thickness and mass and augmentation of fractional shortening per 100 g left ventricular",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -8.15625,
            "text": "Isradipine monotherapy was an effective antihypertensive drug in blacks with essential hypertension, resulting in regression of left ventricular wall thickness and mass and augmentation of fractional shortening per 100 g left ventricular mass",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -8.1640625,
            "text": "Isradipine monotherapy was an effective antihypertensive drug in blacks with essential hypertension, resulting in regression of left ventricular wall thickness and mass and augmentation of fractional shortening per 100",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": -8.15625,
            "text": "with essential hypertension, resulting in regression of left ventricular wall thickness and mass and augmentation of fractional shortening per 100 g left ventricular mass",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.1328125,
            "text": ", resulting in regression of left ventricular wall thickness and mass and augmentation of fractional shortening per 100 g left ventricular",
            "probability": 0.0
        }
    ],
    "56c3184050c68dd416000003_3": [
        {
            "start_logit": 8.8984375,
            "end_logit": 7.8515625,
            "text": "hypertension",
            "probability": 1.0
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -8.3671875,
            "text": "hypertension (WHO classification",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -8.3671875,
            "text": "hypertension (WHO classification I",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 7.8515625,
            "text": "- 0.63 mg twice daily) in combination with bopindolol (1.16 +/- 0.12 mg once daily; n = 30) administered for 3 years to patients with essential hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 7.8515625,
            "text": "patients with essential hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 7.8515625,
            "text": ") in combination with bopindolol (1.16 +/- 0.12 mg once daily; n = 30) administered for 3 years to patients with essential hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 7.8515625,
            "text": "; n = 30) administered for 3 years to patients with essential hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 7.8515625,
            "text": "with essential hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 7.8515625,
            "text": "essential hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 7.8515625,
            "text": "to patients with essential hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 7.8515625,
            "text": "5 +/- 0.63 mg twice daily) in combination with bopindolol (1.16 +/- 0.12 mg once daily; n = 30) administered for 3 years to patients with essential hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -8.265625,
            "text": ", 4.55 +/- 0.56 mg twice daily; n = 11) or isradipine (7.5 +/- 0.63",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -8.3203125,
            "text": ", 4.55 +/- 0.56",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -8.328125,
            "text": ", 4.55 +/- 0.56 mg twice daily; n = 11) or isradipine (7.5 +/- 0",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -8.3359375,
            "text": ", 4.55 +/- 0",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -8.359375,
            "text": ", 4.55 +/- 0.56 mg twice daily; n = 11",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -8.3671875,
            "text": ", 4.55 +/- 0.56 mg twice daily; n = 11) or isradipine (7.5 +/- 0.63 mg twice daily) in combination with bopindolol (1.16",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -8.375,
            "text": ", 4.55 +/- 0.56 mg twice daily; n = 11) or isradipine (7.5 +/- 0.63 mg twice daily) in combination with bopindolol (1",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -8.375,
            "text": ", 4.55",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -8.390625,
            "text": ", 4.55 +/- 0.56 mg twice daily; n =",
            "probability": 0.0
        }
    ],
    "56c3184050c68dd416000003_4": [
        {
            "start_logit": 8.8203125,
            "end_logit": 7.94140625,
            "text": "hypertension",
            "probability": 1.0
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -7.6875,
            "text": "hypertension (mean age 59 years) using casual and ambulatory 24-h blood pressure",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -8.1484375,
            "text": "hypertension (mean age 59 years) using casual and ambulatory 24-h blood pressure measurement",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -8.171875,
            "text": "hypertension (mean age 59",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -8.2109375,
            "text": "hypertension (mean age 59 years) using casual and ambulatory 24",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.234375,
            "end_logit": 7.94140625,
            "text": "with mild-to-moderate hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.234375,
            "end_logit": 7.94140625,
            "text": "patients with mild-to-moderate hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 7.94140625,
            "text": "moderate hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3125,
            "end_logit": 7.94140625,
            "text": "in 45 patients with mild-to-moderate hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.34375,
            "end_logit": 7.94140625,
            "text": "studied in 45 patients with mild-to-moderate hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.34375,
            "end_logit": 7.94140625,
            "text": "-to-moderate hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.34375,
            "end_logit": 7.94140625,
            "text": "45 patients with mild-to-moderate hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 7.94140625,
            "text": "The antihypertensive effect of isradipine was studied in 45 patients with mild-to-moderate hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": -7.6875,
            "text": ") using casual and ambulatory 24-h blood pressure",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -7.6875,
            "text": "age 59 years) using casual and ambulatory 24-h blood pressure",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -7.6875,
            "text": "with mild-to-moderate hypertension (mean age 59 years) using casual and ambulatory 24-h blood pressure",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -7.6875,
            "text": "patients with mild-to-moderate hypertension (mean age 59 years) using casual and ambulatory 24-h blood pressure",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": -7.6875,
            "text": "mean age 59 years) using casual and ambulatory 24-h blood pressure",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": -7.6875,
            "text": "(mean age 59 years) using casual and ambulatory 24-h blood pressure",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": -7.6875,
            "text": "moderate hypertension (mean age 59 years) using casual and ambulatory 24-h blood pressure",
            "probability": 0.0
        }
    ],
    "56c3184050c68dd416000003_5": [
        {
            "start_logit": 8.8515625,
            "end_logit": 7.890625,
            "text": "hypertension",
            "probability": 1.0
        },
        {
            "start_logit": 8.8515625,
            "end_logit": -7.98828125,
            "text": "hypertension and microvascular angina]",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8515625,
            "end_logit": -8.25,
            "text": "hypertension and microvascular angina",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8515625,
            "end_logit": -8.265625,
            "text": "hypertension and microvascular",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.265625,
            "end_logit": 7.890625,
            "text": "patients with arterial hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.28125,
            "end_logit": 7.890625,
            "text": "with arterial hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 7.890625,
            "text": "in patients with arterial hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 7.890625,
            "text": ". Improvement of coronary flow reserve in patients with arterial hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 7.890625,
            "text": "with isradipine. Improvement of coronary flow reserve in patients with arterial hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.328125,
            "end_logit": 7.890625,
            "text": "[Long-term antihypertensive therapy with isradipine. Improvement of coronary flow reserve in patients with arterial hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 7.890625,
            "text": "coronary flow reserve in patients with arterial hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 7.890625,
            "text": "Improvement of coronary flow reserve in patients with arterial hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3671875,
            "end_logit": 7.890625,
            "text": "arterial hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.375,
            "end_logit": 7.890625,
            "text": "of coronary flow reserve in patients with arterial hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.265625,
            "end_logit": -7.98828125,
            "text": "patients with arterial hypertension and microvascular angina]",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": -7.98828125,
            "text": "with arterial hypertension and microvascular angina]",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": -7.98828125,
            "text": "in patients with arterial hypertension and microvascular angina]",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": -7.98828125,
            "text": ". Improvement of coronary flow reserve in patients with arterial hypertension and microvascular angina]",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": -7.98828125,
            "text": "with isradipine. Improvement of coronary flow reserve in patients with arterial hypertension and microvascular angina]",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": -7.98828125,
            "text": "[Long-term antihypertensive therapy with isradipine. Improvement of coronary flow reserve in patients with arterial hypertension and microvascular angina]",
            "probability": 0.0
        }
    ],
    "56c3184050c68dd416000003_6": [
        {
            "start_logit": 8.8671875,
            "end_logit": 7.890625,
            "text": "hypertension",
            "probability": 1.0
        },
        {
            "start_logit": 8.8671875,
            "end_logit": -8.15625,
            "text": "hypertension in motor vehicle drivers]",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 7.890625,
            "text": "Isradipine in arterial hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 7.890625,
            "text": "dipine in arterial hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 7.890625,
            "text": "[Isradipine in arterial hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -8.15625,
            "text": "Isradipine in arterial hypertension in motor vehicle drivers]",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -8.15625,
            "text": "in motor vehicle drivers]",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": -8.15625,
            "text": "dipine in arterial hypertension in motor vehicle drivers]",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": -8.15625,
            "text": "[Isradipine in arterial hypertension in motor vehicle drivers]",
            "probability": 0.0
        }
    ],
    "56c3184050c68dd416000003_7": [
        {
            "start_logit": 8.8671875,
            "end_logit": 7.91796875,
            "text": "hypertension",
            "probability": 1.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 7.91796875,
            "text": "with essential hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 7.91796875,
            "text": "patients with essential hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 7.91796875,
            "text": "elderly patients with essential hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 7.91796875,
            "text": "Evaluation of the safety and efficacy of isradipine in elderly patients with essential hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 7.91796875,
            "text": "of isradipine in elderly patients with essential hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 7.91796875,
            "text": "essential hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 7.91796875,
            "text": "in elderly patients with essential hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 7.91796875,
            "text": "isradipine in elderly patients with essential hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3125,
            "end_logit": 7.91796875,
            "text": "safety and efficacy of isradipine in elderly patients with essential hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3125,
            "end_logit": 7.91796875,
            "text": "of the safety and efficacy of isradipine in elderly patients with essential hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3125,
            "end_logit": 7.91796875,
            "text": "the safety and efficacy of isradipine in elderly patients with essential hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 7.91796875,
            "text": "dipine in elderly patients with essential hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -8.3046875,
            "text": "Evaluation of the safety and",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": -8.3046875,
            "text": "safety and",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": -8.3046875,
            "text": "of the safety and",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": -8.3046875,
            "text": "the safety and",
            "probability": 0.0
        }
    ],
    "56c3184050c68dd416000003_8": [
        {
            "start_logit": 8.921875,
            "end_logit": 7.83203125,
            "text": "hypertension",
            "probability": 1.0
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 7.83203125,
            "text": "of hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1875,
            "end_logit": 7.83203125,
            "text": "treatment of hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 7.83203125,
            "text": "evaluation of the safety and efficacy of isradipine and atenolol in the treatment of hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 7.83203125,
            "text": "multicenter evaluation of the safety and efficacy of isradipine and atenolol in the treatment of hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 7.83203125,
            "text": "isradipine and atenolol in the treatment of hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 7.83203125,
            "text": "of isradipine and atenolol in the treatment of hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 7.83203125,
            "text": "A multicenter evaluation of the safety and efficacy of isradipine and atenolol in the treatment of hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.265625,
            "end_logit": 7.83203125,
            "text": "dipine and atenolol in the treatment of hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.28125,
            "end_logit": 7.83203125,
            "text": "of the safety and efficacy of isradipine and atenolol in the treatment of hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 7.83203125,
            "text": "pine and atenolol in the treatment of hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 7.83203125,
            "text": "safety and efficacy of isradipine and atenolol in the treatment of hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 7.83203125,
            "text": "the treatment of hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 7.83203125,
            "text": "the safety and efficacy of isradipine and atenolol in the treatment of hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.34375,
            "end_logit": 7.83203125,
            "text": "and atenolol in the treatment of hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": -8.3125,
            "text": "evaluation of the safety and",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -8.3125,
            "text": "multicenter evaluation of the safety and",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": -8.3125,
            "text": "A multicenter evaluation of the safety and",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": -8.3125,
            "text": "of the safety and",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": -8.3125,
            "text": "safety and",
            "probability": 0.0
        }
    ],
    "56c3184050c68dd416000003_9": [
        {
            "start_logit": 8.96875,
            "end_logit": 7.78515625,
            "text": "hypertension",
            "probability": 1.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 7.78515625,
            "text": "of isradipine as a therapy for hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 7.78515625,
            "text": "isradipine as a therapy for hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3125,
            "end_logit": 7.78515625,
            "text": "it is advisable to be very careful in the use of isradipine as a therapy for hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3671875,
            "end_logit": 7.78515625,
            "text": "be very careful in the use of isradipine as a therapy for hypertension",
            "probability": 5.960464477539063e-08
        }
    ],
    "56ffd08bcf1c325851000009_1": [
        {
            "start_logit": 10.0703125,
            "end_logit": 9.7421875,
            "text": "7SL RNA",
            "probability": 1.0
        },
        {
            "start_logit": 10.0703125,
            "end_logit": -1.623046875,
            "text": "7",
            "probability": 1.1563301086425781e-05
        },
        {
            "start_logit": -1.724609375,
            "end_logit": 9.7421875,
            "text": "RNA",
            "probability": 7.510185241699219e-06
        },
        {
            "start_logit": -6.2734375,
            "end_logit": 9.7421875,
            "text": "L RNA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.28125,
            "end_logit": 9.7421875,
            "text": "SL RNA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0703125,
            "end_logit": -7.6953125,
            "text": "7SL",
            "probability": 0.0
        },
        {
            "start_logit": -7.39453125,
            "end_logit": 9.7421875,
            "text": "the 7SL RNA",
            "probability": 0.0
        },
        {
            "start_logit": 10.0703125,
            "end_logit": -8.0625,
            "text": "7SL RNA gene",
            "probability": 0.0
        },
        {
            "start_logit": 10.0703125,
            "end_logit": -8.0703125,
            "text": "7S",
            "probability": 0.0
        },
        {
            "start_logit": -7.78125,
            "end_logit": 9.7421875,
            "text": "Alu elements are each a dimer of similar, but not identical, fragments of total size about 300 bp, and originate from the 7SL RNA",
            "probability": 0.0
        },
        {
            "start_logit": 10.0703125,
            "end_logit": -8.140625,
            "text": "7SL RNA gene.",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 9.7421875,
            "text": ", fragments of total size about 300 bp, and originate from the 7SL RNA",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": 9.7421875,
            "text": "elements are each a dimer of similar, but not identical, fragments of total size about 300 bp, and originate from the 7SL RNA",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.7421875,
            "text": ", but not identical, fragments of total size about 300 bp, and originate from the 7SL RNA",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.7421875,
            "text": ", and originate from the 7SL RNA",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.7421875,
            "text": "of similar, but not identical, fragments of total size about 300 bp, and originate from the 7SL RNA",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.7421875,
            "text": "from the 7SL RNA",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.7421875,
            "text": "size about 300 bp, and originate from the 7SL RNA",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.7421875,
            "text": "identical, fragments of total size about 300 bp, and originate from the 7SL RNA",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": 9.7421875,
            "text": "fragments of total size about 300 bp, and originate from the 7SL RNA",
            "probability": 0.0
        }
    ],
    "58cf5c5a8acda34529000003_1": [
        {
            "start_logit": 9.890625,
            "end_logit": 9.65625,
            "text": "telomeric repeats",
            "probability": 1.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -2.09375,
            "text": "telomeric",
            "probability": 7.867813110351562e-06
        },
        {
            "start_logit": -1.8779296875,
            "end_logit": 9.65625,
            "text": "repeats",
            "probability": 7.748603820800781e-06
        },
        {
            "start_logit": -6.9453125,
            "end_logit": 9.65625,
            "text": "in telomeric repeats",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.890625,
            "end_logit": -7.40234375,
            "text": "telomeric repeats (99",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.890625,
            "end_logit": -7.70703125,
            "text": "telomeric repeats (99%",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.1328125,
            "text": "telomeric repeats (99%) and in regions where transcription starts and stop",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.203125,
            "text": "telomeric repeats (99%)",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.21875,
            "text": "telomeric repeats (99%) and in regions where transcription",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.2265625,
            "text": "telomeric repeats (99%) and in regions where transcription starts and",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.25,
            "text": "telomeric repeats (99%) and in regions where transcription starts",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.65625,
            "text": "found in telomeric repeats",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.65625,
            "text": "(\u03b2-D-glucosyl-hydroxymethyluracil) replaces 1% of T in the Leishmania genome and is only found in telomeric repeats",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.65625,
            "text": "replaces 1% of T in the Leishmania genome and is only found in telomeric repeats",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.65625,
            "text": "-D-glucosyl-hydroxymethyluracil) replaces 1% of T in the Leishmania genome and is only found in telomeric repeats",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": 9.65625,
            "text": "\u03b2-D-glucosyl-hydroxymethyluracil) replaces 1% of T in the Leishmania genome and is only found in telomeric repeats",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.65625,
            "text": "Base J (\u03b2-D-glucosyl-hydroxymethyluracil) replaces 1% of T in the Leishmania genome and is only found in telomeric repeats",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.65625,
            "text": "s 1% of T in the Leishmania genome and is only found in telomeric repeats",
            "probability": 0.0
        },
        {
            "start_logit": -8.3671875,
            "end_logit": 9.65625,
            "text": "-glucosyl-hydroxymethyluracil) replaces 1% of T in the Leishmania genome and is only found in telomeric repeats",
            "probability": 0.0
        },
        {
            "start_logit": -8.3671875,
            "end_logit": 9.65625,
            "text": "D-glucosyl-hydroxymethyluracil) replaces 1% of T in the Leishmania genome and is only found in telomeric repeats",
            "probability": 0.0
        }
    ],
    "58cf5c5a8acda34529000003_2": [
        {
            "start_logit": 9.8203125,
            "end_logit": 9.5703125,
            "text": "telomeric repeats",
            "probability": 1.0
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -2.255859375,
            "text": "telomeric",
            "probability": 7.271766662597656e-06
        },
        {
            "start_logit": -2.078125,
            "end_logit": 9.5703125,
            "text": "repeats",
            "probability": 6.794929504394531e-06
        },
        {
            "start_logit": -7.21484375,
            "end_logit": 9.5703125,
            "text": "in telomeric repeats",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -7.58203125,
            "text": "telomeric repeats (99",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -7.82421875,
            "text": "telomeric repeats (99%",
            "probability": 0.0
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -8.2109375,
            "text": "telomeric repeats (99%) and in regions where transcription starts and stop",
            "probability": 0.0
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -8.265625,
            "text": "telomeric repeats (99%)",
            "probability": 0.0
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -8.2734375,
            "text": "telomeric repeats (99%) and in regions where transcription starts and",
            "probability": 0.0
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -8.28125,
            "text": "telomeric repeats (99%) and in regions where transcription",
            "probability": 0.0
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -8.2890625,
            "text": "telomeric repeats (99%) and in regions where transcription starts and stops",
            "probability": 0.0
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -8.296875,
            "text": "telomeric repeats (99%) and",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.5703125,
            "text": "found in telomeric repeats",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.5703125,
            "text": "replaces 1% of T in the Leishmania genome and is only found in telomeric repeats",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.5703125,
            "text": "(\u03b2-D-glucosyl-hydroxymethyluracil) replaces 1% of T in the Leishmania genome and is only found in telomeric repeats",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.5703125,
            "text": "-D-glucosyl-hydroxymethyluracil) replaces 1% of T in the Leishmania genome and is only found in telomeric repeats",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.5703125,
            "text": "\u03b2-D-glucosyl-hydroxymethyluracil) replaces 1% of T in the Leishmania genome and is only found in telomeric repeats",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.5703125,
            "text": "s 1% of T in the Leishmania genome and is only found in telomeric repeats",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": 9.5703125,
            "text": "Base J (\u03b2-D-glucosyl-hydroxymethyluracil) replaces 1% of T in the Leishmania genome and is only found in telomeric repeats",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 9.5703125,
            "text": "-glucosyl-hydroxymethyluracil) replaces 1% of T in the Leishmania genome and is only found in telomeric repeats",
            "probability": 0.0
        }
    ],
    "61f86c03882a024a10000044_1": [
        {
            "start_logit": 3.724609375,
            "end_logit": 8.875,
            "text": "recessive hereditary motor neuropathy",
            "probability": 0.96875
        },
        {
            "start_logit": 0.22265625,
            "end_logit": 8.875,
            "text": "An ancestral 10-bp repeat expansion in VWA1 causes recessive hereditary motor neuropathy",
            "probability": 0.0290374755859375
        },
        {
            "start_logit": -3.310546875,
            "end_logit": 8.875,
            "text": "hereditary motor neuropathy",
            "probability": 0.0008497238159179688
        },
        {
            "start_logit": -3.345703125,
            "end_logit": 8.875,
            "text": "neuropathy",
            "probability": 0.0008234977722167969
        },
        {
            "start_logit": -4.07421875,
            "end_logit": 8.875,
            "text": "motor neuropathy",
            "probability": 0.00039649009704589844
        },
        {
            "start_logit": -6.08203125,
            "end_logit": 8.875,
            "text": "ancestral 10-bp repeat expansion in VWA1 causes recessive hereditary motor neuropathy",
            "probability": 5.3048133850097656e-05
        },
        {
            "start_logit": -6.2734375,
            "end_logit": 8.875,
            "text": "10-bp repeat expansion in VWA1 causes recessive hereditary motor neuropathy",
            "probability": 4.398822784423828e-05
        },
        {
            "start_logit": -6.96484375,
            "end_logit": 8.875,
            "text": "causes recessive hereditary motor neuropathy",
            "probability": 2.2113323211669922e-05
        },
        {
            "start_logit": -7.25390625,
            "end_logit": 8.875,
            "text": "VWA1 causes recessive hereditary motor neuropathy",
            "probability": 1.6450881958007812e-05
        },
        {
            "start_logit": -7.4296875,
            "end_logit": 8.875,
            "text": "expansion in VWA1 causes recessive hereditary motor neuropathy",
            "probability": 1.3887882232666016e-05
        },
        {
            "start_logit": -7.6015625,
            "end_logit": 8.875,
            "text": "in VWA1 causes recessive hereditary motor neuropathy",
            "probability": 1.1682510375976562e-05
        },
        {
            "start_logit": -7.62109375,
            "end_logit": 8.875,
            "text": "-bp repeat expansion in VWA1 causes recessive hereditary motor neuropathy",
            "probability": 1.150369644165039e-05
        },
        {
            "start_logit": -7.66796875,
            "end_logit": 8.875,
            "text": "repeat expansion in VWA1 causes recessive hereditary motor neuropathy",
            "probability": 1.0967254638671875e-05
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 8.875,
            "text": "A1 causes recessive hereditary motor neuropathy",
            "probability": 7.152557373046875e-06
        },
        {
            "start_logit": -8.203125,
            "end_logit": 8.875,
            "text": "bp repeat expansion in VWA1 causes recessive hereditary motor neuropathy",
            "probability": 6.4373016357421875e-06
        },
        {
            "start_logit": 3.724609375,
            "end_logit": -3.2265625,
            "text": "recessive hereditary motor neuropathy.",
            "probability": 5.364418029785156e-06
        },
        {
            "start_logit": 0.22265625,
            "end_logit": -3.2265625,
            "text": "An ancestral 10-bp repeat expansion in VWA1 causes recessive hereditary motor neuropathy.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 3.724609375,
            "end_logit": -7.49609375,
            "text": "recessive",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 3.724609375,
            "end_logit": -8.25,
            "text": "recessive hereditary motor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.310546875,
            "end_logit": -3.2265625,
            "text": "hereditary motor neuropathy.",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_1": [
        {
            "start_logit": 9.8515625,
            "end_logit": 9.6796875,
            "text": "cystic fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": -1.966796875,
            "end_logit": 9.6796875,
            "text": "fibrosis",
            "probability": 7.331371307373047e-06
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -2.20703125,
            "text": "cystic",
            "probability": 6.854534149169922e-06
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -8.1171875,
            "text": "cystic fibrosis (",
            "probability": 0.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -8.2109375,
            "text": "cystic fibrosis (CF",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 9.6796875,
            "text": "of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -8.234375,
            "text": "cystic fibrosis (CF)",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": 9.6796875,
            "text": "diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.6796875,
            "text": "Sweat chloride testing for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -8.328125,
            "text": "cystic fibrosis (CF) involves sweat induction",
            "probability": 0.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -8.3671875,
            "text": "cystic fibrosis (CF) involves sweat induction, collection",
            "probability": 0.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -8.3671875,
            "text": "cystic fibrosis (CF) involves",
            "probability": 0.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -8.375,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and handling, and measurement in an analytical lab",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.6796875,
            "text": "for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.6796875,
            "text": "testing for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -1.966796875,
            "end_logit": -8.1171875,
            "text": "fibrosis (",
            "probability": 0.0
        },
        {
            "start_logit": -1.966796875,
            "end_logit": -8.2109375,
            "text": "fibrosis (CF",
            "probability": 0.0
        },
        {
            "start_logit": -1.966796875,
            "end_logit": -8.234375,
            "text": "fibrosis (CF)",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -2.20703125,
            "text": "of cystic",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": -2.20703125,
            "text": "diagnosis of cystic",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_2": [
        {
            "start_logit": 9.8671875,
            "end_logit": 9.59375,
            "text": "cystic fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -2.1640625,
            "text": "cystic",
            "probability": 7.748603820800781e-06
        },
        {
            "start_logit": -2.1328125,
            "end_logit": 9.59375,
            "text": "fibrosis",
            "probability": 6.079673767089844e-06
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.234375,
            "text": "cystic fibrosis transmembrane",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.3359375,
            "text": "cystic fibrosis transmembrane conductance",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": 9.59375,
            "text": "analysis of the sweat test (ST), associating ST results with epidemiological data, CFTR (cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.390625,
            "text": "cystic fibrosis transmembrane conductance regulator)",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.390625,
            "text": "cystic fibrosis transmembrane conductance regulator) mutations and reasons to",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.390625,
            "text": "cystic fibrosis transmembrane conductance regulator",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.59375,
            "text": "a descriptive analysis of the sweat test (ST), associating ST results with epidemiological data, CFTR (cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 9.59375,
            "text": "associating ST results with epidemiological data, CFTR (cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.59375,
            "text": "To conduct a descriptive analysis of the sweat test (ST), associating ST results with epidemiological data, CFTR (cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.59375,
            "text": "descriptive analysis of the sweat test (ST), associating ST results with epidemiological data, CFTR (cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.59375,
            "text": "(cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.59375,
            "text": "the sweat test (ST), associating ST results with epidemiological data, CFTR (cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": -2.1640625,
            "text": "analysis of the sweat test (ST), associating ST results with epidemiological data, CFTR (cystic",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": -2.1640625,
            "text": "a descriptive analysis of the sweat test (ST), associating ST results with epidemiological data, CFTR (cystic",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": -2.1640625,
            "text": "associating ST results with epidemiological data, CFTR (cystic",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -2.1640625,
            "text": "To conduct a descriptive analysis of the sweat test (ST), associating ST results with epidemiological data, CFTR (cystic",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -2.1640625,
            "text": "descriptive analysis of the sweat test (ST), associating ST results with epidemiological data, CFTR (cystic",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_3": [
        {
            "start_logit": 9.84375,
            "end_logit": 9.71875,
            "text": "Cystic Fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": -1.8447265625,
            "end_logit": 9.71875,
            "text": "Fibrosis",
            "probability": 8.404254913330078e-06
        },
        {
            "start_logit": 9.84375,
            "end_logit": -2.220703125,
            "text": "Cystic",
            "probability": 6.556510925292969e-06
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.03125,
            "text": "Cystic Fibrosis Infants: Revealing Mechanisms beyond Impaired Chloride Transport.The sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.0625,
            "text": "Cystic Fibrosis Infants: Revealing Mechanisms beyond Impaired Chloride Transport.The sweat chloride test remains the gold standard",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.15625,
            "text": "Cystic Fibrosis Infants: Revealing Mechanisms beyond Impaired Chloride Transport.The sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.1640625,
            "text": "Cystic Fibrosis Infants: Revealing Mechanisms beyond Impaired Chloride Transport.The sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (CF",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.203125,
            "text": "Cystic Fibrosis Infants",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.21875,
            "text": "Cystic Fibrosis Infants: Revealing Mechanisms beyond Impaired Chloride Transport",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.25,
            "text": "Cystic Fibrosis Infants: Revealing Mechanisms beyond Impaired Chloride Transport.The sweat chloride test remains the gold standard for confirmatory diagnosis of cystic",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.265625,
            "text": "Cystic Fibrosis Infants: Revealing Mechanisms beyond Impaired Chloride Transport.The sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (CF) in support",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.2734375,
            "text": "Cystic Fibrosis Infants: Revealing Mechanisms beyond Impaired Chloride Transport.The sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (CF)",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.2734375,
            "text": "Cystic Fibrosis Infants: Revealing Mechanisms beyond",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.28125,
            "text": "Cystic Fibrosis Infants: Revealing Mechanisms beyond Impaired Chloride Transport.The sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (CF) in support of universal newborn screening programs",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.28125,
            "text": "Cystic Fibrosis Infants: Revealing Mechanisms beyond Impaired Chloride Transport.The sweat chloride test remains the gold",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.2890625,
            "text": "Cystic Fibrosis Infants:",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.3046875,
            "text": "Cystic Fibrosis Infants: Revealing Mechanisms beyond Impaired Chloride Transport.The sweat chloride test remains",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.71875,
            "text": "Positive Cystic Fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.3203125,
            "text": "Cystic Fibrosis Infants: Revealing Mechanisms beyond Impaired Chloride Transport.The sweat chloride",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.71875,
            "text": "Sweat Metabolome of Screen-Positive Cystic Fibrosis",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_4": [
        {
            "start_logit": 9.828125,
            "end_logit": 9.734375,
            "text": "Cystic Fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": -1.8134765625,
            "end_logit": 9.734375,
            "text": "Fibrosis",
            "probability": 8.821487426757812e-06
        },
        {
            "start_logit": 9.828125,
            "end_logit": -2.271484375,
            "text": "Cystic",
            "probability": 6.079673767089844e-06
        },
        {
            "start_logit": -7.4609375,
            "end_logit": 9.734375,
            "text": "of Cystic Fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.828125,
            "end_logit": -7.89453125,
            "text": "Cystic Fibrosis Patients.The diagnosis is often delayed and the disease is advanced in most patients at",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -7.98046875,
            "text": "Cystic Fibrosis Patients",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.0234375,
            "text": "Cystic Fibrosis Patients.The diagnosis is often delayed and the disease",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.078125,
            "text": "Cystic Fibrosis Patients.The diagnosis is often delayed and the disease is",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.0859375,
            "text": "Cystic Fibrosis Patients.The diagnosis is often delayed and the disease is advanced in",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.171875,
            "text": "Cystic Fibrosis Patients.The diagnosis is often delayed and the disease is advanced in most patients",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.1875,
            "text": "Cystic Fibrosis Patients.The diagnosis is often delayed and the disease is advanced in most patients at the time",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.1875,
            "text": "Cystic Fibrosis Patients.The diagnosis is often",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.1953125,
            "text": "Cystic Fibrosis Patients.The diagnosis is often delayed and the disease is advanced",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.2109375,
            "text": "Cystic Fibrosis Patients.The diagnosis is often delayed and the disease is advanced in most patients at the time of diagnosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.21875,
            "text": "Cystic Fibrosis Patients.The diagnosis is often delayed and the disease is advanced in most patients at the",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.2265625,
            "text": "Cystic Fibrosis Patients.The diagnosis is often delayed and",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.2265625,
            "text": "Cystic Fibrosis Patients.The diagnosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.2421875,
            "text": "Cystic Fibrosis Patients.The diagnosis is often delayed and the disease is advanced in most",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.2421875,
            "text": "Cystic Fibrosis Patients.The diagnosis is",
            "probability": 0.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -8.25,
            "text": "Cystic Fibrosis Patients.The diagnosis is often delayed and the disease is advanced in most patients at the time of",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_5": [
        {
            "start_logit": 9.8359375,
            "end_logit": 9.6875,
            "text": "cystic fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": -1.908203125,
            "end_logit": 9.6875,
            "text": "fibrosis",
            "probability": 7.867813110351562e-06
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -2.236328125,
            "text": "cystic",
            "probability": 6.616115570068359e-06
        },
        {
            "start_logit": -7.67578125,
            "end_logit": 9.6875,
            "text": "In cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -7.83203125,
            "text": "cystic fibrosis (",
            "probability": 0.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -7.8515625,
            "text": "cystic fibrosis (CF)",
            "probability": 0.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -7.87890625,
            "text": "cystic fibrosis (CF",
            "probability": 0.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -8.0078125,
            "text": "cystic fibrosis (CF), sweat chloride concentration has been proposed as an index of CFTR",
            "probability": 0.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -8.0859375,
            "text": "cystic fibrosis (CF), sweat chloride concentration has been proposed as an index of CFTR function for testing systemic drugs designed to activate mutant CFTR",
            "probability": 0.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -8.1328125,
            "text": "cystic fibrosis (CF), sweat chloride concentration has been proposed as an index of CFTR function",
            "probability": 0.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -8.1875,
            "text": "cystic fibrosis (CF), sweat chloride concentration has been proposed as an index of CFTR function for testing systemic drugs designed",
            "probability": 0.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -8.1875,
            "text": "cystic fibrosis (CF), sweat chloride concentration has been proposed as an index",
            "probability": 0.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -8.1953125,
            "text": "cystic fibrosis (CF), sweat chloride concentration has been proposed as an",
            "probability": 0.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -8.203125,
            "text": "cystic fibrosis (CF), sweat chloride concentration has been proposed as an index of CFTR function for testing systemic drugs designed to activate",
            "probability": 0.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -8.21875,
            "text": "cystic fibrosis (CF), sweat chloride concentration has been proposed as an index of CFTR function for testing systemic drugs designed to activate mutant",
            "probability": 0.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -8.234375,
            "text": "cystic fibrosis (CF), sweat chloride concentration has been proposed as an index of CFTR function for testing systemic drugs",
            "probability": 0.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -8.2421875,
            "text": "cystic fibrosis (CF), sweat chloride concentration has been proposed as an index of CFTR function for testing systemic drugs designed to",
            "probability": 0.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -8.2421875,
            "text": "cystic fibrosis (CF), sweat chloride concentration",
            "probability": 0.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -8.25,
            "text": "cystic fibrosis (CF), sweat chloride",
            "probability": 0.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -8.25,
            "text": "cystic fibrosis (CF), sweat chloride concentration has been proposed as an index of",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_6": [
        {
            "start_logit": 9.7890625,
            "end_logit": 9.59375,
            "text": "cystic fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": -2.1328125,
            "end_logit": 9.59375,
            "text": "fibrosis",
            "probability": 6.67572021484375e-06
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -2.357421875,
            "text": "cystic",
            "probability": 6.496906280517578e-06
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -7.94140625,
            "text": "cystic fibrosis (",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -8.0703125,
            "text": "cystic fibrosis (CF",
            "probability": 0.0
        },
        {
            "start_logit": -7.96875,
            "end_logit": 9.59375,
            "text": "of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -8.21875,
            "text": "cystic fibrosis (CF)",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.59375,
            "text": "diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -8.25,
            "text": "cystic fibrosis (CF) involves",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -8.265625,
            "text": "cystic fibrosis (CF) involves sweat induction",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.59375,
            "text": "BACKGROUND Sweat chloride testing for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -8.2890625,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and handling, and measurement in an analytical lab",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -8.3046875,
            "text": "cystic fibrosis (CF) involves sweat induction, collection",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.59375,
            "text": "Sweat chloride testing for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -8.34375,
            "text": "cystic fibrosis (CF) involves sweat",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -8.34375,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and handling, and measurement in an analytical",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -8.3515625,
            "text": "cystic fibrosis (CF) involves sweat induction,",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.59375,
            "text": "for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -2.1328125,
            "end_logit": -7.94140625,
            "text": "fibrosis (",
            "probability": 0.0
        },
        {
            "start_logit": -2.1328125,
            "end_logit": -8.0703125,
            "text": "fibrosis (CF",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_7": [
        {
            "start_logit": 9.9140625,
            "end_logit": 9.6875,
            "text": "cystic fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -2.046875,
            "text": "cystic",
            "probability": 8.046627044677734e-06
        },
        {
            "start_logit": -1.9365234375,
            "end_logit": 9.6875,
            "text": "fibrosis",
            "probability": 7.212162017822266e-06
        },
        {
            "start_logit": -7.6171875,
            "end_logit": 9.6875,
            "text": "of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.09375,
            "text": "cystic fibrosis (CF",
            "probability": 0.0
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 9.6875,
            "text": "diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.21875,
            "text": "cystic fibrosis (CF)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.21875,
            "text": "cystic fibrosis (",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.6875,
            "text": "Sweat chloride testing is the gold standard for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.6875,
            "text": "for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.6875,
            "text": "testing is the gold standard for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.6875,
            "text": "chloride testing is the gold standard for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": 9.6875,
            "text": "the gold standard for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.6875,
            "text": "is the gold standard for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.6875,
            "text": "OBJECTIVES Sweat chloride testing is the gold standard for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 9.6875,
            "text": "gold standard for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -7.6171875,
            "end_logit": -2.046875,
            "text": "of cystic",
            "probability": 0.0
        },
        {
            "start_logit": -7.9765625,
            "end_logit": -2.046875,
            "text": "diagnosis of cystic",
            "probability": 0.0
        },
        {
            "start_logit": -1.9365234375,
            "end_logit": -8.09375,
            "text": "fibrosis (CF",
            "probability": 0.0
        },
        {
            "start_logit": -1.9365234375,
            "end_logit": -8.21875,
            "text": "fibrosis (CF)",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_8": [
        {
            "start_logit": 9.9140625,
            "end_logit": 9.6953125,
            "text": "cystic fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -2.064453125,
            "text": "cystic",
            "probability": 7.808208465576172e-06
        },
        {
            "start_logit": -1.939453125,
            "end_logit": 9.6953125,
            "text": "fibrosis",
            "probability": 7.152557373046875e-06
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.0234375,
            "text": "cystic fibrosis (CF",
            "probability": 0.0
        },
        {
            "start_logit": -7.90625,
            "end_logit": 9.6953125,
            "text": "of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.1875,
            "text": "cystic fibrosis (CF)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.2578125,
            "text": "cystic fibrosis (",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.296875,
            "text": "cystic fibrosis (CF) in support",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": 9.6953125,
            "text": "The sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.3203125,
            "text": "cystic fibrosis (CF) in",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.359375,
            "text": "cystic fibrosis (CF) in support of universal newborn screening programs",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.6953125,
            "text": "sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.6953125,
            "text": "diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.6953125,
            "text": "confirmatory diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.6953125,
            "text": "test remains the gold standard for confirmatory diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.6953125,
            "text": "chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.6953125,
            "text": "the gold standard for confirmatory diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 9.6953125,
            "text": "for confirmatory diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.359375,
            "end_logit": 9.6953125,
            "text": "remains the gold standard for confirmatory diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -1.939453125,
            "end_logit": -8.0234375,
            "text": "fibrosis (CF",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_9": [
        {
            "start_logit": 9.8125,
            "end_logit": 9.59375,
            "text": "cystic fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -2.31640625,
            "text": "cystic",
            "probability": 6.735324859619141e-06
        },
        {
            "start_logit": -2.115234375,
            "end_logit": 9.59375,
            "text": "fibrosis",
            "probability": 6.616115570068359e-06
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.59375,
            "text": "Sweat chloride is of interest as a biomarker for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 9.59375,
            "text": "for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.59375,
            "text": "biomarker for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": -2.31640625,
            "text": "Sweat chloride is of interest as a biomarker for cystic",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -2.31640625,
            "text": "for cystic",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": -2.31640625,
            "text": "biomarker for cystic",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_10": [
        {
            "start_logit": 9.9140625,
            "end_logit": 9.6875,
            "text": "cystic fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -2.046875,
            "text": "cystic",
            "probability": 8.046627044677734e-06
        },
        {
            "start_logit": -1.9365234375,
            "end_logit": 9.6875,
            "text": "fibrosis",
            "probability": 7.212162017822266e-06
        },
        {
            "start_logit": -7.6171875,
            "end_logit": 9.6875,
            "text": "of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.09375,
            "text": "cystic fibrosis (CF",
            "probability": 0.0
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 9.6875,
            "text": "diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.21875,
            "text": "cystic fibrosis (CF)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.21875,
            "text": "cystic fibrosis (",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.6875,
            "text": "Sweat chloride testing is the gold standard for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.6875,
            "text": "for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.6875,
            "text": "testing is the gold standard for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.6875,
            "text": "chloride testing is the gold standard for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": 9.6875,
            "text": "the gold standard for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.6875,
            "text": "is the gold standard for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.6875,
            "text": "OBJECTIVES Sweat chloride testing is the gold standard for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 9.6875,
            "text": "gold standard for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -7.6171875,
            "end_logit": -2.046875,
            "text": "of cystic",
            "probability": 0.0
        },
        {
            "start_logit": -7.9765625,
            "end_logit": -2.046875,
            "text": "diagnosis of cystic",
            "probability": 0.0
        },
        {
            "start_logit": -1.9365234375,
            "end_logit": -8.09375,
            "text": "fibrosis (CF",
            "probability": 0.0
        },
        {
            "start_logit": -1.9365234375,
            "end_logit": -8.21875,
            "text": "fibrosis (CF)",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_11": [
        {
            "start_logit": 9.7890625,
            "end_logit": 9.59375,
            "text": "cystic fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": -2.1328125,
            "end_logit": 9.59375,
            "text": "fibrosis",
            "probability": 6.67572021484375e-06
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -2.357421875,
            "text": "cystic",
            "probability": 6.496906280517578e-06
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -7.94140625,
            "text": "cystic fibrosis (",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -8.0703125,
            "text": "cystic fibrosis (CF",
            "probability": 0.0
        },
        {
            "start_logit": -7.96875,
            "end_logit": 9.59375,
            "text": "of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -8.21875,
            "text": "cystic fibrosis (CF)",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.59375,
            "text": "diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -8.25,
            "text": "cystic fibrosis (CF) involves",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -8.265625,
            "text": "cystic fibrosis (CF) involves sweat induction",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.59375,
            "text": "BACKGROUND Sweat chloride testing for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -8.2890625,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and handling, and measurement in an analytical lab",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -8.3046875,
            "text": "cystic fibrosis (CF) involves sweat induction, collection",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.59375,
            "text": "Sweat chloride testing for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -8.34375,
            "text": "cystic fibrosis (CF) involves sweat",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -8.34375,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and handling, and measurement in an analytical",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -8.3515625,
            "text": "cystic fibrosis (CF) involves sweat induction,",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.59375,
            "text": "for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -2.1328125,
            "end_logit": -7.94140625,
            "text": "fibrosis (",
            "probability": 0.0
        },
        {
            "start_logit": -2.1328125,
            "end_logit": -8.0703125,
            "text": "fibrosis (CF",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_12": [
        {
            "start_logit": 9.90625,
            "end_logit": 9.703125,
            "text": "cystic fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -2.05859375,
            "text": "cystic",
            "probability": 7.748603820800781e-06
        },
        {
            "start_logit": -1.931640625,
            "end_logit": 9.703125,
            "text": "fibrosis",
            "probability": 7.212162017822266e-06
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.171875,
            "text": "cystic fibrosis (CF",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.1796875,
            "text": "cystic fibrosis (CF) diagnosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.0,
            "end_logit": 9.703125,
            "text": "for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.2890625,
            "text": "cystic fibrosis (CF)",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.34375,
            "text": "cystic fibrosis (",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 9.703125,
            "text": "Sweat chloride test is the gold standard test for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.703125,
            "text": "test for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.703125,
            "text": "BACKGROUND Sweat chloride test is the gold standard test for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": 9.703125,
            "text": "the gold standard test for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 9.703125,
            "text": "chloride test is the gold standard test for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": 9.703125,
            "text": "is the gold standard test for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.0,
            "end_logit": -2.05859375,
            "text": "for cystic",
            "probability": 0.0
        },
        {
            "start_logit": -1.931640625,
            "end_logit": -8.171875,
            "text": "fibrosis (CF",
            "probability": 0.0
        },
        {
            "start_logit": -1.931640625,
            "end_logit": -8.1796875,
            "text": "fibrosis (CF) diagnosis",
            "probability": 0.0
        },
        {
            "start_logit": -1.931640625,
            "end_logit": -8.2890625,
            "text": "fibrosis (CF)",
            "probability": 0.0
        },
        {
            "start_logit": -1.931640625,
            "end_logit": -8.34375,
            "text": "fibrosis (",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -2.05859375,
            "text": "Sweat chloride test is the gold standard test for cystic",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_13": [
        {
            "start_logit": 9.796875,
            "end_logit": 9.5859375,
            "text": "cystic fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -2.341796875,
            "text": "cystic",
            "probability": 6.616115570068359e-06
        },
        {
            "start_logit": -2.15625,
            "end_logit": 9.5859375,
            "text": "fibrosis",
            "probability": 6.496906280517578e-06
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 9.5859375,
            "text": "Sweat chloride test is known to be a screening test for the cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.2265625,
            "text": "cystic fibrosis due",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": 9.5859375,
            "text": "the cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.2578125,
            "text": "cystic fibrosis due to",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.265625,
            "text": "cystic fibrosis due to the fact that electrolyte levels in sweat",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.296875,
            "text": "cystic fibrosis due to the fact that electrolyte levels in sweat are elevated",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.3046875,
            "text": "cystic fibrosis due to the fact that electrolyte levels in sweat are",
            "probability": 0.0
        },
        {
            "start_logit": 9.796875,
            "end_logit": -8.3046875,
            "text": "cystic fibrosis due to the fact that electrolyte levels",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 9.5859375,
            "text": "screening test for the cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.5859375,
            "text": "test for the cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.5859375,
            "text": "chloride test is known to be a screening test for the cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.5859375,
            "text": "for the cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.5859375,
            "text": "a screening test for the cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.5859375,
            "text": "be a screening test for the cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.5859375,
            "text": "test is known to be a screening test for the cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": 9.5859375,
            "text": "known to be a screening test for the cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": -2.341796875,
            "text": "Sweat chloride test is known to be a screening test for the cystic",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_14": [
        {
            "start_logit": 9.90625,
            "end_logit": 9.6953125,
            "text": "cystic fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -2.064453125,
            "text": "cystic",
            "probability": 7.867813110351562e-06
        },
        {
            "start_logit": -1.923828125,
            "end_logit": 9.6953125,
            "text": "fibrosis",
            "probability": 7.331371307373047e-06
        },
        {
            "start_logit": -7.640625,
            "end_logit": 9.6953125,
            "text": "for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.09375,
            "text": "cystic fibrosis (",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.109375,
            "text": "cystic fibrosis (CF",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.15625,
            "text": "cystic fibrosis (CF)",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.6953125,
            "text": "Sweat chloride measurement is considered a standard diagnostic tool for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": 9.6953125,
            "text": "OBJECTIVE Sweat chloride measurement is considered a standard diagnostic tool for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.6953125,
            "text": "standard diagnostic tool for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.6953125,
            "text": "diagnostic tool for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.6953125,
            "text": "a standard diagnostic tool for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.6953125,
            "text": "tool for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.6953125,
            "text": "considered a standard diagnostic tool for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.6953125,
            "text": "chloride measurement is considered a standard diagnostic tool for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.6953125,
            "text": "measurement is considered a standard diagnostic tool for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.6953125,
            "text": "is considered a standard diagnostic tool for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -7.640625,
            "end_logit": -2.064453125,
            "text": "for cystic",
            "probability": 0.0
        },
        {
            "start_logit": -1.923828125,
            "end_logit": -8.09375,
            "text": "fibrosis (",
            "probability": 0.0
        },
        {
            "start_logit": -1.923828125,
            "end_logit": -8.109375,
            "text": "fibrosis (CF",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_15": [
        {
            "start_logit": 9.78125,
            "end_logit": 9.59375,
            "text": "cystic fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": -2.126953125,
            "end_logit": 9.59375,
            "text": "fibrosis",
            "probability": 6.735324859619141e-06
        },
        {
            "start_logit": 9.78125,
            "end_logit": -2.373046875,
            "text": "cystic",
            "probability": 6.318092346191406e-06
        },
        {
            "start_logit": 9.78125,
            "end_logit": -7.984375,
            "text": "cystic fibrosis (",
            "probability": 0.0
        },
        {
            "start_logit": -7.83984375,
            "end_logit": 9.59375,
            "text": "Sweat chloride testing for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.0859375,
            "text": "cystic fibrosis (CF",
            "probability": 0.0
        },
        {
            "start_logit": -7.9375,
            "end_logit": 9.59375,
            "text": "diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 9.59375,
            "text": "of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.1796875,
            "text": "cystic fibrosis (CF) involves sweat induction",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.2265625,
            "text": "cystic fibrosis (CF)",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.25,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and handling, and measurement in an analytical lab",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.2578125,
            "text": "cystic fibrosis (CF) involves sweat induction, collection",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.2734375,
            "text": "cystic fibrosis (CF) involves sweat",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.3046875,
            "text": "cystic fibrosis (CF) involves",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.328125,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and handling, and measurement in an analytical",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.328125,
            "text": "cystic fibrosis (CF) involves sweat induction,",
            "probability": 0.0
        },
        {
            "start_logit": 9.78125,
            "end_logit": -8.34375,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and handling, and measurement in an analytical lab.",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.59375,
            "text": "for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.59375,
            "text": "testing for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -2.126953125,
            "end_logit": -7.984375,
            "text": "fibrosis (",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_1": [
        {
            "start_logit": 10.0,
            "end_logit": 9.6953125,
            "text": "bladder cancer",
            "probability": 1.0
        },
        {
            "start_logit": 10.0,
            "end_logit": -1.8671875,
            "text": "bladder",
            "probability": 9.59634780883789e-06
        },
        {
            "start_logit": -1.958984375,
            "end_logit": 9.6953125,
            "text": "cancer",
            "probability": 6.4373016357421875e-06
        },
        {
            "start_logit": 10.0,
            "end_logit": -8.359375,
            "text": "bladder cancer:",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.6953125,
            "text": "Bacillus Calmette-Gu\u00e9rin immunotherapy for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.6953125,
            "text": "Calmette-Gu\u00e9rin immunotherapy for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.6953125,
            "text": "for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": -1.8671875,
            "text": "Bacillus Calmette-Gu\u00e9rin immunotherapy for bladder",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -1.8671875,
            "text": "Calmette-Gu\u00e9rin immunotherapy for bladder",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -1.8671875,
            "text": "for bladder",
            "probability": 0.0
        },
        {
            "start_logit": -1.958984375,
            "end_logit": -8.359375,
            "text": "cancer:",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": -8.359375,
            "text": "Bacillus Calmette-Gu\u00e9rin immunotherapy for bladder cancer:",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": -8.3828125,
            "text": "Bacillus Calmette-Gu",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -8.359375,
            "text": "Calmette-Gu\u00e9rin immunotherapy for bladder cancer:",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -8.3828125,
            "text": "Calmette-Gu",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -8.359375,
            "text": "for bladder cancer:",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_2": [
        {
            "start_logit": 10.0234375,
            "end_logit": 9.75,
            "text": "bladder cancer",
            "probability": 1.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -1.8076171875,
            "text": "bladder",
            "probability": 9.5367431640625e-06
        },
        {
            "start_logit": -1.8115234375,
            "end_logit": 9.75,
            "text": "cancer",
            "probability": 7.212162017822266e-06
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.203125,
            "text": "bladder cancer has been used since",
            "probability": 0.0
        },
        {
            "start_logit": -7.9296875,
            "end_logit": 9.75,
            "text": "Bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.2578125,
            "text": "bladder cancer has been used since 1976 when the first evidence of its ability to lower recurrence and progression rates",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.265625,
            "text": "bladder cancer has been used since 1976",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.296875,
            "text": "bladder cancer has been used since 1976 when the first evidence of its ability to lower recurrence and",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.296875,
            "text": "bladder cancer has been used since 1976 when the first evidence of its ability to",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.3125,
            "text": "bladder cancer has been used since 1976 when the first evidence of its ability",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": 9.75,
            "text": "for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.75,
            "text": "Calmette-Gu\u00e9rin (BCG) immunotherapy for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.359375,
            "end_logit": 9.75,
            "text": "BCG) immunotherapy for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.9296875,
            "end_logit": -1.8076171875,
            "text": "Bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy for bladder",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": -1.8076171875,
            "text": "for bladder",
            "probability": 0.0
        },
        {
            "start_logit": -1.8115234375,
            "end_logit": -8.203125,
            "text": "cancer has been used since",
            "probability": 0.0
        },
        {
            "start_logit": -1.8115234375,
            "end_logit": -8.2578125,
            "text": "cancer has been used since 1976 when the first evidence of its ability to lower recurrence and progression rates",
            "probability": 0.0
        },
        {
            "start_logit": -1.8115234375,
            "end_logit": -8.265625,
            "text": "cancer has been used since 1976",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": -1.8076171875,
            "text": "Calmette-Gu\u00e9rin (BCG) immunotherapy for bladder",
            "probability": 0.0
        },
        {
            "start_logit": -1.8115234375,
            "end_logit": -8.296875,
            "text": "cancer has been used since 1976 when the first evidence of its ability to lower recurrence and",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_3": [
        {
            "start_logit": 10.0546875,
            "end_logit": 9.75,
            "text": "bladder cancer",
            "probability": 1.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -1.720703125,
            "text": "bladder",
            "probability": 1.0371208190917969e-05
        },
        {
            "start_logit": -1.81640625,
            "end_logit": 9.75,
            "text": "cancer",
            "probability": 6.973743438720703e-06
        },
        {
            "start_logit": -7.25390625,
            "end_logit": 9.75,
            "text": "invasive bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 9.75,
            "text": "grade non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -8.2890625,
            "text": "bladder cancer (NM",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": 9.75,
            "text": "-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 9.75,
            "text": "for high-grade non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 9.75,
            "text": "BCG immunotherapy is the choice of care for high-grade non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -8.390625,
            "text": "bladder cancer (NMIB",
            "probability": 0.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -8.390625,
            "text": "bladder cancer (NMIBC) after transurethral resection",
            "probability": 0.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -8.390625,
            "text": "bladder cancer (NMIBC",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 9.75,
            "text": "muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.75,
            "text": "-grade non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.75,
            "text": "non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 9.75,
            "text": "immunotherapy is the choice of care for high-grade non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.75,
            "text": "high-grade non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.75,
            "text": "is the choice of care for high-grade non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.25390625,
            "end_logit": -1.720703125,
            "text": "invasive bladder",
            "probability": 0.0
        },
        {
            "start_logit": -7.95703125,
            "end_logit": -1.720703125,
            "text": "grade non-muscle invasive bladder",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_4": [
        {
            "start_logit": 10.0,
            "end_logit": 9.6953125,
            "text": "Bladder Cancer",
            "probability": 1.0
        },
        {
            "start_logit": 10.0,
            "end_logit": -1.8388671875,
            "text": "Bladder",
            "probability": 9.894371032714844e-06
        },
        {
            "start_logit": -1.916015625,
            "end_logit": 9.6953125,
            "text": "Cancer",
            "probability": 6.735324859619141e-06
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 9.6953125,
            "text": "of Bladder Cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.6953125,
            "text": "the Treatment of Bladder Cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.6953125,
            "text": "Treatment of Bladder Cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.6953125,
            "text": "for the Treatment of Bladder Cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.6953125,
            "text": "(BCG) Immunotherapy for the Treatment of Bladder Cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.6953125,
            "text": "Renal Tuberculosis Following Intravesical Bacillus Calmette-Gu\u00e9rin (BCG) Immunotherapy for the Treatment of Bladder Cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.6953125,
            "text": "Intravesical Bacillus Calmette-Gu\u00e9rin (BCG) Immunotherapy for the Treatment of Bladder Cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.6953125,
            "text": "Bacillus Calmette-Gu\u00e9rin (BCG) Immunotherapy for the Treatment of Bladder Cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.6953125,
            "text": ") Immunotherapy for the Treatment of Bladder Cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": 9.6953125,
            "text": "Following Intravesical Bacillus Calmette-Gu\u00e9rin (BCG) Immunotherapy for the Treatment of Bladder Cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": 9.6953125,
            "text": "Tuberculosis Following Intravesical Bacillus Calmette-Gu\u00e9rin (BCG) Immunotherapy for the Treatment of Bladder Cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": 9.6953125,
            "text": "BCG) Immunotherapy for the Treatment of Bladder Cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.375,
            "end_logit": 9.6953125,
            "text": "Calmette-Gu\u00e9rin (BCG) Immunotherapy for the Treatment of Bladder Cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": 9.6953125,
            "text": "Immunotherapy for the Treatment of Bladder Cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.66015625,
            "end_logit": -1.8388671875,
            "text": "of Bladder",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -1.8388671875,
            "text": "the Treatment of Bladder",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -1.8388671875,
            "text": "Treatment of Bladder",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_5": [
        {
            "start_logit": 10.0234375,
            "end_logit": 9.734375,
            "text": "bladder cancer",
            "probability": 1.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -1.7939453125,
            "text": "bladder",
            "probability": 9.894371032714844e-06
        },
        {
            "start_logit": -1.8681640625,
            "end_logit": 9.734375,
            "text": "cancer",
            "probability": 6.9141387939453125e-06
        },
        {
            "start_logit": -7.86328125,
            "end_logit": 9.734375,
            "text": "superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.734375,
            "text": "40 years since Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.734375,
            "text": "treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.734375,
            "text": "since Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.734375,
            "text": "to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.734375,
            "text": "It is nearly 40 years since Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.734375,
            "text": "an immunotherapy to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.734375,
            "text": "Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.734375,
            "text": "years since Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": 9.734375,
            "text": "(BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.734375,
            "text": "nearly 40 years since Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 9.734375,
            "text": "is nearly 40 years since Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.3671875,
            "end_logit": 9.734375,
            "text": "first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.3671875,
            "end_logit": 9.734375,
            "text": "immunotherapy to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.86328125,
            "end_logit": -1.7939453125,
            "text": "superficial bladder",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": -1.7939453125,
            "text": "40 years since Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": -1.7939453125,
            "text": "treat superficial bladder",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_6": [
        {
            "start_logit": 9.9921875,
            "end_logit": 9.7265625,
            "text": "bladder cancer",
            "probability": 1.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -1.8876953125,
            "text": "bladder",
            "probability": 9.000301361083984e-06
        },
        {
            "start_logit": -1.865234375,
            "end_logit": 9.7265625,
            "text": "cancer",
            "probability": 7.092952728271484e-06
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.2578125,
            "text": "bladder cancer can",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 9.7265625,
            "text": "with bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": -1.8876953125,
            "text": "with bladder",
            "probability": 0.0
        },
        {
            "start_logit": -1.865234375,
            "end_logit": -8.2578125,
            "text": "cancer can",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": -8.2578125,
            "text": "with bladder cancer can",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_7": [
        {
            "start_logit": 10.0234375,
            "end_logit": 9.703125,
            "text": "bladder cancer",
            "probability": 1.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -1.7998046875,
            "text": "bladder",
            "probability": 1.0192394256591797e-05
        },
        {
            "start_logit": -1.9375,
            "end_logit": 9.703125,
            "text": "cancer",
            "probability": 6.4373016357421875e-06
        },
        {
            "start_logit": -7.328125,
            "end_logit": 9.703125,
            "text": "invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.703125,
            "text": "in nonmuscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.703125,
            "text": "nonmuscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.703125,
            "text": "le invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.703125,
            "text": "immunotherapy in nonmuscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.703125,
            "text": "Mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.703125,
            "text": "bovis BCG for immunotherapy in nonmuscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.703125,
            "text": "uscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.703125,
            "text": "BCG for immunotherapy in nonmuscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": 9.703125,
            "text": "Recombinant Mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.703125,
            "text": "for immunotherapy in nonmuscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.328125,
            "end_logit": -1.7998046875,
            "text": "invasive bladder",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": -1.7998046875,
            "text": "in nonmuscle invasive bladder",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -1.7998046875,
            "text": "nonmuscle invasive bladder",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -1.7998046875,
            "text": "le invasive bladder",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": -1.7998046875,
            "text": "immunotherapy in nonmuscle invasive bladder",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": -1.7998046875,
            "text": "Mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_8": [
        {
            "start_logit": 9.9921875,
            "end_logit": 9.7734375,
            "text": "bladder cancer",
            "probability": 1.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -1.8671875,
            "text": "bladder",
            "probability": 8.821487426757812e-06
        },
        {
            "start_logit": -1.7421875,
            "end_logit": 9.7734375,
            "text": "cancer",
            "probability": 7.987022399902344e-06
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.1015625,
            "text": "bladder cancer has been most apparent in patients with carcinoma in situ (CIS), where complete response is increased from 50% to more than 70% and the proportion of patients remaining disease free for 5 years is increased from 20% to 40",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.1171875,
            "text": "bladder cancer has been most apparent in patients with carcinoma in situ (CIS",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.1640625,
            "text": "bladder cancer has been most apparent in patients with carcinoma in situ",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.1640625,
            "text": "bladder cancer has been most apparent in patients with carcinoma in situ (CIS), where complete response is increased from 50% to more than 70",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.1640625,
            "text": "bladder cancer has been most apparent in patients with carcinoma in situ (CIS), where complete response is increased from 50% to more than 70% and the proportion of patients remaining disease free for 5 years is increased from 20% to",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.1953125,
            "text": "bladder cancer has been most apparent in patients with carcinoma in situ (CIS), where complete response is increased from 50% to more than 70% and the proportion of patients remaining disease free for 5 years is increased from 20% to 40%",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.2265625,
            "text": "bladder cancer has been most apparent in patients with carcinoma in situ (",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.2265625,
            "text": "bladder cancer has been most apparent in patients with carcinoma in situ (CIS)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.2265625,
            "text": "bladder cancer has been most apparent in patients with carcinoma in situ (CIS), where complete response is increased from 50% to",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.234375,
            "text": "bladder cancer has been most apparent in patients with carcinoma in situ (CIS), where complete response is increased from 50% to more than 70% and the proportion of patients remaining disease free for 5 years is increased from 20%",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.234375,
            "text": "bladder cancer has been most apparent in patients with carcinoma in situ (CIS), where complete response is increased from 50% to more than 70% and the proportion of patients remaining disease free",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.2421875,
            "text": "bladder cancer has been most apparent in patients with carcinoma in situ (CIS), where complete response is increased from 50% to more than 70%",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.2421875,
            "text": "bladder cancer has been most apparent in patients with carcinoma in situ (CIS), where complete response is increased from 50% to more",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.25,
            "text": "bladder cancer has been most apparent in patients with carcinoma in situ (CIS), where complete response is increased from 50%",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.265625,
            "text": "bladder cancer has been most apparent in patients with carcinoma in situ (CIS), where complete response is increased from 50% to more than 70% and the proportion of patients remaining disease",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.28125,
            "text": "bladder cancer has been most apparent in patients with carcinoma in situ (CIS), where complete response is increased from 50",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.28125,
            "text": "bladder cancer has been most apparent in patients with carcinoma in situ (CIS), where complete response is increased from 50% to more than 70% and the proportion of patients remaining disease free for",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_9": [
        {
            "start_logit": 9.984375,
            "end_logit": 9.6875,
            "text": "bladder cancer",
            "probability": 1.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -1.876953125,
            "text": "bladder",
            "probability": 9.5367431640625e-06
        },
        {
            "start_logit": -1.9638671875,
            "end_logit": 9.6875,
            "text": "cancer",
            "probability": 6.4373016357421875e-06
        },
        {
            "start_logit": -7.7578125,
            "end_logit": 9.6875,
            "text": "invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.265625,
            "text": "bladder cancer (NMIBC) and carcinoma in-situ",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.3125,
            "text": "bladder cancer (NMIBC) and carcinoma in",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.3359375,
            "text": "bladder cancer (NMIBC) and carcinoma in-situ (CIS) in terms of prevention of recurrence and progression. While most a",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.3359375,
            "text": "bladder cancer (NMIBC) and carcinoma in-",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.34375,
            "text": "bladder cancer (NMIBC) and carcinoma in-situ (CIS) in terms",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.34375,
            "text": "bladder cancer (NMIBC)",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.3515625,
            "text": "bladder cancer (NMIBC) and carcinoma in-situ (CIS",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.3671875,
            "text": "bladder cancer (NMIBC) and carcinoma in-situ (CIS) in terms of prevention of recurrence and",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.3828125,
            "text": "bladder cancer (NMIBC) and carcinoma in-situ (CIS) in terms of prevention of recurrence and progression. While most",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.390625,
            "text": "bladder cancer (NMIBC) and",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.3984375,
            "text": "bladder cancer (NMIBC) and carcinoma in-situ (CIS)",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.6875,
            "text": "for high-grade non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.6875,
            "text": "grade non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.6875,
            "text": "-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.6875,
            "text": "non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.6875,
            "text": "the standard of care for high-grade non-muscle invasive bladder cancer",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_10": [
        {
            "start_logit": 10.046875,
            "end_logit": 9.59375,
            "text": "bladder cancer",
            "probability": 1.0
        },
        {
            "start_logit": 10.046875,
            "end_logit": -1.7275390625,
            "text": "bladder",
            "probability": 1.2099742889404297e-05
        },
        {
            "start_logit": -2.158203125,
            "end_logit": 9.59375,
            "text": "cancer",
            "probability": 5.0067901611328125e-06
        },
        {
            "start_logit": -7.3359375,
            "end_logit": 9.59375,
            "text": ") bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 10.046875,
            "end_logit": -8.1015625,
            "text": "bladder cancer (BC",
            "probability": 0.0
        },
        {
            "start_logit": 10.046875,
            "end_logit": -8.34375,
            "text": "bladder cancer (",
            "probability": 0.0
        },
        {
            "start_logit": 10.046875,
            "end_logit": -8.359375,
            "text": "bladder cancer (BC)",
            "probability": 0.0
        },
        {
            "start_logit": 10.046875,
            "end_logit": -8.375,
            "text": "bladder cancer (BC), though its efficacy is limited by high recurrence and",
            "probability": 0.0
        },
        {
            "start_logit": 10.046875,
            "end_logit": -8.3828125,
            "text": "bladder cancer (BC), though its efficacy is limited",
            "probability": 0.0
        },
        {
            "start_logit": 10.046875,
            "end_logit": -8.3984375,
            "text": "bladder cancer (BC), though its efficacy is limited by high recurrence and progression",
            "probability": 0.0
        },
        {
            "start_logit": 10.046875,
            "end_logit": -8.4140625,
            "text": "bladder cancer (BC), though its efficacy is limited by high",
            "probability": 0.0
        },
        {
            "start_logit": -7.984375,
            "end_logit": 9.59375,
            "text": "(T1G3) bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.59375,
            "text": "stage T1 grade 3 (T1G3) bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": 9.59375,
            "text": "for stage T1 grade 3 (T1G3) bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.59375,
            "text": "G3) bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 9.59375,
            "text": "grade 3 (T1G3) bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.59375,
            "text": "Bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy is regarded as the current treatment of choice for stage T1 grade 3 (T1G3) bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.59375,
            "text": "regarded as the current treatment of choice for stage T1 grade 3 (T1G3) bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.59375,
            "text": "3) bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.59375,
            "text": "is regarded as the current treatment of choice for stage T1 grade 3 (T1G3) bladder cancer",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_11": [
        {
            "start_logit": 10.0234375,
            "end_logit": 9.734375,
            "text": "bladder cancer",
            "probability": 1.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -1.791015625,
            "text": "bladder",
            "probability": 9.953975677490234e-06
        },
        {
            "start_logit": -1.8515625,
            "end_logit": 9.734375,
            "text": "cancer",
            "probability": 7.033348083496094e-06
        },
        {
            "start_logit": -8.0,
            "end_logit": 9.734375,
            "text": "invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 9.734375,
            "text": "with non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.34375,
            "text": "bladder cancer (NM",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.34375,
            "text": "bladder cancer (NMIBC) is immunotherapy with intravesical Bacillus Calmette",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.34375,
            "text": "bladder cancer (NMIBC) is immunotherapy with intravesical Bacillus Calmette-Gu\u00e9rin (",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.3515625,
            "text": "bladder cancer (NMIBC) is immunotherapy with intravesical Bacillus Calmette-Gu\u00e9rin (BCG",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.3671875,
            "text": "bladder cancer (NMIBC) is immunotherapy with intravesical Bacillus Calmette-Gu",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.375,
            "text": "bladder cancer (NMIBC) is immunotherapy with intravesical Bacillus Calmette-Gu\u00e9rin (BCG)",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.375,
            "text": "bladder cancer (NMIBC) is immunotherapy with intravesical Bacillus Calmette-Gu\u00e9rin",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.390625,
            "text": "bladder cancer (NMIBC) is immunotherapy with intravesical Bacillus Calm",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.390625,
            "text": "bladder cancer (NMIBC) is immunotherapy with intravesical Bacillus Calmette-Gu\u00e9rin (BCG), which activates the immune system to recognize and destroy malignant cells and",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.3984375,
            "text": "bladder cancer (NMIB",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.3984375,
            "text": "bladder cancer (NMIBC",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 9.734375,
            "text": "-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.734375,
            "text": "patients with non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.734375,
            "text": "for most patients with non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.734375,
            "text": "non-muscle-invasive bladder cancer",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_12": [
        {
            "start_logit": 10.015625,
            "end_logit": 9.734375,
            "text": "bladder cancer",
            "probability": 1.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -1.8134765625,
            "text": "bladder",
            "probability": 9.655952453613281e-06
        },
        {
            "start_logit": -1.8623046875,
            "end_logit": 9.734375,
            "text": "cancer",
            "probability": 6.973743438720703e-06
        },
        {
            "start_logit": -7.90234375,
            "end_logit": 9.734375,
            "text": "superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.734375,
            "text": "treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 9.734375,
            "text": "40 years since Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.734375,
            "text": "since Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.734375,
            "text": "an immunotherapy to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.734375,
            "text": "Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.734375,
            "text": "to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": 9.734375,
            "text": "It is nearly 40 years since Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": 9.734375,
            "text": "years since Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 9.734375,
            "text": "(BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": 9.734375,
            "text": "nearly 40 years since Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.359375,
            "end_logit": 9.734375,
            "text": "first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.3671875,
            "end_logit": 9.734375,
            "text": "immunotherapy to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.3671875,
            "end_logit": 9.734375,
            "text": "used as an immunotherapy to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.90234375,
            "end_logit": -1.8134765625,
            "text": "superficial bladder",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -1.8134765625,
            "text": "treat superficial bladder",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -1.8134765625,
            "text": "40 years since Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_13": [
        {
            "start_logit": 10.015625,
            "end_logit": 9.7109375,
            "text": "bladder cancer",
            "probability": 1.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -1.8193359375,
            "text": "bladder",
            "probability": 9.894371032714844e-06
        },
        {
            "start_logit": -1.9013671875,
            "end_logit": 9.7109375,
            "text": "cancer",
            "probability": 6.735324859619141e-06
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 9.7109375,
            "text": "invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.3203125,
            "text": "bladder cancer (NM",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.3515625,
            "text": "bladder cancer (NMIBC), with proven effects on reducing recurrence, progression, and death from NMIBC",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.3515625,
            "text": "bladder cancer (",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.359375,
            "text": "bladder cancer (NMIBC), with proven effects on reducing recurrence, progression, and death from NM",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.375,
            "text": "bladder cancer (NMIBC)",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.3828125,
            "text": "bladder cancer (NMIBC), with proven effects on reducing recurrence, progression, and death from NMIBC. However",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.390625,
            "text": "bladder cancer (NMIB",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.390625,
            "text": "bladder cancer (NMIBC",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.7109375,
            "text": "-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.7109375,
            "text": "Intravesical immunotherapy with bacille Calmette-Gu\u00e9rin (BCG) vaccine is the main treatment for non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.7109375,
            "text": "for non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.7109375,
            "text": "-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.7109375,
            "text": "non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.7109375,
            "text": "with bacille Calmette-Gu\u00e9rin (BCG) vaccine is the main treatment for non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.7109375,
            "text": "muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.9921875,
            "end_logit": -1.8193359375,
            "text": "invasive bladder",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_14": [
        {
            "start_logit": 10.0234375,
            "end_logit": 9.671875,
            "text": "bladder cancer",
            "probability": 1.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -1.7919921875,
            "text": "bladder",
            "probability": 1.0609626770019531e-05
        },
        {
            "start_logit": -1.9951171875,
            "end_logit": 9.671875,
            "text": "cancer",
            "probability": 6.020069122314453e-06
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.15625,
            "text": "bladder cancer, its long-term efficacy is still arguable as a proportion of up to 30-40%",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.1640625,
            "text": "bladder cancer, its long-term efficacy is still arguable as a proportion of up to 30-40",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.2109375,
            "text": "bladder cancer, its long-term efficacy is still arguable as a proportion of up to 30-40% of patients will develop recurrence or progression of their disease",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.234375,
            "text": "bladder cancer, its long-term efficacy is still arguable as a proportion of up to 30-",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.2578125,
            "text": "bladder cancer, its long-term",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.2734375,
            "text": "bladder cancer, its long-term efficacy is still arguable as a proportion of up to 30",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.2890625,
            "text": "bladder cancer, its long-term efficacy is still arguable as a proportion of up to",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.3359375,
            "text": "bladder cancer, its long-term efficacy is",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.3359375,
            "text": "bladder cancer, its long-term efficacy is still arg",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.34375,
            "text": "bladder cancer, its long-term efficacy is still arguable as a proportion of up to 30-40% of patients will develop recurrence or",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.671875,
            "text": "invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.671875,
            "text": "risk non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 9.671875,
            "text": "for intermediate to high-risk non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.671875,
            "text": "intravesical instillation of Bacille-Calmette-Guerin (BCG) immunotherapy was approved many decades ago as a first line therapy for intermediate to high-risk non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.671875,
            "text": "-risk non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.671875,
            "text": "a first line therapy for intermediate to high-risk non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": -1.7919921875,
            "text": "invasive bladder",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_15": [
        {
            "start_logit": 10.0234375,
            "end_logit": 9.625,
            "text": "bladder cancer",
            "probability": 1.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -1.7890625,
            "text": "bladder",
            "probability": 1.0967254638671875e-05
        },
        {
            "start_logit": -2.072265625,
            "end_logit": 9.625,
            "text": "cancer",
            "probability": 5.543231964111328e-06
        },
        {
            "start_logit": -7.34375,
            "end_logit": 9.625,
            "text": "invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.9296875,
            "end_logit": 9.625,
            "text": "risk non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.3515625,
            "text": "bladder cancer and urothelial CIS and platin-based systemic chemotherapy to improve postcystectomy disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.0,
            "end_logit": 9.625,
            "text": "treat high-risk non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.40625,
            "text": "bladder cancer and urothelial",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.40625,
            "text": "bladder cancer and urothelial CIS and platin",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.4140625,
            "text": "bladder cancer and urothelial CIS and platin-based systemic chemotherapy to improve postcyst",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.4140625,
            "text": "bladder cancer and urothelial CIS",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.421875,
            "text": "bladder cancer and urothelial CIS and plat",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.421875,
            "text": "bladder cancer and urothelial CIS and platin-based systemic chemotherapy to improve postcystectomy disease-specific survival are examples of therapy-related atypia seen in the urinary tract",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.4375,
            "text": "bladder cancer and urothelial CIS and platin-based systemic chemotherapy to improve postcystectomy disease-specific survival are examples of therapy",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.625,
            "text": "-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 9.625,
            "text": "-risk non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.625,
            "text": "after transurethral resection of bladder tumour to reduce recurrences, bacillus Calmette-Gu\u00e9rin (BCG) intravesical immunotherapy to treat high-risk non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.625,
            "text": ", bacillus Calmette-Gu\u00e9rin (BCG) intravesical immunotherapy to treat high-risk non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.625,
            "text": "of bladder tumour to reduce recurrences, bacillus Calmette-Gu\u00e9rin (BCG) intravesical immunotherapy to treat high-risk non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.625,
            "text": "to treat high-risk non-muscle-invasive bladder cancer",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_16": [
        {
            "start_logit": 10.03125,
            "end_logit": 9.7421875,
            "text": "bladder cancer",
            "probability": 1.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -1.751953125,
            "text": "bladder",
            "probability": 1.0132789611816406e-05
        },
        {
            "start_logit": -1.8369140625,
            "end_logit": 9.7421875,
            "text": "cancer",
            "probability": 6.973743438720703e-06
        },
        {
            "start_logit": -7.2109375,
            "end_logit": 9.7421875,
            "text": "invasive bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.1875,
            "text": "bladder cancer and urothelial carcinoma in situ",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.2421875,
            "text": "bladder cancer and urothelial carcinoma in",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.296875,
            "text": "bladder cancer and urothelial carcinoma",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.296875,
            "text": "bladder cancer and urothelial carcinoma in situ, and platinum-based systemic chemotherapy to improve post-cystectomy disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.7421875,
            "text": "risk non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": 9.7421875,
            "text": "treat high risk non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.34375,
            "text": "bladder cancer and urothelial",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.3671875,
            "text": "bladder cancer and urothelial carcinoma in situ, and platinum-based systemic chemotherapy to",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.3828125,
            "text": "bladder cancer and urothelial carcinoma in situ, and platinum-based systemic chemotherapy to improve post-cystectomy disease-specific survival some",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.3828125,
            "text": "bladder cancer and urothelial carcinoma in situ, and platinum-based systemic chemotherapy to improve post-cystectomy disease-specific survival some of the causes of therapy",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 9.7421875,
            "text": "-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.7421875,
            "text": "high risk non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.7421875,
            "text": "of bladder tumor to reduce recurrences, BCG intravesical immunotherapy to treat high risk non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 9.7421875,
            "text": "bladder tumor to reduce recurrences, BCG intravesical immunotherapy to treat high risk non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.7421875,
            "text": "to treat high risk non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.7421875,
            "text": "non-muscle invasive bladder cancer",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_17": [
        {
            "start_logit": 9.96875,
            "end_logit": 9.7109375,
            "text": "bladder cancer",
            "probability": 1.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -1.9423828125,
            "text": "bladder",
            "probability": 8.58306884765625e-06
        },
        {
            "start_logit": -1.9013671875,
            "end_logit": 9.7109375,
            "text": "cancer",
            "probability": 6.973743438720703e-06
        },
        {
            "start_logit": 9.96875,
            "end_logit": -7.83203125,
            "text": "bladder cancer and summarizes the mechanisms of action of BCG, and the important role of intravesical BCG immunotherapy and other immunotherapeutic agents in the therapy and prophylaxis of superficial TCC of the urinary bladder",
            "probability": 0.0
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 9.7109375,
            "text": "review highlights recent developments in intravesical therapy of bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.2578125,
            "text": "bladder cancer and summarizes the mechanisms of action of BCG, and the important role of intravesical BCG immunotherapy and other immunotherapeutic agents in the therapy and prophylaxis of superficial TCC of the",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.296875,
            "text": "bladder cancer and summarizes the mechanisms of",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.328125,
            "text": "bladder cancer and summarizes the mechanisms of action of BCG, and the important role of intravesical BCG immunotherapy and other immunotherapeutic agents in the therapy and prophylaxis of superficial TCC of the urinary",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.3828125,
            "text": "bladder cancer and summarizes the mechanisms of action of BCG, and the important role of intravesical BCG immunotherapy and other immunotherapeutic agents in the therapy and prophylaxis of superficial TCC of",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.3828125,
            "text": "bladder cancer and summarizes the mechanisms of action of BCG, and the important role of intravesical BCG immunotherapy and other immunotherapeutic agents in the therapy and prophylaxis of superficial TCC",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.390625,
            "text": "bladder cancer and summarizes the mechanisms of action",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.7109375,
            "text": "highlights recent developments in intravesical therapy of bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.7109375,
            "text": "This comprehensive review highlights recent developments in intravesical therapy of bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.7109375,
            "text": "comprehensive review highlights recent developments in intravesical therapy of bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.7109375,
            "text": "of bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.7109375,
            "text": "in intravesical therapy of bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -1.9013671875,
            "end_logit": -7.83203125,
            "text": "cancer and summarizes the mechanisms of action of BCG, and the important role of intravesical BCG immunotherapy and other immunotherapeutic agents in the therapy and prophylaxis of superficial TCC of the urinary bladder",
            "probability": 0.0
        },
        {
            "start_logit": -7.99609375,
            "end_logit": -1.9423828125,
            "text": "review highlights recent developments in intravesical therapy of bladder",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -1.9423828125,
            "text": "highlights recent developments in intravesical therapy of bladder",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -1.9423828125,
            "text": "This comprehensive review highlights recent developments in intravesical therapy of bladder",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_18": [
        {
            "start_logit": 10.015625,
            "end_logit": 9.6875,
            "text": "bladder cancer",
            "probability": 1.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -1.802734375,
            "text": "bladder",
            "probability": 1.0192394256591797e-05
        },
        {
            "start_logit": -1.9677734375,
            "end_logit": 9.6875,
            "text": "cancer",
            "probability": 6.258487701416016e-06
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.6875,
            "text": "review summarises the history and development of BCG as a modern cancer treatment, appraises current optimal application of BCG immunotherapy in bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.3671875,
            "text": "bladder cancer, discusses promising new therapies closely related to BCG, and briefly explores the possibility that BCG or related treatments may have an application in other urological malignancies",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.6875,
            "text": "appraises current optimal application of BCG immunotherapy in bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 9.6875,
            "text": "summarises the history and development of BCG as a modern cancer treatment, appraises current optimal application of BCG immunotherapy in bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.6875,
            "text": "in bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.6875,
            "text": "This review summarises the history and development of BCG as a modern cancer treatment, appraises current optimal application of BCG immunotherapy in bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.6875,
            "text": "application of BCG immunotherapy in bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.6875,
            "text": "ises the history and development of BCG as a modern cancer treatment, appraises current optimal application of BCG immunotherapy in bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": -1.802734375,
            "text": "review summarises the history and development of BCG as a modern cancer treatment, appraises current optimal application of BCG immunotherapy in bladder",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": -1.802734375,
            "text": "appraises current optimal application of BCG immunotherapy in bladder",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -1.802734375,
            "text": "summarises the history and development of BCG as a modern cancer treatment, appraises current optimal application of BCG immunotherapy in bladder",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": -1.802734375,
            "text": "in bladder",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": -1.802734375,
            "text": "This review summarises the history and development of BCG as a modern cancer treatment, appraises current optimal application of BCG immunotherapy in bladder",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -1.802734375,
            "text": "application of BCG immunotherapy in bladder",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -1.802734375,
            "text": "ises the history and development of BCG as a modern cancer treatment, appraises current optimal application of BCG immunotherapy in bladder",
            "probability": 0.0
        },
        {
            "start_logit": -1.9677734375,
            "end_logit": -8.3671875,
            "text": "cancer, discusses promising new therapies closely related to BCG, and briefly explores the possibility that BCG or related treatments may have an application in other urological malignancies",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": -8.3515625,
            "text": "review summarises the history and development of BCG as a modern cancer",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_19": [
        {
            "start_logit": 10.015625,
            "end_logit": 9.7109375,
            "text": "bladder cancer",
            "probability": 1.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -1.8232421875,
            "text": "bladder",
            "probability": 9.894371032714844e-06
        },
        {
            "start_logit": -1.8994140625,
            "end_logit": 9.7109375,
            "text": "cancer",
            "probability": 6.735324859619141e-06
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 9.7109375,
            "text": "superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.7109375,
            "text": "of superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.7109375,
            "text": "and prevent the recurrence of superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.7109375,
            "text": "the recurrence of superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.7109375,
            "text": "treat and prevent the recurrence of superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 9.7109375,
            "text": "prevent the recurrence of superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.7109375,
            "text": "to treat and prevent the recurrence of superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.7109375,
            "text": "Immunotherapy by intravesicular delivery of Bacillus Calmette-Gu\u00e9rin (BCG) is used to treat and prevent the recurrence of superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.7109375,
            "text": "used to treat and prevent the recurrence of superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.7109375,
            "text": "recurrence of superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.7109375,
            "text": "of Bacillus Calmette-Gu\u00e9rin (BCG) is used to treat and prevent the recurrence of superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.7109375,
            "text": "Bacillus Calmette-Gu\u00e9rin (BCG) is used to treat and prevent the recurrence of superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 9.7109375,
            "text": "by intravesicular delivery of Bacillus Calmette-Gu\u00e9rin (BCG) is used to treat and prevent the recurrence of superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 9.7109375,
            "text": "is used to treat and prevent the recurrence of superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.98046875,
            "end_logit": -1.8232421875,
            "text": "superficial bladder",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": -1.8232421875,
            "text": "of superficial bladder",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": -1.8232421875,
            "text": "and prevent the recurrence of superficial bladder",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_20": [
        {
            "start_logit": 10.0078125,
            "end_logit": 9.7734375,
            "text": "bladder cancer",
            "probability": 1.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -1.828125,
            "text": "bladder",
            "probability": 9.179115295410156e-06
        },
        {
            "start_logit": -1.7666015625,
            "end_logit": 9.7734375,
            "text": "cancer",
            "probability": 7.68899917602539e-06
        },
        {
            "start_logit": -7.953125,
            "end_logit": 9.7734375,
            "text": "invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.234375,
            "text": "bladder cancer and one of the most successful applications of immunotherapy to the treatment of cancer",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.2421875,
            "text": "bladder cancer and one",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.3203125,
            "text": "bladder cancer and one of the most successful applications of immunotherapy to the treatment of",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.7734375,
            "text": "-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 9.7734375,
            "text": "of non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.7734375,
            "text": "Bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy is currently the most effective treatment of non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.7734375,
            "text": "non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.7734375,
            "text": "muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.7734375,
            "text": "effective treatment of non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.7734375,
            "text": "treatment of non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.7734375,
            "text": "Calmette-Gu\u00e9rin (BCG) immunotherapy is currently the most effective treatment of non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.953125,
            "end_logit": -1.828125,
            "text": "invasive bladder",
            "probability": 0.0
        },
        {
            "start_logit": -1.7666015625,
            "end_logit": -8.234375,
            "text": "cancer and one of the most successful applications of immunotherapy to the treatment of cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -1.828125,
            "text": "-muscle invasive bladder",
            "probability": 0.0
        },
        {
            "start_logit": -1.7666015625,
            "end_logit": -8.2421875,
            "text": "cancer and one",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -1.828125,
            "text": "of non-muscle invasive bladder",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_21": [
        {
            "start_logit": 10.0,
            "end_logit": 9.6875,
            "text": "bladder cancer",
            "probability": 1.0
        },
        {
            "start_logit": 10.0,
            "end_logit": -1.8544921875,
            "text": "bladder",
            "probability": 9.715557098388672e-06
        },
        {
            "start_logit": -1.9677734375,
            "end_logit": 9.6875,
            "text": "cancer",
            "probability": 6.318092346191406e-06
        },
        {
            "start_logit": -7.5546875,
            "end_logit": 9.6875,
            "text": "invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 10.0,
            "end_logit": -8.28125,
            "text": "bladder cancer (NMIBC) and carcinoma in-situ",
            "probability": 0.0
        },
        {
            "start_logit": 10.0,
            "end_logit": -8.3203125,
            "text": "bladder cancer (NMIBC) and carcinoma in",
            "probability": 0.0
        },
        {
            "start_logit": 10.0,
            "end_logit": -8.3359375,
            "text": "bladder cancer (NMIBC)",
            "probability": 0.0
        },
        {
            "start_logit": 10.0,
            "end_logit": -8.3515625,
            "text": "bladder cancer (NMIBC) and carcinoma in-situ (CIS",
            "probability": 0.0
        },
        {
            "start_logit": 10.0,
            "end_logit": -8.359375,
            "text": "bladder cancer (NMIBC) and carcinoma in-",
            "probability": 0.0
        },
        {
            "start_logit": 10.0,
            "end_logit": -8.375,
            "text": "bladder cancer (NM",
            "probability": 0.0
        },
        {
            "start_logit": 10.0,
            "end_logit": -8.3828125,
            "text": "bladder cancer (NMIBC) and carcinoma in-situ (CIS) in terms",
            "probability": 0.0
        },
        {
            "start_logit": 10.0,
            "end_logit": -8.3828125,
            "text": "bladder cancer (NMIBC) and carcinoma in-situ (CIS) in terms of prevention of recurrence and",
            "probability": 0.0
        },
        {
            "start_logit": 10.0,
            "end_logit": -8.390625,
            "text": "bladder cancer (NMIBC) and",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.6875,
            "text": "grade non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.6875,
            "text": "for high-grade non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.6875,
            "text": "-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.6875,
            "text": "administration of Bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy has become the standard of care for high-grade non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.6875,
            "text": "-grade non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.6875,
            "text": "The administration of Bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy has become the standard of care for high-grade non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.6875,
            "text": "non-muscle invasive bladder cancer",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_22": [
        {
            "start_logit": 10.0390625,
            "end_logit": 9.7890625,
            "text": "bladder cancer",
            "probability": 1.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -1.7548828125,
            "text": "bladder",
            "probability": 9.655952453613281e-06
        },
        {
            "start_logit": -1.7216796875,
            "end_logit": 9.7890625,
            "text": "cancer",
            "probability": 7.808208465576172e-06
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.7890625,
            "text": "invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.328125,
            "text": "bladder cancer is persistent or recurs shortly after a full course of bacille Calmette-Gu\u00e9rin (BCG) plus maintenance, further BCG is not likely to work; this meets the new definition of a \"BCG unresponsive",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.3359375,
            "text": "bladder cancer is persistent or recurs shortly after a full course of bacille Calmette-Gu\u00e9rin (BCG",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.3515625,
            "text": "bladder cancer is persistent or recurs shortly after a full course of bacille Calmette",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.359375,
            "text": "bladder cancer is persistent or recurs shortly after a full course of bacille Calmette-Gu",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.7890625,
            "text": "grade non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.375,
            "text": "bladder cancer is persistent or recurs shortly after a full course of bacille Calmette-Gu\u00e9rin (BCG) plus maintenance, further BCG is not likely to work; this meets the new definition of a \"BCG unresponsive\" disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 9.7890625,
            "text": "When T1 high-grade non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.3828125,
            "text": "bladder cancer is persistent or recurs shortly after a full course of bacille Calmette-Gu\u00e9rin",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.390625,
            "text": "bladder cancer is persistent or recurs shortly after a full course of bacille Calmette-Gu\u00e9rin (BCG) plus maintenance, further BCG is not likely to work; this meets the new definition of a \"BCG",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.390625,
            "text": "bladder cancer is persistent or recurs shortly after a full course of bacille Calm",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.3984375,
            "text": "bladder cancer is persistent or recurs shortly after a full course of bacille Calmette-Gu\u00e9rin (BCG)",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.7890625,
            "text": "-grade non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.4140625,
            "text": "bladder cancer is persistent or recurs shortly after a full course of bacille Calmette-Gu\u00e9rin (BCG) plus maintenance, further BCG",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.7890625,
            "text": "-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.421875,
            "text": "bladder cancer is persistent or recurs shortly after a full course of bacille Calmette-Gu\u00e9rin (BCG) plus",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.421875,
            "text": "bladder cancer is persistent or recurs shortly after a full course of bacille Calmette-Gu\u00e9rin (BCG) plus maintenance, further BCG is not likely to work",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_23": [
        {
            "start_logit": 10.03125,
            "end_logit": 9.71875,
            "text": "bladder cancer",
            "probability": 1.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -1.767578125,
            "text": "bladder",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": -1.8828125,
            "end_logit": 9.71875,
            "text": "cancer",
            "probability": 6.67572021484375e-06
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.3359375,
            "text": "bladder cancer treated",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.71875,
            "text": "invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.71875,
            "text": "patients with primary high-grade non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.71875,
            "text": "with primary high-grade non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.71875,
            "text": "-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.71875,
            "text": "grade non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.71875,
            "text": "treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.71875,
            "text": "in patients with primary high-grade non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.71875,
            "text": "Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.71875,
            "text": "primary high-grade non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.71875,
            "text": "of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.71875,
            "text": "-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.71875,
            "text": "-grade non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.71875,
            "text": "muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": -1.767578125,
            "text": "invasive bladder",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -1.767578125,
            "text": "patients with primary high-grade non-muscle-invasive bladder",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -1.767578125,
            "text": "with primary high-grade non-muscle-invasive bladder",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_24": [
        {
            "start_logit": 10.0,
            "end_logit": 9.6796875,
            "text": "bladder cancer",
            "probability": 1.0
        },
        {
            "start_logit": 10.0,
            "end_logit": -1.859375,
            "text": "bladder",
            "probability": 9.655952453613281e-06
        },
        {
            "start_logit": -1.974609375,
            "end_logit": 9.6796875,
            "text": "cancer",
            "probability": 6.258487701416016e-06
        },
        {
            "start_logit": 10.0,
            "end_logit": -8.3046875,
            "text": "bladder cancer and",
            "probability": 0.0
        },
        {
            "start_logit": 10.0,
            "end_logit": -8.328125,
            "text": "bladder cancer and it still remains at the forefront of immunotherapy for cancer",
            "probability": 0.0
        },
        {
            "start_logit": 10.0,
            "end_logit": -8.3515625,
            "text": "bladder cancer and it still remains at the foref",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": 9.6796875,
            "text": "treating bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.6796875,
            "text": "intravesical instillation of Mycobacterium bovis bacille Calmette-Gu\u00e9rin (BCG) has been used for treating bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.6796875,
            "text": "In the past three decades, intravesical instillation of Mycobacterium bovis bacille Calmette-Gu\u00e9rin (BCG) has been used for treating bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.6796875,
            "text": "instillation of Mycobacterium bovis bacille Calmette-Gu\u00e9rin (BCG) has been used for treating bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.6796875,
            "text": "for treating bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.6796875,
            "text": ", intravesical instillation of Mycobacterium bovis bacille Calmette-Gu\u00e9rin (BCG) has been used for treating bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.6796875,
            "text": "used for treating bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.6796875,
            "text": "past three decades, intravesical instillation of Mycobacterium bovis bacille Calmette-Gu\u00e9rin (BCG) has been used for treating bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.6796875,
            "text": "been used for treating bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.6796875,
            "text": "(BCG) has been used for treating bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": -1.859375,
            "text": "treating bladder",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -1.859375,
            "text": "intravesical instillation of Mycobacterium bovis bacille Calmette-Gu\u00e9rin (BCG) has been used for treating bladder",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -1.859375,
            "text": "In the past three decades, intravesical instillation of Mycobacterium bovis bacille Calmette-Gu\u00e9rin (BCG) has been used for treating bladder",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -1.859375,
            "text": "instillation of Mycobacterium bovis bacille Calmette-Gu\u00e9rin (BCG) has been used for treating bladder",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_25": [
        {
            "start_logit": 9.9921875,
            "end_logit": 9.6875,
            "text": "bladder cancer",
            "probability": 1.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -1.8505859375,
            "text": "bladder",
            "probability": 9.655952453613281e-06
        },
        {
            "start_logit": -1.955078125,
            "end_logit": 9.6875,
            "text": "cancer",
            "probability": 6.4373016357421875e-06
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.2265625,
            "text": "bladder cancer, BCG is ineffective in approximately 30-40 % of cases and disease recurs in up to",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.2734375,
            "text": "bladder cancer, BCG is ineffective in approximately 30-40",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.28125,
            "text": "bladder cancer, BCG is ineffective in approximately 30-40 % of cases and disease recurs in up to 50 %",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.2890625,
            "text": "bladder cancer, BCG is ineffective in approximately 30-40 %",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.3125,
            "text": "bladder cancer, BCG is ineffective in approximately 30-",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.3203125,
            "text": "bladder cancer, BCG is ineffective in approximately 30-40 % of cases and disease recurs in up to 50",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.328125,
            "text": "bladder cancer, BCG is ineffective in approximately 30-40 % of cases and disease",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.328125,
            "text": "bladder cancer, BCG is ineffective in approximately 30-40 % of cases and disease recurs in up",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.3359375,
            "text": "bladder cancer, BCG is",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.34375,
            "text": "bladder cancer, BCG is ineffective in approximately 30-40 % of cases and disease recurs",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.6875,
            "text": "invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.6875,
            "text": "progression into muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.6875,
            "text": "effective intravesical therapy for this kind of tumor and represents the only agent known to reduce progression into muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.6875,
            "text": "intravesical therapy for this kind of tumor and represents the only agent known to reduce progression into muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.6875,
            "text": "Although BCG-based therapy is the most effective intravesical therapy for this kind of tumor and represents the only agent known to reduce progression into muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.6875,
            "text": "most effective intravesical therapy for this kind of tumor and represents the only agent known to reduce progression into muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": -1.8505859375,
            "text": "invasive bladder",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_26": [
        {
            "start_logit": 9.9296875,
            "end_logit": 9.640625,
            "text": "bladder cancer",
            "probability": 1.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -2.033203125,
            "text": "bladder",
            "probability": 8.58306884765625e-06
        },
        {
            "start_logit": -2.06640625,
            "end_logit": 9.640625,
            "text": "cancer",
            "probability": 6.258487701416016e-06
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.1796875,
            "text": "bladder cancer immunotherapy",
            "probability": 0.0
        },
        {
            "start_logit": -7.921875,
            "end_logit": 9.640625,
            "text": "for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.640625,
            "text": "for less toxic and more potent therapeutic agents for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.640625,
            "text": "less toxic and more potent therapeutic agents for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.640625,
            "text": "search for less toxic and more potent therapeutic agents for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.640625,
            "text": "of these mycobacteria has been appealing in the search for less toxic and more potent therapeutic agents for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.640625,
            "text": "the search for less toxic and more potent therapeutic agents for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.640625,
            "text": ", the genetic manipulation of these mycobacteria has been appealing in the search for less toxic and more potent therapeutic agents for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": 9.640625,
            "text": "potent therapeutic agents for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": 9.640625,
            "text": "the genetic manipulation of these mycobacteria has been appealing in the search for less toxic and more potent therapeutic agents for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.640625,
            "text": "that BCG is considered an effective vehicle for delivery of antigens due to its unique characteristics, the genetic manipulation of these mycobacteria has been appealing in the search for less toxic and more potent therapeutic agents for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 9.640625,
            "text": "of antigens due to its unique characteristics, the genetic manipulation of these mycobacteria has been appealing in the search for less toxic and more potent therapeutic agents for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 9.640625,
            "text": "agents for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 9.640625,
            "text": "therapeutic agents for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 9.640625,
            "text": "toxic and more potent therapeutic agents for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.921875,
            "end_logit": -2.033203125,
            "text": "for bladder",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -2.033203125,
            "text": "for less toxic and more potent therapeutic agents for bladder",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_27": [
        {
            "start_logit": 10.0,
            "end_logit": 9.734375,
            "text": "bladder cancer",
            "probability": 1.0
        },
        {
            "start_logit": 10.0,
            "end_logit": -1.8525390625,
            "text": "bladder",
            "probability": 9.298324584960938e-06
        },
        {
            "start_logit": -1.8603515625,
            "end_logit": 9.734375,
            "text": "cancer",
            "probability": 7.092952728271484e-06
        },
        {
            "start_logit": 10.0,
            "end_logit": -8.3359375,
            "text": "bladder cancer: inhibition of tumor recurrence and",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.734375,
            "text": "of bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.734375,
            "text": "BCG immunotherapy of bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": 9.734375,
            "text": "immunotherapy of bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -1.8525390625,
            "text": "of bladder",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -1.8525390625,
            "text": "BCG immunotherapy of bladder",
            "probability": 0.0
        },
        {
            "start_logit": -1.8603515625,
            "end_logit": -8.3359375,
            "text": "cancer: inhibition of tumor recurrence and",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": -1.8525390625,
            "text": "immunotherapy of bladder",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -8.3359375,
            "text": "tumor recurrence and",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -8.3359375,
            "text": "of bladder cancer: inhibition of tumor recurrence and",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.3359375,
            "text": "of tumor recurrence and",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -8.3359375,
            "text": "BCG immunotherapy of bladder cancer: inhibition of tumor recurrence and",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": -8.3359375,
            "text": "inhibition of tumor recurrence and",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": -8.3359375,
            "text": "recurrence and",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": -8.3359375,
            "text": ": inhibition of tumor recurrence and",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": -8.3359375,
            "text": "immunotherapy of bladder cancer: inhibition of tumor recurrence and",
            "probability": 0.0
        }
    ],
    "5e776db8835f4e4777000011_1": [
        {
            "start_logit": 9.9609375,
            "end_logit": 9.5234375,
            "text": "Sanofi",
            "probability": 1.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -1.9638671875,
            "text": "San",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": -2.263671875,
            "end_logit": 9.5234375,
            "text": "i",
            "probability": 4.887580871582031e-06
        },
        {
            "start_logit": -5.984375,
            "end_logit": 9.5234375,
            "text": "by Sanofi",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.078125,
            "end_logit": 9.5234375,
            "text": "ofi",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.6171875,
            "end_logit": 9.5234375,
            "text": ". Afrezza has been marketed since February, 2015 by Sanofi",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -7.87890625,
            "text": "Sanofi after getting FDA",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -7.98828125,
            "text": "Sanofi after",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.1640625,
            "text": "Sanofi after getting FDA approval in",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.1640625,
            "text": "Sanofi after getting FDA approval in June 2014",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.234375,
            "text": "Sanofi after getting FDA approval",
            "probability": 0.0
        },
        {
            "start_logit": -7.9375,
            "end_logit": 9.5234375,
            "text": ", 2015 by Sanofi",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.5234375,
            "text": "d Corporation started developing its ultra-rapid-acting insulin Afrezza in a bold bid, probably by managing the issues in which Exubera was not successful. Afrezza has been marketed since February, 2015 by Sanofi",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.5234375,
            "text": "2015 by Sanofi",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.5234375,
            "text": "been marketed since February, 2015 by Sanofi",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 9.5234375,
            "text": "Afrezza has been marketed since February, 2015 by Sanofi",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.5234375,
            "text": ", probably by managing the issues in which Exubera was not successful. Afrezza has been marketed since February, 2015 by Sanofi",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.5234375,
            "text": "marketed since February, 2015 by Sanofi",
            "probability": 0.0
        },
        {
            "start_logit": -5.984375,
            "end_logit": -1.9638671875,
            "text": "by San",
            "probability": 0.0
        },
        {
            "start_logit": -6.6171875,
            "end_logit": -1.9638671875,
            "text": ". Afrezza has been marketed since February, 2015 by San",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_1": [
        {
            "start_logit": 9.9453125,
            "end_logit": 9.640625,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -1.9716796875,
            "text": "Nox",
            "probability": 8.940696716308594e-06
        },
        {
            "start_logit": -2.048828125,
            "end_logit": 9.640625,
            "text": "1",
            "probability": 6.139278411865234e-06
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -7.984375,
            "text": "Nox1 oxidase",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.0859375,
            "text": "Nox1 oxidase, functions as either a canonical or hybrid system using Nox organizing subunit",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.125,
            "text": "Nox1 oxidase, functions as either a canonical or hybrid system using Nox organizing subunit 1 (NoxO1)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.125,
            "text": "Nox1 oxidase, functions as either a canonical or hybrid system using Nox organizing subunit 1 (NoxO1) or p47(phox",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.1484375,
            "text": "Nox1 oxidase, functions as either a canonical or hybrid system using Nox organizing subunit 1",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.1640625,
            "text": "Nox1 oxidase, functions as either a canonical or hybrid system using Nox organizing subunit 1 (NoxO1",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.171875,
            "text": "Nox1 oxidase, functions as either a canonical or hybrid system using Nox organizing subunit 1 (NoxO1) or p47",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.1953125,
            "text": "Nox1 oxidase, functions as either a canonical or hybrid system using Nox",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.203125,
            "text": "Nox1 oxidase, functions as",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.21875,
            "text": "Nox1 oxidase, functions as either a canonical or hybrid system using Nox organizing",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.234375,
            "text": "Nox1 oxidase, functions as either a canonical or hybrid system using Nox organizing subunit 1 (NoxO1) or p47(phox)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.234375,
            "text": "Nox1 oxidase, functions as either a canonical or hybrid system using Nox organizing subunit 1 (NoxO1) or p4",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.2421875,
            "text": "Nox1 oxidase, functions as either a canonical or hybrid system using Nox organizing subunit 1 (Nox",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.2421875,
            "text": "Nox1 oxidase, functions as either a canonical",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.640625,
            "text": ", Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.640625,
            "text": "unique member of this family, Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 9.640625,
            "text": "member of this family, Nox1",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_2": [
        {
            "start_logit": 9.984375,
            "end_logit": 9.59375,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -1.8876953125,
            "text": "Nox",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": -2.166015625,
            "end_logit": 9.59375,
            "text": "1",
            "probability": 5.304813385009766e-06
        },
        {
            "start_logit": -7.78125,
            "end_logit": 9.59375,
            "text": "of Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.59375,
            "text": "the superoxide-producing activity of Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.59375,
            "text": "its interaction with Noxa1 and the superoxide-producing activity of Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": 9.59375,
            "text": "superoxide-producing activity of Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.359375,
            "end_logit": 9.59375,
            "text": "and the superoxide-producing activity of Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.375,
            "end_logit": 9.59375,
            "text": "interaction with Noxa1 and the superoxide-producing activity of Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.375,
            "end_logit": 9.59375,
            "text": "activity of Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -7.78125,
            "end_logit": -1.8876953125,
            "text": "of Nox",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": -1.8876953125,
            "text": "the superoxide-producing activity of Nox",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": -1.8876953125,
            "text": "its interaction with Noxa1 and the superoxide-producing activity of Nox",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": -1.8876953125,
            "text": "superoxide-producing activity of Nox",
            "probability": 0.0
        },
        {
            "start_logit": -8.359375,
            "end_logit": -1.8876953125,
            "text": "and the superoxide-producing activity of Nox",
            "probability": 0.0
        },
        {
            "start_logit": -8.375,
            "end_logit": -1.8876953125,
            "text": "interaction with Noxa1 and the superoxide-producing activity of Nox",
            "probability": 0.0
        },
        {
            "start_logit": -8.375,
            "end_logit": -1.8876953125,
            "text": "activity of Nox",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": -7.98046875,
            "text": "the superoxide",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": -8.015625,
            "text": "the superoxide-producing",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": -7.98046875,
            "text": "its interaction with Noxa1 and the superoxide",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_3": [
        {
            "start_logit": 9.9375,
            "end_logit": 9.6328125,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -2.005859375,
            "text": "Nox",
            "probability": 8.881092071533203e-06
        },
        {
            "start_logit": -2.056640625,
            "end_logit": 9.6328125,
            "text": "1",
            "probability": 6.258487701416016e-06
        },
        {
            "start_logit": 9.9375,
            "end_logit": -7.734375,
            "text": "Nox1, a member of the Nox family",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.078125,
            "text": "Nox1, a member of the Nox family NAP",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.109375,
            "text": "Nox1, a member of the Nox",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.1328125,
            "text": "Nox1, a member of the Nox family NAPDH oxidase",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.15625,
            "text": "Nox1, a member of the Nox family NAPDH oxidases",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.171875,
            "text": "Nox1, a",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.1796875,
            "text": "Nox1, a member",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.2578125,
            "text": "Nox1, a member of the Nox family NAPDH oxidases, requires expression of its regulatory soluble proteins Noxo1 (Nox organizer 1) and Noxa1 (Nox activator 1",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.2578125,
            "text": "Nox1, a member of the Nox family NAPDH oxidases, requires expression of its regulatory soluble proteins Noxo1 (Nox organizer 1) and Noxa1 (Nox activator 1) and is markedly enhanced upon cell stimulation with phorbol 12-myristate 13",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.2734375,
            "text": "Nox1, a member of the Nox family NAPDH oxidases, requires expression of its regulatory soluble proteins Noxo1 (Nox organizer 1) and Noxa1 (Nox",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.28125,
            "text": "Nox1, a member of the Nox family NAPDH oxidases, requires expression of its regulatory soluble proteins Noxo1 (Nox organizer 1)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.28125,
            "text": "Nox1, a member of the Nox family NAPDH",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.2890625,
            "text": "Nox1, a member of the Nox family NAPDH oxidases, requires expression of its regulatory soluble proteins Noxo1 (Nox organizer 1) and Noxa1 (Nox activator",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.2890625,
            "text": "Nox1, a member of the Nox family NAPDH oxidases, requires expression of its regulatory soluble proteins Noxo1 (Nox organizer 1) and Noxa1 (Nox activator 1)",
            "probability": 0.0
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 9.6328125,
            "text": "by Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.6328125,
            "text": "Superoxide production by Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -2.056640625,
            "end_logit": -7.734375,
            "text": "1, a member of the Nox family",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_4": [
        {
            "start_logit": 10.0859375,
            "end_logit": 9.5859375,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -1.60546875,
            "text": "Nox",
            "probability": 1.3828277587890625e-05
        },
        {
            "start_logit": -2.150390625,
            "end_logit": 9.5859375,
            "text": "1",
            "probability": 4.887580871582031e-06
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -8.0703125,
            "text": "Nox1 activation. Thus phosphorylation of Noxo1 at Thr341 appears to play a crucial role in PMA-elicited activation of Nox1, providing a molecular link between PKC-mediated signal transduction and Nox1",
            "probability": 0.0
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -8.0859375,
            "text": "Nox1 activation. Thus phosphorylation of Noxo1 at Thr341 appears to play a crucial role in PMA-elicited activation of Nox1, providing a molecular link between PKC-mediated signal transduction and Nox",
            "probability": 0.0
        },
        {
            "start_logit": -7.63671875,
            "end_logit": 9.5859375,
            "text": "in Nox1",
            "probability": 0.0
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -8.1796875,
            "text": "Nox1 activation. Thus phosphorylation of Noxo1 at Thr341 appears to play a crucial role in PMA-elicited activation of Nox1, providing a molecular link between PKC-mediated signal transduction and Nox1-catalyzed superoxide",
            "probability": 0.0
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -8.2109375,
            "text": "Nox1 activation. Thus phosphorylation of Noxo1 at Thr341 appears to play a crucial role in PMA-elicited activation of Nox1",
            "probability": 0.0
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -8.2109375,
            "text": "Nox1 activation. Thus phosphorylation of Noxo1 at Thr341 appears to play a crucial role in PMA-elicited activation of Nox",
            "probability": 0.0
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -8.2578125,
            "text": "Nox1 activation. Thus phosphorylation of Noxo1 at Thr34",
            "probability": 0.0
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -8.265625,
            "text": "Nox1 activation. Thus phosphorylation of Noxo1 at Thr341 appears to play a crucial role in PMA-elicited activation of Nox1, providing a molecular link between PKC-mediated signal transduction and Nox1-catalyzed superoxide production",
            "probability": 0.0
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -8.28125,
            "text": "Nox1 activation. Thus phosphorylation of Noxo1 at Thr341",
            "probability": 0.0
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -8.28125,
            "text": "Nox1 activation. Thus phosphorylation of Noxo1 at Thr",
            "probability": 0.0
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -8.28125,
            "text": "Nox1 activation. Thus phosphorylation of Noxo1 at Thr341 appears to play a crucial role in PMA-elicited activation of Nox1, providing a molecular link between PKC-mediated signal transduction and Nox1-",
            "probability": 0.0
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -8.3046875,
            "text": "Nox1 activation. Thus phosphorylation of Noxo1 at Thr341 appears to play a crucial role in PMA-elicited activation of Nox1, providing a molecular link between PKC",
            "probability": 0.0
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -8.3203125,
            "text": "Nox1 activation. Thus phosphorylation of Noxo1 at Thr341 appears to play a crucial role in PMA-elicited",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 9.5859375,
            "text": "interact with Noxa1, an interaction that participates in Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.5859375,
            "text": "interaction that participates in Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.5859375,
            "text": "with Noxa1, an interaction that participates in Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.5859375,
            "text": "Noxo1 to sufficiently interact with Noxa1, an interaction that participates in Nox1",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_5": [
        {
            "start_logit": 10.0625,
            "end_logit": 9.640625,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 10.0625,
            "end_logit": -1.69921875,
            "text": "Nox",
            "probability": 1.1861324310302734e-05
        },
        {
            "start_logit": -2.056640625,
            "end_logit": 9.640625,
            "text": "1",
            "probability": 5.4836273193359375e-06
        },
        {
            "start_logit": 10.0625,
            "end_logit": -8.109375,
            "text": "Nox1 activity in different",
            "probability": 0.0
        },
        {
            "start_logit": 10.0625,
            "end_logit": -8.125,
            "text": "Nox1 activity",
            "probability": 0.0
        },
        {
            "start_logit": 10.0625,
            "end_logit": -8.171875,
            "text": "Nox1 activity in",
            "probability": 0.0
        },
        {
            "start_logit": 10.0625,
            "end_logit": -8.1796875,
            "text": "Nox1 activity in different manner",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.640625,
            "text": "regulate Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.640625,
            "text": "Thus phosphorylation of Noxo1 at Thr341 and at Ser154 appears to regulate Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": 9.640625,
            "text": "at Ser154 appears to regulate Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": 9.640625,
            "text": "at Thr341 and at Ser154 appears to regulate Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.359375,
            "end_logit": 9.640625,
            "text": "appears to regulate Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.3671875,
            "end_logit": 9.640625,
            "text": "of Noxo1 at Thr341 and at Ser154 appears to regulate Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": 9.640625,
            "text": "and at Ser154 appears to regulate Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -1.69921875,
            "text": "regulate Nox",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -1.69921875,
            "text": "Thus phosphorylation of Noxo1 at Thr341 and at Ser154 appears to regulate Nox",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": -1.69921875,
            "text": "at Ser154 appears to regulate Nox",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": -1.69921875,
            "text": "at Thr341 and at Ser154 appears to regulate Nox",
            "probability": 0.0
        },
        {
            "start_logit": -8.359375,
            "end_logit": -1.69921875,
            "text": "appears to regulate Nox",
            "probability": 0.0
        },
        {
            "start_logit": -8.3671875,
            "end_logit": -1.69921875,
            "text": "of Noxo1 at Thr341 and at Ser154 appears to regulate Nox",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_6": [
        {
            "start_logit": 9.9765625,
            "end_logit": 9.515625,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -1.892578125,
            "text": "Nox",
            "probability": 1.1026859283447266e-05
        },
        {
            "start_logit": -2.30078125,
            "end_logit": 9.515625,
            "text": "1",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -7.91796875,
            "text": "Nox1 is known to absolutely require both an organizer protein (p47(phox) or Noxo1) andanactivator",
            "probability": 0.0
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 9.515625,
            "text": "and Nox1",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -7.9765625,
            "text": "Nox1 is known to absolutely require both an organizer protein (p47(phox) or Noxo1) andanactivatorprotein",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -7.98828125,
            "text": "Nox1 is known to absolutely require both an organizer protein (p47(phox) or Noxo1) andanactiva",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.0234375,
            "text": "Nox1 is known to absolutely require both an organizer protein (p4",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.03125,
            "text": "Nox1 is known to absolutely require both an organizer protein (p47",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.0859375,
            "text": "Nox1 is known to absolutely require both an organizer protein (p47(phox) or Noxo1) andanact",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.1015625,
            "text": "Nox1 is known to absolutely require both an organizer protein (p47(phox",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.125,
            "text": "Nox1 is known to absolutely require both an organizer protein (p47(phox) or Noxo1) andanactivatorprotein (p67(phox",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.171875,
            "text": "Nox1 is known to absolutely require both an organizer protein (p47(phox) or Noxo1) andanactivatorprotein (p67(phox) or Noxa1); for the p47",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.1796875,
            "text": "Nox1 is known to absolutely require both an organizer",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.1796875,
            "text": "Nox1 is known to absolutely require both an organizer protein (p47(phox) or Noxo1) andanactivatorpro",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.1796875,
            "text": "Nox1 is known to absolutely require both an organizer protein (p47(phox) or Noxo1) andanactivatorprotein (p67(phox) or Noxa1); for the p47(phox",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.21875,
            "text": "Nox1 is known to absolutely require both an organizer protein (p47(phox) or Noxo1",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.2265625,
            "text": "Nox1 is known to absolutely require both an organizer protein (p47(phox) or Noxo1) and",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.2265625,
            "text": "Nox1 is known to absolutely require both",
            "probability": 0.0
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 9.515625,
            "text": "Nox2 and Nox1",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_7": [
        {
            "start_logit": 9.9921875,
            "end_logit": 9.7265625,
            "text": "NOX1",
            "probability": 1.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -1.869140625,
            "text": "NOX",
            "probability": 9.238719940185547e-06
        },
        {
            "start_logit": -1.8505859375,
            "end_logit": 9.7265625,
            "text": "1",
            "probability": 7.212162017822266e-06
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -7.90234375,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -7.96484375,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH-binding",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.0,
            "text": "NOX1 was",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.046875,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH-binding region",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.1171875,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH-binding region of this",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.15625,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH-",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.1875,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.1953125,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.1953125,
            "text": "NOX1 was absolutely",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.203125,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH-binding region of",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.7265625,
            "text": "Studies of cytosolic co-factors showed that the C-terminal cytoplasmic domain of NOX1",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.7265625,
            "text": "the C-terminal cytoplasmic domain of NOX1",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.7265625,
            "text": "of NOX1",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.7265625,
            "text": "C-terminal cytoplasmic domain of NOX1",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.7265625,
            "text": "that the C-terminal cytoplasmic domain of NOX1",
            "probability": 0.0
        },
        {
            "start_logit": -1.8505859375,
            "end_logit": -7.90234375,
            "text": "1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH",
            "probability": 0.0
        },
        {
            "start_logit": -1.8505859375,
            "end_logit": -7.96484375,
            "text": "1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH-binding",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_8": [
        {
            "start_logit": 10.046875,
            "end_logit": 9.6015625,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 10.046875,
            "end_logit": -1.7255859375,
            "text": "Nox",
            "probability": 1.1920928955078125e-05
        },
        {
            "start_logit": -2.111328125,
            "end_logit": 9.6015625,
            "text": "1",
            "probability": 5.185604095458984e-06
        },
        {
            "start_logit": -7.84375,
            "end_logit": 9.6015625,
            "text": "of Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.6015625,
            "text": "shown to interact with the NADPH-binding region of Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.6015625,
            "text": "with the NADPH-binding region of Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.6015625,
            "text": ", NADPH oxidase Organizer 1 (NoxO1) is shown to interact with the NADPH-binding region of Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.6015625,
            "text": "NADPH oxidase Organizer 1 (NoxO1) is shown to interact with the NADPH-binding region of Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.6015625,
            "text": "interact with the NADPH-binding region of Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.6015625,
            "text": "the NADPH-binding region of Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 9.6015625,
            "text": "region of Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 9.6015625,
            "text": "(NoxO1) is shown to interact with the NADPH-binding region of Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.3671875,
            "end_logit": 9.6015625,
            "text": "to interact with the NADPH-binding region of Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.3984375,
            "end_logit": 9.6015625,
            "text": "NADPH-binding region of Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.40625,
            "end_logit": 9.6015625,
            "text": "is shown to interact with the NADPH-binding region of Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -7.84375,
            "end_logit": -1.7255859375,
            "text": "of Nox",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": -1.7255859375,
            "text": "shown to interact with the NADPH-binding region of Nox",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -1.7255859375,
            "text": "with the NADPH-binding region of Nox",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -1.7255859375,
            "text": ", NADPH oxidase Organizer 1 (NoxO1) is shown to interact with the NADPH-binding region of Nox",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": -1.7255859375,
            "text": "NADPH oxidase Organizer 1 (NoxO1) is shown to interact with the NADPH-binding region of Nox",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_9": [
        {
            "start_logit": 9.9921875,
            "end_logit": 9.6484375,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -1.8671875,
            "text": "Nox",
            "probability": 9.953975677490234e-06
        },
        {
            "start_logit": -2.05078125,
            "end_logit": 9.6484375,
            "text": "1",
            "probability": 5.841255187988281e-06
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.140625,
            "text": "Nox1, complexed with p22(phox",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.140625,
            "text": "Nox1, complexed with p22",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.1484375,
            "text": "Nox1, complexed with p22(phox) at",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.21875,
            "text": "Nox1, complexed with p22(phox) at the membrane",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.21875,
            "text": "Nox1, complexed with p22(phox)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.234375,
            "text": "Nox1, complexed with p22(phox) at the",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.265625,
            "text": "Nox1, complexed with p22(",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.2734375,
            "text": "Nox1, complexed with p22(phox) at the membrane, requires its regulatory soluble proteins Noxo1",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.2890625,
            "text": "Nox1, complexed with p22(phox) at the membrane, requires its regulatory soluble",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.2890625,
            "text": "Nox1, complexed with p22(phox) at the membrane, requires its regulatory soluble proteins Nox",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.6484375,
            "text": "NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.6484375,
            "text": "Activation of the non-phagocytic superoxide-producing NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.6484375,
            "text": "phagocytic superoxide-producing NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 9.6484375,
            "text": "oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.6484375,
            "text": "-phagocytic superoxide-producing NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 9.6484375,
            "text": "superoxide-producing NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -1.8671875,
            "text": "NADPH oxidase Nox",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_10": [
        {
            "start_logit": 9.984375,
            "end_logit": 9.3828125,
            "text": "NADPH oxidase 1",
            "probability": 1.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -1.8779296875,
            "text": "NADPH",
            "probability": 1.2814998626708984e-05
        },
        {
            "start_logit": -2.51953125,
            "end_logit": 9.3828125,
            "text": "1",
            "probability": 3.6954879760742188e-06
        },
        {
            "start_logit": -6.26953125,
            "end_logit": 9.3828125,
            "text": "oxidase 1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.984375,
            "end_logit": -7.87890625,
            "text": "NADPH oxidase",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.25,
            "text": "NADPH oxidase 1 assembly and",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.2890625,
            "text": "NADPH oxidase 1 assembly",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": 9.3828125,
            "text": "optimal NADPH oxidase 1",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.3828125,
            "text": "for optimal NADPH oxidase 1",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.3828125,
            "text": "NOXO1 phosphorylation on serine 154 is critical for optimal NADPH oxidase 1",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 9.3828125,
            "text": "critical for optimal NADPH oxidase 1",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 9.3828125,
            "text": "is critical for optimal NADPH oxidase 1",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": -1.8779296875,
            "text": "optimal NADPH",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": -1.8779296875,
            "text": "for optimal NADPH",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": -1.8779296875,
            "text": "NOXO1 phosphorylation on serine 154 is critical for optimal NADPH",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": -1.8779296875,
            "text": "critical for optimal NADPH",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": -1.8779296875,
            "text": "is critical for optimal NADPH",
            "probability": 0.0
        },
        {
            "start_logit": -2.51953125,
            "end_logit": -8.25,
            "text": "1 assembly and",
            "probability": 0.0
        },
        {
            "start_logit": -2.51953125,
            "end_logit": -8.2890625,
            "text": "1 assembly",
            "probability": 0.0
        },
        {
            "start_logit": -6.26953125,
            "end_logit": -7.87890625,
            "text": "oxidase",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_11": [
        {
            "start_logit": 10.0,
            "end_logit": 9.6484375,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 10.0,
            "end_logit": -1.853515625,
            "text": "Nox",
            "probability": 1.0073184967041016e-05
        },
        {
            "start_logit": -2.03515625,
            "end_logit": 9.6484375,
            "text": "1",
            "probability": 5.841255187988281e-06
        },
        {
            "start_logit": 10.0,
            "end_logit": -8.0390625,
            "text": "Nox1 requires both the organizer",
            "probability": 0.0
        },
        {
            "start_logit": 10.0,
            "end_logit": -8.140625,
            "text": "Nox1 requires both the organize",
            "probability": 0.0
        },
        {
            "start_logit": 10.0,
            "end_logit": -8.1640625,
            "text": "Nox1 requires both the organizer protein Noxo1 and the activator protein Noxa1",
            "probability": 0.0
        },
        {
            "start_logit": 10.0,
            "end_logit": -8.171875,
            "text": "Nox1 requires both the organizer protein Noxo1",
            "probability": 0.0
        },
        {
            "start_logit": 10.0,
            "end_logit": -8.1796875,
            "text": "Nox1 requires both the organizer protein Noxo1 and the activator protein Nox",
            "probability": 0.0
        },
        {
            "start_logit": 10.0,
            "end_logit": -8.1875,
            "text": "Nox1 requires",
            "probability": 0.0
        },
        {
            "start_logit": 10.0,
            "end_logit": -8.1875,
            "text": "Nox1 requires both the organizer protein Nox",
            "probability": 0.0
        },
        {
            "start_logit": 10.0,
            "end_logit": -8.1953125,
            "text": "Nox1 requires both the organizer protein Noxo1 and",
            "probability": 0.0
        },
        {
            "start_logit": 10.0,
            "end_logit": -8.203125,
            "text": "Nox1 requires both the organizer protein Noxo1 and the",
            "probability": 0.0
        },
        {
            "start_logit": 10.0,
            "end_logit": -8.203125,
            "text": "Nox1 requires both the",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.6484375,
            "text": "oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.6484375,
            "text": "NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.6484375,
            "text": "Activation of the superoxide-producing NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.6484375,
            "text": "superoxide-producing NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": 9.6484375,
            "text": "of the superoxide-producing NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.3671875,
            "end_logit": 9.6484375,
            "text": "producing NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.375,
            "end_logit": 9.6484375,
            "text": "the superoxide-producing NADPH oxidase Nox1",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_12": [
        {
            "start_logit": 9.953125,
            "end_logit": 9.5703125,
            "text": "NOX1",
            "probability": 1.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -1.9765625,
            "text": "NOX",
            "probability": 9.59634780883789e-06
        },
        {
            "start_logit": -2.21875,
            "end_logit": 9.5703125,
            "text": "1",
            "probability": 5.125999450683594e-06
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.203125,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOXA1 (NOX activating protein 1",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.203125,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.2109375,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.21875,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOXA1 (NOX activating protein 1)",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.21875,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1)",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.2265625,
            "text": "NOX1, an NADPH oxidase",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.234375,
            "text": "NOX1, an NADPH oxidase homologue",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.2578125,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOX",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.2578125,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOXA1 (NOX activating protein 1), as well as the flavocytochrome component p22",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.265625,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOX",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.265625,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOXA1 (NOX",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.2734375,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.2734375,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOXA1 (NOX activating protein 1), as well as the flavocytochrome",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.28125,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.28125,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOXA1 (NOX activating protein 1), as well as the flavocytochrome component",
            "probability": 0.0
        },
        {
            "start_logit": -2.21875,
            "end_logit": -8.203125,
            "text": "1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOXA1 (NOX activating protein 1",
            "probability": 0.0
        },
        {
            "start_logit": -2.21875,
            "end_logit": -8.203125,
            "text": "1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOXA1 (NOX activating protein 1), as well as the flavocytochrome component p22(phox",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_13": [
        {
            "start_logit": 9.9375,
            "end_logit": 9.6328125,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -1.998046875,
            "text": "Nox",
            "probability": 8.940696716308594e-06
        },
        {
            "start_logit": -2.07421875,
            "end_logit": 9.6328125,
            "text": "1",
            "probability": 6.139278411865234e-06
        },
        {
            "start_logit": -7.80078125,
            "end_logit": 9.6328125,
            "text": "of Nox1",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.1640625,
            "text": "Nox1, an oxidase that is likely involved in host defence at the colon, requires novel proteins homologous to p47",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.1953125,
            "text": "Nox1, an oxidase that is likely involved in host defence at the colon, requires novel proteins homologous to p4",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.1953125,
            "text": "Nox1, an",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.203125,
            "text": "Nox1, an oxidase that is likely involved in host defence at the colon, requires novel proteins homologous to p47phox",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.2109375,
            "text": "Nox1, an oxidase",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.21875,
            "text": "Nox1, an oxidase that is likely involved in host defence at the colon, requires novel proteins homologous to p47phox and p67phox",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.21875,
            "text": "Nox1, an oxidase that is likely involved in host defence at the colon, requires novel proteins homologous to p47ph",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.2265625,
            "text": "Nox1, an oxidase that is likely involved in host defence",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.234375,
            "text": "Nox1, an oxidase that is likely involved in host defence at the colon, requires novel proteins homologous to p47phox and p67ph",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.2421875,
            "text": "Nox1, an oxidase that is likely involved in host defence at the colon, requires novel proteins homologous to p47phox and p67",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.25,
            "text": "Nox1, an oxidase that is likely involved in host defence at the colon, requires novel proteins homologous to p47phox and p",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.25,
            "text": "Nox1, an oxidase that is likely involved in host defence at the colon",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.2734375,
            "text": "Nox1, an oxidase that is likely involved in host defence at the colon, requires",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.2734375,
            "text": "Nox1, an oxidase that is likely involved in host defence at the colon, requires novel proteins homologous to p47phox and p67phox, designated Noxo1",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.2734375,
            "text": "Nox1, an oxidase that is likely involved in host defence at the colon, requires novel proteins homologous to p47phox and p67phox, designated Noxo1 and Noxa1",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.6328125,
            "text": "Activation of Nox1",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_14": [
        {
            "start_logit": 9.859375,
            "end_logit": 9.421875,
            "text": "NADPH oxidase 1",
            "probability": 1.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -2.17578125,
            "text": "NADPH",
            "probability": 9.238719940185547e-06
        },
        {
            "start_logit": -2.435546875,
            "end_logit": 9.421875,
            "text": "1",
            "probability": 4.589557647705078e-06
        },
        {
            "start_logit": -6.56640625,
            "end_logit": 9.421875,
            "text": "oxidase 1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.859375,
            "end_logit": -7.77734375,
            "text": "NADPH oxidase 1 with beta",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.859375,
            "end_logit": -7.859375,
            "text": "NADPH oxidase 1 with betaPix and Nox",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.859375,
            "end_logit": -7.90625,
            "text": "NADPH oxidase",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.859375,
            "end_logit": -7.953125,
            "text": "NADPH oxidase 1 with betaPix",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -7.984375,
            "text": "NADPH oxidase 1 with betaPi",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.078125,
            "text": "NADPH oxidase 1 with betaPix and Nox Organize",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.1328125,
            "text": "NADPH oxidase 1 with betaPix and Nox Organizer 1",
            "probability": 0.0
        },
        {
            "start_logit": -7.76953125,
            "end_logit": 9.421875,
            "text": "of NADPH oxidase 1",
            "probability": 0.0
        },
        {
            "start_logit": -7.76953125,
            "end_logit": -2.17578125,
            "text": "of NADPH",
            "probability": 0.0
        },
        {
            "start_logit": -2.435546875,
            "end_logit": -7.77734375,
            "text": "1 with beta",
            "probability": 0.0
        },
        {
            "start_logit": -2.435546875,
            "end_logit": -7.859375,
            "text": "1 with betaPix and Nox",
            "probability": 0.0
        },
        {
            "start_logit": -2.435546875,
            "end_logit": -7.953125,
            "text": "1 with betaPix",
            "probability": 0.0
        },
        {
            "start_logit": -2.435546875,
            "end_logit": -7.984375,
            "text": "1 with betaPi",
            "probability": 0.0
        },
        {
            "start_logit": -2.435546875,
            "end_logit": -8.078125,
            "text": "1 with betaPix and Nox Organize",
            "probability": 0.0
        },
        {
            "start_logit": -2.435546875,
            "end_logit": -8.1328125,
            "text": "1 with betaPix and Nox Organizer 1",
            "probability": 0.0
        },
        {
            "start_logit": -6.56640625,
            "end_logit": -7.77734375,
            "text": "oxidase 1 with beta",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_15": [
        {
            "start_logit": 9.890625,
            "end_logit": 9.4140625,
            "text": "NADPH oxidase 1",
            "probability": 1.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -2.1015625,
            "text": "NADPH",
            "probability": 9.894371032714844e-06
        },
        {
            "start_logit": -2.470703125,
            "end_logit": 9.4140625,
            "text": "1",
            "probability": 4.231929779052734e-06
        },
        {
            "start_logit": -6.23828125,
            "end_logit": 9.4140625,
            "text": "oxidase 1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.890625,
            "end_logit": -7.4765625,
            "text": "NADPH oxidase 1 (NOX",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.890625,
            "end_logit": -7.68359375,
            "text": "NADPH oxidase 1 (NOX1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.890625,
            "end_logit": -7.875,
            "text": "NADPH oxidase 1 (NOX1)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.890625,
            "end_logit": -7.96875,
            "text": "NADPH oxidase 1 (NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX) and the cytosolic partners NOX organizer 1 (NOXO1), NOX",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.0703125,
            "text": "NADPH oxidase",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.0859375,
            "text": "NADPH oxidase 1 (NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX) and the cytosolic partners NOX organizer 1 (NOXO1), NOX activator 1 (NOXA1)",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.1796875,
            "text": "NADPH oxidase 1 (NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX) and the cytosolic partners NOX organizer 1 (NOXO1), NOX activator 1 (NOXA1",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.1875,
            "text": "NADPH oxidase 1 (NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX) and the cytosolic partners NOX organizer 1 (NOXO1)",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.21875,
            "text": "NADPH oxidase 1 (NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.21875,
            "text": "NADPH oxidase 1 (NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX) and the cytosolic partners NOX organizer 1 (NOXO1), NOX activator 1",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.21875,
            "text": "NADPH oxidase 1 (NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX) and the cytosolic partners NOX organizer 1 (NOXO1",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.234375,
            "text": "NADPH oxidase 1 (NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX) and the cytosolic partners NOX organizer 1 (NOXO1), NOX activator 1 (NOX",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.4140625,
            "text": "by NADPH oxidase 1",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.4140625,
            "text": "Reactive oxygen species (ROS) production by NADPH oxidase 1",
            "probability": 0.0
        },
        {
            "start_logit": -2.470703125,
            "end_logit": -7.4765625,
            "text": "1 (NOX",
            "probability": 0.0
        },
        {
            "start_logit": -2.470703125,
            "end_logit": -7.68359375,
            "text": "1 (NOX1",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_16": [
        {
            "start_logit": 9.9140625,
            "end_logit": 9.515625,
            "text": "NOX1",
            "probability": 1.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -2.06640625,
            "text": "NOX",
            "probability": 9.238719940185547e-06
        },
        {
            "start_logit": -2.35546875,
            "end_logit": 9.515625,
            "text": "1",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.2890625,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOXA1 (NOX activating protein 1)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.296875,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.296875,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOXA1 (NOX activating protein 1",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.3046875,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.3046875,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.3046875,
            "text": "NOX1, an NADPH oxidase",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.3203125,
            "text": "NOX1, an NADPH oxidase homologue",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.34375,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOXA1 (NOX activating protein 1), as well as the flavocytochrome component p22",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.34375,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOX",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.34375,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOX",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.3515625,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOXA1 (NOX activating protein 1), as well as the flavocytochrome",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.359375,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOXA1 (NOX",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.359375,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX",
            "probability": 0.0
        },
        {
            "start_logit": -2.35546875,
            "end_logit": -8.2890625,
            "text": "1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOXA1 (NOX activating protein 1)",
            "probability": 0.0
        },
        {
            "start_logit": -2.35546875,
            "end_logit": -8.296875,
            "text": "1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOXA1 (NOX activating protein 1), as well as the flavocytochrome component p22(phox",
            "probability": 0.0
        },
        {
            "start_logit": -2.35546875,
            "end_logit": -8.296875,
            "text": "1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1)",
            "probability": 0.0
        },
        {
            "start_logit": -2.35546875,
            "end_logit": -8.296875,
            "text": "1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOXA1 (NOX activating protein 1",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_17": [
        {
            "start_logit": 9.9765625,
            "end_logit": 9.6015625,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -1.9111328125,
            "text": "Nox",
            "probability": 9.953975677490234e-06
        },
        {
            "start_logit": -2.142578125,
            "end_logit": 9.6015625,
            "text": "1",
            "probability": 5.4836273193359375e-06
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.0859375,
            "text": "Nox1 requires both the organizer",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.1328125,
            "text": "Nox1 requires both",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.1796875,
            "text": "Nox1 requires both the organizer protein Noxo1 and the activator protein Nox",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.1875,
            "text": "Nox1 requires both the organize",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.203125,
            "text": "Nox1 requires both the organizer protein Noxo1 and the activator protein Noxa1",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.2265625,
            "text": "Nox1 requires both the organizer protein Nox",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.2265625,
            "text": "Nox1 requires both the organizer protein Noxo1 and the activator",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.234375,
            "text": "Nox1 requires both the",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.234375,
            "text": "Nox1 requires",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.234375,
            "text": "Nox1 requires both the organizer protein Noxo1",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.2421875,
            "text": "Nox1 requires both the organizer protein Noxo1 and the",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.2421875,
            "text": "Nox1 requires both the organizer protein Noxo1 and",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.6015625,
            "text": "oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.6015625,
            "text": "NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.6015625,
            "text": "Activation of the superoxide-producing NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": 9.6015625,
            "text": "superoxide-producing NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.6015625,
            "text": "of the superoxide-producing NADPH oxidase Nox1",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_18": [
        {
            "start_logit": 9.9609375,
            "end_logit": 9.6015625,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -1.931640625,
            "text": "Nox",
            "probability": 9.834766387939453e-06
        },
        {
            "start_logit": -2.162109375,
            "end_logit": 9.6015625,
            "text": "1",
            "probability": 5.424022674560547e-06
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.1875,
            "text": "Nox1, complexed with p22(phox",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.1875,
            "text": "Nox1, complexed with p22",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.1875,
            "text": "Nox1, complexed with p22(phox) at",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.25,
            "text": "Nox1, complexed with p22(phox)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.2578125,
            "text": "Nox1, complexed with p22(phox) at the membrane",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.265625,
            "text": "Nox1, complexed with p22(phox) at the",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.328125,
            "text": "Nox1, complexed with p22(",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.3359375,
            "text": "Nox1, complexed with p2",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.34375,
            "text": "Nox1, complexed with p22(phox) at the membrane, requires its regulatory soluble proteins Nox",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.3515625,
            "text": "Nox1, complexed with p22(phox) at the membrane, requires its regulatory soluble proteins Noxo1 and Nox",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.6015625,
            "text": "Activation of the non-phagocytic superoxide-producing NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.6015625,
            "text": "NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.6015625,
            "text": "phagocytic superoxide-producing NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.6015625,
            "text": "oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.6015625,
            "text": "-phagocytic superoxide-producing NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": 9.6015625,
            "text": "of the non-phagocytic superoxide-producing NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -1.931640625,
            "text": "Activation of the non-phagocytic superoxide-producing NADPH oxidase Nox",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_19": [
        {
            "start_logit": 9.953125,
            "end_logit": 9.4140625,
            "text": "NADPH oxidase 1",
            "probability": 1.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -1.9765625,
            "text": "NADPH",
            "probability": 1.1205673217773438e-05
        },
        {
            "start_logit": -2.474609375,
            "end_logit": 9.4140625,
            "text": "1",
            "probability": 3.993511199951172e-06
        },
        {
            "start_logit": -6.40234375,
            "end_logit": 9.4140625,
            "text": "oxidase 1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.953125,
            "end_logit": -7.67578125,
            "text": "NADPH oxidase 1 (Nox1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.953125,
            "end_logit": -7.75390625,
            "text": "NADPH oxidase 1 (Nox",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.03125,
            "text": "NADPH oxidase 1 (Nox1)",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.15625,
            "text": "NADPH oxidase 1 (Nox1) is a multicomponent enzyme consisting of p22(phox), Nox organizer 1 (NOXO1), Nox1 activator 1, and Rac1",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.1640625,
            "text": "NADPH oxidase 1 (Nox1) is a multicomponent enzyme consisting of p22(phox",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.1796875,
            "text": "NADPH oxidase 1 (Nox1) is a multicomponent enzyme consisting of p22(phox), Nox organizer 1 (NOXO1), Nox1",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.1875,
            "text": "NADPH oxidase 1 (Nox1) is a multicomponent enzyme consisting of p22(phox)",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.1953125,
            "text": "NADPH oxidase 1 (Nox1) is",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.203125,
            "text": "NADPH oxidase 1 (",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.203125,
            "text": "NADPH oxidase 1 (Nox1) is a multicomponent enzyme consisting of p22",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.2109375,
            "text": "NADPH oxidase",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.2265625,
            "text": "NADPH oxidase 1 (Nox1) is a multicomponent",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.2265625,
            "text": "NADPH oxidase 1 (Nox1) is a multicomponent enzyme consisting of p22(phox), Nox",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.234375,
            "text": "NADPH oxidase 1 (Nox1) is a multicomponent enzyme consisting of p22(phox), Nox organizer 1 (NOXO1",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.2421875,
            "text": "NADPH oxidase 1 (Nox1) is a multicomponent enzyme consisting of p22(phox), Nox organizer",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.25,
            "text": "NADPH oxidase 1 (Nox1) is a multicomponent enzyme consisting of p22(phox), Nox organizer 1 (NOX",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_20": [
        {
            "start_logit": 9.9609375,
            "end_logit": 9.6875,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -1.943359375,
            "text": "Nox",
            "probability": 8.821487426757812e-06
        },
        {
            "start_logit": -1.9619140625,
            "end_logit": 9.6875,
            "text": "1",
            "probability": 6.616115570068359e-06
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -7.7578125,
            "text": "Nox1, a member of the Nox family",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.09375,
            "text": "Nox1, a member of the Nox family NAPDH oxidase",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.1171875,
            "text": "Nox1, a member of the Nox",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.125,
            "text": "Nox1, a member of the Nox family NAP",
            "probability": 0.0
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 9.6875,
            "text": "Superoxide production by Nox1",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.1796875,
            "text": "Nox1, a member",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.1875,
            "text": "Nox1, a member of the Nox family NAPDH oxidases",
            "probability": 0.0
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 9.6875,
            "text": "by Nox1",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.28125,
            "text": "Nox1, a",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.2890625,
            "text": "Nox1, a member of the Nox family NAPDH oxidases, requires expression of its regulatory soluble proteins Noxo1 (Nox organizer 1) and Noxa1 (Nox activator 1",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.2890625,
            "text": "Nox1, a member of the Nox family NAPDH oxidases, requires expression of its regulatory soluble proteins Noxo1 (Nox organizer 1) and Noxa1 (Nox",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.296875,
            "text": "Nox1, a member of the Nox family NAPDH oxidases, requires expression of its regulatory soluble proteins Noxo1 (Nox organize",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.296875,
            "text": "Nox1, a member of the Nox family NAPDH oxidases, requires expression of its regulatory soluble proteins Noxo1 (Nox organizer 1) and Noxa1 (Nox activator",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.3046875,
            "text": "Nox1, a member of the Nox family NAPDH oxidases, requires expression of its regulatory soluble proteins Noxo1 (Nox",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.3046875,
            "text": "Nox1, a member of the Nox family NAPDH",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.3125,
            "text": "Nox1, a member of the Nox family NAPDH oxidases, requires",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.3203125,
            "text": "Nox1, a member of the Nox family NAPDH oxidases, requires expression of its regulatory soluble proteins Noxo1 (Nox organizer 1) and Noxa1 (Nox activator 1) and is markedly enhanced upon cell stimulation with phorbol 12-myristate 13",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_21": [
        {
            "start_logit": 9.984375,
            "end_logit": 9.4375,
            "text": "NADPH oxidase 1",
            "probability": 1.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -1.8798828125,
            "text": "NADPH",
            "probability": 1.2099742889404297e-05
        },
        {
            "start_logit": -2.357421875,
            "end_logit": 9.4375,
            "text": "1",
            "probability": 4.351139068603516e-06
        },
        {
            "start_logit": -6.87109375,
            "end_logit": 9.4375,
            "text": "oxidase 1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.984375,
            "end_logit": -7.42578125,
            "text": "NADPH oxidase 1 (NOX",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.9453125,
            "end_logit": 9.4375,
            "text": "of NADPH oxidase 1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.984375,
            "end_logit": -7.61328125,
            "text": "NADPH oxidase 1 (NOX1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.984375,
            "end_logit": -7.875,
            "text": "NADPH oxidase",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.078125,
            "text": "NADPH oxidase 1 (NOX1)",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.078125,
            "text": "NADPH oxidase 1 (NOX1) mediates endothelial nitric oxide synthase (eNOS",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.15625,
            "text": "NADPH oxidase 1 (NOX1) mediates endothelial nitric oxide",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.15625,
            "text": "NADPH oxidase 1 (NOX1) mediates endothelial nitric oxide synthase",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.1796875,
            "text": "NADPH oxidase 1 (NOX1) mediates endothelial nitric oxide synthase (eNOS)",
            "probability": 0.0
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 9.4375,
            "text": "activation of NADPH oxidase 1",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.4375,
            "text": "NADPH oxidase organiser 1 (NOXO1)-dependent activation of NADPH oxidase 1",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.4375,
            "text": "(NOXO1)-dependent activation of NADPH oxidase 1",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.4375,
            "text": "and NADPH oxidase organiser 1 (NOXO1)-dependent activation of NADPH oxidase 1",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.4375,
            "text": "The p47phox- and NADPH oxidase organiser 1 (NOXO1)-dependent activation of NADPH oxidase 1",
            "probability": 0.0
        },
        {
            "start_logit": -6.9453125,
            "end_logit": -1.8798828125,
            "text": "of NADPH",
            "probability": 0.0
        },
        {
            "start_logit": -2.357421875,
            "end_logit": -7.42578125,
            "text": "1 (NOX",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_22": [
        {
            "start_logit": 9.9921875,
            "end_logit": 9.7265625,
            "text": "NOX1",
            "probability": 1.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -1.869140625,
            "text": "NOX",
            "probability": 9.238719940185547e-06
        },
        {
            "start_logit": -1.8505859375,
            "end_logit": 9.7265625,
            "text": "1",
            "probability": 7.212162017822266e-06
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -7.90234375,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -7.96484375,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH-binding",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.0,
            "text": "NOX1 was",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.046875,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH-binding region",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.1171875,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH-binding region of this",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.15625,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH-",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.1875,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.1953125,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.1953125,
            "text": "NOX1 was absolutely",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.203125,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH-binding region of",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.7265625,
            "text": "Studies of cytosolic co-factors showed that the C-terminal cytoplasmic domain of NOX1",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.7265625,
            "text": "the C-terminal cytoplasmic domain of NOX1",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.7265625,
            "text": "of NOX1",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.7265625,
            "text": "C-terminal cytoplasmic domain of NOX1",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.7265625,
            "text": "that the C-terminal cytoplasmic domain of NOX1",
            "probability": 0.0
        },
        {
            "start_logit": -1.8505859375,
            "end_logit": -7.90234375,
            "text": "1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH",
            "probability": 0.0
        },
        {
            "start_logit": -1.8505859375,
            "end_logit": -7.96484375,
            "text": "1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH-binding",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_23": [
        {
            "start_logit": 9.9609375,
            "end_logit": 9.484375,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -1.9541015625,
            "text": "Nox",
            "probability": 1.0848045349121094e-05
        },
        {
            "start_logit": -2.412109375,
            "end_logit": 9.484375,
            "text": "1",
            "probability": 4.231929779052734e-06
        },
        {
            "start_logit": -8.09375,
            "end_logit": 9.484375,
            "text": "with Nox organizer 1 (NoxO1) to regulate reactive oxygen species (ROS) production by the NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 9.484375,
            "text": "conjunction with Nox organizer 1 (NoxO1) to regulate reactive oxygen species (ROS) production by the NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.484375,
            "text": "the NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.484375,
            "text": "of p67(phox) that acts in conjunction with Nox organizer 1 (NoxO1) to regulate reactive oxygen species (ROS) production by the NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.484375,
            "text": "(NoxO1) to regulate reactive oxygen species (ROS) production by the NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.484375,
            "text": "in conjunction with Nox organizer 1 (NoxO1) to regulate reactive oxygen species (ROS) production by the NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.484375,
            "text": "acts in conjunction with Nox organizer 1 (NoxO1) to regulate reactive oxygen species (ROS) production by the NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.484375,
            "text": "NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.484375,
            "text": "regulate reactive oxygen species (ROS) production by the NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 9.484375,
            "text": "homologue of p67(phox) that acts in conjunction with Nox organizer 1 (NoxO1) to regulate reactive oxygen species (ROS) production by the NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": -1.9541015625,
            "text": "with Nox organizer 1 (NoxO1) to regulate reactive oxygen species (ROS) production by the NADPH oxidase Nox",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -1.9541015625,
            "text": "conjunction with Nox organizer 1 (NoxO1) to regulate reactive oxygen species (ROS) production by the NADPH oxidase Nox",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -1.9541015625,
            "text": "the NADPH oxidase Nox",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -1.9541015625,
            "text": "of p67(phox) that acts in conjunction with Nox organizer 1 (NoxO1) to regulate reactive oxygen species (ROS) production by the NADPH oxidase Nox",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": -1.9541015625,
            "text": "(NoxO1) to regulate reactive oxygen species (ROS) production by the NADPH oxidase Nox",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": -1.9541015625,
            "text": "in conjunction with Nox organizer 1 (NoxO1) to regulate reactive oxygen species (ROS) production by the NADPH oxidase Nox",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": -1.9541015625,
            "text": "acts in conjunction with Nox organizer 1 (NoxO1) to regulate reactive oxygen species (ROS) production by the NADPH oxidase Nox",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_24": [
        {
            "start_logit": 9.9296875,
            "end_logit": 9.6015625,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -2.03125,
            "text": "Nox",
            "probability": 8.881092071533203e-06
        },
        {
            "start_logit": -2.16015625,
            "end_logit": 9.6015625,
            "text": "1",
            "probability": 5.602836608886719e-06
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.234375,
            "text": "Nox1 is highly expressed in the colon, and requires two",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.25,
            "text": "Nox1 is highly expressed in the colon, and requires two cytosolic regulators",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.265625,
            "text": "Nox1 is highly expressed in the colon, and requires two cytosolic regulators, the organize",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.2734375,
            "text": "Nox1 is highly expressed in the colon, and requires two cytosolic regulators, the organizer",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.296875,
            "text": "Nox1 is highly expressed in the colon",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.296875,
            "text": "Nox1 is highly expressed in the colon, and requires two cytosolic regulators, the organizer subunit NoxO1",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.3046875,
            "text": "Nox1 is highly expressed in the colon, and requires two cytosolic regulators, the organizer subunit Nox",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.3046875,
            "text": "Nox1 is highly expressed in the colon, and requires two cytosolic regulators, the organizer subunit NoxO1 and the activator subunit NoxA1, as well as the binding of Rac1",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.3203125,
            "text": "Nox1 is highly expressed in the colon, and requires two cytosolic",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.328125,
            "text": "Nox1 is",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.3359375,
            "text": "Nox1 is highly expressed in the colon, and",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.34375,
            "text": "Nox1 is highly expressed in the colon, and requires two cytosolic regulators, the organizer subunit NoxO1 and the activator subunit NoxA1",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.34375,
            "text": "Nox1 is highly expressed in the colon, and requires two cytosolic regulators, the organizer subunit NoxO1 and the activator subunit NoxA1, as well as the binding of Rac1 GTPase",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.34375,
            "text": "Nox1 is highly expressed in the colon, and requires two cytosolic regulators, the organizer subunit NoxO1 and the activator subunit Nox",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.34375,
            "text": "Nox1 is highly expressed in the",
            "probability": 0.0
        },
        {
            "start_logit": -2.16015625,
            "end_logit": -8.234375,
            "text": "1 is highly expressed in the colon, and requires two",
            "probability": 0.0
        },
        {
            "start_logit": -2.16015625,
            "end_logit": -8.25,
            "text": "1 is highly expressed in the colon, and requires two cytosolic regulators",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_25": [
        {
            "start_logit": 9.9296875,
            "end_logit": 9.6015625,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -2.03125,
            "text": "Nox",
            "probability": 8.881092071533203e-06
        },
        {
            "start_logit": -2.1640625,
            "end_logit": 9.6015625,
            "text": "1",
            "probability": 5.602836608886719e-06
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.203125,
            "text": "Nox1 is highly expressed in the colon, and it requires two cytosolic regulators, NoxO1",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.2109375,
            "text": "Nox1 is highly expressed in the colon, and it requires two",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.21875,
            "text": "Nox1 is highly expressed in the colon, and it requires two cytosolic regulators",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.25,
            "text": "Nox1 is highly expressed in the colon, and it requires two cytosolic regulators, NoxO1 and NoxA1",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.265625,
            "text": "Nox1 is highly expressed in the colon, and it requires two cytosolic regulators, NoxO1 and Nox",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.265625,
            "text": "Nox1 is highly expressed in the colon, and it requires two cytosolic regulators, NoxO1 and NoxA1, as well as the binding of Rac1",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.28125,
            "text": "Nox1 is highly expressed in the colon, and it requires two cytosolic regulators, Nox",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.2890625,
            "text": "Nox1 is highly expressed in the colon",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.296875,
            "text": "Nox1 is highly expressed in the colon, and it requires two cytosolic regulators, NoxO1 and NoxA1, as well as the binding of Rac1 GTPase, for",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.296875,
            "text": "Nox1 is highly expressed in the colon, and it requires two cytosolic",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.3125,
            "text": "Nox1 is highly expressed in the colon, and it requires two cytosolic regulators, NoxO1 and NoxA1, as well as the binding of Rac1 GTPase, for its activity",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.3203125,
            "text": "Nox1 is highly expressed in the colon, and it requires two cytosolic regulators, NoxO1 and NoxA1, as well",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.3203125,
            "text": "Nox1 is highly expressed in the colon, and it requires two cytosolic regulators, NoxO1 and NoxA1, as",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.3203125,
            "text": "Nox1 is highly expressed in the colon, and it requires two cytosolic regulators, NoxO1 and NoxA1, as well as the binding of Rac1 GTPase",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.3203125,
            "text": "Nox1 is highly expressed in the colon, and it requires",
            "probability": 0.0
        },
        {
            "start_logit": -2.1640625,
            "end_logit": -8.203125,
            "text": "1 is highly expressed in the colon, and it requires two cytosolic regulators, NoxO1",
            "probability": 0.0
        },
        {
            "start_logit": -2.1640625,
            "end_logit": -8.2109375,
            "text": "1 is highly expressed in the colon, and it requires two",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_26": [
        {
            "start_logit": 9.9375,
            "end_logit": 9.4765625,
            "text": "NADPH oxidase 1",
            "probability": 1.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -1.998046875,
            "text": "NADPH",
            "probability": 1.043081283569336e-05
        },
        {
            "start_logit": -2.345703125,
            "end_logit": 9.4765625,
            "text": "1",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": -6.1484375,
            "end_logit": 9.4765625,
            "text": "oxidase 1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.9375,
            "end_logit": -7.27734375,
            "text": "NADPH oxidase 1 (NOX",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9375,
            "end_logit": -7.4765625,
            "text": "NADPH oxidase 1 (NOX1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9375,
            "end_logit": -7.6953125,
            "text": "NADPH oxidase 1 (NOX1)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9375,
            "end_logit": -7.8203125,
            "text": "NADPH oxidase 1 (NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX) and the cytosolic partners NOX organizer 1 (NOXO1), NOX",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9375,
            "end_logit": -7.921875,
            "text": "NADPH oxidase 1 (NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX) and the cytosolic partners NOX organizer 1 (NOXO1), NOX activator 1 (NOXA1)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -7.94921875,
            "text": "NADPH oxidase 1 (NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX) and the cytosolic partners NOX organizer 1 (NOXO1), NOX activator 1 (NOX",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.015625,
            "text": "NADPH oxidase",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.0234375,
            "text": "NADPH oxidase 1 (NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX) and the cytosolic partners NOX organizer 1 (NOXO1), NOX activator 1 (NOXA1",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.0390625,
            "text": "NADPH oxidase 1 (NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX) and the cytosolic partners NOX organizer 1 (NOXO1), NOX activator 1",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.078125,
            "text": "NADPH oxidase 1 (NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX) and the cytosolic partners NOX organizer 1 (NOXO1",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.0859375,
            "text": "NADPH oxidase 1 (NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX) and the cytosolic partners NOX organizer 1 (NOXO1)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.0859375,
            "text": "NADPH oxidase 1 (NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.1171875,
            "text": "NADPH oxidase 1 (NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX) and the cytosolic partners NOX organizer 1 (NOXO1), NOX activator",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.125,
            "text": "NADPH oxidase 1 (NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX) and the cytosolic partners NOX organizer 1 (NOX",
            "probability": 0.0
        },
        {
            "start_logit": -8.0,
            "end_logit": 9.4765625,
            "text": "by NADPH oxidase 1",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.4765625,
            "text": "Reactive oxygen species (ROS) production by NADPH oxidase 1",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_27": [
        {
            "start_logit": 9.9375,
            "end_logit": 9.6328125,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -2.005859375,
            "text": "Nox",
            "probability": 8.881092071533203e-06
        },
        {
            "start_logit": -2.056640625,
            "end_logit": 9.6328125,
            "text": "1",
            "probability": 6.258487701416016e-06
        },
        {
            "start_logit": 9.9375,
            "end_logit": -7.734375,
            "text": "Nox1, a member of the Nox family",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.078125,
            "text": "Nox1, a member of the Nox family NAP",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.109375,
            "text": "Nox1, a member of the Nox",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.1328125,
            "text": "Nox1, a member of the Nox family NAPDH oxidase",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.15625,
            "text": "Nox1, a member of the Nox family NAPDH oxidases",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.171875,
            "text": "Nox1, a",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.1796875,
            "text": "Nox1, a member",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.2578125,
            "text": "Nox1, a member of the Nox family NAPDH oxidases, requires expression of its regulatory soluble proteins Noxo1 (Nox organizer 1) and Noxa1 (Nox activator 1",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.2578125,
            "text": "Nox1, a member of the Nox family NAPDH oxidases, requires expression of its regulatory soluble proteins Noxo1 (Nox organizer 1) and Noxa1 (Nox activator 1) and is markedly enhanced upon cell stimulation with phorbol 12-myristate 13",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.2734375,
            "text": "Nox1, a member of the Nox family NAPDH oxidases, requires expression of its regulatory soluble proteins Noxo1 (Nox organizer 1) and Noxa1 (Nox",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.28125,
            "text": "Nox1, a member of the Nox family NAPDH oxidases, requires expression of its regulatory soluble proteins Noxo1 (Nox organizer 1)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.28125,
            "text": "Nox1, a member of the Nox family NAPDH",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.2890625,
            "text": "Nox1, a member of the Nox family NAPDH oxidases, requires expression of its regulatory soluble proteins Noxo1 (Nox organizer 1) and Noxa1 (Nox activator",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.2890625,
            "text": "Nox1, a member of the Nox family NAPDH oxidases, requires expression of its regulatory soluble proteins Noxo1 (Nox organizer 1) and Noxa1 (Nox activator 1)",
            "probability": 0.0
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 9.6328125,
            "text": "by Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.6328125,
            "text": "Superoxide production by Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -2.056640625,
            "end_logit": -7.734375,
            "text": "1, a member of the Nox family",
            "probability": 0.0
        }
    ],
    "58e7902b3e8b6dc87c000007_1": [
        {
            "start_logit": 9.9140625,
            "end_logit": 9.59375,
            "text": "IFN signature",
            "probability": 1.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -2.00390625,
            "text": "IFN",
            "probability": 9.238719940185547e-06
        },
        {
            "start_logit": -2.07421875,
            "end_logit": 9.59375,
            "text": "signature",
            "probability": 6.258487701416016e-06
        },
        {
            "start_logit": -7.4609375,
            "end_logit": 9.59375,
            "text": "I IFN signature",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.28125,
            "text": "IFN signature was assessed in these subjects to identify subpopulations showing both activation and concordance of the type I IFN pathway in the peripheral blood and disease",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.296875,
            "text": "IFN signature was assessed in these subjects to identify subpopulations showing both activation and concordance of the type I IFN pathway in the peripheral blood and disease-affected tissues of each disease and to correlate activation of this pathway in the",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.296875,
            "text": "IFN signature was assessed in these subjects to identify subpopulations showing both activation and concordance of the type I IFN",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.3046875,
            "text": "IFN signature was assessed in these subjects to identify subpopulations showing both activation and concordance of the type I IFN pathway in the peripheral blood and disease-affected tissues of each disease and to correlate activation of this pathway in the WB",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.3046875,
            "text": "IFN signature was assessed in these subjects to identify subpopulations showing both activation and concordance of the type I IFN pathway in the peripheral blood and disease-affected tissues of",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.3203125,
            "text": "IFN signature was assessed in these subjects to identify subpopulations showing both activation and concordance of the type I IFN pathway in",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.3359375,
            "text": "IFN signature was",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.3671875,
            "text": "IFN signature was assessed in these subjects to identify subpopulations showing both activation and concordance of the type I IFN pathway in the peripheral blood and disease-affected tissues of each disease",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.3828125,
            "text": "IFN signature was assessed in these subjects to",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.3828125,
            "text": "IFN signature was assessed in these subjects to identify subpopulations showing both activation and concordance of the type I IFN pathway in the peripheral blood and disease-affected tissues of each disease and to correlate activation of this",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.390625,
            "text": "IFN signature was assessed in these subjects to identify subpopulations showing both activation and concordance of the type I IFN pathway in the peripheral blood and disease-affected",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.390625,
            "text": "IFN signature was assessed in these subjects to identify subpopulations showing both activation and concordance of the type I IFN pathway in the peripheral blood and disease-affected tissues of each disease and to correlate activation of this pathway in",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.390625,
            "text": "IFN signature was assessed in these subjects to identify subpopulations showing both activation and concordance of the type I IFN pathway in the peripheral blood and disease-affected tissues",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.390625,
            "text": "IFN signature was assessed in these subjects to identify subpopulations showing both activation and concordance of the type I IFN pathway in the peripheral blood and disease-affected tissues of each disease and to correlate activation of this pathway in the WB with clinical measurements",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.3984375,
            "text": "IFN signature was assessed in these subjects to identify subpopulations showing both activation and concordance of the type I IFN pathway in the peripheral blood and disease-affected tissues of each disease and to correlate activation of",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.4140625,
            "text": "IFN signature was assessed in these subjects to identify subpopulations showing both activation and concordance of the type I IFN pathway",
            "probability": 0.0
        }
    ],
    "58e7902b3e8b6dc87c000007_2": [
        {
            "start_logit": 9.84375,
            "end_logit": 9.421875,
            "text": "interferon signature",
            "probability": 1.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -2.171875,
            "text": "interferon",
            "probability": 9.238719940185547e-06
        },
        {
            "start_logit": -2.453125,
            "end_logit": 9.421875,
            "text": "signature",
            "probability": 4.589557647705078e-06
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.296875,
            "text": "interferon signature similar",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.3671875,
            "text": "interferon signature similar to but",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.421875,
            "text": "an interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 9.421875,
            "text": "Gene expression analysis of peripheral blood cells from patients with rheumatoid arthritis and multiple sclerosis demonstrate an interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 9.421875,
            "text": "with rheumatoid arthritis and multiple sclerosis demonstrate an interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.421875,
            "text": "from patients with rheumatoid arthritis and multiple sclerosis demonstrate an interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.421875,
            "text": "demonstrate an interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.421875,
            "text": "patients with rheumatoid arthritis and multiple sclerosis demonstrate an interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.421875,
            "text": "cells from patients with rheumatoid arthritis and multiple sclerosis demonstrate an interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.421875,
            "text": "peripheral blood cells from patients with rheumatoid arthritis and multiple sclerosis demonstrate an interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.421875,
            "text": "of peripheral blood cells from patients with rheumatoid arthritis and multiple sclerosis demonstrate an interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": -2.171875,
            "text": "an interferon",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": -2.171875,
            "text": "Gene expression analysis of peripheral blood cells from patients with rheumatoid arthritis and multiple sclerosis demonstrate an interferon",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -2.171875,
            "text": "with rheumatoid arthritis and multiple sclerosis demonstrate an interferon",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -2.171875,
            "text": "from patients with rheumatoid arthritis and multiple sclerosis demonstrate an interferon",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -2.171875,
            "text": "demonstrate an interferon",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -2.171875,
            "text": "patients with rheumatoid arthritis and multiple sclerosis demonstrate an interferon",
            "probability": 0.0
        }
    ],
    "58e7902b3e8b6dc87c000007_3": [
        {
            "start_logit": 9.875,
            "end_logit": 9.46875,
            "text": "interferon signature",
            "probability": 1.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -2.107421875,
            "text": "interferon",
            "probability": 9.357929229736328e-06
        },
        {
            "start_logit": -2.36328125,
            "end_logit": 9.46875,
            "text": "signature",
            "probability": 4.887580871582031e-06
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 9.46875,
            "text": "the interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.46875,
            "text": "of patients with rheumatoid arthritis display a specific expression pattern of interferon-dependent genes in their leukocytes, termed the interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.46875,
            "text": "termed the interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.46875,
            "text": "a fraction of patients with rheumatoid arthritis display a specific expression pattern of interferon-dependent genes in their leukocytes, termed the interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.46875,
            "text": "fraction of patients with rheumatoid arthritis display a specific expression pattern of interferon-dependent genes in their leukocytes, termed the interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.46875,
            "text": ", and a fraction of patients with rheumatoid arthritis display a specific expression pattern of interferon-dependent genes in their leukocytes, termed the interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 9.46875,
            "text": "with rheumatoid arthritis display a specific expression pattern of interferon-dependent genes in their leukocytes, termed the interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.46875,
            "text": "patients with rheumatoid arthritis display a specific expression pattern of interferon-dependent genes in their leukocytes, termed the interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.46875,
            "text": ", psoriasis, and a fraction of patients with rheumatoid arthritis display a specific expression pattern of interferon-dependent genes in their leukocytes, termed the interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.46875,
            "text": "of interferon-dependent genes in their leukocytes, termed the interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.46875,
            "text": "psoriasis, and a fraction of patients with rheumatoid arthritis display a specific expression pattern of interferon-dependent genes in their leukocytes, termed the interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.46875,
            "text": ", dermatomyositis, psoriasis, and a fraction of patients with rheumatoid arthritis display a specific expression pattern of interferon-dependent genes in their leukocytes, termed the interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.46875,
            "text": "specific expression pattern of interferon-dependent genes in their leukocytes, termed the interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.46875,
            "text": "Patients with systemic lupus erythematosus, Sj\u00f6gren's syndrome, dermatomyositis, psoriasis, and a fraction of patients with rheumatoid arthritis display a specific expression pattern of interferon-dependent genes in their leukocytes, termed the interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -7.56640625,
            "end_logit": -2.107421875,
            "text": "the interferon",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": -2.107421875,
            "text": "of patients with rheumatoid arthritis display a specific expression pattern of interferon-dependent genes in their leukocytes, termed the interferon",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -2.107421875,
            "text": "termed the interferon",
            "probability": 0.0
        }
    ],
    "58e7902b3e8b6dc87c000007_4": [
        {
            "start_logit": 9.6875,
            "end_logit": 9.125,
            "text": "interferon signature",
            "probability": 1.0
        },
        {
            "start_logit": 9.6875,
            "end_logit": -2.544921875,
            "text": "interferon",
            "probability": 8.52346420288086e-06
        },
        {
            "start_logit": -2.966796875,
            "end_logit": 9.125,
            "text": "signature",
            "probability": 3.159046173095703e-06
        },
        {
            "start_logit": 9.6875,
            "end_logit": -8.125,
            "text": "interferon signature in lupus)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.703125,
            "end_logit": 9.125,
            "text": ". interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": 9.6875,
            "end_logit": -8.359375,
            "text": "interferon signature in lupus",
            "probability": 0.0
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 9.125,
            "text": ", have led to the identification of gene signatures associated with the activation of specific pathways in these diseases (e.g. interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 9.125,
            "text": "differential gene expression studies performed on selected tissues from patients with autoimmune disorders, have led to the identification of gene signatures associated with the activation of specific pathways in these diseases (e.g. interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 9.125,
            "text": "led to the identification of gene signatures associated with the activation of specific pathways in these diseases (e.g. interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 9.125,
            "text": "identification of gene signatures associated with the activation of specific pathways in these diseases (e.g. interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 9.125,
            "text": "gene expression studies performed on selected tissues from patients with autoimmune disorders, have led to the identification of gene signatures associated with the activation of specific pathways in these diseases (e.g. interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.125,
            "text": "performed on selected tissues from patients with autoimmune disorders, have led to the identification of gene signatures associated with the activation of specific pathways in these diseases (e.g. interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.125,
            "text": "gene signatures associated with the activation of specific pathways in these diseases (e.g. interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": 9.125,
            "text": "the identification of gene signatures associated with the activation of specific pathways in these diseases (e.g. interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.125,
            "text": "studies performed on selected tissues from patients with autoimmune disorders, have led to the identification of gene signatures associated with the activation of specific pathways in these diseases (e.g. interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.125,
            "text": "recently, large-scale differential gene expression studies performed on selected tissues from patients with autoimmune disorders, have led to the identification of gene signatures associated with the activation of specific pathways in these diseases (e.g. interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.125,
            "text": "on selected tissues from patients with autoimmune disorders, have led to the identification of gene signatures associated with the activation of specific pathways in these diseases (e.g. interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.125,
            "text": "scale differential gene expression studies performed on selected tissues from patients with autoimmune disorders, have led to the identification of gene signatures associated with the activation of specific pathways in these diseases (e.g. interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -7.703125,
            "end_logit": -2.544921875,
            "text": ". interferon",
            "probability": 0.0
        },
        {
            "start_logit": -7.9453125,
            "end_logit": -2.544921875,
            "text": ", have led to the identification of gene signatures associated with the activation of specific pathways in these diseases (e.g. interferon",
            "probability": 0.0
        }
    ],
    "58e7902b3e8b6dc87c000007_5": [
        {
            "start_logit": 9.84375,
            "end_logit": 9.46875,
            "text": "interferon signature",
            "probability": 1.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -2.185546875,
            "text": "interferon",
            "probability": 8.64267349243164e-06
        },
        {
            "start_logit": -2.35546875,
            "end_logit": 9.46875,
            "text": "signature",
            "probability": 5.0067901611328125e-06
        },
        {
            "start_logit": -7.8203125,
            "end_logit": 9.46875,
            "text": "I interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.25,
            "text": "interferon signature and",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.3828125,
            "text": "interferon signature and the response to rituximab",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 9.46875,
            "text": "Relationship between the type I interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 9.46875,
            "text": "type I interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.46875,
            "text": "the type I interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": 9.46875,
            "text": "between the type I interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -7.8203125,
            "end_logit": -2.185546875,
            "text": "I interferon",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": -2.185546875,
            "text": "Relationship between the type I interferon",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": -2.185546875,
            "text": "type I interferon",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": -2.185546875,
            "text": "the type I interferon",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": -2.185546875,
            "text": "between the type I interferon",
            "probability": 0.0
        },
        {
            "start_logit": -2.35546875,
            "end_logit": -8.25,
            "text": "signature and",
            "probability": 0.0
        },
        {
            "start_logit": -2.35546875,
            "end_logit": -8.3828125,
            "text": "signature and the response to rituximab",
            "probability": 0.0
        },
        {
            "start_logit": -7.8203125,
            "end_logit": -8.25,
            "text": "I interferon signature and",
            "probability": 0.0
        },
        {
            "start_logit": -7.8203125,
            "end_logit": -8.3828125,
            "text": "I interferon signature and the response to rituximab",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": -8.25,
            "text": "Relationship between the type I interferon signature and",
            "probability": 0.0
        }
    ],
    "58e7902b3e8b6dc87c000007_6": [
        {
            "start_logit": 9.8828125,
            "end_logit": 9.515625,
            "text": "interferon signature",
            "probability": 1.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -2.08203125,
            "text": "interferon",
            "probability": 9.059906005859375e-06
        },
        {
            "start_logit": -2.255859375,
            "end_logit": 9.515625,
            "text": "signature",
            "probability": 5.304813385009766e-06
        },
        {
            "start_logit": -7.71875,
            "end_logit": 9.515625,
            "text": "I interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 9.515625,
            "text": "type I interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.3828125,
            "text": "interferon signature in rheumatoid arthritis",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.515625,
            "text": "the type I interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 9.515625,
            "text": "application to the type I interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.515625,
            "text": "to the type I interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.515625,
            "text": "Importance of correlation between gene expression levels: application to the type I interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.515625,
            "text": "of correlation between gene expression levels: application to the type I interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -7.71875,
            "end_logit": -2.08203125,
            "text": "I interferon",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -2.08203125,
            "text": "type I interferon",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": -2.08203125,
            "text": "the type I interferon",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -2.08203125,
            "text": "application to the type I interferon",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -2.08203125,
            "text": "to the type I interferon",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": -2.08203125,
            "text": "Importance of correlation between gene expression levels: application to the type I interferon",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": -2.08203125,
            "text": "of correlation between gene expression levels: application to the type I interferon",
            "probability": 0.0
        },
        {
            "start_logit": -2.255859375,
            "end_logit": -8.3828125,
            "text": "signature in rheumatoid arthritis",
            "probability": 0.0
        },
        {
            "start_logit": -7.71875,
            "end_logit": -8.3828125,
            "text": "I interferon signature in rheumatoid arthritis",
            "probability": 0.0
        }
    ],
    "517170c48ed59a060a00000d_1": [
        {
            "start_logit": 8.9140625,
            "end_logit": 7.63671875,
            "text": "25",
            "probability": 1.0
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -5.97265625,
            "text": "25 selenoproteins",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -7.8515625,
            "text": "25 selenoproteins.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.703125,
            "end_logit": 7.63671875,
            "text": "of 25",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 7.63671875,
            "text": "The human selenoproteome consists of 25",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 7.63671875,
            "text": "human selenoproteome consists of 25",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.125,
            "end_logit": 7.63671875,
            "text": "selenoproteome consists of 25",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.66796875,
            "end_logit": -5.97265625,
            "text": "selenoproteins",
            "probability": 0.0
        },
        {
            "start_logit": -7.703125,
            "end_logit": -5.97265625,
            "text": "of 25 selenoproteins",
            "probability": 0.0
        },
        {
            "start_logit": -7.9453125,
            "end_logit": -5.97265625,
            "text": "The human selenoproteome consists of 25 selenoproteins",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": -5.97265625,
            "text": "human selenoproteome consists of 25 selenoproteins",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -5.97265625,
            "text": "selenoproteome consists of 25 selenoproteins",
            "probability": 0.0
        },
        {
            "start_logit": -6.66796875,
            "end_logit": -7.8515625,
            "text": "selenoproteins.",
            "probability": 0.0
        },
        {
            "start_logit": -7.125,
            "end_logit": -7.8515625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.703125,
            "end_logit": -7.8515625,
            "text": "of 25 selenoproteins.",
            "probability": 0.0
        },
        {
            "start_logit": -7.9453125,
            "end_logit": -7.7890625,
            "text": "The human selenoproteome consists",
            "probability": 0.0
        },
        {
            "start_logit": -7.9453125,
            "end_logit": -7.8515625,
            "text": "The human selenoproteome consists of 25 selenoproteins.",
            "probability": 0.0
        },
        {
            "start_logit": -7.9453125,
            "end_logit": -7.87109375,
            "text": "The human selenoproteome",
            "probability": 0.0
        },
        {
            "start_logit": -7.9453125,
            "end_logit": -7.890625,
            "text": "The human selenoprote",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": -7.7890625,
            "text": "human selenoproteome consists",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_1": [
        {
            "start_logit": 10.015625,
            "end_logit": 9.7890625,
            "text": "XXY",
            "probability": 1.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -1.79296875,
            "text": "XX",
            "probability": 9.238719940185547e-06
        },
        {
            "start_logit": -1.7119140625,
            "end_logit": 9.7890625,
            "text": "Y",
            "probability": 7.987022399902344e-06
        },
        {
            "start_logit": -8.09375,
            "end_logit": 9.7890625,
            "text": "(XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.7890625,
            "text": "Klinefelter syndrome (XXY",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.453125,
            "text": "XXY)",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": -1.79296875,
            "text": "(XX",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -1.79296875,
            "text": "Klinefelter syndrome (XX",
            "probability": 0.0
        },
        {
            "start_logit": -1.7119140625,
            "end_logit": -8.453125,
            "text": "Y)",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": -8.453125,
            "text": "(XXY)",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -8.4453125,
            "text": "Klinefe",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -8.4453125,
            "text": "Klinefelter syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -8.453125,
            "text": "Klinefelter syndrome (XXY)",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -8.453125,
            "text": "Klinefelt",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -8.453125,
            "text": ")",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_2": [
        {
            "start_logit": 9.984375,
            "end_logit": 9.7890625,
            "text": "XXY",
            "probability": 1.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -1.873046875,
            "text": "XX",
            "probability": 8.52346420288086e-06
        },
        {
            "start_logit": -1.681640625,
            "end_logit": 9.7890625,
            "text": "Y",
            "probability": 8.52346420288086e-06
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.7890625,
            "text": ",XXY",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.265625,
            "text": "XXY or Klinefelter syndrome). 47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.28125,
            "text": "XXY or Klinefelter syndrome). 47,XX",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.7890625,
            "text": "About 1 in 650 boys are born with an extra X chromosome (47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 9.7890625,
            "text": "with an extra X chromosome (47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.7890625,
            "text": "extra X chromosome (47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.7890625,
            "text": "an extra X chromosome (47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.7890625,
            "text": "1 in 650 boys are born with an extra X chromosome (47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.4375,
            "text": "XXY or Klinefelter syndrome)",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.4375,
            "text": "XXY or Klinefelt",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.4375,
            "text": "XXY or Klinefe",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.7890625,
            "text": "(47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.7890625,
            "text": "are born with an extra X chromosome (47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.7890625,
            "text": "boys are born with an extra X chromosome (47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.7890625,
            "text": "in 650 boys are born with an extra X chromosome (47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": -1.873046875,
            "text": ",XX",
            "probability": 0.0
        },
        {
            "start_logit": -1.681640625,
            "end_logit": -8.265625,
            "text": "Y or Klinefelter syndrome). 47,XXY",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_3": [
        {
            "start_logit": 10.03125,
            "end_logit": 9.8046875,
            "text": "XXY",
            "probability": 1.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -1.78515625,
            "text": "XX",
            "probability": 9.238719940185547e-06
        },
        {
            "start_logit": -1.638671875,
            "end_logit": 9.8046875,
            "text": "Y",
            "probability": 8.463859558105469e-06
        },
        {
            "start_logit": -7.73046875,
            "end_logit": 9.8046875,
            "text": ",XXY",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.3359375,
            "text": "XXY), and the characteristic clinical findings include tall stature, immaturity of external genitalia",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.359375,
            "text": "XXY)",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.390625,
            "text": "XXY), and the characteristic clinical findings include tall stature, immaturity",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.40625,
            "text": "XXY),",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.4140625,
            "text": "XXY), and the characteristic clinical findings include tall stature, immaturity of external genitalia, testicular",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 9.8046875,
            "text": ", Klinefelter syndrome is well recognized chromosomal abnormality caused by an additional X chromosome in males (47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.8046875,
            "text": "Klinefelter syndrome is well recognized chromosomal abnormality caused by an additional X chromosome in males (47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 9.8046875,
            "text": "by an additional X chromosome in males (47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 9.8046875,
            "text": "an additional X chromosome in males (47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.8046875,
            "text": "On the other hand, Klinefelter syndrome is well recognized chromosomal abnormality caused by an additional X chromosome in males (47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.8046875,
            "text": "additional X chromosome in males (47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.8046875,
            "text": "other hand, Klinefelter syndrome is well recognized chromosomal abnormality caused by an additional X chromosome in males (47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.8046875,
            "text": "recognized chromosomal abnormality caused by an additional X chromosome in males (47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -7.73046875,
            "end_logit": -1.78515625,
            "text": ",XX",
            "probability": 0.0
        },
        {
            "start_logit": -1.638671875,
            "end_logit": -8.3359375,
            "text": "Y), and the characteristic clinical findings include tall stature, immaturity of external genitalia",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": -1.78515625,
            "text": ", Klinefelter syndrome is well recognized chromosomal abnormality caused by an additional X chromosome in males (47,XX",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_4": [
        {
            "start_logit": 10.0390625,
            "end_logit": 9.8046875,
            "text": "XXY",
            "probability": 1.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -1.7373046875,
            "text": "XX",
            "probability": 9.715557098388672e-06
        },
        {
            "start_logit": -1.6552734375,
            "end_logit": 9.8046875,
            "text": "Y",
            "probability": 8.344650268554688e-06
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.2734375,
            "text": "XXY; the extra sex chromosome is due to meiotic chromosomal nondisjunction",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.296875,
            "text": "XXY; the extra sex chromosome is due to meiotic chromosomal nondis",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.3046875,
            "text": "XXY; the extra sex chromosome is due",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.3125,
            "text": "XXY; the extra sex",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.3203125,
            "text": "XXY; the extra sex chromosome is due to meiotic chromosomal nond",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.3359375,
            "text": "XXY; the extra sex chromosome is",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.3359375,
            "text": "XXY; the extra sex chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.8046875,
            "text": ", XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.8046875,
            "text": "for Klinefelter syndrome is 47, XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.8046875,
            "text": "The formal cytogenetic designation for Klinefelter syndrome is 47, XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.8046875,
            "text": "designation for Klinefelter syndrome is 47, XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.8046875,
            "text": "Klinefelter syndrome is 47, XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.8046875,
            "text": "is 47, XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -1.7373046875,
            "text": ", XX",
            "probability": 0.0
        },
        {
            "start_logit": -1.6552734375,
            "end_logit": -8.2734375,
            "text": "Y; the extra sex chromosome is due to meiotic chromosomal nondisjunction",
            "probability": 0.0
        },
        {
            "start_logit": -1.6552734375,
            "end_logit": -8.296875,
            "text": "Y; the extra sex chromosome is due to meiotic chromosomal nondis",
            "probability": 0.0
        },
        {
            "start_logit": -1.6552734375,
            "end_logit": -8.3046875,
            "text": "Y; the extra sex chromosome is due",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_5": [
        {
            "start_logit": 10.0625,
            "end_logit": 9.8203125,
            "text": "XXY",
            "probability": 1.0
        },
        {
            "start_logit": 10.0625,
            "end_logit": -1.6845703125,
            "text": "XX",
            "probability": 1.0132789611816406e-05
        },
        {
            "start_logit": -1.607421875,
            "end_logit": 9.8203125,
            "text": "Y",
            "probability": 8.58306884765625e-06
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 9.8203125,
            "text": ",XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.8203125,
            "text": "Klinefelter syndrome (KS) is characterized by an additional X chromosome in males leading to a karyotype of 47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.8203125,
            "text": "a karyotype of 47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.8203125,
            "text": "by an additional X chromosome in males leading to a karyotype of 47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.8203125,
            "text": "X chromosome in males leading to a karyotype of 47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": 9.8203125,
            "text": "an additional X chromosome in males leading to a karyotype of 47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": -1.6845703125,
            "text": ",XX",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": -1.6845703125,
            "text": "Klinefelter syndrome (KS) is characterized by an additional X chromosome in males leading to a karyotype of 47,XX",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -1.6845703125,
            "text": "a karyotype of 47,XX",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": -1.6845703125,
            "text": "by an additional X chromosome in males leading to a karyotype of 47,XX",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": -1.6845703125,
            "text": "X chromosome in males leading to a karyotype of 47,XX",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": -1.6845703125,
            "text": "an additional X chromosome in males leading to a karyotype of 47,XX",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": -7.953125,
            "text": "Klinefelter syndrome (KS) is characterized by an additional X",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": -7.953125,
            "text": "by an additional X",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": -7.953125,
            "text": "X",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": -7.953125,
            "text": "an additional X",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": -8.2578125,
            "text": "Klinefelter syndrome (KS) is characterized by an additional X chromosome in",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_6": [
        {
            "start_logit": 10.0078125,
            "end_logit": 9.828125,
            "text": "XXY",
            "probability": 1.0
        },
        {
            "start_logit": -1.5888671875,
            "end_logit": 9.828125,
            "text": "Y",
            "probability": 9.179115295410156e-06
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -1.8271484375,
            "text": "XX",
            "probability": 8.58306884765625e-06
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.828125,
            "text": ",XXY",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.40625,
            "text": "XXY chromosomal abnormality, has been shown to be associated with a number of malignancies, but has not been linked to acute leukemias to",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.4140625,
            "text": "XXY chromosomal abnormality, has been shown to be associated with a number of malignancies, but has not been linked to acute leukemias to date",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.421875,
            "text": "XXY chromosomal abnormality,",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.421875,
            "text": "XXY chromosomal",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.421875,
            "text": "XXY chromosomal abnormality, has been shown to be associated with a number of malignancies, but has not been linked to acute leukemias to date. We p",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": -1.8271484375,
            "text": ",XX",
            "probability": 0.0
        },
        {
            "start_logit": -1.5888671875,
            "end_logit": -8.40625,
            "text": "Y chromosomal abnormality, has been shown to be associated with a number of malignancies, but has not been linked to acute leukemias to",
            "probability": 0.0
        },
        {
            "start_logit": -1.5888671875,
            "end_logit": -8.4140625,
            "text": "Y chromosomal abnormality, has been shown to be associated with a number of malignancies, but has not been linked to acute leukemias to date",
            "probability": 0.0
        },
        {
            "start_logit": -1.5888671875,
            "end_logit": -8.421875,
            "text": "Y chromosomal abnormality,",
            "probability": 0.0
        },
        {
            "start_logit": -1.5888671875,
            "end_logit": -8.421875,
            "text": "Y chromosomal",
            "probability": 0.0
        },
        {
            "start_logit": -1.5888671875,
            "end_logit": -8.421875,
            "text": "Y chromosomal abnormality, has been shown to be associated with a number of malignancies, but has not been linked to acute leukemias to date. We p",
            "probability": 0.0
        },
        {
            "start_logit": -6.1328125,
            "end_logit": -8.421875,
            "text": ". We p",
            "probability": 0.0
        },
        {
            "start_logit": -7.984375,
            "end_logit": -8.40625,
            "text": "with a number of malignancies, but has not been linked to acute leukemias to",
            "probability": 0.0
        },
        {
            "start_logit": -7.984375,
            "end_logit": -8.4140625,
            "text": "with a number of malignancies, but has not been linked to acute leukemias to date",
            "probability": 0.0
        },
        {
            "start_logit": -7.984375,
            "end_logit": -8.421875,
            "text": "with a number of malignancies, but has not been linked to acute leukemias to date. We p",
            "probability": 0.0
        },
        {
            "start_logit": -8.0,
            "end_logit": -8.40625,
            "text": "associated with a number of malignancies, but has not been linked to acute leukemias to",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_7": [
        {
            "start_logit": 10.0390625,
            "end_logit": 9.8125,
            "text": "XXY",
            "probability": 1.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -1.7333984375,
            "text": "XX",
            "probability": 9.715557098388672e-06
        },
        {
            "start_logit": -1.63671875,
            "end_logit": 9.8125,
            "text": "Y",
            "probability": 8.52346420288086e-06
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.3125,
            "text": "XXY; the extra sex",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.328125,
            "text": "XXY; the extra sex chromosome is due to meiotic chromosomal nondisjunction",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.3359375,
            "text": "XXY; the extra sex chromosome is due",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.34375,
            "text": "XXY; the extra sex chromosome",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.359375,
            "text": "XXY; the extra sex chromosome is due to meiotic chromosomal nondis",
            "probability": 0.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -8.3671875,
            "text": "XXY; the extra sex chromosome is due to meiotic chromosomal nond",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.8125,
            "text": ", XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.8125,
            "text": "for Klinefelter syndrome is 47, XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.8125,
            "text": "Klinefelter syndrome is 47, XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.8125,
            "text": "is 47, XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.8125,
            "text": "designation for Klinefelter syndrome is 47, XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.8125,
            "text": "inefelter syndrome is 47, XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -1.7333984375,
            "text": ", XX",
            "probability": 0.0
        },
        {
            "start_logit": -1.63671875,
            "end_logit": -8.3125,
            "text": "Y; the extra sex",
            "probability": 0.0
        },
        {
            "start_logit": -1.63671875,
            "end_logit": -8.328125,
            "text": "Y; the extra sex chromosome is due to meiotic chromosomal nondisjunction",
            "probability": 0.0
        },
        {
            "start_logit": -1.63671875,
            "end_logit": -8.3359375,
            "text": "Y; the extra sex chromosome is due",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -1.7333984375,
            "text": "for Klinefelter syndrome is 47, XX",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_8": [
        {
            "start_logit": 9.9609375,
            "end_logit": 9.625,
            "text": "XXY",
            "probability": 1.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -1.9560546875,
            "text": "XX",
            "probability": 9.298324584960938e-06
        },
        {
            "start_logit": -2.048828125,
            "end_logit": 9.625,
            "text": "Y",
            "probability": 6.020069122314453e-06
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.0859375,
            "text": "XXY chromosomal abnormality may",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.09375,
            "text": "XXY chromosomal abnormality",
            "probability": 0.0
        },
        {
            "start_logit": -7.875,
            "end_logit": 9.625,
            "text": "A case of Klinefelter's syndrome with the development of a mediastinal teratocarcinoma is reported suggesting that the association of a gonadotropin-secreting tumor with the XXY",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.21875,
            "text": "XXY chromosomal",
            "probability": 0.0
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 9.625,
            "text": "case of Klinefelter's syndrome with the development of a mediastinal teratocarcinoma is reported suggesting that the association of a gonadotropin-secreting tumor with the XXY",
            "probability": 0.0
        },
        {
            "start_logit": -7.94921875,
            "end_logit": 9.625,
            "text": "a mediastinal teratocarcinoma is reported suggesting that the association of a gonadotropin-secreting tumor with the XXY",
            "probability": 0.0
        },
        {
            "start_logit": -7.94921875,
            "end_logit": 9.625,
            "text": "of Klinefelter's syndrome with the development of a mediastinal teratocarcinoma is reported suggesting that the association of a gonadotropin-secreting tumor with the XXY",
            "probability": 0.0
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 9.625,
            "text": "the development of a mediastinal teratocarcinoma is reported suggesting that the association of a gonadotropin-secreting tumor with the XXY",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.3671875,
            "text": "XXY chromosomal abnormality may be more",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.375,
            "text": "XXY chromosomal abnormality may be more than",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.375,
            "text": "XXY chromosomal abnormality may be more than coincidental.",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 9.625,
            "text": "a gonadotropin-secreting tumor with the XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 9.625,
            "text": "the association of a gonadotropin-secreting tumor with the XXY",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.4140625,
            "text": "XXY chromosomal abnormality may be more than coincidental",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.625,
            "text": "of a mediastinal teratocarcinoma is reported suggesting that the association of a gonadotropin-secreting tumor with the XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": 9.625,
            "text": "development of a mediastinal teratocarcinoma is reported suggesting that the association of a gonadotropin-secreting tumor with the XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.625,
            "text": "Klinefelter's syndrome with the development of a mediastinal teratocarcinoma is reported suggesting that the association of a gonadotropin-secreting tumor with the XXY",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_9": [
        {
            "start_logit": 10.03125,
            "end_logit": 9.8203125,
            "text": "XXY",
            "probability": 1.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -1.7431640625,
            "text": "XX",
            "probability": 9.59634780883789e-06
        },
        {
            "start_logit": -1.615234375,
            "end_logit": 9.8203125,
            "text": "Y",
            "probability": 8.821487426757812e-06
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.8203125,
            "text": ", XXY",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.3203125,
            "text": "XXY karyotype associated with hypogonadism and infertility",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.3203125,
            "text": "XXY karyotype",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.34375,
            "text": "XXY karyotype associated with hypogonadism",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.8203125,
            "text": "a 47, XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 9.8203125,
            "text": "by a 47, XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.8203125,
            "text": "a chromosomal abnormality characterised by a 47, XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 9.8203125,
            "text": "Klinefelter syndrome (KS) is a chromosomal abnormality characterised by a 47, XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.359375,
            "end_logit": 9.8203125,
            "text": "abnormality characterised by a 47, XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": -1.7431640625,
            "text": ", XX",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -1.7431640625,
            "text": "a 47, XX",
            "probability": 0.0
        },
        {
            "start_logit": -1.615234375,
            "end_logit": -8.3203125,
            "text": "Y karyotype associated with hypogonadism and infertility",
            "probability": 0.0
        },
        {
            "start_logit": -1.615234375,
            "end_logit": -8.3203125,
            "text": "Y karyotype",
            "probability": 0.0
        },
        {
            "start_logit": -1.615234375,
            "end_logit": -8.34375,
            "text": "Y karyotype associated with hypogonadism",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -1.7431640625,
            "text": "by a 47, XX",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": -1.7431640625,
            "text": "a chromosomal abnormality characterised by a 47, XX",
            "probability": 0.0
        },
        {
            "start_logit": -8.3515625,
            "end_logit": -1.7431640625,
            "text": "Klinefelter syndrome (KS) is a chromosomal abnormality characterised by a 47, XX",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_10": [
        {
            "start_logit": 10.0703125,
            "end_logit": 9.8046875,
            "text": "XXY",
            "probability": 1.0
        },
        {
            "start_logit": 10.0703125,
            "end_logit": -1.6640625,
            "text": "XX",
            "probability": 1.043081283569336e-05
        },
        {
            "start_logit": -1.6376953125,
            "end_logit": 9.8046875,
            "text": "Y",
            "probability": 8.225440979003906e-06
        },
        {
            "start_logit": -6.30859375,
            "end_logit": 9.8046875,
            "text": ". The most common cytogenetic defects associated with nonobstructive azoospermia are numerical and structural chromosome abnormalities, including Klinefelter syndrome (47,XXY",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.71484375,
            "end_logit": 9.8046875,
            "text": ",XXY",
            "probability": 0.0
        },
        {
            "start_logit": 10.0703125,
            "end_logit": -8.1015625,
            "text": "XXY) and Y",
            "probability": 0.0
        },
        {
            "start_logit": 10.0703125,
            "end_logit": -8.296875,
            "text": "XXY) and Y chromosome microd",
            "probability": 0.0
        },
        {
            "start_logit": 10.0703125,
            "end_logit": -8.3046875,
            "text": "XXY) and Y chromosome microdelet",
            "probability": 0.0
        },
        {
            "start_logit": 10.0703125,
            "end_logit": -8.3125,
            "text": "XXY) and Y chromosome microdeletions",
            "probability": 0.0
        },
        {
            "start_logit": 10.0703125,
            "end_logit": -8.3359375,
            "text": "XXY)",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 9.8046875,
            "text": "with nonobstructive azoospermia are numerical and structural chromosome abnormalities, including Klinefelter syndrome (47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.8046875,
            "text": "and structural chromosome abnormalities, including Klinefelter syndrome (47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.8046875,
            "text": "including Klinefelter syndrome (47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.8046875,
            "text": "nonobstructive azoospermia are numerical and structural chromosome abnormalities, including Klinefelter syndrome (47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.8046875,
            "text": "abnormalities, including Klinefelter syndrome (47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.8046875,
            "text": "chromosome abnormalities, including Klinefelter syndrome (47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.8046875,
            "text": "obstructive azoospermia are numerical and structural chromosome abnormalities, including Klinefelter syndrome (47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -6.30859375,
            "end_logit": -1.6640625,
            "text": ". The most common cytogenetic defects associated with nonobstructive azoospermia are numerical and structural chromosome abnormalities, including Klinefelter syndrome (47,XX",
            "probability": 0.0
        },
        {
            "start_logit": -7.71484375,
            "end_logit": -1.6640625,
            "text": ",XX",
            "probability": 0.0
        },
        {
            "start_logit": -1.6376953125,
            "end_logit": -8.1015625,
            "text": "Y) and Y",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_11": [
        {
            "start_logit": 10.0234375,
            "end_logit": 9.7890625,
            "text": "XXY",
            "probability": 1.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -1.8134765625,
            "text": "XX",
            "probability": 9.179115295410156e-06
        },
        {
            "start_logit": -1.67578125,
            "end_logit": 9.7890625,
            "text": "Y",
            "probability": 8.285045623779297e-06
        },
        {
            "start_logit": -7.7578125,
            "end_logit": 9.7890625,
            "text": ",XXY",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.3515625,
            "text": "XXY), and the characteristic clinical findings include tall stature, immaturity of external genitalia",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.7890625,
            "text": ", Klinefelter syndrome is well recognized chromosomal abnormality caused by an additional X chromosome in males (47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.7890625,
            "text": "an additional X chromosome in males (47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.7890625,
            "text": "other hand, Klinefelter syndrome is well recognized chromosomal abnormality caused by an additional X chromosome in males (47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.7890625,
            "text": "Klinefelter syndrome is well recognized chromosomal abnormality caused by an additional X chromosome in males (47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.4140625,
            "text": "XXY), and the characteristic clinical findings include tall stature, immaturity",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.4296875,
            "text": "XXY)",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 9.7890625,
            "text": "by an additional X chromosome in males (47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 9.7890625,
            "text": "additional X chromosome in males (47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.4375,
            "text": "XXY), and the characteristic clinical findings include tall stature, immaturity of external genitalia, testicular",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.4375,
            "text": "XXY),",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.7890625,
            "text": "recognized chromosomal abnormality caused by an additional X chromosome in males (47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -7.7578125,
            "end_logit": -1.8134765625,
            "text": ",XX",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": -1.8134765625,
            "text": ", Klinefelter syndrome is well recognized chromosomal abnormality caused by an additional X chromosome in males (47,XX",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": -1.8134765625,
            "text": "an additional X chromosome in males (47,XX",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": -1.8134765625,
            "text": "other hand, Klinefelter syndrome is well recognized chromosomal abnormality caused by an additional X chromosome in males (47,XX",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_12": [
        {
            "start_logit": 9.9921875,
            "end_logit": 9.7109375,
            "text": "XXY",
            "probability": 1.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -1.8671875,
            "text": "XX",
            "probability": 9.357929229736328e-06
        },
        {
            "start_logit": -1.8857421875,
            "end_logit": 9.7109375,
            "text": "Y",
            "probability": 6.973743438720703e-06
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 9.7109375,
            "text": ", XXY",
            "probability": 0.0
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 9.7109375,
            "text": "(10.9%) were found to have chromosomal abnormalities in which Klinefelter's syndrome (47, XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 9.7109375,
            "text": ") were found to have chromosomal abnormalities in which Klinefelter's syndrome (47, XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 9.7109375,
            "text": "patients, 39(10.9%) were found to have chromosomal abnormalities in which Klinefelter's syndrome (47, XXY",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.3671875,
            "text": "XXY) was the most",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.375,
            "text": "XXY)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.3984375,
            "text": "XXY) was",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.421875,
            "text": "XXY) was the",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 9.7109375,
            "text": "which Klinefelter's syndrome (47, XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 9.7109375,
            "text": "found to have chromosomal abnormalities in which Klinefelter's syndrome (47, XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.7109375,
            "text": "have chromosomal abnormalities in which Klinefelter's syndrome (47, XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 9.7109375,
            "text": ", 39(10.9%) were found to have chromosomal abnormalities in which Klinefelter's syndrome (47, XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.7109375,
            "text": "8 patients, 39(10.9%) were found to have chromosomal abnormalities in which Klinefelter's syndrome (47, XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.7109375,
            "text": ".9%) were found to have chromosomal abnormalities in which Klinefelter's syndrome (47, XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.7109375,
            "text": "were found to have chromosomal abnormalities in which Klinefelter's syndrome (47, XXY",
            "probability": 0.0
        },
        {
            "start_logit": -7.6796875,
            "end_logit": -1.8671875,
            "text": ", XX",
            "probability": 0.0
        },
        {
            "start_logit": -7.8671875,
            "end_logit": -1.8671875,
            "text": "(10.9%) were found to have chromosomal abnormalities in which Klinefelter's syndrome (47, XX",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_13": [
        {
            "start_logit": 10.03125,
            "end_logit": 9.8046875,
            "text": "XXY",
            "probability": 1.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -1.75,
            "text": "XX",
            "probability": 9.5367431640625e-06
        },
        {
            "start_logit": -1.66015625,
            "end_logit": 9.8046875,
            "text": "Y",
            "probability": 8.285045623779297e-06
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.3203125,
            "text": "XXY karyotype associated with hypogonadism and infertility",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.3203125,
            "text": "XXY karyotype",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.34375,
            "text": "XXY karyotype associated with hypogonadism",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 9.8046875,
            "text": ", XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.8046875,
            "text": "a 47, XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.8046875,
            "text": "by a 47, XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -1.75,
            "text": ", XX",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -1.75,
            "text": "a 47, XX",
            "probability": 0.0
        },
        {
            "start_logit": -1.66015625,
            "end_logit": -8.3203125,
            "text": "Y karyotype associated with hypogonadism and infertility",
            "probability": 0.0
        },
        {
            "start_logit": -1.66015625,
            "end_logit": -8.3203125,
            "text": "Y karyotype",
            "probability": 0.0
        },
        {
            "start_logit": -1.66015625,
            "end_logit": -8.34375,
            "text": "Y karyotype associated with hypogonadism",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": -1.75,
            "text": "by a 47, XX",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -8.3203125,
            "text": ", XXY karyotype associated with hypogonadism and infertility",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -8.3203125,
            "text": ", XXY karyotype",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -8.34375,
            "text": ", XXY karyotype associated with hypogonadism",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": -8.3203125,
            "text": "with hypogonadism and infertility",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": -8.34375,
            "text": "with hypogonadism",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_14": [
        {
            "start_logit": 10.1015625,
            "end_logit": 9.9140625,
            "text": "XXY",
            "probability": 1.0
        },
        {
            "start_logit": -1.328125,
            "end_logit": 9.9140625,
            "text": "Y",
            "probability": 1.0848045349121094e-05
        },
        {
            "start_logit": 10.1015625,
            "end_logit": -1.5830078125,
            "text": "XX",
            "probability": 1.0132789611816406e-05
        },
        {
            "start_logit": 10.1015625,
            "end_logit": -8.1640625,
            "text": "XXY, XXYY, XXXY and XX",
            "probability": 0.0
        },
        {
            "start_logit": 10.1015625,
            "end_logit": -8.203125,
            "text": "XXY, XXYY, XX",
            "probability": 0.0
        },
        {
            "start_logit": 10.1015625,
            "end_logit": -8.203125,
            "text": "XXY, XX",
            "probability": 0.0
        },
        {
            "start_logit": 10.1015625,
            "end_logit": -8.265625,
            "text": "XXY, XXYY, XXXY and XXX",
            "probability": 0.0
        },
        {
            "start_logit": 10.1015625,
            "end_logit": -8.2734375,
            "text": "XXY, XXYY",
            "probability": 0.0
        },
        {
            "start_logit": 10.1015625,
            "end_logit": -8.3203125,
            "text": "XXY, XXYY, XXXY and XXXXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.9140625,
            "text": "with a variety of different sex chromosome anomalies including XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.9140625,
            "text": "a variety of different sex chromosome anomalies including XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.9140625,
            "text": "sex chromosome anomalies including XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.9140625,
            "text": "Klinefelter's syndrome may be associated with a variety of different sex chromosome anomalies including XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.9140625,
            "text": "associated with a variety of different sex chromosome anomalies including XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.9140625,
            "text": "including XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.9140625,
            "text": "different sex chromosome anomalies including XXY",
            "probability": 0.0
        },
        {
            "start_logit": -1.328125,
            "end_logit": -8.1640625,
            "text": "Y, XXYY, XXXY and XX",
            "probability": 0.0
        },
        {
            "start_logit": -1.328125,
            "end_logit": -8.203125,
            "text": "Y, XXYY, XX",
            "probability": 0.0
        },
        {
            "start_logit": -1.328125,
            "end_logit": -8.203125,
            "text": "Y, XX",
            "probability": 0.0
        },
        {
            "start_logit": -1.328125,
            "end_logit": -8.265625,
            "text": "Y, XXYY, XXXY and XXX",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_15": [
        {
            "start_logit": 10.0078125,
            "end_logit": 9.7890625,
            "text": "XXY",
            "probability": 1.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -1.818359375,
            "text": "XX",
            "probability": 9.059906005859375e-06
        },
        {
            "start_logit": -1.689453125,
            "end_logit": 9.7890625,
            "text": "Y",
            "probability": 8.344650268554688e-06
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.375,
            "text": "XXY chromosomal pattern",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.4140625,
            "text": "XXY chromosomal",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.7890625,
            "text": ",XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.7890625,
            "text": "by a 47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.7890625,
            "text": "a 47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.7890625,
            "text": ", characterised by a 47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.7890625,
            "text": "characterised by a 47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": 9.7890625,
            "text": "Klinefelter's syndrome, characterised by a 47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": 9.7890625,
            "text": "syndrome, characterised by a 47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -1.818359375,
            "text": ",XX",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -1.818359375,
            "text": "by a 47,XX",
            "probability": 0.0
        },
        {
            "start_logit": -1.689453125,
            "end_logit": -8.375,
            "text": "Y chromosomal pattern",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -1.818359375,
            "text": "a 47,XX",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": -1.818359375,
            "text": ", characterised by a 47,XX",
            "probability": 0.0
        },
        {
            "start_logit": -1.689453125,
            "end_logit": -8.4140625,
            "text": "Y chromosomal",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": -1.818359375,
            "text": "characterised by a 47,XX",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": -1.818359375,
            "text": "Klinefelter's syndrome, characterised by a 47,XX",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_16": [
        {
            "start_logit": 10.015625,
            "end_logit": 9.8203125,
            "text": "XXY",
            "probability": 1.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -1.787109375,
            "text": "XX",
            "probability": 9.000301361083984e-06
        },
        {
            "start_logit": -1.6064453125,
            "end_logit": 9.8203125,
            "text": "Y",
            "probability": 8.881092071533203e-06
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.234375,
            "text": "XXY,t(13q;14q)",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.8203125,
            "text": ",XXY",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.2890625,
            "text": "XXY,t(13",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.2890625,
            "text": "XXY,t(13q;14",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.3125,
            "text": "XXY,t(13q;14q",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.3125,
            "text": "XXY,t(13q",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.328125,
            "text": "XXY,t(13q;",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.8203125,
            "text": "with 13/14 translocation abnormality 46,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.8203125,
            "text": "abnormality 46,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": -1.787109375,
            "text": ",XX",
            "probability": 0.0
        },
        {
            "start_logit": -1.6064453125,
            "end_logit": -8.234375,
            "text": "Y,t(13q;14q)",
            "probability": 0.0
        },
        {
            "start_logit": -1.6064453125,
            "end_logit": -8.2890625,
            "text": "Y,t(13",
            "probability": 0.0
        },
        {
            "start_logit": -1.6064453125,
            "end_logit": -8.2890625,
            "text": "Y,t(13q;14",
            "probability": 0.0
        },
        {
            "start_logit": -1.6064453125,
            "end_logit": -8.3125,
            "text": "Y,t(13q;14q",
            "probability": 0.0
        },
        {
            "start_logit": -1.6064453125,
            "end_logit": -8.3125,
            "text": "Y,t(13q",
            "probability": 0.0
        },
        {
            "start_logit": -1.6064453125,
            "end_logit": -8.328125,
            "text": "Y,t(13q;",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": -1.787109375,
            "text": "with 13/14 translocation abnormality 46,XX",
            "probability": 0.0
        }
    ],
    "56c8f4615795f9a73e00001a_1": [
        {
            "start_logit": 9.96875,
            "end_logit": 9.53125,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -1.9267578125,
            "text": "GBs",
            "probability": 1.055002212524414e-05
        },
        {
            "start_logit": -2.322265625,
            "end_logit": 9.53125,
            "text": "e",
            "probability": 4.589557647705078e-06
        },
        {
            "start_logit": -5.796875,
            "end_logit": 9.53125,
            "text": "hape",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.1328125,
            "text": "GBshap",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.375,
            "text": "GBshape: a genome browser database for DNA shape",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.3828125,
            "text": "GBshape: a genome browser database",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.390625,
            "text": "GBshape:",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.40625,
            "text": "GBshape: a genome browser database for DNA shape annotations",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.40625,
            "text": "GBshape: a",
            "probability": 0.0
        },
        {
            "start_logit": -2.322265625,
            "end_logit": -8.375,
            "text": "e: a genome browser database for DNA shape",
            "probability": 0.0
        },
        {
            "start_logit": -2.322265625,
            "end_logit": -8.3828125,
            "text": "e: a genome browser database",
            "probability": 0.0
        },
        {
            "start_logit": -2.322265625,
            "end_logit": -8.390625,
            "text": "e:",
            "probability": 0.0
        },
        {
            "start_logit": -2.322265625,
            "end_logit": -8.40625,
            "text": "e: a genome browser database for DNA shape annotations",
            "probability": 0.0
        },
        {
            "start_logit": -2.322265625,
            "end_logit": -8.40625,
            "text": "e: a",
            "probability": 0.0
        },
        {
            "start_logit": -5.796875,
            "end_logit": -8.1328125,
            "text": "hap",
            "probability": 0.0
        },
        {
            "start_logit": -5.796875,
            "end_logit": -8.375,
            "text": "hape: a genome browser database for DNA shape",
            "probability": 0.0
        },
        {
            "start_logit": -5.796875,
            "end_logit": -8.3828125,
            "text": "hape: a genome browser database",
            "probability": 0.0
        },
        {
            "start_logit": -5.796875,
            "end_logit": -8.390625,
            "text": "hape:",
            "probability": 0.0
        },
        {
            "start_logit": -5.796875,
            "end_logit": -8.40625,
            "text": "hape: a genome browser database for DNA shape annotations",
            "probability": 0.0
        }
    ],
    "56c8f4615795f9a73e00001a_2": [
        {
            "start_logit": 9.984375,
            "end_logit": 9.578125,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -1.912109375,
            "text": "GBs",
            "probability": 1.0192394256591797e-05
        },
        {
            "start_logit": -2.205078125,
            "end_logit": 9.578125,
            "text": "e",
            "probability": 5.066394805908203e-06
        },
        {
            "start_logit": -5.390625,
            "end_logit": 9.578125,
            "text": "hape",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.015625,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.015625,
            "text": "GBshape; freely available at http://rohslab.cmb.usc",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.0546875,
            "text": "GBshape; freely available at http://rohslab",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.0625,
            "text": "GBshape; freely available at http://rohslab.cmb.us",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.1328125,
            "text": "GBshape; freely available at http://rohslab.cm",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.1484375,
            "text": "GBshape; freely available at http://rohslab.cmb",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.1640625,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.1875,
            "text": "GBshape; freely available at http://rohslab.",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.1875,
            "text": "GBshape; freely available at http:/",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.203125,
            "text": "GBshape; freely available at http://rohslab.cmb.",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.2265625,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape/",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.2578125,
            "text": "GBshap",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.265625,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBs",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.296875,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.3125,
            "text": "GBshape; freely available at http://rohs",
            "probability": 0.0
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 9.578125,
            "text": "Genome Browser for DNA shape annotations (GBshape",
            "probability": 0.0
        }
    ],
    "56c8f4615795f9a73e00001a_3": [
        {
            "start_logit": 9.9765625,
            "end_logit": 9.5546875,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -1.9150390625,
            "text": "GBs",
            "probability": 1.043081283569336e-05
        },
        {
            "start_logit": -2.28515625,
            "end_logit": 9.5546875,
            "text": "e",
            "probability": 4.708766937255859e-06
        },
        {
            "start_logit": -5.70703125,
            "end_logit": 9.5546875,
            "text": "hape",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.2578125,
            "text": "GBshap",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.2890625,
            "text": "GBshape can",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.3984375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.4140625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browse",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.421875,
            "text": "GBshape can be",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.4453125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.453125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.4609375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.4609375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.4609375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.46875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome brow",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.46875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.46875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.46875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format,",
            "probability": 0.0
        },
        {
            "start_logit": -2.28515625,
            "end_logit": -8.2890625,
            "text": "e can",
            "probability": 0.0
        },
        {
            "start_logit": -2.28515625,
            "end_logit": -8.3984375,
            "text": "e can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution",
            "probability": 0.0
        }
    ],
    "56c8f4615795f9a73e00001a_4": [
        {
            "start_logit": 9.9609375,
            "end_logit": 9.5546875,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -1.9560546875,
            "text": "GBs",
            "probability": 1.0073184967041016e-05
        },
        {
            "start_logit": -2.271484375,
            "end_logit": 9.5546875,
            "text": "e",
            "probability": 4.887580871582031e-06
        },
        {
            "start_logit": -5.6953125,
            "end_logit": 9.5546875,
            "text": "hape",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.0,
            "text": "GBshape; freely available at http://rohslab",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.046875,
            "text": "GBshape; freely available at http://rohslab.cmb.usc",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.0546875,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.1015625,
            "text": "GBshape; freely available at http://rohslab.cmb.us",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.109375,
            "text": "GBshape; freely available at http://rohslab.cm",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.109375,
            "text": "GBshape; freely available at http://rohslab.cmb",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.1875,
            "text": "GBshape; freely available at http:/",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.203125,
            "text": "GBshape; freely available at http://rohslab.",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.203125,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.2109375,
            "text": "GBshap",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.2109375,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape/",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.2109375,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBs",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.234375,
            "text": "GBshape; freely available at http://rohslab.cmb.",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.2421875,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.265625,
            "text": "GBshape; freely available at http://rohs",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.265625,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape/) provides minor groove width",
            "probability": 0.0
        }
    ],
    "56c8f4615795f9a73e00001a_5": [
        {
            "start_logit": 9.9765625,
            "end_logit": 9.5546875,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -1.9150390625,
            "text": "GBs",
            "probability": 1.043081283569336e-05
        },
        {
            "start_logit": -2.28515625,
            "end_logit": 9.5546875,
            "text": "e",
            "probability": 4.708766937255859e-06
        },
        {
            "start_logit": -5.70703125,
            "end_logit": 9.5546875,
            "text": "hape",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.2578125,
            "text": "GBshap",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.2890625,
            "text": "GBshape can",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.3984375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.4140625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browse",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.421875,
            "text": "GBshape can be",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.4453125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.453125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.4609375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.4609375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.4609375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.46875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome brow",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.46875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.46875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.46875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format,",
            "probability": 0.0
        },
        {
            "start_logit": -2.28515625,
            "end_logit": -8.2890625,
            "text": "e can",
            "probability": 0.0
        },
        {
            "start_logit": -2.28515625,
            "end_logit": -8.3984375,
            "text": "e can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution",
            "probability": 0.0
        }
    ],
    "56c8f4615795f9a73e00001a_6": [
        {
            "start_logit": 9.96875,
            "end_logit": 9.5625,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -1.9345703125,
            "text": "GBs",
            "probability": 1.0132789611816406e-05
        },
        {
            "start_logit": -2.259765625,
            "end_logit": 9.5625,
            "text": "e",
            "probability": 4.887580871582031e-06
        },
        {
            "start_logit": -5.60546875,
            "end_logit": 9.5625,
            "text": "hape",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.2421875,
            "text": "GBshap",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.2734375,
            "text": "GBshape can",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.40625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browse",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.4140625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.4296875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.4296875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.4453125,
            "text": "GBshape can be",
            "probability": 0.0
        },
        {
            "start_logit": -2.259765625,
            "end_logit": -8.2734375,
            "text": "e can",
            "probability": 0.0
        },
        {
            "start_logit": -2.259765625,
            "end_logit": -8.375,
            "text": "e can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as",
            "probability": 0.0
        },
        {
            "start_logit": -2.259765625,
            "end_logit": -8.375,
            "text": "e can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution",
            "probability": 0.0
        },
        {
            "start_logit": -2.259765625,
            "end_logit": -8.40625,
            "text": "e can be used to visualize DNA shape annotations qualitatively in a genome browse",
            "probability": 0.0
        },
        {
            "start_logit": -2.259765625,
            "end_logit": -8.40625,
            "text": "e can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution. As biological applications, we illustrate the periodicity of DNA shape features",
            "probability": 0.0
        },
        {
            "start_logit": -2.259765625,
            "end_logit": -8.4140625,
            "text": "e can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at",
            "probability": 0.0
        },
        {
            "start_logit": -2.259765625,
            "end_logit": -8.4296875,
            "text": "e can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution. As biological applications, we illustrate the periodicity of DNA shape",
            "probability": 0.0
        }
    ],
    "56c8f4615795f9a73e00001a_7": [
        {
            "start_logit": 9.8828125,
            "end_logit": 9.5234375,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -2.1875,
            "text": "GBs",
            "probability": 8.225440979003906e-06
        },
        {
            "start_logit": -2.326171875,
            "end_logit": 9.5234375,
            "text": "e",
            "probability": 4.947185516357422e-06
        },
        {
            "start_logit": -6.05859375,
            "end_logit": 9.5234375,
            "text": "hape",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.4921875,
            "end_logit": 9.5234375,
            "text": ". Our Genome Browser for DNA shape annotations (GBshape",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3125,
            "end_logit": 9.5234375,
            "text": "(GBshape",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.90625,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.0234375,
            "text": "GBshape; freely available at http://rohslab",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.03125,
            "text": "GBshape; freely available at http://rohslab.cmb.usc",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.0859375,
            "text": "GBshape; freely available at http://rohslab.cmb.us",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.09375,
            "text": "GBshape;",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.125,
            "text": "GBshap",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.1640625,
            "text": "GBshape; freely available at http://rohslab.cm",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.1953125,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape/",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.1953125,
            "text": "GBshape; freely available at http:/",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.1953125,
            "text": "GBshape; freely available at http://rohslab.cmb",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.2109375,
            "text": "GBshape; freely available at http://rohslab.",
            "probability": 0.0
        },
        {
            "start_logit": -7.859375,
            "end_logit": 9.5234375,
            "text": "Our Genome Browser for DNA shape annotations (GBshape",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.2265625,
            "text": "GBshape; freely available at http://rohslab.cmb.",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.2421875,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.",
            "probability": 0.0
        }
    ],
    "56c8f4615795f9a73e00001a_8": [
        {
            "start_logit": 10.015625,
            "end_logit": 9.703125,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -1.8330078125,
            "text": "GBs",
            "probability": 9.715557098388672e-06
        },
        {
            "start_logit": -1.939453125,
            "end_logit": 9.703125,
            "text": "e",
            "probability": 6.4373016357421875e-06
        },
        {
            "start_logit": -4.94140625,
            "end_logit": 9.703125,
            "text": "hape",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.0234375,
            "text": "GBshape framework. GBshape",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.1171875,
            "text": "GBshape framework. GBshape can",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.1875,
            "text": "GBshape framework. GBshap",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.2578125,
            "text": "GBshape framework. GBshape can be used to visualize DNA shape annotations qualitatively in a genome browse",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.2734375,
            "text": "GBshape framework. GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.28125,
            "text": "GBshape framework",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.28125,
            "text": "GBshap",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.296875,
            "text": "GBshape framework. GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution",
            "probability": 0.0
        },
        {
            "start_logit": -7.984375,
            "end_logit": 9.703125,
            "text": "genomes can easily be added using the GBshape",
            "probability": 0.0
        },
        {
            "start_logit": -7.984375,
            "end_logit": 9.703125,
            "text": "Additional genomes can easily be added using the GBshape",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.3203125,
            "text": "GBshape framework. GBshape can be used to visualize DNA shape annotations qualitatively in",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.328125,
            "text": "GBshape framework. GBshape can be",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.328125,
            "text": "GBshape framework. GBshape can be used to visualize DNA shape annotations qualitatively in a genome brow",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.3515625,
            "text": "GBshape framework. GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format,",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.3515625,
            "text": "GBshape framework. GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track",
            "probability": 0.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -8.3515625,
            "text": "GBshape framework. GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at",
            "probability": 0.0
        }
    ],
    "56c8f4615795f9a73e00001a_9": [
        {
            "start_logit": 9.9765625,
            "end_logit": 9.5703125,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -1.9140625,
            "text": "GBs",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": -2.236328125,
            "end_logit": 9.5703125,
            "text": "e",
            "probability": 4.947185516357422e-06
        },
        {
            "start_logit": -5.59375,
            "end_logit": 9.5703125,
            "text": "hape",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.015625,
            "text": "GBshape; freely available at http://rohslab",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.015625,
            "text": "GBshape; freely available at http://rohslab.cmb.usc",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.046875,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.0703125,
            "text": "GBshape; freely available at http://rohslab.cmb.us",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.09375,
            "text": "GBshape; freely available at http://rohslab.cm",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.1015625,
            "text": "GBshape; freely available at http://rohslab.cmb",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.1796875,
            "text": "GBshape; freely available at http:/",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.1875,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.1953125,
            "text": "GBshape; freely available at http://rohslab.",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.2109375,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBs",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.2109375,
            "text": "GBshap",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.2265625,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape/",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.2265625,
            "text": "GBshape; freely available at http://rohslab.cmb.",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.2578125,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape/) provides minor groove width",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.2578125,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.2734375,
            "text": "GBshape; freely available at http://rohs",
            "probability": 0.0
        }
    ],
    "56c8f4615795f9a73e00001a_10": [
        {
            "start_logit": 9.9765625,
            "end_logit": 9.5546875,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -1.9150390625,
            "text": "GBs",
            "probability": 1.043081283569336e-05
        },
        {
            "start_logit": -2.28515625,
            "end_logit": 9.5546875,
            "text": "e",
            "probability": 4.708766937255859e-06
        },
        {
            "start_logit": -5.70703125,
            "end_logit": 9.5546875,
            "text": "hape",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.2578125,
            "text": "GBshap",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.2890625,
            "text": "GBshape can",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.3984375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.4140625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browse",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.421875,
            "text": "GBshape can be",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.4453125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.453125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.4609375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.4609375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.4609375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.46875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome brow",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.46875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.46875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.46875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format,",
            "probability": 0.0
        },
        {
            "start_logit": -2.28515625,
            "end_logit": -8.2890625,
            "text": "e can",
            "probability": 0.0
        },
        {
            "start_logit": -2.28515625,
            "end_logit": -8.3984375,
            "text": "e can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution",
            "probability": 0.0
        }
    ],
    "56c8f4615795f9a73e00001a_11": [
        {
            "start_logit": 9.9609375,
            "end_logit": 9.5546875,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -1.9560546875,
            "text": "GBs",
            "probability": 1.0073184967041016e-05
        },
        {
            "start_logit": -2.271484375,
            "end_logit": 9.5546875,
            "text": "e",
            "probability": 4.887580871582031e-06
        },
        {
            "start_logit": -5.6953125,
            "end_logit": 9.5546875,
            "text": "hape",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.0,
            "text": "GBshape; freely available at http://rohslab",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.046875,
            "text": "GBshape; freely available at http://rohslab.cmb.usc",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.0546875,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.1015625,
            "text": "GBshape; freely available at http://rohslab.cmb.us",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.109375,
            "text": "GBshape; freely available at http://rohslab.cm",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.109375,
            "text": "GBshape; freely available at http://rohslab.cmb",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.1875,
            "text": "GBshape; freely available at http:/",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.203125,
            "text": "GBshape; freely available at http://rohslab.",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.203125,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.2109375,
            "text": "GBshap",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.2109375,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape/",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.2109375,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBs",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.234375,
            "text": "GBshape; freely available at http://rohslab.cmb.",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.2421875,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.265625,
            "text": "GBshape; freely available at http://rohs",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.265625,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape/) provides minor groove width",
            "probability": 0.0
        }
    ],
    "5e36cf8eb5b409ea53000007_1": [
        {
            "start_logit": 8.7421875,
            "end_logit": 8.0703125,
            "text": "melanocytes",
            "probability": 1.0
        },
        {
            "start_logit": -6.984375,
            "end_logit": 8.0703125,
            "text": ". Because mutants that lack melanocytes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.984375,
            "end_logit": 8.0703125,
            "text": ". Here we show that a melanocyte umbrella above the kidney marrow protects HSPCs against ultraviolet light in zebrafish. Because mutants that lack melanocytes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7421875,
            "end_logit": -8.4140625,
            "text": "melanocytes have",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.7421875,
            "end_logit": -8.421875,
            "text": "melanocytes have normal steady-state haematopoiesis under standard laboratory conditions, we hypothesized that melanocytes above the stem cell niche protect HSPCs against ultraviolet-light-induced DNA damage.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.03125,
            "end_logit": 8.0703125,
            "text": "Here we show that a melanocyte umbrella above the kidney marrow protects HSPCs against ultraviolet light in zebrafish. Because mutants that lack melanocytes",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0625,
            "end_logit": 8.0703125,
            "text": "lack melanocytes",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0625,
            "end_logit": 8.0703125,
            "text": "a melanocyte umbrella above the kidney marrow protects HSPCs against ultraviolet light in zebrafish. Because mutants that lack melanocytes",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.98046875,
            "end_logit": -8.3828125,
            "text": ". The location of this niche varies across species, but the evolutionary pressures that drive HSPCs to different microenvironments remain",
            "probability": 0.0
        },
        {
            "start_logit": -6.984375,
            "end_logit": -8.375,
            "text": ". Indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of DNA damage",
            "probability": 0.0
        },
        {
            "start_logit": -6.984375,
            "end_logit": -8.3984375,
            "text": ". Indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of DNA damage in HSPCs, as indicated by staining of cyclobutane",
            "probability": 0.0
        },
        {
            "start_logit": -6.984375,
            "end_logit": -8.40625,
            "text": ". Indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of DNA damage in HSPCs",
            "probability": 0.0
        },
        {
            "start_logit": -6.984375,
            "end_logit": -8.40625,
            "text": ". Indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of DNA damage in HSPCs, as indicated by staining of cyclobutane pyrimidine dimers and",
            "probability": 0.0
        },
        {
            "start_logit": -6.984375,
            "end_logit": -8.4140625,
            "text": ". Indeed, after ultraviolet-light irradiation, unpigmented larvae show higher levels of DNA damage in HSPCs, as indicated by staining of cyclobutane pyrimidine dimers",
            "probability": 0.0
        },
        {
            "start_logit": -6.984375,
            "end_logit": -8.4140625,
            "text": ". Because mutants that lack melanocytes have",
            "probability": 0.0
        },
        {
            "start_logit": -6.984375,
            "end_logit": -8.4140625,
            "text": ". Here we show that a melanocyte umbrella above the kidney marrow protects HSPCs against ultraviolet light in zebrafish. Because mutants that lack melanocytes have",
            "probability": 0.0
        },
        {
            "start_logit": -6.98046875,
            "end_logit": -8.421875,
            "text": ". The location of this niche varies across species, but the evolutionary pressures that drive HSPCs to different microenvironments remain unknown.",
            "probability": 0.0
        },
        {
            "start_logit": -6.98046875,
            "end_logit": -8.421875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.984375,
            "end_logit": -8.421875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.984375,
            "end_logit": -8.421875,
            "text": ".",
            "probability": 0.0
        }
    ],
    "54ff45966ad7dcbc12000010_1": [
        {
            "start_logit": 9.9921875,
            "end_logit": 9.6640625,
            "text": "LEKTI",
            "probability": 1.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -1.8642578125,
            "text": "LE",
            "probability": 9.834766387939453e-06
        },
        {
            "start_logit": -1.97265625,
            "end_logit": 9.6640625,
            "text": "I",
            "probability": 6.318092346191406e-06
        },
        {
            "start_logit": -6.046875,
            "end_logit": 9.6640625,
            "text": "KTI",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -7.8984375,
            "text": "LEKT",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.015625,
            "text": "LEKTI (lymphoepithelial Kazal type",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.0703125,
            "text": "LEKTI (lymphoepithelial Kazal type-related inhibitor)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.0859375,
            "text": "LEKTI (lymphoepithelial Kazal",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.1171875,
            "text": "LEKTI (lymphoepithelial Kazal type-related inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.125,
            "text": "LEKTI (lymphoepithelial Kaz",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.125,
            "text": "LEKTI (lymphoepithelial",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.1328125,
            "text": "LEKTI (lymphoepithelial Ka",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.1953125,
            "text": "LEKTI (lymphoepithelial Kazal type-related",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.203125,
            "text": "LEKTI (lympho",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.6640625,
            "text": "Netherton syndrome (NS) is a serious inherited skin disorder caused by mutations in the gene SPINK5 (serine protease inhibitor Kazal type 5) which encodes for a serine protease inhibitor LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.6640625,
            "text": "disorder caused by mutations in the gene SPINK5 (serine protease inhibitor Kazal type 5) which encodes for a serine protease inhibitor LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.6640625,
            "text": "by mutations in the gene SPINK5 (serine protease inhibitor Kazal type 5) which encodes for a serine protease inhibitor LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.6640625,
            "text": "inherited skin disorder caused by mutations in the gene SPINK5 (serine protease inhibitor Kazal type 5) which encodes for a serine protease inhibitor LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.6640625,
            "text": "inhibitor LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": 9.6640625,
            "text": "serine protease inhibitor Kazal type 5) which encodes for a serine protease inhibitor LEKTI",
            "probability": 0.0
        }
    ],
    "54ff45966ad7dcbc12000010_2": [
        {
            "start_logit": 10.140625,
            "end_logit": 9.6953125,
            "text": "LEKTI",
            "probability": 1.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -1.453125,
            "text": "LE",
            "probability": 1.430511474609375e-05
        },
        {
            "start_logit": -1.8505859375,
            "end_logit": 9.6953125,
            "text": "I",
            "probability": 6.139278411865234e-06
        },
        {
            "start_logit": -5.9296875,
            "end_logit": 9.6953125,
            "text": "KTI",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.87890625,
            "end_logit": 9.6953125,
            "text": "(LEKTI",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.44140625,
            "text": "LEKT",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.95703125,
            "text": "LEKTI)",
            "probability": 0.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -8.109375,
            "text": "LEKTI) deficiency",
            "probability": 0.0
        },
        {
            "start_logit": -7.84375,
            "end_logit": 9.6953125,
            "text": "to lymphoepithelial Kazal-type-related inhibitor (LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": -7.9140625,
            "end_logit": 9.6953125,
            "text": "Mutations in the serine protease inhibitor Kazal type 5 (SPINK5) gene leading to lymphoepithelial Kazal-type-related inhibitor (LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.6953125,
            "text": "lymphoepithelial Kazal-type-related inhibitor (LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.6953125,
            "text": "gene leading to lymphoepithelial Kazal-type-related inhibitor (LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.6953125,
            "text": "in the serine protease inhibitor Kazal type 5 (SPINK5) gene leading to lymphoepithelial Kazal-type-related inhibitor (LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.6953125,
            "text": "serine protease inhibitor Kazal type 5 (SPINK5) gene leading to lymphoepithelial Kazal-type-related inhibitor (LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.6953125,
            "text": "(SPINK5) gene leading to lymphoepithelial Kazal-type-related inhibitor (LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.6953125,
            "text": "epithelial Kazal-type-related inhibitor (LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": 9.6953125,
            "text": "leading to lymphoepithelial Kazal-type-related inhibitor (LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": -6.87890625,
            "end_logit": -1.453125,
            "text": "(LE",
            "probability": 0.0
        },
        {
            "start_logit": -7.84375,
            "end_logit": -1.453125,
            "text": "to lymphoepithelial Kazal-type-related inhibitor (LE",
            "probability": 0.0
        },
        {
            "start_logit": -7.9140625,
            "end_logit": -1.453125,
            "text": "Mutations in the serine protease inhibitor Kazal type 5 (SPINK5) gene leading to lymphoepithelial Kazal-type-related inhibitor (LE",
            "probability": 0.0
        }
    ],
    "54ff45966ad7dcbc12000010_3": [
        {
            "start_logit": 10.0234375,
            "end_logit": 9.6171875,
            "text": "LEKTI",
            "probability": 1.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -1.7998046875,
            "text": "LE",
            "probability": 1.1026859283447266e-05
        },
        {
            "start_logit": -2.099609375,
            "end_logit": 9.6171875,
            "text": "I",
            "probability": 5.424022674560547e-06
        },
        {
            "start_logit": -6.16015625,
            "end_logit": 9.6171875,
            "text": "KTI",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.5703125,
            "end_logit": 9.6171875,
            "text": "protein LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.140625,
            "text": "LEKT",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.171875,
            "text": "LEKTI in the skin",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.1796875,
            "text": "LEKTI in the skin and all stratified epithelial tissues",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.1953125,
            "text": "LEKTI in",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.2265625,
            "text": "LEKTI in the",
            "probability": 0.0
        },
        {
            "start_logit": 10.0234375,
            "end_logit": -8.25,
            "text": "LEKTI in the skin and all stratified epithelial",
            "probability": 0.0
        },
        {
            "start_logit": -8.3671875,
            "end_logit": 9.6171875,
            "text": "mutations in the SPINK5 gene and to the consequent lack of expression of its encoded protein LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": 9.6171875,
            "text": "in the SPINK5 gene and to the consequent lack of expression of its encoded protein LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": 9.6171875,
            "text": "NS is due to loss-of-function mutations in the SPINK5 gene and to the consequent lack of expression of its encoded protein LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": 9.6171875,
            "text": "of its encoded protein LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": -8.390625,
            "end_logit": 9.6171875,
            "text": "the SPINK5 gene and to the consequent lack of expression of its encoded protein LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": -8.390625,
            "end_logit": 9.6171875,
            "text": "-of-function mutations in the SPINK5 gene and to the consequent lack of expression of its encoded protein LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": -8.3984375,
            "end_logit": 9.6171875,
            "text": "consequent lack of expression of its encoded protein LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": -8.3984375,
            "end_logit": 9.6171875,
            "text": "is due to loss-of-function mutations in the SPINK5 gene and to the consequent lack of expression of its encoded protein LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": -8.421875,
            "end_logit": 9.6171875,
            "text": "to loss-of-function mutations in the SPINK5 gene and to the consequent lack of expression of its encoded protein LEKTI",
            "probability": 0.0
        }
    ],
    "54ff45966ad7dcbc12000010_4": [
        {
            "start_logit": 10.0703125,
            "end_logit": 9.7109375,
            "text": "LEKTI",
            "probability": 1.0
        },
        {
            "start_logit": 10.0703125,
            "end_logit": -1.65625,
            "text": "LE",
            "probability": 1.1563301086425781e-05
        },
        {
            "start_logit": -1.8154296875,
            "end_logit": 9.7109375,
            "text": "I",
            "probability": 6.854534149169922e-06
        },
        {
            "start_logit": -5.8046875,
            "end_logit": 9.7109375,
            "text": "KTI",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.30078125,
            "end_logit": 9.7109375,
            "text": "(LEKTI",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0703125,
            "end_logit": -7.22265625,
            "text": "LEKT",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.90234375,
            "end_logit": 9.7109375,
            "text": "Lympho-epithelial Kazal-type-related inhibitor (LEKTI",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0703125,
            "end_logit": -7.8359375,
            "text": "LEKTI)",
            "probability": 0.0
        },
        {
            "start_logit": -7.76171875,
            "end_logit": 9.7109375,
            "text": "epithelial Kazal-type-related inhibitor (LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": 10.0703125,
            "end_logit": -8.1953125,
            "text": "LEKTI) is the defective protein of the ichthyosiform condition Netherton syndrome (NS)",
            "probability": 0.0
        },
        {
            "start_logit": 10.0703125,
            "end_logit": -8.2265625,
            "text": "LEKTI) is the defective protein of the ichthyosiform condition Netherton syndrome (",
            "probability": 0.0
        },
        {
            "start_logit": 10.0703125,
            "end_logit": -8.2265625,
            "text": "LEKTI) is the defective protein of the ichthyosiform condition Netherton syndrome (NS",
            "probability": 0.0
        },
        {
            "start_logit": 10.0703125,
            "end_logit": -8.25,
            "text": "LEKTI) is the defective protein of the ichthy",
            "probability": 0.0
        },
        {
            "start_logit": 10.0703125,
            "end_logit": -8.25,
            "text": "LEKTI) is the defective protein of the ichthyosi",
            "probability": 0.0
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 9.7109375,
            "text": "inhibitor (LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 9.7109375,
            "text": "-epithelial Kazal-type-related inhibitor (LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.7109375,
            "text": "Kazal-type-related inhibitor (LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": -8.390625,
            "end_logit": 9.7109375,
            "text": "related inhibitor (LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": -6.30078125,
            "end_logit": -1.65625,
            "text": "(LE",
            "probability": 0.0
        },
        {
            "start_logit": -6.90234375,
            "end_logit": -1.65625,
            "text": "Lympho-epithelial Kazal-type-related inhibitor (LE",
            "probability": 0.0
        }
    ],
    "54ff45966ad7dcbc12000010_5": [
        {
            "start_logit": 9.953125,
            "end_logit": 9.4375,
            "text": "LEKTI",
            "probability": 1.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -1.9814453125,
            "text": "LE",
            "probability": 1.0967254638671875e-05
        },
        {
            "start_logit": -2.486328125,
            "end_logit": 9.4375,
            "text": "I",
            "probability": 3.993511199951172e-06
        },
        {
            "start_logit": -6.23828125,
            "end_logit": 9.4375,
            "text": "KTI",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.1015625,
            "text": "LEKTI is the etiological origin of Netherton syndrome, which causes detachment of the stratum corneum",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.2265625,
            "text": "LEKTI is the etiological origin",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.2421875,
            "text": "LEKTI is the etiological",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.2578125,
            "text": "LEKTI is the etiological origin of Netherton syndrome, which causes detachment of the stratum corneum and chronic inflammation",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.265625,
            "text": "LEKTI is the etiological origin of Netherton syndrome, which causes detachment of the",
            "probability": 0.0
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 9.4375,
            "text": "inhibitor LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.4375,
            "text": "Deficiency in the serine protease inhibitor LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.4375,
            "text": "serine protease inhibitor LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.4375,
            "text": "in the serine protease inhibitor LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": -8.375,
            "end_logit": 9.4375,
            "text": "the serine protease inhibitor LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": -7.87890625,
            "end_logit": -1.9814453125,
            "text": "inhibitor LE",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": -1.9814453125,
            "text": "Deficiency in the serine protease inhibitor LE",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -1.9814453125,
            "text": "serine protease inhibitor LE",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -1.9814453125,
            "text": "in the serine protease inhibitor LE",
            "probability": 0.0
        },
        {
            "start_logit": -8.375,
            "end_logit": -1.9814453125,
            "text": "the serine protease inhibitor LE",
            "probability": 0.0
        },
        {
            "start_logit": -2.486328125,
            "end_logit": -8.1015625,
            "text": "I is the etiological origin of Netherton syndrome, which causes detachment of the stratum corneum",
            "probability": 0.0
        }
    ],
    "53175e9fb166e2b80600000a_1": [
        {
            "start_logit": 10.25,
            "end_logit": 9.890625,
            "text": "LKB1 plays a physiological role in controlling the Wnt-signaling pathway",
            "probability": 1.0
        },
        {
            "start_logit": 10.25,
            "end_logit": -0.495849609375,
            "text": "LKB1 plays a physiological role in controlling the Wnt-signaling pathway and activation of the pathway as a consequence of LKB1 haploinsufficiency might be responsible for the development of harmatomatous polyps.",
            "probability": 3.0934810638427734e-05
        },
        {
            "start_logit": 10.25,
            "end_logit": -1.1826171875,
            "text": "LK",
            "probability": 1.5556812286376953e-05
        },
        {
            "start_logit": -1.1904296875,
            "end_logit": 9.890625,
            "text": "pathway",
            "probability": 1.0788440704345703e-05
        },
        {
            "start_logit": -3.123046875,
            "end_logit": 9.890625,
            "text": "Recent functional genetic studies have pointed out that LKB1 plays a physiological role in controlling the Wnt-signaling pathway",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": 10.25,
            "end_logit": -3.8828125,
            "text": "LKB1 plays",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -3.5703125,
            "end_logit": 9.890625,
            "text": "controlling the Wnt-signaling pathway",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 10.25,
            "end_logit": -4.25390625,
            "text": "LKB1 plays a physiological role in controlling the Wnt-signaling pathway and activation of the pathway",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 10.25,
            "end_logit": -5.0546875,
            "text": "LKB1 plays a physiological role in controlling the Wnt-signaling pathway and",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -5.4453125,
            "end_logit": 9.890625,
            "text": "Wnt-signaling pathway",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.5703125,
            "end_logit": 9.890625,
            "text": "the Wnt-signaling pathway",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -5.60546875,
            "end_logit": 9.890625,
            "text": "that LKB1 plays a physiological role in controlling the Wnt-signaling pathway",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -5.7890625,
            "end_logit": 9.890625,
            "text": "in controlling the Wnt-signaling pathway",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.25,
            "end_logit": -6.171875,
            "text": "LKB1 plays a physiological role in controlling the Wnt-signaling pathway and activation of the pathway as a consequence of LKB1 haploinsufficiency might",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.1171875,
            "end_logit": 9.890625,
            "text": "role in controlling the Wnt-signaling pathway",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.25,
            "end_logit": -6.62109375,
            "text": "LKB1 plays a physiological role in controlling the Wnt-signaling",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.25,
            "end_logit": -6.96484375,
            "text": "LKB1 plays a physiological role in controlling the Wnt-signaling pathway and activation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.62109375,
            "end_logit": 9.890625,
            "text": "physiological role in controlling the Wnt-signaling pathway",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.64453125,
            "end_logit": 9.890625,
            "text": "pointed out that LKB1 plays a physiological role in controlling the Wnt-signaling pathway",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.25,
            "end_logit": -7.02734375,
            "text": "LKB1 plays a physiological role in controlling the Wnt-signaling pathway and activation of the pathway as",
            "probability": 5.960464477539063e-08
        }
    ],
    "5a9d31711d1251d03b00001c_1": [
        {
            "start_logit": 10.15625,
            "end_logit": 9.8125,
            "text": "100 nm",
            "probability": 1.0
        },
        {
            "start_logit": 10.15625,
            "end_logit": -1.3642578125,
            "text": "100",
            "probability": 1.3947486877441406e-05
        },
        {
            "start_logit": -1.55859375,
            "end_logit": 9.8125,
            "text": "nm",
            "probability": 8.165836334228516e-06
        },
        {
            "start_logit": -7.203125,
            "end_logit": 9.8125,
            "text": "diamtere of 100 nm",
            "probability": 0.0
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 9.8125,
            "text": "of 100 nm",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 9.8125,
            "text": "they attained their maximum diamtere of 100 nm",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 9.8125,
            "text": "vesicles increased until they attained their maximum diamtere of 100 nm",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.8125,
            "text": "their maximum diamtere of 100 nm",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.8125,
            "text": "tere of 100 nm",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 9.8125,
            "text": "attained their maximum diamtere of 100 nm",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.8125,
            "text": "maximum diamtere of 100 nm",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.8125,
            "text": "the vesicles increased until they attained their maximum diamtere of 100 nm",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 9.8125,
            "text": "until they attained their maximum diamtere of 100 nm",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.8125,
            "text": "the size of the vesicles increased until they attained their maximum diamtere of 100 nm",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.8125,
            "text": "while the size of the vesicles increased until they attained their maximum diamtere of 100 nm",
            "probability": 0.0
        },
        {
            "start_logit": -7.203125,
            "end_logit": -1.3642578125,
            "text": "diamtere of 100",
            "probability": 0.0
        },
        {
            "start_logit": -7.46484375,
            "end_logit": -1.3642578125,
            "text": "of 100",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -1.3642578125,
            "text": "they attained their maximum diamtere of 100",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": -1.3642578125,
            "text": "vesicles increased until they attained their maximum diamtere of 100",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": -1.3642578125,
            "text": "their maximum diamtere of 100",
            "probability": 0.0
        }
    ],
    "5a7346662dc08e987e00001a_1": [
        {
            "start_logit": 9.8828125,
            "end_logit": 9.4765625,
            "text": "intravenous drug abuse",
            "probability": 1.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -2.109375,
            "text": "intravenous",
            "probability": 9.298324584960938e-06
        },
        {
            "start_logit": -2.396484375,
            "end_logit": 9.4765625,
            "text": "abuse",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": -6.5,
            "end_logit": 9.4765625,
            "text": "drug abuse",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.5625,
            "end_logit": 9.4765625,
            "text": "of intravenous drug abuse",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4453125,
            "end_logit": 9.4765625,
            "text": "Puffy hand syndrome is an unrecognized complication of intravenous drug abuse",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.9140625,
            "text": "intravenous drug",
            "probability": 0.0
        },
        {
            "start_logit": -7.8203125,
            "end_logit": 9.4765625,
            "text": "complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.4765625,
            "text": "unrecognized complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.4765625,
            "text": "hand syndrome is an unrecognized complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.4765625,
            "text": "an unrecognized complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.4765625,
            "text": "syndrome is an unrecognized complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.4765625,
            "text": "y hand syndrome is an unrecognized complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -8.375,
            "end_logit": 9.4765625,
            "text": "is an unrecognized complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -6.5625,
            "end_logit": -2.109375,
            "text": "of intravenous",
            "probability": 0.0
        },
        {
            "start_logit": -7.4453125,
            "end_logit": -2.109375,
            "text": "Puffy hand syndrome is an unrecognized complication of intravenous",
            "probability": 0.0
        },
        {
            "start_logit": -7.8203125,
            "end_logit": -2.109375,
            "text": "complication of intravenous",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -2.109375,
            "text": "unrecognized complication of intravenous",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -2.109375,
            "text": "hand syndrome is an unrecognized complication of intravenous",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": -2.109375,
            "text": "an unrecognized complication of intravenous",
            "probability": 0.0
        }
    ],
    "5a7346662dc08e987e00001a_2": [
        {
            "start_logit": 9.9140625,
            "end_logit": 9.546875,
            "text": "intravenous drug abuse",
            "probability": 1.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -2.044921875,
            "text": "intravenous",
            "probability": 9.179115295410156e-06
        },
        {
            "start_logit": -2.236328125,
            "end_logit": 9.546875,
            "text": "abuse",
            "probability": 5.245208740234375e-06
        },
        {
            "start_logit": -6.453125,
            "end_logit": 9.546875,
            "text": "drug abuse",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.8828125,
            "end_logit": 9.546875,
            "text": "of intravenous drug abuse",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -7.91015625,
            "text": "intravenous drug",
            "probability": 0.0
        },
        {
            "start_logit": -7.71875,
            "end_logit": 9.546875,
            "text": "complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.28125,
            "text": "intravenous drug abuse, which has no",
            "probability": 0.0
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 9.546875,
            "text": "Puffy hand syndrome is a complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 9.546875,
            "text": "a complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -8.375,
            "end_logit": 9.546875,
            "text": "hand syndrome is a complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": 9.546875,
            "text": "syndrome is a complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -8.40625,
            "end_logit": 9.546875,
            "text": ": Puffy hand syndrome is a complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -8.4140625,
            "end_logit": 9.546875,
            "text": "y hand syndrome is a complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -6.8828125,
            "end_logit": -2.044921875,
            "text": "of intravenous",
            "probability": 0.0
        },
        {
            "start_logit": -7.71875,
            "end_logit": -2.044921875,
            "text": "complication of intravenous",
            "probability": 0.0
        },
        {
            "start_logit": -7.95703125,
            "end_logit": -2.044921875,
            "text": "Puffy hand syndrome is a complication of intravenous",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": -2.044921875,
            "text": "a complication of intravenous",
            "probability": 0.0
        },
        {
            "start_logit": -8.375,
            "end_logit": -2.044921875,
            "text": "hand syndrome is a complication of intravenous",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": -2.044921875,
            "text": "syndrome is a complication of intravenous",
            "probability": 0.0
        }
    ],
    "5a7346662dc08e987e00001a_3": [
        {
            "start_logit": 9.90625,
            "end_logit": 9.5,
            "text": "intravenous drug abuse",
            "probability": 1.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -2.068359375,
            "text": "intravenous",
            "probability": 9.417533874511719e-06
        },
        {
            "start_logit": -2.3359375,
            "end_logit": 9.5,
            "text": "abuse",
            "probability": 4.827976226806641e-06
        },
        {
            "start_logit": -6.5078125,
            "end_logit": 9.5,
            "text": "drug abuse",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.796875,
            "end_logit": 9.5,
            "text": "of intravenous drug abuse",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.28125,
            "end_logit": 9.5,
            "text": "Puffy hand syndrome is a complication of intravenous drug abuse",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.90625,
            "end_logit": -7.91796875,
            "text": "intravenous drug",
            "probability": 0.0
        },
        {
            "start_logit": -7.79296875,
            "end_logit": 9.5,
            "text": "complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.2265625,
            "text": "intravenous drug abuse, which has no current",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.2421875,
            "text": "intravenous drug abuse, which has no",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.5,
            "text": "hand syndrome is a complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.5,
            "text": "a complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 9.5,
            "text": "y hand syndrome is a complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -8.3671875,
            "end_logit": 9.5,
            "text": "syndrome is a complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -8.40625,
            "end_logit": 9.5,
            "text": "is a complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -6.796875,
            "end_logit": -2.068359375,
            "text": "of intravenous",
            "probability": 0.0
        },
        {
            "start_logit": -7.28125,
            "end_logit": -2.068359375,
            "text": "Puffy hand syndrome is a complication of intravenous",
            "probability": 0.0
        },
        {
            "start_logit": -7.79296875,
            "end_logit": -2.068359375,
            "text": "complication of intravenous",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": -2.068359375,
            "text": "hand syndrome is a complication of intravenous",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": -2.068359375,
            "text": "a complication of intravenous",
            "probability": 0.0
        }
    ],
    "5a7346662dc08e987e00001a_4": [
        {
            "start_logit": 9.8828125,
            "end_logit": 9.4765625,
            "text": "intravenous drug abuse",
            "probability": 1.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -2.109375,
            "text": "intravenous",
            "probability": 9.298324584960938e-06
        },
        {
            "start_logit": -2.396484375,
            "end_logit": 9.4765625,
            "text": "abuse",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": -6.5,
            "end_logit": 9.4765625,
            "text": "drug abuse",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.5625,
            "end_logit": 9.4765625,
            "text": "of intravenous drug abuse",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4453125,
            "end_logit": 9.4765625,
            "text": "Puffy hand syndrome is an unrecognized complication of intravenous drug abuse",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.9140625,
            "text": "intravenous drug",
            "probability": 0.0
        },
        {
            "start_logit": -7.8203125,
            "end_logit": 9.4765625,
            "text": "complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.4765625,
            "text": "unrecognized complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.4765625,
            "text": "hand syndrome is an unrecognized complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.4765625,
            "text": "an unrecognized complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.4765625,
            "text": "syndrome is an unrecognized complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.4765625,
            "text": "y hand syndrome is an unrecognized complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -8.375,
            "end_logit": 9.4765625,
            "text": "is an unrecognized complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -6.5625,
            "end_logit": -2.109375,
            "text": "of intravenous",
            "probability": 0.0
        },
        {
            "start_logit": -7.4453125,
            "end_logit": -2.109375,
            "text": "Puffy hand syndrome is an unrecognized complication of intravenous",
            "probability": 0.0
        },
        {
            "start_logit": -7.8203125,
            "end_logit": -2.109375,
            "text": "complication of intravenous",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -2.109375,
            "text": "unrecognized complication of intravenous",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -2.109375,
            "text": "hand syndrome is an unrecognized complication of intravenous",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": -2.109375,
            "text": "an unrecognized complication of intravenous",
            "probability": 0.0
        }
    ],
    "5a7346662dc08e987e00001a_5": [
        {
            "start_logit": 9.703125,
            "end_logit": 9.46875,
            "text": "intravenous drug abuse",
            "probability": 1.0
        },
        {
            "start_logit": 9.703125,
            "end_logit": -2.490234375,
            "text": "intravenous",
            "probability": 6.377696990966797e-06
        },
        {
            "start_logit": -2.37890625,
            "end_logit": 9.46875,
            "text": "abuse",
            "probability": 5.662441253662109e-06
        },
        {
            "start_logit": -6.4453125,
            "end_logit": 9.46875,
            "text": "drug abuse",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.703125,
            "end_logit": -7.80078125,
            "text": "intravenous drug abuse this painless syndrome appears during or after a long period of drug addiction it involves the hands and sometimes the forearms and may cause functional aesthetic and social disturbances when the hand volume",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.703125,
            "end_logit": -7.81640625,
            "text": "intravenous drug abuse this painless syndrome appears during or after a long period of drug addiction it involves the hands and sometimes the forearms and may cause functional aesthetic and social disturbances when the hand volume is important",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.703125,
            "end_logit": -7.90625,
            "text": "intravenous drug",
            "probability": 0.0
        },
        {
            "start_logit": 9.703125,
            "end_logit": -7.94921875,
            "text": "intravenous drug abuse this painless syndrome appears during or after a long period of drug addiction it involves the hands and sometimes the forearms and may cause functional aesthetic and social disturbances when the hand volume is",
            "probability": 0.0
        },
        {
            "start_logit": 9.703125,
            "end_logit": -8.0,
            "text": "intravenous drug abuse this painless syndrome appears during or after a long period of drug addiction it involves the hands and sometimes the forearms and may cause functional aesthetic and social disturbances when the hand",
            "probability": 0.0
        },
        {
            "start_logit": 9.703125,
            "end_logit": -8.0703125,
            "text": "intravenous drug abuse this painless syndrome appears during or after a long period of drug addiction it involves the hands and sometimes the forearms and",
            "probability": 0.0
        },
        {
            "start_logit": 9.703125,
            "end_logit": -8.09375,
            "text": "intravenous drug abuse this",
            "probability": 0.0
        },
        {
            "start_logit": 9.703125,
            "end_logit": -8.109375,
            "text": "intravenous drug abuse this painless syndrome appears during or after a long period of drug addiction it involves the hands and sometimes the forearms and may cause functional aesthetic and social disturbances when the hand volume is important physiopathological mechanisms",
            "probability": 0.0
        },
        {
            "start_logit": 9.703125,
            "end_logit": -8.1328125,
            "text": "intravenous drug abuse this painless syndrome appears during or after a long period of drug addiction it involves the hands and sometimes the forearms and may cause functional aesthetic and social disturbances when the hand volume is important physiopathological",
            "probability": 0.0
        },
        {
            "start_logit": 9.703125,
            "end_logit": -8.140625,
            "text": "intravenous drug abuse this painless syndrome appears during or after a long period of drug addiction it involves the hands and sometimes the forearms and may cause functional aesthetic and social disturbances when the hand volume is important physiopathological mechanisms of the puffy hand syndrome are",
            "probability": 0.0
        },
        {
            "start_logit": 9.703125,
            "end_logit": -8.1875,
            "text": "intravenous drug abuse this painless syndrome appears during or after a long period of drug addiction",
            "probability": 0.0
        },
        {
            "start_logit": 9.703125,
            "end_logit": -8.2109375,
            "text": "intravenous drug abuse this painless syndrome appears during or after a long period of drug addiction it involves the hands and sometimes the forearms and may cause functional aesthetic and social disturbances when the hand volume is important physi",
            "probability": 0.0
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 9.46875,
            "text": "of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.46875,
            "text": "puffy hand syndrome is an unrecognized complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 9.46875,
            "text": "complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -2.37890625,
            "end_logit": -7.80078125,
            "text": "abuse this painless syndrome appears during or after a long period of drug addiction it involves the hands and sometimes the forearms and may cause functional aesthetic and social disturbances when the hand volume",
            "probability": 0.0
        }
    ],
    "5a7346662dc08e987e00001a_6": [
        {
            "start_logit": 9.8203125,
            "end_logit": 9.6640625,
            "text": "intravenous drug abuse",
            "probability": 1.0
        },
        {
            "start_logit": -1.9599609375,
            "end_logit": 9.6640625,
            "text": "abuse",
            "probability": 7.62939453125e-06
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -2.2578125,
            "text": "intravenous",
            "probability": 6.616115570068359e-06
        },
        {
            "start_logit": -6.640625,
            "end_logit": 9.6640625,
            "text": "drug abuse",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -7.8984375,
            "text": "intravenous drug",
            "probability": 0.0
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -8.2109375,
            "text": "intravenous drug abuse which has no current available treatment arm and forearm edema are voluminous and cause functional and aesthetic disturbances we report two cases successfully treated by low stretch bandages a 40 year old man and a 34 year old woman both intravenous drug users",
            "probability": 0.0
        },
        {
            "start_logit": -1.9599609375,
            "end_logit": -8.2109375,
            "text": "abuse which has no current available treatment arm and forearm edema are voluminous and cause functional and aesthetic disturbances we report two cases successfully treated by low stretch bandages a 40 year old man and a 34 year old woman both intravenous drug users",
            "probability": 0.0
        },
        {
            "start_logit": -6.640625,
            "end_logit": -7.8984375,
            "text": "drug",
            "probability": 0.0
        },
        {
            "start_logit": -6.640625,
            "end_logit": -8.2109375,
            "text": "drug abuse which has no current available treatment arm and forearm edema are voluminous and cause functional and aesthetic disturbances we report two cases successfully treated by low stretch bandages a 40 year old man and a 34 year old woman both intravenous drug users",
            "probability": 0.0
        },
        {
            "start_logit": -7.78515625,
            "end_logit": -7.72265625,
            "text": "case 1 and 2 5 cm and 1 9 cm respectively for case 2 the patients were taught self bandaging techniques during their hospital stays elastic gloves were fitted at the end of treatment reduction of lymphedema",
            "probability": 0.0
        },
        {
            "start_logit": -7.78515625,
            "end_logit": -7.72265625,
            "text": "of lymphedema",
            "probability": 0.0
        },
        {
            "start_logit": -7.7890625,
            "end_logit": -7.72265625,
            "text": "and 1 9 cm respectively for case 2 the patients were taught self bandaging techniques during their hospital stays elastic gloves were fitted at the end of treatment reduction of lymphedema",
            "probability": 0.0
        },
        {
            "start_logit": -7.79296875,
            "end_logit": -7.72265625,
            "text": "hospital stays elastic gloves were fitted at the end of treatment reduction of lymphedema",
            "probability": 0.0
        },
        {
            "start_logit": -7.78515625,
            "end_logit": -7.82421875,
            "text": "case 1 and 2 5 cm and 1 9 cm respectively for case 2 the patients were taught self bandaging techniques during their hospital stays elastic gloves were fitted at the end of treatment reduction of lymphedema volume",
            "probability": 0.0
        },
        {
            "start_logit": -7.78515625,
            "end_logit": -7.82421875,
            "text": "of lymphedema volume",
            "probability": 0.0
        },
        {
            "start_logit": -7.7890625,
            "end_logit": -7.82421875,
            "text": "and 1 9 cm respectively for case 2 the patients were taught self bandaging techniques during their hospital stays elastic gloves were fitted at the end of treatment reduction of lymphedema volume",
            "probability": 0.0
        },
        {
            "start_logit": -7.79296875,
            "end_logit": -7.82421875,
            "text": "hospital stays elastic gloves were fitted at the end of treatment reduction of lymphedema volume",
            "probability": 0.0
        },
        {
            "start_logit": -7.74609375,
            "end_logit": -7.96484375,
            "text": "multilayer bandaging",
            "probability": 0.0
        },
        {
            "start_logit": -7.78515625,
            "end_logit": -7.9296875,
            "text": "case 1 and 2 5 cm and 1 9 cm respectively for case 2 the patients were taught self bandaging techniques during their hospital stays elastic gloves were fitted at the end of treatment reduction of lymphedema volume remained",
            "probability": 0.0
        },
        {
            "start_logit": -7.78515625,
            "end_logit": -7.9296875,
            "text": "of lymphedema volume remained",
            "probability": 0.0
        }
    ],
    "56cf236f3975bb303a000002_1": [
        {
            "start_logit": 10.0,
            "end_logit": 9.296875,
            "text": "T-type calcium channels",
            "probability": 1.0
        },
        {
            "start_logit": 10.0,
            "end_logit": -1.7998046875,
            "text": "T",
            "probability": 1.519918441772461e-05
        },
        {
            "start_logit": -2.6640625,
            "end_logit": 9.296875,
            "text": "channels",
            "probability": 3.159046173095703e-06
        },
        {
            "start_logit": -5.3046875,
            "end_logit": 9.296875,
            "text": "block T-type calcium channels",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.11328125,
            "end_logit": 9.296875,
            "text": "-type calcium channels",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.25390625,
            "end_logit": 9.296875,
            "text": "type calcium channels",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0,
            "end_logit": -7.46484375,
            "text": "T-type calcium",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.80859375,
            "end_logit": 9.296875,
            "text": "calcium channels",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0,
            "end_logit": -7.84765625,
            "text": "T-type",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0,
            "end_logit": -7.9296875,
            "text": "T-type calcium channels, we examined if more selective T-type calcium channel",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0,
            "end_logit": -7.9375,
            "text": "T-type calcium channels, we examined if more selective T-type calcium channel blockers and also inhibitors of cystathionine-\u03b3-lyase (CSE",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0,
            "end_logit": -7.984375,
            "text": "T-type calcium channels, we examined if more selective T-type calcium channel blockers and also inhibitors of cystathionine-\u03b3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0,
            "end_logit": -8.0,
            "text": "T-type calcium channels, we examined if more selective T-type calcium channel blockers and also inhibitors of cystathionine-\u03b3-lyase (CSE), a major H\u2082S",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0,
            "end_logit": -8.0234375,
            "text": "T-type calcium channels, we examined if more selective T-type calcium",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0,
            "end_logit": -8.0625,
            "text": "T-type calcium channels, we examined if more selective T-type calcium channel blockers and also inhibitors of cystathionine",
            "probability": 0.0
        },
        {
            "start_logit": 10.0,
            "end_logit": -8.078125,
            "text": "T-type calcium channels, we examined if more selective T-type calcium channel blockers and also inhibitors of cystathionine-\u03b3-lyase",
            "probability": 0.0
        },
        {
            "start_logit": 10.0,
            "end_logit": -8.0859375,
            "text": "T-type calcium channels, we examined if more selective T-type calcium channel blockers and also inhibitors of cystathionine-\u03b3-lyase (CSE), a major H\u2082",
            "probability": 0.0
        },
        {
            "start_logit": 10.0,
            "end_logit": -8.1015625,
            "text": "T-type calcium channels, we examined if more selective T-type",
            "probability": 0.0
        },
        {
            "start_logit": 10.0,
            "end_logit": -8.15625,
            "text": "T-type calcium channels, we examined if more selective T",
            "probability": 0.0
        },
        {
            "start_logit": 10.0,
            "end_logit": -8.203125,
            "text": "T-type calcium channels, we examined if more selective T-type calcium channel blockers and also inhibitors of cystathion",
            "probability": 0.0
        }
    ],
    "6026ed981cb411341a0000d2_1": [
        {
            "start_logit": 9.90625,
            "end_logit": 9.6484375,
            "text": "erenumab",
            "probability": 1.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -2.068359375,
            "text": "er",
            "probability": 8.046627044677734e-06
        },
        {
            "start_logit": -2.005859375,
            "end_logit": 9.6484375,
            "text": "umab",
            "probability": 6.616115570068359e-06
        },
        {
            "start_logit": -5.33984375,
            "end_logit": 9.6484375,
            "text": "enumab",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.2890625,
            "end_logit": 9.6484375,
            "text": "(erenumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.84375,
            "end_logit": 9.6484375,
            "text": ", AMG334 (erenumab",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.15625,
            "text": "erenumab), LY2951742 (galcanezumab",
            "probability": 0.0
        },
        {
            "start_logit": -7.92578125,
            "end_logit": 9.6484375,
            "text": "(eptinezumab), AMG334 (erenumab",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.2109375,
            "text": "erenumab), LY2951742 (galcanezumab)",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.2265625,
            "text": "erenumab)",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.2734375,
            "text": "erenumab), LY2951742 (galcanez",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.2890625,
            "text": "erenumab), LY2951742 (galcanezumab) and TEV48125 (fremanezumab)]",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.2890625,
            "text": "eren",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.3046875,
            "text": "erenumab), LY2951742 (galcan",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.3125,
            "text": "erenumab), LY2951742 (galcanezumab) and TEV48125 (fremanezumab",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.3125,
            "text": "erenumab), LY295174",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.3203125,
            "text": "erenumab), LY2951742 (galcanezumab) and TEV48125 (fremanezumab)",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.3515625,
            "text": "erenumab), LY2951742 (galcanezumab) and TEV48125 (fremanez",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.6484375,
            "text": "randomized controlled trials for the prevention of episodic and chronic migraine demonstrating the efficacy and safety of four mAbs targeting the calcitonin gene-related peptide (CGRP) pathway [ALD403 (eptinezumab), AMG334 (erenumab",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.3671875,
            "text": "erenumab), LY2951742 (galcanezumab) and TEV48",
            "probability": 0.0
        }
    ],
    "587e0116ae05ffb474000002_1": [
        {
            "start_logit": 9.859375,
            "end_logit": 9.4453125,
            "text": "CisMapper",
            "probability": 1.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -2.193359375,
            "text": "Cis",
            "probability": 8.761882781982422e-06
        },
        {
            "start_logit": -2.494140625,
            "end_logit": 9.4453125,
            "text": "per",
            "probability": 4.291534423828125e-06
        },
        {
            "start_logit": -6.26953125,
            "end_logit": 9.4453125,
            "text": "Mapper",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.3125,
            "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP-seq data",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.3203125,
            "text": "CisMap",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.3203125,
            "text": "CisMapper: predicting regulatory interactions from transcription",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.3671875,
            "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP-seq",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.3671875,
            "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.375,
            "text": "CisMapper: predicting regulatory interactions from transcription factor",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -8.375,
            "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP-",
            "probability": 0.0
        },
        {
            "start_logit": -2.494140625,
            "end_logit": -8.3125,
            "text": "per: predicting regulatory interactions from transcription factor ChIP-seq data",
            "probability": 0.0
        },
        {
            "start_logit": -2.494140625,
            "end_logit": -8.3203125,
            "text": "per: predicting regulatory interactions from transcription",
            "probability": 0.0
        },
        {
            "start_logit": -2.494140625,
            "end_logit": -8.3671875,
            "text": "per: predicting regulatory interactions from transcription factor ChIP-seq",
            "probability": 0.0
        },
        {
            "start_logit": -2.494140625,
            "end_logit": -8.3671875,
            "text": "per: predicting regulatory interactions from transcription factor ChIP",
            "probability": 0.0
        },
        {
            "start_logit": -2.494140625,
            "end_logit": -8.375,
            "text": "per: predicting regulatory interactions from transcription factor",
            "probability": 0.0
        },
        {
            "start_logit": -2.494140625,
            "end_logit": -8.375,
            "text": "per: predicting regulatory interactions from transcription factor ChIP-",
            "probability": 0.0
        },
        {
            "start_logit": -6.26953125,
            "end_logit": -8.3125,
            "text": "Mapper: predicting regulatory interactions from transcription factor ChIP-seq data",
            "probability": 0.0
        },
        {
            "start_logit": -6.26953125,
            "end_logit": -8.3203125,
            "text": "Map",
            "probability": 0.0
        },
        {
            "start_logit": -6.26953125,
            "end_logit": -8.3203125,
            "text": "Mapper: predicting regulatory interactions from transcription",
            "probability": 0.0
        }
    ],
    "587e0116ae05ffb474000002_2": [
        {
            "start_logit": 9.8671875,
            "end_logit": 9.421875,
            "text": "CisMapper",
            "probability": 1.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -2.203125,
            "text": "Cis",
            "probability": 9.000301361083984e-06
        },
        {
            "start_logit": -2.533203125,
            "end_logit": 9.421875,
            "text": "per",
            "probability": 4.172325134277344e-06
        },
        {
            "start_logit": -6.26171875,
            "end_logit": 9.421875,
            "text": "Mapper",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.1953125,
            "text": "CisMapper, which predicts the regulatory targets of a TF using the correlation between a histone mark at the TF'",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.2734375,
            "text": "CisMapper, which predicts the regulatory targets of",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.28125,
            "text": "CisMapper, which predicts the regulatory targets of a TF using the correlation between a histone mark at the TF's bound sites and the expression of each gene across",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.3125,
            "text": "CisMapper, which predicts the regulatory targets of a TF using the correlation between a histone mark at the TF's bound sites and the expression of each gene across a",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.3203125,
            "text": "CisMapper, which predicts the regulatory targets of a TF using the correlation between a histone mark at the TF",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.328125,
            "text": "CisMapper, which predicts the regulatory targets of a TF using",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.328125,
            "text": "CisMapper, which predicts the regulatory targets of a TF using the correlation between a histone mark at the TF's",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.34375,
            "text": "CisMapper, which predicts the regulatory targets of a TF using the correlation between a histone mark at the TF's bound sites and the expression of each gene across a panel",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.34375,
            "text": "CisMapper, which predicts the regulatory targets of a TF using the correlation between a histone mark at the TF's bound sites and the expression",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.34375,
            "text": "CisMapper, which predicts the regulatory targets of a TF using the correlation between a histone mark at the TF's bound sites and",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.3515625,
            "text": "CisMapper, which predicts the regulatory targets of a TF using the correlation between a histone mark at the TF's bound sites and the expression of each gene across a panel of tissues",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.3515625,
            "text": "CisMapper, which predicts the regulatory targets of a TF using the correlation between a histone mark at the TF's bound sites",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.359375,
            "text": "CisMapper, which predicts the regulatory targets of a TF using the correlation between a histone mark at the TF's bound sites and the expression of",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.3671875,
            "text": "CisMapper, which predicts the regulatory targets of a TF using the correlation between a histone mark at the",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.3671875,
            "text": "CisMap",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.3671875,
            "text": "CisMapper, which predicts the regulatory targets of a TF using the correlation between a histone mark at",
            "probability": 0.0
        }
    ],
    "587e0116ae05ffb474000002_3": [
        {
            "start_logit": 9.890625,
            "end_logit": 9.453125,
            "text": "CisMapper",
            "probability": 1.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -2.14453125,
            "text": "Cis",
            "probability": 9.238719940185547e-06
        },
        {
            "start_logit": -2.458984375,
            "end_logit": 9.453125,
            "text": "per",
            "probability": 4.351139068603516e-06
        },
        {
            "start_logit": -6.55078125,
            "end_logit": 9.453125,
            "text": "Mapper",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.0859375,
            "text": "CisMapper is",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.2734375,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than the distance-based approaches currently used",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.2734375,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.28125,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than the distance-based approaches currently",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.2890625,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than the distance-based approaches currently used, and is particularly advantageous for predicting the long-range regulatory interactions typical of tissue-specific gene expression",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.296875,
            "text": "CisMap",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.3203125,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than the distance-based approaches currently used, and is particularly advantageous for predicting the long-range",
            "probability": 0.0
        },
        {
            "start_logit": -7.89453125,
            "end_logit": 9.453125,
            "text": "that CisMapper",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.3359375,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than the distance-based approaches currently used, and",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.34375,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than the distance-based approaches currently used, and is particularly advantageous for predicting the long-range regulatory interactions typical",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.359375,
            "text": "CisMapper is more accurate at predicting the target genes of a",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.3671875,
            "text": "CisMapper is more accurate at",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.375,
            "text": "CisMapper is more accurate at predicting the target genes of",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.375,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than the distance",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.390625,
            "text": "CisMapper is more accurate at predicting the target genes",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.390625,
            "text": "CisMapper is more",
            "probability": 0.0
        }
    ],
    "587e0116ae05ffb474000002_4": [
        {
            "start_logit": 9.9765625,
            "end_logit": 9.7265625,
            "text": "CisMapper",
            "probability": 1.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -1.9287109375,
            "text": "Cis",
            "probability": 8.64267349243164e-06
        },
        {
            "start_logit": -1.8759765625,
            "end_logit": 9.7265625,
            "text": "per",
            "probability": 7.152557373046875e-06
        },
        {
            "start_logit": -5.9296875,
            "end_logit": 9.7265625,
            "text": "Mapper",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.1484375,
            "text": "CisMap",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.15625,
            "text": "CisMapper also predicts which TF binding sites regulate a given gene more accurately than using genomic distance. Unlike distance-based methods, CisMapper",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.1875,
            "text": "CisMapper also predicts which TF binding sites regulate",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.203125,
            "text": "CisMapper also predicts which TF binding sites regulate a given gene more accurately than using genomic distance. Unlike distance-based methods, CisMap",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.21875,
            "text": "CisMapper also predicts which TF binding sites regulate a given gene more accurately than using genomic distance. Unlike distance-based methods, CisMapper can",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.21875,
            "text": "CisMapper also predicts which TF binding sites regulate a",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.21875,
            "text": "CisMapper also predicts which TF binding sites regulate a given gene more",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.2265625,
            "text": "CisMapper also predicts which TF binding sites",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.2265625,
            "text": "CisMapper also",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.28125,
            "text": "CisMapper also predicts which TF binding sites regulate a given gene more accurately",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.3046875,
            "text": "CisMapper also predicts which TF binding sites regulate a given",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.3125,
            "text": "CisMapper also predicts which TF binding sites regulate a given gene more accurately than using genomic distance. Unlike distance-based methods, CisMapper can predict which transcription start site of a gene is regulated",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.3125,
            "text": "CisMapper also predicts which TF binding sites regulate a given gene more accurately than using genomic distance. Unlike distance-based methods, CisMapper can predict which transcription start site",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.3203125,
            "text": "CisMapper also predicts which TF binding sites regulate a given gene more accurately than using genomic distance. Unlike distance-based methods, CisMapper can predict which transcription start",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.328125,
            "text": "CisMapper also predicts which TF binding sites regulate a given gene more accurately than",
            "probability": 0.0
        },
        {
            "start_logit": 9.9765625,
            "end_logit": -8.3359375,
            "text": "CisMapper also predicts which TF binding sites regulate a given gene more accurately than using genomic distance. Unlike distance",
            "probability": 0.0
        }
    ],
    "587e0116ae05ffb474000002_5": [
        {
            "start_logit": 9.921875,
            "end_logit": 9.5,
            "text": "CisMapper",
            "probability": 1.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -2.05078125,
            "text": "Cis",
            "probability": 9.655952453613281e-06
        },
        {
            "start_logit": -2.376953125,
            "end_logit": 9.5,
            "text": "per",
            "probability": 4.589557647705078e-06
        },
        {
            "start_logit": -6.1328125,
            "end_logit": 9.5,
            "text": "Mapper",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.2265625,
            "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP-seq data",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.2734375,
            "text": "CisMapper: predicting regulatory interactions from transcription",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.28125,
            "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP-seq",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.296875,
            "text": "CisMap",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.296875,
            "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.3046875,
            "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP-",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.3359375,
            "text": "CisMapper: predicting regulatory interactions from transcription factor",
            "probability": 0.0
        },
        {
            "start_logit": -2.376953125,
            "end_logit": -8.2265625,
            "text": "per: predicting regulatory interactions from transcription factor ChIP-seq data",
            "probability": 0.0
        },
        {
            "start_logit": -2.376953125,
            "end_logit": -8.2734375,
            "text": "per: predicting regulatory interactions from transcription",
            "probability": 0.0
        },
        {
            "start_logit": -2.376953125,
            "end_logit": -8.28125,
            "text": "per: predicting regulatory interactions from transcription factor ChIP-seq",
            "probability": 0.0
        },
        {
            "start_logit": -2.376953125,
            "end_logit": -8.296875,
            "text": "per: predicting regulatory interactions from transcription factor ChIP",
            "probability": 0.0
        },
        {
            "start_logit": -2.376953125,
            "end_logit": -8.3046875,
            "text": "per: predicting regulatory interactions from transcription factor ChIP-",
            "probability": 0.0
        },
        {
            "start_logit": -2.376953125,
            "end_logit": -8.3359375,
            "text": "per: predicting regulatory interactions from transcription factor",
            "probability": 0.0
        },
        {
            "start_logit": -6.1328125,
            "end_logit": -8.2265625,
            "text": "Mapper: predicting regulatory interactions from transcription factor ChIP-seq data",
            "probability": 0.0
        },
        {
            "start_logit": -6.1328125,
            "end_logit": -8.2734375,
            "text": "Mapper: predicting regulatory interactions from transcription",
            "probability": 0.0
        },
        {
            "start_logit": -6.1328125,
            "end_logit": -8.28125,
            "text": "Mapper: predicting regulatory interactions from transcription factor ChIP-seq",
            "probability": 0.0
        }
    ],
    "587e0116ae05ffb474000002_6": [
        {
            "start_logit": 9.921875,
            "end_logit": 9.5,
            "text": "CisMapper",
            "probability": 1.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -2.05078125,
            "text": "Cis",
            "probability": 9.655952453613281e-06
        },
        {
            "start_logit": -2.376953125,
            "end_logit": 9.5,
            "text": "per",
            "probability": 4.589557647705078e-06
        },
        {
            "start_logit": -6.1328125,
            "end_logit": 9.5,
            "text": "Mapper",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.2265625,
            "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP-seq data",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.2734375,
            "text": "CisMapper: predicting regulatory interactions from transcription",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.28125,
            "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP-seq",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.296875,
            "text": "CisMap",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.296875,
            "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.3046875,
            "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP-",
            "probability": 0.0
        },
        {
            "start_logit": 9.921875,
            "end_logit": -8.3359375,
            "text": "CisMapper: predicting regulatory interactions from transcription factor",
            "probability": 0.0
        },
        {
            "start_logit": -2.376953125,
            "end_logit": -8.2265625,
            "text": "per: predicting regulatory interactions from transcription factor ChIP-seq data",
            "probability": 0.0
        },
        {
            "start_logit": -2.376953125,
            "end_logit": -8.2734375,
            "text": "per: predicting regulatory interactions from transcription",
            "probability": 0.0
        },
        {
            "start_logit": -2.376953125,
            "end_logit": -8.28125,
            "text": "per: predicting regulatory interactions from transcription factor ChIP-seq",
            "probability": 0.0
        },
        {
            "start_logit": -2.376953125,
            "end_logit": -8.296875,
            "text": "per: predicting regulatory interactions from transcription factor ChIP",
            "probability": 0.0
        },
        {
            "start_logit": -2.376953125,
            "end_logit": -8.3046875,
            "text": "per: predicting regulatory interactions from transcription factor ChIP-",
            "probability": 0.0
        },
        {
            "start_logit": -2.376953125,
            "end_logit": -8.3359375,
            "text": "per: predicting regulatory interactions from transcription factor",
            "probability": 0.0
        },
        {
            "start_logit": -6.1328125,
            "end_logit": -8.2265625,
            "text": "Mapper: predicting regulatory interactions from transcription factor ChIP-seq data",
            "probability": 0.0
        },
        {
            "start_logit": -6.1328125,
            "end_logit": -8.2734375,
            "text": "Mapper: predicting regulatory interactions from transcription",
            "probability": 0.0
        },
        {
            "start_logit": -6.1328125,
            "end_logit": -8.28125,
            "text": "Mapper: predicting regulatory interactions from transcription factor ChIP-seq",
            "probability": 0.0
        }
    ],
    "587e0116ae05ffb474000002_7": [
        {
            "start_logit": 9.9609375,
            "end_logit": 9.546875,
            "text": "CisMapper",
            "probability": 1.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -1.97265625,
            "text": "Cis",
            "probability": 9.953975677490234e-06
        },
        {
            "start_logit": -2.25390625,
            "end_logit": 9.546875,
            "text": "per",
            "probability": 5.0067901611328125e-06
        },
        {
            "start_logit": -6.453125,
            "end_logit": 9.546875,
            "text": "Mapper",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -7.93359375,
            "text": "CisMapper is",
            "probability": 0.0
        },
        {
            "start_logit": -7.76171875,
            "end_logit": 9.546875,
            "text": "that CisMapper",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.1953125,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.203125,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than the distance-based approaches currently used",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.2109375,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than the distance-based approaches currently",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.2421875,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than the distance-based approaches currently used, and is particularly advantageous for predicting the long-range",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.25,
            "text": "CisMap",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.265625,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than the distance-based approaches currently used, and",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.3046875,
            "text": "CisMapper is more accurate at predicting the target genes of a",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.3046875,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than the distance-based approaches currently used, and is particularly advantageous for predicting the long-range regulatory interactions typical",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.3125,
            "text": "CisMapper is more accurate at predicting the target genes of",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.3203125,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than the distance",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.328125,
            "text": "CisMapper is more accurate at predicting the target genes",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.328125,
            "text": "CisMapper is more accurate at",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.3359375,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than the distance-based approaches currently used,",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.3359375,
            "text": "CisMapper is more accurate at predicting the target genes of a TF",
            "probability": 0.0
        }
    ],
    "60314c361cb411341a00012e_1": [
        {
            "start_logit": 10.1328125,
            "end_logit": 10.0703125,
            "text": "inflammation of the aorta",
            "probability": 1.0
        },
        {
            "start_logit": -0.66357421875,
            "end_logit": 10.0703125,
            "text": "aorta",
            "probability": 2.0444393157958984e-05
        },
        {
            "start_logit": 10.1328125,
            "end_logit": -1.4775390625,
            "text": "inflammation",
            "probability": 9.655952453613281e-06
        },
        {
            "start_logit": -6.40234375,
            "end_logit": 10.0703125,
            "text": "of the aorta",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.55078125,
            "end_logit": 10.0703125,
            "text": "the aorta",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.02734375,
            "end_logit": 10.0703125,
            "text": "the inflammation of the aorta",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1328125,
            "end_logit": -7.69921875,
            "text": "inflammation of the aorta due to various causes.",
            "probability": 0.0
        },
        {
            "start_logit": 10.1328125,
            "end_logit": -7.73828125,
            "text": "inflammation of the aorta due to various causes",
            "probability": 0.0
        },
        {
            "start_logit": -7.734375,
            "end_logit": 10.0703125,
            "text": "Aortitis is the inflammation of the aorta",
            "probability": 0.0
        },
        {
            "start_logit": 10.1328125,
            "end_logit": -7.9765625,
            "text": "inflammation of the",
            "probability": 0.0
        },
        {
            "start_logit": 10.1328125,
            "end_logit": -8.0859375,
            "text": "inflammation of the aorta due to various",
            "probability": 0.0
        },
        {
            "start_logit": -0.66357421875,
            "end_logit": -7.69921875,
            "text": "aorta due to various causes.",
            "probability": 0.0
        },
        {
            "start_logit": -0.66357421875,
            "end_logit": -7.73828125,
            "text": "aorta due to various causes",
            "probability": 0.0
        },
        {
            "start_logit": -7.02734375,
            "end_logit": -1.4775390625,
            "text": "the inflammation",
            "probability": 0.0
        },
        {
            "start_logit": -0.66357421875,
            "end_logit": -8.0859375,
            "text": "aorta due to various",
            "probability": 0.0
        },
        {
            "start_logit": -7.734375,
            "end_logit": -1.4775390625,
            "text": "Aortitis is the inflammation",
            "probability": 0.0
        },
        {
            "start_logit": -6.40234375,
            "end_logit": -7.69921875,
            "text": "of the aorta due to various causes.",
            "probability": 0.0
        },
        {
            "start_logit": -6.40234375,
            "end_logit": -7.73828125,
            "text": "of the aorta due to various causes",
            "probability": 0.0
        },
        {
            "start_logit": -6.55078125,
            "end_logit": -7.69921875,
            "text": "the aorta due to various causes.",
            "probability": 0.0
        },
        {
            "start_logit": -6.55078125,
            "end_logit": -7.73828125,
            "text": "the aorta due to various causes",
            "probability": 0.0
        }
    ],
    "60314c361cb411341a00012e_2": [
        {
            "start_logit": 9.9921875,
            "end_logit": 9.984375,
            "text": "inflammation of the aorta",
            "probability": 1.0
        },
        {
            "start_logit": -1.0595703125,
            "end_logit": 9.984375,
            "text": "aorta",
            "probability": 1.5914440155029297e-05
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -1.85546875,
            "text": "inflammation",
            "probability": 7.271766662597656e-06
        },
        {
            "start_logit": -6.453125,
            "end_logit": 9.984375,
            "text": "the aorta",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.55859375,
            "end_logit": 9.984375,
            "text": "of the aorta",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.85546875,
            "end_logit": 9.984375,
            "text": "the inflammation of the aorta",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 9.984375,
            "text": "Aortitis is the inflammation of the aorta",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.984375,
            "text": "REVIEW: Aortitis is the inflammation of the aorta",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.234375,
            "text": "inflammation of the",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.2734375,
            "text": "inflammation of the aorta due",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.984375,
            "text": ": Aortitis is the inflammation of the aorta",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.984375,
            "text": "PURPOSE OF REVIEW: Aortitis is the inflammation of the aorta",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.984375,
            "text": "OF REVIEW: Aortitis is the inflammation of the aorta",
            "probability": 0.0
        },
        {
            "start_logit": -8.359375,
            "end_logit": 9.984375,
            "text": "itis is the inflammation of the aorta",
            "probability": 0.0
        },
        {
            "start_logit": -1.0595703125,
            "end_logit": -8.2734375,
            "text": "aorta due",
            "probability": 0.0
        },
        {
            "start_logit": -7.85546875,
            "end_logit": -1.85546875,
            "text": "the inflammation",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": -1.85546875,
            "text": "Aortitis is the inflammation",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -1.85546875,
            "text": "REVIEW: Aortitis is the inflammation",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -1.85546875,
            "text": ": Aortitis is the inflammation",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -1.85546875,
            "text": "PURPOSE OF REVIEW: Aortitis is the inflammation",
            "probability": 0.0
        }
    ],
    "60314c361cb411341a00012e_3": [
        {
            "start_logit": 10.03125,
            "end_logit": 9.96875,
            "text": "inflammation of the aorta",
            "probability": 1.0
        },
        {
            "start_logit": -1.0615234375,
            "end_logit": 9.96875,
            "text": "aorta",
            "probability": 1.519918441772461e-05
        },
        {
            "start_logit": 10.03125,
            "end_logit": -1.7744140625,
            "text": "inflammation",
            "probability": 7.927417755126953e-06
        },
        {
            "start_logit": -5.34375,
            "end_logit": 9.96875,
            "text": "to inflammation of the aorta",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.64453125,
            "end_logit": 9.96875,
            "text": "term ascribed to inflammation of the aorta",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.765625,
            "end_logit": 9.96875,
            "text": "of the aorta",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.82421875,
            "end_logit": 9.96875,
            "text": "Aortitis is the all-encompassing pathological term ascribed to inflammation of the aorta",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.86328125,
            "end_logit": 9.96875,
            "text": "the aorta",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.0,
            "end_logit": 9.96875,
            "text": "the all-encompassing pathological term ascribed to inflammation of the aorta",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.03125,
            "end_logit": -7.22265625,
            "text": "inflammation of the aorta.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.21875,
            "end_logit": 9.96875,
            "text": "ascribed to inflammation of the aorta",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.03125,
            "end_logit": -7.8046875,
            "text": "inflammation of the",
            "probability": 0.0
        },
        {
            "start_logit": -7.90625,
            "end_logit": 9.96875,
            "text": "encompassing pathological term ascribed to inflammation of the aorta",
            "probability": 0.0
        },
        {
            "start_logit": -7.94921875,
            "end_logit": 9.96875,
            "text": "pathological term ascribed to inflammation of the aorta",
            "probability": 0.0
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 9.96875,
            "text": "all-encompassing pathological term ascribed to inflammation of the aorta",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.96875,
            "text": "-encompassing pathological term ascribed to inflammation of the aorta",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.96875,
            "text": "is the all-encompassing pathological term ascribed to inflammation of the aorta",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.96875,
            "text": "itis is the all-encompassing pathological term ascribed to inflammation of the aorta",
            "probability": 0.0
        },
        {
            "start_logit": -5.34375,
            "end_logit": -1.7744140625,
            "text": "to inflammation",
            "probability": 0.0
        },
        {
            "start_logit": -1.0615234375,
            "end_logit": -7.22265625,
            "text": "aorta.",
            "probability": 0.0
        }
    ],
    "5891c90949702f2e01000001_1": [
        {
            "start_logit": 9.9609375,
            "end_logit": 9.515625,
            "text": "INCA",
            "probability": 1.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -1.9501953125,
            "text": "INC",
            "probability": 1.055002212524414e-05
        },
        {
            "start_logit": -2.3359375,
            "end_logit": 9.515625,
            "text": "A",
            "probability": 4.589557647705078e-06
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.4140625,
            "text": "INCA: synonymous codon usage analysis and clustering by means of self",
            "probability": 0.0
        },
        {
            "start_logit": -2.3359375,
            "end_logit": -8.4140625,
            "text": "A: synonymous codon usage analysis and clustering by means of self",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -8.4140625,
            "text": "synonymous codon usage analysis and clustering by means of self",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -8.4140625,
            "text": "codon usage analysis and clustering by means of self",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": -8.4140625,
            "text": "analysis and clustering by means of self",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": -8.4140625,
            "text": "of self",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -8.4140625,
            "text": "clustering by means of self",
            "probability": 0.0
        }
    ],
    "5891c90949702f2e01000001_2": [
        {
            "start_logit": 9.9140625,
            "end_logit": 9.484375,
            "text": "INCA",
            "probability": 1.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -2.021484375,
            "text": "INC",
            "probability": 9.953975677490234e-06
        },
        {
            "start_logit": -2.3671875,
            "end_logit": 9.484375,
            "text": "A",
            "probability": 4.589557647705078e-06
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.3046875,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI, the primary strength of INC",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.328125,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI, the primary strength of INCA",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.328125,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CA",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.34375,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI, the primary strength of INCA has",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.3671875,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.3671875,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI, the primary strength",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.3828125,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.3828125,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI,",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.40625,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in",
            "probability": 0.0
        },
        {
            "start_logit": -2.3671875,
            "end_logit": -8.3046875,
            "text": "A) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI, the primary strength of INC",
            "probability": 0.0
        },
        {
            "start_logit": -2.3671875,
            "end_logit": -8.328125,
            "text": "A) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI, the primary strength of INCA",
            "probability": 0.0
        },
        {
            "start_logit": -2.3671875,
            "end_logit": -8.328125,
            "text": "A) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CA",
            "probability": 0.0
        },
        {
            "start_logit": -2.3671875,
            "end_logit": -8.34375,
            "text": "A) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI, the primary strength of INCA has",
            "probability": 0.0
        },
        {
            "start_logit": -2.3671875,
            "end_logit": -8.3671875,
            "text": "A) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and",
            "probability": 0.0
        },
        {
            "start_logit": -2.3671875,
            "end_logit": -8.3671875,
            "text": "A) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI, the primary strength",
            "probability": 0.0
        },
        {
            "start_logit": -2.3671875,
            "end_logit": -8.3828125,
            "text": "A) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and",
            "probability": 0.0
        },
        {
            "start_logit": -2.3671875,
            "end_logit": -8.3828125,
            "text": "A) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI,",
            "probability": 0.0
        }
    ],
    "5891c90949702f2e01000001_3": [
        {
            "start_logit": 9.9140625,
            "end_logit": 9.4609375,
            "text": "INCA",
            "probability": 1.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -2.029296875,
            "text": "INC",
            "probability": 1.0192394256591797e-05
        },
        {
            "start_logit": -2.44140625,
            "end_logit": 9.4609375,
            "text": "A",
            "probability": 4.291534423828125e-06
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.359375,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.4140625,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 9.4609375,
            "text": "INteractive Codon usage Analysis (INCA",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 9.4609375,
            "text": "(INCA",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.4609375,
            "text": "Codon usage Analysis (INCA",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.4609375,
            "text": "Analysis (INCA",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": -2.029296875,
            "text": "INteractive Codon usage Analysis (INC",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -2.029296875,
            "text": "(INC",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -2.029296875,
            "text": "Codon usage Analysis (INC",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -2.029296875,
            "text": "Analysis (INC",
            "probability": 0.0
        },
        {
            "start_logit": -2.44140625,
            "end_logit": -8.359375,
            "text": "A) provides an array of features useful in analysis of synonymous codon usage in whole genomes",
            "probability": 0.0
        },
        {
            "start_logit": -2.44140625,
            "end_logit": -8.4140625,
            "text": "A) provides an array of features useful in analysis of synonymous codon usage in",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": -8.359375,
            "text": "in analysis of synonymous codon usage in whole genomes",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": -8.359375,
            "text": "of synonymous codon usage in whole genomes",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": -8.4140625,
            "text": "in analysis of synonymous codon usage in",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": -8.359375,
            "text": "INteractive Codon usage Analysis (INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -8.359375,
            "text": "(INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes",
            "probability": 0.0
        }
    ],
    "5891c90949702f2e01000001_4": [
        {
            "start_logit": 9.9140625,
            "end_logit": 9.4609375,
            "text": "INCA",
            "probability": 1.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -2.048828125,
            "text": "INC",
            "probability": 1.0073184967041016e-05
        },
        {
            "start_logit": -2.44921875,
            "end_logit": 9.4609375,
            "text": "A",
            "probability": 4.291534423828125e-06
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.421875,
            "text": "INCA: synonymous codon usage analysis and clustering by means of self-organizing map",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.4453125,
            "text": "INCA: synonymous codon usage analysis and clustering by",
            "probability": 0.0
        },
        {
            "start_logit": -2.44921875,
            "end_logit": -8.421875,
            "text": "A: synonymous codon usage analysis and clustering by means of self-organizing map",
            "probability": 0.0
        },
        {
            "start_logit": -2.44921875,
            "end_logit": -8.4453125,
            "text": "A: synonymous codon usage analysis and clustering by",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -8.421875,
            "text": "synonymous codon usage analysis and clustering by means of self-organizing map",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -8.4453125,
            "text": "synonymous codon usage analysis and clustering by",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -8.421875,
            "text": "codon usage analysis and clustering by means of self-organizing map",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -8.421875,
            "text": "analysis and clustering by means of self-organizing map",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -8.421875,
            "text": "of self-organizing map",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -8.4453125,
            "text": "codon usage analysis and clustering by",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -8.4453125,
            "text": "analysis and clustering by",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -8.421875,
            "text": "clustering by means of self-organizing map",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -8.4453125,
            "text": "clustering by",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": -8.421875,
            "text": "-organizing map",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": -8.421875,
            "text": "organizing map",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": -8.421875,
            "text": "map",
            "probability": 0.0
        }
    ],
    "5891c90949702f2e01000001_5": [
        {
            "start_logit": 9.8515625,
            "end_logit": 9.375,
            "text": "INCA",
            "probability": 1.0
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -2.1875,
            "text": "INC",
            "probability": 9.59634780883789e-06
        },
        {
            "start_logit": -2.630859375,
            "end_logit": 9.375,
            "text": "A",
            "probability": 3.814697265625e-06
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -8.46875,
            "text": "INCA) provides an array of features useful",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": 9.375,
            "text": "INteractive Codon usage Analysis (INCA",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.375,
            "text": "Codon usage Analysis (INCA",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.375,
            "text": "(INCA",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.375,
            "text": "Analysis (INCA",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": -2.1875,
            "text": "INteractive Codon usage Analysis (INC",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": -2.1875,
            "text": "Codon usage Analysis (INC",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -2.1875,
            "text": "(INC",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -2.1875,
            "text": "Analysis (INC",
            "probability": 0.0
        },
        {
            "start_logit": -2.630859375,
            "end_logit": -8.46875,
            "text": "A) provides an array of features useful",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": -8.46875,
            "text": "INteractive Codon usage Analysis (INCA) provides an array of features useful",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": -8.46875,
            "text": "Codon usage Analysis (INCA) provides an array of features useful",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -8.46875,
            "text": "(INCA) provides an array of features useful",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -8.46875,
            "text": ") provides an array of features useful",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -8.46875,
            "text": "Analysis (INCA) provides an array of features useful",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": -8.46875,
            "text": "provides an array of features useful",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -8.46875,
            "text": "an array of features useful",
            "probability": 0.0
        }
    ],
    "5891c90949702f2e01000001_6": [
        {
            "start_logit": 9.8984375,
            "end_logit": 9.4453125,
            "text": "INCA",
            "probability": 1.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -2.072265625,
            "text": "INC",
            "probability": 9.953975677490234e-06
        },
        {
            "start_logit": -2.4921875,
            "end_logit": 9.4453125,
            "text": "A",
            "probability": 4.172325134277344e-06
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.3984375,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.4375,
            "text": "INCA) provides an array of features useful",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.4453125,
            "text": "INteractive Codon usage Analysis (INCA",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.4453125,
            "text": "Codon usage Analysis (INCA",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.4453125,
            "text": "(INCA",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": -2.072265625,
            "text": "INteractive Codon usage Analysis (INC",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -2.072265625,
            "text": "Codon usage Analysis (INC",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -2.072265625,
            "text": "(INC",
            "probability": 0.0
        },
        {
            "start_logit": -2.4921875,
            "end_logit": -8.3984375,
            "text": "A) provides an array of features useful in analysis of synonymous codon usage in whole genomes",
            "probability": 0.0
        },
        {
            "start_logit": -2.4921875,
            "end_logit": -8.4375,
            "text": "A) provides an array of features useful",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -8.3984375,
            "text": "of synonymous codon usage in whole genomes",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": -8.3984375,
            "text": "in analysis of synonymous codon usage in whole genomes",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": -8.3984375,
            "text": "synonymous codon usage in whole genomes",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": -8.3984375,
            "text": "INteractive Codon usage Analysis (INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": -8.3984375,
            "text": "analysis of synonymous codon usage in whole genomes",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -8.3984375,
            "text": "codon usage in whole genomes",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": -8.4375,
            "text": "INteractive Codon usage",
            "probability": 0.0
        }
    ],
    "5891c90949702f2e01000001_7": [
        {
            "start_logit": 9.90625,
            "end_logit": 9.4921875,
            "text": "INCA",
            "probability": 1.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -2.037109375,
            "text": "INC",
            "probability": 9.715557098388672e-06
        },
        {
            "start_logit": -2.345703125,
            "end_logit": 9.4921875,
            "text": "A",
            "probability": 4.76837158203125e-06
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.3046875,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI, the primary strength of INC",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.3359375,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI, the primary strength of INCA",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.3515625,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI, the primary strength of INCA has",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.359375,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI, the primary strength",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.3671875,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.3671875,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CA",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.375,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.3828125,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI,",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.40625,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes",
            "probability": 0.0
        },
        {
            "start_logit": -2.345703125,
            "end_logit": -8.3046875,
            "text": "A) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI, the primary strength of INC",
            "probability": 0.0
        },
        {
            "start_logit": -2.345703125,
            "end_logit": -8.3359375,
            "text": "A) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI, the primary strength of INCA",
            "probability": 0.0
        },
        {
            "start_logit": -2.345703125,
            "end_logit": -8.3515625,
            "text": "A) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI, the primary strength of INCA has",
            "probability": 0.0
        },
        {
            "start_logit": -2.345703125,
            "end_logit": -8.359375,
            "text": "A) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI, the primary strength",
            "probability": 0.0
        },
        {
            "start_logit": -2.345703125,
            "end_logit": -8.3671875,
            "text": "A) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and",
            "probability": 0.0
        },
        {
            "start_logit": -2.345703125,
            "end_logit": -8.3671875,
            "text": "A) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CA",
            "probability": 0.0
        },
        {
            "start_logit": -2.345703125,
            "end_logit": -8.375,
            "text": "A) provides an array of features useful in analysis of synonymous codon usage in",
            "probability": 0.0
        },
        {
            "start_logit": -2.345703125,
            "end_logit": -8.3828125,
            "text": "A) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI,",
            "probability": 0.0
        }
    ],
    "5891c90949702f2e01000001_8": [
        {
            "start_logit": 9.90625,
            "end_logit": 9.4921875,
            "text": "INCA",
            "probability": 1.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -2.046875,
            "text": "INC",
            "probability": 9.655952453613281e-06
        },
        {
            "start_logit": -2.37109375,
            "end_logit": 9.4921875,
            "text": "A",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.3046875,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI, the primary strength of INC",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.328125,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI, the primary strength of INCA",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.3359375,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI, the primary strength of INCA has",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.359375,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CA",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.3828125,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.390625,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI, the primary strength",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.3984375,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI,",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.4140625,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.4375,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI, the primary",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.4375,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI, the",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -8.4375,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 9.4921875,
            "text": "INteractive Codon usage Analysis (INCA",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -2.046875,
            "text": "INteractive Codon usage Analysis (INC",
            "probability": 0.0
        },
        {
            "start_logit": -2.37109375,
            "end_logit": -8.3046875,
            "text": "A) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI, the primary strength of INC",
            "probability": 0.0
        },
        {
            "start_logit": -2.37109375,
            "end_logit": -8.328125,
            "text": "A) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI, the primary strength of INCA",
            "probability": 0.0
        },
        {
            "start_logit": -2.37109375,
            "end_logit": -8.3359375,
            "text": "A) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI, the primary strength of INCA has",
            "probability": 0.0
        },
        {
            "start_logit": -2.37109375,
            "end_logit": -8.359375,
            "text": "A) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CA",
            "probability": 0.0
        }
    ],
    "5891c90949702f2e01000001_9": [
        {
            "start_logit": 9.9921875,
            "end_logit": 9.375,
            "text": "INCA",
            "probability": 1.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -1.857421875,
            "text": "INC",
            "probability": 1.3113021850585938e-05
        },
        {
            "start_logit": -2.607421875,
            "end_logit": 9.375,
            "text": "A",
            "probability": 3.337860107421875e-06
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.3046875,
            "text": "INCA has",
            "probability": 0.0
        },
        {
            "start_logit": -7.7265625,
            "end_logit": 9.375,
            "text": "of INCA",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.390625,
            "text": "INCA has numerous options for the interactive graphical display of calculated values",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.3984375,
            "text": "INCA has numerous",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.40625,
            "text": "INCA has numerous options for the interactive graphical display of calculated values, thus allowing visual detection of various trends in codon usage. Finally, INCA includes a specific unsupervised neural network",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.4140625,
            "text": "INCA has numerous options for the interactive graphical display of calculated values, thus allowing visual detection of various trends in codon usage. Finally, INCA includes",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.4296875,
            "text": "INCA has numerous options for",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.4296875,
            "text": "INCA has numerous options for the interactive graphical display of calculated values, thus allowing visual detection of various trends in codon usage",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.453125,
            "text": "INCA has numerous options for the interactive graphical display of calculated values, thus allowing",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.375,
            "text": "codon bias', effective Nc and CAI, the primary strength of INCA",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 9.375,
            "text": "codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI, the primary strength of INCA",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.375,
            "text": "computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI, the primary strength of INCA",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": 9.375,
            "text": "'codon bias', effective Nc and CAI, the primary strength of INCA",
            "probability": 0.0
        },
        {
            "start_logit": -7.7265625,
            "end_logit": -1.857421875,
            "text": "of INC",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": -1.857421875,
            "text": "codon bias', effective Nc and CAI, the primary strength of INC",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": -1.857421875,
            "text": "codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI, the primary strength of INC",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": -1.857421875,
            "text": "computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI, the primary strength of INC",
            "probability": 0.0
        }
    ],
    "5891c90949702f2e01000001_10": [
        {
            "start_logit": 9.953125,
            "end_logit": 9.515625,
            "text": "INCA",
            "probability": 1.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -1.9599609375,
            "text": "INC",
            "probability": 1.0371208190917969e-05
        },
        {
            "start_logit": -2.33203125,
            "end_logit": 9.515625,
            "text": "A",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.1953125,
            "text": "INCA includes a specific unsupervised neural network",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.2421875,
            "text": "INCA includes a specific unsupervised neural network algorithm, the self-organizing map, used for gene clustering according to the preferred utilization of codons.AVAILABILITY: INCA",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.3046875,
            "text": "INCA includes a specific unsupervised neural network algorithm, the self-organizing map, used for gene clustering according to the preferred utilization of codons.AVAILABILITY: INC",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.3203125,
            "text": "INCA includes a specific unsupervised neural network algorithm, the self-organizing map, used for gene clustering according to the preferred utilization of codons.AVAILABILITY: INCA is available for the Win32 platform",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.328125,
            "text": "INCA includes a specific unsupervised neural network algorithm, the self-organizing map, used for gene clustering according to the preferred utilization of codons.AVAILABILITY: INCA is",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.34375,
            "text": "INCA includes",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.359375,
            "text": "INCA includes a specific unsupervised neural network algorithm, the self-organizing map, used for gene clustering",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.3671875,
            "text": "INCA includes a specific unsupervised neural network algorithm, the self-organizing map, used for gene clustering according",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.3828125,
            "text": "INCA includes a specific unsupervised neural network algorithm, the self-organizing map, used for gene clustering according to",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.3828125,
            "text": "INCA includes a specific unsupervised neural network algorithm, the self-organizing",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.515625,
            "text": ", INCA",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -1.9599609375,
            "text": ", INC",
            "probability": 0.0
        },
        {
            "start_logit": -2.33203125,
            "end_logit": -8.1953125,
            "text": "A includes a specific unsupervised neural network",
            "probability": 0.0
        },
        {
            "start_logit": -2.33203125,
            "end_logit": -8.2421875,
            "text": "A includes a specific unsupervised neural network algorithm, the self-organizing map, used for gene clustering according to the preferred utilization of codons.AVAILABILITY: INCA",
            "probability": 0.0
        },
        {
            "start_logit": -2.33203125,
            "end_logit": -8.3046875,
            "text": "A includes a specific unsupervised neural network algorithm, the self-organizing map, used for gene clustering according to the preferred utilization of codons.AVAILABILITY: INC",
            "probability": 0.0
        },
        {
            "start_logit": -2.33203125,
            "end_logit": -8.3203125,
            "text": "A includes a specific unsupervised neural network algorithm, the self-organizing map, used for gene clustering according to the preferred utilization of codons.AVAILABILITY: INCA is available for the Win32 platform",
            "probability": 0.0
        },
        {
            "start_logit": -2.33203125,
            "end_logit": -8.328125,
            "text": "A includes a specific unsupervised neural network algorithm, the self-organizing map, used for gene clustering according to the preferred utilization of codons.AVAILABILITY: INCA is",
            "probability": 0.0
        }
    ],
    "5891c90949702f2e01000001_11": [
        {
            "start_logit": 9.9609375,
            "end_logit": 9.515625,
            "text": "INCA",
            "probability": 1.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -1.9501953125,
            "text": "INC",
            "probability": 1.055002212524414e-05
        },
        {
            "start_logit": -2.3359375,
            "end_logit": 9.515625,
            "text": "A",
            "probability": 4.589557647705078e-06
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.4140625,
            "text": "INCA: synonymous codon usage analysis and clustering by means of self",
            "probability": 0.0
        },
        {
            "start_logit": -2.3359375,
            "end_logit": -8.4140625,
            "text": "A: synonymous codon usage analysis and clustering by means of self",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -8.4140625,
            "text": "synonymous codon usage analysis and clustering by means of self",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -8.4140625,
            "text": "codon usage analysis and clustering by means of self",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": -8.4140625,
            "text": "analysis and clustering by means of self",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": -8.4140625,
            "text": "of self",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -8.4140625,
            "text": "clustering by means of self",
            "probability": 0.0
        }
    ],
    "6277e4ee56bf9aee6f000008_1": [
        {
            "start_logit": -0.9951171875,
            "end_logit": -3.736328125,
            "text": "NSAIDs",
            "probability": 0.6435546875
        },
        {
            "start_logit": -1.8232421875,
            "end_logit": -4.39453125,
            "text": "acetaminophen for controlling fever and inflammation and be cautious about using NSAIDs",
            "probability": 0.145263671875
        },
        {
            "start_logit": -2.103515625,
            "end_logit": -4.39453125,
            "text": "NSAIDs",
            "probability": 0.10968017578125
        },
        {
            "start_logit": -1.8232421875,
            "end_logit": -6.4609375,
            "text": "acetaminophen for controlling fever and inflammation and be cautious about using NSAIDs in management of COVID-19 patients until there are enough evidence.",
            "probability": 0.0184783935546875
        },
        {
            "start_logit": -1.8232421875,
            "end_logit": -6.49609375,
            "text": "acetaminophen",
            "probability": 0.01776123046875
        },
        {
            "start_logit": -2.103515625,
            "end_logit": -6.4609375,
            "text": "NSAIDs in management of COVID-19 patients until there are enough evidence.",
            "probability": 0.013946533203125
        },
        {
            "start_logit": -0.9951171875,
            "end_logit": -7.61328125,
            "text": "NSAIDs have been effective in treating respiratory infections caused by influenza and rhinovirus, since there is no clinical trial on COVID-19 and case-reports and clinical experiences are indicative of elongation of treatment duration",
            "probability": 0.0133056640625
        },
        {
            "start_logit": -0.9951171875,
            "end_logit": -7.69140625,
            "text": "NSAIDs have",
            "probability": 0.01230621337890625
        },
        {
            "start_logit": -0.9951171875,
            "end_logit": -7.765625,
            "text": "NSAIDs have been effective in treating respiratory infections caused by influenza and rhinovirus, since there is no clinical trial on COVID-19",
            "probability": 0.01146697998046875
        },
        {
            "start_logit": -1.8232421875,
            "end_logit": -7.76171875,
            "text": "acetaminophen for controlling fever and inflammation",
            "probability": 0.00501251220703125
        },
        {
            "start_logit": -5.37890625,
            "end_logit": -4.39453125,
            "text": "as acetaminophen for controlling fever and inflammation and be cautious about using NSAIDs",
            "probability": 0.004154205322265625
        },
        {
            "start_logit": -6.51171875,
            "end_logit": -4.39453125,
            "text": "using NSAIDs",
            "probability": 0.0013380050659179688
        },
        {
            "start_logit": -6.85546875,
            "end_logit": -4.39453125,
            "text": "use substitutes such as acetaminophen for controlling fever and inflammation and be cautious about using NSAIDs",
            "probability": 0.0009489059448242188
        },
        {
            "start_logit": -7.125,
            "end_logit": -4.39453125,
            "text": "substitutes such as acetaminophen for controlling fever and inflammation and be cautious about using NSAIDs",
            "probability": 0.0007271766662597656
        },
        {
            "start_logit": -5.37890625,
            "end_logit": -6.4609375,
            "text": "as acetaminophen for controlling fever and inflammation and be cautious about using NSAIDs in management of COVID-19 patients until there are enough evidence.",
            "probability": 0.0005240440368652344
        },
        {
            "start_logit": -5.37890625,
            "end_logit": -6.49609375,
            "text": "as acetaminophen",
            "probability": 0.0005078315734863281
        },
        {
            "start_logit": -5.64453125,
            "end_logit": -6.4609375,
            "text": ".",
            "probability": 0.0004017353057861328
        },
        {
            "start_logit": -6.51171875,
            "end_logit": -6.4609375,
            "text": "using NSAIDs in management of COVID-19 patients until there are enough evidence.",
            "probability": 0.00017082691192626953
        },
        {
            "start_logit": -5.37890625,
            "end_logit": -7.76171875,
            "text": "as acetaminophen for controlling fever and inflammation",
            "probability": 0.00014388561248779297
        },
        {
            "start_logit": -6.85546875,
            "end_logit": -6.4609375,
            "text": "use substitutes such as acetaminophen for controlling fever and inflammation and be cautious about using NSAIDs in management of COVID-19 patients until there are enough evidence.",
            "probability": 0.00012117624282836914
        }
    ],
    "6277e4ee56bf9aee6f000008_2": [
        {
            "start_logit": 3.775390625,
            "end_logit": 3.66796875,
            "text": "pain",
            "probability": 0.998046875
        },
        {
            "start_logit": -3.228515625,
            "end_logit": 3.66796875,
            "text": "Pharmacological approaches like acetaminophen, NSAIDS, spasmolytics etc. can be used if non-pharmacological therapy is inadequate. As per the current strength of evidence, acetaminophen and ibuprofen can be safely administered for pain",
            "probability": 0.0009026527404785156
        },
        {
            "start_logit": -4.41015625,
            "end_logit": 3.66796875,
            "text": ". As per the current strength of evidence, acetaminophen and ibuprofen can be safely administered for pain",
            "probability": 0.00027751922607421875
        },
        {
            "start_logit": -4.6640625,
            "end_logit": 3.66796875,
            "text": "ibuprofen can be safely administered for pain",
            "probability": 0.0002161264419555664
        },
        {
            "start_logit": 3.775390625,
            "end_logit": -4.7734375,
            "text": "pain management in children with COVID-19.",
            "probability": 0.00021445751190185547
        },
        {
            "start_logit": -5.06640625,
            "end_logit": 3.66796875,
            "text": "NSAIDS, spasmolytics etc. can be used if non-pharmacological therapy is inadequate. As per the current strength of evidence, acetaminophen and ibuprofen can be safely administered for pain",
            "probability": 0.00014400482177734375
        },
        {
            "start_logit": -5.84375,
            "end_logit": 3.66796875,
            "text": "acetaminophen and ibuprofen can be safely administered for pain",
            "probability": 6.592273712158203e-05
        },
        {
            "start_logit": 3.775390625,
            "end_logit": -6.11328125,
            "text": "pain management",
            "probability": 5.638599395751953e-05
        },
        {
            "start_logit": -6.03125,
            "end_logit": 3.66796875,
            "text": ", acetaminophen and ibuprofen can be safely administered for pain",
            "probability": 5.46574592590332e-05
        },
        {
            "start_logit": -6.54296875,
            "end_logit": 3.66796875,
            "text": ", NSAIDS, spasmolytics etc. can be used if non-pharmacological therapy is inadequate. As per the current strength of evidence, acetaminophen and ibuprofen can be safely administered for pain",
            "probability": 3.2901763916015625e-05
        },
        {
            "start_logit": -6.5546875,
            "end_logit": 3.66796875,
            "text": "and ibuprofen can be safely administered for pain",
            "probability": 3.266334533691406e-05
        },
        {
            "start_logit": -6.609375,
            "end_logit": 3.66796875,
            "text": "current strength of evidence, acetaminophen and ibuprofen can be safely administered for pain",
            "probability": 3.063678741455078e-05
        },
        {
            "start_logit": -6.64453125,
            "end_logit": 3.66796875,
            "text": "for pain",
            "probability": 2.9742717742919922e-05
        },
        {
            "start_logit": -6.69921875,
            "end_logit": 3.66796875,
            "text": "safely administered for pain",
            "probability": 2.8133392333984375e-05
        },
        {
            "start_logit": -6.76953125,
            "end_logit": 3.66796875,
            "text": ", spasmolytics etc. can be used if non-pharmacological therapy is inadequate. As per the current strength of evidence, acetaminophen and ibuprofen can be safely administered for pain",
            "probability": 2.6226043701171875e-05
        },
        {
            "start_logit": 3.775390625,
            "end_logit": -6.88671875,
            "text": "pain management in children",
            "probability": 2.5987625122070312e-05
        },
        {
            "start_logit": -6.98046875,
            "end_logit": 3.66796875,
            "text": "like acetaminophen, NSAIDS, spasmolytics etc. can be used if non-pharmacological therapy is inadequate. As per the current strength of evidence, acetaminophen and ibuprofen can be safely administered for pain",
            "probability": 2.1219253540039062e-05
        },
        {
            "start_logit": -7.0546875,
            "end_logit": 3.66796875,
            "text": "approaches like acetaminophen, NSAIDS, spasmolytics etc. can be used if non-pharmacological therapy is inadequate. As per the current strength of evidence, acetaminophen and ibuprofen can be safely administered for pain",
            "probability": 1.9788742065429688e-05
        },
        {
            "start_logit": 3.775390625,
            "end_logit": -7.59765625,
            "text": "pain management in",
            "probability": 1.2814998626708984e-05
        },
        {
            "start_logit": -3.228515625,
            "end_logit": -4.53515625,
            "text": "Pharmacological approaches like acetaminophen, NSAIDS, spasmolytics etc. can be used if non-pharmacological therapy is inadequate. As per the current strength of evidence, acetaminophen and ibuprofen",
            "probability": 2.384185791015625e-07
        }
    ],
    "6277e4ee56bf9aee6f000008_3": [
        {
            "start_logit": 8.0625,
            "end_logit": 7.5078125,
            "text": "Paracetamol",
            "probability": 1.0
        },
        {
            "start_logit": 8.0625,
            "end_logit": -2.322265625,
            "text": "Paracetamol (acetaminophen) has been proposed as an alternative to NSAIDs but there are issues with liver toxicity at high doses. There are clearly COVID-19 cases where NSAIDs",
            "probability": 5.3942203521728516e-05
        },
        {
            "start_logit": 8.0625,
            "end_logit": -5.0625,
            "text": "Paracetamol (acetaminophen) has been proposed as an alternative to NSAIDs but there are issues with liver toxicity at high doses.",
            "probability": 3.4570693969726562e-06
        },
        {
            "start_logit": 8.0625,
            "end_logit": -5.93359375,
            "text": "Paracetamol (acetaminophen) has been proposed as an alternative to NSAIDs",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 8.0625,
            "end_logit": -6.5390625,
            "text": "Paracetamol (acetaminophen) has been proposed as an alternative to NSAIDs but there are issues with liver toxicity at high doses. There are clearly COVID-19 cases where NSAIDs should not be used, but there is no strong evidence that NSAIDs must",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.0625,
            "end_logit": -6.70703125,
            "text": "Paracetamol (acetaminophen) has been proposed as an alternative to NSAIDs but there are issues with liver toxicity at high doses. There are clearly COVID-19 cases where NSAIDs should",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.0625,
            "end_logit": -6.79296875,
            "text": "Paracetamol (acetaminophen) has been proposed as an alternative to NSAIDs but there are issues with liver toxicity at high doses. There are clearly COVID-19 cases where NSAIDs should not be used, but there is no strong evidence that NSAIDs",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.0625,
            "end_logit": -6.82421875,
            "text": "Paracetamol (acetaminophen) has been proposed as an alternative to NSAIDs but there are issues with liver toxicity at high doses. There are clearly COVID-19 cases where NSAIDs should not be used, but there is no strong evidence that NSAIDs must be avoided",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.0625,
            "end_logit": -6.8828125,
            "text": "Paracetamol (acetaminophen",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.0625,
            "end_logit": -6.98828125,
            "text": "Paracetamol (acetaminophen)",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.0625,
            "end_logit": -7.10546875,
            "text": "Paracetamol (acetaminophen) has been proposed as an alternative to NSAIDs but there are issues with liver toxicity at high doses. There are clearly COVID-19 cases where NSAIDs should not be used",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.0625,
            "end_logit": -7.1640625,
            "text": "Paracetamol (acetaminophen) has been proposed",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.0625,
            "end_logit": -7.171875,
            "text": "Paracetamol (acetaminophen) has been proposed as an alternative to NSAIDs but there are issues with liver toxicity at high doses. There are clearly COVID-19 cases where NSAIDs should not",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.0625,
            "end_logit": -7.26953125,
            "text": "Paracetamol (acetaminophen) has",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.0625,
            "end_logit": -7.39453125,
            "text": "Paracetamol (acetaminophen) has been proposed as an alternative to NSAIDs but there are issues with liver toxicity at high doses. There are clearly COVID-19 cases where NSAIDs should not be used, but there is no strong evidence that NSAIDs must be avoided in",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.0625,
            "end_logit": -7.40625,
            "text": "Paracetamol (acetaminophen) has been proposed as an alternative",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 1.3154296875,
            "end_logit": -2.322265625,
            "text": "NSAIDs",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 1.3154296875,
            "end_logit": -5.0625,
            "text": "NSAIDs should not be used, but there is no strong evidence that NSAIDs must be avoided in all patients with COVID-19; clinicians must weigh these choices on an individual basis.",
            "probability": 0.0
        },
        {
            "start_logit": 1.3154296875,
            "end_logit": -6.5390625,
            "text": "NSAIDs should not be used, but there is no strong evidence that NSAIDs must",
            "probability": 0.0
        },
        {
            "start_logit": 1.3154296875,
            "end_logit": -6.70703125,
            "text": "NSAIDs should",
            "probability": 0.0
        }
    ],
    "6277e4ee56bf9aee6f000008_4": [
        {
            "start_logit": 7.33203125,
            "end_logit": 5.28515625,
            "text": "paracetamol",
            "probability": 0.98193359375
        },
        {
            "start_logit": 7.33203125,
            "end_logit": 1.2568359375,
            "text": "paracetamol can be listed as the first option in these patients, and then NSAIDs can also be reliably used for pain",
            "probability": 0.017425537109375
        },
        {
            "start_logit": 7.33203125,
            "end_logit": -2.30078125,
            "text": "paracetamol can be listed as the first option in these patients, and then NSAIDs",
            "probability": 0.0004982948303222656
        },
        {
            "start_logit": 0.76953125,
            "end_logit": 1.2568359375,
            "text": "pain",
            "probability": 2.4616718292236328e-05
        },
        {
            "start_logit": 7.33203125,
            "end_logit": -6.42578125,
            "text": "paracetamol can be listed as the first option in these patients, and then NSAIDs can also be reliably used for pain management",
            "probability": 8.046627044677734e-06
        },
        {
            "start_logit": 7.33203125,
            "end_logit": -6.953125,
            "text": "paracetamol can be listed as the first option in these patients, and then NSAIDs can",
            "probability": 4.827976226806641e-06
        },
        {
            "start_logit": 7.33203125,
            "end_logit": -7.1484375,
            "text": "paracetamol can be listed as the first option in these patients, and then NSAIDs can also be reliably used for pain management in patients with COVID-19 if there are no absolute contraindications such as kidney failure or gastric bleeding.",
            "probability": 3.933906555175781e-06
        },
        {
            "start_logit": 7.33203125,
            "end_logit": -7.5625,
            "text": "paracetamol can be listed as the first option in these patients, and then NSAIDs can also be reliably used",
            "probability": 2.562999725341797e-06
        },
        {
            "start_logit": 7.33203125,
            "end_logit": -7.6328125,
            "text": "paracetamol can be listed as the first option in these patients, and then NSAIDs can also",
            "probability": 2.384185791015625e-06
        },
        {
            "start_logit": 7.33203125,
            "end_logit": -7.66015625,
            "text": "paracetamol can",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": 7.33203125,
            "end_logit": -7.671875,
            "text": "paracetamol can be listed as the first option in these patients, and then NSAIDs can also be",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": -1.650390625,
            "end_logit": 1.2568359375,
            "text": "NSAIDs can also be reliably used for pain",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": 7.33203125,
            "end_logit": -7.87890625,
            "text": "paracetamol can be listed as the first option in these patients, and then NSAIDs can also be reliably used for pain management in patients with COVID-19 if there are no absolute contraindications",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": 7.33203125,
            "end_logit": -8.0,
            "text": "paracetamol can be listed as the first option",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": 7.33203125,
            "end_logit": -8.0234375,
            "text": "paracetamol can be listed as the first option in these patients, and then NSAIDs can also be reliably",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": -7.71484375,
            "end_logit": 5.28515625,
            "text": ", paracetamol",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.79296875,
            "end_logit": 5.28515625,
            "text": "analgesia, paracetamol",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -1.650390625,
            "end_logit": -2.30078125,
            "text": "NSAIDs",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.4609375,
            "end_logit": 1.2568359375,
            "text": "then NSAIDs can also be reliably used for pain",
            "probability": 0.0
        },
        {
            "start_logit": 0.76953125,
            "end_logit": -6.42578125,
            "text": "pain management",
            "probability": 0.0
        }
    ],
    "6277e4ee56bf9aee6f000008_5": [
        {
            "start_logit": 8.0625,
            "end_logit": 8.296875,
            "text": "Paracetamol",
            "probability": 1.0
        },
        {
            "start_logit": 8.0625,
            "end_logit": -4.88671875,
            "text": "Paracetamol (acetaminophen) has been proposed as an alternative to NSAIDs",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": 8.0625,
            "end_logit": -6.40625,
            "text": "Paracetamol (acetaminophen",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.0625,
            "end_logit": -6.66015625,
            "text": "Paracetamol (acetaminophen) has been proposed as an alternative to NSAIDs but there are issues with liver toxicity",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0625,
            "end_logit": -6.81640625,
            "text": "Paracetamol (acetaminophen)",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0625,
            "end_logit": -6.8203125,
            "text": "Paracetamol (acetaminophen) has been proposed as an alternative to NSAIDs but there are issues with liver",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0625,
            "end_logit": -7.05078125,
            "text": "Paracetamol (acetaminophen) has been proposed",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.0625,
            "end_logit": -7.08984375,
            "text": "Paracetamol (acetaminophen) has been proposed as an alternative",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.0625,
            "end_logit": -7.6328125,
            "text": "Paracetamol (acetaminophen) has",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.0625,
            "end_logit": -7.671875,
            "text": "Paracetamol (acetaminophen) has been proposed as an alternative to",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.0625,
            "end_logit": -7.8046875,
            "text": "Paracetamol (acetaminophen) has been proposed as an alternative to NSAIDs but there are issues with liver toxicity at high doses",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.0625,
            "end_logit": -7.84765625,
            "text": "Paracetamol (acetaminophen) has been proposed as an alternative to NSAIDs but",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.0625,
            "end_logit": -7.84765625,
            "text": "Paracetamol (acetaminophen) has been proposed as an",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.0625,
            "end_logit": -7.8828125,
            "text": "Paracetamol (acetaminophen) has been",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.0625,
            "end_logit": -7.94140625,
            "text": "Paracetamol (acetaminophen) has been proposed as",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0625,
            "end_logit": -8.0703125,
            "text": "Paracetamol (acetaminophen) has been proposed as an alternative to NSAIDs but there are issues with liver toxicity at",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0625,
            "end_logit": -8.140625,
            "text": "Paracetamol (acetaminophen) has been proposed as an alternative to NSAIDs but there are issues with liver toxicity at high",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.796875,
            "end_logit": -4.88671875,
            "text": "NSAIDs",
            "probability": 0.0
        },
        {
            "start_logit": -6.12109375,
            "end_logit": -4.88671875,
            "text": "(acetaminophen) has been proposed as an alternative to NSAIDs",
            "probability": 0.0
        },
        {
            "start_logit": -6.96875,
            "end_logit": -4.88671875,
            "text": "proposed as an alternative to NSAIDs",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_1": [
        {
            "start_logit": 8.5234375,
            "end_logit": 8.1953125,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -6.85546875,
            "end_logit": 8.1953125,
            "text": "risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 8.1953125,
            "text": "for high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 8.1953125,
            "text": ", improved survival as part of post-consolidation therapy for high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": 8.1953125,
            "text": "; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 8.1953125,
            "text": "of post-consolidation therapy for high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.265625,
            "end_logit": 8.1953125,
            "text": "-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.1953125,
            "text": "therapy for high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.1953125,
            "text": "against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 8.1953125,
            "text": "-consolidation therapy for high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 8.1953125,
            "text": "Dinutuximab (Unituxin\u2122; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3125,
            "end_logit": 8.1953125,
            "text": "part of post-consolidation therapy for high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3125,
            "end_logit": 8.1953125,
            "text": "survival as part of post-consolidation therapy for high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3125,
            "end_logit": 8.1953125,
            "text": "improved survival as part of post-consolidation therapy for high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3125,
            "end_logit": 8.1953125,
            "text": "consolidation therapy for high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": -8.3515625,
            "text": "; ch14.18), a monoclonal antibody against disial",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -8.3828125,
            "text": "; ch14.18), a monoclonal antibody against disialog",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -8.3984375,
            "text": "; ch14",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -8.40625,
            "text": "; ch14.18), a monoclonal antibody against disialogangli",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": -8.3515625,
            "text": "against disial",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_2": [
        {
            "start_logit": 8.3203125,
            "end_logit": 8.4375,
            "text": "Neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.0078125,
            "end_logit": 8.4375,
            "text": "Risk Neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.72265625,
            "end_logit": 8.4375,
            "text": "in High-Risk Neuroblastoma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 8.4375,
            "text": "Review in High-Risk Neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 8.4375,
            "text": "-Risk Neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 8.4375,
            "text": "High-Risk Neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 8.4375,
            "text": "A Review in High-Risk Neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.4375,
            "text": "Dinutuximab: A Review in High-Risk Neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 8.4375,
            "text": "utuximab: A Review in High-Risk Neuroblastoma",
            "probability": 5.960464477539063e-08
        }
    ],
    "589a247078275d0c4a000035_3": [
        {
            "start_logit": 8.3984375,
            "end_logit": 8.296875,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -8.0,
            "end_logit": 8.296875,
            "text": "of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3984375,
            "end_logit": -8.15625,
            "text": "neuroblastoma cells. This intravenous drug is approved in the EU",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 8.296875,
            "text": "; Unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3984375,
            "end_logit": -8.3046875,
            "text": "neuroblastoma cells",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3984375,
            "end_logit": -8.3203125,
            "text": "neuroblastoma cells. This intravenous drug is approved in the EU and USA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3984375,
            "end_logit": -8.3203125,
            "text": "neuroblastoma cells. This intravenous drug is approved in the EU and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3984375,
            "end_logit": -8.3203125,
            "text": "neuroblastoma cells. This intravenous drug is approved in the EU and USA as combination therapy with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3984375,
            "end_logit": -8.328125,
            "text": "neuroblastoma cells. This intravenous drug is approved in the EU and USA as combination therapy with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3984375,
            "end_logit": -8.328125,
            "text": "neuroblastoma cells. This intravenous drug is approved in the EU and USA as combination therapy with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-2 and isotretinoin for the postconso",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3984375,
            "end_logit": -8.3359375,
            "text": "neuroblastoma cells. This intravenous drug is approved in the EU and USA as combination therapy with granulocyte-macrophage colony-stimulating factor (GM-CSF)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3984375,
            "end_logit": -8.3359375,
            "text": "neuroblastoma cells. This intravenous drug is approved in the EU and USA as combination therapy with granulocyte-macrophage colony-stimulating factor (GM",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3984375,
            "end_logit": -8.3359375,
            "text": "neuroblastoma cells.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.234375,
            "end_logit": 8.296875,
            "text": "Dinutuximab (ch14.18; Unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.95703125,
            "end_logit": -8.15625,
            "text": ". This intravenous drug is approved in the EU",
            "probability": 0.0
        },
        {
            "start_logit": -6.95703125,
            "end_logit": -8.3203125,
            "text": ". This intravenous drug is approved in the EU and USA",
            "probability": 0.0
        },
        {
            "start_logit": -6.95703125,
            "end_logit": -8.3203125,
            "text": ". This intravenous drug is approved in the EU and",
            "probability": 0.0
        },
        {
            "start_logit": -6.95703125,
            "end_logit": -8.3203125,
            "text": ". This intravenous drug is approved in the EU and USA as combination therapy with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL",
            "probability": 0.0
        },
        {
            "start_logit": -6.95703125,
            "end_logit": -8.328125,
            "text": ". This intravenous drug is approved in the EU and USA as combination therapy with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)",
            "probability": 0.0
        },
        {
            "start_logit": -6.95703125,
            "end_logit": -8.328125,
            "text": ". This intravenous drug is approved in the EU and USA as combination therapy with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-2 and isotretinoin for the postconso",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_4": [
        {
            "start_logit": 8.34375,
            "end_logit": 8.3671875,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": 8.3671875,
            "text": "risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.34375,
            "end_logit": -8.1484375,
            "text": "neuroblastoma, with its benefits outweighing its risks",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 8.3671875,
            "text": "with GM-CSF, IL-2 and isotretinoin represents an important advance in the postconsolidation treatment of patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 8.3671875,
            "text": ", IL-2 and isotretinoin represents an important advance in the postconsolidation treatment of patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 8.3671875,
            "text": "advance in the postconsolidation treatment of patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": 8.3671875,
            "text": "patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.265625,
            "end_logit": 8.3671875,
            "text": "with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.265625,
            "end_logit": 8.3671875,
            "text": "and isotretinoin represents an important advance in the postconsolidation treatment of patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.28125,
            "end_logit": 8.3671875,
            "text": "of patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.28125,
            "end_logit": 8.3671875,
            "text": "combination with GM-CSF, IL-2 and isotretinoin represents an important advance in the postconsolidation treatment of patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.34375,
            "end_logit": -8.3046875,
            "text": "neuroblastoma, with its benefits outweigh",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.34375,
            "end_logit": -8.34375,
            "text": "neuroblastoma, with its benefits outweighing",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.34375,
            "end_logit": -8.3828125,
            "text": "neuroblastoma, with",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.078125,
            "end_logit": -8.1484375,
            "text": "risk neuroblastoma, with its benefits outweighing its risks",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -8.1484375,
            "text": ", with its benefits outweighing its risks",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -8.1484375,
            "text": "with GM-CSF, IL-2 and isotretinoin represents an important advance in the postconsolidation treatment of patients with high-risk neuroblastoma, with its benefits outweighing its risks",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -8.1484375,
            "text": ", IL-2 and isotretinoin represents an important advance in the postconsolidation treatment of patients with high-risk neuroblastoma, with its benefits outweighing its risks",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": -8.3046875,
            "text": "risk neuroblastoma, with its benefits outweigh",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -8.1484375,
            "text": "advance in the postconsolidation treatment of patients with high-risk neuroblastoma, with its benefits outweighing its risks",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_5": [
        {
            "start_logit": 8.4453125,
            "end_logit": 8.3203125,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.2421875,
            "end_logit": 8.3203125,
            "text": "risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.91015625,
            "end_logit": 8.3203125,
            "text": "with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 8.3203125,
            "text": "patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.078125,
            "end_logit": 8.3203125,
            "text": "pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.171875,
            "end_logit": 8.3203125,
            "text": "of pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 8.3203125,
            "text": "treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 8.3203125,
            "text": "-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 8.3203125,
            "text": "high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": 8.3203125,
            "text": "Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 8.3203125,
            "text": "the treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.34375,
            "end_logit": 8.3203125,
            "text": "utuximab for the treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        }
    ],
    "589a247078275d0c4a000035_6": [
        {
            "start_logit": 8.375,
            "end_logit": 8.328125,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.83984375,
            "end_logit": 8.328125,
            "text": "risk neuroblastoma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.015625,
            "end_logit": 8.328125,
            "text": "of pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 8.328125,
            "text": "with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 8.328125,
            "text": "patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.078125,
            "end_logit": 8.328125,
            "text": "<br><b>CONCLUSIONS</b>: Dinutuximab is the first anti-GD2 monoclonal antibody approved in combination with GM-CSF, IL-2, and RA for maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 8.328125,
            "text": "pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.109375,
            "end_logit": 8.328125,
            "text": "with GM-CSF, IL-2, and RA for maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.125,
            "end_logit": 8.328125,
            "text": "maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 8.328125,
            "text": ", IL-2, and RA for maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.15625,
            "end_logit": 8.328125,
            "text": "treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.375,
            "end_logit": -8.4140625,
            "text": "neuroblastoma who achieve at least",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.83984375,
            "end_logit": -8.4140625,
            "text": "risk neuroblastoma who achieve at least",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": -8.4140625,
            "text": "of pediatric patients with high-risk neuroblastoma who achieve at least",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": -8.359375,
            "text": "<br><b>CONCLUSIONS</b>: Dinutuximab is the first anti-GD2",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": -8.3671875,
            "text": "<br>",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": -8.4140625,
            "text": "with high-risk neuroblastoma who achieve at least",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": -8.375,
            "text": "<br><b>CONCLUSIONS</b>: Dinutuximab is the first anti-GD",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -8.4140625,
            "text": "patients with high-risk neuroblastoma who achieve at least",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": -8.359375,
            "text": ", and hypotension.<br><b>CONCLUSIONS</b>: Dinutuximab is the first anti-GD2",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_7": [
        {
            "start_logit": 8.375,
            "end_logit": 8.2421875,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.0625,
            "end_logit": 8.2421875,
            "text": "risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.19140625,
            "end_logit": 8.2421875,
            "text": "with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.953125,
            "end_logit": 8.2421875,
            "text": "patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 8.2421875,
            "text": "[IL-2]), and isotretinoin (13-cis-retinoic acid [RA]) for maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0,
            "end_logit": 8.2421875,
            "text": "of pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.09375,
            "end_logit": 8.2421875,
            "text": "pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.125,
            "end_logit": 8.2421875,
            "text": "-retinoic acid [RA]) for maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.125,
            "end_logit": 8.2421875,
            "text": "maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.125,
            "end_logit": 8.2421875,
            "text": "treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 8.2421875,
            "text": "-cis-retinoic acid [RA]) for maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.375,
            "end_logit": -8.359375,
            "text": "neuroblastoma who",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.375,
            "end_logit": -8.375,
            "text": "neuroblastoma who achieve at least",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.0625,
            "end_logit": -8.359375,
            "text": "risk neuroblastoma who",
            "probability": 0.0
        },
        {
            "start_logit": -7.0625,
            "end_logit": -8.375,
            "text": "risk neuroblastoma who achieve at least",
            "probability": 0.0
        },
        {
            "start_logit": -7.19140625,
            "end_logit": -8.359375,
            "text": "with high-risk neuroblastoma who",
            "probability": 0.0
        },
        {
            "start_logit": -7.19140625,
            "end_logit": -8.375,
            "text": "with high-risk neuroblastoma who achieve at least",
            "probability": 0.0
        },
        {
            "start_logit": -7.953125,
            "end_logit": -8.359375,
            "text": "patients with high-risk neuroblastoma who",
            "probability": 0.0
        },
        {
            "start_logit": -7.953125,
            "end_logit": -8.375,
            "text": "patients with high-risk neuroblastoma who achieve at least",
            "probability": 0.0
        },
        {
            "start_logit": -7.97265625,
            "end_logit": -8.359375,
            "text": "[IL-2]), and isotretinoin (13-cis-retinoic acid [RA]) for maintenance treatment of pediatric patients with high-risk neuroblastoma who",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_8": [
        {
            "start_logit": 8.3828125,
            "end_logit": 8.328125,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.203125,
            "end_logit": 8.328125,
            "text": "risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.984375,
            "end_logit": 8.328125,
            "text": "5 mg/m<br><b>CONCLUSION</b>: Dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.09375,
            "end_logit": 8.328125,
            "text": "with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 8.328125,
            "text": "patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 8.328125,
            "text": "The recommended dosage of dinutuximab is 17.5 mg/m<br><b>CONCLUSION</b>: Dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.140625,
            "end_logit": 8.328125,
            "text": "pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.15625,
            "end_logit": 8.328125,
            "text": "is 17.5 mg/m<br><b>CONCLUSION</b>: Dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 8.328125,
            "text": "-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 8.328125,
            "text": "in pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 8.328125,
            "text": "dosage of dinutuximab is 17.5 mg/m<br><b>CONCLUSION</b>: Dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 8.328125,
            "text": "recommended dosage of dinutuximab is 17.5 mg/m<br><b>CONCLUSION</b>: Dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 8.328125,
            "text": ".5 mg/m<br><b>CONCLUSION</b>: Dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 8.328125,
            "text": "combination immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 8.328125,
            "text": "Dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -8.390625,
            "text": "neuroblastoma.<br>",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -8.40625,
            "text": "neuroblastoma.<br",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.8515625,
            "end_logit": -8.390625,
            "text": ".<br>",
            "probability": 0.0
        },
        {
            "start_logit": -6.8515625,
            "end_logit": -8.40625,
            "text": ".<br",
            "probability": 0.0
        },
        {
            "start_logit": -7.203125,
            "end_logit": -8.390625,
            "text": "risk neuroblastoma.<br>",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_9": [
        {
            "start_logit": 8.4765625,
            "end_logit": 8.2890625,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.44921875,
            "end_logit": 8.2890625,
            "text": "risk neuroblastoma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -8.3125,
            "text": "neuroblastoma and is now considered part",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -8.328125,
            "text": "neuroblastoma and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -8.375,
            "text": "neuroblastoma and is now considered part of standard of care in this patient population",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 8.2890625,
            "text": "pediatric high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.21875,
            "end_logit": 8.2890625,
            "text": ", or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 8.2890625,
            "text": "treatment of pediatric high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.234375,
            "end_logit": 8.2890625,
            "text": ", represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.234375,
            "end_logit": 8.2890625,
            "text": "the treatment of pediatric high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": 8.2890625,
            "text": "of pediatric high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 8.2890625,
            "text": "advance in the treatment of pediatric high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.265625,
            "end_logit": 8.2890625,
            "text": "an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 8.2890625,
            "text": "dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 8.2890625,
            "text": "therapeutic advance in the treatment of pediatric high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.44921875,
            "end_logit": -8.3125,
            "text": "risk neuroblastoma and is now considered part",
            "probability": 0.0
        },
        {
            "start_logit": -7.44921875,
            "end_logit": -8.328125,
            "text": "risk neuroblastoma and",
            "probability": 0.0
        },
        {
            "start_logit": -7.44921875,
            "end_logit": -8.375,
            "text": "risk neuroblastoma and is now considered part of standard of care in this patient population",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": -8.3125,
            "text": "pediatric high-risk neuroblastoma and is now considered part",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": -8.328125,
            "text": "pediatric high-risk neuroblastoma and",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_10": [
        {
            "start_logit": 8.4375,
            "end_logit": 8.2734375,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 8.2734375,
            "text": "pediatric neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.046875,
            "end_logit": 8.2734375,
            "text": "The pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0625,
            "end_logit": 8.2734375,
            "text": "<b>PURPOSE</b>: The pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 8.2734375,
            "text": "clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.3984375,
            "text": "neuroblastoma are reviewed.<br>",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.40625,
            "text": "neuroblastoma are reviewed.<br><b>SUMMARY</b>: Dinutuximab (Unituxin, United Therapeutics",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.4140625,
            "text": "neuroblastoma are",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.4453125,
            "text": "neuroblastoma are reviewed.<br><b>",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.4453125,
            "text": "neuroblastoma are reviewed.<br><b",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.4453125,
            "text": "neuroblastoma are reviewed.<br><b>SUMMARY</b>: Dinutuximab (Unituxin, United Therapeutics)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.79296875,
            "end_logit": -8.3984375,
            "text": ".<br>",
            "probability": 0.0
        },
        {
            "start_logit": -6.79296875,
            "end_logit": -8.40625,
            "text": ".<br><b>SUMMARY</b>: Dinutuximab (Unituxin, United Therapeutics",
            "probability": 0.0
        },
        {
            "start_logit": -6.79296875,
            "end_logit": -8.4453125,
            "text": ".<br><b>",
            "probability": 0.0
        },
        {
            "start_logit": -6.79296875,
            "end_logit": -8.4453125,
            "text": ".<br><b",
            "probability": 0.0
        },
        {
            "start_logit": -6.79296875,
            "end_logit": -8.4453125,
            "text": ".<br><b>SUMMARY</b>: Dinutuximab (Unituxin, United Therapeutics)",
            "probability": 0.0
        },
        {
            "start_logit": -7.98828125,
            "end_logit": -8.296875,
            "text": "with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -8.296875,
            "text": "combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -8.296875,
            "text": "risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": -8.296875,
            "text": "in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_11": [
        {
            "start_logit": 8.234375,
            "end_logit": 8.4921875,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.76171875,
            "end_logit": 8.4921875,
            "text": "risk neuroblastoma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.0625,
            "end_logit": 8.4921875,
            "text": "with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0625,
            "end_logit": 8.4921875,
            "text": "summarizes the milestones in the development of dinutuximab leading to this first approval for use (in combination with granulocyte macrophage colony-stimulating factor, interleukin-2 and 13-cis retinoic acid) in the treatment of paediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 8.4921875,
            "text": "of paediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 8.4921875,
            "text": "patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.15625,
            "end_logit": 8.4921875,
            "text": "treatment of paediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.15625,
            "end_logit": 8.4921875,
            "text": "the milestones in the development of dinutuximab leading to this first approval for use (in combination with granulocyte macrophage colony-stimulating factor, interleukin-2 and 13-cis retinoic acid) in the treatment of paediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 8.4921875,
            "text": "(in combination with granulocyte macrophage colony-stimulating factor, interleukin-2 and 13-cis retinoic acid) in the treatment of paediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.171875,
            "end_logit": 8.4921875,
            "text": "in combination with granulocyte macrophage colony-stimulating factor, interleukin-2 and 13-cis retinoic acid) in the treatment of paediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.171875,
            "end_logit": 8.4921875,
            "text": "with granulocyte macrophage colony-stimulating factor, interleukin-2 and 13-cis retinoic acid) in the treatment of paediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1875,
            "end_logit": 8.4921875,
            "text": "-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1875,
            "end_logit": 8.4921875,
            "text": "combination with granulocyte macrophage colony-stimulating factor, interleukin-2 and 13-cis retinoic acid) in the treatment of paediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.234375,
            "end_logit": -8.390625,
            "text": "neuroblastoma who achieve at least",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.234375,
            "end_logit": -8.4140625,
            "text": "neuroblastoma who achieve at",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.234375,
            "end_logit": -8.4140625,
            "text": "neuroblastoma who achieve at least partial response to prior first-line multiagent, multimodality therapy.<br>",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.76171875,
            "end_logit": -8.390625,
            "text": "risk neuroblastoma who achieve at least",
            "probability": 0.0
        },
        {
            "start_logit": -7.76171875,
            "end_logit": -8.4140625,
            "text": "risk neuroblastoma who achieve at",
            "probability": 0.0
        },
        {
            "start_logit": -7.76171875,
            "end_logit": -8.4140625,
            "text": "risk neuroblastoma who achieve at least partial response to prior first-line multiagent, multimodality therapy.<br>",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": -8.3984375,
            "text": "article summarizes the milestones",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_12": [
        {
            "start_logit": 8.546875,
            "end_logit": 8.234375,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.6015625,
            "end_logit": 8.234375,
            "text": "risk neuroblastoma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.09375,
            "end_logit": 8.234375,
            "text": "of high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.15625,
            "end_logit": 8.234375,
            "text": "treatment of high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 8.234375,
            "text": "dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.171875,
            "end_logit": 8.234375,
            "text": "US FDA has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 8.234375,
            "text": "The US FDA has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 8.234375,
            "text": "the treatment of high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1875,
            "end_logit": 8.234375,
            "text": "-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 8.234375,
            "text": "of dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 8.234375,
            "text": "recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 8.234375,
            "text": "use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 8.234375,
            "text": "FDA has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 8.234375,
            "text": "the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        }
    ],
    "589a247078275d0c4a000035_13": [
        {
            "start_logit": 8.515625,
            "end_logit": 8.1796875,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.92578125,
            "end_logit": 8.1796875,
            "text": "of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.09375,
            "end_logit": 8.1796875,
            "text": "National Cancer Institute are developing dinutuximab (Unituxin\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.125,
            "end_logit": 8.1796875,
            "text": "; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 8.1796875,
            "text": "the National Cancer Institute are developing dinutuximab (Unituxin\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1875,
            "end_logit": 8.1796875,
            "text": "treatment of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1875,
            "end_logit": 8.1796875,
            "text": "United Therapeutics Corporation and the National Cancer Institute are developing dinutuximab (Unituxin\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 8.1796875,
            "text": "developing dinutuximab (Unituxin\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 8.1796875,
            "text": ", a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 8.1796875,
            "text": "the treatment of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.21875,
            "end_logit": 8.1796875,
            "text": "Cancer Institute are developing dinutuximab (Unituxin\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 8.1796875,
            "text": "and the National Cancer Institute are developing dinutuximab (Unituxin\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 8.1796875,
            "text": "Unituxin\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 8.1796875,
            "text": "), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 8.1796875,
            "text": "a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 8.1796875,
            "text": ", for the treatment of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.09375,
            "end_logit": -8.328125,
            "text": "National Cancer Institute",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": -8.3515625,
            "text": "National Cancer Institute are developing dinutuximab (Unituxin\u2122; ch14.18), a monoclonal antibody targeting GD2",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -8.25,
            "text": "United Therapeutics Corporation",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -8.3515625,
            "text": "; ch14.18), a monoclonal antibody targeting GD2",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_14": [
        {
            "start_logit": 7.99609375,
            "end_logit": 8.6484375,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.828125,
            "end_logit": 8.6484375,
            "text": "risk neuroblastoma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 8.6484375,
            "text": "high-risk neuroblastoma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 8.6484375,
            "text": "-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 8.6484375,
            "text": "Immunotherapy of high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.265625,
            "end_logit": 8.6484375,
            "text": "of high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.99609375,
            "end_logit": -8.296875,
            "text": "neuroblastoma using the anti-GD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.99609375,
            "end_logit": -8.3125,
            "text": "neuroblastoma using the anti-GD2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.99609375,
            "end_logit": -8.359375,
            "text": "neuroblastoma using the anti-GD2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.99609375,
            "end_logit": -8.3828125,
            "text": "neuroblastoma using the anti-GD2 antibody dinutuximab induces antibody-dependent cell-mediated",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.99609375,
            "end_logit": -8.3984375,
            "text": "neuroblastoma using the anti-GD2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (ADCC)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.99609375,
            "end_logit": -8.4140625,
            "text": "neuroblastoma using the anti-GD2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (ADCC",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.99609375,
            "end_logit": -8.4296875,
            "text": "neuroblastoma using the anti-GD2 antibody dinutuximab induces antibody-dependent cell",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.99609375,
            "end_logit": -8.4375,
            "text": "neuroblastoma using the anti-GD2 antibody dinutuximab induces antibody-dependent",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.99609375,
            "end_logit": -8.4453125,
            "text": "neuroblastoma using the anti-GD2 antibody dinutuximab induces antibody-dependent cell-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.828125,
            "end_logit": -8.296875,
            "text": "risk neuroblastoma using the anti-GD",
            "probability": 0.0
        },
        {
            "start_logit": -7.828125,
            "end_logit": -8.3125,
            "text": "risk neuroblastoma using the anti-GD2",
            "probability": 0.0
        },
        {
            "start_logit": -7.828125,
            "end_logit": -8.359375,
            "text": "risk neuroblastoma using the anti-GD2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity",
            "probability": 0.0
        },
        {
            "start_logit": -7.828125,
            "end_logit": -8.3828125,
            "text": "risk neuroblastoma using the anti-GD2 antibody dinutuximab induces antibody-dependent cell-mediated",
            "probability": 0.0
        },
        {
            "start_logit": -7.828125,
            "end_logit": -8.3984375,
            "text": "risk neuroblastoma using the anti-GD2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (ADCC)",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_15": [
        {
            "start_logit": 8.375,
            "end_logit": 8.2421875,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.0625,
            "end_logit": 8.2421875,
            "text": "risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.19140625,
            "end_logit": 8.2421875,
            "text": "with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.953125,
            "end_logit": 8.2421875,
            "text": "patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 8.2421875,
            "text": "[IL-2]), and isotretinoin (13-cis-retinoic acid [RA]) for maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0,
            "end_logit": 8.2421875,
            "text": "of pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.09375,
            "end_logit": 8.2421875,
            "text": "pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.125,
            "end_logit": 8.2421875,
            "text": "-retinoic acid [RA]) for maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.125,
            "end_logit": 8.2421875,
            "text": "maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.125,
            "end_logit": 8.2421875,
            "text": "treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 8.2421875,
            "text": "-cis-retinoic acid [RA]) for maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.375,
            "end_logit": -8.359375,
            "text": "neuroblastoma who",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.375,
            "end_logit": -8.375,
            "text": "neuroblastoma who achieve at least",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.0625,
            "end_logit": -8.359375,
            "text": "risk neuroblastoma who",
            "probability": 0.0
        },
        {
            "start_logit": -7.0625,
            "end_logit": -8.375,
            "text": "risk neuroblastoma who achieve at least",
            "probability": 0.0
        },
        {
            "start_logit": -7.19140625,
            "end_logit": -8.359375,
            "text": "with high-risk neuroblastoma who",
            "probability": 0.0
        },
        {
            "start_logit": -7.19140625,
            "end_logit": -8.375,
            "text": "with high-risk neuroblastoma who achieve at least",
            "probability": 0.0
        },
        {
            "start_logit": -7.953125,
            "end_logit": -8.359375,
            "text": "patients with high-risk neuroblastoma who",
            "probability": 0.0
        },
        {
            "start_logit": -7.953125,
            "end_logit": -8.375,
            "text": "patients with high-risk neuroblastoma who achieve at least",
            "probability": 0.0
        },
        {
            "start_logit": -7.97265625,
            "end_logit": -8.359375,
            "text": "[IL-2]), and isotretinoin (13-cis-retinoic acid [RA]) for maintenance treatment of pediatric patients with high-risk neuroblastoma who",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_16": [
        {
            "start_logit": 8.4453125,
            "end_logit": 8.3046875,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.7265625,
            "end_logit": 8.3046875,
            "text": "risk neuroblastoma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.109375,
            "end_logit": 8.3046875,
            "text": "with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 8.3046875,
            "text": "of pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.15625,
            "end_logit": 8.3046875,
            "text": "patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 8.3046875,
            "text": "with GM-CSF, IL-2, and RA for maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -8.34375,
            "text": "neuroblastoma who achieve at least a partial",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -8.3515625,
            "text": "neuroblastoma who achieve at least",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.21875,
            "end_logit": 8.3046875,
            "text": "Dinutuximab is the first anti-GD2 monoclonal antibody approved in combination with GM-CSF, IL-2, and RA for maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.21875,
            "end_logit": 8.3046875,
            "text": "pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.21875,
            "end_logit": 8.3046875,
            "text": ", IL-2, and RA for maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -8.390625,
            "text": "neuroblastoma who achieve at least a partial response",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -8.4140625,
            "text": "neuroblastoma who achieve",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7265625,
            "end_logit": -8.34375,
            "text": "risk neuroblastoma who achieve at least a partial",
            "probability": 0.0
        },
        {
            "start_logit": -7.7265625,
            "end_logit": -8.3515625,
            "text": "risk neuroblastoma who achieve at least",
            "probability": 0.0
        },
        {
            "start_logit": -7.7265625,
            "end_logit": -8.390625,
            "text": "risk neuroblastoma who achieve at least a partial response",
            "probability": 0.0
        },
        {
            "start_logit": -7.7265625,
            "end_logit": -8.4140625,
            "text": "risk neuroblastoma who achieve",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": -8.34375,
            "text": "with high-risk neuroblastoma who achieve at least a partial",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": -8.3515625,
            "text": "with high-risk neuroblastoma who achieve at least",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": -8.390625,
            "text": "with high-risk neuroblastoma who achieve at least a partial response",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_17": [
        {
            "start_logit": 8.515625,
            "end_logit": 8.1796875,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.92578125,
            "end_logit": 8.1796875,
            "text": "of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.09375,
            "end_logit": 8.1796875,
            "text": "National Cancer Institute are developing dinutuximab (Unituxin\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.125,
            "end_logit": 8.1796875,
            "text": "; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 8.1796875,
            "text": "the National Cancer Institute are developing dinutuximab (Unituxin\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1875,
            "end_logit": 8.1796875,
            "text": "treatment of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1875,
            "end_logit": 8.1796875,
            "text": "United Therapeutics Corporation and the National Cancer Institute are developing dinutuximab (Unituxin\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 8.1796875,
            "text": "developing dinutuximab (Unituxin\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 8.1796875,
            "text": ", a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 8.1796875,
            "text": "the treatment of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.21875,
            "end_logit": 8.1796875,
            "text": "Cancer Institute are developing dinutuximab (Unituxin\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 8.1796875,
            "text": "and the National Cancer Institute are developing dinutuximab (Unituxin\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 8.1796875,
            "text": "Unituxin\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 8.1796875,
            "text": "), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 8.1796875,
            "text": "a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 8.1796875,
            "text": ", for the treatment of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.09375,
            "end_logit": -8.328125,
            "text": "National Cancer Institute",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": -8.3515625,
            "text": "National Cancer Institute are developing dinutuximab (Unituxin\u2122; ch14.18), a monoclonal antibody targeting GD2",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -8.25,
            "text": "United Therapeutics Corporation",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -8.3515625,
            "text": "; ch14.18), a monoclonal antibody targeting GD2",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_18": [
        {
            "start_logit": 8.3671875,
            "end_logit": 8.3671875,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.23046875,
            "end_logit": 8.3671875,
            "text": "risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 8.3671875,
            "text": "with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.046875,
            "end_logit": 8.3671875,
            "text": "pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.046875,
            "end_logit": 8.3671875,
            "text": "patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 8.3671875,
            "text": "of pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 8.3671875,
            "text": "with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 8.3671875,
            "text": "combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 8.3671875,
            "text": "-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 8.3671875,
            "text": "treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.171875,
            "end_logit": 8.3671875,
            "text": "in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.171875,
            "end_logit": 8.3671875,
            "text": ", interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1875,
            "end_logit": 8.3671875,
            "text": "the treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 8.3671875,
            "text": "use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 8.3671875,
            "text": "Dinutuximab (Unituxin, United Therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 8.3671875,
            "text": "approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1953125,
            "end_logit": -8.4375,
            "text": "Dinutuximab (Unituxin, United Therapeutics",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_19": [
        {
            "start_logit": 8.5078125,
            "end_logit": 8.28125,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 8.28125,
            "text": "in pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.125,
            "end_logit": 8.28125,
            "text": "risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.140625,
            "end_logit": 8.28125,
            "text": "patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.15625,
            "end_logit": 8.28125,
            "text": "with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 8.28125,
            "text": "pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1875,
            "end_logit": 8.28125,
            "text": "Dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.234375,
            "end_logit": 8.28125,
            "text": "combination immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 8.28125,
            "text": "CONCLUSION Dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": 8.28125,
            "text": "is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 8.28125,
            "text": "-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.28125,
            "end_logit": 8.28125,
            "text": "that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 8.28125,
            "text": "as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 8.28125,
            "text": "efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 8.28125,
            "text": "part of combination immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.28125,
            "text": "of combination immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        }
    ],
    "589a247078275d0c4a000035_20": [
        {
            "start_logit": 8.53125,
            "end_logit": 8.2109375,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.16015625,
            "end_logit": 8.2109375,
            "text": "risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.203125,
            "end_logit": 8.2109375,
            "text": "with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 8.2109375,
            "text": "shown to significantly improve survival rates in patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 8.2109375,
            "text": "patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": 8.2109375,
            "text": "been shown to significantly improve survival rates in patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": 8.2109375,
            "text": "called ch14.18), a monoclonal antibody targeting the disialoganglioside GD2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 8.2109375,
            "text": "improve survival rates in patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 8.2109375,
            "text": "in patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.265625,
            "end_logit": 8.2109375,
            "text": "(formerly called ch14.18), a monoclonal antibody targeting the disialoganglioside GD2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.28125,
            "end_logit": 8.2109375,
            "text": "formerly called ch14.18), a monoclonal antibody targeting the disialoganglioside GD2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.28125,
            "end_logit": 8.2109375,
            "text": "Dinutuximab (formerly called ch14.18), a monoclonal antibody targeting the disialoganglioside GD2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.28125,
            "end_logit": 8.2109375,
            "text": ", a monoclonal antibody targeting the disialoganglioside GD2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 8.2109375,
            "text": "has been shown to significantly improve survival rates in patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 8.2109375,
            "text": "the disialoganglioside GD2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.2109375,
            "text": "targeting the disialoganglioside GD2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": -8.296875,
            "text": "called ch14.18), a monoclonal antibody targeting the disialoganglioside GD2",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -8.34375,
            "text": "shown to significantly improve survival rates",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -8.3203125,
            "text": "called ch14.18), a monoclonal antibody targeting the disialoganglioside GD",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -8.3203125,
            "text": "called ch14.18), a monoclonal antibody targeting the disial",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_21": [
        {
            "start_logit": 8.53125,
            "end_logit": 8.15625,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.89453125,
            "end_logit": 8.15625,
            "text": "of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.53125,
            "end_logit": -8.2890625,
            "text": "neuroblastoma cells",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 8.15625,
            "text": "; Unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.234375,
            "end_logit": 8.15625,
            "text": "antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.265625,
            "end_logit": 8.15625,
            "text": "Dinutuximab (ch14.18; Unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 8.15625,
            "text": "the surface of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.15625,
            "text": "that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 8.15625,
            "text": ") is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 8.15625,
            "text": "-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.328125,
            "end_logit": 8.15625,
            "text": "mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.328125,
            "end_logit": 8.15625,
            "text": "Unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.328125,
            "end_logit": 8.15625,
            "text": "chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 8.15625,
            "text": "on the surface of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.89453125,
            "end_logit": -8.2890625,
            "text": "of neuroblastoma cells",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": -8.2890625,
            "text": "; Unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": -8.3203125,
            "text": "; Unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disial",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": -8.328125,
            "text": "; Unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": -8.328125,
            "text": "; Unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": -8.3515625,
            "text": "; Unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialogangli",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_22": [
        {
            "start_logit": 8.546875,
            "end_logit": 8.234375,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.6015625,
            "end_logit": 8.234375,
            "text": "risk neuroblastoma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.09375,
            "end_logit": 8.234375,
            "text": "of high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.15625,
            "end_logit": 8.234375,
            "text": "treatment of high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 8.234375,
            "text": "dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.171875,
            "end_logit": 8.234375,
            "text": "US FDA has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 8.234375,
            "text": "The US FDA has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 8.234375,
            "text": "the treatment of high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1875,
            "end_logit": 8.234375,
            "text": "-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 8.234375,
            "text": "of dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 8.234375,
            "text": "recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 8.234375,
            "text": "use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 8.234375,
            "text": "FDA has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 8.234375,
            "text": "the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        }
    ],
    "589a247078275d0c4a000035_23": [
        {
            "start_logit": 8.4453125,
            "end_logit": 8.3203125,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.2421875,
            "end_logit": 8.3203125,
            "text": "risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.91015625,
            "end_logit": 8.3203125,
            "text": "with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 8.3203125,
            "text": "patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.078125,
            "end_logit": 8.3203125,
            "text": "pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.171875,
            "end_logit": 8.3203125,
            "text": "of pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 8.3203125,
            "text": "treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 8.3203125,
            "text": "-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 8.3203125,
            "text": "high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": 8.3203125,
            "text": "Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 8.3203125,
            "text": "the treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.34375,
            "end_logit": 8.3203125,
            "text": "utuximab for the treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        }
    ],
    "589a247078275d0c4a000035_24": [
        {
            "start_logit": 8.609375,
            "end_logit": 8.171875,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": 8.609375,
            "end_logit": -8.1953125,
            "text": "neuroblastoma: A case series",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.609375,
            "end_logit": -8.2421875,
            "text": "neuroblastoma: A case",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.609375,
            "end_logit": -8.3125,
            "text": "neuroblastoma:",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.609375,
            "end_logit": -8.328125,
            "text": "neuroblastoma: A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.109375,
            "end_logit": 8.171875,
            "text": "risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.21875,
            "end_logit": 8.171875,
            "text": "patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 8.171875,
            "text": "with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 8.171875,
            "text": "pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 8.171875,
            "text": "following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 8.171875,
            "text": "-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.28125,
            "end_logit": 8.171875,
            "text": "in pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.171875,
            "text": "with dinutuximab in pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 8.171875,
            "text": "complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.328125,
            "end_logit": 8.171875,
            "text": "dinutuximab in pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3671875,
            "end_logit": 8.171875,
            "text": "treatment with dinutuximab in pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3828125,
            "end_logit": 8.171875,
            "text": "utuximab in pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.390625,
            "end_logit": 8.171875,
            "text": "high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.109375,
            "end_logit": -8.1953125,
            "text": "risk neuroblastoma: A case series",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": -8.2421875,
            "text": "risk neuroblastoma: A case",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_25": [
        {
            "start_logit": 8.46875,
            "end_logit": 8.296875,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -7.75,
            "end_logit": 8.296875,
            "text": "risk neuroblastoma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 8.296875,
            "text": "study (ANBL0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0,
            "end_logit": 8.296875,
            "text": "phase III study (ANBL0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 8.296875,
            "text": "Findings of the randomized phase III study (ANBL0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.109375,
            "end_logit": 8.296875,
            "text": "randomized phase III study (ANBL0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.125,
            "end_logit": 8.296875,
            "text": "the randomized phase III study (ANBL0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 8.296875,
            "text": "III study (ANBL0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.171875,
            "end_logit": 8.296875,
            "text": "(ANBL0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 8.296875,
            "text": "to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 8.296875,
            "text": "with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 8.296875,
            "text": "of the randomized phase III study (ANBL0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 8.296875,
            "text": ") led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 8.296875,
            "text": "dinutuximab for the treatment of children with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 8.296875,
            "text": "ANBL0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 8.296875,
            "text": "treatment of children with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.84765625,
            "end_logit": -8.328125,
            "text": "study (ANBL00",
            "probability": 0.0
        },
        {
            "start_logit": -7.84765625,
            "end_logit": -8.34375,
            "text": "study (ANBL",
            "probability": 0.0
        },
        {
            "start_logit": -7.84765625,
            "end_logit": -8.359375,
            "text": "study",
            "probability": 0.0
        },
        {
            "start_logit": -8.0,
            "end_logit": -8.3203125,
            "text": "phase III",
            "probability": 0.0
        }
    ],
    "5c8cd26a0101eac870000003_1": [
        {
            "start_logit": 10.03125,
            "end_logit": 9.5234375,
            "text": "secreted protein content",
            "probability": 1.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -1.72265625,
            "text": "secreted",
            "probability": 1.2993812561035156e-05
        },
        {
            "start_logit": -2.099609375,
            "end_logit": 9.5234375,
            "text": "content",
            "probability": 5.364418029785156e-06
        },
        {
            "start_logit": -5.6953125,
            "end_logit": 9.5234375,
            "text": "protein content",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.03125,
            "end_logit": -6.86328125,
            "text": "secreted protein content (exoproteome) revealed that many enzymes involved in carbohydrate hydrolysis were regulated by VdSec22 or VdSso1.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.7421875,
            "end_logit": 9.5234375,
            "text": "the secreted protein content",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.03125,
            "end_logit": -7.25390625,
            "text": "secreted protein content (exoproteome) revealed that many enzymes involved in carbohydrate hydrolysis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.03125,
            "end_logit": -7.4765625,
            "text": "secreted protein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.03125,
            "end_logit": -7.5,
            "text": "secreted protein content (exoproteome)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.03125,
            "end_logit": -7.6015625,
            "text": "secreted protein content (exoproteome) revealed that many enzymes involved in carbohydrate hydrolysis were",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.03125,
            "end_logit": -7.625,
            "text": "secreted protein content (exoproteome) revealed",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.03125,
            "end_logit": -7.6328125,
            "text": "secreted protein content (exoproteome) revealed that many enzymes involved in carbohydrate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.03125,
            "end_logit": -7.68359375,
            "text": "secreted protein content (exoproteome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.20703125,
            "end_logit": 9.5234375,
            "text": "Comparative analyses of the secreted protein content",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.03125,
            "end_logit": -7.7578125,
            "text": "secreted protein content (exoprote",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.03125,
            "end_logit": -7.8125,
            "text": "secreted protein content (exopro",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -7.8203125,
            "text": "secreted protein content (exoproteome) revealed that many enzymes involved in carbohydrate hydrolysis were regulated by VdSec22 or VdSso1",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -7.8671875,
            "text": "secreted protein content (exoproteome) revealed that many enzymes involved in carbohydrate hydrolysis were regulated by VdSec22",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -7.875,
            "text": "secreted protein content (exoproteome) revealed that many enzymes involved in carbohydrate hydrolysis were regulated by VdSec2",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -7.96484375,
            "text": "secreted protein content (exoproteome) revealed that many enzymes involved in carbohydrate hydrolysis were regulated by",
            "probability": 0.0
        }
    ],
    "5cb0e4a6ecadf2e73f00005b_1": [
        {
            "start_logit": 9.9609375,
            "end_logit": 9.0703125,
            "text": "surfaceome predictor",
            "probability": 1.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -1.8798828125,
            "text": "surface",
            "probability": 1.7523765563964844e-05
        },
        {
            "start_logit": -3.015625,
            "end_logit": 9.0703125,
            "text": "predictor",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -6.95703125,
            "text": "surfaceome predictor SURFY, based on machine learning",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.39453125,
            "end_logit": 9.0703125,
            "text": "the surfaceome predictor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -7.3671875,
            "text": "surfaceome predictor SURF",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.578125,
            "end_logit": 9.0703125,
            "text": "ome predictor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -7.484375,
            "text": "surfaceome predictor SURFY",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -7.73046875,
            "text": "surfaceome predictor SURFY,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.87109375,
            "end_logit": 9.0703125,
            "text": "surfaceome, we developed the surfaceome predictor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -7.91015625,
            "text": "surfaceome predictor SURFY, based on machine learning.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -7.96484375,
            "text": "surfaceome predictor SURFY, based on machine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -7.99609375,
            "text": "surfaceome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 9.0703125,
            "text": "analysis of the human surfaceome, we developed the surfaceome predictor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.47265625,
            "end_logit": 9.0703125,
            "text": "human surfaceome, we developed the surfaceome predictor",
            "probability": 0.0
        },
        {
            "start_logit": -7.7734375,
            "end_logit": 9.0703125,
            "text": "enable analysis of the human surfaceome, we developed the surfaceome predictor",
            "probability": 0.0
        },
        {
            "start_logit": -7.90234375,
            "end_logit": 9.0703125,
            "text": "o enable analysis of the human surfaceome, we developed the surfaceome predictor",
            "probability": 0.0
        },
        {
            "start_logit": -7.91015625,
            "end_logit": 9.0703125,
            "text": "of the human surfaceome, we developed the surfaceome predictor",
            "probability": 0.0
        },
        {
            "start_logit": -7.9296875,
            "end_logit": 9.0703125,
            "text": "developed the surfaceome predictor",
            "probability": 0.0
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 9.0703125,
            "text": "the human surfaceome, we developed the surfaceome predictor",
            "probability": 0.0
        }
    ],
    "550618f58e1671127b000007_1": [
        {
            "start_logit": 10.125,
            "end_logit": 9.546875,
            "text": "PPI-1",
            "probability": 1.0
        },
        {
            "start_logit": 10.125,
            "end_logit": -1.4990234375,
            "text": "PPI",
            "probability": 1.5914440155029297e-05
        },
        {
            "start_logit": -2.171875,
            "end_logit": 9.546875,
            "text": "1",
            "probability": 4.589557647705078e-06
        },
        {
            "start_logit": -5.98828125,
            "end_logit": 9.546875,
            "text": "-1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.12109375,
            "end_logit": 9.546875,
            "text": "(PPI-1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.62890625,
            "end_logit": 9.546875,
            "text": ". Phosphatase-1 is restrained by its endogenous inhibitor, protein phosphatase inhibitor-1 (PPI-1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.125,
            "end_logit": -8.0859375,
            "text": "PPI-1)",
            "probability": 0.0
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 9.546875,
            "text": ", protein phosphatase inhibitor-1 (PPI-1",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.546875,
            "text": "by its endogenous inhibitor, protein phosphatase inhibitor-1 (PPI-1",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.546875,
            "text": "protein phosphatase inhibitor-1 (PPI-1",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": 9.546875,
            "text": "inhibitor, protein phosphatase inhibitor-1 (PPI-1",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.546875,
            "text": "with an imbalance of protein kinase A and phosphatase-1 activities, are hallmarks of heart failure. Phosphatase-1 is restrained by its endogenous inhibitor, protein phosphatase inhibitor-1 (PPI-1",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.546875,
            "text": "associated with an imbalance of protein kinase A and phosphatase-1 activities, are hallmarks of heart failure. Phosphatase-1 is restrained by its endogenous inhibitor, protein phosphatase inhibitor-1 (PPI-1",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 9.546875,
            "text": "of protein kinase A and phosphatase-1 activities, are hallmarks of heart failure. Phosphatase-1 is restrained by its endogenous inhibitor, protein phosphatase inhibitor-1 (PPI-1",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.546875,
            "text": "an imbalance of protein kinase A and phosphatase-1 activities, are hallmarks of heart failure. Phosphatase-1 is restrained by its endogenous inhibitor, protein phosphatase inhibitor-1 (PPI-1",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.546875,
            "text": "its endogenous inhibitor, protein phosphatase inhibitor-1 (PPI-1",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.546875,
            "text": ", associated with an imbalance of protein kinase A and phosphatase-1 activities, are hallmarks of heart failure. Phosphatase-1 is restrained by its endogenous inhibitor, protein phosphatase inhibitor-1 (PPI-1",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 9.546875,
            "text": "of heart failure. Phosphatase-1 is restrained by its endogenous inhibitor, protein phosphatase inhibitor-1 (PPI-1",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 9.546875,
            "text": "phosphatase inhibitor-1 (PPI-1",
            "probability": 0.0
        },
        {
            "start_logit": -6.12109375,
            "end_logit": -1.4990234375,
            "text": "(PPI",
            "probability": 0.0
        }
    ],
    "550618f58e1671127b000007_2": [
        {
            "start_logit": 9.9609375,
            "end_logit": 9.34375,
            "text": "Inhibitor 1",
            "probability": 1.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -1.943359375,
            "text": "Inhibitor",
            "probability": 1.239776611328125e-05
        },
        {
            "start_logit": -2.58203125,
            "end_logit": 9.34375,
            "text": "1",
            "probability": 3.5762786865234375e-06
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -7.7734375,
            "text": "Inhibitor 1 (I-1)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -7.78515625,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), a major eukaryotic Ser/Thr phosphatase. Nonphosphorylated I-1 is inactive, whereas phosphorylated I-1 is a potent PP1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -7.8515625,
            "text": "Inhibitor 1 (I-1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -7.859375,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), a major eukaryotic Ser/Thr phosphatase. Nonphosphorylated I-1 is inactive, whereas phosphorylated I",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -7.86328125,
            "text": "Inhibitor 1 (I",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -7.88671875,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), a major eukaryotic Ser/Thr phosphatase. Nonphosphorylated I-1 is inactive, whereas phosphorylated I-1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -7.90625,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), a major eukaryotic Ser/Thr phosphatase. Nonphosphorylated I-1 is inactive, whereas phosphorylated I-1 is a potent PP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -7.9375,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), a major eukaryotic Ser/Thr phosphatase. Nonphosphorylated I-1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -7.99609375,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), a major eukaryotic Ser/Thr phosphatase. Nonphosphorylated I-1 is inactive, whereas phosphorylated I-",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.015625,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.046875,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.0703125,
            "text": "Inhibitor 1 (I-",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.078125,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.0859375,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), a major eukaryotic Ser/Thr phosphatase. Nonphosphorylated I",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.09375,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), a major eukaryotic Ser/Thr phosphatase. Nonphosphorylated I-",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.09375,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), a major eukaryotic Ser/Thr phosphatase. Nonphosphoryl",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.109375,
            "text": "Inhibitor 1 (I-1) is",
            "probability": 0.0
        }
    ],
    "550618f58e1671127b000007_3": [
        {
            "start_logit": 9.8671875,
            "end_logit": 9.3125,
            "text": "inhibitor 1",
            "probability": 1.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -2.09375,
            "text": "inhibitor",
            "probability": 1.1026859283447266e-05
        },
        {
            "start_logit": -2.626953125,
            "end_logit": 9.3125,
            "text": "1",
            "probability": 3.7550926208496094e-06
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.2265625,
            "text": "inhibitor 1 is a potent protein phosphatase 1",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.2578125,
            "text": "inhibitor 1 is a potent protein phosphatase 1 inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": -7.77734375,
            "end_logit": 9.3125,
            "text": "phosphorylated inhibitor 1",
            "probability": 0.0
        },
        {
            "start_logit": 9.8671875,
            "end_logit": -8.359375,
            "text": "inhibitor 1 is a potent protein phosphatase",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 9.3125,
            "text": "Ser67-phosphorylated inhibitor 1",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.3125,
            "text": "-phosphorylated inhibitor 1",
            "probability": 0.0
        },
        {
            "start_logit": -7.77734375,
            "end_logit": -2.09375,
            "text": "phosphorylated inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -2.09375,
            "text": "Ser67-phosphorylated inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": -2.09375,
            "text": "-phosphorylated inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": -2.626953125,
            "end_logit": -8.2265625,
            "text": "1 is a potent protein phosphatase 1",
            "probability": 0.0
        },
        {
            "start_logit": -2.626953125,
            "end_logit": -8.2578125,
            "text": "1 is a potent protein phosphatase 1 inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": -2.626953125,
            "end_logit": -8.359375,
            "text": "1 is a potent protein phosphatase",
            "probability": 0.0
        },
        {
            "start_logit": -7.77734375,
            "end_logit": -8.2265625,
            "text": "phosphorylated inhibitor 1 is a potent protein phosphatase 1",
            "probability": 0.0
        },
        {
            "start_logit": -7.77734375,
            "end_logit": -8.2578125,
            "text": "phosphorylated inhibitor 1 is a potent protein phosphatase 1 inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": -7.77734375,
            "end_logit": -8.359375,
            "text": "phosphorylated inhibitor 1 is a potent protein phosphatase",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -8.1171875,
            "text": "Ser67",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -8.2265625,
            "text": "Ser67-phosphorylated inhibitor 1 is a potent protein phosphatase 1",
            "probability": 0.0
        }
    ],
    "550618f58e1671127b000007_4": [
        {
            "start_logit": 9.953125,
            "end_logit": 9.375,
            "text": "Inhibitor 1",
            "probability": 1.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -1.962890625,
            "text": "Inhibitor",
            "probability": 1.1920928955078125e-05
        },
        {
            "start_logit": -2.517578125,
            "end_logit": 9.375,
            "text": "1",
            "probability": 3.874301910400391e-06
        },
        {
            "start_logit": 9.953125,
            "end_logit": -7.75390625,
            "text": "Inhibitor 1 (I-1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.953125,
            "end_logit": -7.80859375,
            "text": "Inhibitor 1 (I-1)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.953125,
            "end_logit": -7.83203125,
            "text": "Inhibitor 1 (I",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.03125,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), the predominating Ser/Thr phosphatase in the heart",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.0625,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1)",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.078125,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.109375,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.1796875,
            "text": "Inhibitor 1 (I-",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.1875,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.203125,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), the predominating Ser/Thr phosphatase in the",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.2265625,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), the predominating Ser/",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.2265625,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), the predominating Ser/Thr",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.2421875,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), the predominating Ser/Thr phosphatase in",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.2421875,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.2734375,
            "text": "Inhibitor 1 (I-1) is",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.296875,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.3046875,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), the predom",
            "probability": 0.0
        }
    ],
    "550618f58e1671127b000007_5": [
        {
            "start_logit": 9.9609375,
            "end_logit": 9.3671875,
            "text": "Inhibitor 1",
            "probability": 1.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -1.94921875,
            "text": "Inhibitor",
            "probability": 1.2218952178955078e-05
        },
        {
            "start_logit": -2.5390625,
            "end_logit": 9.3671875,
            "text": "1",
            "probability": 3.7550926208496094e-06
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -7.80078125,
            "text": "Inhibitor 1 (I-1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -7.87890625,
            "text": "Inhibitor 1 (I",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -7.90625,
            "text": "Inhibitor 1 (I-1)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.0625,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.0703125,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.0859375,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.140625,
            "text": "Inhibitor 1 (I-",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.1484375,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.1953125,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.2109375,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), a major eukaryotic Ser/",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.2109375,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), a major eukaryotic Ser/Thr",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.234375,
            "text": "Inhibitor 1 (I-1) is",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.265625,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.28125,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.3046875,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.3046875,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), a major eukaryotic Ser",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.3125,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), a",
            "probability": 0.0
        }
    ],
    "550618f58e1671127b000007_6": [
        {
            "start_logit": 9.9140625,
            "end_logit": 9.3359375,
            "text": "Inhibitor 1",
            "probability": 1.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -2.05078125,
            "text": "Inhibitor",
            "probability": 1.1324882507324219e-05
        },
        {
            "start_logit": -2.609375,
            "end_logit": 9.3359375,
            "text": "1",
            "probability": 3.635883331298828e-06
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -7.859375,
            "text": "Inhibitor 1 (I-1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -7.94921875,
            "text": "Inhibitor 1 (I",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -7.96484375,
            "text": "Inhibitor 1 (I-1)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -7.9765625,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), the predominating Ser/Thr phosphatase in the heart",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.1640625,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.1796875,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.1875,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.2421875,
            "text": "Inhibitor 1 (I-",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.2578125,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.2734375,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), the predominating Ser/",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.2890625,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), the predominating Ser/Thr phosphatase in the",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.2890625,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), the predominating Ser/Thr",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.3046875,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.34375,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.359375,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), the",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.359375,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), the predominating Ser/Thr phosphatase in",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.3671875,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1),",
            "probability": 0.0
        }
    ],
    "5881f9b65bf093691f000001_1": [
        {
            "start_logit": 10.0703125,
            "end_logit": 9.578125,
            "text": "Parasympathetic neurons",
            "probability": 1.0
        },
        {
            "start_logit": 10.0703125,
            "end_logit": -1.69921875,
            "text": "Parasympathetic",
            "probability": 1.2636184692382812e-05
        },
        {
            "start_logit": -2.08203125,
            "end_logit": 9.578125,
            "text": "neurons",
            "probability": 5.245208740234375e-06
        },
        {
            "start_logit": 10.0703125,
            "end_logit": -7.6875,
            "text": "Parasympathetic neurons originate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0703125,
            "end_logit": -8.2734375,
            "text": "Parasympathetic neurons originate from nerve-associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": 10.0703125,
            "end_logit": -8.296875,
            "text": "Parasympathetic neurons originate from",
            "probability": 0.0
        },
        {
            "start_logit": -2.08203125,
            "end_logit": -7.6875,
            "text": "neurons originate",
            "probability": 0.0
        },
        {
            "start_logit": -2.08203125,
            "end_logit": -8.2734375,
            "text": "neurons originate from nerve-associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -2.08203125,
            "end_logit": -8.296875,
            "text": "neurons originate from",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -7.6875,
            "text": "originate",
            "probability": 0.0
        },
        {
            "start_logit": -7.62109375,
            "end_logit": -8.2734375,
            "text": "from nerve-associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -7.62109375,
            "end_logit": -8.296875,
            "text": "from",
            "probability": 0.0
        },
        {
            "start_logit": -7.94921875,
            "end_logit": -8.2734375,
            "text": "glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -7.95703125,
            "end_logit": -8.2734375,
            "text": "peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": -8.2734375,
            "text": "associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": -8.2734375,
            "text": "nerve-associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -8.2734375,
            "text": "progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -8.2734375,
            "text": "-associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -8.2734375,
            "text": "originate from nerve-associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -8.296875,
            "text": "originate from",
            "probability": 0.0
        }
    ],
    "5881f9b65bf093691f000001_2": [
        {
            "start_logit": 10.09375,
            "end_logit": 9.6875,
            "text": "Parasympathetic neurons",
            "probability": 1.0
        },
        {
            "start_logit": 10.09375,
            "end_logit": -1.6259765625,
            "text": "Parasympathetic",
            "probability": 1.2218952178955078e-05
        },
        {
            "start_logit": -1.8232421875,
            "end_logit": 9.6875,
            "text": "neurons",
            "probability": 6.616115570068359e-06
        },
        {
            "start_logit": -6.20703125,
            "end_logit": 9.6875,
            "text": ". Parasympathetic neurons",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.09375,
            "end_logit": -8.1171875,
            "text": "Parasympathetic neurons originate",
            "probability": 0.0
        },
        {
            "start_logit": 10.09375,
            "end_logit": -8.1796875,
            "text": "Parasympathetic neurons originate from nerve-associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.6875,
            "text": "Neurodevelopment. Parasympathetic neurons",
            "probability": 0.0
        },
        {
            "start_logit": -6.20703125,
            "end_logit": -1.6259765625,
            "text": ". Parasympathetic",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -1.6259765625,
            "text": "Neurodevelopment. Parasympathetic",
            "probability": 0.0
        },
        {
            "start_logit": -1.8232421875,
            "end_logit": -8.1171875,
            "text": "neurons originate",
            "probability": 0.0
        },
        {
            "start_logit": -1.8232421875,
            "end_logit": -8.1796875,
            "text": "neurons originate from nerve-associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -6.20703125,
            "end_logit": -8.1171875,
            "text": ". Parasympathetic neurons originate",
            "probability": 0.0
        },
        {
            "start_logit": -6.20703125,
            "end_logit": -8.1796875,
            "text": ". Parasympathetic neurons originate from nerve-associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -7.05859375,
            "end_logit": -8.1796875,
            "text": "from nerve-associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -7.5078125,
            "end_logit": -8.1171875,
            "text": "originate",
            "probability": 0.0
        },
        {
            "start_logit": -7.5078125,
            "end_logit": -8.1796875,
            "text": "originate from nerve-associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -8.1796875,
            "text": "nerve-associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": -8.1796875,
            "text": "peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": -8.1796875,
            "text": "-associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -8.1796875,
            "text": "associated peripheral glial progenitors",
            "probability": 0.0
        }
    ],
    "5881f9b65bf093691f000001_3": [
        {
            "start_logit": 9.9921875,
            "end_logit": 9.5390625,
            "text": "Parasympathetic neurons",
            "probability": 1.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -1.8857421875,
            "text": "Parasympathetic",
            "probability": 1.0967254638671875e-05
        },
        {
            "start_logit": -2.19921875,
            "end_logit": 9.5390625,
            "text": "neurons",
            "probability": 5.066394805908203e-06
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -7.85546875,
            "text": "Parasympathetic neurons originate from nerve-associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -7.89453125,
            "text": "Parasympathetic neurons originate",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.2265625,
            "text": "Parasympathetic neurons originate from",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.3671875,
            "text": "Parasympathetic neurons originate from nerve-associated peripheral glial",
            "probability": 0.0
        },
        {
            "start_logit": -2.19921875,
            "end_logit": -7.85546875,
            "text": "neurons originate from nerve-associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -2.19921875,
            "end_logit": -7.89453125,
            "text": "neurons originate",
            "probability": 0.0
        },
        {
            "start_logit": -2.19921875,
            "end_logit": -8.2265625,
            "text": "neurons originate from",
            "probability": 0.0
        },
        {
            "start_logit": -2.19921875,
            "end_logit": -8.3671875,
            "text": "neurons originate from nerve-associated peripheral glial",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": -7.85546875,
            "text": "from nerve-associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": -7.85546875,
            "text": "peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -7.85546875,
            "text": "nerve-associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -7.85546875,
            "text": "glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -7.85546875,
            "text": "associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -7.85546875,
            "text": "-associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": -7.85546875,
            "text": "originate from nerve-associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": -7.89453125,
            "text": "originate",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": -8.2265625,
            "text": "from",
            "probability": 0.0
        }
    ],
    "5881f9b65bf093691f000001_4": [
        {
            "start_logit": 10.09375,
            "end_logit": 9.6875,
            "text": "Parasympathetic neurons",
            "probability": 1.0
        },
        {
            "start_logit": 10.09375,
            "end_logit": -1.6259765625,
            "text": "Parasympathetic",
            "probability": 1.2218952178955078e-05
        },
        {
            "start_logit": -1.8232421875,
            "end_logit": 9.6875,
            "text": "neurons",
            "probability": 6.616115570068359e-06
        },
        {
            "start_logit": -6.20703125,
            "end_logit": 9.6875,
            "text": ". Parasympathetic neurons",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.09375,
            "end_logit": -8.1171875,
            "text": "Parasympathetic neurons originate",
            "probability": 0.0
        },
        {
            "start_logit": 10.09375,
            "end_logit": -8.1796875,
            "text": "Parasympathetic neurons originate from nerve-associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.6875,
            "text": "Neurodevelopment. Parasympathetic neurons",
            "probability": 0.0
        },
        {
            "start_logit": -6.20703125,
            "end_logit": -1.6259765625,
            "text": ". Parasympathetic",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -1.6259765625,
            "text": "Neurodevelopment. Parasympathetic",
            "probability": 0.0
        },
        {
            "start_logit": -1.8232421875,
            "end_logit": -8.1171875,
            "text": "neurons originate",
            "probability": 0.0
        },
        {
            "start_logit": -1.8232421875,
            "end_logit": -8.1796875,
            "text": "neurons originate from nerve-associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -6.20703125,
            "end_logit": -8.1171875,
            "text": ". Parasympathetic neurons originate",
            "probability": 0.0
        },
        {
            "start_logit": -6.20703125,
            "end_logit": -8.1796875,
            "text": ". Parasympathetic neurons originate from nerve-associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -7.05859375,
            "end_logit": -8.1796875,
            "text": "from nerve-associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -7.5078125,
            "end_logit": -8.1171875,
            "text": "originate",
            "probability": 0.0
        },
        {
            "start_logit": -7.5078125,
            "end_logit": -8.1796875,
            "text": "originate from nerve-associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -8.1796875,
            "text": "nerve-associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": -8.1796875,
            "text": "peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": -8.1796875,
            "text": "-associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -8.1796875,
            "text": "associated peripheral glial progenitors",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_1": [
        {
            "start_logit": 9.9375,
            "end_logit": 9.765625,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": -1.7451171875,
            "end_logit": 9.765625,
            "text": "difficile",
            "probability": 8.463859558105469e-06
        },
        {
            "start_logit": 9.9375,
            "end_logit": -2.005859375,
            "text": "Clostridium",
            "probability": 7.68899917602539e-06
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 9.765625,
            "text": "Fecal microbiota transplantation is a highly effective intervention for patients suffering from recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.765625,
            "text": "patients suffering from recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.3359375,
            "text": "Clostridium difficile, a",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.765625,
            "text": "from recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.765625,
            "text": "recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.765625,
            "text": "for patients suffering from recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 9.765625,
            "text": "intervention for patients suffering from recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.40625,
            "text": "Clostridium difficile, a common",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.765625,
            "text": "effective intervention for patients suffering from recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.765625,
            "text": "suffering from recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": -2.005859375,
            "text": "Fecal microbiota transplantation is a highly effective intervention for patients suffering from recurrent Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -1.7451171875,
            "end_logit": -8.3359375,
            "text": "difficile, a",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": -2.005859375,
            "text": "patients suffering from recurrent Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -1.7451171875,
            "end_logit": -8.40625,
            "text": "difficile, a common",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -2.005859375,
            "text": "from recurrent Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -2.005859375,
            "text": "recurrent Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -2.005859375,
            "text": "for patients suffering from recurrent Clostridium",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_2": [
        {
            "start_logit": 9.8828125,
            "end_logit": 9.7109375,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": -1.8515625,
            "end_logit": 9.7109375,
            "text": "difficile",
            "probability": 7.987022399902344e-06
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -2.134765625,
            "text": "Clostridium",
            "probability": 7.212162017822266e-06
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 9.7109375,
            "text": "of Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.1953125,
            "text": "Clostridium difficile Proct",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.2421875,
            "text": "Clostridium difficile Proctitis Following Total Colectomy",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.2890625,
            "text": "Clostridium difficile Proctitis Following Total",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.328125,
            "text": "Clostridium difficile Proctitis",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 9.7109375,
            "text": "Fecal Microbiota Transplantation for Treatment of Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 9.7109375,
            "text": "Treatment of Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.7109375,
            "text": "-Fecal Microbiota Transplantation for Treatment of Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.7109375,
            "text": "for Treatment of Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -1.8515625,
            "end_logit": -8.1953125,
            "text": "difficile Proct",
            "probability": 0.0
        },
        {
            "start_logit": -7.9453125,
            "end_logit": -2.134765625,
            "text": "of Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -1.8515625,
            "end_logit": -8.2421875,
            "text": "difficile Proctitis Following Total Colectomy",
            "probability": 0.0
        },
        {
            "start_logit": -1.8515625,
            "end_logit": -8.2890625,
            "text": "difficile Proctitis Following Total",
            "probability": 0.0
        },
        {
            "start_logit": -1.8515625,
            "end_logit": -8.328125,
            "text": "difficile Proctitis",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": -2.134765625,
            "text": "Fecal Microbiota Transplantation for Treatment of Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -2.134765625,
            "text": "Treatment of Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -2.134765625,
            "text": "-Fecal Microbiota Transplantation for Treatment of Clostridium",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_3": [
        {
            "start_logit": 9.8125,
            "end_logit": 9.625,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": -2.083984375,
            "end_logit": 9.625,
            "text": "difficile",
            "probability": 6.794929504394531e-06
        },
        {
            "start_logit": 9.8125,
            "end_logit": -2.31640625,
            "text": "Clostridium",
            "probability": 6.556510925292969e-06
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.2734375,
            "text": "Clostridium difficile carriage rates following fecal microbiota transplantation",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.2734375,
            "text": "Clostridium difficile carriage rates following fecal microbiota",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.28125,
            "text": "Clostridium difficile carriage",
            "probability": 0.0
        },
        {
            "start_logit": 9.8125,
            "end_logit": -8.3515625,
            "text": "Clostridium difficile carriage rates",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.625,
            "text": "the asymptomatic Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.625,
            "text": "asymptomatic Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.625,
            "text": "assess the asymptomatic Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.625,
            "text": "We aimed to assess the asymptomatic Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": 9.625,
            "text": "aimed to assess the asymptomatic Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.625,
            "text": "to assess the asymptomatic Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -2.083984375,
            "end_logit": -8.2734375,
            "text": "difficile carriage rates following fecal microbiota transplantation",
            "probability": 0.0
        },
        {
            "start_logit": -2.083984375,
            "end_logit": -8.2734375,
            "text": "difficile carriage rates following fecal microbiota",
            "probability": 0.0
        },
        {
            "start_logit": -2.083984375,
            "end_logit": -8.28125,
            "text": "difficile carriage",
            "probability": 0.0
        },
        {
            "start_logit": -2.083984375,
            "end_logit": -8.3515625,
            "text": "difficile carriage rates",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -2.31640625,
            "text": "the asymptomatic Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -2.31640625,
            "text": "asymptomatic Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -2.31640625,
            "text": "assess the asymptomatic Clostridium",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_4": [
        {
            "start_logit": 9.9453125,
            "end_logit": 9.71875,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -1.9990234375,
            "text": "Clostridium",
            "probability": 8.225440979003906e-06
        },
        {
            "start_logit": -1.8681640625,
            "end_logit": 9.71875,
            "text": "difficile",
            "probability": 7.450580596923828e-06
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.265625,
            "text": "Clostridium difficile infection,",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.3515625,
            "text": "Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.71875,
            "text": "infusion of donor feces into a recipient's intestinal tract, has been used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.71875,
            "text": "recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.71875,
            "text": "the infusion of donor feces into a recipient's intestinal tract, has been used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.71875,
            "text": "a recipient's intestinal tract, has been used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.71875,
            "text": "of donor feces into a recipient's intestinal tract, has been used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.71875,
            "text": "used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.71875,
            "text": "treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.71875,
            "text": "been used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.71875,
            "text": "has been used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.71875,
            "text": "Fecal transplantation, the infusion of donor feces into a recipient's intestinal tract, has been used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -1.8681640625,
            "end_logit": -8.265625,
            "text": "difficile infection,",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -1.9990234375,
            "text": "infusion of donor feces into a recipient's intestinal tract, has been used for decades to treat recurrent Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -1.9990234375,
            "text": "recurrent Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -1.8681640625,
            "end_logit": -8.3515625,
            "text": "difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -1.9990234375,
            "text": "the infusion of donor feces into a recipient's intestinal tract, has been used for decades to treat recurrent Clostridium",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_5": [
        {
            "start_logit": 9.96875,
            "end_logit": 9.7265625,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -1.9130859375,
            "text": "Clostridium",
            "probability": 8.881092071533203e-06
        },
        {
            "start_logit": -1.8056640625,
            "end_logit": 9.7265625,
            "text": "difficile",
            "probability": 7.748603820800781e-06
        },
        {
            "start_logit": 9.96875,
            "end_logit": -7.953125,
            "text": "Clostridium difficile Infection in Two English Hospitals: A Review.Fecal microbiota transplant (FM",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.046875,
            "text": "Clostridium difficile Infection in Two English Hospitals: A Review.Fecal microbiota transplant (FMT) has emerged as a highly efficacious treatment for difficult cases of refractory and/or recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.078125,
            "text": "Clostridium difficile Infection in Two English Hospitals: A Review.Fecal microbiota transplant (FMT) has emerged as a highly efficacious treatment for difficult cases of refractory and/or recurrent Clostridium difficile infection (CDI)",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.109375,
            "text": "Clostridium difficile Infection in Two English Hospitals: A Review.Fecal microbiota transplant (FMT)",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.1171875,
            "text": "Clostridium difficile Infection in Two English Hospitals: A Review.Fecal microbiota transplant",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.1328125,
            "text": "Clostridium difficile Infection in Two English Hospitals: A Review.Fecal microbiota",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.15625,
            "text": "Clostridium difficile Infection in Two English Hospitals: A Review.Fecal microbiota transplant (FMT",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.1875,
            "text": "Clostridium difficile Infection in",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.1953125,
            "text": "Clostridium difficile Infection in Two English Hospitals: A Review.Fecal microbiota transplant (FMT) has emerged as a highly efficacious treatment for difficult cases of refractory and/or recurrent Clostridium difficile infection (CDI",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.203125,
            "text": "Clostridium difficile Infection in Two English Hospitals: A Review.Fecal microbiota transplant (FMT) has emerged as a highly efficacious treatment for difficult cases of refractory and/or recurrent Clostridium difficile infection (",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.265625,
            "text": "Clostridium difficile Infection in Two English Hospitals: A Review.Fecal microbiota transplant (FMT) has emerged as a highly efficacious treatment for difficult cases of refractory and/or recurrent Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.28125,
            "text": "Clostridium difficile Infection in Two English Hospitals: A Review.Fecal microbiota transplant (FMT) has emerged as a highly efficacious treatment for difficult cases of refractory and/or recurrent Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.3125,
            "text": "Clostridium difficile Infection in Two English Hospitals: A Review.Fecal microbiota transplant (",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.3125,
            "text": "Clostridium difficile Infection in Two English Hospitals: A Review.Fecal microbiota transplant (FMT) has emerged",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.3203125,
            "text": "Clostridium difficile Infection in Two English",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.3203125,
            "text": "Clostridium difficile Infection in Two",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 9.7265625,
            "text": "Patients with Recurrent Clostridium difficile",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_6": [
        {
            "start_logit": 9.9296875,
            "end_logit": 9.71875,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -2.025390625,
            "text": "Clostridium",
            "probability": 7.867813110351562e-06
        },
        {
            "start_logit": -1.853515625,
            "end_logit": 9.71875,
            "text": "difficile",
            "probability": 7.569789886474609e-06
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.1328125,
            "text": "Clostridium difficile Infection following Fecal Microbiota",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.2109375,
            "text": "Clostridium difficile Infection following Fecal Microbiota Transplantation",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.3046875,
            "text": "Clostridium difficile Infection",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.71875,
            "text": "Recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.71875,
            "text": "from Recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.71875,
            "text": "Complete Microbiota Engraftment Is Not Essential for Recovery from Recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.71875,
            "text": "Recovery from Recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 9.71875,
            "text": "for Recovery from Recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -1.853515625,
            "end_logit": -8.1328125,
            "text": "difficile Infection following Fecal Microbiota",
            "probability": 0.0
        },
        {
            "start_logit": -1.853515625,
            "end_logit": -8.2109375,
            "text": "difficile Infection following Fecal Microbiota Transplantation",
            "probability": 0.0
        },
        {
            "start_logit": -1.853515625,
            "end_logit": -8.3046875,
            "text": "difficile Infection",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -2.025390625,
            "text": "Recurrent Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": -2.025390625,
            "text": "from Recurrent Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": -2.025390625,
            "text": "Complete Microbiota Engraftment Is Not Essential for Recovery from Recurrent Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": -2.025390625,
            "text": "Recovery from Recurrent Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -8.3515625,
            "end_logit": -2.025390625,
            "text": "for Recovery from Recurrent Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -8.1328125,
            "text": "following Fecal Microbiota",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_7": [
        {
            "start_logit": 9.9453125,
            "end_logit": 9.71875,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -1.9990234375,
            "text": "Clostridium",
            "probability": 8.225440979003906e-06
        },
        {
            "start_logit": -1.8681640625,
            "end_logit": 9.71875,
            "text": "difficile",
            "probability": 7.450580596923828e-06
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.265625,
            "text": "Clostridium difficile infection,",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.3515625,
            "text": "Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.71875,
            "text": "infusion of donor feces into a recipient's intestinal tract, has been used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.71875,
            "text": "recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.71875,
            "text": "the infusion of donor feces into a recipient's intestinal tract, has been used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.71875,
            "text": "a recipient's intestinal tract, has been used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.71875,
            "text": "of donor feces into a recipient's intestinal tract, has been used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.71875,
            "text": "used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.71875,
            "text": "treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.71875,
            "text": "been used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.71875,
            "text": "has been used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.71875,
            "text": "Fecal transplantation, the infusion of donor feces into a recipient's intestinal tract, has been used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -1.8681640625,
            "end_logit": -8.265625,
            "text": "difficile infection,",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -1.9990234375,
            "text": "infusion of donor feces into a recipient's intestinal tract, has been used for decades to treat recurrent Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -1.9990234375,
            "text": "recurrent Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -1.8681640625,
            "end_logit": -8.3515625,
            "text": "difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -1.9990234375,
            "text": "the infusion of donor feces into a recipient's intestinal tract, has been used for decades to treat recurrent Clostridium",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_8": [
        {
            "start_logit": 9.9453125,
            "end_logit": 9.7265625,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -1.99609375,
            "text": "Clostridium",
            "probability": 8.165836334228516e-06
        },
        {
            "start_logit": -1.822265625,
            "end_logit": 9.7265625,
            "text": "difficile",
            "probability": 7.748603820800781e-06
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.1875,
            "text": "Clostridium difficile infection, with near 90%",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.1953125,
            "text": "Clostridium difficile infection, with near 90",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.7265625,
            "text": "Fecal microbiota transplantation (FMT) has an incomparable efficacy to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.3359375,
            "text": "Clostridium difficile infection, with near",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.3515625,
            "text": "Clostridium difficile infection, with near 90% of success",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.7265625,
            "text": "recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.7265625,
            "text": "treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": 9.7265625,
            "text": "efficacy to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.7265625,
            "text": "(FMT) has an incomparable efficacy to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 9.7265625,
            "text": "has an incomparable efficacy to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": 9.7265625,
            "text": "an incomparable efficacy to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 9.7265625,
            "text": "to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.3671875,
            "end_logit": 9.7265625,
            "text": "incomparable efficacy to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -1.822265625,
            "end_logit": -8.1875,
            "text": "difficile infection, with near 90%",
            "probability": 0.0
        },
        {
            "start_logit": -1.822265625,
            "end_logit": -8.1953125,
            "text": "difficile infection, with near 90",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": -1.99609375,
            "text": "Fecal microbiota transplantation (FMT) has an incomparable efficacy to treat recurrent Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -1.99609375,
            "text": "recurrent Clostridium",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_9": [
        {
            "start_logit": 9.96875,
            "end_logit": 9.796875,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": -1.669921875,
            "end_logit": 9.796875,
            "text": "difficile",
            "probability": 8.821487426757812e-06
        },
        {
            "start_logit": 9.96875,
            "end_logit": -1.93359375,
            "text": "Clostridium",
            "probability": 7.987022399902344e-06
        },
        {
            "start_logit": -8.09375,
            "end_logit": 9.796875,
            "text": "recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.3046875,
            "text": "Clostridium difficile infection, has emerged as a promising therapy for intestinal MDR bacterial dec",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.3046875,
            "text": "Clostridium difficile infection, has emerged as a promising therapy for intestinal MDR bacterial decolonization",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.796875,
            "text": "for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.34375,
            "text": "Clostridium difficile infection, has emerged as a promising therapy for intestinal MDR",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.3515625,
            "text": "Clostridium difficile infection, has emerged as a promising",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.3515625,
            "text": "Clostridium difficile infection, has emerged as a promising therapy for intestinal MDR bacterial decolon",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.796875,
            "text": "effective treatment for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.796875,
            "text": "treatment for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.796875,
            "text": "Fecal microbiota transplantation (FMT), a highly effective treatment for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.796875,
            "text": "a highly effective treatment for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.796875,
            "text": ", a highly effective treatment for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 9.796875,
            "text": "highly effective treatment for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -1.669921875,
            "end_logit": -8.3046875,
            "text": "difficile infection, has emerged as a promising therapy for intestinal MDR bacterial dec",
            "probability": 0.0
        },
        {
            "start_logit": -1.669921875,
            "end_logit": -8.3046875,
            "text": "difficile infection, has emerged as a promising therapy for intestinal MDR bacterial decolonization",
            "probability": 0.0
        },
        {
            "start_logit": -1.669921875,
            "end_logit": -8.34375,
            "text": "difficile infection, has emerged as a promising therapy for intestinal MDR",
            "probability": 0.0
        },
        {
            "start_logit": -1.669921875,
            "end_logit": -8.3515625,
            "text": "difficile infection, has emerged as a promising",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_10": [
        {
            "start_logit": 9.9375,
            "end_logit": 9.7578125,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": -1.7470703125,
            "end_logit": 9.7578125,
            "text": "difficile",
            "probability": 8.463859558105469e-06
        },
        {
            "start_logit": 9.9375,
            "end_logit": -1.9853515625,
            "text": "Clostridium",
            "probability": 7.987022399902344e-06
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.2265625,
            "text": "Clostridium difficile infection (R",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.2890625,
            "text": "Clostridium difficile infection (R-CDI",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.3046875,
            "text": "Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.3046875,
            "text": "Clostridium difficile infection (R-CDI)",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.3203125,
            "text": "Clostridium difficile infection (R-CDI) that cannot be cured with antibiotics alone",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.328125,
            "text": "Clostridium difficile infection (R-CDI) that cannot",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.3359375,
            "text": "Clostridium difficile infection (R-CDI) that cannot be cured",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.3515625,
            "text": "Clostridium difficile infection (R-CDI) that cannot be",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.7578125,
            "text": "Fecal microbiota transplantation (FMT) is increasingly being used for treatment of recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.3828125,
            "text": "Clostridium difficile infection (R-CDI) that cann",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.7578125,
            "text": "recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.7578125,
            "text": "of recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.7578125,
            "text": "treatment of recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.7578125,
            "text": "used for treatment of recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.7578125,
            "text": "for treatment of recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.7578125,
            "text": "OBJECTIVES Fecal microbiota transplantation (FMT) is increasingly being used for treatment of recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": 9.7578125,
            "text": "being used for treatment of recurrent Clostridium difficile",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_11": [
        {
            "start_logit": 9.96875,
            "end_logit": 9.7265625,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -1.9306640625,
            "text": "Clostridium",
            "probability": 8.761882781982422e-06
        },
        {
            "start_logit": -1.8291015625,
            "end_logit": 9.7265625,
            "text": "difficile",
            "probability": 7.569789886474609e-06
        },
        {
            "start_logit": -7.703125,
            "end_logit": 9.7265625,
            "text": "with Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.078125,
            "text": "Clostridium difficile infection (CDI",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.1328125,
            "text": "Clostridium difficile infection (",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.171875,
            "text": "Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.171875,
            "text": "Clostridium difficile infection (CDI)",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.7265625,
            "text": "Fecal microbiota transplantation (FMT) restores a diverse bacterial profile to the gastrointestinal tract and may effectively treat patients with Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.7265625,
            "text": "may effectively treat patients with Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.7265625,
            "text": "patients with Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.7265625,
            "text": "treat patients with Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.7265625,
            "text": "gastrointestinal tract and may effectively treat patients with Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.7265625,
            "text": "diverse bacterial profile to the gastrointestinal tract and may effectively treat patients with Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.7265625,
            "text": "and may effectively treat patients with Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.7265625,
            "text": "the gastrointestinal tract and may effectively treat patients with Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.7265625,
            "text": "BACKGROUND Fecal microbiota transplantation (FMT) restores a diverse bacterial profile to the gastrointestinal tract and may effectively treat patients with Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.7265625,
            "text": "a diverse bacterial profile to the gastrointestinal tract and may effectively treat patients with Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": 9.7265625,
            "text": "effectively treat patients with Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": 9.7265625,
            "text": "(FMT) restores a diverse bacterial profile to the gastrointestinal tract and may effectively treat patients with Clostridium difficile",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_12": [
        {
            "start_logit": 9.84375,
            "end_logit": 9.71875,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": -1.861328125,
            "end_logit": 9.71875,
            "text": "difficile",
            "probability": 8.285045623779297e-06
        },
        {
            "start_logit": 9.84375,
            "end_logit": -2.205078125,
            "text": "Clostridium",
            "probability": 6.616115570068359e-06
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.0234375,
            "text": "Clostridium difficile infection (rCDI) by fecal microbiota transplantation (FM",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.1796875,
            "text": "Clostridium difficile infection (rCDI) by fecal microbiota",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.2109375,
            "text": "Clostridium difficile infection (rC",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.234375,
            "text": "Clostridium difficile infection (rCDI) by fecal microbiota transplantation (",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.25,
            "text": "Clostridium difficile infection (rCDI) by fecal microbiota transplantation",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.296875,
            "text": "Clostridium difficile infection (rCDI) by fecal microbiota transplantation (FMT",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.3125,
            "text": "Clostridium difficile infection (",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.3125,
            "text": "Clostridium difficile infection (rCDI",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.328125,
            "text": "Clostridium difficile infection (rCDI) by fecal microbiota transplantation (FMT)",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.34375,
            "text": "Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.3515625,
            "text": "Clostridium difficile infection (rCDI)",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.71875,
            "text": "recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.375,
            "text": "Clostridium difficile infection (rCDI) by fecal microbiota transplantation (FMT), using either heterologous donor stool samples or autologous stool samples, were characterized by Illumina next-generation",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.3828125,
            "text": "Clostridium difficile infection (rCDI) by fecal microbiota transplantation (FMT), using either heterologous donor stool samples or autologous stool samples, were",
            "probability": 0.0
        },
        {
            "start_logit": 9.84375,
            "end_logit": -8.390625,
            "text": "Clostridium difficile infection (rCDI) by fecal microbiota transplantation (FMT), using either heterologous donor stool samples or autologous stool samples, were characterized by Illumina next-generation sequencing",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.71875,
            "text": "for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.71875,
            "text": "subjects treated for recurrent Clostridium difficile",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_13": [
        {
            "start_logit": 9.9375,
            "end_logit": 9.75,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": -1.7763671875,
            "end_logit": 9.75,
            "text": "difficile",
            "probability": 8.165836334228516e-06
        },
        {
            "start_logit": 9.9375,
            "end_logit": -2.01953125,
            "text": "Clostridium",
            "probability": 7.748603820800781e-06
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.140625,
            "text": "Clostridium difficile infections, with potential applications against other diseases associated with changes in gut microbiota",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.2734375,
            "text": "Clostridium difficile infections, with potential",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.2890625,
            "text": "Clostridium difficile infections, with potential applications against other diseases associated with changes",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -8.296875,
            "text": "Clostridium difficile infections, with potential applications against other diseases associated with changes in gut",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.75,
            "text": "Fecal microbiota transplantation is a compelling treatment for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.75,
            "text": "recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.75,
            "text": "for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.75,
            "text": "treatment for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -1.7763671875,
            "end_logit": -8.140625,
            "text": "difficile infections, with potential applications against other diseases associated with changes in gut microbiota",
            "probability": 0.0
        },
        {
            "start_logit": -1.7763671875,
            "end_logit": -8.2734375,
            "text": "difficile infections, with potential",
            "probability": 0.0
        },
        {
            "start_logit": -1.7763671875,
            "end_logit": -8.2890625,
            "text": "difficile infections, with potential applications against other diseases associated with changes",
            "probability": 0.0
        },
        {
            "start_logit": -1.7763671875,
            "end_logit": -8.296875,
            "text": "difficile infections, with potential applications against other diseases associated with changes in gut",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -2.01953125,
            "text": "Fecal microbiota transplantation is a compelling treatment for recurrent Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": -2.01953125,
            "text": "recurrent Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -2.01953125,
            "text": "for recurrent Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": -2.01953125,
            "text": "treatment for recurrent Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -8.140625,
            "text": "Fecal microbiota transplantation is a compelling treatment for recurrent Clostridium difficile infections, with potential applications against other diseases associated with changes in gut microbiota",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_14": [
        {
            "start_logit": 9.9609375,
            "end_logit": 9.7265625,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -1.95703125,
            "text": "Clostridium",
            "probability": 8.404254913330078e-06
        },
        {
            "start_logit": -1.8310546875,
            "end_logit": 9.7265625,
            "text": "difficile",
            "probability": 7.510185241699219e-06
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.078125,
            "text": "Clostridium difficile infection, but well-designed, randomized-controlled trials and Long-term follow-up registries are stilt required",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.2265625,
            "text": "Clostridium difficile infection, but well-designed, randomized-controlled trials and Long-term follow-up",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.234375,
            "text": "Clostridium difficile infection, but well-designed, randomized-controlled trials and Long-term follow-up registries are sti",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.25,
            "text": "Clostridium difficile infection, but well-designed, randomized-controlled",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.2578125,
            "text": "Clostridium difficile infection, but well-designed, randomized-controlled trials and Long-term follow-up registries are",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.2890625,
            "text": "Clostridium difficile infection, but well-designed",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.296875,
            "text": "Clostridium difficile infection, but well-designed, randomized-controlled trials and Long-term follow",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.3046875,
            "text": "Clostridium difficile infection, but well-designed, randomized-controlled trials and Long-term",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.3125,
            "text": "Clostridium difficile infection, but well-designed, randomized-controlled trials",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.3203125,
            "text": "Clostridium difficile infection, but well-designed, randomized",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.3203125,
            "text": "Clostridium difficile infection, but well-designed, randomized-controlled trials and",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.3203125,
            "text": "Clostridium difficile infection, but well-designed, randomized-controlled trials and Long-term follow-",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.328125,
            "text": "Clostridium difficile infection, but well-designed, randomized-controlled trials and Long-term follow-up registries",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.7265625,
            "text": "Fecal microbiota transplantation (FMT) holds considerable promise as a therapy for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.7265625,
            "text": "recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 9.7265625,
            "text": "for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.7265625,
            "text": "(FMT) holds considerable promise as a therapy for recurrent Clostridium difficile",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_15": [
        {
            "start_logit": 9.984375,
            "end_logit": 9.8203125,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": -1.6123046875,
            "end_logit": 9.8203125,
            "text": "difficile",
            "probability": 9.179115295410156e-06
        },
        {
            "start_logit": 9.984375,
            "end_logit": -1.89453125,
            "text": "Clostridium",
            "probability": 8.165836334228516e-06
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.1171875,
            "text": "Clostridium difficile infection (CDI",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.171875,
            "text": "Clostridium difficile infection (",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.2734375,
            "text": "Clostridium difficile infection (CDI) and is considered as a treatment for other gastrointestinal (GI)",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.2734375,
            "text": "Clostridium difficile infection (CDI) and is considered as a treatment for other gastrointestinal (GI",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.28125,
            "text": "Clostridium difficile infection (CDI)",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.8203125,
            "text": "Fecal microbiota transplantation (FMT) is an effective treatment for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.2890625,
            "text": "Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.3125,
            "text": "Clostridium difficile infection (CDI) and is considered as a treatment for other gastrointestinal (",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 9.8203125,
            "text": "recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.8203125,
            "text": "for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.8203125,
            "text": "treatment for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.8203125,
            "text": "effective treatment for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": 9.8203125,
            "text": "(FMT) is an effective treatment for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -1.6123046875,
            "end_logit": -8.1171875,
            "text": "difficile infection (CDI",
            "probability": 0.0
        },
        {
            "start_logit": -1.6123046875,
            "end_logit": -8.171875,
            "text": "difficile infection (",
            "probability": 0.0
        },
        {
            "start_logit": -1.6123046875,
            "end_logit": -8.2734375,
            "text": "difficile infection (CDI) and is considered as a treatment for other gastrointestinal (GI)",
            "probability": 0.0
        },
        {
            "start_logit": -1.6123046875,
            "end_logit": -8.2734375,
            "text": "difficile infection (CDI) and is considered as a treatment for other gastrointestinal (GI",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_16": [
        {
            "start_logit": 9.953125,
            "end_logit": 9.75,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -1.9580078125,
            "text": "Clostridium",
            "probability": 8.285045623779297e-06
        },
        {
            "start_logit": -1.7900390625,
            "end_logit": 9.75,
            "text": "difficile",
            "probability": 7.927417755126953e-06
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.3125,
            "text": "Clostridium difficile infection with ulcerative panc",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.3125,
            "text": "Clostridium difficile infection with ulcerative pancolitis, as an alternative in case of antibiotic therapy",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.3125,
            "text": "Clostridium difficile infection with ulcerative",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.3203125,
            "text": "Clostridium difficile infection with ulcerative pancoli",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.3359375,
            "text": "Clostridium difficile infection with ulcerative pancolitis",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.359375,
            "text": "Clostridium difficile infection with ulcerative pancolitis, as an alternative in case of antibiotic therapy failure",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.359375,
            "text": "Clostridium difficile infection with ulcerative pancolitis, as an alternative",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.75,
            "text": "recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.75,
            "text": "Fecal microbiota transplantation is relatively simple to perform, well-tolerated, safe and effective in recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.75,
            "text": ", safe and effective in recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.75,
            "text": "effective in recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 9.75,
            "text": "in recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.75,
            "text": "perform, well-tolerated, safe and effective in recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.75,
            "text": "safe and effective in recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.75,
            "text": ", well-tolerated, safe and effective in recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.75,
            "text": "tolerated, safe and effective in recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.75,
            "text": "well-tolerated, safe and effective in recurrent Clostridium difficile",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_17": [
        {
            "start_logit": 9.9140625,
            "end_logit": 9.7265625,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": -1.8212890625,
            "end_logit": 9.7265625,
            "text": "difficile",
            "probability": 7.987022399902344e-06
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -2.0625,
            "text": "Clostridium",
            "probability": 7.569789886474609e-06
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.3046875,
            "text": "Clostridium difficile infection and coexistent inflammatory",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.3125,
            "text": "Clostridium difficile infection and coexist",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.328125,
            "text": "Clostridium difficile infection and coexistent inflammatory bowel disease",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.328125,
            "text": "Clostridium difficile infection and coexistent inflammatory bowel",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.3515625,
            "text": "Clostridium difficile infection and coexistent inflammatory bowel disease remains unclear",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.359375,
            "text": "Clostridium difficile infection and",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 9.7265625,
            "text": "recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.7265625,
            "text": "use of fecal microbiota transplantation in recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.7265625,
            "text": "fecal microbiota transplantation in recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.7265625,
            "text": "in recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.7265625,
            "text": "of fecal microbiota transplantation in recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.7265625,
            "text": "The use of fecal microbiota transplantation in recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -1.8212890625,
            "end_logit": -8.3046875,
            "text": "difficile infection and coexistent inflammatory",
            "probability": 0.0
        },
        {
            "start_logit": -1.8212890625,
            "end_logit": -8.3125,
            "text": "difficile infection and coexist",
            "probability": 0.0
        },
        {
            "start_logit": -1.8212890625,
            "end_logit": -8.328125,
            "text": "difficile infection and coexistent inflammatory bowel disease",
            "probability": 0.0
        },
        {
            "start_logit": -1.8212890625,
            "end_logit": -8.328125,
            "text": "difficile infection and coexistent inflammatory bowel",
            "probability": 0.0
        },
        {
            "start_logit": -1.8212890625,
            "end_logit": -8.3515625,
            "text": "difficile infection and coexistent inflammatory bowel disease remains unclear",
            "probability": 0.0
        }
    ],
    "589630f378275d0c4a000007_1": [
        {
            "start_logit": 8.3125,
            "end_logit": 8.421875,
            "text": "proteasome",
            "probability": 1.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 8.421875,
            "text": ", proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 8.421875,
            "text": ", and pomalidomide), proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.125,
            "end_logit": 8.421875,
            "text": "improved by the introduction of novel therapeutics such as immunomodulatory agents (thalidomide, lenalidomide, and pomalidomide), proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 8.421875,
            "text": "introduction of novel therapeutics such as immunomodulatory agents (thalidomide, lenalidomide, and pomalidomide), proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.171875,
            "end_logit": 8.421875,
            "text": ", lenalidomide, and pomalidomide), proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.171875,
            "end_logit": 8.421875,
            "text": "idomide), proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.171875,
            "end_logit": 8.421875,
            "text": "is significantly improved by the introduction of novel therapeutics such as immunomodulatory agents (thalidomide, lenalidomide, and pomalidomide), proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 8.421875,
            "text": "and pomalidomide), proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3125,
            "end_logit": -8.4609375,
            "text": "proteasome inhibitors (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3125,
            "end_logit": -8.4609375,
            "text": "proteasome inhibitors (bortezomib, carfilzomib, and ixazomib)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.03125,
            "end_logit": -8.4609375,
            "text": ", and ixazomib)",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": -8.4609375,
            "text": ", proteasome inhibitors (",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": -8.4609375,
            "text": ", proteasome inhibitors (bortezomib, carfilzomib, and ixazomib)",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": -8.4609375,
            "text": ", and pomalidomide), proteasome inhibitors (",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": -8.4609375,
            "text": ", and pomalidomide), proteasome inhibitors (bortezomib, carfilzomib, and ixazomib)",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -8.4609375,
            "text": "improved by the introduction of novel therapeutics such as immunomodulatory agents (thalidomide, lenalidomide, and pomalidomide), proteasome inhibitors (",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -8.4609375,
            "text": "improved by the introduction of novel therapeutics such as immunomodulatory agents (thalidomide, lenalidomide, and pomalidomide), proteasome inhibitors (bortezomib, carfilzomib, and ixazomib)",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": -8.4609375,
            "text": "and ixazomib)",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -8.4609375,
            "text": "introduction of novel therapeutics such as immunomodulatory agents (thalidomide, lenalidomide, and pomalidomide), proteasome inhibitors (",
            "probability": 0.0
        }
    ],
    "589630f378275d0c4a000007_2": [
        {
            "start_logit": 8.1171875,
            "end_logit": 8.578125,
            "text": "proteasome",
            "probability": 1.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 8.578125,
            "text": "generation proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 8.578125,
            "text": "second-generation proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 8.578125,
            "text": "-generation proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": 8.578125,
            "text": "the second-generation proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.1171875,
            "end_logit": -8.4140625,
            "text": "proteasome inhibitor, selectivity and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.125,
            "end_logit": -8.4140625,
            "text": "generation proteasome inhibitor, selectivity and",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -8.4140625,
            "text": "second-generation proteasome inhibitor, selectivity and",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -8.4140625,
            "text": "-generation proteasome inhibitor, selectivity and",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -8.4140625,
            "text": "inhibitor, selectivity and",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -8.4140625,
            "text": "the second-generation proteasome inhibitor, selectivity and",
            "probability": 0.0
        }
    ],
    "589630f378275d0c4a000007_3": [
        {
            "start_logit": 8.296875,
            "end_logit": 8.4296875,
            "text": "proteasome",
            "probability": 1.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 8.4296875,
            "text": "oral proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 8.4296875,
            "text": ", the first oral proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 8.4296875,
            "text": "for multiple myeloma: ixazomib, the first oral proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.171875,
            "end_logit": 8.4296875,
            "text": ": ixazomib, the first oral proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 8.4296875,
            "text": "new therapies for multiple myeloma: ixazomib, the first oral proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1875,
            "end_logit": 8.4296875,
            "text": "three new therapies for multiple myeloma: ixazomib, the first oral proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1875,
            "end_logit": 8.4296875,
            "text": "approved three new therapies for multiple myeloma: ixazomib, the first oral proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 8.4296875,
            "text": "the first oral proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 8.4296875,
            "text": "first oral proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.21875,
            "end_logit": 8.4296875,
            "text": "therapies for multiple myeloma: ixazomib, the first oral proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.296875,
            "end_logit": -8.4453125,
            "text": "proteasome inhibitor; and daratumumab and elotuzumab, two monoclonal antibodies that target CD38 and SLAMF7, respectively",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.046875,
            "end_logit": -8.4453125,
            "text": "oral proteasome inhibitor; and daratumumab and elotuzumab, two monoclonal antibodies that target CD38 and SLAMF7, respectively",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": -8.4453125,
            "text": ", the first oral proteasome inhibitor; and daratumumab and elotuzumab, two monoclonal antibodies that target CD38 and SLAMF7, respectively",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": -8.4453125,
            "text": "that target CD38 and SLAMF7, respectively",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -8.4453125,
            "text": "for multiple myeloma: ixazomib, the first oral proteasome inhibitor; and daratumumab and elotuzumab, two monoclonal antibodies that target CD38 and SLAMF7, respectively",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -8.4453125,
            "text": "target CD38 and SLAMF7, respectively",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -8.4453125,
            "text": ": ixazomib, the first oral proteasome inhibitor; and daratumumab and elotuzumab, two monoclonal antibodies that target CD38 and SLAMF7, respectively",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -8.4453125,
            "text": "new therapies for multiple myeloma: ixazomib, the first oral proteasome inhibitor; and daratumumab and elotuzumab, two monoclonal antibodies that target CD38 and SLAMF7, respectively",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -8.4453125,
            "text": "and daratumumab and elotuzumab, two monoclonal antibodies that target CD38 and SLAMF7, respectively",
            "probability": 0.0
        }
    ],
    "589630f378275d0c4a000007_4": [
        {
            "start_logit": 8.3359375,
            "end_logit": 8.4296875,
            "text": "proteasome",
            "probability": 1.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 8.4296875,
            "text": "oral proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 8.4296875,
            "text": "first oral proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 8.4296875,
            "text": "the first oral proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 8.4296875,
            "text": ", the first oral proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 8.4296875,
            "text": "Ixazomib, the first oral proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3359375,
            "end_logit": -8.3984375,
            "text": "proteasome inhibitor to be evaluated in multiple myeloma, exerts substantial anti-myeloma activity as",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3359375,
            "end_logit": -8.40625,
            "text": "proteasome inhibitor to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3359375,
            "end_logit": -8.40625,
            "text": "proteasome inhibitor to be evaluated in multiple myeloma, exerts substantial anti-myeloma activity as a single agent and particularly in combination with immunomodulatory drugs and it may",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0390625,
            "end_logit": -8.3984375,
            "text": "oral proteasome inhibitor to be evaluated in multiple myeloma, exerts substantial anti-myeloma activity as",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": -8.40625,
            "text": "oral proteasome inhibitor to",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": -8.40625,
            "text": "oral proteasome inhibitor to be evaluated in multiple myeloma, exerts substantial anti-myeloma activity as a single agent and particularly in combination with immunomodulatory drugs and it may",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -8.3984375,
            "text": "first oral proteasome inhibitor to be evaluated in multiple myeloma, exerts substantial anti-myeloma activity as",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -8.3984375,
            "text": ", exerts substantial anti-myeloma activity as",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -8.40625,
            "text": "first oral proteasome inhibitor to",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -8.40625,
            "text": "first oral proteasome inhibitor to be evaluated in multiple myeloma, exerts substantial anti-myeloma activity as a single agent and particularly in combination with immunomodulatory drugs and it may",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -8.40625,
            "text": ", exerts substantial anti-myeloma activity as a single agent and particularly in combination with immunomodulatory drugs and it may",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -8.40625,
            "text": "with immunomodulatory drugs and it may",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -8.3984375,
            "text": "evaluated in multiple myeloma, exerts substantial anti-myeloma activity as",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -8.40625,
            "text": "evaluated in multiple myeloma, exerts substantial anti-myeloma activity as a single agent and particularly in combination with immunomodulatory drugs and it may",
            "probability": 0.0
        }
    ],
    "589630f378275d0c4a000007_5": [
        {
            "start_logit": 8.28125,
            "end_logit": 8.4609375,
            "text": "proteasome",
            "probability": 1.0
        },
        {
            "start_logit": -7.875,
            "end_logit": 8.4609375,
            "text": "generation proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 8.4609375,
            "text": "introduction of bortezomib in 2003, several next-generation proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.15625,
            "end_logit": 8.4609375,
            "text": ", several next-generation proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 8.4609375,
            "text": "several next-generation proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.171875,
            "end_logit": 8.4609375,
            "text": "the introduction of bortezomib in 2003, several next-generation proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1875,
            "end_logit": 8.4609375,
            "text": "of bortezomib in 2003, several next-generation proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -8.296875,
            "text": "introduction of bortezomib in 2003",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -8.296875,
            "text": "the introduction of bortezomib in 2003",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -8.296875,
            "text": "of bortezomib in 2003",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -8.4375,
            "text": "introduction of bortezomib in",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -8.4375,
            "text": "the introduction of bortezomib in",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -8.4375,
            "text": "of bortezomib in",
            "probability": 0.0
        }
    ],
    "589630f378275d0c4a000007_6": [
        {
            "start_logit": 8.375,
            "end_logit": 8.3984375,
            "text": "proteasome",
            "probability": 1.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 8.3984375,
            "text": "oral proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 8.3984375,
            "text": "study was to characterize the pharmacokinetics of the oral proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.15625,
            "end_logit": 8.3984375,
            "text": "characterize the pharmacokinetics of the oral proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.171875,
            "end_logit": 8.3984375,
            "text": "the oral proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 8.3984375,
            "text": "the pharmacokinetics of the oral proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1875,
            "end_logit": 8.3984375,
            "text": "present study was to characterize the pharmacokinetics of the oral proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.375,
            "end_logit": -8.4453125,
            "text": "proteasome inhibitor, ixazomib, in patients with solid tumours",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0625,
            "end_logit": -8.4453125,
            "text": "oral proteasome inhibitor, ixazomib, in patients with solid tumours",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": -8.4453125,
            "text": "study was to characterize the pharmacokinetics of the oral proteasome inhibitor, ixazomib, in patients with solid tumours",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": -8.4453125,
            "text": ", in patients with solid tumours",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": -8.4453125,
            "text": ", ixazomib, in patients with solid tumours",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": -8.4453125,
            "text": "patients with solid tumours",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": -8.4453125,
            "text": "characterize the pharmacokinetics of the oral proteasome inhibitor, ixazomib, in patients with solid tumours",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -8.4453125,
            "text": "the oral proteasome inhibitor, ixazomib, in patients with solid tumours",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -8.4453125,
            "text": "the pharmacokinetics of the oral proteasome inhibitor, ixazomib, in patients with solid tumours",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -8.4453125,
            "text": "present study was to characterize the pharmacokinetics of the oral proteasome inhibitor, ixazomib, in patients with solid tumours",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -8.4453125,
            "text": "in patients with solid tumours",
            "probability": 0.0
        }
    ],
    "589630f378275d0c4a000007_7": [
        {
            "start_logit": 8.40625,
            "end_logit": 8.3671875,
            "text": "proteasome",
            "probability": 1.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 8.3671875,
            "text": "oral proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.40625,
            "end_logit": -8.1328125,
            "text": "proteasome inhibitor, in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.28125,
            "end_logit": 8.3671875,
            "text": "an oral proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.3671875,
            "text": ", an oral proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.40625,
            "end_logit": -8.34375,
            "text": "proteasome inhibitor, in solid tumour patients with moderate or severe hepatic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.40625,
            "end_logit": -8.359375,
            "text": "proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.40625,
            "end_logit": -8.3671875,
            "text": "proteasome inhibitor, in solid",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.359375,
            "end_logit": 8.3671875,
            "text": "ixazomib, an oral proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.359375,
            "end_logit": 8.3671875,
            "text": "of ixazomib, an oral proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3671875,
            "end_logit": 8.3671875,
            "text": "azomib, an oral proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -8.1328125,
            "text": "oral proteasome inhibitor, in",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -8.1328125,
            "text": ", in",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.1328125,
            "text": "inhibitor, in",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -8.34375,
            "text": "oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -8.359375,
            "text": "oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": -8.1328125,
            "text": "an oral proteasome inhibitor, in",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -8.3671875,
            "text": "oral proteasome inhibitor, in solid",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": -8.1328125,
            "text": ", an oral proteasome inhibitor, in",
            "probability": 0.0
        },
        {
            "start_logit": -8.359375,
            "end_logit": -8.1328125,
            "text": "ixazomib, an oral proteasome inhibitor, in",
            "probability": 0.0
        }
    ],
    "589630f378275d0c4a000007_8": [
        {
            "start_logit": 8.3671875,
            "end_logit": 8.40625,
            "text": "proteasome",
            "probability": 1.0
        },
        {
            "start_logit": -7.7890625,
            "end_logit": 8.40625,
            "text": ", proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.203125,
            "end_logit": 8.40625,
            "text": "Ixazomib is the first oral, proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.21875,
            "end_logit": 8.40625,
            "text": "oral, proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.234375,
            "end_logit": 8.40625,
            "text": "first oral, proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": 8.40625,
            "text": "is the first oral, proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 8.40625,
            "text": "azomib is the first oral, proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 8.40625,
            "text": "the first oral, proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 8.40625,
            "text": "mib is the first oral, proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3125,
            "end_logit": 8.40625,
            "text": "b is the first oral, proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3671875,
            "end_logit": -8.375,
            "text": "proteasome inhibitor to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7890625,
            "end_logit": -8.375,
            "text": ", proteasome inhibitor to",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -8.375,
            "text": "Ixazomib is the first oral, proteasome inhibitor to",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -8.375,
            "text": "inhibitor to",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -8.375,
            "text": "oral, proteasome inhibitor to",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -8.375,
            "text": "first oral, proteasome inhibitor to",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -8.375,
            "text": "is the first oral, proteasome inhibitor to",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": -8.375,
            "text": "azomib is the first oral, proteasome inhibitor to",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -8.375,
            "text": "the first oral, proteasome inhibitor to",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": -8.375,
            "text": "mib is the first oral, proteasome inhibitor to",
            "probability": 0.0
        }
    ],
    "589630f378275d0c4a000007_9": [
        {
            "start_logit": 8.3203125,
            "end_logit": 8.4296875,
            "text": "proteasome",
            "probability": 1.0
        },
        {
            "start_logit": -7.921875,
            "end_logit": 8.4296875,
            "text": "oral proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 8.4296875,
            "text": ", an oral proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.21875,
            "end_logit": 8.4296875,
            "text": "an oral proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 8.4296875,
            "text": "(ixazomib), an oral proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.296875,
            "end_logit": 8.4296875,
            "text": "b), an oral proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 8.4296875,
            "text": "), an oral proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2578125,
            "end_logit": -8.3984375,
            "text": "(ix",
            "probability": 0.0
        }
    ],
    "589630f378275d0c4a000007_10": [
        {
            "start_logit": 8.4375,
            "end_logit": 8.3203125,
            "text": "proteasome",
            "probability": 1.0
        },
        {
            "start_logit": -7.88671875,
            "end_logit": 8.3203125,
            "text": "population pharmacokinetic analysis of the investigational oral proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 8.3203125,
            "text": "analysis of the investigational oral proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.109375,
            "end_logit": 8.3203125,
            "text": "This population pharmacokinetic analysis of the investigational oral proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.140625,
            "end_logit": 8.3203125,
            "text": "oral proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.3046875,
            "text": "proteasome inhibitor ixazomib assessed the feasibility of switching from body surface area (BSA)-based to fixed dosing, and the impact of baseline covariates on ixazomib pharmacokinetics",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.203125,
            "end_logit": 8.3203125,
            "text": "investigational oral proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.34375,
            "text": "proteasome inhibitor ixazomib assessed the feasibility of switching from body surface area (BSA)-based to fixed dosing, and the impact of baseline covariates",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.3515625,
            "text": "proteasome inhibitor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.3515625,
            "text": "proteasome inhibitor ixazomib assessed the feasibility of switching from body surface area (BSA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.234375,
            "end_logit": 8.3203125,
            "text": "of the investigational oral proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.234375,
            "end_logit": 8.3203125,
            "text": "pharmacokinetic analysis of the investigational oral proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.3671875,
            "text": "proteasome inhibitor ixazomib assessed the feasibility of switching from body surface area (BSA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.390625,
            "text": "proteasome inhibitor ix",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.390625,
            "text": "proteasome inhibitor ixazomi",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.390625,
            "text": "proteasome inhibitor ixazomib assessed the feasibility of switching from body surface",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.40625,
            "text": "proteasome inhibitor ixazomib assessed the feasibility of switching from body surface area (BSA)-based to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.40625,
            "text": "proteasome inhibitor ixazomib assessed the feasibility of switching from body surface area (BSA)-based to fixed dosing, and the impact of baseline",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.40625,
            "text": "proteasome inhibitor ixazomib",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4375,
            "end_logit": -8.4140625,
            "text": "proteasome inhibitor ixazomib assessed the feasibility of switching from body surface area (BSA)-based to fixed dosing, and the impact of baseline covariates on ixazomi",
            "probability": 5.960464477539063e-08
        }
    ],
    "55201a316b348bb82c000019_1": [
        {
            "start_logit": 10.1171875,
            "end_logit": 9.765625,
            "text": "55 S",
            "probability": 1.0
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -1.3544921875,
            "text": "55",
            "probability": 1.4960765838623047e-05
        },
        {
            "start_logit": -1.5078125,
            "end_logit": 9.765625,
            "text": "S",
            "probability": 9.000301361083984e-06
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -7.64453125,
            "text": "55 S, consisting of 39 S large and 28 S small subunits.",
            "probability": 0.0
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -7.8046875,
            "text": "55 S, consisting of 39 S large and 28",
            "probability": 0.0
        },
        {
            "start_logit": -7.4609375,
            "end_logit": 9.765625,
            "text": "mitochondrial ribosome (mitoribosome) has a highly protein-rich composition with a small sedimentation coefficient of 55 S",
            "probability": 0.0
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -7.828125,
            "text": "55 S, consisting of 39 S large and",
            "probability": 0.0
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -7.828125,
            "text": "55 S, consisting of 39 S large and 28 S small subunits",
            "probability": 0.0
        },
        {
            "start_logit": -7.4765625,
            "end_logit": 9.765625,
            "text": "small sedimentation coefficient of 55 S",
            "probability": 0.0
        },
        {
            "start_logit": -7.6171875,
            "end_logit": 9.765625,
            "text": "sedimentation coefficient of 55 S",
            "probability": 0.0
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -7.9765625,
            "text": "55 S, consisting of 39 S large and 28 S",
            "probability": 0.0
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -8.015625,
            "text": "55 S, consisting of 39 S large and 28 S small",
            "probability": 0.0
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -8.03125,
            "text": "55 S, consisting",
            "probability": 0.0
        },
        {
            "start_logit": 10.1171875,
            "end_logit": -8.03125,
            "text": "55 S, consisting of 39 S",
            "probability": 0.0
        },
        {
            "start_logit": -7.828125,
            "end_logit": 9.765625,
            "text": "of 55 S",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 9.765625,
            "text": "The mammalian mitochondrial ribosome (mitoribosome) has a highly protein-rich composition with a small sedimentation coefficient of 55 S",
            "probability": 0.0
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 9.765625,
            "text": "a small sedimentation coefficient of 55 S",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.765625,
            "text": "ribosome (mitoribosome) has a highly protein-rich composition with a small sedimentation coefficient of 55 S",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.765625,
            "text": "mitoribosome) has a highly protein-rich composition with a small sedimentation coefficient of 55 S",
            "probability": 0.0
        },
        {
            "start_logit": -7.4609375,
            "end_logit": -1.3544921875,
            "text": "mitochondrial ribosome (mitoribosome) has a highly protein-rich composition with a small sedimentation coefficient of 55",
            "probability": 0.0
        }
    ],
    "55201a316b348bb82c000019_2": [
        {
            "start_logit": 10.1328125,
            "end_logit": 9.7890625,
            "text": "55 S",
            "probability": 1.0
        },
        {
            "start_logit": 10.1328125,
            "end_logit": -1.34375,
            "text": "55",
            "probability": 1.4603137969970703e-05
        },
        {
            "start_logit": -1.4736328125,
            "end_logit": 9.7890625,
            "text": "S",
            "probability": 9.059906005859375e-06
        },
        {
            "start_logit": 10.1328125,
            "end_logit": -7.92578125,
            "text": "55 S mammalian mitochondrial ribosome",
            "probability": 0.0
        },
        {
            "start_logit": 10.1328125,
            "end_logit": -7.98828125,
            "text": "55 S mammalian mitochondrial ribosome (referred to hereafter as \"mitoribosome\") is",
            "probability": 0.0
        },
        {
            "start_logit": 10.1328125,
            "end_logit": -8.046875,
            "text": "55 S mammalian mitochondrial ribosome (referred to hereafter as \"mitoribosome\") is protein-rich, containing nearly twice as much protein as the Escherichia coli ribosome",
            "probability": 0.0
        },
        {
            "start_logit": 10.1328125,
            "end_logit": -8.046875,
            "text": "55 S mammalian mitochondrial ribosome (referred to hereafter as \"mitoribosome\")",
            "probability": 0.0
        },
        {
            "start_logit": 10.1328125,
            "end_logit": -8.0859375,
            "text": "55 S mammalian mitochondrial ribosome (referred to hereafter as \"mitoribos",
            "probability": 0.0
        },
        {
            "start_logit": 10.1328125,
            "end_logit": -8.1015625,
            "text": "55 S mammalian mitochondrial ribosome (referred to hereafter as \"mitoribosome",
            "probability": 0.0
        },
        {
            "start_logit": 10.1328125,
            "end_logit": -8.109375,
            "text": "55 S mammalian mitochondrial ribosome (referred to hereafter as \"mitoribosome\") is protein",
            "probability": 0.0
        },
        {
            "start_logit": 10.1328125,
            "end_logit": -8.1171875,
            "text": "55 S mammalian mitochondrial ribosome (referred to hereafter as \"mitori",
            "probability": 0.0
        },
        {
            "start_logit": 10.1328125,
            "end_logit": -8.1328125,
            "text": "55 S mammalian mitochondrial ribosome (referred to hereafter as \"mitoribosome\") is protein-rich, containing nearly twice as much protein as",
            "probability": 0.0
        },
        {
            "start_logit": 10.1328125,
            "end_logit": -8.1484375,
            "text": "55 S mammalian mitochondrial ribosome (referred to hereafter as \"mitoribosome\") is protein-",
            "probability": 0.0
        },
        {
            "start_logit": 10.1328125,
            "end_logit": -8.15625,
            "text": "55 S mammalian mitochondrial ribosome (referred to hereafter as \"mitoribosome\") is protein-rich",
            "probability": 0.0
        },
        {
            "start_logit": 10.1328125,
            "end_logit": -8.171875,
            "text": "55 S mammalian mitochondrial ribosome (referred to hereafter as \"mitoribosome\") is protein-rich, containing nearly twice as much protein as the Escherichia coli ribosome.",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 9.7890625,
            "text": "The 55 S",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": -1.34375,
            "text": "The 55",
            "probability": 0.0
        },
        {
            "start_logit": -1.4736328125,
            "end_logit": -7.92578125,
            "text": "S mammalian mitochondrial ribosome",
            "probability": 0.0
        },
        {
            "start_logit": -1.4736328125,
            "end_logit": -7.98828125,
            "text": "S mammalian mitochondrial ribosome (referred to hereafter as \"mitoribosome\") is",
            "probability": 0.0
        },
        {
            "start_logit": -1.4736328125,
            "end_logit": -8.046875,
            "text": "S mammalian mitochondrial ribosome (referred to hereafter as \"mitoribosome\") is protein-rich, containing nearly twice as much protein as the Escherichia coli ribosome",
            "probability": 0.0
        }
    ],
    "55201a316b348bb82c000019_3": [
        {
            "start_logit": 10.0390625,
            "end_logit": 9.6484375,
            "text": "55 S",
            "probability": 1.0
        },
        {
            "start_logit": 10.0390625,
            "end_logit": -1.6298828125,
            "text": "55",
            "probability": 1.2636184692382812e-05
        },
        {
            "start_logit": -1.8515625,
            "end_logit": 9.6484375,
            "text": "S",
            "probability": 6.854534149169922e-06
        },
        {
            "start_logit": -7.18359375,
            "end_logit": 9.6484375,
            "text": "The sedimentation coefficient of the intact monosome was about 55 S",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.703125,
            "end_logit": 9.6484375,
            "text": "about 55 S",
            "probability": 0.0
        },
        {
            "start_logit": -7.7421875,
            "end_logit": 9.6484375,
            "text": "sedimentation coefficient of the intact monosome was about 55 S",
            "probability": 0.0
        },
        {
            "start_logit": -7.84375,
            "end_logit": 9.6484375,
            "text": "ome was about 55 S",
            "probability": 0.0
        },
        {
            "start_logit": -7.88671875,
            "end_logit": 9.6484375,
            "text": "intact monosome was about 55 S",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 9.6484375,
            "text": "the intact monosome was about 55 S",
            "probability": 0.0
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 9.6484375,
            "text": "monosome was about 55 S",
            "probability": 0.0
        },
        {
            "start_logit": -7.18359375,
            "end_logit": -1.6298828125,
            "text": "The sedimentation coefficient of the intact monosome was about 55",
            "probability": 0.0
        },
        {
            "start_logit": -7.703125,
            "end_logit": -1.6298828125,
            "text": "about 55",
            "probability": 0.0
        },
        {
            "start_logit": -7.7421875,
            "end_logit": -1.6298828125,
            "text": "sedimentation coefficient of the intact monosome was about 55",
            "probability": 0.0
        },
        {
            "start_logit": -7.84375,
            "end_logit": -1.6298828125,
            "text": "ome was about 55",
            "probability": 0.0
        },
        {
            "start_logit": -7.88671875,
            "end_logit": -1.6298828125,
            "text": "intact monosome was about 55",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": -1.6298828125,
            "text": "the intact monosome was about 55",
            "probability": 0.0
        },
        {
            "start_logit": -7.97265625,
            "end_logit": -1.6298828125,
            "text": "monosome was about 55",
            "probability": 0.0
        },
        {
            "start_logit": -7.18359375,
            "end_logit": -7.93359375,
            "text": "The sedimentation coefficient",
            "probability": 0.0
        },
        {
            "start_logit": -7.18359375,
            "end_logit": -8.140625,
            "text": "The sedimentation coefficient of the intact monosome was",
            "probability": 0.0
        },
        {
            "start_logit": -7.18359375,
            "end_logit": -8.2578125,
            "text": "The sedimentation coefficient of",
            "probability": 0.0
        }
    ],
    "5e2a1096aa19d7443100000e_1": [
        {
            "start_logit": 9.03125,
            "end_logit": 7.70703125,
            "text": "mRNA",
            "probability": 1.0
        },
        {
            "start_logit": 9.03125,
            "end_logit": -8.0703125,
            "text": "mRNA encoding vascular endothelial growth factor A (VEGF-A), in vivo",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.03125,
            "end_logit": -8.125,
            "text": "mRNA encoding vascular endothelial growth factor A (VEGF",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.03125,
            "end_logit": -8.1328125,
            "text": "mRNA encoding vascular endothelial growth factor A (VEGF-A)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.03125,
            "end_logit": -8.2109375,
            "text": "mRNA encoding vascular endothelial growth factor A",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.03125,
            "end_logit": -8.2109375,
            "text": "mRNA encoding vascular endothelial growth factor A (VEGF-A), in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.03125,
            "end_logit": -8.234375,
            "text": "mRNA encoding vascular endothelial growth factor",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.03125,
            "end_logit": -8.234375,
            "text": "mRNA encoding vascular endothelial",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.03125,
            "end_logit": -8.25,
            "text": "mRNA encoding vascular endothelial growth factor A (VEGF-A",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.03125,
            "end_logit": -8.2734375,
            "text": "mRNA encoding vascular endothelial growth",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 7.70703125,
            "text": "modified mRNA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 7.70703125,
            "text": "to AZD8601, a modified mRNA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.359375,
            "end_logit": 7.70703125,
            "text": "a modified mRNA",
            "probability": 0.0
        },
        {
            "start_logit": -8.375,
            "end_logit": 7.70703125,
            "text": "Here, we longitudinally and comprehensively characterize microvascular responses to AZD8601, a modified mRNA",
            "probability": 0.0
        },
        {
            "start_logit": -8.375,
            "end_logit": 7.70703125,
            "text": ", a modified mRNA",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": 7.70703125,
            "text": "we longitudinally and comprehensively characterize microvascular responses to AZD8601, a modified mRNA",
            "probability": 0.0
        },
        {
            "start_logit": -8.3984375,
            "end_logit": 7.70703125,
            "text": "AZD8601, a modified mRNA",
            "probability": 0.0
        },
        {
            "start_logit": -8.4140625,
            "end_logit": 7.70703125,
            "text": "microvascular responses to AZD8601, a modified mRNA",
            "probability": 0.0
        },
        {
            "start_logit": -8.4140625,
            "end_logit": 7.70703125,
            "text": "characterize microvascular responses to AZD8601, a modified mRNA",
            "probability": 0.0
        },
        {
            "start_logit": -8.4140625,
            "end_logit": 7.70703125,
            "text": ", we longitudinally and comprehensively characterize microvascular responses to AZD8601, a modified mRNA",
            "probability": 0.0
        }
    ],
    "5caa0247ecadf2e73f000055_1": [
        {
            "start_logit": 10.25,
            "end_logit": 10.1328125,
            "text": "of moesin (Mo",
            "probability": 1.0
        },
        {
            "start_logit": -0.1597900390625,
            "end_logit": 10.1328125,
            "text": "Mo",
            "probability": 3.045797348022461e-05
        },
        {
            "start_logit": 10.25,
            "end_logit": -0.94384765625,
            "text": "of",
            "probability": 1.5556812286376953e-05
        },
        {
            "start_logit": 10.25,
            "end_logit": -4.17578125,
            "text": "of moesin (Moe",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 10.25,
            "end_logit": -4.59375,
            "text": "of moesin (",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 10.25,
            "end_logit": -4.69921875,
            "text": "of moesin (Moe)",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 10.25,
            "end_logit": -5.8984375,
            "text": "of moesin (Moe).",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.25,
            "end_logit": -6.234375,
            "text": "of mo",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.25,
            "end_logit": -6.2421875,
            "text": "of moesin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.30078125,
            "end_logit": 10.1328125,
            "text": "(Mo",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.62890625,
            "end_logit": 10.1328125,
            "text": "recruitment of moesin (Mo",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.66796875,
            "end_logit": 10.1328125,
            "text": "moesin (Mo",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.83203125,
            "end_logit": 10.1328125,
            "text": "by Crb recruitment of moesin (Mo",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.01171875,
            "end_logit": 10.1328125,
            "text": "esin (Mo",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.09375,
            "end_logit": 10.1328125,
            "text": "Crb, acting in parallel with the epidermal growth factor receptor (Egfr) pathway, is required for tracheal cell apical constriction and for organising an actomyosin complex, which we propose is mediated by Crb recruitment of moesin (Mo",
            "probability": 0.0
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 10.1328125,
            "text": "apical constriction and for organising an actomyosin complex, which we propose is mediated by Crb recruitment of moesin (Mo",
            "probability": 0.0
        },
        {
            "start_logit": -7.5546875,
            "end_logit": 10.1328125,
            "text": "propose is mediated by Crb recruitment of moesin (Mo",
            "probability": 0.0
        },
        {
            "start_logit": -7.5546875,
            "end_logit": 10.1328125,
            "text": "tracheal cell apical constriction and for organising an actomyosin complex, which we propose is mediated by Crb recruitment of moesin (Mo",
            "probability": 0.0
        },
        {
            "start_logit": -7.5546875,
            "end_logit": 10.1328125,
            "text": ", acting in parallel with the epidermal growth factor receptor (Egfr) pathway, is required for tracheal cell apical constriction and for organising an actomyosin complex, which we propose is mediated by Crb recruitment of moesin (Mo",
            "probability": 0.0
        },
        {
            "start_logit": -7.55859375,
            "end_logit": 10.1328125,
            "text": "in parallel with the epidermal growth factor receptor (Egfr) pathway, is required for tracheal cell apical constriction and for organising an actomyosin complex, which we propose is mediated by Crb recruitment of moesin (Mo",
            "probability": 0.0
        }
    ],
    "5e4604d83f54159529000003_1": [
        {
            "start_logit": 10.0,
            "end_logit": 9.5625,
            "text": "carotid and vertebral artery dissection",
            "probability": 1.0
        },
        {
            "start_logit": 10.0,
            "end_logit": -1.8916015625,
            "text": "carotid",
            "probability": 1.0609626770019531e-05
        },
        {
            "start_logit": -2.212890625,
            "end_logit": 9.5625,
            "text": "dissection",
            "probability": 4.947185516357422e-06
        },
        {
            "start_logit": -6.3125,
            "end_logit": 9.5625,
            "text": ") carotid and vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.828125,
            "end_logit": 9.5625,
            "text": "and vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.89453125,
            "end_logit": 9.5625,
            "text": "artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0,
            "end_logit": -7.56640625,
            "text": "carotid and vertebral artery",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.140625,
            "end_logit": 9.5625,
            "text": "vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0,
            "end_logit": -8.0859375,
            "text": "carotid and vertebral",
            "probability": 0.0
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 9.5625,
            "text": "(within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -7.96875,
            "end_logit": 9.5625,
            "text": "within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 9.5625,
            "text": "acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.5625,
            "text": "in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 9.5625,
            "text": "7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 9.5625,
            "text": "multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.5625,
            "text": "days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.5625,
            "text": "prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.5625,
            "text": "trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.5625,
            "text": "CADISS is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -6.3125,
            "end_logit": -1.8916015625,
            "text": ") carotid",
            "probability": 0.0
        }
    ],
    "5e4604d83f54159529000003_2": [
        {
            "start_logit": 10.0078125,
            "end_logit": 9.578125,
            "text": "carotid and vertebral artery dissection",
            "probability": 1.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -1.8662109375,
            "text": "carotid",
            "probability": 1.0609626770019531e-05
        },
        {
            "start_logit": -2.181640625,
            "end_logit": 9.578125,
            "text": "dissection",
            "probability": 5.066394805908203e-06
        },
        {
            "start_logit": -6.22265625,
            "end_logit": 9.578125,
            "text": ") carotid and vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.75390625,
            "end_logit": 9.578125,
            "text": "and vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.8515625,
            "end_logit": 9.578125,
            "text": "artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.015625,
            "end_logit": 9.578125,
            "text": "vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -7.59375,
            "text": "carotid and vertebral artery",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.09375,
            "text": "carotid and vertebral",
            "probability": 0.0
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 9.578125,
            "text": "(within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -7.96875,
            "end_logit": 9.578125,
            "text": "within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.578125,
            "text": "acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.578125,
            "text": "in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.578125,
            "text": "7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.578125,
            "text": "multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.578125,
            "text": "prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.578125,
            "text": "trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.578125,
            "text": "days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.578125,
            "text": "CADISS is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -6.22265625,
            "end_logit": -1.8662109375,
            "text": ") carotid",
            "probability": 0.0
        }
    ],
    "5e4604d83f54159529000003_3": [
        {
            "start_logit": 10.0078125,
            "end_logit": 9.578125,
            "text": "carotid and vertebral artery dissection",
            "probability": 1.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -1.8662109375,
            "text": "carotid",
            "probability": 1.0609626770019531e-05
        },
        {
            "start_logit": -2.181640625,
            "end_logit": 9.578125,
            "text": "dissection",
            "probability": 5.066394805908203e-06
        },
        {
            "start_logit": -6.22265625,
            "end_logit": 9.578125,
            "text": ") carotid and vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.75390625,
            "end_logit": 9.578125,
            "text": "and vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.8515625,
            "end_logit": 9.578125,
            "text": "artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.015625,
            "end_logit": 9.578125,
            "text": "vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -7.59375,
            "text": "carotid and vertebral artery",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.09375,
            "text": "carotid and vertebral",
            "probability": 0.0
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 9.578125,
            "text": "(within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -7.96875,
            "end_logit": 9.578125,
            "text": "within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.578125,
            "text": "acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.578125,
            "text": "in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.578125,
            "text": "7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.578125,
            "text": "multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.578125,
            "text": "prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.578125,
            "text": "trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.578125,
            "text": "days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.578125,
            "text": "CADISS is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -6.22265625,
            "end_logit": -1.8662109375,
            "text": ") carotid",
            "probability": 0.0
        }
    ],
    "5e4604d83f54159529000003_4": [
        {
            "start_logit": 10.0078125,
            "end_logit": 9.578125,
            "text": "carotid and vertebral artery dissection",
            "probability": 1.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -1.8662109375,
            "text": "carotid",
            "probability": 1.0609626770019531e-05
        },
        {
            "start_logit": -2.181640625,
            "end_logit": 9.578125,
            "text": "dissection",
            "probability": 5.066394805908203e-06
        },
        {
            "start_logit": -6.22265625,
            "end_logit": 9.578125,
            "text": ") carotid and vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.75390625,
            "end_logit": 9.578125,
            "text": "and vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.8515625,
            "end_logit": 9.578125,
            "text": "artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.015625,
            "end_logit": 9.578125,
            "text": "vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -7.59375,
            "text": "carotid and vertebral artery",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.09375,
            "text": "carotid and vertebral",
            "probability": 0.0
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 9.578125,
            "text": "(within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -7.96875,
            "end_logit": 9.578125,
            "text": "within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.578125,
            "text": "acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.578125,
            "text": "in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.578125,
            "text": "7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.578125,
            "text": "multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.578125,
            "text": "prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.578125,
            "text": "trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.578125,
            "text": "days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.578125,
            "text": "CADISS is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -6.22265625,
            "end_logit": -1.8662109375,
            "text": ") carotid",
            "probability": 0.0
        }
    ],
    "5e4604d83f54159529000003_5": [
        {
            "start_logit": 9.9921875,
            "end_logit": 9.625,
            "text": "carotid and vertebral artery dissection",
            "probability": 1.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -1.9033203125,
            "text": "carotid",
            "probability": 9.715557098388672e-06
        },
        {
            "start_logit": -2.076171875,
            "end_logit": 9.625,
            "text": "dissection",
            "probability": 5.662441253662109e-06
        },
        {
            "start_logit": -6.15625,
            "end_logit": 9.625,
            "text": ") carotid and vertebral artery dissection",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.67578125,
            "end_logit": 9.625,
            "text": "and vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -7.25,
            "text": "carotid and vertebral artery",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.94921875,
            "end_logit": 9.625,
            "text": "vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.015625,
            "end_logit": 9.625,
            "text": "artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -7.875,
            "text": "carotid and vertebral",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.3125,
            "text": "carotid and",
            "probability": 0.0
        },
        {
            "start_logit": -7.96875,
            "end_logit": 9.625,
            "text": "(within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 9.625,
            "text": "acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 9.625,
            "text": "within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 9.625,
            "text": "in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.625,
            "text": "CADISS is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 9.625,
            "text": "7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.625,
            "text": "multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.625,
            "text": "trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.625,
            "text": "prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.625,
            "text": "days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        }
    ],
    "56c073fcef6e394741000020_1": [
        {
            "start_logit": 10.125,
            "end_logit": 9.890625,
            "text": "Spermidine protects against \u03b1-synuclein neurotoxicity",
            "probability": 1.0
        },
        {
            "start_logit": -1.1318359375,
            "end_logit": 9.890625,
            "text": "neurotoxicity",
            "probability": 1.2934207916259766e-05
        },
        {
            "start_logit": 10.125,
            "end_logit": -1.498046875,
            "text": "Spermidine",
            "probability": 1.1324882507324219e-05
        },
        {
            "start_logit": 10.125,
            "end_logit": -3.291015625,
            "text": "Spermidine protects against \u03b1-synuclein neurotoxicity.",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": 10.125,
            "end_logit": -5.984375,
            "text": "Spermidine protects against \u03b1-synuclein",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.41015625,
            "end_logit": 9.890625,
            "text": "against \u03b1-synuclein neurotoxicity",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.125,
            "end_logit": -7.33984375,
            "text": "Spermidine protects",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.13671875,
            "end_logit": 9.890625,
            "text": "protects against \u03b1-synuclein neurotoxicity",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.2734375,
            "end_logit": 9.890625,
            "text": "\u03b1-synuclein neurotoxicity",
            "probability": 0.0
        },
        {
            "start_logit": 10.125,
            "end_logit": -7.57421875,
            "text": "Spermidine protects against \u03b1",
            "probability": 0.0
        },
        {
            "start_logit": 10.125,
            "end_logit": -7.69140625,
            "text": "Spermidine protects against",
            "probability": 0.0
        },
        {
            "start_logit": 10.125,
            "end_logit": -7.7421875,
            "text": "Spermidine protects against \u03b1-",
            "probability": 0.0
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 9.890625,
            "text": "-synuclein neurotoxicity",
            "probability": 0.0
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 9.890625,
            "text": "synuclein neurotoxicity",
            "probability": 0.0
        },
        {
            "start_logit": -1.1318359375,
            "end_logit": -3.291015625,
            "text": "neurotoxicity.",
            "probability": 0.0
        },
        {
            "start_logit": -5.18359375,
            "end_logit": -3.291015625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.41015625,
            "end_logit": -3.291015625,
            "text": "against \u03b1-synuclein neurotoxicity.",
            "probability": 0.0
        },
        {
            "start_logit": -7.13671875,
            "end_logit": -3.291015625,
            "text": "protects against \u03b1-synuclein neurotoxicity.",
            "probability": 0.0
        },
        {
            "start_logit": -7.2734375,
            "end_logit": -3.291015625,
            "text": "\u03b1-synuclein neurotoxicity.",
            "probability": 0.0
        },
        {
            "start_logit": -7.57421875,
            "end_logit": -3.291015625,
            "text": "-synuclein neurotoxicity.",
            "probability": 0.0
        }
    ],
    "56c073fcef6e394741000020_2": [
        {
            "start_logit": 9.984375,
            "end_logit": 9.7890625,
            "text": "Spermidine protects against \u03b1-synuclein neurotoxicity",
            "probability": 1.0
        },
        {
            "start_logit": -1.455078125,
            "end_logit": 9.7890625,
            "text": "neurotoxicity",
            "probability": 1.0728836059570312e-05
        },
        {
            "start_logit": 9.984375,
            "end_logit": -1.810546875,
            "text": "Spermidine",
            "probability": 9.059906005859375e-06
        },
        {
            "start_logit": -6.3359375,
            "end_logit": 9.7890625,
            "text": "against \u03b1-synuclein neurotoxicity",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.70703125,
            "end_logit": 9.7890625,
            "text": "protects against \u03b1-synuclein neurotoxicity",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.984375,
            "end_logit": -7.109375,
            "text": "Spermidine protects against \u03b1-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.921875,
            "end_logit": 9.7890625,
            "text": "\u03b1-synuclein neurotoxicity",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.43359375,
            "end_logit": 9.7890625,
            "text": "synuclein neurotoxicity",
            "probability": 0.0
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 9.7890625,
            "text": "-synuclein neurotoxicity",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -7.9609375,
            "text": "Spermidine protects against \u03b1-",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -7.98828125,
            "text": "Spermidine protects against \u03b1",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.09375,
            "text": "Spermidine protects",
            "probability": 0.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -8.125,
            "text": "Spermidine protects against",
            "probability": 0.0
        },
        {
            "start_logit": -6.3359375,
            "end_logit": -7.109375,
            "text": "against \u03b1-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -6.70703125,
            "end_logit": -7.109375,
            "text": "protects against \u03b1-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -6.921875,
            "end_logit": -7.109375,
            "text": "\u03b1-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -6.3359375,
            "end_logit": -7.9609375,
            "text": "against \u03b1-",
            "probability": 0.0
        },
        {
            "start_logit": -6.3359375,
            "end_logit": -7.98828125,
            "text": "against \u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -6.3359375,
            "end_logit": -8.125,
            "text": "against",
            "probability": 0.0
        },
        {
            "start_logit": -7.43359375,
            "end_logit": -7.109375,
            "text": "synuclein",
            "probability": 0.0
        }
    ],
    "606074ab94d57fd87900003e_1": [
        {
            "start_logit": 9.953125,
            "end_logit": 9.453125,
            "text": "Rtpca",
            "probability": 1.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -1.94140625,
            "text": "Rt",
            "probability": 1.1324882507324219e-05
        },
        {
            "start_logit": -2.455078125,
            "end_logit": 9.453125,
            "text": "a",
            "probability": 4.112720489501953e-06
        },
        {
            "start_logit": -6.19921875,
            "end_logit": 9.453125,
            "text": "pca",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.953125,
            "end_logit": -7.82421875,
            "text": "Rtpc",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.125,
            "text": "Rtpca: an R package",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.171875,
            "text": "Rtpca: an R",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.21875,
            "text": "Rtpca: an",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.2890625,
            "text": "Rtpca: an R package for differential thermal proximity coaggregation",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.2890625,
            "text": "Rtpca:",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.3046875,
            "text": "Rtpca: an R package for differential thermal proximity coag",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.3359375,
            "text": "Rtpca: an R package for differential thermal proximity coaggr",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.3359375,
            "text": "Rtpca: an R package for differential thermal proximity coaggreg",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.34375,
            "text": "Rtpca: an R package for differential thermal proximity coaggregation analysis",
            "probability": 0.0
        },
        {
            "start_logit": -2.455078125,
            "end_logit": -8.125,
            "text": "a: an R package",
            "probability": 0.0
        },
        {
            "start_logit": -2.455078125,
            "end_logit": -8.171875,
            "text": "a: an R",
            "probability": 0.0
        },
        {
            "start_logit": -2.455078125,
            "end_logit": -8.21875,
            "text": "a: an",
            "probability": 0.0
        },
        {
            "start_logit": -2.455078125,
            "end_logit": -8.2890625,
            "text": "a: an R package for differential thermal proximity coaggregation",
            "probability": 0.0
        },
        {
            "start_logit": -2.455078125,
            "end_logit": -8.2890625,
            "text": "a:",
            "probability": 0.0
        },
        {
            "start_logit": -2.455078125,
            "end_logit": -8.3046875,
            "text": "a: an R package for differential thermal proximity coag",
            "probability": 0.0
        }
    ],
    "606074ab94d57fd87900003e_2": [
        {
            "start_logit": 9.9921875,
            "end_logit": 9.578125,
            "text": "Rtpca",
            "probability": 1.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -1.873046875,
            "text": "Rt",
            "probability": 1.0728836059570312e-05
        },
        {
            "start_logit": -2.1796875,
            "end_logit": 9.578125,
            "text": "a",
            "probability": 5.185604095458984e-06
        },
        {
            "start_logit": -6.09375,
            "end_logit": 9.578125,
            "text": "pca",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -7.7578125,
            "text": "Rtpc",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.2734375,
            "text": "Rtpca is an R package",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.2734375,
            "text": "Rtpca is an R",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.2890625,
            "text": "Rtpca is an",
            "probability": 0.0
        },
        {
            "start_logit": 9.9921875,
            "end_logit": -8.3046875,
            "text": "Rtpca is",
            "probability": 0.0
        },
        {
            "start_logit": -2.1796875,
            "end_logit": -8.2734375,
            "text": "a is an R package",
            "probability": 0.0
        },
        {
            "start_logit": -2.1796875,
            "end_logit": -8.2734375,
            "text": "a is an R",
            "probability": 0.0
        },
        {
            "start_logit": -2.1796875,
            "end_logit": -8.2890625,
            "text": "a is an",
            "probability": 0.0
        },
        {
            "start_logit": -2.1796875,
            "end_logit": -8.3046875,
            "text": "a is",
            "probability": 0.0
        },
        {
            "start_logit": -6.09375,
            "end_logit": -7.7578125,
            "text": "pc",
            "probability": 0.0
        },
        {
            "start_logit": -6.09375,
            "end_logit": -8.2734375,
            "text": "pca is an R package",
            "probability": 0.0
        },
        {
            "start_logit": -6.09375,
            "end_logit": -8.2734375,
            "text": "pca is an R",
            "probability": 0.0
        },
        {
            "start_logit": -6.09375,
            "end_logit": -8.2890625,
            "text": "pca is an",
            "probability": 0.0
        },
        {
            "start_logit": -6.09375,
            "end_logit": -8.3046875,
            "text": "pca is",
            "probability": 0.0
        },
        {
            "start_logit": -6.56640625,
            "end_logit": -8.2265625,
            "text": ". It offers user-friendly tools to explore datasets for their protein-protein interaction predictive performance and easily integrates with available R packages.AVAILABILITY: Rtpca is available from Bioconductor",
            "probability": 0.0
        },
        {
            "start_logit": -6.56640625,
            "end_logit": -8.2734375,
            "text": ". It offers user-friendly tools to explore datasets for their protein-protein interaction predictive performance and easily integrates with available R packages.AVAILABILITY: Rtpca is available from Bioconductor (https://bioconductor",
            "probability": 0.0
        }
    ],
    "513ce494bee46bd34c000009_1": [
        {
            "start_logit": 10.0859375,
            "end_logit": 9.640625,
            "text": "polycystic kidney disease (PKD)",
            "probability": 1.0
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -1.6357421875,
            "text": "polycystic",
            "probability": 1.2814998626708984e-05
        },
        {
            "start_logit": -2.05078125,
            "end_logit": 9.640625,
            "text": ")",
            "probability": 5.424022674560547e-06
        },
        {
            "start_logit": -5.33984375,
            "end_logit": 9.640625,
            "text": "(PKD)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.05078125,
            "end_logit": 9.640625,
            "text": "recessive polycystic kidney disease (PKD)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.1171875,
            "end_logit": 9.640625,
            "text": "kidney disease (PKD)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -6.7265625,
            "text": "polycystic kidney disease (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.48828125,
            "end_logit": 9.640625,
            "text": "disease (PKD)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.69921875,
            "end_logit": 9.640625,
            "text": "D)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.76171875,
            "end_logit": 9.640625,
            "text": "PKD)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -7.69921875,
            "text": "polycystic kidney disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -8.0,
            "text": "polycystic kidney disease (PK",
            "probability": 0.0
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -8.2265625,
            "text": "polycystic kidney",
            "probability": 0.0
        },
        {
            "start_logit": -7.82421875,
            "end_logit": 9.640625,
            "text": "of autosomal recessive polycystic kidney disease (PKD)",
            "probability": 0.0
        },
        {
            "start_logit": -7.92578125,
            "end_logit": 9.640625,
            "text": "development of autosomal recessive polycystic kidney disease (PKD)",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 9.640625,
            "text": "in the collecting ducts of kidney tubules this is accompanied by development of autosomal recessive polycystic kidney disease (PKD)",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 9.640625,
            "text": "of kidney tubules this is accompanied by development of autosomal recessive polycystic kidney disease (PKD)",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.640625,
            "text": "accompanied by development of autosomal recessive polycystic kidney disease (PKD)",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 9.640625,
            "text": "by development of autosomal recessive polycystic kidney disease (PKD)",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.640625,
            "text": "is accompanied by development of autosomal recessive polycystic kidney disease (PKD)",
            "probability": 0.0
        }
    ],
    "5a885daa61bb38fb24000018_1": [
        {
            "start_logit": 10.328125,
            "end_logit": 9.6875,
            "text": "Asp(D)-Glu-(E)-Ala(A)-Asp(D)",
            "probability": 1.0
        },
        {
            "start_logit": 10.328125,
            "end_logit": -0.89208984375,
            "text": "Asp",
            "probability": 2.5451183319091797e-05
        },
        {
            "start_logit": -1.853515625,
            "end_logit": 9.6875,
            "text": ")",
            "probability": 5.125999450683594e-06
        },
        {
            "start_logit": -5.203125,
            "end_logit": 9.6875,
            "text": "including Asp(D)-Glu-(E)-Ala(A)-Asp(D)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 10.328125,
            "end_logit": -6.92578125,
            "text": "Asp(D)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.328125,
            "end_logit": -6.953125,
            "text": "Asp(D)-Glu-(E)-Ala(A)-Asp(D",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.328125,
            "end_logit": -7.01953125,
            "text": "Asp(D)-Glu-(E)-Ala(A)-Asp(D) which is part of a more extended motif",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.328125,
            "end_logit": -7.05078125,
            "text": "Asp(D)-Glu-(E)-Ala(A)-Asp",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.5859375,
            "end_logit": 9.6875,
            "text": ". These proteins share eight conserved amino acid motifs, including Asp(D)-Glu-(E)-Ala(A)-Asp(D)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.62109375,
            "end_logit": 9.6875,
            "text": "-Asp(D)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.328125,
            "end_logit": -7.41015625,
            "text": "Asp(D)-Glu-(E)-Ala(A)-Asp(D) which is part",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.328125,
            "end_logit": -7.41015625,
            "text": "Asp(D",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.328125,
            "end_logit": -7.55859375,
            "text": "Asp(D)-Glu",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.328125,
            "end_logit": -7.625,
            "text": "Asp(D)-Glu-(E)-Ala(A)-Asp(D) which is part of a more extended motif.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.328125,
            "end_logit": -7.671875,
            "text": "Asp(D)-Glu-(E)-Ala(A)",
            "probability": 0.0
        },
        {
            "start_logit": -7.05078125,
            "end_logit": 9.6875,
            "text": "D)-Glu-(E)-Ala(A)-Asp(D)",
            "probability": 0.0
        },
        {
            "start_logit": 10.328125,
            "end_logit": -7.71484375,
            "text": "Asp(D)-Glu-(E)-Ala(A)-Asp(D) which",
            "probability": 0.0
        },
        {
            "start_logit": -7.21875,
            "end_logit": 9.6875,
            "text": "-Glu-(E)-Ala(A)-Asp(D)",
            "probability": 0.0
        },
        {
            "start_logit": 10.328125,
            "end_logit": -7.890625,
            "text": "Asp(D)-Glu-(E)-Ala(A)-Asp(D) which is part of a",
            "probability": 0.0
        },
        {
            "start_logit": -7.2578125,
            "end_logit": 9.6875,
            "text": "(D)-Glu-(E)-Ala(A)-Asp(D)",
            "probability": 0.0
        }
    ],
    "52b2e409f828ad283c00000e_1": [
        {
            "start_logit": 8.8984375,
            "end_logit": 7.859375,
            "text": "schizophrenia",
            "probability": 1.0
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -8.0078125,
            "text": "schizophrenia in Canada",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -8.28125,
            "text": "schizophrenia in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -8.3125,
            "text": "schizophrenia in Canada from",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -8.3125,
            "text": "schizophrenia in Canada from 2005",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -8.3203125,
            "text": "schizophrenia in Canada from 2005 to",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -8.3359375,
            "text": "schizophrenia in Canada from 2005 to 2009",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.80078125,
            "end_logit": 7.859375,
            "text": "with schizophrenia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 7.859375,
            "text": "adults with schizophrenia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 7.859375,
            "text": "To describe the frequency and trends in the use of antipsychotics for adults with schizophrenia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 7.859375,
            "text": "describe the frequency and trends in the use of antipsychotics for adults with schizophrenia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.21875,
            "end_logit": 7.859375,
            "text": "use of antipsychotics for adults with schizophrenia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.234375,
            "end_logit": 7.859375,
            "text": "frequency and trends in the use of antipsychotics for adults with schizophrenia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.234375,
            "end_logit": 7.859375,
            "text": "for adults with schizophrenia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.25,
            "end_logit": 7.859375,
            "text": "in the use of antipsychotics for adults with schizophrenia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 7.859375,
            "text": "antipsychotics for adults with schizophrenia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 7.859375,
            "text": "of antipsychotics for adults with schizophrenia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 7.859375,
            "text": "the use of antipsychotics for adults with schizophrenia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 7.859375,
            "text": "trends in the use of antipsychotics for adults with schizophrenia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.80078125,
            "end_logit": -8.0078125,
            "text": "with schizophrenia in Canada",
            "probability": 0.0
        }
    ],
    "52b2e409f828ad283c00000e_2": [
        {
            "start_logit": 8.90625,
            "end_logit": 7.828125,
            "text": "schizophrenia",
            "probability": 1.0
        },
        {
            "start_logit": 8.90625,
            "end_logit": -7.95703125,
            "text": "schizophrenia was listed as the indication. RESULTS: First-generation antipsychotic (FGA) recommendations for adults with schizophrenia increased by 38",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -7.9609375,
            "text": "schizophrenia was listed as the indication. RESULTS: First-generation antipsychotic (FGA) recommendations for adults with schizophrenia increased by 38% between 2005 and 2009, from 329 380 to 454 96",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -8.0625,
            "text": "schizophrenia was listed as the indication. RESULTS: First-generation antipsychotic (FGA) recommendations for adults with schizophrenia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -8.0859375,
            "text": "schizophrenia was listed as the indication. RESULTS: First-generation antipsychotic (FGA) recommendations for adults with schizophrenia increased by 38%",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -8.1953125,
            "text": "schizophrenia was listed as the indication. RESULTS: First-generation antipsychotic (FGA) recommendations for adults with schizophrenia increased by 38% between 2005 and 2009, from 329 380 to",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -8.1953125,
            "text": "schizophrenia was listed as the indication",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -8.1953125,
            "text": "schizophrenia was listed as the indication. RESULTS: First-generation antipsychotic (FGA) recommendations for adults with schizophrenia increased by 38% between 2005 and 2009, from 329 380",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -8.234375,
            "text": "schizophrenia was listed as the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -8.2421875,
            "text": "schizophrenia was listed as the indication. RESULTS: First-generation antipsychotic (FGA) recommendations for adults with schizophrenia increased by 38% between 2005 and 2009, from 329 380 to 454 960",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -8.2578125,
            "text": "schizophrenia was listed as the indication. RESULTS: First-generation antipsychotic (FGA) recommendations for adults with schizophrenia increased by 38% between 2005 and 2009, from 329 380 to 454",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -8.2734375,
            "text": "schizophrenia was listed as the indication. RESULTS: First-generation antipsychotic (FGA) recommendations for adults with schizophrenia increased by",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -8.3046875,
            "text": "schizophrenia was listed as the indication. RESULTS: First-generation antipsychotic (FG",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -8.3359375,
            "text": "schizophrenia was listed as the indication. RESULTS: First-generation antipsychotic (FGA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -8.3359375,
            "text": "schizophrenia was listed as the indication. RESULTS: First-generation antipsychotic (FGA) recommendations for adults with schizophrenia increased by 38% between 2005 and 2009",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -8.34375,
            "text": "schizophrenia was listed as the indication. RESULTS: First-generation antipsychotic (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -8.3515625,
            "text": "schizophrenia was listed as the indication. RESULTS: First-generation antipsychotic (FGA) recommendations for adults with schizophrenia increased by 38% between 2005 and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -8.3671875,
            "text": "schizophrenia was listed as the indication. RESULTS: First-generation antipsychotic (FGA) recommendations for adults with schizophrenia increased by 38% between 2005 and 2009, from 329 380 to 454 960 recommendations. There were notable increases in recommendations for chlorpromazine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.9140625,
            "end_logit": 7.828125,
            "text": "which schizophrenia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 7.828125,
            "text": "recommendations were estimated using CDTI data in which schizophrenia",
            "probability": 5.960464477539063e-08
        }
    ],
    "52b2e409f828ad283c00000e_3": [
        {
            "start_logit": 8.5625,
            "end_logit": 8.0234375,
            "text": "schizophrenia",
            "probability": 1.0
        },
        {
            "start_logit": -6.71484375,
            "end_logit": 8.0234375,
            "text": ". Its pharmacological profile is close to that of clozapine: it has dopamine (D2), histamine (H1), serotonin (5-HT2) and adrenergic (alpha 1)-blocking activities. Its best indication seems to be paranoid schizophrenia",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.71875,
            "end_logit": 8.0234375,
            "text": ". Its best indication seems to be paranoid schizophrenia",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.94921875,
            "end_logit": 8.0234375,
            "text": "oid schizophrenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.4609375,
            "end_logit": 8.0234375,
            "text": "since 1980. Its pharmacological profile is close to that of clozapine: it has dopamine (D2), histamine (H1), serotonin (5-HT2) and adrenergic (alpha 1)-blocking activities. Its best indication seems to be paranoid schizophrenia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 8.0234375,
            "text": "paranoid schizophrenia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5625,
            "end_logit": -8.1171875,
            "text": "schizophrenia, although some data suggest bipolar action.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.62890625,
            "end_logit": 8.0234375,
            "text": "1980. Its pharmacological profile is close to that of clozapine: it has dopamine (D2), histamine (H1), serotonin (5-HT2) and adrenergic (alpha 1)-blocking activities. Its best indication seems to be paranoid schizophrenia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5625,
            "end_logit": -8.1953125,
            "text": "schizophrenia, although some data suggest bipolar action",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5625,
            "end_logit": -8.265625,
            "text": "schizophrenia, although some data suggest",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 8.0234375,
            "text": "be paranoid schizophrenia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.078125,
            "end_logit": 8.0234375,
            "text": "seems to be paranoid schizophrenia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.109375,
            "end_logit": 8.0234375,
            "text": "indication seems to be paranoid schizophrenia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.71484375,
            "end_logit": -8.1171875,
            "text": ". Its pharmacological profile is close to that of clozapine: it has dopamine (D2), histamine (H1), serotonin (5-HT2) and adrenergic (alpha 1)-blocking activities.",
            "probability": 0.0
        },
        {
            "start_logit": -6.71484375,
            "end_logit": -8.1171875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.71875,
            "end_logit": -8.1171875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.71875,
            "end_logit": -8.1171875,
            "text": ". Its best indication seems to be paranoid schizophrenia, although some data suggest bipolar action.",
            "probability": 0.0
        },
        {
            "start_logit": -6.71875,
            "end_logit": -8.1171875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.71484375,
            "end_logit": -8.171875,
            "text": ". Its pharmacological profile is close to that of clozapine: it has dopamine (D2), histamine (H1), serotonin (5-HT2) and adrenergic (alpha 1",
            "probability": 0.0
        },
        {
            "start_logit": -6.71875,
            "end_logit": -8.1953125,
            "text": ". Its best indication seems to be paranoid schizophrenia, although some data suggest bipolar action",
            "probability": 0.0
        }
    ],
    "6252f496e764a53204000020_1": [
        {
            "start_logit": 10.3828125,
            "end_logit": 7.6328125,
            "text": "ABCG1 is an ATP binding cassette (ABC) transporter that removes excess cholesterol from peripheral tissues.",
            "probability": 0.68896484375
        },
        {
            "start_logit": 10.3828125,
            "end_logit": 6.8359375,
            "text": "ABCG1 is an ATP binding cassette (ABC) transporter",
            "probability": 0.310546875
        },
        {
            "start_logit": 10.3828125,
            "end_logit": -0.39794921875,
            "text": "ABC",
            "probability": 0.00022411346435546875
        },
        {
            "start_logit": 1.140625,
            "end_logit": 7.6328125,
            "text": "ATP binding cassette (ABC) transporter that removes excess cholesterol from peripheral tissues.",
            "probability": 6.67572021484375e-05
        },
        {
            "start_logit": 1.140625,
            "end_logit": 6.8359375,
            "text": "ATP binding cassette (ABC) transporter",
            "probability": 3.0100345611572266e-05
        },
        {
            "start_logit": -0.1878662109375,
            "end_logit": 7.6328125,
            "text": ".",
            "probability": 1.7702579498291016e-05
        },
        {
            "start_logit": -1.34765625,
            "end_logit": 7.6328125,
            "text": "an ATP binding cassette (ABC) transporter that removes excess cholesterol from peripheral tissues.",
            "probability": 5.4836273193359375e-06
        },
        {
            "start_logit": -1.34765625,
            "end_logit": 6.8359375,
            "text": "an ATP binding cassette (ABC) transporter",
            "probability": 2.5033950805664062e-06
        },
        {
            "start_logit": 10.3828125,
            "end_logit": -5.36328125,
            "text": "ABCG1 is an ATP binding cassette (ABC) transporter that removes excess cholesterol from",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": 10.3828125,
            "end_logit": -5.45703125,
            "text": "ABCG1 is an ATP binding cassette (ABC) transporter that",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 10.3828125,
            "end_logit": -5.640625,
            "text": "ABCG1 is an ATP binding cassette (ABC) transporter that removes excess cholesterol",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 10.3828125,
            "end_logit": -5.65625,
            "text": "ABCG1 is an ATP binding cassette (ABC) transporter that removes excess cholesterol from peripheral tissues",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 10.3828125,
            "end_logit": -5.75,
            "text": "ABCG1 is an ATP binding cassette (ABC",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 10.3828125,
            "end_logit": -5.9765625,
            "text": "ABCG1 is an ATP binding cassette (ABC) transporter that removes excess cholesterol from peripheral",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 10.3828125,
            "end_logit": -6.2421875,
            "text": "ABCG1 is an ATP binding cassette (ABC) transporter that removes excess",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 10.3828125,
            "end_logit": -6.3828125,
            "text": "ABCG1 is an ATP binding cassette (ABC)",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 10.3828125,
            "end_logit": -6.45703125,
            "text": "ABCG1 is an ATP binding cassette",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 10.3828125,
            "end_logit": -6.49609375,
            "text": "ABCG1 is",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 10.3828125,
            "end_logit": -6.515625,
            "text": "ABCG1 is an ATP binding cassette (",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -4.203125,
            "end_logit": 7.6328125,
            "text": "transporter that removes excess cholesterol from peripheral tissues.",
            "probability": 3.5762786865234375e-07
        }
    ],
    "601ee4c61cb411341a000066_1": [
        {
            "start_logit": 9.953125,
            "end_logit": 9.78125,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": -1.671875,
            "end_logit": 9.78125,
            "text": "7",
            "probability": 8.940696716308594e-06
        },
        {
            "start_logit": 9.953125,
            "end_logit": -1.8505859375,
            "text": "196",
            "probability": 8.881092071533203e-06
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.078125,
            "text": "1967 was performed using a deceased donor heart,",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.2734375,
            "text": "1967 was performed using a deceased donor heart",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.328125,
            "text": "1967 was performed using a deceased donor",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.328125,
            "text": "1967 was performed using a deceased",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.3359375,
            "text": "1967 was",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.3515625,
            "text": "1967 was performed using a",
            "probability": 0.0
        },
        {
            "start_logit": 9.953125,
            "end_logit": -8.359375,
            "text": "1967 was performed",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.78125,
            "text": "in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 9.78125,
            "text": "the first human heart transplant in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.78125,
            "text": "first human heart transplant in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": 9.78125,
            "text": "human heart transplant in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.78125,
            "text": "heart transplant in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 9.78125,
            "text": "transplant in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -1.671875,
            "end_logit": -8.078125,
            "text": "7 was performed using a deceased donor heart,",
            "probability": 0.0
        },
        {
            "start_logit": -1.671875,
            "end_logit": -8.2734375,
            "text": "7 was performed using a deceased donor heart",
            "probability": 0.0
        },
        {
            "start_logit": -1.671875,
            "end_logit": -8.328125,
            "text": "7 was performed using a deceased donor",
            "probability": 0.0
        },
        {
            "start_logit": -1.671875,
            "end_logit": -8.328125,
            "text": "7 was performed using a deceased",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_2": [
        {
            "start_logit": 10.03125,
            "end_logit": 9.8203125,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -1.6640625,
            "text": "196",
            "probability": 1.0371208190917969e-05
        },
        {
            "start_logit": -1.59765625,
            "end_logit": 9.8203125,
            "text": "7",
            "probability": 8.940696716308594e-06
        },
        {
            "start_logit": -6.84375,
            "end_logit": 9.8203125,
            "text": "In 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.03125,
            "end_logit": -7.890625,
            "text": "1967, Christian Barnard performed the first successful human-to",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -7.9609375,
            "text": "1967, Christian Bar",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -7.96484375,
            "text": "1967, Christian Barnar",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.046875,
            "text": "1967, Christian Barnard",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.0546875,
            "text": "1967, Chr",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.0625,
            "text": "1967, Christian",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.1015625,
            "text": "1967, Christ",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.15625,
            "text": "1967, Christian Barnard performed",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.1953125,
            "text": "1967, Christian Barnard performed the",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.203125,
            "text": "1967, Christian Barnard performed the first successful human-",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.234375,
            "text": "1967, Christian Barnard performed the first successful human-to-human heart transplant",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.25,
            "text": "1967, Christian Barnard performed the first successful human-to-human heart",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.265625,
            "text": "1967, Christian Barnard performed the first successful human-to-",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.2890625,
            "text": "1967,",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.2890625,
            "text": "1967, Christian Barnard performed the first successful human",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.296875,
            "text": "1967, Christian Barnard performed the first",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_3": [
        {
            "start_logit": 10.0546875,
            "end_logit": 9.875,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -1.59765625,
            "text": "196",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": -1.4375,
            "end_logit": 9.875,
            "text": "7",
            "probability": 1.0132789611816406e-05
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -8.015625,
            "text": "1967, there has been substantial progress in the field of heart transplantation, especially over the last several",
            "probability": 0.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -8.0625,
            "text": "1967, there has been substantial progress in the field of heart transplantation, especially over the last several decades",
            "probability": 0.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -8.1953125,
            "text": "1967, there has been substantial progress in the field of heart transplantation, especially over the",
            "probability": 0.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -8.1953125,
            "text": "1967, there has been substantial progress in the field of heart transplantation, especially over the last",
            "probability": 0.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -8.2109375,
            "text": "1967, there has been substantial progress in the field of heart transplantation, especially",
            "probability": 0.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -8.265625,
            "text": "1967, there has been",
            "probability": 0.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -8.265625,
            "text": "1967, there has been substantial",
            "probability": 0.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -8.265625,
            "text": "1967, there has",
            "probability": 0.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -8.265625,
            "text": "1967, there has been substantial progress in the",
            "probability": 0.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -8.28125,
            "text": "1967, there has been substantial progress",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.875,
            "text": "by Christiaan Barnard in 1967",
            "probability": 0.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -8.296875,
            "text": "1967, there has been substantial progress in the field of heart transplantation,",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.875,
            "text": "in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.875,
            "text": "Christiaan Barnard in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.875,
            "text": "Since the first successful human heart transplant performed by Christiaan Barnard in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.875,
            "text": "the first successful human heart transplant performed by Christiaan Barnard in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.875,
            "text": "first successful human heart transplant performed by Christiaan Barnard in 1967",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_4": [
        {
            "start_logit": 10.0703125,
            "end_logit": 9.859375,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": 10.0703125,
            "end_logit": -1.513671875,
            "text": "196",
            "probability": 1.138448715209961e-05
        },
        {
            "start_logit": -1.4287109375,
            "end_logit": 9.859375,
            "text": "7",
            "probability": 1.0073184967041016e-05
        },
        {
            "start_logit": -7.60546875,
            "end_logit": 9.859375,
            "text": ", 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.859375,
            "text": "on December 3rd, 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.859375,
            "text": "human heart transplant that had been carried out by the South African surgeon, Christiaan ('Chris') Barnard at Groote Schuur Hospital in Cape Town on December 3rd, 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.859375,
            "text": "Hospital in Cape Town on December 3rd, 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.859375,
            "text": "first human heart transplant that had been carried out by the South African surgeon, Christiaan ('Chris') Barnard at Groote Schuur Hospital in Cape Town on December 3rd, 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.859375,
            "text": "the first human heart transplant that had been carried out by the South African surgeon, Christiaan ('Chris') Barnard at Groote Schuur Hospital in Cape Town on December 3rd, 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.859375,
            "text": ", Christiaan ('Chris') Barnard at Groote Schuur Hospital in Cape Town on December 3rd, 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.859375,
            "text": "at Groote Schuur Hospital in Cape Town on December 3rd, 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.859375,
            "text": "anniversary of the first human heart transplant that had been carried out by the South African surgeon, Christiaan ('Chris') Barnard at Groote Schuur Hospital in Cape Town on December 3rd, 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.60546875,
            "end_logit": -1.513671875,
            "text": ", 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -1.513671875,
            "text": "on December 3rd, 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -1.513671875,
            "text": "human heart transplant that had been carried out by the South African surgeon, Christiaan ('Chris') Barnard at Groote Schuur Hospital in Cape Town on December 3rd, 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -1.513671875,
            "text": "Hospital in Cape Town on December 3rd, 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -1.513671875,
            "text": "50th anniversary of the first human heart transplant that had been carried out by the South African surgeon, Christiaan ('Chris') Barnard at Groote Schuur Hospital in Cape Town on December 3rd, 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -1.513671875,
            "text": "first human heart transplant that had been carried out by the South African surgeon, Christiaan ('Chris') Barnard at Groote Schuur Hospital in Cape Town on December 3rd, 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": -1.513671875,
            "text": "the first human heart transplant that had been carried out by the South African surgeon, Christiaan ('Chris') Barnard at Groote Schuur Hospital in Cape Town on December 3rd, 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -1.513671875,
            "text": ", Christiaan ('Chris') Barnard at Groote Schuur Hospital in Cape Town on December 3rd, 196",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_5": [
        {
            "start_logit": 10.0625,
            "end_logit": 9.7734375,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": 10.0625,
            "end_logit": -1.607421875,
            "text": "196",
            "probability": 1.1324882507324219e-05
        },
        {
            "start_logit": -1.6943359375,
            "end_logit": 9.7734375,
            "text": "7",
            "probability": 7.748603820800781e-06
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 9.7734375,
            "text": "It has been 40 years since the first human-to-human heart transplant performed in South Africa by Christiaan Barnard in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.7734375,
            "text": "has been 40 years since the first human-to-human heart transplant performed in South Africa by Christiaan Barnard in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.7734375,
            "text": "December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.7734375,
            "text": "in South Africa by Christiaan Barnard in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.7734375,
            "text": "human-to-human heart transplant performed in South Africa by Christiaan Barnard in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.7734375,
            "text": "first human-to-human heart transplant performed in South Africa by Christiaan Barnard in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.7734375,
            "text": "by Christiaan Barnard in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": -1.607421875,
            "text": "It has been 40 years since the first human-to-human heart transplant performed in South Africa by Christiaan Barnard in December 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -1.607421875,
            "text": "has been 40 years since the first human-to-human heart transplant performed in South Africa by Christiaan Barnard in December 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": -1.607421875,
            "text": "December 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -1.607421875,
            "text": "in South Africa by Christiaan Barnard in December 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": -1.607421875,
            "text": "human-to-human heart transplant performed in South Africa by Christiaan Barnard in December 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": -1.607421875,
            "text": "first human-to-human heart transplant performed in South Africa by Christiaan Barnard in December 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": -1.607421875,
            "text": "by Christiaan Barnard in December 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": -8.2265625,
            "text": "It has been 40 years since the first human-to-human heart transplant performed in South Africa by Christiaan Bar",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": -8.2265625,
            "text": "It has been 40 years since the first human-to",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": -8.265625,
            "text": "It has been 40 years since the first human-to-human heart transplant performed in South Africa",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_6": [
        {
            "start_logit": 10.0546875,
            "end_logit": 9.890625,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": -1.37890625,
            "end_logit": 9.890625,
            "text": "7",
            "probability": 1.0967254638671875e-05
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -1.58203125,
            "text": "196",
            "probability": 1.043081283569336e-05
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -8.1015625,
            "text": "1967, there has been substantial progress in the field of heart transplantation, especially over the last several",
            "probability": 0.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -8.140625,
            "text": "1967, there has been substantial progress in the field of heart transplantation, especially over the last several decades",
            "probability": 0.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -8.25,
            "text": "1967, there has been substantial progress in the field of heart transplantation, especially over the",
            "probability": 0.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -8.2578125,
            "text": "1967, there has been substantial progress in the field of heart transplantation, especially",
            "probability": 0.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -8.265625,
            "text": "1967, there has been substantial progress in the field of heart transplantation, especially over the last",
            "probability": 0.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -8.296875,
            "text": "1967, there has been substantial progress in the",
            "probability": 0.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -8.3125,
            "text": "1967, there has been substantial progress",
            "probability": 0.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -8.3125,
            "text": "1967, there has been substantial",
            "probability": 0.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -8.3203125,
            "text": "1967, there has been substantial progress in the field of heart transplantation, especially over",
            "probability": 0.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -8.328125,
            "text": "1967, there has",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.890625,
            "text": "the first successful human heart transplant performed by Christiaan Barnard in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.890625,
            "text": "by Christiaan Barnard in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.890625,
            "text": "first successful human heart transplant performed by Christiaan Barnard in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.890625,
            "text": "successful human heart transplant performed by Christiaan Barnard in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.890625,
            "text": "Christiaan Barnard in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.890625,
            "text": "human heart transplant performed by Christiaan Barnard in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.890625,
            "text": "heart transplant performed by Christiaan Barnard in 1967",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_7": [
        {
            "start_logit": 10.03125,
            "end_logit": 9.890625,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": -1.40625,
            "end_logit": 9.890625,
            "text": "7",
            "probability": 1.0788440704345703e-05
        },
        {
            "start_logit": 10.03125,
            "end_logit": -1.6708984375,
            "text": "196",
            "probability": 9.5367431640625e-06
        },
        {
            "start_logit": -7.3359375,
            "end_logit": 9.890625,
            "text": "in 1967",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.0625,
            "text": "1967, the field of heart transplantation has advanced to",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 9.890625,
            "text": "Since the first human heart transplantation was performed in 1967",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.1484375,
            "text": "1967, the field of heart transplantation has",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.15625,
            "text": "1967, the field of heart transplantation has advanced",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.890625,
            "text": "the first human heart transplantation was performed in 1967",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.2265625,
            "text": "1967, the",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.234375,
            "text": "1967,",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.890625,
            "text": "human heart transplantation was performed in 1967",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.265625,
            "text": "1967, the field",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 9.890625,
            "text": "first human heart transplantation was performed in 1967",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.3046875,
            "text": "1967, the field of heart transplantation has advanced to the point where survival and acceptable quality of life are",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.3046875,
            "text": "1967, the field of heart transplantation has advanced to the",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.3203125,
            "text": "1967, the field of heart transplantation has advanced to the point where survival and",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.3359375,
            "text": "1967, the field of heart transplantation has advanced to the point where survival and acceptable quality of",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.34375,
            "text": "1967, the field of",
            "probability": 0.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -8.3515625,
            "text": "1967, the field of heart transplantation has advanced to the point where survival and acceptable quality of life are commonplace",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_8": [
        {
            "start_logit": 10.03125,
            "end_logit": 9.6953125,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": 10.03125,
            "end_logit": -1.7021484375,
            "text": "196",
            "probability": 1.1324882507324219e-05
        },
        {
            "start_logit": -1.9228515625,
            "end_logit": 9.6953125,
            "text": "7",
            "probability": 6.496906280517578e-06
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 9.6953125,
            "text": "in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.6953125,
            "text": "The first human-to-human heart transplant was performed 50 years ago in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.6953125,
            "text": "first human-to-human heart transplant was performed 50 years ago in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.6953125,
            "text": "heart transplant was performed 50 years ago in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 9.6953125,
            "text": "human heart transplant was performed 50 years ago in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.359375,
            "end_logit": 9.6953125,
            "text": "performed 50 years ago in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.3671875,
            "end_logit": 9.6953125,
            "text": "-human heart transplant was performed 50 years ago in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": -1.7021484375,
            "text": "in 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -1.7021484375,
            "text": "The first human-to-human heart transplant was performed 50 years ago in 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": -1.7021484375,
            "text": "first human-to-human heart transplant was performed 50 years ago in 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": -1.7021484375,
            "text": "heart transplant was performed 50 years ago in 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": -1.7021484375,
            "text": "human heart transplant was performed 50 years ago in 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.359375,
            "end_logit": -1.7021484375,
            "text": "performed 50 years ago in 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.3671875,
            "end_logit": -1.7021484375,
            "text": "-human heart transplant was performed 50 years ago in 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -8.140625,
            "text": "The first human-to-human heart transplant was performed 50 years ago",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -8.1640625,
            "text": "The first human-to",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -8.1640625,
            "text": "The first human-to-human heart transplant was performed 50",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_9": [
        {
            "start_logit": 9.96875,
            "end_logit": 9.8125,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": -1.615234375,
            "end_logit": 9.8125,
            "text": "7",
            "probability": 9.298324584960938e-06
        },
        {
            "start_logit": 9.96875,
            "end_logit": -1.837890625,
            "text": "196",
            "probability": 8.761882781982422e-06
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 9.8125,
            "text": "in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 9.8125,
            "text": "Since the first human-to-human heart transplantation, performed in 1967",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.359375,
            "text": "1967,",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.375,
            "text": "1967, advances in organ donation, surgical techniques",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.8125,
            "text": "first human-to-human heart transplantation, performed in 1967",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.40625,
            "text": "1967, advances in organ donation,",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.40625,
            "text": "1967, advances in organ donation, surgical techniques,",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.4140625,
            "text": "1967, advances in organ donation",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.4140625,
            "text": "1967, advances in organ donation, surgical techniques, organ preservation, perioperative care, immunologic risk assessment, immunosuppression agents, monitoring of graft function and",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.421875,
            "text": "1967, advances in organ donation, surgical techniques, organ preservation,",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.421875,
            "text": "1967, advances in organ donation, surgical",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.4296875,
            "text": "1967, advances in organ",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.4296875,
            "text": "1967, advances in organ donation, surgical techniques, organ preservation, perioperative care, immunologic risk assessment, immunosuppression agents, monitoring of graft function and surveillance of long-term complications have drastically",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.4375,
            "text": "1967, advances in organ donation, surgical techniques, organ preservation, perioperative care, immunologic risk assessment, immunosuppression agents, monitoring of graft",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.4375,
            "text": "1967, advances in organ donation, surgical techniques, organ preservation, perioperative care, immunologic risk assessment, immunosuppression agents, monitoring of graft function and surveillance of long-term complications have drastically increased recipient survival",
            "probability": 0.0
        },
        {
            "start_logit": -7.84765625,
            "end_logit": -1.837890625,
            "text": "in 196",
            "probability": 0.0
        },
        {
            "start_logit": -1.615234375,
            "end_logit": -8.359375,
            "text": "7,",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_10": [
        {
            "start_logit": 9.96875,
            "end_logit": 9.84375,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": -1.515625,
            "end_logit": 9.84375,
            "text": "7",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": 9.96875,
            "end_logit": -1.8115234375,
            "text": "196",
            "probability": 8.64267349243164e-06
        },
        {
            "start_logit": 9.96875,
            "end_logit": -7.88671875,
            "text": "1967 was performed using a deceased donor heart,",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.015625,
            "text": "1967 was performed using a deceased donor heart, the advent of brain death criteria",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.0234375,
            "text": "1967 was performed using a deceased donor heart, the advent of brain death criteria and the ability to avoid long warm ischemic times led donation after cardiac death (DCD)",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.03125,
            "text": "1967 was performed using a deceased donor heart, the advent of brain death criteria and the ability to avoid long warm ischemic times led donation after cardiac death",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.0546875,
            "text": "1967 was performed using a deceased donor heart, the advent of brain death criteria and the ability to avoid long warm ischemic times led donation after cardiac death (DCD) transplantation to",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.1328125,
            "text": "1967 was performed using a deceased donor heart, the advent of brain death criteria and",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.1640625,
            "text": "1967 was performed using a deceased donor heart, the advent of brain death criteria and the ability to avoid long warm ischemic times led donation after cardiac death (DCD) transplantation",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 9.84375,
            "text": "in 1967",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.1875,
            "text": "1967 was performed using a deceased donor heart",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.1953125,
            "text": "1967 was",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.203125,
            "text": "1967 was performed using a deceased donor heart, the advent of brain death criteria and the ability to avoid long warm ischemic times led donation after cardiac death (DCD",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.84375,
            "text": "the first human heart transplant in 1967",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.2265625,
            "text": "1967 was performed using a deceased donor heart, the advent of brain death criteria and the ability to avoid long warm ischemic times",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.234375,
            "text": "1967 was performed using a deceased donor heart, the advent of brain death criteria and the ability to avoid long warm ischemic times led donation after cardiac death (DCD) transplantation to fall out of favor. Due the",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.234375,
            "text": "1967 was performed using a deceased donor",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.2421875,
            "text": "1967 was performed using a deceased donor heart, the advent of brain death criteria and the ability to avoid long warm ischemic times led donation after cardiac death (",
            "probability": 0.0
        },
        {
            "start_logit": 9.96875,
            "end_logit": -8.2421875,
            "text": "1967 was performed using a deceased donor heart, the advent of brain death criteria and the ability to",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_11": [
        {
            "start_logit": 9.984375,
            "end_logit": 9.65625,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": 9.984375,
            "end_logit": -1.796875,
            "text": "196",
            "probability": 1.0609626770019531e-05
        },
        {
            "start_logit": -2.015625,
            "end_logit": 9.65625,
            "text": "7",
            "probability": 6.139278411865234e-06
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.65625,
            "text": "first successful heart transplant operation performed by Professor Christiaan Barnard and his team in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.65625,
            "text": "The Human Tissue Act of 1983 had its origin in the first successful heart transplant operation performed by Professor Christiaan Barnard and his team in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.65625,
            "text": "successful heart transplant operation performed by Professor Christiaan Barnard and his team in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": 9.65625,
            "text": "by Professor Christiaan Barnard and his team in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": 9.65625,
            "text": "or Christiaan Barnard and his team in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.65625,
            "text": "the first successful heart transplant operation performed by Professor Christiaan Barnard and his team in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.65625,
            "text": "Human Tissue Act of 1983 had its origin in the first successful heart transplant operation performed by Professor Christiaan Barnard and his team in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.65625,
            "text": "in the first successful heart transplant operation performed by Professor Christiaan Barnard and his team in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": 9.65625,
            "text": "heart transplant operation performed by Professor Christiaan Barnard and his team in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 9.65625,
            "text": "had its origin in the first successful heart transplant operation performed by Professor Christiaan Barnard and his team in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": -1.796875,
            "text": "first successful heart transplant operation performed by Professor Christiaan Barnard and his team in December 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": -1.796875,
            "text": "The Human Tissue Act of 1983 had its origin in the first successful heart transplant operation performed by Professor Christiaan Barnard and his team in December 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": -1.796875,
            "text": "successful heart transplant operation performed by Professor Christiaan Barnard and his team in December 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": -1.796875,
            "text": "by Professor Christiaan Barnard and his team in December 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": -1.796875,
            "text": "or Christiaan Barnard and his team in December 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": -1.796875,
            "text": "the first successful heart transplant operation performed by Professor Christiaan Barnard and his team in December 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": -1.796875,
            "text": "Human Tissue Act of 1983 had its origin in the first successful heart transplant operation performed by Professor Christiaan Barnard and his team in December 196",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_12": [
        {
            "start_logit": 10.046875,
            "end_logit": 9.875,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": -1.4443359375,
            "end_logit": 9.875,
            "text": "7",
            "probability": 1.0192394256591797e-05
        },
        {
            "start_logit": 10.046875,
            "end_logit": -1.6435546875,
            "text": "196",
            "probability": 9.953975677490234e-06
        },
        {
            "start_logit": 10.046875,
            "end_logit": -7.97265625,
            "text": "1967 in South Africa",
            "probability": 0.0
        },
        {
            "start_logit": 10.046875,
            "end_logit": -8.1875,
            "text": "1967 in South",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.875,
            "text": "It has been 50 years since Dr. Christiaan Barnard performed the first human-to-human heart transplant in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 9.875,
            "text": "first human-to-human heart transplant in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 9.875,
            "text": "Christiaan Barnard performed the first human-to-human heart transplant in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.875,
            "text": "has been 50 years since Dr. Christiaan Barnard performed the first human-to-human heart transplant in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.875,
            "text": "December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.875,
            "text": ". Christiaan Barnard performed the first human-to-human heart transplant in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.875,
            "text": "Dr. Christiaan Barnard performed the first human-to-human heart transplant in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.875,
            "text": "human-to-human heart transplant in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.875,
            "text": "the first human-to-human heart transplant in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.875,
            "text": "human heart transplant in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.875,
            "text": "-to-human heart transplant in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -1.4443359375,
            "end_logit": -7.97265625,
            "text": "7 in South Africa",
            "probability": 0.0
        },
        {
            "start_logit": -1.4443359375,
            "end_logit": -8.1875,
            "text": "7 in South",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -1.6435546875,
            "text": "It has been 50 years since Dr. Christiaan Barnard performed the first human-to-human heart transplant in December 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -1.6435546875,
            "text": "first human-to-human heart transplant in December 196",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_13": [
        {
            "start_logit": 10.0625,
            "end_logit": 9.8671875,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": 10.0625,
            "end_logit": -1.572265625,
            "text": "196",
            "probability": 1.0728836059570312e-05
        },
        {
            "start_logit": -1.4521484375,
            "end_logit": 9.8671875,
            "text": "7",
            "probability": 9.894371032714844e-06
        },
        {
            "start_logit": -6.7265625,
            "end_logit": 9.8671875,
            "text": "December 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0625,
            "end_logit": -8.0859375,
            "text": "1967, by Christiaan Barnard in South Africa",
            "probability": 0.0
        },
        {
            "start_logit": 10.0625,
            "end_logit": -8.0859375,
            "text": "1967, by Christiaan Barnard in South",
            "probability": 0.0
        },
        {
            "start_logit": 10.0625,
            "end_logit": -8.1953125,
            "text": "1967, by Christiaan Bar",
            "probability": 0.0
        },
        {
            "start_logit": 10.0625,
            "end_logit": -8.203125,
            "text": "1967,",
            "probability": 0.0
        },
        {
            "start_logit": 10.0625,
            "end_logit": -8.2109375,
            "text": "1967, by Christiaan Barnard in",
            "probability": 0.0
        },
        {
            "start_logit": 10.0625,
            "end_logit": -8.2109375,
            "text": "1967, by Christiaa",
            "probability": 0.0
        },
        {
            "start_logit": 10.0625,
            "end_logit": -8.21875,
            "text": "1967, by Christiaan Barnar",
            "probability": 0.0
        },
        {
            "start_logit": 10.0625,
            "end_logit": -8.2265625,
            "text": "1967, by Christiaan Barnard",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": 9.8671875,
            "text": "The first successful human heart transplantation was reported on 3 December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 9.8671875,
            "text": "on 3 December 1967",
            "probability": 0.0
        },
        {
            "start_logit": 10.0625,
            "end_logit": -8.2578125,
            "text": "1967, by Christiaan",
            "probability": 0.0
        },
        {
            "start_logit": 10.0625,
            "end_logit": -8.28125,
            "text": "1967, by Christ",
            "probability": 0.0
        },
        {
            "start_logit": 10.0625,
            "end_logit": -8.296875,
            "text": "1967, by Chr",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 9.8671875,
            "text": "3 December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 9.8671875,
            "text": "successful human heart transplantation was reported on 3 December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.8671875,
            "text": "human heart transplantation was reported on 3 December 1967",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_14": [
        {
            "start_logit": 10.015625,
            "end_logit": 9.8359375,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": 10.015625,
            "end_logit": -1.6953125,
            "text": "196",
            "probability": 9.894371032714844e-06
        },
        {
            "start_logit": -1.53125,
            "end_logit": 9.8359375,
            "text": "7",
            "probability": 9.715557098388672e-06
        },
        {
            "start_logit": -7.83984375,
            "end_logit": 9.8359375,
            "text": "December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.8359375,
            "text": "first human-to-human heart transplant was performed at Groote Schuur Hospital on the 2nd December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.8359375,
            "text": "human-to-human heart transplant was performed at Groote Schuur Hospital on the 2nd December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.8359375,
            "text": "human heart transplant was performed at Groote Schuur Hospital on the 2nd December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.8359375,
            "text": "at Groote Schuur Hospital on the 2nd December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.8359375,
            "text": "performed at Groote Schuur Hospital on the 2nd December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.8359375,
            "text": "on the 2nd December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.8359375,
            "text": "heart transplant was performed at Groote Schuur Hospital on the 2nd December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.8359375,
            "text": "The world's first human-to-human heart transplant was performed at Groote Schuur Hospital on the 2nd December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 9.8359375,
            "text": "-human heart transplant was performed at Groote Schuur Hospital on the 2nd December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.83984375,
            "end_logit": -1.6953125,
            "text": "December 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -1.6953125,
            "text": "first human-to-human heart transplant was performed at Groote Schuur Hospital on the 2nd December 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": -1.6953125,
            "text": "human-to-human heart transplant was performed at Groote Schuur Hospital on the 2nd December 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": -1.6953125,
            "text": "human heart transplant was performed at Groote Schuur Hospital on the 2nd December 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": -1.6953125,
            "text": "at Groote Schuur Hospital on the 2nd December 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": -1.6953125,
            "text": "performed at Groote Schuur Hospital on the 2nd December 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": -1.6953125,
            "text": "on the 2nd December 196",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_15": [
        {
            "start_logit": 10.0859375,
            "end_logit": 9.890625,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -1.51953125,
            "text": "196",
            "probability": 1.1146068572998047e-05
        },
        {
            "start_logit": -1.408203125,
            "end_logit": 9.890625,
            "text": "7",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 9.890625,
            "text": "50 years have passed since the first human to human heart transplantation, performed by Christiaan Barnard in Cape Town December 3rd 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.890625,
            "text": "human heart transplantation, performed by Christiaan Barnard in Cape Town December 3rd 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.890625,
            "text": "by Christiaan Barnard in Cape Town December 3rd 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": 9.890625,
            "text": "human to human heart transplantation, performed by Christiaan Barnard in Cape Town December 3rd 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.890625,
            "text": "performed by Christiaan Barnard in Cape Town December 3rd 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.890625,
            "text": "Christiaan Barnard in Cape Town December 3rd 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.890625,
            "text": "since the first human to human heart transplantation, performed by Christiaan Barnard in Cape Town December 3rd 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 9.890625,
            "text": "the first human to human heart transplantation, performed by Christiaan Barnard in Cape Town December 3rd 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": 9.890625,
            "text": "3rd 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 9.890625,
            "text": "in Cape Town December 3rd 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.37109375,
            "end_logit": -1.51953125,
            "text": "50 years have passed since the first human to human heart transplantation, performed by Christiaan Barnard in Cape Town December 3rd 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -1.51953125,
            "text": "human heart transplantation, performed by Christiaan Barnard in Cape Town December 3rd 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": -1.51953125,
            "text": "by Christiaan Barnard in Cape Town December 3rd 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": -1.51953125,
            "text": "human to human heart transplantation, performed by Christiaan Barnard in Cape Town December 3rd 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": -1.51953125,
            "text": "performed by Christiaan Barnard in Cape Town December 3rd 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": -1.51953125,
            "text": "Christiaan Barnard in Cape Town December 3rd 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": -1.51953125,
            "text": "since the first human to human heart transplantation, performed by Christiaan Barnard in Cape Town December 3rd 196",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_16": [
        {
            "start_logit": 10.0078125,
            "end_logit": 9.8046875,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -1.7236328125,
            "text": "196",
            "probability": 9.834766387939453e-06
        },
        {
            "start_logit": -1.6376953125,
            "end_logit": 9.8046875,
            "text": "7",
            "probability": 8.761882781982422e-06
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -7.97265625,
            "text": "1967, he led the team that performed the world's first human-to",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.0625,
            "text": "1967, he led the team that performed the world'",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.1171875,
            "text": "1967, he led the team that performed the world",
            "probability": 0.0
        },
        {
            "start_logit": -7.9140625,
            "end_logit": 9.8046875,
            "text": "In 1967",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.125,
            "text": "1967, he led the team that performed the world's",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.2109375,
            "text": "1967,",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.2109375,
            "text": "1967, he",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.2578125,
            "text": "1967, he led the team",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.2578125,
            "text": "1967, he led the team that",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.265625,
            "text": "1967, he led",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.3046875,
            "text": "1967, he led the team that performed the world's first human-",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.3203125,
            "text": "1967, he led the team that performed the world's first human-to-human heart transplant",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.3203125,
            "text": "1967, he led the",
            "probability": 0.0
        },
        {
            "start_logit": -1.6376953125,
            "end_logit": -7.97265625,
            "text": "7, he led the team that performed the world's first human-to",
            "probability": 0.0
        },
        {
            "start_logit": -7.9140625,
            "end_logit": -1.7236328125,
            "text": "In 196",
            "probability": 0.0
        },
        {
            "start_logit": -1.6376953125,
            "end_logit": -8.0625,
            "text": "7, he led the team that performed the world'",
            "probability": 0.0
        },
        {
            "start_logit": -1.6376953125,
            "end_logit": -8.1171875,
            "text": "7, he led the team that performed the world",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_17": [
        {
            "start_logit": 10.078125,
            "end_logit": 9.953125,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": -1.216796875,
            "end_logit": 9.953125,
            "text": "7",
            "probability": 1.239776611328125e-05
        },
        {
            "start_logit": 10.078125,
            "end_logit": -1.521484375,
            "text": "196",
            "probability": 1.0371208190917969e-05
        },
        {
            "start_logit": 10.078125,
            "end_logit": -8.0390625,
            "text": "1967, and later to the first infusion of bone marrow-derived cells to the human myocardium in 2002, significant progress has been made in h",
            "probability": 0.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -8.046875,
            "text": "1967, and later to the first infusion of bone marrow-derived cells to the human myocardium in 2002",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 9.953125,
            "text": "in 1967",
            "probability": 0.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -8.1953125,
            "text": "1967, and later to the first infusion of bone marrow-derived cells to the human myocardium in 2002, significant progress has been made",
            "probability": 0.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -8.2265625,
            "text": "1967, and later to the first infusion of bone marrow-derived cells to the human myocardium",
            "probability": 0.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -8.2265625,
            "text": "1967, and later to the first infusion of bone marrow-derived cells to",
            "probability": 0.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -8.25,
            "text": "1967, and later to the first infusion of bone marrow-derived cells to the human myocardium in",
            "probability": 0.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -8.2578125,
            "text": "1967, and later to the first infusion of bone marrow-derived cells to the human myocardium in 2002, significant progress has been made in",
            "probability": 0.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -8.2734375,
            "text": "1967, and later to the first infusion of bone marrow-derived cells to the human myocardium in 2002, significant progress has been",
            "probability": 0.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -8.2734375,
            "text": "1967, and",
            "probability": 0.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -8.2734375,
            "text": "1967, and later to the first infusion of bone marrow-derived cells to the",
            "probability": 0.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -8.2890625,
            "text": "1967, and later to the first infusion of bone marrow",
            "probability": 0.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -8.296875,
            "text": "1967, and later to the first infusion of bone marrow-derived",
            "probability": 0.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -8.296875,
            "text": "1967, and later to the first infusion of bone marrow-",
            "probability": 0.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -8.3046875,
            "text": "1967, and later to",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.953125,
            "text": "successful heart transplant in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.953125,
            "text": "first successful heart transplant in 1967",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_18": [
        {
            "start_logit": 10.078125,
            "end_logit": 9.859375,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -1.5341796875,
            "text": "196",
            "probability": 1.1324882507324219e-05
        },
        {
            "start_logit": -1.478515625,
            "end_logit": 9.859375,
            "text": "7",
            "probability": 9.59634780883789e-06
        },
        {
            "start_logit": -7.33984375,
            "end_logit": 9.859375,
            "text": "December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": 9.859375,
            "text": "at Groote Schuur Hospital, Cape Town, on 3 December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.859375,
            "text": "on 3 December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.859375,
            "text": "3 December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 9.859375,
            "text": "performed at Groote Schuur Hospital, Cape Town, on 3 December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.859375,
            "text": "Groote Schuur Hospital, Cape Town, on 3 December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.859375,
            "text": "Article on the first heart transplant, performed at Groote Schuur Hospital, Cape Town, on 3 December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.859375,
            "text": "first heart transplant, performed at Groote Schuur Hospital, Cape Town, on 3 December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.859375,
            "text": "heart transplant, performed at Groote Schuur Hospital, Cape Town, on 3 December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.859375,
            "text": "on the first heart transplant, performed at Groote Schuur Hospital, Cape Town, on 3 December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.859375,
            "text": "the first heart transplant, performed at Groote Schuur Hospital, Cape Town, on 3 December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": 9.859375,
            "text": "Hospital, Cape Town, on 3 December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.33984375,
            "end_logit": -1.5341796875,
            "text": "December 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": -1.5341796875,
            "text": "at Groote Schuur Hospital, Cape Town, on 3 December 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -1.5341796875,
            "text": "on 3 December 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -1.5341796875,
            "text": "3 December 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": -1.5341796875,
            "text": "performed at Groote Schuur Hospital, Cape Town, on 3 December 196",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_19": [
        {
            "start_logit": 10.1015625,
            "end_logit": 9.90625,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": 10.1015625,
            "end_logit": -1.4365234375,
            "text": "196",
            "probability": 1.1920928955078125e-05
        },
        {
            "start_logit": -1.3154296875,
            "end_logit": 9.90625,
            "text": "7",
            "probability": 1.1146068572998047e-05
        },
        {
            "start_logit": 10.1015625,
            "end_logit": -7.5859375,
            "text": "1967, in Cape Town, South Africa",
            "probability": 0.0
        },
        {
            "start_logit": 10.1015625,
            "end_logit": -7.93359375,
            "text": "1967, in Cape Town, South",
            "probability": 0.0
        },
        {
            "start_logit": -7.77734375,
            "end_logit": 9.90625,
            "text": ", 1967",
            "probability": 0.0
        },
        {
            "start_logit": 10.1015625,
            "end_logit": -8.0078125,
            "text": "1967, in Cape Town",
            "probability": 0.0
        },
        {
            "start_logit": 10.1015625,
            "end_logit": -8.078125,
            "text": "1967, in Cape Town, South Africa, Dr. Christian Barnard revolution",
            "probability": 0.0
        },
        {
            "start_logit": 10.1015625,
            "end_logit": -8.0859375,
            "text": "1967, in Cape Town, South Africa, Dr. Christian Bar",
            "probability": 0.0
        },
        {
            "start_logit": -7.90234375,
            "end_logit": 9.90625,
            "text": "On December 3, 1967",
            "probability": 0.0
        },
        {
            "start_logit": 10.1015625,
            "end_logit": -8.125,
            "text": "1967, in Cape Town, South Africa, Dr. Christian Barnar",
            "probability": 0.0
        },
        {
            "start_logit": 10.1015625,
            "end_logit": -8.140625,
            "text": "1967, in Cape Town, South Africa, Dr. Christian",
            "probability": 0.0
        },
        {
            "start_logit": 10.1015625,
            "end_logit": -8.1484375,
            "text": "1967, in Cape Town, South Africa, Dr. Christ",
            "probability": 0.0
        },
        {
            "start_logit": 10.1015625,
            "end_logit": -8.1484375,
            "text": "1967, in Cape",
            "probability": 0.0
        },
        {
            "start_logit": 10.1015625,
            "end_logit": -8.1953125,
            "text": "1967, in Cape Town, South Africa, Dr. Christian Barnard revolutionized organ transplantation",
            "probability": 0.0
        },
        {
            "start_logit": 10.1015625,
            "end_logit": -8.203125,
            "text": "1967, in Cape Town, South Africa, Dr. Christian Barnard",
            "probability": 0.0
        },
        {
            "start_logit": 10.1015625,
            "end_logit": -8.2578125,
            "text": "1967, in Cape Town, South Africa, Dr. Christian Barnard revolutionized",
            "probability": 0.0
        },
        {
            "start_logit": 10.1015625,
            "end_logit": -8.265625,
            "text": "1967, in Cape Town,",
            "probability": 0.0
        },
        {
            "start_logit": 10.1015625,
            "end_logit": -8.265625,
            "text": "1967, in Cape Town, South Africa, Dr. Chr",
            "probability": 0.0
        },
        {
            "start_logit": 10.1015625,
            "end_logit": -8.265625,
            "text": "1967, in Cape Town, South Africa, Dr. Christian Barnard revolutionized organ transplantation with",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_20": [
        {
            "start_logit": 9.9296875,
            "end_logit": 9.8671875,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": -1.482421875,
            "end_logit": 9.8671875,
            "text": "7",
            "probability": 1.1026859283447266e-05
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -1.90625,
            "text": "196",
            "probability": 7.68899917602539e-06
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -7.859375,
            "text": "1967 and followed this by introducing the technique of heterotopic heart transplantation in 1974",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.171875,
            "text": "1967 and followed this by",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.203125,
            "text": "1967 and followed this by introducing the technique of heterotopic heart transplantation in",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.28125,
            "text": "1967 and followed this by introducing the technique of heterotopic heart transplantation",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.296875,
            "text": "1967 and followed this",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.3046875,
            "text": "1967 and followed this by introducing the",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.3125,
            "text": "1967 and followed this by introducing the technique",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.3203125,
            "text": "1967 and followed this by introducing the technique of heterotopic heart",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -8.328125,
            "text": "1967 and followed this by introducing the technique of heterotopic",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.8671875,
            "text": "1st human-to-human orthotopic heart transplantation in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.8671875,
            "text": "in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 9.8671875,
            "text": "human orthotopic heart transplantation in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.8671875,
            "text": "-human orthotopic heart transplantation in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.359375,
            "end_logit": 9.8671875,
            "text": "-to-human orthotopic heart transplantation in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.359375,
            "end_logit": 9.8671875,
            "text": "human-to-human orthotopic heart transplantation in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.375,
            "end_logit": 9.8671875,
            "text": "heart transplantation in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -1.482421875,
            "end_logit": -7.859375,
            "text": "7 and followed this by introducing the technique of heterotopic heart transplantation in 1974",
            "probability": 0.0
        }
    ],
    "5fdb2e23a43ad3127800000a_1": [
        {
            "start_logit": 10.140625,
            "end_logit": 9.8828125,
            "text": "cis-regulatory elements",
            "probability": 1.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -1.46484375,
            "text": "cis",
            "probability": 1.1682510375976562e-05
        },
        {
            "start_logit": -1.38671875,
            "end_logit": 9.8828125,
            "text": "elements",
            "probability": 9.834766387939453e-06
        },
        {
            "start_logit": -5.578125,
            "end_logit": 9.8828125,
            "text": "regulatory elements",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.171875,
            "end_logit": 9.8828125,
            "text": "-regulatory elements",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.5390625,
            "end_logit": 9.8828125,
            "text": "of cis-regulatory elements",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.515625,
            "text": "cis-regulatory elements is central to understanding gene transcription. Hypersensitivity of cis-regulatory elements",
            "probability": 0.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.76953125,
            "text": "cis-regulatory elements is central to understanding gene transcription. Hypersensitivity of cis-regulatory elements to",
            "probability": 0.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.78125,
            "text": "cis-regulatory elements is central to understanding gene transcription. Hypersensitivity of cis-regulatory elements to digestion with DNaseI remains",
            "probability": 0.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.8125,
            "text": "cis-regulatory elements is central to understanding gene transcription",
            "probability": 0.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.84375,
            "text": "cis-regulatory elements is central to understanding gene transcription. Hypersensitivity of cis-regulatory",
            "probability": 0.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -7.9453125,
            "text": "cis-regulatory elements is central to understanding gene transcription. Hypersensitivity of cis-regulatory elements to digestion with DNaseI remains the gold-standard approach to locating such elements",
            "probability": 0.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -8.015625,
            "text": "cis-regulatory elements is central to understanding gene transcription. Hypersensitivity of cis-regulatory elements to digestion with DNaseI remains the gold-standard",
            "probability": 0.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -8.0390625,
            "text": "cis-regulatory elements is central to understanding gene transcription. Hypersensitivity of cis-regulatory elements to digestion",
            "probability": 0.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -8.0546875,
            "text": "cis-regulatory elements is central to understanding gene transcription. Hypersensitivity of cis",
            "probability": 0.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -8.0703125,
            "text": "cis-regulatory elements is central to understanding gene transcription. Hypersensitivity of cis-regulatory elements to digestion with DNaseI",
            "probability": 0.0
        },
        {
            "start_logit": 10.140625,
            "end_logit": -8.09375,
            "text": "cis-regulatory elements is central to understanding gene transcription. Hypersensitivity of cis-regulatory elements to digestion with DNaseI remains the gold",
            "probability": 0.0
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 9.8828125,
            "text": "identification of cis-regulatory elements",
            "probability": 0.0
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 9.8828125,
            "text": "The identification of cis-regulatory elements",
            "probability": 0.0
        },
        {
            "start_logit": -6.5390625,
            "end_logit": -1.46484375,
            "text": "of cis",
            "probability": 0.0
        }
    ],
    "5fdb2e23a43ad3127800000a_2": [
        {
            "start_logit": 10.1328125,
            "end_logit": 9.8125,
            "text": "cis-regulatory elements",
            "probability": 1.0
        },
        {
            "start_logit": 10.1328125,
            "end_logit": -1.4619140625,
            "text": "cis",
            "probability": 1.2814998626708984e-05
        },
        {
            "start_logit": -1.546875,
            "end_logit": 9.8125,
            "text": "elements",
            "probability": 8.52346420288086e-06
        },
        {
            "start_logit": -5.5,
            "end_logit": 9.8125,
            "text": "regulatory elements",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.98046875,
            "end_logit": 9.8125,
            "text": "-regulatory elements",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.25,
            "end_logit": 9.8125,
            "text": "of cis-regulatory elements",
            "probability": 0.0
        },
        {
            "start_logit": -7.3984375,
            "end_logit": 9.8125,
            "text": "Hypersensitivity of cis-regulatory elements",
            "probability": 0.0
        },
        {
            "start_logit": 10.1328125,
            "end_logit": -7.7734375,
            "text": "cis-regulatory elements to",
            "probability": 0.0
        },
        {
            "start_logit": 10.1328125,
            "end_logit": -7.8671875,
            "text": "cis-regulatory elements to digestion with DNaseI remains",
            "probability": 0.0
        },
        {
            "start_logit": 10.1328125,
            "end_logit": -7.8828125,
            "text": "cis-regulatory elements to digestion",
            "probability": 0.0
        },
        {
            "start_logit": 10.1328125,
            "end_logit": -7.9765625,
            "text": "cis-regulatory elements to digestion with DNaseI remains the gold-standard",
            "probability": 0.0
        },
        {
            "start_logit": 10.1328125,
            "end_logit": -8.0,
            "text": "cis-regulatory elements to digestion with DNaseI remains the gold-standard approach to locating such elements",
            "probability": 0.0
        },
        {
            "start_logit": 10.1328125,
            "end_logit": -8.0234375,
            "text": "cis-regulatory elements to digestion with DNaseI remains the gold",
            "probability": 0.0
        },
        {
            "start_logit": -7.25,
            "end_logit": -1.4619140625,
            "text": "of cis",
            "probability": 0.0
        },
        {
            "start_logit": -7.3984375,
            "end_logit": -1.4619140625,
            "text": "Hypersensitivity of cis",
            "probability": 0.0
        },
        {
            "start_logit": -1.546875,
            "end_logit": -7.7734375,
            "text": "elements to",
            "probability": 0.0
        },
        {
            "start_logit": -1.546875,
            "end_logit": -7.8671875,
            "text": "elements to digestion with DNaseI remains",
            "probability": 0.0
        },
        {
            "start_logit": -1.546875,
            "end_logit": -7.8828125,
            "text": "elements to digestion",
            "probability": 0.0
        },
        {
            "start_logit": -1.546875,
            "end_logit": -7.9765625,
            "text": "elements to digestion with DNaseI remains the gold-standard",
            "probability": 0.0
        },
        {
            "start_logit": -1.546875,
            "end_logit": -8.0,
            "text": "elements to digestion with DNaseI remains the gold-standard approach to locating such elements",
            "probability": 0.0
        }
    ],
    "5fdb2e23a43ad3127800000a_3": [
        {
            "start_logit": 10.1015625,
            "end_logit": 9.8203125,
            "text": "cis-regulatory elements",
            "probability": 1.0
        },
        {
            "start_logit": 10.1015625,
            "end_logit": -1.5478515625,
            "text": "cis",
            "probability": 1.1563301086425781e-05
        },
        {
            "start_logit": -1.52734375,
            "end_logit": 9.8203125,
            "text": "elements",
            "probability": 8.940696716308594e-06
        },
        {
            "start_logit": -5.68359375,
            "end_logit": 9.8203125,
            "text": "regulatory elements",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.09375,
            "end_logit": 9.8203125,
            "text": "of cis-regulatory elements",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.23046875,
            "end_logit": 9.8203125,
            "text": "-regulatory elements",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.125,
            "end_logit": 9.8203125,
            "text": "identification of cis-regulatory elements",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1015625,
            "end_logit": -7.609375,
            "text": "cis-regulatory elements is central to understanding gene transcription",
            "probability": 0.0
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 9.8203125,
            "text": "The identification of cis-regulatory elements",
            "probability": 0.0
        },
        {
            "start_logit": 10.1015625,
            "end_logit": -7.98046875,
            "text": "cis-regulatory elements is central",
            "probability": 0.0
        },
        {
            "start_logit": -6.09375,
            "end_logit": -1.5478515625,
            "text": "of cis",
            "probability": 0.0
        },
        {
            "start_logit": -7.125,
            "end_logit": -1.5478515625,
            "text": "identification of cis",
            "probability": 0.0
        },
        {
            "start_logit": -7.56640625,
            "end_logit": -1.5478515625,
            "text": "The identification of cis",
            "probability": 0.0
        },
        {
            "start_logit": -1.52734375,
            "end_logit": -7.609375,
            "text": "elements is central to understanding gene transcription",
            "probability": 0.0
        },
        {
            "start_logit": -1.52734375,
            "end_logit": -7.98046875,
            "text": "elements is central",
            "probability": 0.0
        },
        {
            "start_logit": -5.68359375,
            "end_logit": -7.609375,
            "text": "regulatory elements is central to understanding gene transcription",
            "probability": 0.0
        },
        {
            "start_logit": -5.68359375,
            "end_logit": -7.98046875,
            "text": "regulatory elements is central",
            "probability": 0.0
        },
        {
            "start_logit": -6.09375,
            "end_logit": -7.609375,
            "text": "of cis-regulatory elements is central to understanding gene transcription",
            "probability": 0.0
        },
        {
            "start_logit": -6.23046875,
            "end_logit": -7.609375,
            "text": "-regulatory elements is central to understanding gene transcription",
            "probability": 0.0
        },
        {
            "start_logit": -6.09375,
            "end_logit": -7.98046875,
            "text": "of cis-regulatory elements is central",
            "probability": 0.0
        }
    ],
    "53318685d6d3ac6a3400003d_1": [
        {
            "start_logit": 9.8828125,
            "end_logit": 9.7265625,
            "text": "autosomal dominant",
            "probability": 1.0
        },
        {
            "start_logit": -1.8134765625,
            "end_logit": 9.7265625,
            "text": "dominant",
            "probability": 8.344650268554688e-06
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -2.126953125,
            "text": "autosomal",
            "probability": 7.152557373046875e-06
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.94140625,
            "text": "autosomal dominant mode",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.0390625,
            "text": "autosomal dominant mode of inheritance",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.203125,
            "text": "autosomal dominant mode of",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.3046875,
            "text": "autosomal dominant mode of inheritance, distinct facial and skeleton features (a hoarse voice and internal notch of",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 9.7265625,
            "text": "an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": -1.8134765625,
            "end_logit": -7.94140625,
            "text": "dominant mode",
            "probability": 0.0
        },
        {
            "start_logit": -1.8134765625,
            "end_logit": -8.0390625,
            "text": "dominant mode of inheritance",
            "probability": 0.0
        },
        {
            "start_logit": -1.8134765625,
            "end_logit": -8.203125,
            "text": "dominant mode of",
            "probability": 0.0
        },
        {
            "start_logit": -1.8134765625,
            "end_logit": -8.3046875,
            "text": "dominant mode of inheritance, distinct facial and skeleton features (a hoarse voice and internal notch of",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -2.126953125,
            "text": "an autosomal",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -7.94140625,
            "text": "an autosomal dominant mode",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -8.0390625,
            "text": "an autosomal dominant mode of inheritance",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -8.203125,
            "text": "an autosomal dominant mode of",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": -8.3046875,
            "text": "an autosomal dominant mode of inheritance, distinct facial and skeleton features (a hoarse voice and internal notch of",
            "probability": 0.0
        }
    ],
    "53318685d6d3ac6a3400003d_2": [
        {
            "start_logit": 9.890625,
            "end_logit": 9.796875,
            "text": "autosomal dominant",
            "probability": 1.0
        },
        {
            "start_logit": -1.568359375,
            "end_logit": 9.796875,
            "text": "dominant",
            "probability": 1.055002212524414e-05
        },
        {
            "start_logit": 9.890625,
            "end_logit": -2.103515625,
            "text": "autosomal",
            "probability": 6.794929504394531e-06
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.03125,
            "text": "autosomal dominant or an autosomal recessive (AR) mode of inheritance",
            "probability": 0.0
        },
        {
            "start_logit": -7.96875,
            "end_logit": 9.796875,
            "text": "an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.140625,
            "text": "autosomal dominant or",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.1484375,
            "text": "autosomal dominant or an autosomal recessive (AR) mode",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.234375,
            "text": "autosomal dominant or an autosomal recessive (AR) mode of",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.2890625,
            "text": "autosomal dominant or an autosomal recessive (AR",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -8.296875,
            "text": "autosomal dominant or an autosomal recessive",
            "probability": 0.0
        },
        {
            "start_logit": -1.568359375,
            "end_logit": -8.03125,
            "text": "dominant or an autosomal recessive (AR) mode of inheritance",
            "probability": 0.0
        },
        {
            "start_logit": -1.568359375,
            "end_logit": -8.140625,
            "text": "dominant or",
            "probability": 0.0
        },
        {
            "start_logit": -1.568359375,
            "end_logit": -8.1484375,
            "text": "dominant or an autosomal recessive (AR) mode",
            "probability": 0.0
        },
        {
            "start_logit": -1.568359375,
            "end_logit": -8.234375,
            "text": "dominant or an autosomal recessive (AR) mode of",
            "probability": 0.0
        },
        {
            "start_logit": -1.568359375,
            "end_logit": -8.2890625,
            "text": "dominant or an autosomal recessive (AR",
            "probability": 0.0
        },
        {
            "start_logit": -1.568359375,
            "end_logit": -8.296875,
            "text": "dominant or an autosomal recessive",
            "probability": 0.0
        },
        {
            "start_logit": -7.96875,
            "end_logit": -2.103515625,
            "text": "an autosomal",
            "probability": 0.0
        },
        {
            "start_logit": -7.93359375,
            "end_logit": -8.03125,
            "text": "autosomal recessive (AR) mode of inheritance",
            "probability": 0.0
        },
        {
            "start_logit": -7.96875,
            "end_logit": -8.03125,
            "text": "an autosomal dominant or an autosomal recessive (AR) mode of inheritance",
            "probability": 0.0
        },
        {
            "start_logit": -7.93359375,
            "end_logit": -8.1484375,
            "text": "autosomal recessive (AR) mode",
            "probability": 0.0
        }
    ],
    "53318685d6d3ac6a3400003d_3": [
        {
            "start_logit": 9.9296875,
            "end_logit": 9.703125,
            "text": "autosomal dominant",
            "probability": 1.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -2.009765625,
            "text": "autosomal",
            "probability": 8.285045623779297e-06
        },
        {
            "start_logit": -1.8662109375,
            "end_logit": 9.703125,
            "text": "dominant",
            "probability": 7.569789886474609e-06
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -6.17578125,
            "text": "autosomal dominant mode of inheritance",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -7.17578125,
            "text": "autosomal dominant mode",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5703125,
            "end_logit": 9.703125,
            "text": "an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -7.82421875,
            "text": "autosomal dominant mode of",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": 9.703125,
            "text": "The condition appeared to be sporadic in 16 cases but the observation of vertical transmission in three families was consistent with an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.703125,
            "text": "vertical transmission in three families was consistent with an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.703125,
            "text": "condition appeared to be sporadic in 16 cases but the observation of vertical transmission in three families was consistent with an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.703125,
            "text": "three families was consistent with an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.703125,
            "text": "with an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.703125,
            "text": "was consistent with an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.703125,
            "text": "consistent with an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.703125,
            "text": "families was consistent with an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 9.703125,
            "text": "transmission in three families was consistent with an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 9.703125,
            "text": "sporadic in 16 cases but the observation of vertical transmission in three families was consistent with an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": -1.8662109375,
            "end_logit": -6.17578125,
            "text": "dominant mode of inheritance",
            "probability": 0.0
        },
        {
            "start_logit": -1.8662109375,
            "end_logit": -7.17578125,
            "text": "dominant mode",
            "probability": 0.0
        },
        {
            "start_logit": -7.5703125,
            "end_logit": -2.009765625,
            "text": "an autosomal",
            "probability": 0.0
        }
    ],
    "5c5312097e3cb0e231000011_1": [
        {
            "start_logit": 9.9140625,
            "end_logit": 9.5703125,
            "text": "Ohio",
            "probability": 1.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -1.994140625,
            "text": "Oh",
            "probability": 9.5367431640625e-06
        },
        {
            "start_logit": -2.140625,
            "end_logit": 9.5703125,
            "text": "io",
            "probability": 5.841255187988281e-06
        },
        {
            "start_logit": -7.81640625,
            "end_logit": 9.5703125,
            "text": "in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.3984375,
            "text": "Ohio,",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.5703125,
            "text": "measles outbreak in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 9.5703125,
            "text": "a 2014 measles outbreak in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.5703125,
            "text": "Recent outbreaks in Amish communities include a 2014 measles outbreak in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.5703125,
            "text": "2014 measles outbreak in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -7.81640625,
            "end_logit": -1.994140625,
            "text": "in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -1.994140625,
            "text": "measles outbreak in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -1.994140625,
            "text": "a 2014 measles outbreak in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -1.994140625,
            "text": "Recent outbreaks in Amish communities include a 2014 measles outbreak in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": -1.994140625,
            "text": "2014 measles outbreak in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -2.140625,
            "end_logit": -8.3984375,
            "text": "io,",
            "probability": 0.0
        },
        {
            "start_logit": -7.81640625,
            "end_logit": -8.3984375,
            "text": "in Ohio,",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -8.3984375,
            "text": "measles outbreak in Ohio,",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -8.3984375,
            "text": "a 2014 measles outbreak in Ohio,",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -8.3984375,
            "text": "Recent outbreaks in Amish communities include a 2014 measles outbreak in Ohio,",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": -8.3984375,
            "text": ",",
            "probability": 0.0
        }
    ],
    "5c5312097e3cb0e231000011_2": [
        {
            "start_logit": 9.828125,
            "end_logit": 9.3515625,
            "text": "Ohio",
            "probability": 1.0
        },
        {
            "start_logit": 9.828125,
            "end_logit": -2.18359375,
            "text": "Oh",
            "probability": 9.655952453613281e-06
        },
        {
            "start_logit": -2.630859375,
            "end_logit": 9.3515625,
            "text": "io",
            "probability": 3.874301910400391e-06
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 9.3515625,
            "text": "in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.3515625,
            "text": "Measles outbreaks in the United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.3515625,
            "text": "with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.3515625,
            "text": "outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.3515625,
            "text": "outbreaks in the United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.3515625,
            "text": "a 2014 outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.3515625,
            "text": "individuals, with a 2014 outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.3515625,
            "text": "with a 2014 outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -2.18359375,
            "text": "in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -2.18359375,
            "text": "Measles outbreaks in the United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": -2.18359375,
            "text": "with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -2.18359375,
            "text": "outbreak in Amish communities in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -2.18359375,
            "text": "outbreaks in the United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": -2.18359375,
            "text": "a 2014 outbreak in Amish communities in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": -2.18359375,
            "text": "individuals, with a 2014 outbreak in Amish communities in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": -2.18359375,
            "text": "with a 2014 outbreak in Amish communities in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -8.140625,
            "text": "Measles outbreaks in the United States",
            "probability": 0.0
        }
    ],
    "5c5312097e3cb0e231000011_3": [
        {
            "start_logit": 9.9609375,
            "end_logit": 9.6796875,
            "text": "Ohio",
            "probability": 1.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -1.890625,
            "text": "Oh",
            "probability": 9.417533874511719e-06
        },
        {
            "start_logit": -1.9287109375,
            "end_logit": 9.6796875,
            "text": "io",
            "probability": 6.854534149169922e-06
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.25,
            "text": "Ohio were",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.265625,
            "text": "Ohio were transmission primarily within households, the small proportion of Amish people affected, and the large number of people in",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.328125,
            "text": "Ohio were transmission primarily within households, the small proportion of Amish people affected, and the large number of people in the",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.34375,
            "text": "Ohio were transmission primarily within households, the small proportion of Amish people affected, and the large number of people in the Amish community",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.359375,
            "text": "Ohio were transmission primarily",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": 9.6796875,
            "text": "in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.3828125,
            "text": "Ohio were transmission primarily within households, the small proportion of Amish people affected, and the large",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.40625,
            "text": "Ohio were transmission primarily within households",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.40625,
            "text": "Ohio were transmission primarily within households, the small proportion of Amish people affected",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.4140625,
            "text": "Ohio were transmission primarily within",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.4140625,
            "text": "Ohio were transmission primarily within households, the small proportion",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.4140625,
            "text": "Ohio were transmission primarily within households, the small",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.4140625,
            "text": "Ohio were transmission primarily within households,",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 9.6796875,
            "text": "a measles outbreak in the Amish community in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.6796875,
            "text": "key epidemiologic features of a measles outbreak in the Amish community in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.6796875,
            "text": "CONCLUSIONS The key epidemiologic features of a measles outbreak in the Amish community in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.6796875,
            "text": "measles outbreak in the Amish community in Ohio",
            "probability": 0.0
        }
    ],
    "5c5312097e3cb0e231000011_4": [
        {
            "start_logit": 9.9453125,
            "end_logit": 9.5234375,
            "text": "Ohio",
            "probability": 1.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -1.94140625,
            "text": "Oh",
            "probability": 1.043081283569336e-05
        },
        {
            "start_logit": -2.27734375,
            "end_logit": 9.5234375,
            "text": "io",
            "probability": 4.947185516357422e-06
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.1953125,
            "text": "Ohio push",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.3515625,
            "text": "Ohio pushing the annual cases to the highest national number reported in the last 20",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.359375,
            "text": "Ohio pushing the annual cases to",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.3984375,
            "text": "Ohio pushing the annual cases to the highest national number reported in the",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -8.3984375,
            "text": "Ohio pushing the annual cases to the highest national number reported",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 9.5234375,
            "text": "in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 9.5234375,
            "text": "Measles outbreaks in the United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 9.5234375,
            "text": "outbreaks in the United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 9.5234375,
            "text": "with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.5234375,
            "text": "outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 9.5234375,
            "text": "a 2014 outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -1.94140625,
            "text": "in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -1.94140625,
            "text": "Measles outbreaks in the United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -1.94140625,
            "text": "outbreaks in the United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": -1.94140625,
            "text": "with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": -1.94140625,
            "text": "outbreak in Amish communities in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": -1.94140625,
            "text": "a 2014 outbreak in Amish communities in Oh",
            "probability": 0.0
        }
    ],
    "5c5312097e3cb0e231000011_5": [
        {
            "start_logit": 9.9609375,
            "end_logit": 9.6640625,
            "text": "Ohio",
            "probability": 1.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -1.8798828125,
            "text": "Oh",
            "probability": 9.655952453613281e-06
        },
        {
            "start_logit": -1.9404296875,
            "end_logit": 9.6640625,
            "text": "io",
            "probability": 6.735324859619141e-06
        },
        {
            "start_logit": -7.78125,
            "end_logit": 9.6640625,
            "text": "in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.203125,
            "text": "Ohio, resulting in 36",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.34375,
            "text": "Ohio, resulting in 368",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.375,
            "text": "Ohio,",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.375,
            "text": "Ohio, resulting in 368 cases reported",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.6640625,
            "text": "measles outbreak in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 9.6640625,
            "text": "a 2014 measles outbreak in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -7.78125,
            "end_logit": -1.8798828125,
            "text": "in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -1.9404296875,
            "end_logit": -8.203125,
            "text": "io, resulting in 36",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": -1.8798828125,
            "text": "measles outbreak in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": -1.8798828125,
            "text": "a 2014 measles outbreak in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -1.9404296875,
            "end_logit": -8.34375,
            "text": "io, resulting in 368",
            "probability": 0.0
        },
        {
            "start_logit": -1.9404296875,
            "end_logit": -8.375,
            "text": "io,",
            "probability": 0.0
        },
        {
            "start_logit": -1.9404296875,
            "end_logit": -8.375,
            "text": "io, resulting in 368 cases reported",
            "probability": 0.0
        },
        {
            "start_logit": -7.78125,
            "end_logit": -8.203125,
            "text": "in Ohio, resulting in 36",
            "probability": 0.0
        },
        {
            "start_logit": -7.78125,
            "end_logit": -8.34375,
            "text": "in Ohio, resulting in 368",
            "probability": 0.0
        },
        {
            "start_logit": -7.78125,
            "end_logit": -8.375,
            "text": "in Ohio,",
            "probability": 0.0
        }
    ],
    "5c5312097e3cb0e231000011_6": [
        {
            "start_logit": 9.9609375,
            "end_logit": 9.6796875,
            "text": "Ohio",
            "probability": 1.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -1.890625,
            "text": "Oh",
            "probability": 9.417533874511719e-06
        },
        {
            "start_logit": -1.9287109375,
            "end_logit": 9.6796875,
            "text": "io",
            "probability": 6.854534149169922e-06
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.25,
            "text": "Ohio were",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.265625,
            "text": "Ohio were transmission primarily within households, the small proportion of Amish people affected, and the large number of people in",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.328125,
            "text": "Ohio were transmission primarily within households, the small proportion of Amish people affected, and the large number of people in the",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.34375,
            "text": "Ohio were transmission primarily within households, the small proportion of Amish people affected, and the large number of people in the Amish community",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.359375,
            "text": "Ohio were transmission primarily",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": 9.6796875,
            "text": "in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.3828125,
            "text": "Ohio were transmission primarily within households, the small proportion of Amish people affected, and the large",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.40625,
            "text": "Ohio were transmission primarily within households",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.40625,
            "text": "Ohio were transmission primarily within households, the small proportion of Amish people affected",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.4140625,
            "text": "Ohio were transmission primarily within",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.4140625,
            "text": "Ohio were transmission primarily within households, the small proportion",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.4140625,
            "text": "Ohio were transmission primarily within households, the small",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -8.4140625,
            "text": "Ohio were transmission primarily within households,",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 9.6796875,
            "text": "a measles outbreak in the Amish community in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.6796875,
            "text": "key epidemiologic features of a measles outbreak in the Amish community in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.6796875,
            "text": "CONCLUSIONS The key epidemiologic features of a measles outbreak in the Amish community in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 9.6796875,
            "text": "measles outbreak in the Amish community in Ohio",
            "probability": 0.0
        }
    ],
    "5c5312097e3cb0e231000011_7": [
        {
            "start_logit": 9.9140625,
            "end_logit": 9.4765625,
            "text": "Ohio",
            "probability": 1.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -2.0,
            "text": "Oh",
            "probability": 1.0371208190917969e-05
        },
        {
            "start_logit": -2.349609375,
            "end_logit": 9.4765625,
            "text": "io",
            "probability": 4.708766937255859e-06
        },
        {
            "start_logit": -6.5625,
            "end_logit": 9.4765625,
            "text": ".Measles outbreaks in the United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Ohio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.11328125,
            "end_logit": 9.4765625,
            "text": "in Ohio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.2578125,
            "text": "Ohio push",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.3046875,
            "text": "Ohio pushing the annual cases to",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.375,
            "text": "Ohio pushing the annual cases to the highest national number reported in the last 20",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.3828125,
            "text": "Ohio pushing the annual cases to the highest national number reported",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 9.4765625,
            "text": "a 2014 outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 9.4765625,
            "text": "Modeling Measles Transmission in the North American Amish and Options for Outbreak Response.Measles outbreaks in the United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.4765625,
            "text": "outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.4765625,
            "text": "2014 outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 9.4765625,
            "text": "Options for Outbreak Response.Measles outbreaks in the United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 9.4765625,
            "text": "with a 2014 outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.4765625,
            "text": "for Outbreak Response.Measles outbreaks in the United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.4765625,
            "text": "communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.4765625,
            "text": "Measles outbreaks in the United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -6.5625,
            "end_logit": -2.0,
            "text": ".Measles outbreaks in the United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -7.11328125,
            "end_logit": -2.0,
            "text": "in Oh",
            "probability": 0.0
        }
    ],
    "61f95f9f882a024a1000004e_1": [
        {
            "start_logit": 9.8828125,
            "end_logit": 8.796875,
            "text": "Oguchi disease",
            "probability": 1.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -2.04296875,
            "text": "Og",
            "probability": 1.9550323486328125e-05
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -4.39453125,
            "text": "Oguchi disease, a",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": -3.4296875,
            "end_logit": 8.796875,
            "text": "disease",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -6.29296875,
            "text": "Oguchi disease, a rare subtype of congenital stationary night blindness (CSNB",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -6.578125,
            "text": "Oguchi disease,",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -6.77734375,
            "text": "Oguchi disease, a rare subtype of congenital stationary night blindness",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.01171875,
            "text": "Oguchi disease, a rare subtype of congenital stationary night blindness (CSNB)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.01953125,
            "text": "Oguchi disease, a rare subtype of congenital stationary night blindness (CS",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.2578125,
            "text": "Oguchi",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.484375,
            "text": "Oguchi disease, a rare subtype of congenital stationary night blindness (CSNB).",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.5703125,
            "text": "Oguch",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -7.95703125,
            "text": "Oguchi disease, a rare",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -8.09375,
            "text": "Oguchi disease, a rare subtype",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.046875,
            "end_logit": 8.796875,
            "text": "uchi disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.08203125,
            "end_logit": 8.796875,
            "text": "i disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.2578125,
            "end_logit": 8.796875,
            "text": "cause Oguchi disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 8.796875,
            "text": "Biallelic mutations in G-Protein coupled receptor kinase 1 (GRK1) cause Oguchi disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 8.796875,
            "text": "in G-Protein coupled receptor kinase 1 (GRK1) cause Oguchi disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 8.796875,
            "text": "G-Protein coupled receptor kinase 1 (GRK1) cause Oguchi disease",
            "probability": 0.0
        }
    ]
}
